{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Exploration of the human Tau protein modification Subgraph\n",
    "\n",
    "The goal of this notebook is to extract a subgraph from `hbp_knowledge` that containts the Tau protein, its post-translational modifications, and the upstream controllers that induce the corresponding phosphorylations.\n",
    "\n",
    "The BEL graph used in this notebook is retreived using the `hbp_knowledge` package that wraps the curated BEL content deposited at https://github.com/pharmacome/knowledge. Most of the BEL files in this repository correspond to exactly one article. However, some that are topic-oriented contain information from several articles."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import time\n",
    "import sys\n",
    "from collections import defaultdict\n",
    "from operator import attrgetter\n",
    "\n",
    "import matplotlib.pyplot as plt\n",
    "\n",
    "import bio2bel_hgnc\n",
    "import bio2bel_drugbank\n",
    "import hbp_knowledge\n",
    "import pandas as pd\n",
    "import pybel\n",
    "import pybel.struct\n",
    "import pybel_jupyter\n",
    "import pybel_tools\n",
    "from pybel.dsl import *\n",
    "from pybel.manager.citation_utils import get_pubmed_citation_response\n",
    "from pybel_tools.filters import get_variants_to_controllers\n",
    "from pybel_jupyter import to_jupyter"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "%matplotlib inline"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Environment"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "3.7.3 (default, Mar 27 2019, 09:23:39) \n",
      "[Clang 10.0.0 (clang-1000.11.45.5)]\n"
     ]
    }
   ],
   "source": [
    "print(sys.version)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Tue Apr 16 14:50:58 2019\n"
     ]
    }
   ],
   "source": [
    "print(time.asctime())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "HBP-Knowledge    v0.0.4-dev\n",
      "PyBEL            v0.13.2-dev\n",
      "PyBEL-Tools      v0.7.3-dev\n",
      "PyBEL-Jupyter    v0.2.2-dev\n",
      "Bio2BEL HGNC     v0.2.4-dev\n",
      "Bio2BEL DrugBank v0.1.2-dev\n"
     ]
    }
   ],
   "source": [
    "print(f\"\"\"HBP-Knowledge    v{hbp_knowledge.VERSION}\n",
    "PyBEL            v{pybel.get_version()}\n",
    "PyBEL-Tools      v{pybel_tools.get_version()}\n",
    "PyBEL-Jupyter    v{pybel_jupyter.get_version()}\n",
    "Bio2BEL HGNC     v{bio2bel_hgnc.get_version()}\n",
    "Bio2BEL DrugBank v{bio2bel_drugbank.get_version()}\"\"\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Data\n",
    "\n",
    "## Acquiring and Normalizing the Graph\n",
    "\n",
    "Retrieve the graph from `hbp_knowledge`."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "graph = hbp_knowledge.repository.get_graph()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Remove pathologies from the graph - they aren't the focus of this notebook."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "pybel.struct.remove_pathologies(graph)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Normalize the proteins in the network using [Bio2BEL HGNC](https://github.com/bio2bel/hgnc)."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "hgnc_manager = bio2bel_hgnc.Manager()\n",
    "\n",
    "if not hgnc_manager.is_populated():\n",
    "    raise RuntimeError('Populate Bio2BEL HGNC first!')\n",
    "\n",
    "hgnc_manager.normalize_genes(graph)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Normalize the chemicals in the network using [Bio2BEL DrugBank](https://github.com/bio2bel/drugbank)."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:root:could not normalize a(DRUGBANK:Facinicline) (None:Facinicline)\n"
     ]
    }
   ],
   "source": [
    "drugbank_manager = bio2bel_drugbank.Manager()\n",
    "\n",
    "if not drugbank_manager.is_populated():\n",
    "    raise RuntimeError('Populate Bio2BEL DrugBank first!')\n",
    "    \n",
    "drugbank_manager.normalize_drugs(graph)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Summarize the normalized graph"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Human Brain Pharmacome Knowledge v0.0.4-dev\n",
      "Number of Nodes: 4885\n",
      "Number of Edges: 14497\n",
      "Number of Citations: 328\n",
      "Number of Authors: 1837\n",
      "Network Density: 6.08E-04\n",
      "Number of Components: 126\n",
      "Number of Warnings: 28\n"
     ]
    }
   ],
   "source": [
    "graph.summarize()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Counter({'CHEBI': 382,\n",
       "         'GO': 543,\n",
       "         'MESH': 413,\n",
       "         'HBP': 445,\n",
       "         'HP': 9,\n",
       "         'MGI': 237,\n",
       "         'PUBCHEM': 100,\n",
       "         'FPLX': 127,\n",
       "         'HGNCGENEFAMILY': 32,\n",
       "         'CTO': 1,\n",
       "         'UNIPROT': 12,\n",
       "         'TAXONOMY': 4,\n",
       "         'RGD': 77,\n",
       "         'INTERPRO': 64,\n",
       "         'GFAM': 8,\n",
       "         'MESHC': 4,\n",
       "         'DRUGBANK': 1,\n",
       "         'DNSNP': 2,\n",
       "         'NCBIGENE': 2,\n",
       "         'DBSNP': 13,\n",
       "         'ECCODE': 18,\n",
       "         'PFAM': 2,\n",
       "         'CL': 3,\n",
       "         'SCOMP': 1,\n",
       "         'SFAM': 2,\n",
       "         'BRCO': 1,\n",
       "         'MIRBASE': 3,\n",
       "         'HGNC': 1,\n",
       "         'hgnc': 1486})"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pybel.struct.summary.count_namespaces(graph)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Selecting the Subgraph"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Identify any `pybel.dsl.Protein` that is a variant of `pybel.dsl.Protein('HGNC', 'MAPT')` that contains either a phosphorylation or hyper-phosphorylation."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<BEL p(hgnc:MAPT)>"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "mapt_protein = Protein('hgnc', 'MAPT')\n",
    "mapt_protein"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "modifications = set() # {'Ph', 'hyperphosphorylation'} "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "there are 74 variants of Tau with 199 unique upstream controllers\n"
     ]
    }
   ],
   "source": [
    "modified_mapts = get_variants_to_controllers(graph, mapt_protein, modifications)\n",
    "\n",
    "n_variants = len(modified_mapts)\n",
    "n_controllers = len(set(\n",
    "    controller\n",
    "    for controllers in modified_mapts.values()\n",
    "    for controller in controllers\n",
    "))\n",
    "\n",
    "print(f'there are {n_variants} variants of Tau with {n_controllers} unique upstream controllers')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 4000x1200 with 2 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "controller_to_modification = defaultdict(set)\n",
    "for variant, controllers in modified_mapts.items():\n",
    "    for controller in controllers:\n",
    "        controller_to_modification[controller].add(variant)\n",
    "        \n",
    "\n",
    "fig, (rax, lax) = plt.subplots(1, 2, figsize=(10, 3), dpi=400)\n",
    "\n",
    "h = [len(v) for v in controller_to_modification.values()]\n",
    "lax.hist(h, bins=max(h), align='right')\n",
    "lax.set_title(f'Promiscuity of Controllers ($n={n_controllers}$)')\n",
    "lax.set_xlabel('Number PTMs')\n",
    "lax.set_ylabel('Count')\n",
    "\n",
    "h = [len(v) for v in modified_mapts.values()]\n",
    "rax.hist(h)\n",
    "rax.set_title(f'Promiscuity of PTMs ($n={n_variants}$)')\n",
    "rax.set_xlabel('Number Controllers')\n",
    "rax.set_ylabel('Count')\n",
    "\n",
    "plt.tight_layout()\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Get the subgraph of containing all of the neighbors (via any relationships) of any of the phosphorlyated variants identified in the previous cell. Additionally, throw away any `pybel.dsl.Pathology` nodes, since they appear as hubs and provide little information."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "None vNone\n",
      "Number of Nodes: 382\n",
      "Number of Edges: 1076\n",
      "Number of Citations: 136\n",
      "Number of Authors: 788\n",
      "Network Density: 7.39E-03\n",
      "Number of Components: 1\n",
      "Number of Warnings: 0\n"
     ]
    }
   ],
   "source": [
    "ptm_graph = pybel.struct.get_subgraph_by_neighborhood(graph, modified_mapts)\n",
    "ptm_graph.summarize()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Display the subgraph using `pybel_jupyter`."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/javascript": [
       "function init_d3_force(d3, graph, chart, width, height, function_colors) {\n",
       "    var focus_node = null;\n",
       "    var highlight_node = null;\n",
       "\n",
       "    // Highlight color variables\n",
       "\n",
       "    // Highlight color of the node boundering\n",
       "    const highlight_node_boundering = \"#4EB2D4\";\n",
       "\n",
       "    // Highlight color of the edge\n",
       "    const highlighted_link_color = \"#4EB2D4\";\n",
       "\n",
       "    // Text highlight color\n",
       "    const highlight_text = \"#4EB2D4\";\n",
       "\n",
       "    // Size when zooming scale\n",
       "    var size = d3.scalePow().exponent(1)\n",
       "        .domain([1, 100])\n",
       "        .range([8, 24]);\n",
       "\n",
       "    // Simulation parameters\n",
       "    const linkDistance = 100;\n",
       "    const fCharge = -1000;\n",
       "    const linkStrength = 0.7;\n",
       "    const collideStrength = 1;\n",
       "\n",
       "    // Simulation defined with variables\n",
       "    var simulation = d3.forceSimulation()\n",
       "        .force(\"link\", d3.forceLink()\n",
       "            .distance(linkDistance)\n",
       "            .strength(linkStrength)\n",
       "        )\n",
       "        .force(\"collide\", d3.forceCollide()\n",
       "            .radius(function (d) {\n",
       "                return d.r + 10\n",
       "            })\n",
       "            .strength(collideStrength)\n",
       "        )\n",
       "        .force(\"charge\", d3.forceManyBody()\n",
       "            .strength(fCharge)\n",
       "        )\n",
       "        .force(\"center\", d3.forceCenter(width / 2, height / 2))\n",
       "        .force(\"y\", d3.forceY(0))\n",
       "        .force(\"x\", d3.forceX(0));\n",
       "\n",
       "    // Pin down functionality\n",
       "    var node_drag = d3.drag()\n",
       "        .on(\"start\", dragstarted)\n",
       "        .on(\"drag\", dragged)\n",
       "        .on(\"end\", dragended);\n",
       "\n",
       "    function dragstarted(d) {\n",
       "        if (!d3.event.active) simulation.alphaTarget(0.3).restart();\n",
       "        d.fx = d.x;\n",
       "        d.fy = d.y;\n",
       "    }\n",
       "\n",
       "    function dragged(d) {\n",
       "        d.fx = d3.event.x;\n",
       "        d.fy = d3.event.y;\n",
       "    }\n",
       "\n",
       "    function dragended(d) {\n",
       "        if (!d3.event.active) simulation.alphaTarget(0);\n",
       "    }\n",
       "\n",
       "    function releasenode(d) {\n",
       "        d.fx = null;\n",
       "        d.fy = null;\n",
       "    }\n",
       "\n",
       "    //END Pin down functionality\n",
       "\n",
       "\n",
       "    /**\n",
       "     * Gets the best name for a node object\n",
       "     * @param {object} d object\n",
       "     * @returns {str} canonical name of the node\n",
       "     */\n",
       "    function getCanonicalName(d) {\n",
       "        if (d.name && !(d.variants || d.reactants || d.products || d.members)) {\n",
       "            return d.name\n",
       "        } else if (d.bel) {\n",
       "            return d.bel\n",
       "        } else {\n",
       "            console.log('Undefined node: ' + d);\n",
       "            return 'UNDEFINED'\n",
       "        }\n",
       "    }\n",
       "\n",
       "    const color_circunferencia = \"black\";\n",
       "    const default_link_color = \"#AAAAAA\";\n",
       "    const nominal_base_node_size = 8;\n",
       "\n",
       "    // Normal and highlighted stroke of the links (double the width of the link when highlighted)\n",
       "    const nominal_stroke = 1.5;\n",
       "\n",
       "    // Zoom variables\n",
       "    const min_zoom = 0.1;\n",
       "    const max_zoom = 10;\n",
       "\n",
       "    var svg = d3.select(chart).append(\"svg\")\n",
       "        .attr(\"width\", width)\n",
       "        .attr(\"height\", height);\n",
       "\n",
       "    // // Create definition for arrowhead.\n",
       "    svg.append(\"defs\").append(\"marker\")\n",
       "        .attr(\"id\", \"arrowhead\")\n",
       "        .attr(\"viewBox\", \"0 -5 10 10\")\n",
       "        .attr(\"refX\", 20)\n",
       "        .attr(\"refY\", 0)\n",
       "        .attr(\"markerUnits\", \"strokeWidth\")\n",
       "        .attr(\"markerWidth\", 6)\n",
       "        .attr(\"markerHeight\", 6)\n",
       "        .attr(\"orient\", \"auto\")\n",
       "        .append(\"path\")\n",
       "        .attr(\"d\", \"M0,-5L10,0L0,5\");\n",
       "\n",
       "    // // Create definition for stub.\n",
       "    svg.append(\"defs\").append(\"marker\")\n",
       "        .attr(\"id\", \"stub\")\n",
       "        .attr(\"viewBox\", \"-1 -5 2 10\")\n",
       "        .attr(\"refX\", 15)\n",
       "        .attr(\"refY\", 0)\n",
       "        .attr(\"markerUnits\", \"strokeWidth\")\n",
       "        .attr(\"markerWidth\", 6)\n",
       "        .attr(\"markerHeight\", 6)\n",
       "        .attr(\"orient\", \"auto\")\n",
       "        .append(\"path\")\n",
       "        .attr(\"d\", \"M 0,0 m -1,-5 L 1,-5 L 1,5 L -1,5 Z\");\n",
       "\n",
       "    // Background\n",
       "    svg.append(\"rect\")\n",
       "        .attr(\"width\", \"100%\")\n",
       "        .attr(\"height\", \"100%\")\n",
       "        .attr(\"fill\", \"#ffffff\")\n",
       "        .style(\"pointer-events\", \"all\")\n",
       "        // Zoom + panning functionality\n",
       "        .call(d3.zoom()\n",
       "            .scaleExtent([min_zoom, max_zoom])\n",
       "            .on(\"zoom\", zoomed))\n",
       "        .on(\"dblclick.zoom\", null);\n",
       "\n",
       "\n",
       "    function zoomed() {\n",
       "        g.attr(\"transform\", d3.event.transform);\n",
       "    }\n",
       "\n",
       "    // g = svg object where the graph will be appended\n",
       "    var g = svg.append(\"g\");\n",
       "\n",
       "    var linkedByIndex = {};\n",
       "    graph.links.forEach(function (d) {\n",
       "        linkedByIndex[d.source + \",\" + d.target] = true;\n",
       "    });\n",
       "\n",
       "    function isConnected(a, b) {\n",
       "        return linkedByIndex[a.index + \",\" + b.index] || linkedByIndex[b.index + \",\" + a.index] || a.index == b.index;\n",
       "    }\n",
       "\n",
       "    function ticked() {\n",
       "        link.attr(\"x1\", function (d) {\n",
       "            return d.source.x;\n",
       "        })\n",
       "            .attr(\"y1\", function (d) {\n",
       "                return d.source.y;\n",
       "            })\n",
       "            .attr(\"x2\", function (d) {\n",
       "                return d.target.x;\n",
       "            })\n",
       "            .attr(\"y2\", function (d) {\n",
       "                return d.target.y;\n",
       "            });\n",
       "\n",
       "        node\n",
       "            .attr(\"transform\", function (d) {\n",
       "                return \"translate(\" + d.x + \", \" + d.y + \")\";\n",
       "            });\n",
       "    }\n",
       "\n",
       "\n",
       "    simulation\n",
       "        .nodes(graph.nodes)\n",
       "        .on(\"tick\", ticked);\n",
       "\n",
       "    simulation.force(\"link\")\n",
       "        .links(graph.links);\n",
       "\n",
       "    // Definition of links nodes text...\n",
       "\n",
       "    var link = g.selectAll(\".link\")\n",
       "        .data(graph.links)\n",
       "        .enter().append(\"line\")\n",
       "        .style(\"stroke-width\", nominal_stroke)\n",
       "        .style(\"stroke\", default_link_color)\n",
       "        .style(\"stroke-dasharray\", function (d) {\n",
       "            if (['decreases', 'directlyDecreases', 'increases', 'directlyIncreases', 'negativeCorrelation',\n",
       "                'positiveCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"none\"\n",
       "            } else {\n",
       "                return \"4, 4\"\n",
       "            }\n",
       "        })\n",
       "        .attr(\"marker-start\", function (d) {\n",
       "            if ('positiveCorrelation' == d.relation) {\n",
       "                return \"url(#arrowhead)\"\n",
       "            }\n",
       "            else if ('negativeCorrelation' == d.relation) {\n",
       "                return \"url(#stub)\"\n",
       "            }\n",
       "            else {\n",
       "                return \"\"\n",
       "            }\n",
       "        })\n",
       "        .attr(\"marker-end\", function (d) {\n",
       "            if (['increases', 'directlyIncreases', 'positiveCorrelation', 'isA', 'partOf'].indexOf(d.relation) >= 0) {\n",
       "                return \"url(#arrowhead)\"\n",
       "            } else if (['decreases', 'directlyDecreases', 'negativeCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"url(#stub)\"\n",
       "            } else {\n",
       "                return \"\"\n",
       "            }\n",
       "        });\n",
       "\n",
       "    var node = g.selectAll(\".nodes\")\n",
       "        .data(graph.nodes)\n",
       "        .enter().append(\"g\")\n",
       "        .attr(\"class\", \"node\")\n",
       "        // Next two lines -> Pin down functionality\n",
       "        .on('dblclick', releasenode)\n",
       "        .call(node_drag);\n",
       "\n",
       "    var circle = node.append(\"path\")\n",
       "        .attr(\"d\", d3.symbol()\n",
       "            .size(function (d) {\n",
       "                return Math.PI * Math.pow(size(d.size) || nominal_base_node_size, 2);\n",
       "            })\n",
       "        )\n",
       "        .attr(\"class\", function (d) {\n",
       "            return d.function\n",
       "        })\n",
       "        .style('fill', function (d) {\n",
       "            return function_colors[d.function]\n",
       "        })\n",
       "        .style(\"stroke-width\", nominal_stroke)\n",
       "        .style(\"stroke\", color_circunferencia);\n",
       "\n",
       "    var text = node.append(\"text\")\n",
       "        .attr(\"class\", \"node-name\")\n",
       "        // .attr(\"id\", nodehashes[d])\n",
       "        .attr(\"fill\", \"black\")\n",
       "        .attr(\"dx\", 12)\n",
       "        .attr(\"dy\", \".35em\")\n",
       "        .text(function (d) {\n",
       "            return getCanonicalName(d)\n",
       "        });\n",
       "\n",
       "    // Highlight on mouseenter and back to normal on mouseout\n",
       "    node.on(\"mouseenter\", function (d) {\n",
       "        set_highlight(d);\n",
       "    })\n",
       "        .on(\"mousedown\", function () {\n",
       "            d3.event.stopPropagation();\n",
       "        }).on(\"mouseout\", function () {\n",
       "        exit_highlight();\n",
       "    });\n",
       "\n",
       "    function exit_highlight() {\n",
       "        highlight_node = null;\n",
       "        if (focus_node === null) {\n",
       "            if (highlight_node_boundering != color_circunferencia) {\n",
       "                circle.style(\"stroke\", color_circunferencia);\n",
       "                text.style(\"fill\", \"black\");\n",
       "                link.style(\"stroke\", default_link_color);\n",
       "            }\n",
       "        }\n",
       "    }\n",
       "\n",
       "    function set_highlight(d) {\n",
       "        if (focus_node !== null) d = focus_node;\n",
       "        highlight_node = d;\n",
       "\n",
       "        if (highlight_node_boundering != color_circunferencia) {\n",
       "            circle.style(\"stroke\", function (o) {\n",
       "                return isConnected(d, o) ? highlight_node_boundering : color_circunferencia;\n",
       "            });\n",
       "            text.style(\"fill\", function (o) {\n",
       "                return isConnected(d, o) ? highlight_text : \"black\";\n",
       "            });\n",
       "            link.style(\"stroke\", function (o) {\n",
       "                return o.source.index == d.index || o.target.index == d.index ? highlighted_link_color : default_link_color;\n",
       "            });\n",
       "        }\n",
       "    }\n",
       "\n",
       "\n",
       "    // Freeze the graph when space is pressed\n",
       "    function freezeGraph() {\n",
       "        // Space button Triggers STOP\n",
       "        if (d3.event.keyCode == 32) {\n",
       "            simulation.stop();\n",
       "        }\n",
       "    }\n",
       "\n",
       "    // Call freezeGraph when a key is pressed, freezeGraph checks whether this key is \"Space\" that triggers the freeze\n",
       "    d3.select(window).on(\"keydown\", freezeGraph);\n",
       "}\n",
       "\n",
       "require.config({\n",
       "    paths: {\n",
       "        d3: '//cdnjs.cloudflare.com/ajax/libs/d3/4.5.0/d3.min'\n",
       "    }\n",
       "});\n",
       "\n",
       "var elementInnerHTML = \"<div id='zxbueavsrqkjythd'></div>\";\n",
       "\n",
       "element.append(elementInnerHTML);\n",
       "\n",
       "require(['d3'], function (d3) {\n",
       "    return init_d3_force(d3, {\"directed\": true, \"graph\": {\"annotation_list\": {\"AssayType\": [\"B\"], \"Braak_Stage\": [\"Stage I\", \"Stage II\", \"Stage III\", \"Stage IV\", \"Stage V\", \"Stage VI\"], \"Cell_Line\": [\"BV2\", \"CG-4\", \"CHO\", \"COS7\", \"Chicken embryo fibroblasts\", \"HCN2A\", \"HEK293\", \"HEK293T\", \"HNPC\", \"HeLa\", \"Human fibroblasts\", \"N2a\", \"NIH/3T3\", \"NT2\", \"PC12\", \"SH-SY5Y\", \"SK-N-SH\", \"neural stem cell\"], \"Disease_Progression\": [\"Early Stage\", \"Late Stage\"], \"Duration\": [\"2 hours\"], \"Enzyme_Acitvity\": [\"1 U/ml\"], \"ExpGroup\": [\"healthy controls\"], \"ExpMethod\": [\"in vitro\", \"in vivo\"], \"GOCC\": [\"axon cytoplasm\", \"membrane raft\", \"neuron projection\"], \"HBP_Disease\": [\"Autism Spectrum Disorder (ASD)\", \"Corticobasal Degeneration\", \"Frontotemporal Lobar Degeneration\", \"Lewy Body Disease, Diffuse\"], \"Half_life\": [\"29 min\", \"30 min\", \"70 min\"], \"HasQuantitativeInformation\": [\"False\", \"True\"], \"IC50\": [\"0.2 mM\", \"0.4 mM\", \"0.4 mg/ml\", \"0.6 mM\", \"160 mM\", \"19 nM\", \"2 mM\", \"30 nM\", \"35 mM\", \"38 nM\", \"4.5 mM\", \"45 nM\", \"450 nM\", \"5-50 nM\", \"50 mM\", \"54 nM\", \"62 nM\", \"65 nM\", \"78 nM\", \"90 nM\"], \"Ki\": [\"110 nM\", \"210 nM\", \"38 M\", \"39 nM\", \"4-80 nM\", \"40 nM\", \"5 nM\", \"8 M\"], \"Km\": [\"114 M\", \"16 M\", \"2.7 M\", \"200 M\", \"5 M\", \"59 M\", \"8-15 M\"], \"Km_ATP\": [\"10 M\", \"2 M\"], \"MeasurementRelation\": [\"=\", \"~\"], \"MeasurementType\": [\"CSF concentration\", \"IC50\", \"Ki\", \"brain concertration\", \"dose\", \"plasma concentration\"], \"MeasurementUnits\": [\"mg\", \"nM\", \"M\"], \"MeasurementValue\": [\"1.3\", \"1.4\", \"1.9\"], \"Method\": [\"Atomic Force Microscopy\", \"Bradford Assay\", \"CD Spectroscopy\", \"Cell Viability Assay, MTT\", \"Chromatin Immunoprecipitation\", \"Chromatography\", \"Chromatography, Affinity\", \"Chromatography, FPLC\", \"Chromatography, Gel filtration\", \"Chromatography, Immunoaffinity\", \"Chromatography, Ni-NTA-Sepharose\", \"Chymotrypsin Assay\", \"Co-Immunoprecipitation\", \"Comet Assay\", \"Confocal Laser Microscopy\", \"Confocal Microscopy\", \"Confocal Microscopy, Laser Scanning\", \"Deglycosylation Assay\", \"Degradation Assay, 20S Proteasomal\", \"Dephosphorylation Assay\", \"Dephosphorylation Assay, Colorimetric\", \"Dot Blot\", \"Dot blot\", \"ELISA\", \"Electron Microscopy\", \"Electron Microscopy, Immunological\", \"Electron Microscopy, Transmission\", \"Electrophoretic Mobility Shift Assay\", \"Enhanced Chemioluminescence visualization (ECL)\", \"F-actin depolymerization assay\", \"Flow Cytometry\", \"Fluorescence Microscopy\", \"Fluorescence Microscopy, Confocal\", \"Fluorescence Resonance Energy Transfer\", \"Fluorescence Spectrophotometry\", \"Immunoaffinity Chromatography\", \"Immunoaffinity purification\", \"Immunoblotting\", \"Immunocytochemistry\", \"Immunofluorescence\", \"Immunofluorescence Imaging\", \"Immunohistochemistry\", \"Immunoprecipitation\", \"Imunofluorescence\", \"In vitro actin-bundling assay\", \"In-vivo two photon calcium imaging\", \"LDH Assay\", \"Laser Capture Microdissection\", \"Liquid Chromatography\", \"Mass Spectrometry\", \"Microarray\", \"Microtubule Co-Sedimentation Assay\", \"Microtubule Sedimentation Assay\", \"Microtubule polymerization Assay\", \"Microtubule polzmerization Assay\", \"Microtubule-binding Assay\", \"NBT colorimetric fructosamine assay\", \"NMR Spectroscopy\", \"Non-denaturing Fast Halo Assay\", \"Phosphorylation Assay\", \"Protease-coupled Assay\", \"Pull-down Assay\", \"Pull-down Assay, GFP\", \"Pull-down Assay, GST\", \"Pull-down Assay, His-tagged\", \"Pull-down assay, GST\", \"Pull-down assay, His-tagged\", \"RNA Interference, shRNA\", \"RNA Interference, siRNA\", \"RP HPLC\", \"RT-PCR\", \"SDS-PAGE\", \"Scanning electron microscopy (SEM)\", \"Surface Plasmon Resonance\", \"Tandem Affinity Purification, TAP\", \"Tau aggregation assay\", \"Terminal Continuation RNA Amplification\", \"Thioflavin T Assay\", \"Thioflavin T Fluorescence Assay\", \"Transglutaminase Assay\", \"Transmission electron microscopy (TEM)\", \"Tubulin polymerization assay, light scattering method\", \"Turbidometric Analysis\", \"Ubiquitination Assay\", \"Western Blot\", \"Yeast Two-Hybrid Assay\"], \"MouseStrain\": [\"K3 model with hyperphoshorylated tau resembling FTD\", \"Tau X Drp1+/-\", \"rTg4510\"], \"PublicationType\": [\"Comment\", \"Research\", \"Review\"], \"Research_Model\": [\"5xFAD mice\", \"APP/PS1 x rTg4510 mice\", \"APPPS1 mice\", \"APPswe x P301L transgenic mice\", \"E4FAD mice\", \"HD murine model\", \"K3 model with hyperphoshorylated tau resembling FTD\", \"LRRK2 transgenic mice\", \"P301S mice\", \"PS19 mice\", \"SAMP8 mice\", \"TPR50 mice\", \"Ts65Dn mice\", \"hTau E391 transgenic mice\", \"p25 transgenic mice\", \"pR5 mice\", \"rTg4510 mice\", \"streptozotocin (STZ)-induced DB murine model\"], \"Study_Group\": [\"Han chinese\", \"Korean population\", \"Spanish cohort\", \"Tet-mev-1 mice\"], \"Substrate_Concentration\": [\"0.5 M\"], \"TauIsoform\": [\"Isoform F (441 aa)\"], \"TauIsoformGradient\": [\"3R-High\", \"3R-Low\", \"3R-Medium\", \"3R-Very High\", \"4R-High\", \"4R-Low\", \"4R-Medium\", \"4R-Very High\"], \"Tau_Antibody\": [\"9G3\", \"Anti-pS422\", \"TN1\", \"TOC1\", \"Tau-12\", \"Tau-13\", \"Tau-5\", \"TauC3\", \"pY18\"], \"Tau_Domain\": [\"proline-rich domain\"], \"Tau_Epitope\": [\"AD2\", \"AP422\", \"AT270\", \"AT8\"], \"Tau_Motif\": [\"KXGS\", \"PHF6\"], \"Tau_State\": [\"Paired Helical Filament\"], \"Tau_Structure\": [\"microtubule-binding region\", \"projection domain\"], \"Vmax\": [\"0.8-4 M/min/mg\", \"106 nM/min/mg\", \"140 nM/min/mg\", \"2400 nM/min/mg\", \"59 M\", \"650 nM/min/mg\", \"656 nM/min/mg\", \"80 nM/min/mg\"]}, \"annotation_pattern\": {\"ArticleCompoundNumber\": \".*\", \"Figure\": \".*\", \"MeasurementRangeLower\": \".*\", \"MeasurementRangeUpper\": \".*\", \"MeasurementValue\": \".*\", \"Page\": \".*\", \"Species\": \"^\\\\d+$\"}, \"annotation_url\": {\"Anatomy\": \"https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno\", \"Cell\": \"https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno\", \"CellLine\": \"https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno\", \"CellStructure\": \"https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno\", \"Confidence\": \"https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno\", \"Disease\": \"https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno\", \"Gender\": \"https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno\", \"MeSHAnatomy\": \"https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno\", \"MeSHDisease\": \"https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno\", \"Species\": \"https://arty.scai.fraunhofer.de/artifactory/bel/annotation/species-taxonomy-id/species-taxonomy-id-20170511.belanno\", \"Subgraph\": \"https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno\", \"TextLocation\": \"https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno\"}, \"document_metadata\": {}, \"namespace_pattern\": {\"CL\": \"^\\\\d{7}$\", \"DBSNP\": \"rs[0-9]+\", \"DNSNP\": \"rs[0-9]+\", \"ECCODE\": \"^\\\\d+\\\\.-\\\\.-\\\\.-|\\\\d+\\\\.\\\\d+\\\\.-\\\\.-|\\\\d+\\\\.\\\\d+\\\\.\\\\d+\\\\.-|\\\\d+\\\\.\\\\d+\\\\.\\\\d+\\\\.(n)?\\\\d+$\", \"HBP\": \".*\", \"NCBIGENE\": \"^\\\\d+$\", \"PUBCHEM\": \"^\\\\d+$\", \"TAXONOMY\": \"^\\\\d+$\", \"UNIPROT\": \"^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\\\\.\\\\d+)?$\"}, \"namespace_url\": {\"BRCO\": \"https://arty.scai.fraunhofer.de/artifactory/bel/namespace/brain-region-ontology/brain-region-ontology-1.0.0.belns\", \"CHEBI\": \"https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns\", \"CTO\": \"https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns\", \"DO\": \"https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns\", \"DOID\": \"https://raw.githubusercontent.com/pharmacome/terminology/c0c576e3d3ab9b25a3982251a4ee2fd7c49e1679/external/doid-names.belns\", \"DRUGBANK\": \"https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns\", \"ECCODE\": \"https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns\", \"FB\": \"https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/fb-names.belns\", \"FPLX\": \"https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns\", \"GFAM\": \"https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc.genefamily-names.belns\", \"GO\": \"https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns\", \"HBP\": \"https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/export/hbp-names.belns\", \"HGNC\": \"https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns\", \"HGNCGENEFAMILY\": \"https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns\", \"HP\": \"https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns\", \"INTERPRO\": \"https://arty.scai.fraunhofer.de/artifactory/bel/namespace/interpro/interpro-20170731.belns\", \"MESH\": \"https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/mesh-names.belns\", \"MESHC\": \"https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-chemicals/mesh-chemicals-20170725.belns\", \"MGI\": \"https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mgi-mouse-genes/mgi-mouse-genes-20170725.belns\", \"MIRBASE\": \"https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns\", \"NCBIGENE\": \"https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns\", \"PFAM\": \"https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns\", \"RGD\": \"https://arty.scai.fraunhofer.de/artifactory/bel/namespace/rgd-rat-genes/rgd-rat-genes-20170725.belns\", \"SCOMP\": \"https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns\", \"SFAM\": \"https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns\"}, \"namespaces_uncached\": [], \"pybel_version\": \"0.13.2-dev\"}, \"links\": [{\"annotations\": {\"MeSHAnatomy\": {\"Dopaminergic Neurons\": true}, \"MeSHDisease\": {\"Machado-Joseph Disease\": true}}, \"citation\": {\"authors\": [\"Bezard E\", \"Boland B\", \"Corti O\", \"Duchen MR\", \"Eskelinen EL\", \"Henriques A\", \"Kroemer G\", \"Levine B\", \"Louis C\", \"Mallucci GR\", \"Martin OR\", \"Millan MJ\", \"Mochel F\", \"Mollereau B\", \"Nixon RA\", \"Pastores GM\", \"Rubinsztein DC\", \"Spedding M\", \"Yu WH\"], \"date\": \"2018-09-01\", \"first\": \"Boland B\", \"last\": \"Millan MJ\", \"name\": \"Nature reviews. Drug discovery\", \"pages\": \"660-688\", \"reference\": \"30116051\", \"title\": \"Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \" Moreover, the flavonol fisetin stimulated auto- phagic degradation of phosphorylated tau in cortical neu- rons via mTORC1-dependent activation of TFEB and the cytoprotective transcription factor nuclear factor eryth- roid 2-related factor 2 (NFE2L2) 149 . Fisetin also reduced A accumulation in an APP/PS1 mouse model of AD 150 . \", \"key\": \"5268e3ec3586829fb9039df46379f8180ba35cb3ddc6e4230807c8439be510b1d52cf54bef045036adc902290677c27025a5a7bdd37997015eb9d7f8e4c97dfa\", \"line\": 605, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 95, \"target\": 273}, {\"annotations\": {\"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Bezard E\", \"Boland B\", \"Corti O\", \"Duchen MR\", \"Eskelinen EL\", \"Henriques A\", \"Kroemer G\", \"Levine B\", \"Louis C\", \"Mallucci GR\", \"Martin OR\", \"Millan MJ\", \"Mochel F\", \"Mollereau B\", \"Nixon RA\", \"Pastores GM\", \"Rubinsztein DC\", \"Spedding M\", \"Yu WH\"], \"date\": \"2018-09-01\", \"first\": \"Boland B\", \"last\": \"Millan MJ\", \"name\": \"Nature reviews. Drug discovery\", \"pages\": \"660-688\", \"reference\": \"30116051\", \"title\": \"Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Both aggregates and mutant forms of tau likewise block the proteasome, and its ability to degrade hyper- phosphorylated and oligomeric tau is reduced compared with its ability to degrade physiological tau 3,55,68 . \", \"key\": \"7de75ad13dda764d0d5a719c6a092f9b7dbba1aed0e3c8cd9abfd25582643680c989b463796b3d9721ac3cdd068f0b4df997f94e4f8704647ca4745d4341d8bc\", \"line\": 248, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"decreases\", \"source\": 273, \"target\": 244}, {\"annotations\": {\"MeSHAnatomy\": {\"Dopaminergic Neurons\": true}}, \"citation\": {\"authors\": [\"Bezard E\", \"Boland B\", \"Corti O\", \"Duchen MR\", \"Eskelinen EL\", \"Henriques A\", \"Kroemer G\", \"Levine B\", \"Louis C\", \"Mallucci GR\", \"Martin OR\", \"Millan MJ\", \"Mochel F\", \"Mollereau B\", \"Nixon RA\", \"Pastores GM\", \"Rubinsztein DC\", \"Spedding M\", \"Yu WH\"], \"date\": \"2018-09-01\", \"first\": \"Boland B\", \"last\": \"Millan MJ\", \"name\": \"Nature reviews. Drug discovery\", \"pages\": \"660-688\", \"reference\": \"30116051\", \"title\": \"Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \" Moreover, reductions in levels of hyper phosphorylated tau and A were seen in metformin- treated neurons 117,118 , while it blunted neuronal loss in a neurochemical lesion model of PD in mice 119 .\", \"key\": \"5a13e01891202bdd0b4e60d13a45c0b9f97abb0a984f9b6fb06f7c287f4f0a6814bd6bbba4dc226081965b140fc555119837148215b546f74043b2467934434c\", \"line\": 469, \"relation\": \"decreases\", \"source\": 27, \"target\": 273}, {\"annotations\": {\"MeSHDisease\": {\"Machado-Joseph Disease\": true}}, \"citation\": {\"authors\": [\"Bezard E\", \"Boland B\", \"Corti O\", \"Duchen MR\", \"Eskelinen EL\", \"Henriques A\", \"Kroemer G\", \"Levine B\", \"Louis C\", \"Mallucci GR\", \"Martin OR\", \"Millan MJ\", \"Mochel F\", \"Mollereau B\", \"Nixon RA\", \"Pastores GM\", \"Rubinsztein DC\", \"Spedding M\", \"Yu WH\"], \"date\": \"2018-09-01\", \"first\": \"Boland B\", \"last\": \"Millan MJ\", \"name\": \"Nature reviews. Drug discovery\", \"pages\": \"660-688\", \"reference\": \"30116051\", \"title\": \"Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Cilostazol improved cognition and reduced levels of A42 and hyperphosphorylated tau following intra- cerebroventricular injection of A2535 into mice 162,163 .\", \"key\": \"2529efcb2ffa7879985979f5dd2857fa8ad695c3b63e075df91204794ab7d817dc04ead54b8dd7de805e149e7e286eeb645c74cf982417bb07d7ba47209c0967\", \"line\": 666, \"relation\": \"decreases\", \"source\": 19, \"target\": 273}, {\"citation\": {\"authors\": [\"Bezard E\", \"Boland B\", \"Corti O\", \"Duchen MR\", \"Eskelinen EL\", \"Henriques A\", \"Kroemer G\", \"Levine B\", \"Louis C\", \"Mallucci GR\", \"Martin OR\", \"Millan MJ\", \"Mochel F\", \"Mollereau B\", \"Nixon RA\", \"Pastores GM\", \"Rubinsztein DC\", \"Spedding M\", \"Yu WH\"], \"date\": \"2018-09-01\", \"first\": \"Boland B\", \"last\": \"Millan MJ\", \"name\": \"Nature reviews. Drug discovery\", \"pages\": \"660-688\", \"reference\": \"30116051\", \"title\": \"Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Among compounds that inhibit HSP90, geldanamycin promoted elimination of both hyper- phosphorylated tau and oligomeric -synuclein in cell lines 219,220 . \", \"key\": \"9ee9472e11382f909bfc799ad2b280a417402ca39cc085a1fed6c02042223b7bb85e77e9dfe1b1298f7c7e3793b36094cbedc41001210c4765df551240c5bc06\", \"line\": 806, \"relation\": \"decreases\", \"source\": 23, \"target\": 273}, {\"key\": \"60a27ad8a8e2f13bfdda5943bb300d5632db69e766c7a3fc4020273a3ac8c2c4ac20c6e04c565d2d2cfbc694aaf4651f94a68744c4a34a34b5d81df5e312047f\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 273}, {\"key\": \"9fbd9218812f1cd82827e2d73f3b6af04acbe1f408aaedcdc53c6fc17a36272c67cdcc254874f5473ba4443fa19971fe4877420e735c04f4f7353480d8e1f8b2\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 276}, {\"key\": \"582d8ee5c53b45d6a2eb006248f4abfd047d5a2c188982d1102b792ded738c100ea610bf0ad7804c15218c8ee71318cefb98298f05cca226dcaf5e9a986eb792\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 296}, {\"key\": \"6e80cb7af05a0aeb0fd1a5a6a379c00886c30a49efc737f0bf6b55b65fb80aafe668021c816e60c0df56d3e756d7c04d84e2548a8924b84ab267bda69c09d245\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 268}, {\"key\": \"90b589893ab291da8b432c788632d3df36cb31613b59eb0863f47fc58dc4fdcef450b96b7b20ae514090513ac35ed407e8a88acd562ae5e5aff4ef0c3bbcdf9e\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 277}, {\"key\": \"3b6ffebeddbebde6c3905b01aaa4be230b94b17322cab62b5d8c64683772441e4eab8a1a3bdc3096a7cace38d5c493f74403405c847500990d0def53c38a78bc\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 292}, {\"key\": \"09505215df0db1264915198df6f54ea647eb376b6ede05f22846b2d289a2907fa049769b8eb45a919e706a2eb7c7a96704537753eeb5e7c30a012888cd5296de\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 304}, {\"key\": \"eebcf16f2a72a6dd4dc2a7c998f8e0a493a18d62dcea40fff76725bc76913265752441825f74379919c03aa1d40df1def80b127ebb22b941b78566f341f191cc\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 298}, {\"key\": \"2d72e87620f44a4a0b86095d660d2dc96fe74ddf3f16ed9ece6050eae626ca3156e0b47c861f5cf2bf272e6f4cc907f63116197b4ef6efa6de0fe018fec3a37d\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 310}, {\"key\": \"c28131e97f8ddda4cb5d66338c512fa72d213478d3fb903b8c56be8fa837ddff3d924706e0f313af666e52f58ab0a35cc9e27bbc842535cf78fc089b80c6649f\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 301}, {\"key\": \"c755a243c8801219c163d4e46710afa8d12ffbc4d708fbac3f37c56598da5fa5f16337fac610ba5c73e1d883e815e367b64e8ce3f072c827d2ff5282e9634520\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 279}, {\"key\": \"5d37469120db288dcc4f6126359bfa083679b28c187bb80e803a55fc8fab6b2a5fd1c457e79f42cd634befc78bac7f83195c78c06b90120921bc86ac4863eadf\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 283}, {\"citation\": {\"authors\": [\"Berry RW\", \"Binder LI\", \"Lukas TJ\", \"Reynolds MR\"], \"date\": \"2006-04-04\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"Biochemistry\", \"pages\": \"4314-26\", \"reference\": \"16566606\", \"title\": \"Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.\", \"type\": \"PubMed\", \"volume\": \"45\"}, \"evidence\": \"Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.\", \"key\": \"0bf6e5036e34ee161a440af5b6504e8ce8c3202ea9499db09f08d05043c018e55b7f6206e21ca44597c5993c059ad666f1eb94e0f06c0ae4e54951ef9919718b\", \"line\": 927, \"relation\": \"negativeCorrelation\", \"source\": 244, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 283}, {\"key\": \"a654279531b0ee9071d7de2d8393fe1cb48e67597ed68f21d0e3c502baa4ddf9a05c842c4533c55344b8302b0d80d6f1b548d9fe8199c7fb88326a3b8944cea6\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 248}, {\"key\": \"213a46846a62680cc05d2ed2719a937dff6a8fabf62eab17e78a50282285efef229adb3605d9160e01e020062742249185e5f3756340776a7a7cac3951c27468\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 311}, {\"key\": \"00cd31584fe0407a463b5f7c83f775500283b69e337e4b8aaf94c3c85d86086f3a7bf5dec7d6066c6b3bf85e98504829cabdd93a8fc45aff05a8586d1640e5ba\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 266}, {\"key\": \"233175822018f00d5bba682b71d9619e69b1ffcbc798ef965753963c52979fe53377c90e3fec2a692a31e92e3e0183cf12a6286f7e77474e51b0e10554f3d71b\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 323}, {\"citation\": {\"authors\": [\"Feng Y\", \"Jiang J\", \"Liu XH\", \"Liu ZC\", \"Luo HB\", \"Shu XJ\", \"Wang JZ\", \"Wang XC\", \"Xia YY\", \"Xiong YS\", \"Ye K\", \"Yin G\", \"Yu G\", \"Zeng K\"], \"date\": \"2014-11-18\", \"first\": \"Luo HB\", \"last\": \"Wang JZ\", \"name\": \"Proceedings of the National Academy of Sciences of the United States of America\", \"pages\": \"16586-91\", \"reference\": \"25378699\", \"title\": \"SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination.\", \"type\": \"PubMed\", \"volume\": \"111\"}, \"evidence\": \"Furthermore, the enhanced SUMO-immunoreactivity, costained with the hyperphosphorylated tau, is detected in cerebral cortex of the AD brains, and -amyloid exposure of rat primary hippocampal neurons induces a dose-dependent SUMOylation of the hyperphosphorylated tau. Our findings suggest that tau SUMOylation reciprocally stimulates its phosphorylation and inhibits the ubiquitination-mediated tau degradation, which provides a new insight into the AD-like tau accumulation.\", \"key\": \"bf785e3f7946efe72898b8897c4aac73bddf83f152ae446ae015717ea07c3352a43772c0834f7bbd4fa88104b0af3378a9f67f5292ebbf185a7311fa452320d2\", \"line\": 3487, \"relation\": \"positiveCorrelation\", \"source\": 244, \"subject\": {\"modifier\": \"Degradation\"}, \"target\": 323}, {\"citation\": {\"authors\": [\"Albrecht F\", \"Arendt T\", \"Arsalan-Werner A\", \"Flach K\", \"Goedert M\", \"Herrmann L\", \"Hilbrich I\", \"Holzer M\", \"Ramminger E\"], \"date\": \"2014-09-01\", \"first\": \"Flach K\", \"last\": \"Holzer M\", \"name\": \"Biochimica et biophysica acta\", \"pages\": \"1527-38\", \"reference\": \"24905733\", \"title\": \"Axotrophin/MARCH7 acts as an E3 ubiquitin ligase and ubiquitinates tau protein in vitro impairing microtubule binding.\", \"type\": \"PubMed\", \"volume\": \"1842\"}, \"evidence\": \"We show that axotrophin/MARCH7, a RING-variant domain containing protein with similarity to E3 ubiquitin ligases interacts with tau. We find here that tau becomes mono-ubiquitinated by recombinant tau-interacting RING-variant domain, which diminishes its microtubule-binding. Tau becomes mono-ubiquitinated by recombinant tau-interacting RING-variant domain reducing microtubule-binding.\", \"key\": \"35f6f2fed1297d47f7da5ba8dcf671ed44a3b02cf657de5432b1f5e66df845dfffc0a768b7cd9ecb6c7389c5a03419fb232e2ec9ee03af7d060ba6c17e9f258e\", \"line\": 3513, \"relation\": \"negativeCorrelation\", \"source\": 244, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 323}, {\"key\": \"1db8f17343211693622cb88d2cde2cdb16e928f591973bfefdad7cd961f5833254d55f34dfca66cd04cf34c2ac98ccc894b662b9d10420aa749361cc7d7f8677\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 312}, {\"key\": \"48434f1a0950c1e259ca1d0ee4ba246e9b3b6dc5c83a3b4962e01e09b9ff1e6c32370ffdf1cfa0e0bf13b74ab856463c1753770d6b239fdf8a8457b21ca5e1c3\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 253}, {\"key\": \"12f00e027663d2c3c27b9031ece1b5e2672eea22a2771fe6f90d024f0b58e8431e6a321a3cca2cee2ca3374e7b17a78cac015d0e6952c61f420e98a854681a38\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 275}, {\"key\": \"6f4878c34a13760637b7aecdee2a92b15391a9e5a5973a01ec0e5343ffadeff0507e745fff54c9faa3b156353be93b3ea35d188b12c321e4413d1b29a237c51d\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 308}, {\"key\": \"7e2720882d6fa374e003f55619af6acd72fd0b6b0e056fde3d6279807f12e1a267d65521562730f5dba91f947c117b5e137ea104b51b15316054d30a3af35372\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 294}, {\"key\": \"2714f25fd551cc93a6168f53f7fcf9c2596f16b86ba72d1f433f89c41071dbde24149a95f0bbae9412f913ef2cebc7ae8c3db37e22ff9d9b9e208f1ff4ffa468\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 267}, {\"key\": \"e9376004be7b84bf56f47e4828a8c984e20f8eddac066713a1529dfe57e77179abf2c734918af3b3cdbd08f58710111c218212eca535f3091dba78a4bda76cc7\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 302}, {\"key\": \"20e1ea78e96cb36f525e0e45cc7f5332dd2df238c65814ebddbe5d5cf482816b61a22c5dbadc5bbff243ff55622579401238c919a9fd8686159c4ff68f8f04e4\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 300}, {\"key\": \"b73b43ed20dd33c2dd82cb5765b88c8350e2a19afc2a5e15dbebf79372f29ddcdb78185e07e9938834f7a2c0fa71e838dd80671eedab018fdfe9a26de8b39cd1\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 274}, {\"key\": \"2be8b79a7687f6209f8a3996bf3f698c639a499ff5e227afee9e9f9987bafb00cc5154c7a7a2da064d8a188f3f25517f9da525a27b8450692a8f015d3ccb69cf\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 325}, {\"key\": \"758dd3f9f47d2ab5dd8538f81b0176cdeebcd1457b9595df319a2eae964617033716ca7e93bd32bda8d8f5ede1e80bd525915e1fff2980ba8d6b0a7ab6e7dfb4\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 309}, {\"key\": \"3b9e3f081f70520f7fee006195f47374179be17956f2556b8b53d1897f525c60f9a0cdbcd4d76d35a30621e3a42fd0ca22089d216824305ee9bf52b7334ee0cb\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 324}, {\"key\": \"6837e9f753c8a9a6822155b2aab76c6bfa02af33060602567cf2aa84fb01af8eac3205af72c3931778468d5cdbda3073392fef579d33fb0c67e535fd6a025faf\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 316}, {\"key\": \"90a6c378f94c9844416d6ad3e3627b3b08caf39e72519388ff95370e106cb9cde183b066c4e1d208031608c195fa64b4f09eceab6692f45950cbc0a3d5615e30\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 270}, {\"key\": \"43f3a05a562aea7d640aaac845125159fcfbdd06303b001b5cf1eec04af58dabda000353c3cf4551bae1aea91c8b1be6e3f2669e44287e4a25d0655b1d33aab4\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 315}, {\"annotations\": {\"Method\": {\"ELISA\": true, \"Immunocytochemistry\": true, \"Microtubule-binding Assay\": true, \"Pull-down Assay, GST\": true, \"Pull-down Assay, His-tagged\": true}}, \"citation\": {\"authors\": [\"Davies P\", \"Lu KP\", \"Lu PJ\", \"Wulf G\", \"Zhou XZ\"], \"date\": \"1999-06-24\", \"first\": \"Lu PJ\", \"last\": \"Lu KP\", \"name\": \"Nature\", \"pages\": \"784-8\", \"reference\": \"10391244\", \"title\": \"The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein.\", \"type\": \"PubMed\", \"volume\": \"399\"}, \"evidence\": \"To examine whether Pin1 affects the ability of pTau to bind microtubules, we generated pTau in vitro using purified Cdc2 (refs 17, 18), and determined its ability to bind Taxol-stabilized microtubules with or without Pin1. Although Cdc2 phosphorylation disrupted the ability of tau to bind microtubules; the binding was fully restored by preincubation with Pin1 (Fig. 5a). Furthermore, Pin1 was detected in the fraction of tau-bound microtubules (Fig. 5a). However, no Pin1 was detected in the microtubule fraction if pTau was not added (Fig. 5a), indicating that Pin1 does not bind microtubules directly. Thus, Pin1 binds pTau and restores its ability to bind microtubules.\", \"key\": \"a51a3166dae2e16694ae0594ccde7e823e13988ceab561642f6f81dbe77f9aa71f0794fd7ca258dd3e13dbffc10eee6225a2ed588fd23eaca7f37c266d10133a\", \"line\": 530, \"relation\": \"negativeCorrelation\", \"source\": 244, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 315}, {\"key\": \"0d694edef5a43e0242a38b64a47d77c72e2440986dadfa23882fab98821d3dcde3cf57689f20f472342626a733d0e8fb9ed38aa20ae300bed5e01cf6dd3bbd23\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 314}, {\"key\": \"69c01b0d6c247180799c5c9e06f248562b622a3bfef9d7718216b5084448efcdd928b55e823d5a1d86350962633367c3818de3ca83844d5a405a6e9e9c165590\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 255}, {\"key\": \"6a1d02ff262a505b4bd9395492c734f23e9b0b1431c0fa30a1eb886ecd32e77d6ca2271905db5f2e92bc53bd1e851ba4e6f903f9b26832caced4d5dc492ca7d3\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 278}, {\"key\": \"95c5dd8b94bb7d99770ceb32f637aa8bb1a23274675e1d4bfb7c8312569c0669e5978b90e21ec5ff71ac056579588f2a0f26135e2660a9e1e8a4f0b032a309c6\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 320}, {\"key\": \"750543557afa0a8d9a8c5ef96edc68b2be7a6ae2f8844ceaabe008f8cca224278a1ed18999a6e5f2a25e9f7abbbf08aeab8de80d2988dd6c8b424ff23221051a\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 282}, {\"citation\": {\"authors\": [\"Berry RW\", \"Binder LI\", \"Lukas TJ\", \"Reynolds MR\"], \"date\": \"2006-04-04\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"Biochemistry\", \"pages\": \"4314-26\", \"reference\": \"16566606\", \"title\": \"Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.\", \"type\": \"PubMed\", \"volume\": \"45\"}, \"evidence\": \"Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.\", \"key\": \"c53edab48408b91c7c36f9272963fdd74c860172867907a70da0545dd110aa358400a17652dd6d6bd2ed615131592a6d205fefdb713e8e448cd14d63ded81edd\", \"line\": 925, \"relation\": \"negativeCorrelation\", \"source\": 244, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 282}, {\"key\": \"5dfb58d8aaec19dca766f910c5daa3183e4e9eada1060622d91815a34356c7e7c82c726922e016bfea5b95401a58e39fdb92eeec41d0717970c206adc5276ab5\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 313}, {\"key\": \"9cfb692e3b39903e05776d10e5ec184405b65b7ee2afbee7a958ac60be2e0a8de0d684efe5a7fcc4198d4d76591b906798952e7cda8584eb982d9758803184ed\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 318}, {\"key\": \"f807efa795193e2277fd27d6898fdd78cf1f8f4bf17beb00dd53697b6493f47fbbf864410c18e80a6c51351f44199fc0b1158773ab29ebc889da9b6ad7d37db9\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 258}, {\"key\": \"a589c91b7da07245f713a8f9a53701e0008f348024f3b4d7269a3669aa6d8aed7ae4b796af132d744cc9019d6ca8a5fbbe1efad97628a39edf287178d99d12f6\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 299}, {\"key\": \"3dd217dbf24e05387967c81e77bc580eae4bb79dbbaa0ec812338e6abafcc6f5c8365a7efe2732b7e571e9e3cec08e53f75be35fb922dff737ec143c8103218b\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 289}, {\"key\": \"b5a7580436fab73483c3bf632d8d96c31184a0db526b830295612a8803372d4a10f1dcb86deb274827053122aeb2c70c8301b931ee0b11eabe854e38f9a29917\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 319}, {\"key\": \"c4e71f1866eab20795e7e1d4b54fe09effb8b376e41712f8a130fe5192e07d83b0749cc2e2297b62cbea4bb7b1033909ea6d6423fa06166cb07543cee4249d48\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 286}, {\"annotations\": {\"MeSHAnatomy\": {\"Post-Synaptic Density\": true}, \"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Arnal I\", \"Borel E\", \"Buisson A\", \"De Seranno S\", \"Elie A\", \"Frandemiche ML\", \"Lant F\", \"Rush T\"], \"date\": \"2014-04-23\", \"first\": \"Frandemiche ML\", \"last\": \"Buisson A\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"6084-97\", \"reference\": \"24760868\", \"title\": \"Activity-dependent tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"34\"}, \"evidence\": \"Conversely, only Abetao exposure promoted significant tau phosphorylation on Ser 404 (**p\\u00050.05, 1-way ANOVA; control 15.67\\u00042.418 vs Abetao 32.65 \\u0004 3.76 vs Bic/4-AP 26.75 \\u0004 1.17 vs Abetao         Bic/4-AP 24.97 \\u0004 4.48, N \\u0003 4). These results revealed that, although synaptic activation or Abetao promote tau translocation to PSD fractions, the synaptic tau displays a different phosphorylation profile that may be responsible for the conditional tau properties observed.\", \"key\": \"b8cf1016e59560c3968abda5ed2e32e30ea51db209cabf7b3a35a45a3a91db66e84797e3d6e26118a2a4cd6c82b429a27b1ad2a2ef2011d5478eeec37e6a48f3\", \"line\": 308, \"relation\": \"association\", \"source\": 244, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 286}, {\"key\": \"481cd63ca4930ecfe5c4e431566dc145030aa1941e132a2ad2fd08f815e25fbb138e10c64f6ecaa549df0147f863989105960777e3de08c419f54e26e5864b95\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 322}, {\"key\": \"2e9afa0e3f757ad3ec552d58b35161aa2aad8333c51f883b7fd085fe870898715e075b936ff8e3e2a2ecda3313386ea8f6113a424e64061fa6a19fd80f130eee\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 265}, {\"key\": \"4737e895104c68da1ac7227e4da9508ccdf1da28dc5cdde6abc32fa233eec1913b232c6f55aa102cba382f6048b0649ff9b8440bcebf87574e5453fba5b17af8\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 259}, {\"key\": \"57f6dfc4cb18d002fb185a5f8ddb26897f5c0e93f59d9f1ee55374a026a04da6c975e40dd70e3f890ef9f9793c8b77bf916ea47533ecfee045a95797915ad8ba\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 290}, {\"key\": \"7391a54abfd55423811d434067fd745d72a2f722a56868eb1338cef88c90901f5a8111168581998fd4707fbea406351a9877b6c8483e9ddd61218759c52b2080\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 293}, {\"key\": \"0efa2343a1aab409feeae95a44c4251f713383a6e606f151efb4055e8f77a89d772738244ac3792bc5938f0fe885967c3489d8612cccddfd37a4a5dd7ed7c968\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 305}, {\"key\": \"3ac854b76cef562012fc8b8acf211e20a7996539c45ae26ba2f1a8adcba17ef368f29c86e0ece2ec0d3fc5fff87223d3465d2117bc63b39f22fcdf77926fac20\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 281}, {\"citation\": {\"authors\": [\"Berry RW\", \"Binder LI\", \"Lukas TJ\", \"Reynolds MR\"], \"date\": \"2006-04-04\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"Biochemistry\", \"pages\": \"4314-26\", \"reference\": \"16566606\", \"title\": \"Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.\", \"type\": \"PubMed\", \"volume\": \"45\"}, \"evidence\": \"Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.\", \"key\": \"c066880dac41f2a7934e6ba02312e1c8d2ad7fc58f34012076a094e8ca0c343e2296d81f70a294ab2d9870de42f40209127299ec13fba63e4320e8847662b136\", \"line\": 926, \"relation\": \"negativeCorrelation\", \"source\": 244, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 281}, {\"key\": \"1ea70b1fdc71c02106277625f2caa4a966e913c03fe8ad751981023e6b74cc994370be7baa25ecf05138e10d08c4f2af7320c3a733cae82b6b055734105d1821\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 303}, {\"key\": \"4ad669bbcd5d29a1650f1634886e69b8c1fa857c0a72d465bc712942048467be30356193c3ec80f5f5448507c2fad01b5d17af2bdde88f7e6fb97023911e029d\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 280}, {\"citation\": {\"authors\": [\"Berry RW\", \"Binder LI\", \"Lukas TJ\", \"Reynolds MR\"], \"date\": \"2006-04-04\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"Biochemistry\", \"pages\": \"4314-26\", \"reference\": \"16566606\", \"title\": \"Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.\", \"type\": \"PubMed\", \"volume\": \"45\"}, \"evidence\": \"Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.\", \"key\": \"a81d36c47da39a19a02e1af8462b1417a98d31d992fd908d625f9e5db7f5f7060580994cdc55e36349bcfcb9ea1d62d0096738fd025f69769c4476a1013a0851\", \"line\": 924, \"relation\": \"negativeCorrelation\", \"source\": 244, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 280}, {\"key\": \"e1055b2103f62666e9b9901d8de09cd00e41082aa4331fa9691c178b132fd642566afd9cd6f698ea101b53fd24f588969e613aa3baf2c6cf52dead3fbdda1d2d\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 254}, {\"key\": \"1631b68679802335af5ff80fe434043dfaf84a54c8fd6d5f4e8025cff98c232f694b486c452a1c033e6638fc5cbc258e8b76477f903d862587dfe4da3cf06896\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 247}, {\"key\": \"90f955cdf4e52ade389e8e80c810d7959b0792ad78f8a86eaa0083bda9938d1d2db7bd4c0dbcf878a564b623a955468f922ba3315a7cf693d58a9889670c6686\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 249}, {\"key\": \"f331474061d8420a9d0b22a9a209adeca0b96c80867792cb1c63830cc912c379a03f93fa521f0b83be162a4d1dd520b68c8d8819746325caef389ec2dccb2f34\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 321}, {\"key\": \"078c742698d53179d7016109c55d53d4e7dd9a366bcc900f91a381ed967651bbd76a8e08adb07a81f4252889b5b440ab9f2ccfecc0a7d93a218c4e2d6cc38077\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 261}, {\"key\": \"8fa4b56112f5e7dda49e8717fd7d14532c9d727b48e3e38b961d647d0b12c64a107f38d078c6d16acdc829d6394ad597d560257a8d9d5031e8a611f61be8ce10\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 250}, {\"key\": \"2036677a22f0540542c4293a42a992b1e06ca924d454dd87915e5d8e632c722212a41aa40426c7ca2da41be9bb17b8bf97befdf3470d177bef3e5e559ad08eea\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 251}, {\"key\": \"79cc3a5bf744bfb5eed35e094825c131342fe825bec9ce844c021b95a862cb9ac19f33787997f01a3caeeeb5ec72a2a3b8c0b6a98517c59ed43010d75b49b670\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 257}, {\"key\": \"50403cc7ef5ce4172930d644a5740cda8918061439e7d529c0f888ba1b049a77a5339ec7d3482657b832429d9e62714c7fafa0d13366824ad8debfc61eaefc20\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 306}, {\"key\": \"d8f5dbe27e2f901b00245591d8c644f36471e040fe61f154b667ec94a3b2a34a2eaeae82e26aa5c4d8486adc484bf9af398389a6762c8bb8b2787f1417f6366f\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 269}, {\"key\": \"8d6bf5089dd5843561afd9eb68f1d01f3e6bffe12e4edcfc4c3991b9a862612ca3ce419a5d8074a59bfa9a5e495eb82808b10154cae9a3ef1de7ae4404e96e6a\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 288}, {\"key\": \"4bd03865d374824d2c1f09c2c012d0221b222d9c1898e93390a95ce833f14388df6827ccfd76f42001eaa49ca0a99d5fb0399f6dda67d786dfe4b54064a144c0\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 291}, {\"key\": \"3a92d83cf4f01b5d9f4ae62a3edc3e4a042a47a573fa4b50cb6d784ff585d49dd9aeaba4095ff2e3f02430ffaf3ac3aa1ed0dfe5af3a57a673725f8886e4a800\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 295}, {\"key\": \"46943c887dd9e811ba4a4c9852441f23a0122626a7519ad57c4a9d1d86cbabdd28a41ba3af57bc4bbb0b49320173ede3d68f56edc739e7d10aec21ceb16bfbc9\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 260}, {\"key\": \"7c4dab41f0b789fe1a52f61758835723c3b320276f1f4dd19c15f5910c60497a112c4ec2b291ad3da3ffec9bbc530290dd67b167ac4d3ad55e2338982297e705\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 297}, {\"key\": \"1fa9714bfe01a17bd6ebb45683cb13f63610cbf173da4e9f09f28f4a4726128b3c709fcbf20996f2fceb16912480f6ae969dd45c8cb3b1cff2b468fc0381284d\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 271}, {\"key\": \"dfded498586f38542541f89e06c18c50aab599965f7f620a1c6d9d19302b9c11441341cdab191241e1be1d568da795d62cad7fbaaf7b62035feaa1471e21fd0f\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 287}, {\"key\": \"36fef62fb5d29c3680a68524509dd14eb61bbb96d51f4fe5dce8c6d8f4f72eace27b743373c84c5caa6d7797f8eb0e76ff241757244ba87a4605a464ca7b9f0c\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 317}, {\"key\": \"37cf4d588383f071abc8ef3979f4e295bcf1299649d88e7b621d291558a7fa846dcaed10c39addc92b0061588f36a5453e3d3333a0d01cd57b314fb29eb469c2\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 246}, {\"key\": \"3102342f91f0888797568c603e6b58356f87b8b2977787095327eeedc4f9f1ec8b15f59b277a90bc2929127856303b9189985c88371094fc75ededb943df392f\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 256}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Notably, tau has intrinsic acetyltransferase activity and so can catalyse auto-acetylation at certain Lys sites, including Lys280\", \"key\": \"69500bf06fdc509f87cdfdb90c0e70d15458305c725074a4320af5536f82a164ea1fbc4e4580b8da87dfae363f913e4c316ec9aa7d24fea2f6888e98ea6bf623\", \"line\": 258, \"relation\": \"directlyIncreases\", \"source\": 244, \"target\": 256}, {\"key\": \"f277e5a8684b70395a690e1e32db41f7b2e60e13cb883fa133b68e7055583c1016f7e7b4895b59d57c1c02775719968036427a8593f25a41e831de8f928df09c\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 262}, {\"key\": \"b30e07545cadedd019962e98505f37579c951a63724c05c1355db47823fa8f034428326271a189d53d8cef0537bd22bd9c41fafddded82ec8e9c7c308b728b29\", \"relation\": \"hasVariant\", \"source\": 244, \"target\": 307}, {\"annotations\": {\"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Hyman BT\", \"Kay KR\", \"Mandelkow EM\", \"Polydoro M\", \"Saidi LJ\", \"Sanchez L\", \"Spires-Jones TL\"], \"date\": \"2015-01-01\", \"first\": \"Saidi LJ\", \"last\": \"Spires-Jones TL\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"937-47\", \"reference\": \"25374103\", \"title\": \"Carboxy terminus heat shock protein 70 interacting protein reduces tau-associated degenerative changes.\", \"type\": \"PubMed\", \"volume\": \"44\"}, \"evidence\": \"In the pathological case of Alzheimers disease (AD) tau becomes hyperphosphorylated, detaches from the microtubules, misfolds, and mislocalizes to the somatodendritic compartment where it aggregates into neurofibrillary tangles.\", \"key\": \"03d98f6eaa262f097c922c919b9ba74584210cc6b5f352831b85b5648dabbc81481bd5d7065fb74e7186da4b61fd5e058aec9a2437632c11eb9174a10b1e5905\", \"line\": 93, \"object\": {\"effect\": {\"fromLoc\": {\"name\": \"axon\", \"namespace\": \"GO\"}, \"toLoc\": {\"name\": \"somatodendritic compartment\", \"namespace\": \"GO\"}}, \"modifier\": \"Translocation\"}, \"relation\": \"increases\", \"source\": 276, \"target\": 276}, {\"citation\": {\"authors\": [\"Nordberg A\"], \"date\": \"2001-02-01\", \"first\": \"Nordberg A\", \"last\": \"Nordberg A\", \"name\": \"Biological psychiatry\", \"pages\": \"200-10\", \"reference\": \"11230871\", \"title\": \"Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications.\", \"type\": \"PubMed\", \"volume\": \"49\"}, \"evidence\": \"Possible factors such as amyloid peptide accumulation, hyperphosphorylation of tau protein, oxidative stress, and modification of cell membrane during the development of AD may be related to decreased protein levels of nAChRs (Farooqui et al 1995; Smith et al 1996)\", \"key\": \"01987dded7d57a741eab1af2297f10d9a0dc569ae4276e55bf818e9eb9bc85e5284c1e15b795caeda517c6ce4705a9ea2c53527e9e4bc7fb8c5cda678d270bfa\", \"line\": 245, \"relation\": \"negativeCorrelation\", \"source\": 276, \"target\": 156}, {\"annotations\": {\"MeSHAnatomy\": {\"Brain\": true}, \"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Shi Y\"], \"date\": \"2009-02-01\", \"first\": \"Shi Y\", \"last\": \"Shi Y\", \"name\": \"Science in China. Series C, Life sciences\", \"pages\": \"135-46\", \"reference\": \"19277525\", \"title\": \"Assembly and structure of protein phosphatase 2A.\", \"type\": \"PubMed\", \"volume\": \"52\"}, \"evidence\": \"Upon hyperphosphorylation, the protein Tau has a strong tendency to polymerize into neurofibrillary tangles in the brain, a hallmark of Alzheimers disease\", \"key\": \"17dee52e046e0a446da3fa75956afcf7514f36931350ee49bb5dbf4f768aecac5d7425cc96c2f830b123827b5b1315fb66c9e924ba17fb58fcebab6ef1f71de1\", \"line\": 226, \"relation\": \"increases\", \"source\": 276, \"target\": 35}, {\"citation\": {\"authors\": [\"Ihara Y\", \"Morishima-Kawashima M\", \"Nixon R\"], \"date\": \"2012-08-01\", \"first\": \"Ihara Y\", \"last\": \"Nixon R\", \"name\": \"Cold Spring Harbor perspectives in medicine\", \"reference\": \"22908190\", \"title\": \"The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"2\"}, \"evidence\": \"Neurofibrillary tangles composed of tau proteins in a hyperphosphorylated state are rarely observed in abundance except in AD and a limited number of aging-related tauopathies.\", \"key\": \"e40a29ce15d6465f3b85296986d09aa4f80194b418d9472e187c0bbccf7b3ede150369b1c26d45870588d11fdbb52db3297b496cb81c2f3fa7778bb6bb8c40a3\", \"line\": 835, \"relation\": \"association\", \"source\": 276, \"target\": 35}, {\"citation\": {\"authors\": [\"Ferrer I\", \"Torrent L\"], \"date\": \"2012-02-01\", \"first\": \"Torrent L\", \"last\": \"Ferrer I\", \"name\": \"Current Alzheimer research\", \"pages\": \"248-56\", \"reference\": \"22299660\", \"title\": \"PP2A and Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"9\"}, \"evidence\": \"The excessive accumulation of phosphate groups in tau is associated with its altered capacity in promoting microtubule assembly  and  stability  [4-6].\", \"key\": \"1c5e8fd5f7e77ac23c50264676b2c7d6ad47c97f0df2662542f36fcb17736131738fb7808ae37b865783cc34214bd5fb6f8bcd6bcc628b92f7d940528d4a9606\", \"line\": 79, \"relation\": \"decreases\", \"source\": 276, \"target\": 85}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Hyperphosphorylation of tau at the repeat domain reduces its microtubule binding, which may cause microtubule disassembly, leading to axonal transport deficits.\", \"key\": \"0c290c2c85ecc73d14d9c353630f3409e80d05b473bb42701020fde450594d0048ead01fefde38ccacef81be14f322dbc57fccc22fb67cd2d34aa9e284e93c7b\", \"line\": 673, \"relation\": \"decreases\", \"source\": 276, \"target\": 85}, {\"annotations\": {\"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Ferrer I\", \"Torrent L\"], \"date\": \"2012-02-01\", \"first\": \"Torrent L\", \"last\": \"Ferrer I\", \"name\": \"Current Alzheimer research\", \"pages\": \"248-56\", \"reference\": \"22299660\", \"title\": \"PP2A and Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"9\"}, \"evidence\": \" Studies  in  transgenic  mice  and  in  cell  cultures  have shown a connection between PP2A loss of function and tau hyper-phosphorylation  and  aggregation  into  PHF. \", \"key\": \"2c8e357e2101192d1cdef7e8ddb62429b4d5aa202247e8accd036998307648e9022721e4dc63e7e0fb576a4de0ec52ec7a11053b61279080d060023cca4ee320\", \"line\": 113, \"object\": {\"modifier\": \"Activity\"}, \"relation\": \"negativeCorrelation\", \"source\": 276, \"target\": 167}, {\"citation\": {\"authors\": [\"Chung KM\", \"Hernndez N\", \"Sproul AA\", \"Yu WH\"], \"date\": \"2018-05-18\", \"first\": \"Chung KM\", \"last\": \"Yu WH\", \"name\": \"Neuroscience letters\", \"reference\": \"29758300\", \"title\": \"Alzheimer's disease and the autophagic-lysosomal system.\", \"type\": \"PubMed\"}, \"evidence\": \"However, when tau becomes hyperphosphorylated, it detaches from microtubules and aggregates, resulting in depolymerization of microtubules and formation of insoluble tau deposits [40]\", \"key\": \"d427151c592ea715a42f3d4ebba5043d9b2df16fcebc296ddd2d55c67acd1e5ff73d9816b0193f8bcea0df3a7a8621898cd71b272b2a76b11ccf1372aee1bc57\", \"line\": 270, \"relation\": \"decreases\", \"source\": 276, \"target\": 111}, {\"annotations\": {\"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Hyman BT\", \"Kay KR\", \"Mandelkow EM\", \"Polydoro M\", \"Saidi LJ\", \"Sanchez L\", \"Spires-Jones TL\"], \"date\": \"2015-01-01\", \"first\": \"Saidi LJ\", \"last\": \"Spires-Jones TL\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"937-47\", \"reference\": \"25374103\", \"title\": \"Carboxy terminus heat shock protein 70 interacting protein reduces tau-associated degenerative changes.\", \"type\": \"PubMed\", \"volume\": \"44\"}, \"evidence\": \"In the pathological case of Alzheimers disease (AD) tau becomes hyperphosphorylated, detaches from the microtubules, misfolds, and mislocalizes to the somatodendritic compartment where it aggregates into neurofibrillary tangles.\", \"key\": \"e4b9b3ae944134405756362c502173be1037e0b7895fdfd5078cae4233a06a035587b3e63d183f39ba9505ccf04f697c7c0964ae1037c06e4d1c73ac228ddad5\", \"line\": 91, \"relation\": \"decreases\", \"source\": 276, \"target\": 111}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Hyperphosphorylation of tau at the repeat domain reduces its microtubule binding, which may cause microtubule disassembly, leading to axonal transport deficits.\", \"key\": \"693dcd9b83a9f0c159c125089b1c07f490dc57de75414e982b8df1f4b52410af81fc99d7efbce9b6befd771816dd61a74b2a3a4c6bbed4a33771baa14b8e9ab4\", \"line\": 671, \"relation\": \"decreases\", \"source\": 276, \"target\": 111}, {\"citation\": {\"authors\": [\"Chung KM\", \"Hernndez N\", \"Sproul AA\", \"Yu WH\"], \"date\": \"2018-05-18\", \"first\": \"Chung KM\", \"last\": \"Yu WH\", \"name\": \"Neuroscience letters\", \"reference\": \"29758300\", \"title\": \"Alzheimer's disease and the autophagic-lysosomal system.\", \"type\": \"PubMed\"}, \"evidence\": \"However, when tau becomes hyperphosphorylated, it detaches from microtubules and aggregates, resulting in depolymerization of microtubules and formation of insoluble tau deposits [40]\", \"key\": \"beb701b5f96be48171628e453bfa1ff75e09224e7f4384c7c6f132ef2806fdea029c915a71cc6079b6e8f714d63ed709d1d68b8b9973e56a9171a3900812559f\", \"line\": 271, \"relation\": \"increases\", \"source\": 276, \"target\": 39}, {\"citation\": {\"authors\": [\"Dickey CA\", \"Gestwicki JE\", \"Kiray J\", \"Koren J\", \"Miyata Y\"], \"date\": \"2011-09-01\", \"first\": \"Miyata Y\", \"last\": \"Gestwicki JE\", \"name\": \"Future medicinal chemistry\", \"pages\": \"1523-37\", \"reference\": \"21882945\", \"title\": \"Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.\", \"type\": \"PubMed\", \"volume\": \"3\"}, \"evidence\": \"However, hyperphosphorylated forms of tau are more prone to aggregate, which might decrease their solubility and remove them from normal cycling\", \"key\": \"820bfdd1cc59643f0813c418fee764c496f60bd165b4a3e973d52bd7f0ed91f5d398319f51fa6d50f20c94479cb43bbdf4773d9149266b6d0301c7ba80d54bbc\", \"line\": 118, \"relation\": \"increases\", \"source\": 276, \"target\": 39}, {\"annotations\": {\"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Hyman BT\", \"Kay KR\", \"Mandelkow EM\", \"Polydoro M\", \"Saidi LJ\", \"Sanchez L\", \"Spires-Jones TL\"], \"date\": \"2015-01-01\", \"first\": \"Saidi LJ\", \"last\": \"Spires-Jones TL\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"937-47\", \"reference\": \"25374103\", \"title\": \"Carboxy terminus heat shock protein 70 interacting protein reduces tau-associated degenerative changes.\", \"type\": \"PubMed\", \"volume\": \"44\"}, \"evidence\": \"In the pathological case of Alzheimers disease (AD) tau becomes hyperphosphorylated, detaches from the microtubules, misfolds, and mislocalizes to the somatodendritic compartment where it aggregates into neurofibrillary tangles.\", \"key\": \"f1e942b3b00c44d87f70718873602c41beb0722611baa34d44ec990b550b9a69ac6622c7f7c2d598d018643ddf3f3acdcf6edd0da798db28bccee1ca7ebe94d4\", \"line\": 94, \"relation\": \"increases\", \"source\": 276, \"subject\": {\"effect\": {\"fromLoc\": {\"name\": \"axon\", \"namespace\": \"GO\"}, \"toLoc\": {\"name\": \"somatodendritic compartment\", \"namespace\": \"GO\"}}, \"modifier\": \"Translocation\"}, \"target\": 39}, {\"annotations\": {\"MeSHAnatomy\": {\"Hippocampus\": true}}, \"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Mouzon B\", \"Mullan M\", \"Paris D\", \"Schweig JE\", \"Yao H\"], \"date\": \"2017-09-06\", \"first\": \"Schweig JE\", \"last\": \"Paris D\", \"name\": \"Acta neuropathologica communications\", \"pages\": \"69\", \"reference\": \"28877763\", \"title\": \"Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \"Abnormal Syk activation seems to fol- low tau hyperphosphorylation (S202) in the hippocampus of Tg P301S mice (Fig. 6), as well as the formation of MC1-tau pathological conformers (data not shown here but MC1 and pSyk colocalization were quantified below).\", \"key\": \"41b88ac3a123e22275f2ea85ae75720b7915c74e96f159b37135532988480483ad08968e56dce3c1ad307fa900ed03962d7786f6fd4ed1a57a193fc5e1c191a5\", \"line\": 178, \"relation\": \"association\", \"source\": 276, \"target\": 39}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Notably, as aggregated tau in patients with a tauopathy or in transgenic mice invariably show hyperphosphorylation, and tau hyperphosphorylation precedes aggregation, phosphorylation has been assumed to drive tau aggregation\", \"key\": \"59eebbc15d71698bdae66816473847f6790d4e737cc8dfc0c74bd534e4d8b95e345e09e79460fb3af258614ebb20a38ed6f39eddecaeb9d045a45534c2d2b02e\", \"line\": 599, \"relation\": \"increases\", \"source\": 276, \"target\": 39}, {\"citation\": {\"authors\": [\"Chung KM\", \"Hernndez N\", \"Sproul AA\", \"Yu WH\"], \"date\": \"2018-05-18\", \"first\": \"Chung KM\", \"last\": \"Yu WH\", \"name\": \"Neuroscience letters\", \"reference\": \"29758300\", \"title\": \"Alzheimer's disease and the autophagic-lysosomal system.\", \"type\": \"PubMed\"}, \"evidence\": \"However, when tau becomes hyperphosphorylated, it detaches from microtubules and aggregates, resulting in depolymerization of microtubules and formation of insoluble tau deposits [40]\", \"key\": \"ca7c775d4420749bf49e6894ba99d8253df2a772d49ae86beb7f99c64a8b8823fc81dd5d3c5d112ef8df4a9245b4759567d684367cfde59da5ea09df79084396\", \"line\": 272, \"relation\": \"increases\", \"source\": 276, \"target\": 84}, {\"annotations\": {\"Species\": {\"6239\": true}}, \"citation\": {\"authors\": [\"Baumeister R\", \"Biernat J\", \"Fatouros C\", \"Koushika SP\", \"Mandelkow E\", \"Mandelkow EM\", \"Pir GJ\", \"Schmidt E\"], \"date\": \"2012-08-15\", \"first\": \"Fatouros C\", \"last\": \"Baumeister R\", \"name\": \"Human molecular genetics\", \"pages\": \"3587-603\", \"reference\": \"22611162\", \"title\": \"Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"Aberrant phosphorylation and aggregation of Tau have been linked to axonal transport problems, synaptic malfunction and degeneration (6).\", \"key\": \"13fb8317c329a40e4eaec53d7af538653bbdb0a6f11527486da6271f0f8f052c18211fcad94da416510b2ea982891a21a2450b09f52656ac291439fb897cb2c4\", \"line\": 154, \"relation\": \"decreases\", \"source\": 276, \"target\": 79}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Hyperphosphorylation of tau at the repeat domain reduces its microtubule binding, which may cause microtubule disassembly, leading to axonal transport deficits.\", \"key\": \"2f69768f956518a1a4ded49930a6315011fb696b0e74e793f06ec537688f776c0e4f20b1597fbfa7b0806362e77bd01da6f28bf4959605be69227f3b0a3e3ad6\", \"line\": 672, \"relation\": \"decreases\", \"source\": 276, \"target\": 79}, {\"annotations\": {\"Species\": {\"6239\": true}}, \"citation\": {\"authors\": [\"Baumeister R\", \"Biernat J\", \"Fatouros C\", \"Koushika SP\", \"Mandelkow E\", \"Mandelkow EM\", \"Pir GJ\", \"Schmidt E\"], \"date\": \"2012-08-15\", \"first\": \"Fatouros C\", \"last\": \"Baumeister R\", \"name\": \"Human molecular genetics\", \"pages\": \"3587-603\", \"reference\": \"22611162\", \"title\": \"Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"Aberrant phosphorylation and aggregation of Tau have been linked to axonal transport problems, synaptic malfunction and degeneration (6).\", \"key\": \"10cd713ef8c0e6589af52ba9229d6e4514b39cde99c8cfab74450c9d028e60178a825974831aa74c61e49d6c22a886d84bbc0e120e0c6fe245b9948c5d04c296\", \"line\": 155, \"relation\": \"decreases\", \"source\": 276, \"target\": 91}, {\"annotations\": {\"Species\": {\"6239\": true}}, \"citation\": {\"authors\": [\"Baumeister R\", \"Biernat J\", \"Fatouros C\", \"Koushika SP\", \"Mandelkow E\", \"Mandelkow EM\", \"Pir GJ\", \"Schmidt E\"], \"date\": \"2012-08-15\", \"first\": \"Fatouros C\", \"last\": \"Baumeister R\", \"name\": \"Human molecular genetics\", \"pages\": \"3587-603\", \"reference\": \"22611162\", \"title\": \"Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"Aberrant phosphorylation and aggregation of Tau have been linked to axonal transport problems, synaptic malfunction and degeneration (6).\", \"key\": \"70eec88a2b856bd8434d305fe79bc125ffc7238513af6030e400c16c195bf7adefc9e9a1ffdffd3e156e6c591a4df8c7614cad0007e44af73c9fba979638bade\", \"line\": 156, \"relation\": \"decreases\", \"source\": 276, \"target\": 83}, {\"annotations\": {\"Confidence\": {\"High\": true}, \"MeSHAnatomy\": {\"Brain\": true}}, \"citation\": {\"authors\": [\"Carlson GA\", \"Cho H\", \"Commins C\", \"Costantino I\", \"DeVos SL\", \"Frosch MP\", \"Hyman BT\", \"Irimia D\", \"Mller DJ\", \"Nicholls SB\", \"Nobuhara CK\", \"Pitstick R\", \"Roe AD\", \"Takeda S\", \"Wegmann S\"], \"date\": \"2015-10-13\", \"first\": \"Takeda S\", \"last\": \"Hyman BT\", \"name\": \"Nature communications\", \"pages\": \"8490\", \"reference\": \"26458742\", \"title\": \"Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer's disease brain.\", \"type\": \"PubMed\", \"volume\": \"6\"}, \"evidence\": \"The HMW tau species from the AD brain were highly phosphorylated compared with those from control brain (Fig. 6m).\", \"key\": \"f66e9538179dd416cc4e41eefee220acbde61506e1186fff9eae13412001f4d194fb030198bcc540f7bb89bb3af0de7b3304226532c677fb680de4c9b77d7ee7\", \"line\": 121, \"relation\": \"increases\", \"source\": 276, \"target\": 60}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"For example, hyperphosphorylated tau but not unphosphorylated tau can interact with the kinesin-associated protein JUN Nterminal kinase-interacting protein 1 (JIP1) and thus impair the formation of the kinesin complex,which mediates axonal transport\", \"key\": \"8cb61e91784c346cd55b0518879d353cce46a6a019016c948b32d87ad327212c558f7ac111f153983fe194b371336e2713d7ff9b6d1e3d2bdee56245e8f15f5d\", \"line\": 243, \"relation\": \"increases\", \"source\": 276, \"target\": 129}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"For instance, hyperphosphorylated tau can interact with JIP1 and thus impair the formation of kinesin complex\", \"key\": \"40ca849c7373f8e6a1069499140f503dd87e00ce3497f59502852c86f1d1a51b2c8c916ee8482df4244538b535c489c076f327b09e1fe1f65250c37af88b383a\", \"line\": 741, \"relation\": \"increases\", \"source\": 276, \"target\": 129}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"In a Drosophila melanogaster model of tauopathy, the hyperphosphorylation of tau led to the abnormal alignment and accumulation of Factin filaments, and thereby induced neurodegeneration\", \"key\": \"c96613ddbf7bb6c3905f0ceefa0e1dcea029dd3ff7d0596a6c613b2cdbd635ac7c5ae4146d8d90b40f50386a1ed052ad011ff5d5e9ec86752c6088c7d6ed006f\", \"line\": 746, \"relation\": \"increases\", \"source\": 276, \"target\": 102}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Hyperphosphorylation, mutations and overexpression of tau can drive the mislocalization of tau into postsynaptic spines, resulting in synaptic dysfunction\", \"key\": \"a26d5bcaa3c47816164b19c21e08275d715c1de49924366179024cca97b3e72ccfb11f726716a21aa1a1360afaa4556c9a53c603654594d5d71e3329d3eda6f4\", \"line\": 761, \"object\": {\"modifier\": \"Activity\"}, \"relation\": \"decreases\", \"source\": 276, \"target\": 37}, {\"annotations\": {\"Species\": {\"7227\": true}}, \"citation\": {\"authors\": [\"Jin S\", \"Wu J\", \"Xiong Y\", \"Xu Z\", \"Zhang YQ\", \"Zhao K\"], \"date\": \"2013-03-19\", \"first\": \"Xiong Y\", \"last\": \"Zhang YQ\", \"name\": \"Proceedings of the National Academy of Sciences of the United States of America\", \"pages\": \"4604-9\", \"reference\": \"23487739\", \"title\": \"HDAC6 mutations rescue human tau-induced microtubule defects in Drosophila.\", \"type\": \"PubMed\", \"volume\": \"110\"}, \"evidence\": \"Overexpressed tau was hyperphosphorylated and resulted in decreased MT density and greater fragmentation. Using genetic screen, a histone deacetylase 6 (HDAC6) null mutation rescued tau-induced MT defects in both muscles and neurons. Genetic and pharmacological inhibition of the tubulin-specific deacetylase activity of HDAC6 indicates that the rescue effect may be mediated by increased MT acetylation.\", \"key\": \"d27b6e592bf75a98eb0e8116483015e0f7f4569fe17d9af643c3a756b839f8479cb9c645dc06547f7baf69b5bd7435db3eae55ed833c216c6f410c7d59b62206\", \"line\": 3260, \"relation\": \"decreases\", \"source\": 276, \"target\": 36}, {\"citation\": {\"authors\": [\"Dehennaut V\", \"Drougat L\", \"Guinez C\", \"Lefebvre T\", \"Michalski JC\", \"Mir AM\", \"Mortuaire M\", \"Olivier S\", \"Vercoutter-Edouart AS\"], \"date\": \"2010-02-01\", \"first\": \"Lefebvre T\", \"last\": \"Michalski JC\", \"name\": \"Biochimica et biophysica acta\", \"pages\": \"67-79\", \"reference\": \"19732809\", \"title\": \"Dysregulation of the nutrient/stress sensor O-GlcNAcylation is involved in the etiology of cardiovascular disorders, type-2 diabetes and Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"1800\"}, \"evidence\": \"These results are in accord with our previous study showing that Tau hyperphosphorylation is associated with a decrease in its O-GlcNAcylation level. A recent observation argues for the hypothesis that O-GlcNAcylation occurs first and that its modification reflects on the phosphorylation status.\", \"key\": \"e303bbb04098d1508e438882f77dfc61258cce8089a807f96f994401c57bff614648acbe06cb66102efacbce1eeba075922f7524dc37eb61b069e6d4b90f911b\", \"line\": 3436, \"relation\": \"negativeCorrelation\", \"source\": 276, \"target\": 272}, {\"annotations\": {\"Cell\": {\"neuron\": true}, \"MeSHAnatomy\": {\"Brain\": true}, \"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Bertrand D\", \"Dani JA\"], \"date\": \"2007-01-01\", \"first\": \"Dani JA\", \"last\": \"Bertrand D\", \"name\": \"Annual review of pharmacology and toxicology\", \"pages\": \"699-729\", \"reference\": \"17009926\", \"title\": \"Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system.\", \"type\": \"PubMed\", \"volume\": \"47\"}, \"evidence\": \"This prospect was supported by the finding that 7 nAChRs were found in plaques (159), and 7 and 4 subunits positively correlated with neurons that accumulated A and hyperphosphorylated tau in AD brain tissue (161).\", \"key\": \"92c4bf708c26ecb8ca230aa647063231fe523d74ae036aefa1f10ce13766c7b28aeebf596fabfca5af90b712aae4a813b334d3486a509b517c76b0a559073d0b\", \"line\": 362, \"relation\": \"positiveCorrelation\", \"source\": 276, \"target\": 220}, {\"annotations\": {\"Confidence\": {\"High\": true}, \"MeSHAnatomy\": {\"Brain\": true}}, \"citation\": {\"authors\": [\"Carlson GA\", \"Cho H\", \"Commins C\", \"Costantino I\", \"DeVos SL\", \"Frosch MP\", \"Hyman BT\", \"Irimia D\", \"Mller DJ\", \"Nicholls SB\", \"Nobuhara CK\", \"Pitstick R\", \"Roe AD\", \"Takeda S\", \"Wegmann S\"], \"date\": \"2015-10-13\", \"first\": \"Takeda S\", \"last\": \"Hyman BT\", \"name\": \"Nature communications\", \"pages\": \"8490\", \"reference\": \"26458742\", \"title\": \"Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer's disease brain.\", \"type\": \"PubMed\", \"volume\": \"6\"}, \"evidence\": \" Phosphatase treatment dephosphorylated tau in rTg4510 brain extract (Fig. 7d) without changing HMW tau levels (Fig. 7e), resulting in a signicant reduction of cellular uptake of tau (Fig. 7f). \", \"key\": \"0ebf14c08fb3e3c7f9d1be9d7d4d7d0da1b7b2ba440606c902013cff0ac1760b43a5500e65e3e94c60ca5c64a7fec32a2a09003ac3dd7edbab76a74becfaafed\", \"line\": 128, \"object\": {\"effect\": {\"fromLoc\": {\"name\": \"Extracellular Space\", \"namespace\": \"MESH\"}, \"toLoc\": {\"name\": \"Intracellular Space\", \"namespace\": \"MESH\"}}, \"modifier\": \"Translocation\"}, \"relation\": \"increases\", \"source\": 276, \"target\": 244}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"First, hyperphosphorylation of tau might induce tau missorting from axons to the somatodendritic compartment, which can cause synaptic dysfunction\", \"key\": \"c90d5df47a3116e8854115188c4aca4ff6b46a523350728c7b739b1c5aa5b1fd344710461f453b989f8efcee770d4939296f0de2a093ec2b491f2febbe15e863\", \"line\": 218, \"object\": {\"effect\": {\"fromLoc\": {\"name\": \"axon\", \"namespace\": \"GO\"}, \"toLoc\": {\"name\": \"somatodendritic compartment\", \"namespace\": \"GO\"}}, \"modifier\": \"Translocation\"}, \"relation\": \"increases\", \"source\": 276, \"target\": 244}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Hyperphosphorylation, mutations and overexpression of tau can drive the mislocalization of tau into postsynaptic spines, resulting in synaptic dysfunction\", \"key\": \"ce6476c7c5ce5d7a3a8e454e309e20e0d0afcc9bfd6c48ed857db9ea5f4df51f726634fa0555d00b180a7e243cc9c24fe70364390073ff6b60bc36f52116a667\", \"line\": 757, \"object\": {\"effect\": {\"fromLoc\": {\"name\": \"axon\", \"namespace\": \"GO\"}, \"toLoc\": {\"name\": \"Dendritic Spines\", \"namespace\": \"MESH\"}}, \"modifier\": \"Translocation\"}, \"relation\": \"increases\", \"source\": 276, \"target\": 244}, {\"annotations\": {\"Confidence\": {\"Medium\": true}, \"MeSHAnatomy\": {\"Cerebral Cortex\": true, \"Hippocampus\": true}}, \"citation\": {\"authors\": [\"Jiang S\", \"Perry G\", \"Shen L\", \"Siedlak SL\", \"Tang B\", \"Wang C\", \"Wang X\", \"Zhang F\", \"Zhu X\"], \"date\": \"2016-02-03\", \"first\": \"Wang C\", \"last\": \"Zhu X\", \"name\": \"Scientific reports\", \"pages\": \"20352\", \"reference\": \"26837465\", \"title\": \"Estrogen receptor- is localized to neurofibrillary tangles in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"6\"}, \"evidence\": \"To confirm the localization of ER  in NFTs, double fluorescence staining with antibodies to ER  and hyperphosphorylated tau (PHF-1) revealed that ER -positive NFTs were also positive for PHF-1 (Fig.2AF).\", \"key\": \"51cb44ceaff802bb1273b08f19bf3a7cbe82c73930ce677e9ed9e732daccf7ad83beee50b148b7cd22e2617bba5a993546715e0135e2a482f48f81a0ff8022fa\", \"line\": 76, \"relation\": \"association\", \"source\": 276, \"target\": 228}, {\"annotations\": {\"Cell\": {\"neuron\": true}, \"MeSHAnatomy\": {\"Brain\": true}, \"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Bertrand D\", \"Dani JA\"], \"date\": \"2007-01-01\", \"first\": \"Dani JA\", \"last\": \"Bertrand D\", \"name\": \"Annual review of pharmacology and toxicology\", \"pages\": \"699-729\", \"reference\": \"17009926\", \"title\": \"Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system.\", \"type\": \"PubMed\", \"volume\": \"47\"}, \"evidence\": \"This prospect was supported by the finding that 7 nAChRs were found in plaques (159), and 7 and 4 subunits positively correlated with neurons that accumulated A and hyperphosphorylated tau in AD brain tissue (161).\", \"key\": \"c704c258c18f09b583541dcc7010686db22f9219f4c458b089b24ac2d6e2ed203ad1878190dac544f172b5a618f436fd5cd22f97cacb84254dc20af6e441aa23\", \"line\": 360, \"relation\": \"positiveCorrelation\", \"source\": 276, \"target\": 221}, {\"annotations\": {\"MeSHAnatomy\": {\"Hippocampus\": true}}, \"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Mouzon B\", \"Mullan M\", \"Paris D\", \"Schweig JE\", \"Yao H\"], \"date\": \"2017-09-06\", \"first\": \"Schweig JE\", \"last\": \"Paris D\", \"name\": \"Acta neuropathologica communications\", \"pages\": \"69\", \"reference\": \"28877763\", \"title\": \"Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \"Abnormal Syk activation seems to fol- low tau hyperphosphorylation (S202) in the hippocampus of Tg P301S mice (Fig. 6), as well as the formation of MC1-tau pathological conformers (data not shown here but MC1 and pSyk colocalization were quantified below).\", \"key\": \"55906d3eb103aa88457ea4284e03941e343662c579c076612169d958725a5be6e1aeadea043243c487edb2b4b6059a2ea0155636291fbe00446e0b7af317343e\", \"line\": 177, \"object\": {\"modifier\": \"Activity\"}, \"relation\": \"association\", \"source\": 276, \"target\": 366}, {\"citation\": {\"authors\": [\"Morsy A\", \"Trippier PC\"], \"date\": \"2018-11-30\", \"first\": \"Morsy A\", \"last\": \"Trippier PC\", \"name\": \"Journal of medicinal chemistry\", \"reference\": \"30444369\", \"title\": \"Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.\", \"type\": \"PubMed\"}, \"evidence\": \"Moreover,  estradiol  has  been  shown  to  inhibit  tau  hyperphosphorylation  and  can  also  modulate glycogen  synthase  kinase-3  (GSK-3)  activity,  a  kinase  that  is  involved  in  tau  phosphorylation. Estradiol  deactivates  GSK-3  by  inducing  its  phosphorylation,  thereafter  reducing  tau phosphorylation. \", \"key\": \"96b063e7be12467ba6ad243aa430aae79814b3f6d73719c82115f68e2c03f89e5f6c354c4d9a098f8a43b2e1c5332643e6c54c2fee7d5ddef556ae59133b929c\", \"line\": 169, \"relation\": \"decreases\", \"source\": 74, \"target\": 276}, {\"citation\": {\"authors\": [\"Nordberg A\"], \"date\": \"2001-02-01\", \"first\": \"Nordberg A\", \"last\": \"Nordberg A\", \"name\": \"Biological psychiatry\", \"pages\": \"200-10\", \"reference\": \"11230871\", \"title\": \"Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications.\", \"type\": \"PubMed\", \"volume\": \"49\"}, \"evidence\": \"Possible factors such as amyloid peptide accumulation, hyperphosphorylation of tau protein, oxidative stress, and modification of cell membrane during the development of AD may be related to decreased protein levels of nAChRs (Farooqui et al 1995; Smith et al 1996)\", \"key\": \"7f11bf57888d143ddc1e0368bcc3a170b151d3a8dc4aa205d88657e3dfe38fb9e6b252ea3f0f3e531d7af2645cf8682e4041648b75ec43f740273d9d16443e57\", \"line\": 245, \"relation\": \"negativeCorrelation\", \"source\": 156, \"target\": 276}, {\"citation\": {\"authors\": [\"Batra SK\", \"Datta K\", \"Pandey P\", \"Seshacharyulu P\"], \"date\": \"2013-07-10\", \"first\": \"Seshacharyulu P\", \"last\": \"Batra SK\", \"name\": \"Cancer letters\", \"pages\": \"9-18\", \"reference\": \"23454242\", \"title\": \"Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer.\", \"type\": \"PubMed\", \"volume\": \"335\"}, \"evidence\": \"In Alzheimer's disease, inhibition of PP2A activity by SET leads to hyper phosphorylation of the Tau protein [47].\", \"key\": \"595728cc5fd83db9f5da1b170ecfb6a948f4bf28c0a1f66164604dd965f6fc836f5feed53aeae78c7e2e9f7f17ecb27266b867604d98df0af730e395dd1a6ec0\", \"line\": 191, \"relation\": \"decreases\", \"source\": 167, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 276}, {\"annotations\": {\"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Ferrer I\", \"Torrent L\"], \"date\": \"2012-02-01\", \"first\": \"Torrent L\", \"last\": \"Ferrer I\", \"name\": \"Current Alzheimer research\", \"pages\": \"248-56\", \"reference\": \"22299660\", \"title\": \"PP2A and Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"9\"}, \"evidence\": \" Studies  in  transgenic  mice  and  in  cell  cultures  have shown a connection between PP2A loss of function and tau hyper-phosphorylation  and  aggregation  into  PHF. \", \"key\": \"7f7a4b8a8355c8ef7891dc935468918247969261362a6cf9c95112f1a602580f09e43ec89fba454547abd0d4d8062ebcf3233df565457538ea32079a9dc7ed1d\", \"line\": 113, \"relation\": \"negativeCorrelation\", \"source\": 167, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 276}, {\"annotations\": {\"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Ferrer I\", \"Torrent L\"], \"date\": \"2012-02-01\", \"first\": \"Torrent L\", \"last\": \"Ferrer I\", \"name\": \"Current Alzheimer research\", \"pages\": \"248-56\", \"reference\": \"22299660\", \"title\": \"PP2A and Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"9\"}, \"evidence\": \"Trans- genic  mice  with  reduced  PP2A  activity  show  increased  tau phosphorylation  at  Ser202/Thr205  and  Ser42  [46]. \", \"key\": \"42a2fb5b30ca9ba7db9df688829bfca599c0197221e942878af36aa691630e444cf28606f802209267b7af80e4e63950079062ab8beaa428c714fbc42107c145\", \"line\": 122, \"relation\": \"decreases\", \"source\": 167, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 296}, {\"citation\": {\"authors\": [\"Dewachter I\", \"Terwel D\", \"Van Leuven F\"], \"date\": \"2002-01-01\", \"first\": \"Terwel D\", \"last\": \"Van Leuven F\", \"name\": \"Neuromolecular medicine\", \"pages\": \"151-65\", \"reference\": \"12428809\", \"title\": \"Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"2\"}, \"evidence\": \" Tau protein is rapidly dephosphorylated by endogenous phosphatases such as protein phosphatases 1, 2A, and 2B (cal- cineurin) that are all present in the brain, and effec- tively dephosphorylate tau protein in vitro. \", \"key\": \"37c3e3deae526a03a06702881ee57a0e4c4e27392bcbd41822f8dabd6e0e7b17ecdadfa4b380192b0065a1d05316f6a50243fa80d0e418645bc27f7d247586aa\", \"line\": 135, \"relation\": \"decreases\", \"source\": 167, \"target\": 286}, {\"annotations\": {\"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Ferrer I\", \"Torrent L\"], \"date\": \"2012-02-01\", \"first\": \"Torrent L\", \"last\": \"Ferrer I\", \"name\": \"Current Alzheimer research\", \"pages\": \"248-56\", \"reference\": \"22299660\", \"title\": \"PP2A and Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"9\"}, \"evidence\": \"Trans- genic  mice  with  reduced  PP2A  activity  show  increased  tau phosphorylation  at  Ser202/Thr205  and  Ser42  [46]. \", \"key\": \"d7e5141d00b2fb6ec58b3dfbfd7ce0b6091dc7ef4539c7251b76086a1346ecdb0f4dc93030229328c36f2a099846230655871202a147d8552a0804d71f5838a1\", \"line\": 121, \"relation\": \"decreases\", \"source\": 167, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 291}, {\"citation\": {\"authors\": [\"Shi Y\"], \"date\": \"2009-02-01\", \"first\": \"Shi Y\", \"last\": \"Shi Y\", \"name\": \"Science in China. Series C, Life sciences\", \"pages\": \"135-46\", \"reference\": \"19277525\", \"title\": \"Assembly and structure of protein phosphatase 2A.\", \"type\": \"PubMed\", \"volume\": \"52\"}, \"evidence\": \"A key function of PP2A is thought to dephosphorylate the hyperphosphorylated Tau protein\", \"key\": \"e48c066d306dc1c58d59b8019681b13a8376e000785f04145f841c7ffc05ec4d3776a92466d5fa1989e3af07f951dbc65d20f434343c9fb55905e901f5d23f2c\", \"line\": 232, \"relation\": \"decreases\", \"source\": 105, \"target\": 276}, {\"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"For instance, the B subunit specifically and markedly facilitates dephosphory- lation of tau by PP2A (Sontag et al.,1996; Xu et al.,2008).\", \"key\": \"a2f2b7367b1f7072edbc5e93625ff4f8668aecc6ea73582d2d1e3a9393ea778d82f0d05bf4e1da09fc5df512c735c0b04294033621bbd0175425dc353fbcb6f4\", \"line\": 190, \"relation\": \"decreases\", \"source\": 105, \"target\": 286}, {\"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Besides Ser/Thr kinases, the protein tyrosine kinase src promotes the phosphorylation of PP2A on Tyr-307, resulting in PP2A inactivation and subsequent tau phosphorylation (Xiong et al.,2013; Arif et al.,2014).\", \"key\": \"4ebebebedad2b45ebd6b732c64a785c41a86b67b380af4cd5cf2c691e04484abffc0d404c9f662bf0a198de881d191273acc73c08df91ba177cf1c1d5b526b81\", \"line\": 422, \"relation\": \"decreases\", \"source\": 105, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 286}, {\"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"While many PP2A holoenzymes have the potential to indirectly affect tau phosphorylation by modulating key tau protein kinases (For example see Louis et al., 2011), biochemical and structural studies have demonstrated that PP2A/B is the primary PP2A isoform that mediates tau dephosphorylation (Sontag et al.,1996, 1999; Xu et al.,2008).\", \"key\": \"238ac13e709b108164e1999c8a372a956541166e1e9ae74e6cd530f9f505a89fde27b8df9be6d8f25a96508f4ca19ecc92139004baf36c504a93f08e87c3f2ce\", \"line\": 428, \"relation\": \"decreases\", \"source\": 105, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 286}, {\"citation\": {\"authors\": [\"Shi Y\"], \"date\": \"2009-02-01\", \"first\": \"Shi Y\", \"last\": \"Shi Y\", \"name\": \"Science in China. Series C, Life sciences\", \"pages\": \"135-46\", \"reference\": \"19277525\", \"title\": \"Assembly and structure of protein phosphatase 2A.\", \"type\": \"PubMed\", \"volume\": \"52\"}, \"evidence\": \"Previous investigations indicate that specific dephosphorylation of Tau appeared to be mediated by the B family of regulatory subunits\", \"key\": \"88449a221056e79a8bab3738dd8e7954861f9d19f0347bd3ebd40f2ef4962f89759cb464679620f1f4570f9abb94e77df153a9cf260b4842706654afaf50720c\", \"line\": 236, \"relation\": \"decreases\", \"source\": 199, \"target\": 276}, {\"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"For instance, the B subunit specifically and markedly facilitates dephosphory- lation of tau by PP2A (Sontag et al.,1996; Xu et al.,2008).\", \"key\": \"50947a9f35d8efa3b2d6af08a2e0bd8365d3a986275647a7ed6aaccade731641874f1ed5f450dfc36f526361747e28d46635f55837cac5b7982143d00c1c6a3d\", \"line\": 189, \"relation\": \"decreases\", \"source\": 199, \"target\": 286}, {\"annotations\": {\"MeSHAnatomy\": {\"Hippocampus\": true}, \"Species\": {\"10116\": true}}, \"citation\": {\"authors\": [\"Ferrer I\", \"Torrent L\"], \"date\": \"2012-02-01\", \"first\": \"Torrent L\", \"last\": \"Ferrer I\", \"name\": \"Current Alzheimer research\", \"pages\": \"248-56\", \"reference\": \"22299660\", \"title\": \"PP2A and Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"9\"}, \"evidence\": \"Further experiments based on the injection of a PP2A inhibitor in the rat hippocampus demon- strated tau hyper-phosphorylation, and learning and memory deficits  [49,  50]. \", \"key\": \"767c8baf5a5100f7e68b3b924eb13529e7318920152fdc721a4604a9683276e397066d4b98696800d3a7f27a1f354aea44485565c5c324d03e1382f6397f8cb3\", \"line\": 153, \"relation\": \"increases\", \"source\": 11, \"target\": 276}, {\"citation\": {\"authors\": [\"Ferrer I\", \"Torrent L\"], \"date\": \"2012-02-01\", \"first\": \"Torrent L\", \"last\": \"Ferrer I\", \"name\": \"Current Alzheimer research\", \"pages\": \"248-56\", \"reference\": \"22299660\", \"title\": \"PP2A and Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"9\"}, \"evidence\": \"Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].\", \"key\": \"5bdbafed522bc9b928484e0464ae4e7180854deb4c951b6e9f8150e11596a154ab57e61985cedba50723fcec5c7013e946305c5a3c5251044be477d48b5191c5\", \"line\": 135, \"relation\": \"increases\", \"source\": 11, \"target\": 304}, {\"citation\": {\"authors\": [\"Ferrer I\", \"Torrent L\"], \"date\": \"2012-02-01\", \"first\": \"Torrent L\", \"last\": \"Ferrer I\", \"name\": \"Current Alzheimer research\", \"pages\": \"248-56\", \"reference\": \"22299660\", \"title\": \"PP2A and Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"9\"}, \"evidence\": \"Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].\", \"key\": \"939ccc13cff538f62ac8f970a63adb4966ac22673448249fef9a8839f9e5a255cc22d394cde12846fbb760d3fc3b01adff9a0a9233beda1dd34e07b45f75b756\", \"line\": 137, \"relation\": \"increases\", \"source\": 11, \"target\": 309}, {\"citation\": {\"authors\": [\"Ferrer I\", \"Torrent L\"], \"date\": \"2012-02-01\", \"first\": \"Torrent L\", \"last\": \"Ferrer I\", \"name\": \"Current Alzheimer research\", \"pages\": \"248-56\", \"reference\": \"22299660\", \"title\": \"PP2A and Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"9\"}, \"evidence\": \"Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].\", \"key\": \"384207dfdf26197ec7ebddf696633768e2818725a375f02d310f0c34ce334763e30a62de12154e054842ae7584110ff75ddd9b2923e9a70944476398da6db12a\", \"line\": 133, \"relation\": \"increases\", \"source\": 11, \"target\": 289}, {\"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"In vivo use of phosphatase inhibitors such as okadaic acid has been shown in many studies to induce cognitive impairment and widespread neurotoxic effects that are reminiscent of the hallmark pathological processes occurring in AD pathology, i.e., the accumulation of P-tau, amyloidogenesis, synapse loss and neurodegeneration (Malchiodi-Albedi et al., 1997; Arendt et al., 1998; Sun et al.,2003; Kamat et al.,2013)\", \"key\": \"bc5bfb21c5bce4ad5224d69253b1203fc4d1e36c934297c77ef0a98b656115e99b961c6533317b6cf09685ee7a14aa77a5196631b0e7f6b6b1999366cd6d35c2\", \"line\": 343, \"relation\": \"increases\", \"source\": 11, \"target\": 286}, {\"citation\": {\"authors\": [\"Dorval V\", \"Fraser PE\"], \"date\": \"2006-04-14\", \"first\": \"Dorval V\", \"last\": \"Fraser PE\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"9919-24\", \"reference\": \"16464864\", \"title\": \"Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein.\", \"type\": \"PubMed\", \"volume\": \"281\"}, \"evidence\": \"Both brain proteins were preferentially modified by SUMO1, as compared with SUMO2 or SUMO3. Tau contains two SUMO consensus sequences with Lys(340) as the major sumoylation site. Although both tau and alpha-synuclein are targets for proteasomal degradation, only tau sumoylation was affected by inhibitors of the proteasome pathway. Treatment with the phosphatase inhibitor, okadaic acid, or the microtubule depolymerizing drug, colchicine, up-regulated tau sumoylation.\", \"key\": \"4db286ec2b38de59f8c78d546fe1a29947d6c8220788c23ed9bfd8fdb0291c29b7689e88ad86721bb00079731c74cc1ef6aa5409900bd7b883ba337004b4b1e2\", \"line\": 3715, \"relation\": \"increases\", \"source\": 11, \"target\": 322}, {\"citation\": {\"authors\": [\"Ferrer I\", \"Torrent L\"], \"date\": \"2012-02-01\", \"first\": \"Torrent L\", \"last\": \"Ferrer I\", \"name\": \"Current Alzheimer research\", \"pages\": \"248-56\", \"reference\": \"22299660\", \"title\": \"PP2A and Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"9\"}, \"evidence\": \"Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].\", \"key\": \"fd014b61d8c78175196f90babaca3896cc88b76dd74b0332b3fef4ae9284fc488de4a153afe299ec0712339b0b33fbd1e0976fc5d0d46028e3bd985bf157a251\", \"line\": 134, \"relation\": \"increases\", \"source\": 11, \"target\": 290}, {\"citation\": {\"authors\": [\"Dorval V\", \"Fraser PE\"], \"date\": \"2006-04-14\", \"first\": \"Dorval V\", \"last\": \"Fraser PE\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"9919-24\", \"reference\": \"16464864\", \"title\": \"Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein.\", \"type\": \"PubMed\", \"volume\": \"281\"}, \"evidence\": \"Both brain proteins were preferentially modified by SUMO1, as compared with SUMO2 or SUMO3. Tau contains two SUMO consensus sequences with Lys(340) as the major sumoylation site. Although both tau and alpha-synuclein are targets for proteasomal degradation, only tau sumoylation was affected by inhibitors of the proteasome pathway. Treatment with the phosphatase inhibitor, okadaic acid, or the microtubule depolymerizing drug, colchicine, up-regulated tau sumoylation.\", \"key\": \"aad8d238b449862955d7910a810c21f26865cbdafe8d5be67c1b7348e6df742760ee9d5ca6f0b6179bc893607f55179ed8d9db347a2c072099ec834d70064c1f\", \"line\": 3717, \"relation\": \"positiveCorrelation\", \"source\": 11, \"target\": 290}, {\"citation\": {\"authors\": [\"Ferrer I\", \"Torrent L\"], \"date\": \"2012-02-01\", \"first\": \"Torrent L\", \"last\": \"Ferrer I\", \"name\": \"Current Alzheimer research\", \"pages\": \"248-56\", \"reference\": \"22299660\", \"title\": \"PP2A and Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"9\"}, \"evidence\": \"Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].\", \"key\": \"02b8117d173f654ee11ad938c41483f78c936780ce7bf3a3472e373afa11b8389f091edb696d0b7e871998cf062da73af53b84455b6542cd9eec7fe6494e07e2\", \"line\": 136, \"relation\": \"increases\", \"source\": 11, \"target\": 306}, {\"citation\": {\"authors\": [\"Ferrer I\", \"Torrent L\"], \"date\": \"2012-02-01\", \"first\": \"Torrent L\", \"last\": \"Ferrer I\", \"name\": \"Current Alzheimer research\", \"pages\": \"248-56\", \"reference\": \"22299660\", \"title\": \"PP2A and Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"9\"}, \"evidence\": \"Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].\", \"key\": \"c4bdcf642f1be1e3b510ecddf67ca191da7389b2c381887c6cbf2281542303de61fe43020fa941350bcc5456bc53b781009d64893349a20804cde15964c4876a\", \"line\": 138, \"relation\": \"increases\", \"source\": 11, \"target\": 297}, {\"citation\": {\"authors\": [\"Ferrer I\", \"Torrent L\"], \"date\": \"2012-02-01\", \"first\": \"Torrent L\", \"last\": \"Ferrer I\", \"name\": \"Current Alzheimer research\", \"pages\": \"248-56\", \"reference\": \"22299660\", \"title\": \"PP2A and Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"9\"}, \"evidence\": \"Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].\", \"key\": \"e804d75d199cd6c5af4938be5d4d831d9d8d93a1e2db18df5f5541adcac3f4580a8cce69d5c615dcbd8952963ac2ff09f6e5db4e0173045516f226f782dbe8b4\", \"line\": 132, \"relation\": \"increases\", \"source\": 11, \"target\": 287}, {\"citation\": {\"authors\": [\"Brundin P\", \"Ciechanover A\"], \"date\": \"2003-10-09\", \"first\": \"Ciechanover A\", \"last\": \"Brundin P\", \"name\": \"Neuron\", \"pages\": \"427-46\", \"reference\": \"14556719\", \"title\": \"The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg.\", \"type\": \"PubMed\", \"volume\": \"40\"}, \"evidence\": \"In conjunction with the formation of neurofibrillary tangles, the synthesis of the tau protein increases, and it undergoes an abnormal posttranslational modification characterized by hyperphosphorylation\", \"key\": \"7759a25826470898dc4d4dfa0559a9ac8a967e316291987c9cdb081b6e1d3f3201b62d1bc64b8a89acdd6bac631e6d02bbe5934e799510ad6b629fe9a6e5b1c2\", \"line\": 676, \"relation\": \"increases\", \"source\": 67, \"target\": 276}, {\"citation\": {\"authors\": [\"Ihara Y\", \"Morishima-Kawashima M\", \"Nixon R\"], \"date\": \"2012-08-01\", \"first\": \"Ihara Y\", \"last\": \"Nixon R\", \"name\": \"Cold Spring Harbor perspectives in medicine\", \"reference\": \"22908190\", \"title\": \"The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"2\"}, \"evidence\": \"Neurofibrillary tangles composed of tau proteins in a hyperphosphorylated state are rarely observed in abundance except in AD and a limited number of aging-related tauopathies.\", \"key\": \"31f56ec85997dbbb14e8f9c01ccb20444ff5f4485b385e523d7a3ee654d5d822eab5d8453f4d12702b332ab457f4fbcd1c46b32a760de086712dd889fdbb7d89\", \"line\": 835, \"relation\": \"association\", \"source\": 35, \"target\": 276}, {\"annotations\": {\"Anatomy\": {\"CA1 field of hippocampus\": true, \"CA3 field of hippocampus\": true, \"cerebral cortex\": true, \"dentate gyrus granule cell layer\": true}, \"Research_Model\": {\"hTau E391 transgenic mice\": true}, \"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Kraemer BC\", \"Leverenz JB\", \"McMillan PJ\", \"Raskind M\", \"Robinson L\", \"Schellenberg G\"], \"date\": \"2011-11-01\", \"first\": \"McMillan PJ\", \"last\": \"Schellenberg G\", \"name\": \"Journal of neuropathology and experimental neurology\", \"pages\": \"1006-19\", \"reference\": \"22002427\", \"title\": \"Truncation of tau at E391 promotes early pathologic changes in transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"70\"}, \"evidence\": \"E391-3610 mice (higher expressers) exhibit robust somatodendritic distribution of phospho- Ser 202/Thr 205 tau throughout the cortex, in hippocampal CA3 pyramidal neurons, CA1 apical dendrites and cell bodies and dentate granule cells.\", \"key\": \"b95d2718e3f9c217747ce3bfa45ce1378fc8db43e671e2c59b1ecd53ac3f9c4a95850b0718dcaa70a7ca506e2f17caa5f00a06dd523cdab74185e0f79d696ca5\", \"line\": 2580, \"relation\": \"positiveCorrelation\", \"source\": 35, \"target\": 290}, {\"key\": \"57c3f80fa4cb2d67627be5f3a911f2dc0a9075218b7f86fe13bfe3799d85648c66ab14384fff87067baaefee83575490c760854f0a4f5ef97888e1e4507eeb25\", \"relation\": \"hasComponent\", \"source\": 109, \"target\": 276}, {\"annotations\": {\"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Ihara Y\", \"Morishima-Kawashima M\", \"Nixon R\"], \"date\": \"2012-08-01\", \"first\": \"Ihara Y\", \"last\": \"Nixon R\", \"name\": \"Cold Spring Harbor perspectives in medicine\", \"reference\": \"22908190\", \"title\": \"The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"2\"}, \"evidence\": \"Recently, it has been shown that soluble Ab oligomers isolated from AD cortex can induce tau hyperphosphorylation at AD-relevant epitopes and subsequent neuritic degeneration (Jin et al. 2011).\", \"key\": \"fc904cb09fe189125692884527cedaa9e12825b580c3bbf1ee2d2dd096b08fb6d4068025de258d3670a9acc40eece0c49c20fac18eb6b3db2c668da34d48b8c2\", \"line\": 465, \"relation\": \"increases\", \"source\": 57, \"target\": 276}, {\"key\": \"fa586e0398d613d0a75b22538751ac332f09922ce0cfa4a12fdbedb69764331d7f4e221d57eaf4c2235c108a1f0572a5b568184d691fdcd5ea3c5df0731e93f3\", \"relation\": \"hasComponent\", \"source\": 138, \"target\": 276}, {\"key\": \"a66d34c84718b3a43ecf0e3a56bd4b5f1bed1a58e4a0fe440027990ac15dcab8273a7c1e8215d5a3f265d4d915489daf808fd92eef461d9f5b332c7722520b05\", \"relation\": \"hasComponent\", \"source\": 125, \"target\": 276}, {\"citation\": {\"authors\": [\"Ihara Y\", \"Morishima-Kawashima M\", \"Nixon R\"], \"date\": \"2012-08-01\", \"first\": \"Ihara Y\", \"last\": \"Nixon R\", \"name\": \"Cold Spring Harbor perspectives in medicine\", \"reference\": \"22908190\", \"title\": \"The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"2\"}, \"evidence\": \"On the other hand, it has been reported that the E3 ligase CHIP (carboxyl terminus of the Hsc70-interacting protein) binds to tau and is involved in the degradation of abnormal forms of tau, including insoluble tau and hyperphosphorylated tau, coordinately with Hsp70 (Petrucelli et al. 2004; Dickey et al. 2006).\", \"key\": \"10f433282d155befa09346eb42b4c9d2e27e0240250831422514eb12d9a62477c329379c273b03fbd981eb67094108f9037bb23e42e201ef255e03d45358c6bc\", \"line\": 502, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 125, \"target\": 276}, {\"annotations\": {\"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Acton PJ\", \"Bigio EH\", \"Chen-Dodson E\", \"De Felice FG\", \"Fernandez SJ\", \"Jerecic J\", \"Kinney GG\", \"Klein WL\", \"Lacor PN\", \"Lambert MP\", \"Shughrue PJ\", \"Velasco PT\", \"Wu D\"], \"date\": \"2008-09-01\", \"first\": \"De Felice FG\", \"last\": \"Klein WL\", \"name\": \"Neurobiology of aging\", \"pages\": \"1334-47\", \"reference\": \"17403556\", \"title\": \"Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"29\"}, \"evidence\": \"These results confirm that the tau hyperphosphorylation stimulated by soluble ADDL preparations is indeed oligomer-induced. Tau hyperphosphorylation induced by 10\\u0003M Abeta fibrils (Fig. 3N) was partially blocked (Fig. 3O), consistent with shared epitopes between oligomers and fibrils.\", \"key\": \"98adb00058e611e55e7b0436fc3743e1d2bdd403b525c47dab98e626db9765d0eb1b7c75efad80f474abfb9786cc8c440311a86c7ea6b5d5e7cc8c9e8bd606ef\", \"line\": 172, \"relation\": \"increases\", \"source\": 52, \"target\": 276}, {\"annotations\": {\"MeSHDisease\": {\"Alzheimer Disease\": true}, \"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Acton PJ\", \"Bigio EH\", \"Chen-Dodson E\", \"De Felice FG\", \"Fernandez SJ\", \"Jerecic J\", \"Kinney GG\", \"Klein WL\", \"Lacor PN\", \"Lambert MP\", \"Shughrue PJ\", \"Velasco PT\", \"Wu D\"], \"date\": \"2008-09-01\", \"first\": \"De Felice FG\", \"last\": \"Klein WL\", \"name\": \"Neurobiology of aging\", \"pages\": \"1334-47\", \"reference\": \"17403556\", \"title\": \"Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"29\"}, \"evidence\": \"Importantly, pre-incubation of AD brain extracts with NU1 significantly blocked the increase in Thr231 phosphotau immunofluorescence (Fig. 6G), establishing the tau hyperphosphorylation was induced by Abeta oligomers in the AD brain extracts. NU1 also prevented the binding of brain-derived ADDLs to synaptic hot-spots (Fig. 6H and I). In NU1-treated cultures, the presence of large extracellular aggregates indicates that the antibody sequesters ADDLs and prevents their interactions with neurons (Fig. 6I).\", \"key\": \"6d44eb07392b3ee6a62e0e8466426274e0bff403bf0fb4f2a98e27b9cfde8f4af491329edb9ac22ca75522241c13e649de3a13d26d008a11b9a974545ca162df\", \"line\": 253, \"relation\": \"increases\", \"source\": 52, \"target\": 276}, {\"annotations\": {\"MeSHAnatomy\": {\"Dendrites\": true}}, \"citation\": {\"authors\": [\"Balaji V\", \"Kaniyappan S\", \"Mandelkow E\", \"Mandelkow EM\", \"Wang Y\"], \"date\": \"2018-01-01\", \"first\": \"Balaji V\", \"last\": \"Mandelkow EM\", \"name\": \"Autophagy\", \"pages\": \"2139-2154\", \"reference\": \"30145931\", \"title\": \"Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \"In addition, it has been reported that in cultured neurons, A oligomers induce MAPT missorting into the somatodendritic compartment, and the missorted MAPT is phosphorylated mainly at the 12E8 (p-S262/p-S356) and AT8 (p-S202/p-T205) sites [6].\", \"key\": \"487eac3206d8669a9e6ef330c58af29708fc93e4e6335e659a02b010a19e78212403502898ba8a92726823b11e90bbfa6533eb01715473ef8fb1b12d6eb509a6\", \"line\": 147, \"relation\": \"positiveCorrelation\", \"source\": 52, \"target\": 312}, {\"annotations\": {\"MeSHAnatomy\": {\"Post-Synaptic Density\": true}, \"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Arnal I\", \"Borel E\", \"Buisson A\", \"De Seranno S\", \"Elie A\", \"Frandemiche ML\", \"Lant F\", \"Rush T\"], \"date\": \"2014-04-23\", \"first\": \"Frandemiche ML\", \"last\": \"Buisson A\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"6084-97\", \"reference\": \"24760868\", \"title\": \"Activity-dependent tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"34\"}, \"evidence\": \"Thr-205 phosphorylated tau was only increased under synaptic activation in the PSD fraction (control 24.57 \\u0004 0.9754 vs Bic/4-AP 38.90 \\u0004 1.936; Fig. 9E), whereas it was decreased after Abetao treatment (control 24.57 \\u0004 0.9754 vs Abeta 13.64 \\u0004 2.416). Synaptic activation after Abetao exposure did not produce any significant Thr-205 phosphorylation of tau (Abeta          Bic/4-AP 22.89\\u00042.796 vs Bic/ 4-AP 38.90 \\u0004 1.93 vs Abeta 13.64\\u00042.50).\", \"key\": \"6a95253b9074083f4abed294a7ad01b24cbb15ad2a769f7a2c9abf9dd34f7d18b6f904a154ef0de3adedae65ef3af72e3ae79bb135634ed352d3037f9c1c7517\", \"line\": 290, \"relation\": \"decreases\", \"source\": 52, \"target\": 312}, {\"annotations\": {\"MeSHAnatomy\": {\"Post-Synaptic Density\": true}, \"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Arnal I\", \"Borel E\", \"Buisson A\", \"De Seranno S\", \"Elie A\", \"Frandemiche ML\", \"Lant F\", \"Rush T\"], \"date\": \"2014-04-23\", \"first\": \"Frandemiche ML\", \"last\": \"Buisson A\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"6084-97\", \"reference\": \"24760868\", \"title\": \"Activity-dependent tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"34\"}, \"evidence\": \"Conversely, only Abetao exposure promoted significant tau phosphorylation on Ser 404 (**p\\u00050.05, 1-way ANOVA; control 15.67\\u00042.418 vs Abetao 32.65 \\u0004 3.76 vs Bic/4-AP 26.75 \\u0004 1.17 vs Abetao         Bic/4-AP 24.97 \\u0004 4.48, N \\u0003 4). These results revealed that, although synaptic activation or Abetao promote tau translocation to PSD fractions, the synaptic tau displays a different phosphorylation profile that may be responsible for the conditional tau properties observed.\", \"key\": \"bd82404dcb6690b90cc862275e0bd6f7c2ccd2a4edbe06a8fa1aa24338902a84ddc50aaf8306d3a709fe129bfc13a2879c88f2c61310dd4dba6f0c2fec7fd59c\", \"line\": 307, \"relation\": \"regulates\", \"source\": 52, \"target\": 286}, {\"citation\": {\"authors\": [\"Choi H\", \"Gwon Y\", \"Jung YK\", \"Kam TI\", \"Kim C\", \"Kim Y\", \"Koh JY\", \"Park H\"], \"date\": \"2012-06-15\", \"first\": \"Park H\", \"last\": \"Jung YK\", \"name\": \"Human molecular genetics\", \"pages\": \"2725-37\", \"reference\": \"22419736\", \"title\": \"Neuropathogenic role of adenylate kinase-1 in A-mediated tau phosphorylation via AMPK and GSK3.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"Soluble oligomers of Ab42 serve as the prominent synapto- toxic form and induce tau hyperphosphorylation\", \"key\": \"3ef5cdc6a17ac3b7a6d9d6f9163fd314967dbaeff17ab5bd722fd9d9c4428f3d32f3f1efcb9ead09cc187e6d71eb9afe6237fd7c955881416cdf320833475420\", \"line\": 106, \"relation\": \"increases\", \"source\": 52, \"target\": 286}, {\"annotations\": {\"MeSHAnatomy\": {\"Dendrites\": true}}, \"citation\": {\"authors\": [\"Balaji V\", \"Kaniyappan S\", \"Mandelkow E\", \"Mandelkow EM\", \"Wang Y\"], \"date\": \"2018-01-01\", \"first\": \"Balaji V\", \"last\": \"Mandelkow EM\", \"name\": \"Autophagy\", \"pages\": \"2139-2154\", \"reference\": \"30145931\", \"title\": \"Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \"In addition, it has been reported that in cultured neurons, A oligomers induce MAPT missorting into the somatodendritic compartment, and the missorted MAPT is phosphorylated mainly at the 12E8 (p-S262/p-S356) and AT8 (p-S202/p-T205) sites [6].\", \"key\": \"9efaafb2f74f5f364d9ba07aacf6ef3d9ff308141d643108872c4a7d92e50f1b3a52a3a13ecbac9d197714fdeb81ded29e52d5ab4203044bdc9b458a5102b5d1\", \"line\": 146, \"relation\": \"positiveCorrelation\", \"source\": 52, \"target\": 290}, {\"annotations\": {\"MeSHAnatomy\": {\"Dendrites\": true}}, \"citation\": {\"authors\": [\"Balaji V\", \"Kaniyappan S\", \"Mandelkow E\", \"Mandelkow EM\", \"Wang Y\"], \"date\": \"2018-01-01\", \"first\": \"Balaji V\", \"last\": \"Mandelkow EM\", \"name\": \"Autophagy\", \"pages\": \"2139-2154\", \"reference\": \"30145931\", \"title\": \"Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \"In addition, it has been reported that in cultured neurons, A oligomers induce MAPT missorting into the somatodendritic compartment, and the missorted MAPT is phosphorylated mainly at the 12E8 (p-S262/p-S356) and AT8 (p-S202/p-T205) sites [6].\", \"key\": \"00557165bb142e95028e4e2c259cba0381d8205b5c1e0f920a9a9c03d78b8f56ca7cf1e2efb5f0781814b4dd8416627fbb1eee0c2852ab54b1ab0faa586ab123\", \"line\": 145, \"relation\": \"positiveCorrelation\", \"source\": 52, \"target\": 303}, {\"annotations\": {\"MeSHAnatomy\": {\"Post-Synaptic Density\": true}, \"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Arnal I\", \"Borel E\", \"Buisson A\", \"De Seranno S\", \"Elie A\", \"Frandemiche ML\", \"Lant F\", \"Rush T\"], \"date\": \"2014-04-23\", \"first\": \"Frandemiche ML\", \"last\": \"Buisson A\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"6084-97\", \"reference\": \"24760868\", \"title\": \"Activity-dependent tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"34\"}, \"evidence\": \"Conversely, only Abetao exposure promoted significant tau phosphorylation on Ser 404 (**p\\u00050.05, 1-way ANOVA; control 15.67\\u00042.418 vs Abetao 32.65 \\u0004 3.76 vs Bic/4-AP 26.75 \\u0004 1.17 vs Abetao         Bic/4-AP 24.97 \\u0004 4.48, N \\u0003 4). These results revealed that, although synaptic activation or Abetao promote tau translocation to PSD fractions, the synaptic tau displays a different phosphorylation profile that may be responsible for the conditional tau properties observed.\", \"key\": \"c1147413afe4f4865b42f1fc5600bc2292689cd2ebfabb4d11271ffcc6740378b594ff853036ba166f1c8b36127250c8605ca391da378eb3586d866c40717dfe\", \"line\": 306, \"relation\": \"increases\", \"source\": 52, \"target\": 306}, {\"annotations\": {\"MeSHAnatomy\": {\"Dendrites\": true}}, \"citation\": {\"authors\": [\"Balaji V\", \"Kaniyappan S\", \"Mandelkow E\", \"Mandelkow EM\", \"Wang Y\"], \"date\": \"2018-01-01\", \"first\": \"Balaji V\", \"last\": \"Mandelkow EM\", \"name\": \"Autophagy\", \"pages\": \"2139-2154\", \"reference\": \"30145931\", \"title\": \"Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \"In addition, it has been reported that in cultured neurons, A oligomers induce MAPT missorting into the somatodendritic compartment, and the missorted MAPT is phosphorylated mainly at the 12E8 (p-S262/p-S356) and AT8 (p-S202/p-T205) sites [6].\", \"key\": \"37db981111e3ecf6efe988dfff7b83105b27da42adc9ccbc62765b37da6c917b53616f42c320819d50153bc725025ced7a231d2297d3076da194143d9566a2ac\", \"line\": 144, \"relation\": \"positiveCorrelation\", \"source\": 52, \"target\": 297}, {\"annotations\": {\"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Acton PJ\", \"Bigio EH\", \"Chen-Dodson E\", \"De Felice FG\", \"Fernandez SJ\", \"Jerecic J\", \"Kinney GG\", \"Klein WL\", \"Lacor PN\", \"Lambert MP\", \"Shughrue PJ\", \"Velasco PT\", \"Wu D\"], \"date\": \"2008-09-01\", \"first\": \"De Felice FG\", \"last\": \"Klein WL\", \"name\": \"Neurobiology of aging\", \"pages\": \"1334-47\", \"reference\": \"17403556\", \"title\": \"Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"29\"}, \"evidence\": \"Moreover, the presence of large extracellular aggregates in NU1-treated cultures (Fig. 5N) suggests that the antibody effectively sequesters ADDLs and prevents their interactions with neurons (Fig. 5O). No inhibition of ADDL binding was associated with PP1 and LY294002 (Fig. 5H, I, K and L, respectively), but both kinase inhibitors effectively blocked ADDL-induced tau hyperphosphorylation (Fig. 5G and J).\", \"key\": \"bb60f356ba27aac6b4fe55a3d2963ac75bd828b0ea1d3fb5c632f46f54acc6a35283f2a5be02ce5db6c5e49492a42f81d3422985c25e60b1157a2b8a7a00800c\", \"line\": 225, \"relation\": \"decreases\", \"source\": 65, \"target\": 276}, {\"annotations\": {\"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Acton PJ\", \"Bigio EH\", \"Chen-Dodson E\", \"De Felice FG\", \"Fernandez SJ\", \"Jerecic J\", \"Kinney GG\", \"Klein WL\", \"Lacor PN\", \"Lambert MP\", \"Shughrue PJ\", \"Velasco PT\", \"Wu D\"], \"date\": \"2008-09-01\", \"first\": \"De Felice FG\", \"last\": \"Klein WL\", \"name\": \"Neurobiology of aging\", \"pages\": \"1334-47\", \"reference\": \"17403556\", \"title\": \"Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"29\"}, \"evidence\": \"Interestingly, we found that tau hyperphosphorylation at Thr231 was completely blocked by the Src family tyrosine kinase inhibitor, 4-amino-5-(4- chlorophenyl)-7(t-butyl)pyrazol(3,4-d)pyramide (PP1), and by the phosphatidylinositol 3-kinase inhibitor, LY294002 (Fig. 5).\", \"key\": \"e7257beb1630bf1d3c449b24cf85159461996820595bd27ef81282fb0baa294a4dfdda97a403dd25f134f2dbc189ebd71a635c659db8a78d3363e56fd3cba7d1\", \"line\": 202, \"relation\": \"decreases\", \"source\": 65, \"target\": 315}, {\"annotations\": {\"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Acton PJ\", \"Bigio EH\", \"Chen-Dodson E\", \"De Felice FG\", \"Fernandez SJ\", \"Jerecic J\", \"Kinney GG\", \"Klein WL\", \"Lacor PN\", \"Lambert MP\", \"Shughrue PJ\", \"Velasco PT\", \"Wu D\"], \"date\": \"2008-09-01\", \"first\": \"De Felice FG\", \"last\": \"Klein WL\", \"name\": \"Neurobiology of aging\", \"pages\": \"1334-47\", \"reference\": \"17403556\", \"title\": \"Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"29\"}, \"evidence\": \"Moreover, the presence of large extracellular aggregates in NU1-treated cultures (Fig. 5N) suggests that the antibody effectively sequesters ADDLs and prevents their interactions with neurons (Fig. 5O). No inhibition of ADDL binding was associated with PP1 and LY294002 (Fig. 5H, I, K and L, respectively), but both kinase inhibitors effectively blocked ADDL-induced tau hyperphosphorylation (Fig. 5G and J).\", \"key\": \"79e5ce4b341990b15a90ac4b868c12bb7d467cef8a9fb2a0ad5aed5c0a8f7499c5a3d7016b74df285b5851a826320228db55136c66f4760f126400b6f85ffbf1\", \"line\": 226, \"relation\": \"decreases\", \"source\": 14, \"target\": 276}, {\"annotations\": {\"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Acton PJ\", \"Bigio EH\", \"Chen-Dodson E\", \"De Felice FG\", \"Fernandez SJ\", \"Jerecic J\", \"Kinney GG\", \"Klein WL\", \"Lacor PN\", \"Lambert MP\", \"Shughrue PJ\", \"Velasco PT\", \"Wu D\"], \"date\": \"2008-09-01\", \"first\": \"De Felice FG\", \"last\": \"Klein WL\", \"name\": \"Neurobiology of aging\", \"pages\": \"1334-47\", \"reference\": \"17403556\", \"title\": \"Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"29\"}, \"evidence\": \"Interestingly, we found that tau hyperphosphorylation at Thr231 was completely blocked by the Src family tyrosine kinase inhibitor, 4-amino-5-(4- chlorophenyl)-7(t-butyl)pyrazol(3,4-d)pyramide (PP1), and by the phosphatidylinositol 3-kinase inhibitor, LY294002 (Fig. 5).\", \"key\": \"338f50b8d62deb4deb32873a3e8de1dd97709050c632d916f0ff4518f2dcc207a486ce8b441ad0c9250680e510008b593fef7a5d92e6e2d20ae59cc1ee2182e3\", \"line\": 203, \"relation\": \"decreases\", \"source\": 14, \"target\": 315}, {\"annotations\": {\"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Acton PJ\", \"Bigio EH\", \"Chen-Dodson E\", \"De Felice FG\", \"Fernandez SJ\", \"Jerecic J\", \"Kinney GG\", \"Klein WL\", \"Lacor PN\", \"Lambert MP\", \"Shughrue PJ\", \"Velasco PT\", \"Wu D\"], \"date\": \"2008-09-01\", \"first\": \"De Felice FG\", \"last\": \"Klein WL\", \"name\": \"Neurobiology of aging\", \"pages\": \"1334-47\", \"reference\": \"17403556\", \"title\": \"Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"29\"}, \"evidence\": \"Inhibition occurred even though ADDLs were still bound to cell surfaces, indicating that those kinases are involved in signal transduction coupling between ADDL binding and tau hyperphosphorylation.\", \"key\": \"899b6377b06dc8dd2ca9142f873c9c1aa3322033962d4fe1cdac6b4b175dd202eea7f917958cfdbf6a0d74529be7779897161cb13cae4e405c9006fe3dded77a\", \"line\": 213, \"relation\": \"increases\", \"source\": 112, \"target\": 276}, {\"key\": \"385e9cd92d568d9c175ff691c4814121fdbfd6eb14d46968df3763029207c3667cdcefed1d64547f8b7444e07bcd272f476e347bc29bc88922494d35d7fede82\", \"relation\": \"hasComponent\", \"source\": 127, \"target\": 276}, {\"citation\": {\"authors\": [\"Dickey CA\", \"Gestwicki JE\", \"Kiray J\", \"Koren J\", \"Miyata Y\"], \"date\": \"2011-09-01\", \"first\": \"Miyata Y\", \"last\": \"Gestwicki JE\", \"name\": \"Future medicinal chemistry\", \"pages\": \"1523-37\", \"reference\": \"21882945\", \"title\": \"Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.\", \"type\": \"PubMed\", \"volume\": \"3\"}, \"evidence\": \"Hsp27 has emerged as a potential target for tau regulation based on early findings that it preferentially binds to phosphorylated and hyperphosphorylated tau and promotes their clearance [125,126]\", \"key\": \"7af9e62daa0df86d917cc68d83fce5d6d3153a4c32e770fa44175489192d7cb9fa24aedf37b3b12dea6a9402bc37c73d738384ee29c794aa25efd7389cea12ea\", \"line\": 348, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 127, \"target\": 276}, {\"citation\": {\"authors\": [\"Dickey CA\", \"Gestwicki JE\", \"Kiray J\", \"Koren J\", \"Miyata Y\"], \"date\": \"2011-09-01\", \"first\": \"Miyata Y\", \"last\": \"Gestwicki JE\", \"name\": \"Future medicinal chemistry\", \"pages\": \"1523-37\", \"reference\": \"21882945\", \"title\": \"Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.\", \"type\": \"PubMed\", \"volume\": \"3\"}, \"evidence\": \"This model is consistent with the data that hyperphosphorylated tau appears to be specifically selected for degradation by some chaperone machines, such as the Hsp90FKBP51 complex, without effects on normal tau [132,136].\", \"key\": \"19c7191a7a9ff378d2835776b0b2b93a45d9c84872dd9c4d2f00c81ac487cd2326ce25142c8b7c326911cc3d02b66f95d1d94c6039f7e7677aec554517bb1d91\", \"line\": 439, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 115, \"target\": 276}, {\"citation\": {\"authors\": [\"Hyman BT\", \"Kay KR\", \"Mandelkow EM\", \"Polydoro M\", \"Saidi LJ\", \"Sanchez L\", \"Spires-Jones TL\"], \"date\": \"2015-01-01\", \"first\": \"Saidi LJ\", \"last\": \"Spires-Jones TL\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"937-47\", \"reference\": \"25374103\", \"title\": \"Carboxy terminus heat shock protein 70 interacting protein reduces tau-associated degenerative changes.\", \"type\": \"PubMed\", \"volume\": \"44\"}, \"evidence\": \"Recent data suggest that a critical mediator of refolding or clearance of hyperphosphorylated tau is via the HSP70/HSP90 heat shock pathways in which a specific E3 ubiquitin ligase, CHIP (carboxy terminus Hsp70 interacting protein), can recognize and target for degradation abnormal but not normal tau molecules [1416].\", \"key\": \"6296fedbd33b30cf93543f75afbf5873b0298ab643ab6c015781839c8de3b2ca0bec824cdedb8ca36e905a7f6467c0f66e1a53c3b5ad82ea43cb192a478c083d\", \"line\": 130, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"regulates\", \"source\": 162, \"target\": 276}, {\"citation\": {\"authors\": [\"Blair LJ\", \"Koren J 3rd\", \"Shelton LB\"], \"date\": \"2017-01-01\", \"first\": \"Shelton LB\", \"last\": \"Blair LJ\", \"name\": \"Frontiers in neuroscience\", \"pages\": \"724\", \"reference\": \"29311797\", \"title\": \"Imbalances in the Hsp90 Chaperone Machinery: Implications for Tauopathies.\", \"type\": \"PubMed\", \"volume\": \"11\"}, \"evidence\": \"Previous studies have shown that Hsp90 inhibition decreased the levels of hyperphosphorylated and/or mutated tau species both in cells and mice.\", \"key\": \"61cd26d337dd788961dc8199ddcecd39b21a7dfa69a9c12caffeb6161b6ac79bcc629150698e97fff49419e5a619fbca61865a671d7c2cf82e6f0962481524e4\", \"line\": 476, \"relation\": \"increases\", \"source\": 162, \"target\": 276}, {\"citation\": {\"authors\": [\"Hyman BT\", \"Kay KR\", \"Mandelkow EM\", \"Polydoro M\", \"Saidi LJ\", \"Sanchez L\", \"Spires-Jones TL\"], \"date\": \"2015-01-01\", \"first\": \"Saidi LJ\", \"last\": \"Spires-Jones TL\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"937-47\", \"reference\": \"25374103\", \"title\": \"Carboxy terminus heat shock protein 70 interacting protein reduces tau-associated degenerative changes.\", \"type\": \"PubMed\", \"volume\": \"44\"}, \"evidence\": \"Several publications suggest that molecular chaperones, e.g., heat shock protein 70 and 90 (Hsp70, Hsp90) play a fundamental role in the clearance of misfolded proteins including tau [12].\", \"key\": \"3192df49844763a0d3d466ace24b7c36b9a9a6015b92f973d85fb73cf8c52d7cebd6abc2cdbcf1497cb16aab348ca2e73e242b2beaa8ef7c0aad8e92e4771664\", \"line\": 170, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 162, \"target\": 277}, {\"citation\": {\"authors\": [\"Dickey CA\", \"Gestwicki JE\", \"Kiray J\", \"Koren J\", \"Miyata Y\"], \"date\": \"2011-09-01\", \"first\": \"Miyata Y\", \"last\": \"Gestwicki JE\", \"name\": \"Future medicinal chemistry\", \"pages\": \"1523-37\", \"reference\": \"21882945\", \"title\": \"Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.\", \"type\": \"PubMed\", \"volume\": \"3\"}, \"evidence\": \"For example, it has recently been shown that Hsp90 promotes taus phosphorylation by its ability to stabilize GSK3b [118]\", \"key\": \"fcd5b3171ca12447007de686e641dec0d35296bc7551bc91ef8e4868e5127d5695a12c0d537277dca549a21310d6e23d8533fabeaf9b555ddf064f2342c4dc36\", \"line\": 319, \"relation\": \"increases\", \"source\": 162, \"target\": 286}, {\"citation\": {\"authors\": [\"Dickey CA\", \"Gestwicki JE\", \"Kiray J\", \"Koren J\", \"Miyata Y\"], \"date\": \"2011-09-01\", \"first\": \"Miyata Y\", \"last\": \"Gestwicki JE\", \"name\": \"Future medicinal chemistry\", \"pages\": \"1523-37\", \"reference\": \"21882945\", \"title\": \"Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.\", \"type\": \"PubMed\", \"volume\": \"3\"}, \"evidence\": \"Together, multiple studies suggest that Hsp90 regulates the stability of both phospho- and mutant-tau\", \"key\": \"85d112a6ccabf6d991ed78a219b6d93cced87a96215b7c71bbacc34b743f14496db4cc7f1c3279ba0120b61c85be02ba2dcfa4b71bf55a943eb5285a97d4d413\", \"line\": 340, \"relation\": \"regulates\", \"source\": 162, \"target\": 286}, {\"annotations\": {\"MeSHAnatomy\": {\"Hippocampus\": true}}, \"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Mouzon B\", \"Mullan M\", \"Paris D\", \"Schweig JE\", \"Yao H\"], \"date\": \"2017-09-06\", \"first\": \"Schweig JE\", \"last\": \"Paris D\", \"name\": \"Acta neuropathologica communications\", \"pages\": \"69\", \"reference\": \"28877763\", \"title\": \"Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \"Abnormal Syk activation seems to fol- low tau hyperphosphorylation (S202) in the hippocampus of Tg P301S mice (Fig. 6), as well as the formation of MC1-tau pathological conformers (data not shown here but MC1 and pSyk colocalization were quantified below).\", \"key\": \"2614ad1d561aceaed3b1ba1eaeff05765bef3e27a1357e53ce38db62af243ca164567be20c5ede80c758b231481c52479477afb63dc6f5b6adbe879699e6bf9e\", \"line\": 178, \"relation\": \"association\", \"source\": 39, \"target\": 276}, {\"annotations\": {\"Confidence\": {\"High\": true}, \"MeSHAnatomy\": {\"Intracellular Space\": true}, \"PublicationType\": {\"Review\": true}}, \"citation\": {\"authors\": [\"Binder LI\", \"Himmelstein DS\", \"Lancia JK\", \"Ward SM\"], \"date\": \"2012-08-01\", \"first\": \"Ward SM\", \"last\": \"Binder LI\", \"name\": \"Biochemical Society transactions\", \"pages\": \"667-71\", \"reference\": \"22817713\", \"title\": \"Tau oligomers and tau toxicity in neurodegenerative disease.\", \"type\": \"PubMed\", \"volume\": \"40\"}, \"evidence\": \"TNT1 also co-localizes in tissue with the phospho-epitope defined by the AT8 antibody, indicating that PAD exposure represents an early event in AD pathology\", \"key\": \"63250c47710bb1b5ed995ad7ca71a025fddd4cb3f5843c6297a77ec726610a6a93295d7b4527a796c257253ed15a8bd43cb3d62a54b48cccedb9a43627913c0b\", \"line\": 171, \"relation\": \"association\", \"source\": 39, \"target\": 312}, {\"annotations\": {\"Species\": {\"6239\": true}}, \"citation\": {\"authors\": [\"Choudhary B\", \"Mandelkow E\", \"Pir GJ\"], \"date\": \"2017-12-01\", \"first\": \"Pir GJ\", \"last\": \"Mandelkow E\", \"name\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\", \"pages\": \"5137-5148\", \"reference\": \"29191965\", \"title\": \"&lt;i&gt;Caenorhabditis elegans&lt;/i&gt; models of tauopathy.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"Nonetheless, it is assumed that tau aggregation may be driven by phosphorylation at certain sites (95), whereas phosphorylation at other sites may inhibit aggregation (96).\", \"key\": \"7c93888c7e592a4bb1a4b13e683eb078eac000fd1e9dccdc77a8a47e5a4aa7e85115979bdb23dc9467231d0fd5d69d57344af3234a905bbda790bca98bc32134\", \"line\": 267, \"relation\": \"positiveCorrelation\", \"source\": 39, \"target\": 286}, {\"annotations\": {\"Confidence\": {\"High\": true}, \"MeSHAnatomy\": {\"Intracellular Space\": true}, \"PublicationType\": {\"Review\": true}}, \"citation\": {\"authors\": [\"Binder LI\", \"Himmelstein DS\", \"Lancia JK\", \"Ward SM\"], \"date\": \"2012-08-01\", \"first\": \"Ward SM\", \"last\": \"Binder LI\", \"name\": \"Biochemical Society transactions\", \"pages\": \"667-71\", \"reference\": \"22817713\", \"title\": \"Tau oligomers and tau toxicity in neurodegenerative disease.\", \"type\": \"PubMed\", \"volume\": \"40\"}, \"evidence\": \"TNT1 also co-localizes in tissue with the phospho-epitope defined by the AT8 antibody, indicating that PAD exposure represents an early event in AD pathology\", \"key\": \"5060686421c8005ce37efa0beb4533d87c43c928021b9df3c93208cbee502094bc526b72ad8f8fa39aa0901de52298f7ca7324e9f72a6b5e81f81ec7c8803b50\", \"line\": 170, \"relation\": \"association\", \"source\": 39, \"target\": 290}, {\"citation\": {\"authors\": [\"Blair LJ\", \"Koren J 3rd\", \"Shelton LB\"], \"date\": \"2017-01-01\", \"first\": \"Shelton LB\", \"last\": \"Blair LJ\", \"name\": \"Frontiers in neuroscience\", \"pages\": \"724\", \"reference\": \"29311797\", \"title\": \"Imbalances in the Hsp90 Chaperone Machinery: Implications for Tauopathies.\", \"type\": \"PubMed\", \"volume\": \"11\"}, \"evidence\": \"The Hsp90 N-terminal domain inhibitor, EC102, was used to demonstrate degradation of hyperphosphorylated pathologically relevant tau in cells (Dickey et al., 2007a).\", \"key\": \"80d2d91624d051b191e2713e88ff12214b26cdff7b679c06533252cbbc401ef8bb47a68e58e57f2fd5e5b28e62b0d8b663b1c632222b15b5f6bcc3cc4627718c\", \"line\": 483, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 59, \"target\": 276}, {\"key\": \"1db0e15aafd7e30423e3bbdd0dd59b0510f107e830bb9ce164b2bb9882c989b6e49d69bb556c38fdbd6f5a13291fd1009a29fd1994473637347074b7b5a36d50\", \"relation\": \"hasComponent\", \"source\": 129, \"target\": 276}, {\"citation\": {\"authors\": [\"Alonso AC\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Kpke E\", \"Shaikh S\", \"Tung YC\"], \"date\": \"1993-11-15\", \"first\": \"Kpke E\", \"last\": \"Grundke-Iqbal I\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"24374-84\", \"reference\": \"8226987\", \"title\": \"Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"268\"}, \"evidence\": \">8 phosphates per tau molecules (vs 2 in adult healthy brain); can also be increased during development, hibernation and temperature, heat and oxydative stress These phosphorylated states are detected by specific antibodies and are targets of proline-directed kinases (SP motifs), non-proline kinases (KXGS motif) Weakens tau-MT interaction especially S261 in R1 and S214 in proline-rich domain\", \"key\": \"167e5b1ebe4541fddf99975ec66854af9e4eaac7e2afe1e7557990b54a031514325e0c2e0a40f647de2986dc83610c060ba847e7a09cf590f18faf1ddf461f76\", \"line\": 2818, \"relation\": \"increases\", \"source\": 97, \"target\": 276}, {\"annotations\": {\"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"An FM\", \"Chen S\", \"Gao XD\", \"Liu AR\", \"Wang Y\", \"Xu Z\", \"Yao WB\", \"Yin L\"], \"date\": \"2015-08-06\", \"first\": \"An FM\", \"last\": \"Gao XD\", \"name\": \"Neuroscience\", \"pages\": \"75-84\", \"reference\": \"25987199\", \"title\": \"Glucagon-like peptide-1 regulates mitochondrial biogenesis and tau phosphorylation against advanced glycation end product-induced neuronal insult: Studies in vivo and in vitro.\", \"type\": \"PubMed\", \"volume\": \"300\"}, \"evidence\": \"In this study, we demonstrated that GLP-1RA could inhibit oxidative stress and repair mitochondrial damage in addition to decreasing tau hyperphosphorylation in PC12 cells treated with AGEs. Importantly, we first observed AGEs in the circulatory system could induce tau hyperphosphorylation after we injected AGEs (1g/kg bodyweight) into the mice tail vein. We found GLP-1RA could promote mitochondrial biogenesis and antioxidant system via regulating peroxisome proliferator-activated receptor  coactivator 1 (PGC-1) signaling pathway in vivo besides down-regulating the activity of glycogen synthase kinase 3 (GSK-3) to reverse tau hyperphosphorylation directly.\", \"key\": \"dea066975aa36b693cfcc5efb88a3efb3c1399b1bec3a5f1116fd1f277c3ae39b490457193be9efb8fbc69e9c15e0247076688f60ef5c720af3070699f45963d\", \"line\": 2407, \"relation\": \"increases\", \"source\": 48, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 276}, {\"citation\": {\"authors\": [\"Cavallaro RA\", \"Ciraci V\", \"Ferrer I\", \"Fuso A\", \"Nicolia V\", \"Scarpa S\"], \"date\": \"2017-01-01\", \"first\": \"Nicolia V\", \"last\": \"Fuso A\", \"name\": \"Current Alzheimer research\", \"pages\": \"753-759\", \"reference\": \"28176663\", \"title\": \"GSK3 5'-flanking DNA Methylation and Expression in Alzheimer's Disease Patients.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \"Thus, our results suggest that Tau hyperphosphorylation was a result of ribosylated AGEs, rather than due to a direct reaction involving D-ribose.\", \"key\": \"cb2064b6b75b53bacbb6f398471440ea56d20cec38e378984ac2a821a4cf1501d61df4da3c90fc8e5f287cfbd50ca2753d003bc1a8d2fe28350a862680ffcc4f\", \"line\": 2298, \"relation\": \"increases\", \"source\": 48, \"target\": 304}, {\"citation\": {\"authors\": [\"Cavallaro RA\", \"Ciraci V\", \"Ferrer I\", \"Fuso A\", \"Nicolia V\", \"Scarpa S\"], \"date\": \"2017-01-01\", \"first\": \"Nicolia V\", \"last\": \"Fuso A\", \"name\": \"Current Alzheimer research\", \"pages\": \"753-759\", \"reference\": \"28176663\", \"title\": \"GSK3 5'-flanking DNA Methylation and Expression in Alzheimer's Disease Patients.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \"Thus, our results suggest that Tau hyperphosphorylation was a result of ribosylated AGEs, rather than due to a direct reaction involving D-ribose.\", \"key\": \"3cf9e1cfa40aef49ebff307384da129720dd07dd331a41a063a01590355cc6b86382fc96519bc07b4443b3c7e6b5acf75967c50fca6a9c515b6e1b73a44228c8\", \"line\": 2296, \"relation\": \"increases\", \"source\": 48, \"target\": 311}, {\"citation\": {\"authors\": [\"Cavallaro RA\", \"Ciraci V\", \"Ferrer I\", \"Fuso A\", \"Nicolia V\", \"Scarpa S\"], \"date\": \"2017-01-01\", \"first\": \"Nicolia V\", \"last\": \"Fuso A\", \"name\": \"Current Alzheimer research\", \"pages\": \"753-759\", \"reference\": \"28176663\", \"title\": \"GSK3 5'-flanking DNA Methylation and Expression in Alzheimer's Disease Patients.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \"Thus, our results suggest that Tau hyperphosphorylation was a result of ribosylated AGEs, rather than due to a direct reaction involving D-ribose.\", \"key\": \"4411d43441a3fab51b7ccc1c35f49dbe0fcbd15240c22004a529f1916db23701e8ea9f6120ac23ca6352fcb78ba0272ad22b1b0d2b5cfee7a9ce81eb5af6141e\", \"line\": 2297, \"relation\": \"increases\", \"source\": 48, \"target\": 294}, {\"citation\": {\"authors\": [\"Alonso AC\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Kpke E\", \"Shaikh S\", \"Tung YC\"], \"date\": \"1993-11-15\", \"first\": \"Kpke E\", \"last\": \"Grundke-Iqbal I\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"24374-84\", \"reference\": \"8226987\", \"title\": \"Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"268\"}, \"evidence\": \">8 phosphates per tau molecules (vs 2 in adult healthy brain); can also be increased during development, hibernation and temperature, heat and oxydative stress These phosphorylated states are detected by specific antibodies and are targets of proline-directed kinases (SP motifs), non-proline kinases (KXGS motif) Weakens tau-MT interaction especially S261 in R1 and S214 in proline-rich domain\", \"key\": \"52df3267ca2896aad0d1c0acf2d79212cc7aa578e5a184474b735bf5aa9a6dd5939254dd71f8cdf754b2a17715617cede1c643914944a91e126b625ed2360881\", \"line\": 2819, \"relation\": \"increases\", \"source\": 96, \"target\": 276}, {\"annotations\": {\"Research_Model\": {\"5xFAD mice\": true}, \"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Ando K\", \"Brion JP\", \"D'Amico E\", \"Duyckaerts C\", \"Erneux C\", \"Jia Y\", \"Leroy K\", \"Luo HR\", \"Pouillon V\", \"Schurmans S\", \"Stygelbout V\"], \"date\": \"2014-02-01\", \"first\": \"Stygelbout V\", \"last\": \"Brion JP\", \"name\": \"Brain : a journal of neurology\", \"pages\": \"537-52\", \"reference\": \"24401760\", \"title\": \"Inositol trisphosphate 3-kinase B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology.\", \"type\": \"PubMed\", \"volume\": \"137\"}, \"evidence\": \"We show here that ITPKB protein level was increased 3-fold in the cerebral cortex of most patients with Alzheimer's disease compared with control subjects, and accumulated in dystrophic neurites associated to amyloid plaques. In mouse Neuro-2a neuroblastoma cells, Itpkb overexpression was associated with increased cell apoptosis and increased -secretase 1 activity leading to overproduction of amyloid- peptides. In this cellular model, an inhibitor of mitogen-activated kinase kinases 1/2 completely prevented overproduction of amyloid- peptides. Transgenic overexpression of ITPKB in mouse forebrain neurons was not sufficient to induce amyloid plaque formation or tau hyperphosphorylation. However, in the 5X familial Alzheimer's disease mouse model, neuronal ITPKB overexpression significantly increased extracellular signal-regulated kinases 1/2 activation and -secretase 1 activity, resulting in exacerbated Alzheimer's disease pathology as shown by increased astrogliosis, amyloid-40 peptide production and tau hyperphosphorylation.\", \"key\": \"4b3949709f51c63f83b838eba89b8dcc89af67354f864c27759b36fa5516fbd366683551a40680a8015e5f22db91e01c56c71319f892115ec0e50fcd2b24e124\", \"line\": 2877, \"relation\": \"increases\", \"source\": 202, \"target\": 276}, {\"citation\": {\"authors\": [\"Huang L\", \"Liu C\", \"Qin C\", \"Sheng SL\", \"Sui XL\", \"Tao JJ\", \"Wu J\", \"Xu YF\", \"Yao ZG\", \"Zhang L\", \"Zhu H\"], \"date\": \"2014-01-01\", \"first\": \"Zhang L\", \"last\": \"Qin C\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"1193-205\", \"reference\": \"24844691\", \"title\": \"Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"41\"}, \"evidence\": \"In the present study, we tested the potential of two selective HDAC6 inhibitors, tubastatin A and ACY-1215, to rescue cognitive deficits in a mouse model of AD. We found that both tubastatin A and ACY-1215 alleviated behavioral deficits, altered amyloid- (A) load, and reduced tau hyperphosphorylation in AD mice without obvious adverse effects. Our data suggested that tubastatin A and ACY-1215 not only promoted tubulin acetylation, but also reduced production and facilitated autophagic clearance of A and hyperphosphorylated tau.\", \"key\": \"fae7643244e42a7c1cde446a8de15610d60872a46b1394ed211368f9485701ec4ffa9e5d1c664a10218a084fbc8c8fc9ca0440f6c06c5aba78b4ee1e483ca236\", \"line\": 2982, \"relation\": \"decreases\", \"source\": 47, \"target\": 276}, {\"citation\": {\"authors\": [\"Dehennaut V\", \"Drougat L\", \"Guinez C\", \"Lefebvre T\", \"Michalski JC\", \"Mir AM\", \"Mortuaire M\", \"Olivier S\", \"Vercoutter-Edouart AS\"], \"date\": \"2010-02-01\", \"first\": \"Lefebvre T\", \"last\": \"Michalski JC\", \"name\": \"Biochimica et biophysica acta\", \"pages\": \"67-79\", \"reference\": \"19732809\", \"title\": \"Dysregulation of the nutrient/stress sensor O-GlcNAcylation is involved in the etiology of cardiovascular disorders, type-2 diabetes and Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"1800\"}, \"evidence\": \"These results are in accord with our previous study showing that Tau hyperphosphorylation is associated with a decrease in its O-GlcNAcylation level. A recent observation argues for the hypothesis that O-GlcNAcylation occurs first and that its modification reflects on the phosphorylation status.\", \"key\": \"0c32ee0328f1023c42a5a861e2adaadfaa690a76c51bef8c14ea2d6b2e907a4295c02bfe6d53c69033db8e93f3400662bf714495f4d89b315ea493b7e9609630\", \"line\": 3436, \"relation\": \"negativeCorrelation\", \"source\": 272, \"target\": 276}, {\"annotations\": {\"Research_Model\": {\"rTg4510 mice\": true}}, \"citation\": {\"authors\": [\"Boehm J\", \"Bourgeois C\", \"Dudilot A\", \"Lauzon M\", \"Leclerc N\", \"Mondragn-Rodrguez S\", \"Trillaud-Doppia E\"], \"date\": \"2012-09-14\", \"first\": \"Mondragn-Rodrguez S\", \"last\": \"Boehm J\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"32040-53\", \"reference\": \"22833681\", \"title\": \"Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.\", \"type\": \"PubMed\", \"volume\": \"287\"}, \"evidence\": \"Acute treatment of rTg4510 mice with an O-GlcNAcase inhibitor transiently reduced tau phosphorylation at epitopes implicated in tau pathology. More importantly, long-term inhibitor treatment strongly increased tau O-GlcNAcylation, reduced the number of dystrophic neurons, and protected against the formation of pathological tau species without altering the phosphorylation of non-pathological tau.\", \"key\": \"229eea8a082e3274da64c3ca4991dcfe6cba99502604f9286b486d23869734d334bad6f5ab3d238b192b0147ebcd0f0f4a45c67e369b22bac076f28db377ce2d\", \"line\": 2510, \"relation\": \"positiveCorrelation\", \"source\": 272, \"target\": 304}, {\"annotations\": {\"Research_Model\": {\"rTg4510 mice\": true}}, \"citation\": {\"authors\": [\"Boehm J\", \"Bourgeois C\", \"Dudilot A\", \"Lauzon M\", \"Leclerc N\", \"Mondragn-Rodrguez S\", \"Trillaud-Doppia E\"], \"date\": \"2012-09-14\", \"first\": \"Mondragn-Rodrguez S\", \"last\": \"Boehm J\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"32040-53\", \"reference\": \"22833681\", \"title\": \"Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.\", \"type\": \"PubMed\", \"volume\": \"287\"}, \"evidence\": \"Acute treatment of rTg4510 mice with an O-GlcNAcase inhibitor transiently reduced tau phosphorylation at epitopes implicated in tau pathology. More importantly, long-term inhibitor treatment strongly increased tau O-GlcNAcylation, reduced the number of dystrophic neurons, and protected against the formation of pathological tau species without altering the phosphorylation of non-pathological tau.\", \"key\": \"4dfe9dc57f3eadbe1818055e7960b961386b19aaa78939d94bd1114aaecc868c125f8d30fb9e80cde10ea7371880590e4bea4681cf91d0b9b058f91e02abfdc1\", \"line\": 2507, \"relation\": \"positiveCorrelation\", \"source\": 272, \"target\": 312}, {\"citation\": {\"authors\": [\"Gong CX\", \"Li X\", \"Lu F\", \"Wang JZ\"], \"date\": \"2006-04-01\", \"first\": \"Li X\", \"last\": \"Gong CX\", \"name\": \"The European journal of neuroscience\", \"pages\": \"2078-86\", \"reference\": \"16630055\", \"title\": \"Concurrent alterations of O-GlcNAcylation and phosphorylation of tau in mouse brains during fasting.\", \"type\": \"PubMed\", \"volume\": \"23\"}, \"evidence\": \"We recently discovered that the human brain tau is also modified by O-GlcNAcylation in addition to phosphorylation and that O-GlcNAcylation modulates phosphorylation of tau inversely (Liu et al.,2004a). We found that fasting induced a time-dependent decrease in tau O-GlcNAcylation and concurrent hyperphosphorylation of tau at most of the phosphorylation sites studied.\", \"key\": \"c8488d2e4dd67eb26437bae5a03166a4b1e100e6428055079278b8eba9bb64645c3fad0785460158f9719fde10dabaa142a485937692f90d647f12449723011a\", \"line\": 690, \"relation\": \"negativeCorrelation\", \"source\": 272, \"target\": 286}, {\"annotations\": {\"Research_Model\": {\"rTg4510 mice\": true}}, \"citation\": {\"authors\": [\"Boehm J\", \"Bourgeois C\", \"Dudilot A\", \"Lauzon M\", \"Leclerc N\", \"Mondragn-Rodrguez S\", \"Trillaud-Doppia E\"], \"date\": \"2012-09-14\", \"first\": \"Mondragn-Rodrguez S\", \"last\": \"Boehm J\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"32040-53\", \"reference\": \"22833681\", \"title\": \"Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.\", \"type\": \"PubMed\", \"volume\": \"287\"}, \"evidence\": \"Acute treatment of rTg4510 mice with an O-GlcNAcase inhibitor transiently reduced tau phosphorylation at epitopes implicated in tau pathology. More importantly, long-term inhibitor treatment strongly increased tau O-GlcNAcylation, reduced the number of dystrophic neurons, and protected against the formation of pathological tau species without altering the phosphorylation of non-pathological tau.\", \"key\": \"bb4409ddd643ba0bbacf5e96e9f564a7a37cbadeec45b750ad011a7670a26ce7a6a2e20a08cc5f498d44eaa5e0e864361cb7cd2b0687c2f91938dc2be629191a\", \"line\": 2506, \"relation\": \"positiveCorrelation\", \"source\": 272, \"target\": 290}, {\"annotations\": {\"Research_Model\": {\"rTg4510 mice\": true}}, \"citation\": {\"authors\": [\"Boehm J\", \"Bourgeois C\", \"Dudilot A\", \"Lauzon M\", \"Leclerc N\", \"Mondragn-Rodrguez S\", \"Trillaud-Doppia E\"], \"date\": \"2012-09-14\", \"first\": \"Mondragn-Rodrguez S\", \"last\": \"Boehm J\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"32040-53\", \"reference\": \"22833681\", \"title\": \"Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.\", \"type\": \"PubMed\", \"volume\": \"287\"}, \"evidence\": \"Acute treatment of rTg4510 mice with an O-GlcNAcase inhibitor transiently reduced tau phosphorylation at epitopes implicated in tau pathology. More importantly, long-term inhibitor treatment strongly increased tau O-GlcNAcylation, reduced the number of dystrophic neurons, and protected against the formation of pathological tau species without altering the phosphorylation of non-pathological tau.\", \"key\": \"49c2c8b48b5b8466f9c0a985470406fa950332e2cd01f1503752560573e4cebd4d278de13573ca62136dc8912dfc1435c4a4682a31a8be13b091d9fbc0777f08\", \"line\": 2509, \"relation\": \"positiveCorrelation\", \"source\": 272, \"target\": 303}, {\"annotations\": {\"Research_Model\": {\"rTg4510 mice\": true}}, \"citation\": {\"authors\": [\"Boehm J\", \"Bourgeois C\", \"Dudilot A\", \"Lauzon M\", \"Leclerc N\", \"Mondragn-Rodrguez S\", \"Trillaud-Doppia E\"], \"date\": \"2012-09-14\", \"first\": \"Mondragn-Rodrguez S\", \"last\": \"Boehm J\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"32040-53\", \"reference\": \"22833681\", \"title\": \"Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.\", \"type\": \"PubMed\", \"volume\": \"287\"}, \"evidence\": \"Acute treatment of rTg4510 mice with an O-GlcNAcase inhibitor transiently reduced tau phosphorylation at epitopes implicated in tau pathology. More importantly, long-term inhibitor treatment strongly increased tau O-GlcNAcylation, reduced the number of dystrophic neurons, and protected against the formation of pathological tau species without altering the phosphorylation of non-pathological tau.\", \"key\": \"2d4109e569f1110503d59f93389a4dbbf15da57c25cb375384ac98702f838edd0970f22d3be4f5a40121eb78af20ca8dcd2474c29effeeeae3300ae47ff947c4\", \"line\": 2508, \"relation\": \"positiveCorrelation\", \"source\": 272, \"target\": 297}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Furthermore, Nglycosylation may facilitate tau hyperphosphorylation, as it suppresses the dephosphorylation and accelerates the phosphorylation of tau, probably because it changes the conformation of tau\", \"key\": \"017757fc21db2560f3f8a246e623c21d653b4bc0692f543ffa0ae03aeff7bf16de18ea8c318367375d2614416cf6dd52706a990aa0f8d4395a626e031ac08b51\", \"line\": 308, \"relation\": \"increases\", \"source\": 284, \"target\": 276}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Furthermore, Nglycosylation may facilitate tau hyperphosphorylation, as it suppresses the dephosphorylation and accelerates the phosphorylation of tau, probably because it changes the conformation of tau\", \"key\": \"90d4547a90b26d798425b36cbd1e820c9c51d47325aaa5391a91ad27b888886b7e58777173fb8c4dd911d3f71294f9b1fca504adb950d868503e6e3acd592262\", \"line\": 309, \"relation\": \"increases\", \"source\": 284, \"target\": 286}, {\"annotations\": {\"Cell\": {\"neuron\": true}, \"MeSHAnatomy\": {\"Brain\": true}, \"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Bertrand D\", \"Dani JA\"], \"date\": \"2007-01-01\", \"first\": \"Dani JA\", \"last\": \"Bertrand D\", \"name\": \"Annual review of pharmacology and toxicology\", \"pages\": \"699-729\", \"reference\": \"17009926\", \"title\": \"Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system.\", \"type\": \"PubMed\", \"volume\": \"47\"}, \"evidence\": \"This prospect was supported by the finding that 7 nAChRs were found in plaques (159), and 7 and 4 subunits positively correlated with neurons that accumulated A and hyperphosphorylated tau in AD brain tissue (161).\", \"key\": \"e0b3f9f6b450d94c5590ffe095209d25f08601dbfea2ccb262e27e54c1be40127537d7e9b20f2cd9558b370a7b9417901eb88b4e5285c85ba268ae91a12b3e89\", \"line\": 362, \"relation\": \"positiveCorrelation\", \"source\": 220, \"target\": 276}, {\"citation\": {\"authors\": [\"Chung KM\", \"Hernndez N\", \"Sproul AA\", \"Yu WH\"], \"date\": \"2018-05-18\", \"first\": \"Chung KM\", \"last\": \"Yu WH\", \"name\": \"Neuroscience letters\", \"reference\": \"29758300\", \"title\": \"Alzheimer's disease and the autophagic-lysosomal system.\", \"type\": \"PubMed\"}, \"evidence\": \"For example, Babu et al. has shown that p62/ knockout mice have increased levels of hyperphosphorylated tau, reduction of synaptophysin and changes in short term memory compared to p62+/ [54]\", \"key\": \"d2ff7ef3b59c443609c05de3ed0772721838bcaffb458b444c84f63b59f47aa359a873569e176df4c309ef2bb2807057ef6bc2e6d1fc7b9567fa29b55788ddaa\", \"line\": 325, \"relation\": \"decreases\", \"source\": 362, \"target\": 276}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"In AD, the OGlcNAcylation of tau is reduced  an effect that might contribute to the hyperphosphorylation and aggregation of tau\", \"key\": \"fe28c30517a199328e5055c07d4281b68df6be24dac8fa9090e436fad15528e70e54c52d2a15fdfc33f87e7b484219c5bfc6ae0da1355f435df7b1998a37274a\", \"line\": 322, \"relation\": \"decreases\", \"source\": 285, \"target\": 276}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"In contrast to Nglycosylation, OGlcNAcylation (a type of Oglycosylation) of tau may protect it against phosphorylation, as it occupies the Ser or Thr residue of SerPro or Thr-Pro motifs\", \"key\": \"7b2b7aa5fcb467a7dfc22906b20888285169df217c9129f3b56122703e7ed53f140cbf258c24d5908df74de4bd22421be39bdcc7a4ccd87af3298ffe6abd88d9\", \"line\": 313, \"relation\": \"decreases\", \"source\": 285, \"target\": 286}, {\"annotations\": {\"Confidence\": {\"Medium\": true}, \"MeSHAnatomy\": {\"Cerebral Cortex\": true, \"Hippocampus\": true}}, \"citation\": {\"authors\": [\"Jiang S\", \"Perry G\", \"Shen L\", \"Siedlak SL\", \"Tang B\", \"Wang C\", \"Wang X\", \"Zhang F\", \"Zhu X\"], \"date\": \"2016-02-03\", \"first\": \"Wang C\", \"last\": \"Zhu X\", \"name\": \"Scientific reports\", \"pages\": \"20352\", \"reference\": \"26837465\", \"title\": \"Estrogen receptor- is localized to neurofibrillary tangles in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"6\"}, \"evidence\": \"To confirm the localization of ER  in NFTs, double fluorescence staining with antibodies to ER  and hyperphosphorylated tau (PHF-1) revealed that ER -positive NFTs were also positive for PHF-1 (Fig.2AF).\", \"key\": \"7dc430b4fd4d988c315b909cdd1a74d6f03d5095653a03301edf0eb1f5244bf71c36ac253d75dd635ca8523fc2c37484acaf7eed4f23e3884ea1d17dea90bdd5\", \"line\": 76, \"relation\": \"association\", \"source\": 228, \"target\": 276}, {\"citation\": {\"authors\": [\"Arzberger T\", \"Banzhaf-Strathmann J\", \"Benito E\", \"Edbauer D\", \"Fischer A\", \"Kretzschmar H\", \"May S\", \"Tahirovic S\"], \"date\": \"2014-08-01\", \"first\": \"Banzhaf-Strathmann J\", \"last\": \"Edbauer D\", \"name\": \"The EMBO journal\", \"pages\": \"1667-80\", \"reference\": \"25001178\", \"title\": \"MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"33\"}, \"evidence\": \"In primary neurons, overexpression of miR-125b causes tau hyperphosphorylation and an upregulation of p35, cdk5, and p44/42-MAPK signaling. In parallel, the phosphatases DUSP6 and PPP1CA and the anti-apoptotic factor Bcl-W are downregulated as direct targets of miR-125b. Knockdown of these phosphatases induces tau hyperphosphorylation, and overexpression of PPP1CA and Bcl-W prevents miR-125b-induced tau phosphorylation, suggesting that they mediate the effects of miR-125b on tau. Conversely, suppression of miR-125b in neurons by tough decoys reduces tau phosphorylation and kinase expression/activity. Injecting miR-125b into the hippocampus of mice impairs associative learning and is accompanied by downregulation of Bcl-W, DUSP6, and PPP1CA, resulting in increased tau phosphorylation in vivo. Importantly, DUSP6 and PPP1CA are also reduced in AD brains.\", \"key\": \"35d341a2d86baf18fb93a28bc91a8b728a9580cbf508b56cc4bf99445b21d958e5e05bf1e0351c3a62642d4bea7a9e52d9d776ff7516bc06e1d847e348323a21\", \"line\": 3910, \"relation\": \"directlyDecreases\", \"source\": 345, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 276}, {\"citation\": {\"authors\": [\"Hyman BT\", \"Kay KR\", \"Mandelkow EM\", \"Polydoro M\", \"Saidi LJ\", \"Sanchez L\", \"Spires-Jones TL\"], \"date\": \"2015-01-01\", \"first\": \"Saidi LJ\", \"last\": \"Spires-Jones TL\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"937-47\", \"reference\": \"25374103\", \"title\": \"Carboxy terminus heat shock protein 70 interacting protein reduces tau-associated degenerative changes.\", \"type\": \"PubMed\", \"volume\": \"44\"}, \"evidence\": \"Recent data suggest that a critical mediator of refolding or clearance of hyperphosphorylated tau is via the HSP70/HSP90 heat shock pathways in which a specific E3 ubiquitin ligase, CHIP (carboxy terminus Hsp70 interacting protein), can recognize and target for degradation abnormal but not normal tau molecules [1416].\", \"key\": \"2778c79d07d4577be83b8bc46da4e837cc9fff718d494a8380351d4cc88f012cd948c84e2ca587f5c3e2774e4b995c6eecf520c42e6f6d9806b26e213ce346a1\", \"line\": 131, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 364, \"target\": 276}, {\"annotations\": {\"TextLocation\": {\"Review\": true}}, \"citation\": {\"authors\": [\"Chesser AS\", \"Johnson GV\", \"Pritchard SM\"], \"date\": \"2013-09-03\", \"first\": \"Chesser AS\", \"last\": \"Johnson GV\", \"name\": \"Frontiers in neurology\", \"pages\": \"122\", \"reference\": \"24027553\", \"title\": \"Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"4\"}, \"evidence\": \" However, another study, also using HEK cells and ubiquitin K48 and K63 mutants, demonstrated that in the presence of the E3 ligase CHIP, tau could be ubiquitylated by both K48 and K63 linkages (100). The likelihood that in vivo tau can be ubiquitylated in multiple ways is supported by studies showing tau isolated from NFTs in human brain has several forms of ubiquitin linkages as well as mono-ubiquitylation (101, 102). These data suggest that the physical structure of the ubiquitin chain is unlikely to be a sufficient signal for selectively targeting tau to either the proteasome or autophagy.\", \"key\": \"c22f361cfda196b4f5cbbd41e91dd411fef4d1a81b7afa8ca0b8aa523504f21c79dbf8937befdd1b4766a217ae229c6c23d8cac29c6b2dab58df597a71bcd1e5\", \"line\": 868, \"relation\": \"increases\", \"source\": 364, \"target\": 323}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Tau is known to be ubiquitylated through Lys48 linkages by CHIP for proteasomal degradation\", \"key\": \"3a558ad95cda4fd820f6c1842f73f1150c2c962a81f38a9b09a7bb3ac709b4a334f3849a5a3df0b9c11f59f3d782f372a25c39dac29f05610a2793bf6de3633d\", \"line\": 359, \"relation\": \"increases\", \"source\": 364, \"target\": 324}, {\"annotations\": {\"MeSHAnatomy\": {\"Cerebral Cortex\": true}}, \"citation\": {\"authors\": [\"Blair LJ\", \"Koren J 3rd\", \"Shelton LB\"], \"date\": \"2017-01-01\", \"first\": \"Shelton LB\", \"last\": \"Blair LJ\", \"name\": \"Frontiers in neuroscience\", \"pages\": \"724\", \"reference\": \"29311797\", \"title\": \"Imbalances in the Hsp90 Chaperone Machinery: Implications for Tauopathies.\", \"type\": \"PubMed\", \"volume\": \"11\"}, \"evidence\": \" In tauopathic mice, CHIP regulates the removal of tau species that have undergone abnormal phosphorylation and folding (Dickey et al., 2007b).\", \"key\": \"4f0253fad8e234794774bf37d911b26f8f108d8f8886c55a416724734ceecaa505618355bc4ed9e7c5ac7a78d53c6ace5ffd3480acb27c5925400601e227c907\", \"line\": 280, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 364, \"target\": 278}, {\"annotations\": {\"MeSHAnatomy\": {\"Cerebral Cortex\": true}}, \"citation\": {\"authors\": [\"Blair LJ\", \"Koren J 3rd\", \"Shelton LB\"], \"date\": \"2017-01-01\", \"first\": \"Shelton LB\", \"last\": \"Blair LJ\", \"name\": \"Frontiers in neuroscience\", \"pages\": \"724\", \"reference\": \"29311797\", \"title\": \"Imbalances in the Hsp90 Chaperone Machinery: Implications for Tauopathies.\", \"type\": \"PubMed\", \"volume\": \"11\"}, \"evidence\": \" In tauopathic mice, CHIP regulates the removal of tau species that have undergone abnormal phosphorylation and folding (Dickey et al., 2007b).\", \"key\": \"1adbae0d48ae6c7f13dfcade51d6fac48dc70b42afc6ddda495504a2f372e07ecc4f01e12c54188d3234c3ddbe303f687ced51f5bdc24f9cec4ce157255b7db2\", \"line\": 279, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 364, \"target\": 286}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"The pro-aggregant mouse lines developed ADlike features (including missorting of tau into the somatodendritic compartment, tau conformational changes, tau hyperphosphorylation, NFTs and cognitive deficits), whereas the anti-aggregant lines show almost no pathology\", \"key\": \"03c99fc64a64fdb96debd1ceaff28142364463f469fb7f7bed7f0712e25daa027b992b3c29833514fd8195af551162dcb33547fe37eb0475e79bd316b05d7b52\", \"line\": 735, \"relation\": \"increases\", \"source\": 328, \"target\": 276}, {\"annotations\": {\"Species\": {\"6239\": true}}, \"citation\": {\"authors\": [\"Baumeister R\", \"Biernat J\", \"Fatouros C\", \"Koushika SP\", \"Mandelkow E\", \"Mandelkow EM\", \"Pir GJ\", \"Schmidt E\"], \"date\": \"2012-08-15\", \"first\": \"Fatouros C\", \"last\": \"Baumeister R\", \"name\": \"Human molecular genetics\", \"pages\": \"3587-603\", \"reference\": \"22611162\", \"title\": \"Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"Overall, Tau, both in the soluble and in the insoluble fractions, was phosphorylated to a higher degree in the pro-aggregant strain compared with the other two strains.\", \"key\": \"964f9973089f89637a2b30ed13b44ba82390465945455ccdb0ddc2cf5e7d2a2a58a6d2093a54966874c547ca275956369cca5b43079a123049837efda3dd0020\", \"line\": 113, \"relation\": \"increases\", \"source\": 328, \"target\": 286}, {\"annotations\": {\"Cell\": {\"hippocampal neuron\": true}}, \"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Mouzon B\", \"Mullan M\", \"Paris D\", \"Schweig JE\", \"Yao H\"], \"date\": \"2017-09-06\", \"first\": \"Schweig JE\", \"last\": \"Paris D\", \"name\": \"Acta neuropathologica communications\", \"pages\": \"69\", \"reference\": \"28877763\", \"title\": \"Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \"Hippocampal neurons of Tg Tau P301S mice exhibit a high level of tau hyperphosphorylation (Fig. 4b) as well as an accumulation of pathogenic tau conformers (MC1, not shown) compared to WT littermates (Fig. 4a).\", \"key\": \"2474139dbd1c2f90b93c817f718135260385a5e2ca50937ac7dffa14ad9ffe82092e2cc57c1e30c3260c6dc9af8de10d6ea1e661dcdc2ec137f2be898d1b9b46\", \"line\": 146, \"relation\": \"increases\", \"source\": 330, \"target\": 276}, {\"annotations\": {\"Cell\": {\"cerebral cortex neuron\": true}}, \"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Mouzon B\", \"Mullan M\", \"Paris D\", \"Schweig JE\", \"Yao H\"], \"date\": \"2017-09-06\", \"first\": \"Schweig JE\", \"last\": \"Paris D\", \"name\": \"Acta neuropathologica communications\", \"pages\": \"69\", \"reference\": \"28877763\", \"title\": \"Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \"Cortical neurons of Tg Tau P301S mice also exhibit an increased level of tau hyperphosphorylation (Fig. 5b) compared to wild-type littermates (Fig. 5a).\", \"key\": \"30fbe7e90a6fcd0d1ec313d74519fd5a5571e401227a0a41917d0497a12eeefb190e5f81a8143e0075296f3ac13964de9e2c9ae076eb1855e10c530c756fc331\", \"line\": 161, \"relation\": \"increases\", \"source\": 330, \"target\": 276}, {\"annotations\": {\"Research_Model\": {\"TPR50 mice\": true}, \"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Hattori M\", \"Horiguchi T\", \"Iwashita H\", \"Matsumoto Y\", \"Nakamura K\", \"Obayashi Y\", \"Onishi T\", \"Yano T\"], \"date\": \"2014-03-01\", \"first\": \"Onishi T\", \"last\": \"Iwashita H\", \"name\": \"Neuroscience research\", \"pages\": \"76-85\", \"reference\": \"24406748\", \"title\": \"Early-onset cognitive deficits and axonal transport dysfunction in P301S mutant tau transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"80\"}, \"evidence\": \"We developed a transgenic mouse, named TPR50, harboring human P301S tau. Tau phosphorylation in the hippocampus of TPR50 mice increased with age, particularly at S202/T205. Therefore, cognitive dysfunction in TPR50 mice may result from early MT dysfunction and impaired axonal transport rather than accumulation of insoluble tau and neurodegeneration.\", \"key\": \"bab1557e73185d3c0d333839df20cb3c445937c3682e17ca683120bf15848689473c130b154892f125c6f7372837b40b2ea617721cac7190741a2f1be9946e3f\", \"line\": 2524, \"relation\": \"positiveCorrelation\", \"source\": 330, \"target\": 312}, {\"annotations\": {\"Research_Model\": {\"TPR50 mice\": true}, \"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Hattori M\", \"Horiguchi T\", \"Iwashita H\", \"Matsumoto Y\", \"Nakamura K\", \"Obayashi Y\", \"Onishi T\", \"Yano T\"], \"date\": \"2014-03-01\", \"first\": \"Onishi T\", \"last\": \"Iwashita H\", \"name\": \"Neuroscience research\", \"pages\": \"76-85\", \"reference\": \"24406748\", \"title\": \"Early-onset cognitive deficits and axonal transport dysfunction in P301S mutant tau transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"80\"}, \"evidence\": \"We developed a transgenic mouse, named TPR50, harboring human P301S tau. Tau phosphorylation in the hippocampus of TPR50 mice increased with age, particularly at S202/T205. Therefore, cognitive dysfunction in TPR50 mice may result from early MT dysfunction and impaired axonal transport rather than accumulation of insoluble tau and neurodegeneration.\", \"key\": \"3405409837116ad0d681170e553167780a4ed440da741cdfbc630ac8992ce5fbca633b55d0a82dd3b3eb57f7f43f69e616f8e6bce29f087e5f62b2092bcc1c44\", \"line\": 2523, \"relation\": \"positiveCorrelation\", \"source\": 330, \"target\": 290}, {\"annotations\": {\"MeSHAnatomy\": {\"Brain\": true, \"Spinal Cord\": true}, \"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Dewachter I\", \"Terwel D\", \"Van Leuven F\"], \"date\": \"2002-01-01\", \"first\": \"Terwel D\", \"last\": \"Van Leuven F\", \"name\": \"Neuromolecular medicine\", \"pages\": \"151-65\", \"reference\": \"12428809\", \"title\": \"Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"2\"}, \"evidence\": \"Neuronally overexpressed GSK-3 was demonstrated to hyperphosphorylate tau protein in vivo in the brain and spinal cord of double- transgenic mice (Spittaels et al., 2000) thereby reducing the amount of protein tau associated with microtubules by 50% (Spittaels et al., 2000).\", \"key\": \"4a0ecfa71c8aa90870d12b7b000429997b4752a7ddf998f35746d94ac775ec2d88d485fdf2db5b488ce487a55e0cc056d89f3f1105e1cf89de493cebfb8dd509\", \"line\": 199, \"relation\": \"increases\", \"source\": 232, \"target\": 276}, {\"citation\": {\"authors\": [\"De Filippis D\", \"Esposito G\", \"Iuvone T\", \"Lu J\", \"Savani C\", \"Scuderi C\", \"Sheen V\", \"Steardo L\", \"Steardo L Jr\"], \"date\": \"2008-06-01\", \"first\": \"Esposito G\", \"last\": \"Steardo L\", \"name\": \"Journal of cellular and molecular medicine\", \"pages\": \"914-27\", \"reference\": \"18494933\", \"title\": \"S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells.\", \"type\": \"PubMed\", \"volume\": \"12\"}, \"evidence\": \"For example, ongoing inflammation can trigger various cell stress-response pathways, including overexpression of the secreted glycoprotein Dickopff-1 (DKK-1). DKK-1 up-regulates GSK-3 activity, promotes tau hyper-phosphorylation, NFT formation and neuronal degeneration. Thus, DKK-1 inhibits Wnt signalling in a manner similar to A, and thereby fosters a self-sustaining feedback loop resulting in cellular injury\", \"key\": \"c4d164c1244482d856634287eb1aae835bf2d4a5e0237636d816a9209e88222ad5b19773f4fbc1e001ffbda5b7c41384477948d0b1d555a83372c293db264247\", \"line\": 715, \"relation\": \"increases\", \"source\": 232, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 276}, {\"citation\": {\"reference\": \"10.4172/2168-975X.1000126\", \"type\": \"DOI\"}, \"evidence\": \"Glycogen synthase 3 (GSK3) is one of the main serine-threonine kinase responsible for tau phosphorylation and has been shown to affect tau phosphorylation at multiple AD relevant epitopes including Ser396, Ser404, Thr231 and Ser202\", \"key\": \"ab3b6f44bb41e8af4009adb2a2082bbb30544b86eee77390d1732ee74bf2107fe6626dcad574842f7724ec6f791a6e49e7c8347f420fa0e69f3432b40154a64b\", \"line\": 148, \"relation\": \"increases\", \"source\": 232, \"target\": 304}, {\"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Bachmeier C\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Jin C\", \"Laco G\", \"Lin Y\", \"Mullan M\", \"Paris D\"], \"date\": \"2014-12-05\", \"first\": \"Paris D\", \"last\": \"Mullan M\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"33927-44\", \"reference\": \"25331948\", \"title\": \"The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid- production and Tau hyperphosphorylation.\", \"type\": \"PubMed\", \"volume\": \"289\"}, \"evidence\": \"We further confirmed that possibility by showing that Tau phosphorylation at the typical GSK3 sites (PHF-1 and CP13) is reduced following treatment of SH-SY5Y cells with BAY61-3606, whereas Tau phosphorylation at the RZ3 site was not significantly impacted in SH-SY5Y cells (Fig. 9C).\", \"key\": \"5605646353f958818992fce423a4c37365635f0dbe56350dbcea4d6e67d5042ccb5402cb41f36e0650f081c6c02880973b1bac5d030aa935d62860ce02e94dd6\", \"line\": 313, \"relation\": \"increases\", \"source\": 232, \"target\": 304}, {\"annotations\": {\"Cell_Line\": {\"COS7\": true}, \"Method\": {\"Deglycosylation Assay\": true, \"Dephosphorylation Assay\": true, \"Immunoblotting\": true, \"Immunocytochemistry\": true, \"Phosphorylation Assay\": true, \"Pull-down Assay, His-tagged\": true, \"SDS-PAGE\": true, \"Ubiquitination Assay\": true}}, \"citation\": {\"authors\": [\"Gygi SP\", \"Kosik KS\", \"Schwartz D\", \"Shimura H\"], \"date\": \"2004-02-06\", \"first\": \"Shimura H\", \"last\": \"Kosik KS\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"4869-76\", \"reference\": \"14612456\", \"title\": \"CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival.\", \"type\": \"PubMed\", \"volume\": \"279\"}, \"evidence\": \"These data indicated that phosphorylation of PP2A dephosphorylation sites is an important recognition signal for ubiquitination. We used 200 g of amino-terminal His-tagged full-length recombinant human tau in an in vitro phosphorylation reaction with GSK-3Beta. When phosphorylated, the tau protein reacted on immunoblots with PHF1 (25, 26) and AT8 (24), indicating that at least sites Ser202, Thr205, Ser396, and Ser404 were phosphorylated. Following GSK-3Beta incubation, this tau served as an excellent substrate for in vitro ubiquitination using UbcH5B and the cofactor fraction from AD tau immunoprecipitates (Fig. 2a). This finding suggested that GSK-3Beta can place phosphates on tau that create recognition sites for an E3 Ub ligase.\", \"key\": \"f728708da34cdf66ea55e0f5e0b084924ad2225a8efbba0a27f58a0e7245ad6886fb6716d7ba2ddc79f05e0bf9a18e906972b695566cbaf9a79a98f4e0ec674c\", \"line\": 391, \"relation\": \"directlyIncreases\", \"source\": 232, \"target\": 304}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"f078e4939b4bcb1e7f51c80ea951b942f71e44c6eb4a5ac6ec4a5aa05d9e13f25cc443f2d5633379c1715985cce8dd84f0686a6d31ca897299e6f0a27b7057a4\", \"line\": 1116, \"relation\": \"increases\", \"source\": 232, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 304}, {\"citation\": {\"authors\": [\"Gamblin TC\", \"Sun Q\"], \"date\": \"2009-06-30\", \"first\": \"Sun Q\", \"last\": \"Gamblin TC\", \"name\": \"Biochemistry\", \"pages\": \"6002-11\", \"reference\": \"19459590\", \"title\": \"Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization.\", \"type\": \"PubMed\", \"volume\": \"48\"}, \"evidence\": \"Because S199/S202/T205E, S396/S404E, 6-Phos and 7-Phos all demonstrated an AD-like shift in mobility as a result of phosphorylation-like changes, we conclude that they have the characteristics of hyperphosphorylated tau. These mutants will therefore be referred to as pseudo-hyperphosphorylated tau throughout the manuscript. On the basis of the observations that pseudohyperphosphorylated tau has decreased affinity for microtubules and reduced inducer-initiated rates of nucleation and polymerization, we propose that this combination could be the cause of the increased cytotoxicity of hyperphosphorylated tau in Alzheimer's disease and also explain the potentially beneficial role of tau polymerization and NFT formation.\", \"key\": \"e3691709488e492d76563df6e4cf63d6b294d745ac0102574a5c9553f2e90ebcf04b695bb5dcc6f52cd0659db64da4e168e87d5de277b3a3db274840aa5e8b82\", \"line\": 2464, \"relation\": \"increases\", \"source\": 232, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 304}, {\"annotations\": {\"Cell_Line\": {\"N2a\": true, \"SH-SY5Y\": true}}, \"citation\": {\"authors\": [\"Fan SJ\", \"Huang FI\", \"Liou JP\", \"Yang CR\"], \"date\": \"2018-05-29\", \"first\": \"Fan SJ\", \"last\": \"Yang CR\", \"name\": \"Cell death &amp; disease\", \"pages\": \"655\", \"reference\": \"29844403\", \"title\": \"The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.\", \"type\": \"PubMed\", \"volume\": \"9\"}, \"evidence\": \"This study aimed to investigate the protective effects and mechanism of the novel HDAC6 inhibitor, MPT0G211, using an AD model. Our results indicated that MPT0G211 significantly reduced tau phosphorylation and aggregation, the processes highly correlated with the formation of NFTs. This HDAC6 inhibitory activity resulted in an increase in acetylated Hsp90, which decreased Hsp90 and HDAC6 binding, causing ubiquitination of phosphorylated tau proteins. In addition, a significant increase of phospho-glycogen synthase kinase-3 (phospho-GSK3) on Ser9 (the inactive form) through Akt phosphorylation was associated with the inhibition of phospho-tau Ser396 in response to MPT0G211 treatment.\", \"key\": \"a16c8438b51435b58c848ea16883464c6675d4fd2781deaae0aa755bdb253e34753280c6b72758c0ff80c96cc40ce855ae410f182bb2aca91e12fc2a5ff39e80\", \"line\": 3395, \"relation\": \"positiveCorrelation\", \"source\": 232, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 304}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"20287a7bcbb66d2ed3aaa705b7ccda5046846dba63a03ddc65afa5a158c5778372b7fa4c7945b32f11fd8daf97182260bc3758d37bc9b2b419d2949699cadfac\", \"line\": 1110, \"relation\": \"increases\", \"source\": 232, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 311}, {\"annotations\": {\"Cell_Line\": {\"COS7\": true}, \"Method\": {\"Deglycosylation Assay\": true, \"Dephosphorylation Assay\": true, \"Immunoblotting\": true, \"Immunocytochemistry\": true, \"Phosphorylation Assay\": true, \"Pull-down Assay, His-tagged\": true, \"SDS-PAGE\": true, \"Ubiquitination Assay\": true}}, \"citation\": {\"authors\": [\"Gygi SP\", \"Kosik KS\", \"Schwartz D\", \"Shimura H\"], \"date\": \"2004-02-06\", \"first\": \"Shimura H\", \"last\": \"Kosik KS\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"4869-76\", \"reference\": \"14612456\", \"title\": \"CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival.\", \"type\": \"PubMed\", \"volume\": \"279\"}, \"evidence\": \"These data indicated that phosphorylation of PP2A dephosphorylation sites is an important recognition signal for ubiquitination. We used 200 g of amino-terminal His-tagged full-length recombinant human tau in an in vitro phosphorylation reaction with GSK-3Beta. When phosphorylated, the tau protein reacted on immunoblots with PHF1 (25, 26) and AT8 (24), indicating that at least sites Ser202, Thr205, Ser396, and Ser404 were phosphorylated. Following GSK-3Beta incubation, this tau served as an excellent substrate for in vitro ubiquitination using UbcH5B and the cofactor fraction from AD tau immunoprecipitates (Fig. 2a). This finding suggested that GSK-3Beta can place phosphates on tau that create recognition sites for an E3 Ub ligase.\", \"key\": \"a8c9ea63fcc79d3d15e6184a339fc378bab85833f660044bbcecdf6a3a9b9b450ac658f8f291ad105dc68aa95ccdd504ff6d08cb0328ad98021801ae958a59d6\", \"line\": 390, \"relation\": \"directlyIncreases\", \"source\": 232, \"target\": 312}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"15d89e9d216b2c064343fe7416b9e5722b38aec3fdb1628ce3f7e49f71e497075a6e82a437336f4a22cdaf324d10bc568a3e18b82e3c3de2f352fd0472b060ed\", \"line\": 1113, \"relation\": \"increases\", \"source\": 232, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 312}, {\"citation\": {\"authors\": [\"Andreadis A\", \"Binder LI\", \"Brady ST\", \"Fu Y\", \"Kanaan NM\", \"LaPointe NE\", \"Morfini GA\", \"Patterson KR\", \"Pigino GF\", \"Song Y\"], \"date\": \"2011-07-06\", \"first\": \"Kanaan NM\", \"last\": \"Binder LI\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"9858-68\", \"reference\": \"21734277\", \"title\": \"Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"Filamentous, but not soluble, forms of wild-type tau inhibit anterograde, kinesin-based fast axonal transport (FAT) by activating axonal protein phosphatase 1 (PP1) and glycogen synthase kinase 3 (GSK3), independent of microtubule binding. Amino acids 2-18 of tau, comprising a phosphatase-activating domain (PAD), are necessary and sufficient for activation of this pathway. Various pathogenic forms of tau displaying increased exposure of PAD inhibited anterograde FAT in squid axoplasm. Immunohistochemical studies using a novel PAD-specific monoclonal antibody in human postmortem tissue indicated that increased PAD exposure represents an early pathogenic event in AD that closely associates in time with AT8 immunoreactivity. We propose a model of pathogenesis in which disease-associated changes in tau conformation lead to increased exposure of PAD, activation of PP1-GSK3, and inhibition of FAT\", \"key\": \"964f4bc0a5d9b8237c50b221bdc0fce870d0cd90f44f2ecad0bb6cdfd5bc145983e742e95e253696bc4eab6d5f96c26d54f4737a8bc341956a09b217a868bc1e\", \"line\": 3851, \"relation\": \"directlyIncreases\", \"source\": 232, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 312}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"888d0aebffa9b7dc4149a76244af3256c845c20e9aa363a1f82568f987118edf58c79b141dc674f7b36f4f1f7eeff14adefcb084b0654df9357014ce7667027e\", \"line\": 1117, \"relation\": \"increases\", \"source\": 232, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 309}, {\"citation\": {\"reference\": \"10.4172/2168-975X.1000126\", \"type\": \"DOI\"}, \"evidence\": \"Glycogen synthase 3 (GSK3) is one of the main serine-threonine kinase responsible for tau phosphorylation and has been shown to affect tau phosphorylation at multiple AD relevant epitopes including Ser396, Ser404, Thr231 and Ser202\", \"key\": \"de08fc296ebe24ead740988563611fad57037673eb8c5c25797ff4e914abb46525fe3b06f52d189b94a95b7605309b73c86369d61d12f365f67ec6e4d51b47b0\", \"line\": 150, \"relation\": \"increases\", \"source\": 232, \"target\": 315}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"02bcb3da558fe2c42e7d7ec6c3d0941ad68d76bbfea5d4ee4efd299d97777228c03a9bc94265d5ee64ba9ba8d2ba83fc63a94c973dd286e6feef6764e9e94521\", \"line\": 1115, \"relation\": \"increases\", \"source\": 232, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 315}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"be21fff161dc246831b972c48b24298350595cbc76f78641f157d926b74b23fc260b63fc554cb6452694afa84fefa63b094664c0133cd3892410130b2985bfa2\", \"line\": 1114, \"relation\": \"increases\", \"source\": 232, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 314}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"c30aefaf492a5cb2db875628e15abc1b98ee4fa6bf9605b9db6a92ec31af4cb0258df2740fd6183fd330c5d6af63aad856ddd0221f730808d9dc76fd3311a3f9\", \"line\": 1119, \"relation\": \"increases\", \"source\": 232, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 313}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"b05ae3d9e1ef5e8adfd4719a1a1f3d284d2b08df8dce0f8dbc74f4fd71b8702ed0156c7da5a1c1d8b2ad9fc31fdfe41b8830d74b456e7c697f421e1cba6cd61e\", \"line\": 1111, \"relation\": \"increases\", \"source\": 232, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 289}, {\"citation\": {\"authors\": [\"Gamblin TC\", \"Sun Q\"], \"date\": \"2009-06-30\", \"first\": \"Sun Q\", \"last\": \"Gamblin TC\", \"name\": \"Biochemistry\", \"pages\": \"6002-11\", \"reference\": \"19459590\", \"title\": \"Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization.\", \"type\": \"PubMed\", \"volume\": \"48\"}, \"evidence\": \"Because S199/S202/T205E, S396/S404E, 6-Phos and 7-Phos all demonstrated an AD-like shift in mobility as a result of phosphorylation-like changes, we conclude that they have the characteristics of hyperphosphorylated tau. These mutants will therefore be referred to as pseudo-hyperphosphorylated tau throughout the manuscript. On the basis of the observations that pseudohyperphosphorylated tau has decreased affinity for microtubules and reduced inducer-initiated rates of nucleation and polymerization, we propose that this combination could be the cause of the increased cytotoxicity of hyperphosphorylated tau in Alzheimer's disease and also explain the potentially beneficial role of tau polymerization and NFT formation.\", \"key\": \"f62a3c8de8be418c9f721a94d3da88ee74b6e7f4d48d86baa8750bd6459bedc81b74164b380da69cb8d62928528adb83c1b5264b1868dac4b2165503125599c2\", \"line\": 2462, \"relation\": \"increases\", \"source\": 232, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 289}, {\"citation\": {\"authors\": [\"Andreadis A\", \"Binder LI\", \"Brady ST\", \"Fu Y\", \"Kanaan NM\", \"LaPointe NE\", \"Morfini GA\", \"Patterson KR\", \"Pigino GF\", \"Song Y\"], \"date\": \"2011-07-06\", \"first\": \"Kanaan NM\", \"last\": \"Binder LI\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"9858-68\", \"reference\": \"21734277\", \"title\": \"Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"Filamentous, but not soluble, forms of wild-type tau inhibit anterograde, kinesin-based fast axonal transport (FAT) by activating axonal protein phosphatase 1 (PP1) and glycogen synthase kinase 3 (GSK3), independent of microtubule binding. Amino acids 2-18 of tau, comprising a phosphatase-activating domain (PAD), are necessary and sufficient for activation of this pathway. Various pathogenic forms of tau displaying increased exposure of PAD inhibited anterograde FAT in squid axoplasm. Immunohistochemical studies using a novel PAD-specific monoclonal antibody in human postmortem tissue indicated that increased PAD exposure represents an early pathogenic event in AD that closely associates in time with AT8 immunoreactivity. We propose a model of pathogenesis in which disease-associated changes in tau conformation lead to increased exposure of PAD, activation of PP1-GSK3, and inhibition of FAT\", \"key\": \"e455cf5a72dc5328f3d4fa9fc6f1cbed7fb0f54da8d0adc7d7a638d83edba85cdc69de8bd2a98476135eeddd861a2c32e7e9f1d3a68ac0dd994c8e9c7945eed4\", \"line\": 3849, \"relation\": \"directlyIncreases\", \"source\": 232, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 289}, {\"citation\": {\"authors\": [\"Morsy A\", \"Trippier PC\"], \"date\": \"2018-11-30\", \"first\": \"Morsy A\", \"last\": \"Trippier PC\", \"name\": \"Journal of medicinal chemistry\", \"reference\": \"30444369\", \"title\": \"Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.\", \"type\": \"PubMed\"}, \"evidence\": \"Moreover,  estradiol  has  been  shown  to  inhibit  tau  hyperphosphorylation  and  can  also  modulate glycogen  synthase  kinase-3  (GSK-3)  activity,  a  kinase  that  is  involved  in  tau  phosphorylation. Estradiol  deactivates  GSK-3  by  inducing  its  phosphorylation,  thereafter  reducing  tau phosphorylation. \", \"key\": \"6cc210036528a95d6b1f2974773c8eaf4124dea1f2af26af53d16fbd19e6b29c0f44f90d29fd6ace42f57d7ce7e691c18c107c883f732214205407bb92c3fd91\", \"line\": 172, \"relation\": \"increases\", \"source\": 232, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 286}, {\"citation\": {\"authors\": [\"Dewachter I\", \"Terwel D\", \"Van Leuven F\"], \"date\": \"2002-01-01\", \"first\": \"Terwel D\", \"last\": \"Van Leuven F\", \"name\": \"Neuromolecular medicine\", \"pages\": \"151-65\", \"reference\": \"12428809\", \"title\": \"Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"2\"}, \"evidence\": \" Among the specific proline-dependent kinases that can phosphorylate protein tau at dif- ferent sites in vitro, special attention is dedicated to glycogen-synthase kinase-3 (GSK-3) (Michel et al., 1998), mitogen-activated protein kinase (MAPK) (Drewes et al., 1992), stress-activated protein kinases (SAPKs) (Goedert et al., 1997) and cyclin-dependent kinases (CDKs) including cdc2 and cdk5 (Baumann et al., 1993; Patrick et al., 1999).\", \"key\": \"69e3934509a07ace4e26276d74de48f774ddb95d9c14b2ec9174aeae3e9584fde20c75c9d28d6123e5d15a2a8add3b2912fc53acc0c56c892aef7a1b0b1a3835\", \"line\": 111, \"relation\": \"increases\", \"source\": 232, \"target\": 286}, {\"citation\": {\"authors\": [\"Chung KM\", \"Hernndez N\", \"Sproul AA\", \"Yu WH\"], \"date\": \"2018-05-18\", \"first\": \"Chung KM\", \"last\": \"Yu WH\", \"name\": \"Neuroscience letters\", \"reference\": \"29758300\", \"title\": \"Alzheimer's disease and the autophagic-lysosomal system.\", \"type\": \"PubMed\"}, \"evidence\": \"Tau phosphorylation, the major disease-related post-translational modification, is highly regulated by glycogen synthase kinase-3 (GSK-3), cyclin-dependent kinase 5 (CDK5), mitogen-activated protein kinase (MAPK) and other kinases.\", \"key\": \"00bb6b7bca59e9c1a4117f962ffd3924a89086c0d3cd26e6f35447a12df0bef1a0a937d1ca8f92e4a38647da93cf6f487714ac6b26f261919e3ee0a8c204a476\", \"line\": 287, \"relation\": \"increases\", \"source\": 232, \"target\": 286}, {\"citation\": {\"authors\": [\"Dickey CA\", \"Gestwicki JE\", \"Kiray J\", \"Koren J\", \"Miyata Y\"], \"date\": \"2011-09-01\", \"first\": \"Miyata Y\", \"last\": \"Gestwicki JE\", \"name\": \"Future medicinal chemistry\", \"pages\": \"1523-37\", \"reference\": \"21882945\", \"title\": \"Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.\", \"type\": \"PubMed\", \"volume\": \"3\"}, \"evidence\": \"Phosphorylation of tau by the kinases GSK3b, Cdk5 and MARK2 is a major regulator of its microtubule interactions\", \"key\": \"b7183639914eef979ddbea3156bd67f41168dc3bd3d266669ce828aff13945a9941e3a545985dcc771ce71845d4f12706ec134786128d7b35de1591c6e13d25a\", \"line\": 95, \"relation\": \"directlyIncreases\", \"source\": 232, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 286}, {\"annotations\": {\"Species\": {\"6239\": true}}, \"citation\": {\"authors\": [\"Choudhary B\", \"Mandelkow E\", \"Pir GJ\"], \"date\": \"2017-12-01\", \"first\": \"Pir GJ\", \"last\": \"Mandelkow E\", \"name\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\", \"pages\": \"5137-5148\", \"reference\": \"29191965\", \"title\": \"&lt;i&gt;Caenorhabditis elegans&lt;/i&gt; models of tauopathy.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"The responsible kinases include 1) proline-directed protein kinases (PDPKs) targeting SP or TP motifs [e.g., GSK3b, cyclindependent kinase (CDK)-5, and MAPKs]; 2) nonproline directed protein kinases targeting KXGS-motifs [e.g., PKA, microtubule affinity-regulating kinase and synapses of the amphid defective (SADK)]; 3) protein kinases specific for tyrosines (e.g., Src, Lck, Syk, Fyn, and c-Abl kinase) (91).\", \"key\": \"d469f694b857b52e5c6e33a22d563916f3bb4a40d433df939a34926f1f7ba26cb1794ce2262be3ca50da330b8d90b36ce28ba5c1244dc14e8013f2571ed85c85\", \"line\": 245, \"relation\": \"directlyIncreases\", \"source\": 232, \"target\": 286}, {\"annotations\": {\"MeSHAnatomy\": {\"Cerebral Cortex\": true}}, \"citation\": {\"authors\": [\"Blair LJ\", \"Koren J 3rd\", \"Shelton LB\"], \"date\": \"2017-01-01\", \"first\": \"Shelton LB\", \"last\": \"Blair LJ\", \"name\": \"Frontiers in neuroscience\", \"pages\": \"724\", \"reference\": \"29311797\", \"title\": \"Imbalances in the Hsp90 Chaperone Machinery: Implications for Tauopathies.\", \"type\": \"PubMed\", \"volume\": \"11\"}, \"evidence\": \"Cdc37 is also required for the stable folding of protein kinases in coordination with Hsp90 (Calderwood, 2015). Many of these kinases are known to phosphorylate tau at sites associated with AD, such as GSK3 and MAPK13 (Taipale et al., 2012; Jin et al., 2016).\", \"key\": \"c21aa9951195cecd6849998798453c241767ddf06cae4f81c38ab3f73d3a86c11130202eef7e0e8ab57b0556d5d89f4412597eaa2159bc42953c0a8ed48ff221\", \"line\": 294, \"relation\": \"increases\", \"source\": 232, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 286}, {\"annotations\": {\"CellLine\": {\"HEK293\": true}, \"Cell_Line\": {\"COS7\": true}, \"Method\": {\"Chromatography, FPLC\": true, \"Co-Immunoprecipitation\": true, \"Immunoprecipitation\": true, \"Pull-down Assay, GST\": true, \"SDS-PAGE\": true}}, \"citation\": {\"authors\": [\"Agarwal-Mawal A\", \"Cafferty PW\", \"Han D\", \"Lin R\", \"Paudel HK\", \"Qureshi HY\", \"Yuan Z\"], \"date\": \"2003-04-11\", \"first\": \"Agarwal-Mawal A\", \"last\": \"Paudel HK\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"12722-8\", \"reference\": \"12551948\", \"title\": \"14-3-3 connects glycogen synthase kinase-3 beta to tau within a brain microtubule-associated tau phosphorylation complex.\", \"type\": \"PubMed\", \"volume\": \"278\"}, \"evidence\": \"In cells that were co-transfected with fixed amounts of FLAG-tau and HA-GSK3Beta but different amounts of Xpress-14-3-3zeta, FLAG-tau phosphorylation increased progressively with the increase in the amount of Xpress-14-3-3zeta (lanes 79). This increase was evident not only by an increased immunoreactivity against all tau phosphorylation-sensitive antibodies tested but also by a retarded mobility of FLAG-tau on the SDS gel, a characteristic feature of hyperphosphorylated tau (2, 3). Thus, 14-3-3zeta profoundly stimulated GSK3Beta-catalyzed tau phosphorylation in vivo.\", \"key\": \"f666629f81f1dda4951393102291dd016edb42b8ced34480c283bd7df656f72495e7cea6523405101ed63f77f5e0c07f3fa4c26294902c1d527ac89866461fb5\", \"line\": 776, \"relation\": \"increases\", \"source\": 232, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 286}, {\"citation\": {\"authors\": [\"An FM\", \"Chen S\", \"Gao XD\", \"Liu AR\", \"Yao WB\", \"Yin DK\", \"Yin L\"], \"date\": \"2014-01-03\", \"first\": \"Chen S\", \"last\": \"Gao XD\", \"name\": \"Neuroscience\", \"pages\": \"137-46\", \"reference\": \"24183963\", \"title\": \"Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation.\", \"type\": \"PubMed\", \"volume\": \"256\"}, \"evidence\": \"Recently, Li et al. (2012b) have demonstrated in their study that AGEs can induce tau hyperphosphorylation through receptor for advanced glycation end product (RAGE)-mediated glycogen synthase kinase 3 (GSK-3) activation and targeting RAGE/GSK-3 pathway can improve AD-like changes.\", \"key\": \"db8195289edda596f9c0dc3922b24abc127916fa894846d149ca9edb33e914de853eefc4eaa8525f3824487eb68b663b683f6582268de07561ee44a79296be8b\", \"line\": 387, \"relation\": \"increases\", \"source\": 232, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 286}, {\"annotations\": {\"Cell_Line\": {\"neural stem cell\": true}, \"Method\": {\"Electrophoretic Mobility Shift Assay\": true, \"Immunofluorescence\": true, \"RNA Interference, siRNA\": true, \"RT-PCR\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"De Filippis D\", \"Esposito G\", \"Iuvone T\", \"Lu J\", \"Savani C\", \"Scuderi C\", \"Sheen V\", \"Steardo L\", \"Steardo L Jr\"], \"date\": \"2008-06-01\", \"first\": \"Esposito G\", \"last\": \"Steardo L\", \"name\": \"Journal of cellular and molecular medicine\", \"pages\": \"914-27\", \"reference\": \"18494933\", \"title\": \"S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells.\", \"type\": \"PubMed\", \"volume\": \"12\"}, \"evidence\": \"In addition, as revealed by Western blot, small interfering RNA and immunofluorescence analysis, S100B-induced JNK activation increased expression of Dickopff-1 that, in turn, promoted glycogen synthase kinase 3-beta phosphorylation and beta-catenin degradation, causing canonical Wnt pathway disruption and tau protein hyperphosphorylation.\", \"key\": \"dab57261d50295b097d318dd78d3ba46af075ff7f7f538bbb3bb1bcde1ca2cbb61f61517df1be0c8050928343fbf315e20761f7e7314c386bf604dcd4b961ff6\", \"line\": 671, \"relation\": \"increases\", \"source\": 232, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 286}, {\"annotations\": {\"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Cuadrado A\", \"Kgler S\", \"Lastres-Becker I\"], \"date\": \"2018-04-01\", \"first\": \"Cuadrado A\", \"last\": \"Lastres-Becker I\", \"name\": \"Redox biology\", \"pages\": \"522-534\", \"reference\": \"29121589\", \"title\": \"Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \"Taken together, our results show that DMF reduces GSK-3 activity in vivo as determined by a significant and subtle reduction in the phosphorylation levels of its two substrates TAU and CRMP2 respectively.\", \"key\": \"ce3d06b9b738203ac15c76b00537be666031019ba5b1ed016775f19844cf930d67cf3ab64840d0edc6b8baceabfb5a14f72c5ae56569cda59b5a805aea6beb81\", \"line\": 1030, \"relation\": \"directlyIncreases\", \"source\": 232, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 286}, {\"annotations\": {\"Ki\": {\"4-80 nM\": true}}, \"citation\": {\"authors\": [\"Bibb JA\", \"Biernat J\", \"Greengard P\", \"Gussio R\", \"Kunick C\", \"Leost M\", \"Link A\", \"Mandelkow EM\", \"Meijer L\", \"Sausville EA\", \"Schultz C\", \"Senderowicz AM\", \"Snyder GL\", \"Wu YZ\", \"Zaharevitz DW\"], \"date\": \"2000-10-01\", \"first\": \"Leost M\", \"last\": \"Meijer L\", \"name\": \"European journal of biochemistry\", \"pages\": \"5983-94\", \"reference\": \"10998059\", \"title\": \"Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25.\", \"type\": \"PubMed\", \"volume\": \"267\"}, \"evidence\": \"Alsterpaullone, the most active paullone, was demonstrated to act by competing with ATP for binding to GSK-3beta. Alsterpaullone inhibits the phosphorylation of tau in vivo at sites which are typically phosphorylated by GSK-3beta in Alzheimer's disease. Alsterpaullone also inhibits the CDK5/p25-dependent phosphorylation of DARPP-32 in mouse striatum slices in vitro. \", \"key\": \"7e8cd51a1f72b05594bdc95c42e311bbda6be3d2dc628de4c1183a6568c6d4f1273f0ff0c7a3336c5ffabac9fcc12ff891091b9c69012eeb0cce98b3c797b0e9\", \"line\": 1202, \"relation\": \"increases\", \"source\": 232, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 286}, {\"annotations\": {\"Confidence\": {\"High\": true}, \"MeSHDisease\": {\"Alzheimer Disease\": true}, \"Subgraph\": {\"Amyloidogenic subgraph\": true, \"Cyclin-CDK subgraph\": true, \"GSK3 subgraph\": true, \"Interleukin signaling subgraph\": true, \"Tau protein subgraph\": true}}, \"citation\": {\"authors\": [\"Olsen I\", \"Singhrao SK\"], \"date\": \"2016-06-15\", \"first\": \"Olsen I\", \"last\": \"Singhrao SK\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"45-53\", \"reference\": \"27314526\", \"title\": \"Inflammasome Involvement in Alzheimer's Disease.\", \"type\": \"PubMed\", \"volume\": \"54\"}, \"evidence\": \"Pro-inammatory IL-18 increases AD-associated A beta deposition in human neuron-like cells in culture [55]. IL-18 also increases the expression of glycogen synthase kinase 3 beta (GSK-3 beta ) and cyclin-dependent kinase 5, both of which are involved in hyperphos- phorylation of the tau protein [56]. \", \"key\": \"a38e47c8df699f73175afc3b9ab5e4588db394627de2a50163234aa0f05f601e6ac6a4549170a7051921acba4b6cbc55a7c4d31c7eff61fdf5879513309442d1\", \"line\": 235, \"relation\": \"increases\", \"source\": 232, \"target\": 286}, {\"citation\": {\"reference\": \"10.4172/2168-975X.1000126\", \"type\": \"DOI\"}, \"evidence\": \"Glycogen synthase 3 (GSK3) is one of the main serine-threonine kinase responsible for tau phosphorylation and has been shown to affect tau phosphorylation at multiple AD relevant epitopes including Ser396, Ser404, Thr231 and Ser202\", \"key\": \"8ba6a93b5c2905819f2bd6f82e4b3258e55bb724c7a9a2b08d74dbf36e5daee975738d95e21d4628b8ead11534fa376134dcd6f613c589f7bcdeaa28bf298653\", \"line\": 151, \"relation\": \"increases\", \"source\": 232, \"target\": 290}, {\"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Bachmeier C\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Jin C\", \"Laco G\", \"Lin Y\", \"Mullan M\", \"Paris D\"], \"date\": \"2014-12-05\", \"first\": \"Paris D\", \"last\": \"Mullan M\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"33927-44\", \"reference\": \"25331948\", \"title\": \"The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid- production and Tau hyperphosphorylation.\", \"type\": \"PubMed\", \"volume\": \"289\"}, \"evidence\": \"We further confirmed that possibility by showing that Tau phosphorylation at the typical GSK3 sites (PHF-1 and CP13) is reduced following treatment of SH-SY5Y cells with BAY61-3606, whereas Tau phosphorylation at the RZ3 site was not significantly impacted in SH-SY5Y cells (Fig. 9C).\", \"key\": \"4060a06a825c405494481b860d85344138f4d4ddeade8672b74454ba46de8ec14cd1cd03baaa0202fa91ad02187755385760e6bd10360a6ff94b995bb77708de\", \"line\": 315, \"relation\": \"increases\", \"source\": 232, \"target\": 290}, {\"annotations\": {\"Cell_Line\": {\"COS7\": true}, \"Method\": {\"Deglycosylation Assay\": true, \"Dephosphorylation Assay\": true, \"Immunoblotting\": true, \"Immunocytochemistry\": true, \"Phosphorylation Assay\": true, \"Pull-down Assay, His-tagged\": true, \"SDS-PAGE\": true, \"Ubiquitination Assay\": true}}, \"citation\": {\"authors\": [\"Gygi SP\", \"Kosik KS\", \"Schwartz D\", \"Shimura H\"], \"date\": \"2004-02-06\", \"first\": \"Shimura H\", \"last\": \"Kosik KS\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"4869-76\", \"reference\": \"14612456\", \"title\": \"CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival.\", \"type\": \"PubMed\", \"volume\": \"279\"}, \"evidence\": \"These data indicated that phosphorylation of PP2A dephosphorylation sites is an important recognition signal for ubiquitination. We used 200 g of amino-terminal His-tagged full-length recombinant human tau in an in vitro phosphorylation reaction with GSK-3Beta. When phosphorylated, the tau protein reacted on immunoblots with PHF1 (25, 26) and AT8 (24), indicating that at least sites Ser202, Thr205, Ser396, and Ser404 were phosphorylated. Following GSK-3Beta incubation, this tau served as an excellent substrate for in vitro ubiquitination using UbcH5B and the cofactor fraction from AD tau immunoprecipitates (Fig. 2a). This finding suggested that GSK-3Beta can place phosphates on tau that create recognition sites for an E3 Ub ligase.\", \"key\": \"f004b7af61c3d9d8a7e51d1430fe7bd0c87540aa3a377cc2c8ad4d27ab75c61bc1dd1c762e4591c4d1c7c761bc6b5b75304795463b591f9ab0e13875f0807c47\", \"line\": 389, \"relation\": \"directlyIncreases\", \"source\": 232, \"target\": 290}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"daf33a5d3a06f049dd07c557955d67758ad93c59150fc7e209b92e202cf2b993cc11ff191cd0407b68fd47816ac7b7672ed5f42e26c4e11cfadd0dabe524eef9\", \"line\": 1112, \"relation\": \"increases\", \"source\": 232, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 290}, {\"citation\": {\"authors\": [\"Andreadis A\", \"Binder LI\", \"Brady ST\", \"Fu Y\", \"Kanaan NM\", \"LaPointe NE\", \"Morfini GA\", \"Patterson KR\", \"Pigino GF\", \"Song Y\"], \"date\": \"2011-07-06\", \"first\": \"Kanaan NM\", \"last\": \"Binder LI\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"9858-68\", \"reference\": \"21734277\", \"title\": \"Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"Filamentous, but not soluble, forms of wild-type tau inhibit anterograde, kinesin-based fast axonal transport (FAT) by activating axonal protein phosphatase 1 (PP1) and glycogen synthase kinase 3 (GSK3), independent of microtubule binding. Amino acids 2-18 of tau, comprising a phosphatase-activating domain (PAD), are necessary and sufficient for activation of this pathway. Various pathogenic forms of tau displaying increased exposure of PAD inhibited anterograde FAT in squid axoplasm. Immunohistochemical studies using a novel PAD-specific monoclonal antibody in human postmortem tissue indicated that increased PAD exposure represents an early pathogenic event in AD that closely associates in time with AT8 immunoreactivity. We propose a model of pathogenesis in which disease-associated changes in tau conformation lead to increased exposure of PAD, activation of PP1-GSK3, and inhibition of FAT\", \"key\": \"7dcf9eb2816016636cc77287dcdea842b169e28c98d24d61f8f8470b310b24701b660720dce8d478eb30b80481f28e2a32c5990f676cfd809355083259974cf0\", \"line\": 3850, \"relation\": \"directlyIncreases\", \"source\": 232, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 290}, {\"annotations\": {\"MeSHAnatomy\": {\"Brain\": true, \"Spinal Cord\": true}, \"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Dewachter I\", \"Terwel D\", \"Van Leuven F\"], \"date\": \"2002-01-01\", \"first\": \"Terwel D\", \"last\": \"Van Leuven F\", \"name\": \"Neuromolecular medicine\", \"pages\": \"151-65\", \"reference\": \"12428809\", \"title\": \"Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"2\"}, \"evidence\": \" More- over, the unbound tau protein was hyperphospho- rylated and especially at the AD-2 epitope, e.g., an epitope shown to contain serine 396 and serine 404.\", \"key\": \"c0815e67365f830153f1cade8eb11493aef8bb7580180028d6044e9dd16cb9f2cf6ab0e6d71e9261117f07ddd61e79e7123bc8c2b2d88e8f20d50d7459f2a1c1\", \"line\": 210, \"relation\": \"increases\", \"source\": 232, \"target\": 305}, {\"citation\": {\"reference\": \"10.4172/2168-975X.1000126\", \"type\": \"DOI\"}, \"evidence\": \"Glycogen synthase 3 (GSK3) is one of the main serine-threonine kinase responsible for tau phosphorylation and has been shown to affect tau phosphorylation at multiple AD relevant epitopes including Ser396, Ser404, Thr231 and Ser202\", \"key\": \"31872a87524d459a9e2a806ecd7f32a5ef327afcf5d497669f2b88f3f1103dbadab450d3711158d13ff83ae8b79c1048bb21e10461c4eeffb199617afb3249aa\", \"line\": 149, \"relation\": \"increases\", \"source\": 232, \"target\": 306}, {\"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Bachmeier C\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Jin C\", \"Laco G\", \"Lin Y\", \"Mullan M\", \"Paris D\"], \"date\": \"2014-12-05\", \"first\": \"Paris D\", \"last\": \"Mullan M\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"33927-44\", \"reference\": \"25331948\", \"title\": \"The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid- production and Tau hyperphosphorylation.\", \"type\": \"PubMed\", \"volume\": \"289\"}, \"evidence\": \"We further confirmed that possibility by showing that Tau phosphorylation at the typical GSK3 sites (PHF-1 and CP13) is reduced following treatment of SH-SY5Y cells with BAY61-3606, whereas Tau phosphorylation at the RZ3 site was not significantly impacted in SH-SY5Y cells (Fig. 9C).\", \"key\": \"383463199d3054143a9be1bf70ad9d9d3d4f5015b2dfc85f5756ec6547daf4e08971e13f14bc1006ce9960b7384768b808ec00ca2a137cdadec0001fc987c3ce\", \"line\": 314, \"relation\": \"increases\", \"source\": 232, \"target\": 306}, {\"annotations\": {\"Cell_Line\": {\"COS7\": true}, \"Method\": {\"Deglycosylation Assay\": true, \"Dephosphorylation Assay\": true, \"Immunoblotting\": true, \"Immunocytochemistry\": true, \"Phosphorylation Assay\": true, \"Pull-down Assay, His-tagged\": true, \"SDS-PAGE\": true, \"Ubiquitination Assay\": true}}, \"citation\": {\"authors\": [\"Gygi SP\", \"Kosik KS\", \"Schwartz D\", \"Shimura H\"], \"date\": \"2004-02-06\", \"first\": \"Shimura H\", \"last\": \"Kosik KS\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"4869-76\", \"reference\": \"14612456\", \"title\": \"CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival.\", \"type\": \"PubMed\", \"volume\": \"279\"}, \"evidence\": \"These data indicated that phosphorylation of PP2A dephosphorylation sites is an important recognition signal for ubiquitination. We used 200 g of amino-terminal His-tagged full-length recombinant human tau in an in vitro phosphorylation reaction with GSK-3Beta. When phosphorylated, the tau protein reacted on immunoblots with PHF1 (25, 26) and AT8 (24), indicating that at least sites Ser202, Thr205, Ser396, and Ser404 were phosphorylated. Following GSK-3Beta incubation, this tau served as an excellent substrate for in vitro ubiquitination using UbcH5B and the cofactor fraction from AD tau immunoprecipitates (Fig. 2a). This finding suggested that GSK-3Beta can place phosphates on tau that create recognition sites for an E3 Ub ligase.\", \"key\": \"bda30db0d802c4bb03dc1a4a096dc9e7e77c3042ab0c6aebf7610fb1bec533b2c4c77b1f255c0ee2229e435b434e32f56f7c8827c73e5512802199d5a4ed9411\", \"line\": 392, \"relation\": \"directlyIncreases\", \"source\": 232, \"target\": 306}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"2f465eb423870aba37881de25c775d2dba1c77837652d7d174e142af1060ea328724d95b0ac2453ebc7fa45b5b54bed857dc35d2ac12d5c2733d3997e5e6ef90\", \"line\": 1118, \"relation\": \"increases\", \"source\": 232, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 306}, {\"citation\": {\"authors\": [\"Gamblin TC\", \"Sun Q\"], \"date\": \"2009-06-30\", \"first\": \"Sun Q\", \"last\": \"Gamblin TC\", \"name\": \"Biochemistry\", \"pages\": \"6002-11\", \"reference\": \"19459590\", \"title\": \"Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization.\", \"type\": \"PubMed\", \"volume\": \"48\"}, \"evidence\": \"Because S199/S202/T205E, S396/S404E, 6-Phos and 7-Phos all demonstrated an AD-like shift in mobility as a result of phosphorylation-like changes, we conclude that they have the characteristics of hyperphosphorylated tau. These mutants will therefore be referred to as pseudo-hyperphosphorylated tau throughout the manuscript. On the basis of the observations that pseudohyperphosphorylated tau has decreased affinity for microtubules and reduced inducer-initiated rates of nucleation and polymerization, we propose that this combination could be the cause of the increased cytotoxicity of hyperphosphorylated tau in Alzheimer's disease and also explain the potentially beneficial role of tau polymerization and NFT formation.\", \"key\": \"98bb32e796e7a576216063e6b35ba9f51257239b186c33960c7c5de9b64627a7447fb14e207660ee75fe2dc9702e04dd61a0cb3ed2d4d4bdc901fe7e2d82d2f4\", \"line\": 2465, \"relation\": \"increases\", \"source\": 232, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 306}, {\"annotations\": {\"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Ferreira-Vieira TH\", \"Guimaraes IM\", \"Ribeiro FM\", \"Silva FR\"], \"date\": \"2016-01-01\", \"first\": \"Ferreira-Vieira TH\", \"last\": \"Ribeiro FM\", \"name\": \"Current neuropharmacology\", \"pages\": \"101-15\", \"reference\": \"26813123\", \"title\": \"Alzheimer's disease: Targeting the Cholinergic System.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \"It has been shown that activation of M1 receptors decreases tau hyperphosphorylation via activation of PKC and inhibition of GSK-3\", \"key\": \"21ef9f1ceb29b2806f5be3d649b498e4d4dc348917014b3313b5b43179902fb788e2f3712f58916199f2203ab74e0e27712d135d35a6cf40d871915ef1fca878\", \"line\": 668, \"relation\": \"decreases\", \"source\": 219, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 276}, {\"annotations\": {\"CellLine\": {\"PC12\": true}}, \"citation\": {\"authors\": [\"Bu G\", \"Jiang S\", \"Li Y\", \"Xu H\", \"Zhang C\", \"Zhang YW\", \"Zhao Y\"], \"date\": \"2014-04-01\", \"first\": \"Jiang S\", \"last\": \"Zhang YW\", \"name\": \"Neuroscience bulletin\", \"pages\": \"295-307\", \"reference\": \"24590577\", \"title\": \"M1 muscarinic acetylcholine receptor in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"30\"}, \"evidence\": \"Stimulation of M1 mAChR by two agonists, carbachol and AF102B, time- and dose-dependently decreases tau phosphorylation in PC12 cells[81]. Chronic treatment with AF267B also alleviates tau pathology in 3Tg AD mice, possibly by activating PKC and inhibiting GSK-3beta\", \"key\": \"7f713547866f40aac29443685d27505edd21bd411d618b72019bbf065a243b8f111ec46e953a4d07a9a2124cc0d0d850426ec1c9fe044d3e8495f3c888ef97da\", \"line\": 463, \"relation\": \"decreases\", \"source\": 219, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 286}, {\"citation\": {\"authors\": [\"Arzberger T\", \"Banzhaf-Strathmann J\", \"Benito E\", \"Edbauer D\", \"Fischer A\", \"Kretzschmar H\", \"May S\", \"Tahirovic S\"], \"date\": \"2014-08-01\", \"first\": \"Banzhaf-Strathmann J\", \"last\": \"Edbauer D\", \"name\": \"The EMBO journal\", \"pages\": \"1667-80\", \"reference\": \"25001178\", \"title\": \"MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"33\"}, \"evidence\": \"In primary neurons, overexpression of miR-125b causes tau hyperphosphorylation and an upregulation of p35, cdk5, and p44/42-MAPK signaling. In parallel, the phosphatases DUSP6 and PPP1CA and the anti-apoptotic factor Bcl-W are downregulated as direct targets of miR-125b. Knockdown of these phosphatases induces tau hyperphosphorylation, and overexpression of PPP1CA and Bcl-W prevents miR-125b-induced tau phosphorylation, suggesting that they mediate the effects of miR-125b on tau. Conversely, suppression of miR-125b in neurons by tough decoys reduces tau phosphorylation and kinase expression/activity. Injecting miR-125b into the hippocampus of mice impairs associative learning and is accompanied by downregulation of Bcl-W, DUSP6, and PPP1CA, resulting in increased tau phosphorylation in vivo. Importantly, DUSP6 and PPP1CA are also reduced in AD brains.\", \"key\": \"286f291644eefdc8928d4e4da33dd76f5eb2926b41da1720603200d69fca7f6ef5335dc8f6bac39fefa738799012a983bfaebdef7f35b83996be9d0a21bc298b\", \"line\": 3911, \"relation\": \"directlyIncreases\", \"source\": 217, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 276}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"The reaction with the diagnostic antibodies (Fig. 4) is similar to the examples shown previously for cdk2 (Fig. 2), MAP kinase [8], or GSK-3 [26], indicating the phosphorylation of the SP motifs for which these antibodies are sensitive (serines 199, 202, 235, 396, 404; see Fig. 1)\", \"key\": \"a462eddabef3e7741bd3eb005f7e1c55838a550838d92109398c2b6ce6b69a24d49c6e0d824fd397a7f6d32f0d0c3d6f3abc9dc7d963fd3083449162f2d79aa4\", \"line\": 127, \"relation\": \"directlyIncreases\", \"source\": 217, \"target\": 304}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"ca376640462675a0ea57e13cc25db31f2129b450eed10b1c37a478db331f878cfd6b97b772b6336993f180d5664fb335388120ad4651b74ef975fa409e802989\", \"line\": 1134, \"relation\": \"increases\", \"source\": 217, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 311}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"e33f64f056647410f45f37a3af9e775196e0da616c3a2c580ab9779eacc93341ab73fd3e1e7b7e68323fc559135cf2b67049dfcc1b7e9d0e70e3d0505702e464\", \"line\": 1136, \"relation\": \"increases\", \"source\": 217, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 312}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"57351fd3eb2f0c7fedd61b0207a0c059e21c2af864fc38968cf50f2fb0f4df2e17e9c927a006a509f444d1c6e12ea5234f2bcab7c6f2dea0b65d279a6e4d9706\", \"line\": 1138, \"relation\": \"increases\", \"source\": 217, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 309}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"0e883ec62374a7a185679328dbe7616097813e6faba46b33c35b202d35cc67b7044116429b746620af05b614203d3cd1acdbecaacc048e6dcef08ddf1d77334d\", \"line\": 1137, \"relation\": \"increases\", \"source\": 217, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 315}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"The reaction with the diagnostic antibodies (Fig. 4) is similar to the examples shown previously for cdk2 (Fig. 2), MAP kinase [8], or GSK-3 [26], indicating the phosphorylation of the SP motifs for which these antibodies are sensitive (serines 199, 202, 235, 396, 404; see Fig. 1)\", \"key\": \"51ad5c2ddbf8214d2ce5a6176b979943dcead45ebd5de7a82f9489f7ee6c9acb8a1721871c949b1e9ab3f2b1dda105e3c8a5af47f6ecca5372f332a86bd7c19e\", \"line\": 124, \"relation\": \"directlyIncreases\", \"source\": 217, \"target\": 289}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"5e4cd0012ca70f924475a6a9e579debec51c3db840baa5a69b90eddb59462ee0b5e8886f532ace21f61d2283df3a3a2062f9953a2a36777b17d58c4ec5ac078b\", \"line\": 1135, \"relation\": \"increases\", \"source\": 217, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 289}, {\"citation\": {\"authors\": [\"Dewachter I\", \"Terwel D\", \"Van Leuven F\"], \"date\": \"2002-01-01\", \"first\": \"Terwel D\", \"last\": \"Van Leuven F\", \"name\": \"Neuromolecular medicine\", \"pages\": \"151-65\", \"reference\": \"12428809\", \"title\": \"Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"2\"}, \"evidence\": \" Among the specific proline-dependent kinases that can phosphorylate protein tau at dif- ferent sites in vitro, special attention is dedicated to glycogen-synthase kinase-3 (GSK-3) (Michel et al., 1998), mitogen-activated protein kinase (MAPK) (Drewes et al., 1992), stress-activated protein kinases (SAPKs) (Goedert et al., 1997) and cyclin-dependent kinases (CDKs) including cdc2 and cdk5 (Baumann et al., 1993; Patrick et al., 1999).\", \"key\": \"bfb226ffef2327774f06054104928849fb579e8ec00b4dd719276b73e17729ce637609619530bd003dc74dc58503396fb72590a269624e95ccb2c8d56d582b4e\", \"line\": 115, \"relation\": \"increases\", \"source\": 217, \"target\": 286}, {\"citation\": {\"authors\": [\"Chung KM\", \"Hernndez N\", \"Sproul AA\", \"Yu WH\"], \"date\": \"2018-05-18\", \"first\": \"Chung KM\", \"last\": \"Yu WH\", \"name\": \"Neuroscience letters\", \"reference\": \"29758300\", \"title\": \"Alzheimer's disease and the autophagic-lysosomal system.\", \"type\": \"PubMed\"}, \"evidence\": \"Tau phosphorylation, the major disease-related post-translational modification, is highly regulated by glycogen synthase kinase-3 (GSK-3), cyclin-dependent kinase 5 (CDK5), mitogen-activated protein kinase (MAPK) and other kinases.\", \"key\": \"fe52363be0329c5d6dbba57e37868cbba2062db333057d547947b33722ebd223d9fbda891cd9ef34c1f2aa85486b5e1300e56fb9de839275a5a78dbd9a92f555\", \"line\": 288, \"relation\": \"increases\", \"source\": 217, \"target\": 286}, {\"annotations\": {\"Confidence\": {\"High\": true}, \"MeSHAnatomy\": {\"Brain\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"In conclusion, this cdc2-like kinase activity towards tau occurs in brain tissue and has an Mr of 31 kDa. These features are suggestive of other cdc2-like kinases cloned recently from brain, termed nclk [ 141, PSSARLE [28], or cdk5 [42,49]. Indeed, the 31 kDa protein reacted with an antibody specific for cdk5. Thus, the kinase isolated here is very similar if not identical to cdk5.\", \"key\": \"04b5db7c0ae041caa6bb9b4af97179369031af31ca2e418bfc8cc1cc2544efe304eebc28781cbeb75bc5be212c698724e7359018ebb254c382b4aec3b8e1d8c6\", \"line\": 104, \"relation\": \"directlyIncreases\", \"source\": 217, \"target\": 286}, {\"citation\": {\"authors\": [\"Dickey CA\", \"Gestwicki JE\", \"Kiray J\", \"Koren J\", \"Miyata Y\"], \"date\": \"2011-09-01\", \"first\": \"Miyata Y\", \"last\": \"Gestwicki JE\", \"name\": \"Future medicinal chemistry\", \"pages\": \"1523-37\", \"reference\": \"21882945\", \"title\": \"Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.\", \"type\": \"PubMed\", \"volume\": \"3\"}, \"evidence\": \"Phosphorylation of tau by the kinases GSK3b, Cdk5 and MARK2 is a major regulator of its microtubule interactions\", \"key\": \"6f89259ae6aec86a6397b3f781acaf00c671ccd130f0c8a9004e8db5ec760941af1b8ab322f8cb08ea0c656148ebb58696f33edc738a0be7049da6f8418078b3\", \"line\": 96, \"relation\": \"directlyIncreases\", \"source\": 217, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 286}, {\"annotations\": {\"Species\": {\"6239\": true}}, \"citation\": {\"authors\": [\"Choudhary B\", \"Mandelkow E\", \"Pir GJ\"], \"date\": \"2017-12-01\", \"first\": \"Pir GJ\", \"last\": \"Mandelkow E\", \"name\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\", \"pages\": \"5137-5148\", \"reference\": \"29191965\", \"title\": \"&lt;i&gt;Caenorhabditis elegans&lt;/i&gt; models of tauopathy.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"The responsible kinases include 1) proline-directed protein kinases (PDPKs) targeting SP or TP motifs [e.g., GSK3b, cyclindependent kinase (CDK)-5, and MAPKs]; 2) nonproline directed protein kinases targeting KXGS-motifs [e.g., PKA, microtubule affinity-regulating kinase and synapses of the amphid defective (SADK)]; 3) protein kinases specific for tyrosines (e.g., Src, Lck, Syk, Fyn, and c-Abl kinase) (91).\", \"key\": \"3398880968f81f80bb3a8bc7edd1f1ca3e174e848802ee76d924897fc1987edb9a77774044d289e89f3652e97a8a857d200677998705b23af391a46d45c6d9c1\", \"line\": 246, \"relation\": \"directlyIncreases\", \"source\": 217, \"target\": 286}, {\"annotations\": {\"Confidence\": {\"High\": true}, \"MeSHDisease\": {\"Alzheimer Disease\": true}, \"Subgraph\": {\"Amyloidogenic subgraph\": true, \"Cyclin-CDK subgraph\": true, \"GSK3 subgraph\": true, \"Interleukin signaling subgraph\": true, \"Tau protein subgraph\": true}}, \"citation\": {\"authors\": [\"Olsen I\", \"Singhrao SK\"], \"date\": \"2016-06-15\", \"first\": \"Olsen I\", \"last\": \"Singhrao SK\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"45-53\", \"reference\": \"27314526\", \"title\": \"Inflammasome Involvement in Alzheimer's Disease.\", \"type\": \"PubMed\", \"volume\": \"54\"}, \"evidence\": \"Pro-inammatory IL-18 increases AD-associated A beta deposition in human neuron-like cells in culture [55]. IL-18 also increases the expression of glycogen synthase kinase 3 beta (GSK-3 beta ) and cyclin-dependent kinase 5, both of which are involved in hyperphos- phorylation of the tau protein [56]. \", \"key\": \"17370489d9f73bb9ce11ca7740a3c5411b2ed6119a5a6479cd594aca6301f34dbe7c7d4c536f48862aac7430774418f86475013d3d32c7ba283212c67c1d8075\", \"line\": 236, \"relation\": \"increases\", \"source\": 217, \"target\": 286}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"The reaction with the diagnostic antibodies (Fig. 4) is similar to the examples shown previously for cdk2 (Fig. 2), MAP kinase [8], or GSK-3 [26], indicating the phosphorylation of the SP motifs for which these antibodies are sensitive (serines 199, 202, 235, 396, 404; see Fig. 1)\", \"key\": \"3d78f7f38009ae844f11a01975f7fa02b77e41a359e6cac891e0f2f43f149b8922fac9e35b089b66012e600da9805216a88c7d7fc4ed803c34cd3ab9fc83faf2\", \"line\": 125, \"relation\": \"directlyIncreases\", \"source\": 217, \"target\": 290}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"The reaction with the diagnostic antibodies (Fig. 4) is similar to the examples shown previously for cdk2 (Fig. 2), MAP kinase [8], or GSK-3 [26], indicating the phosphorylation of the SP motifs for which these antibodies are sensitive (serines 199, 202, 235, 396, 404; see Fig. 1)\", \"key\": \"c3f432df4d90fa2fcca5a3b450681aeaf2d624844093f98b61fde28b04b63193508f9849c3fbdb8d1f4190160c89cc5bae2885f6f4654ed35cb78e753e7b6d45\", \"line\": 128, \"relation\": \"directlyIncreases\", \"source\": 217, \"target\": 306}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"The reaction with the diagnostic antibodies (Fig. 4) is similar to the examples shown previously for cdk2 (Fig. 2), MAP kinase [8], or GSK-3 [26], indicating the phosphorylation of the SP motifs for which these antibodies are sensitive (serines 199, 202, 235, 396, 404; see Fig. 1)\", \"key\": \"14c77e07369989621f502a072fc843dadad2e08973907e2a66f8529b0c136e93a368ddc7219561825ba87f69a3811c2ee526bc2ac4eefa7609f392778684d7db\", \"line\": 126, \"relation\": \"directlyIncreases\", \"source\": 217, \"target\": 295}, {\"annotations\": {\"Cell\": {\"neuron\": true}, \"MeSHAnatomy\": {\"Brain\": true}, \"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Bertrand D\", \"Dani JA\"], \"date\": \"2007-01-01\", \"first\": \"Dani JA\", \"last\": \"Bertrand D\", \"name\": \"Annual review of pharmacology and toxicology\", \"pages\": \"699-729\", \"reference\": \"17009926\", \"title\": \"Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system.\", \"type\": \"PubMed\", \"volume\": \"47\"}, \"evidence\": \"This prospect was supported by the finding that 7 nAChRs were found in plaques (159), and 7 and 4 subunits positively correlated with neurons that accumulated A and hyperphosphorylated tau in AD brain tissue (161).\", \"key\": \"3d304cb93fb78b05cfda89976e8e994ead49993be43ca30a0d1400a7f378ff1e34fa6f708b0bba50993241a95bd419187bfcc03da1d83ac5f1eb68c697aba9ab\", \"line\": 360, \"relation\": \"positiveCorrelation\", \"source\": 221, \"target\": 276}, {\"annotations\": {\"MeSHAnatomy\": {\"Hippocampus\": true}}, \"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Mouzon B\", \"Mullan M\", \"Paris D\", \"Schweig JE\", \"Yao H\"], \"date\": \"2017-09-06\", \"first\": \"Schweig JE\", \"last\": \"Paris D\", \"name\": \"Acta neuropathologica communications\", \"pages\": \"69\", \"reference\": \"28877763\", \"title\": \"Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \"Abnormal Syk activation seems to fol- low tau hyperphosphorylation (S202) in the hippocampus of Tg P301S mice (Fig. 6), as well as the formation of MC1-tau pathological conformers (data not shown here but MC1 and pSyk colocalization were quantified below).\", \"key\": \"6888e1cbed0994b3bb8232e911b73ecf359dbc59cd9d13b79d8770ee1b58994ff3d5ac90f26b3ebbd073f2b04991a9cb667645dc68494baa2a2143ecf4586f5c\", \"line\": 177, \"relation\": \"association\", \"source\": 366, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 276}, {\"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Mouzon B\", \"Mullan M\", \"Paris D\", \"Schweig JE\", \"Yao H\"], \"date\": \"2017-09-06\", \"first\": \"Schweig JE\", \"last\": \"Paris D\", \"name\": \"Acta neuropathologica communications\", \"pages\": \"69\", \"reference\": \"28877763\", \"title\": \"Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \"Altogether, these data suggest that only certain pathogenic forms of tau (MC1, Y18) promote Syk activation, whereas Syk activation appears to directly in- duce tau phosphorylation at Y18 and to indirectly regulate tau phosphorylation at multiple epitopes (S396/404, S202) as well as tau misfolding (MC1, TOC1).\", \"key\": \"28cc63e6d31dcdc6f217fc0969c6a8fe2f24d34068284f1eb3f4918e1d98e8b2eef5791cd898f5702b1f2d4cb0d5935f85816c40678c22abdc2ff98ba6c06038\", \"line\": 223, \"relation\": \"increases\", \"source\": 366, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 277}, {\"annotations\": {\"CellStructure\": {\"Neurites\": true}, \"MeSHAnatomy\": {\"Brain\": true}, \"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Mouzon B\", \"Mullan M\", \"Paris D\", \"Schweig JE\", \"Yao H\"], \"date\": \"2017-09-06\", \"first\": \"Schweig JE\", \"last\": \"Paris D\", \"name\": \"Acta neuropathologica communications\", \"pages\": \"69\", \"reference\": \"28877763\", \"title\": \"Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \" We found an increase in Syk activation in DNs surrounding A  deposits as well as in neurons displaying an accumu- lation of phosphorylated Tau at Y18 and elevated levels of MC1 pathogenic tau conformers in AD brain sections whereas only weak immunoreactivity for pSyk was ob- served in brain sections from a non-demented control (Figs. 15, 16 and 17).\", \"key\": \"665ec37c66d90634a6636f418da2d84e9d7799f94d410662de92bd634a9e1d5e48cc2d6c9f2b124b3be84936dc5cb4baef2fad1c5a2199c31f8f453df0ce378b\", \"line\": 259, \"relation\": \"positiveCorrelation\", \"source\": 366, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 277}, {\"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Bachmeier C\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Jin C\", \"Laco G\", \"Lin Y\", \"Mullan M\", \"Paris D\"], \"date\": \"2014-12-05\", \"first\": \"Paris D\", \"last\": \"Mullan M\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"33927-44\", \"reference\": \"25331948\", \"title\": \"The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid- production and Tau hyperphosphorylation.\", \"type\": \"PubMed\", \"volume\": \"289\"}, \"evidence\": \"Syk has been shown to mediate the phosphorylation of Tau at Tyr-18 (56).\", \"key\": \"12d597edc8a0b5edf6a2c80d0a1521ea60e1c13009b7be7a63873abede2ccd9f62ca5d972d73f79ea7277035879d5317762ecfa8eae12d0d3c32188d24ea5283\", \"line\": 281, \"relation\": \"regulates\", \"source\": 366, \"target\": 318}, {\"annotations\": {\"MeSHAnatomy\": {\"Neurons\": true}}, \"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Mouzon B\", \"Mullan M\", \"Paris D\", \"Schweig JE\", \"Yao H\"], \"date\": \"2017-09-06\", \"first\": \"Schweig JE\", \"last\": \"Paris D\", \"name\": \"Acta neuropathologica communications\", \"pages\": \"69\", \"reference\": \"28877763\", \"title\": \"Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \" We found that tau phosphorylation at Y18 is significantly increased in neurons that are also immunopositive for pSyk (Fig. 10d, p < 0.05) which is consistent with previous data showing that in vitro Syk can phosphorylates tau at Y18.\", \"key\": \"38e49028550f49bdc9c3eb9aabc18a2d88b86254dccf6948ceac110d00882403156927251ad1a9e9fc90417b3fca66c11dddf3598095b2176d9aa94b6f753c34\", \"line\": 204, \"relation\": \"positiveCorrelation\", \"source\": 366, \"target\": 318}, {\"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Mouzon B\", \"Mullan M\", \"Paris D\", \"Schweig JE\", \"Yao H\"], \"date\": \"2017-09-06\", \"first\": \"Schweig JE\", \"last\": \"Paris D\", \"name\": \"Acta neuropathologica communications\", \"pages\": \"69\", \"reference\": \"28877763\", \"title\": \"Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \" We found that tau phosphorylation at Y18 is significantly increased in neurons that are also immunopositive for pSyk (Fig. 10d, p < 0.05) which is consistent with previous data showing that in vitro Syk can phosphorylates tau at Y18.\", \"key\": \"917efafbba6cce1c72adf3b6533df2e89053a0e00218850743fd4cc96873b0e0f4b380f5afd689935af4e8b1b4c820bf6cba144924a0b884842d2bfe5e244c67\", \"line\": 206, \"relation\": \"directlyIncreases\", \"source\": 366, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 318}, {\"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Mouzon B\", \"Mullan M\", \"Paris D\", \"Schweig JE\", \"Yao H\"], \"date\": \"2017-09-06\", \"first\": \"Schweig JE\", \"last\": \"Paris D\", \"name\": \"Acta neuropathologica communications\", \"pages\": \"69\", \"reference\": \"28877763\", \"title\": \"Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \"Altogether, these data suggest that only certain pathogenic forms of tau (MC1, Y18) promote Syk activation, whereas Syk activation appears to directly in- duce tau phosphorylation at Y18 and to indirectly regulate tau phosphorylation at multiple epitopes (S396/404, S202) as well as tau misfolding (MC1, TOC1).\", \"key\": \"456481bb87080b3d93b2f81cfec786de54263a2998e5d96509b2e34280819fe6e259763ed0b6fb4d46e425147eabfc5f57ab49b780f6fbde5e04fe9fe0f38f29\", \"line\": 220, \"relation\": \"directlyIncreases\", \"source\": 366, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 318}, {\"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Mouzon B\", \"Mullan M\", \"Paris D\", \"Schweig JE\", \"Yao H\"], \"date\": \"2017-09-06\", \"first\": \"Schweig JE\", \"last\": \"Paris D\", \"name\": \"Acta neuropathologica communications\", \"pages\": \"69\", \"reference\": \"28877763\", \"title\": \"Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \" Interestingly, Syk up- regulation in SH-SY5Y cells leads to a significant in- crease (1.7-fold) in phosphorylated tau at Y18 (Fig. 14c, p < 0.01) and at S396/404 (Fig. 14d, 3-fold, p < 0.0001) compared to control cells.\", \"key\": \"7173300b2eb40142f6d8efbb2cc1bab2317547f4ee4d5f7cbafb7b0ac93872b9eba253dfde712ce3b5ae36cfdb614987d1e013b5d571657165c3fc26ab84c764\", \"line\": 230, \"relation\": \"increases\", \"source\": 366, \"target\": 318}, {\"annotations\": {\"CellStructure\": {\"Neurites\": true}, \"MeSHAnatomy\": {\"Brain\": true}, \"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Mouzon B\", \"Mullan M\", \"Paris D\", \"Schweig JE\", \"Yao H\"], \"date\": \"2017-09-06\", \"first\": \"Schweig JE\", \"last\": \"Paris D\", \"name\": \"Acta neuropathologica communications\", \"pages\": \"69\", \"reference\": \"28877763\", \"title\": \"Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \" We found an increase in Syk activation in DNs surrounding A  deposits as well as in neurons displaying an accumu- lation of phosphorylated Tau at Y18 and elevated levels of MC1 pathogenic tau conformers in AD brain sections whereas only weak immunoreactivity for pSyk was ob- served in brain sections from a non-demented control (Figs. 15, 16 and 17).\", \"key\": \"4490de37969e6d69d386aa3ae8443b10967f5a2a8b11a20897971ed6adc727f221c2e0111b0ee48b6a85a1011490b4219ab4677eb3438a47a16090ee52534e4a\", \"line\": 258, \"relation\": \"positiveCorrelation\", \"source\": 366, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 318}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"In addition, tau can be phosphorylated by tyrosine kinases such as the SRC family members LCK, SYK and FYN at Tyr18, and the ABL family members ARG and ABL1 at Tyr394 (REF. 45).\", \"key\": \"528eb9be73ee5e970e322740179bf8cd49432910f07ab4cf6f9f2d91e46ce7cbea34c5b8b583f7ab0e05608035eafce57e1e2e9819601a6ec028f38e88313e37\", \"line\": 173, \"relation\": \"directlyIncreases\", \"source\": 366, \"target\": 318}, {\"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Mouzon B\", \"Mullan M\", \"Paris D\", \"Schweig JE\", \"Yao H\"], \"date\": \"2017-09-06\", \"first\": \"Schweig JE\", \"last\": \"Paris D\", \"name\": \"Acta neuropathologica communications\", \"pages\": \"69\", \"reference\": \"28877763\", \"title\": \"Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \"Altogether, these data suggest that only certain pathogenic forms of tau (MC1, Y18) promote Syk activation, whereas Syk activation appears to directly in- duce tau phosphorylation at Y18 and to indirectly regulate tau phosphorylation at multiple epitopes (S396/404, S202) as well as tau misfolding (MC1, TOC1).\", \"key\": \"7434b45e70c90ec94b4e89e6c111aaeccc95d4c957295d2e9f4c1ef975d65a77451c0736624711f2cdbca57de086446f4260406f32d2020d209586c314923b44\", \"line\": 222, \"relation\": \"increases\", \"source\": 366, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 290}, {\"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Mouzon B\", \"Mullan M\", \"Paris D\", \"Schweig JE\", \"Yao H\"], \"date\": \"2017-09-06\", \"first\": \"Schweig JE\", \"last\": \"Paris D\", \"name\": \"Acta neuropathologica communications\", \"pages\": \"69\", \"reference\": \"28877763\", \"title\": \"Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \"Altogether, these data suggest that only certain pathogenic forms of tau (MC1, Y18) promote Syk activation, whereas Syk activation appears to directly in- duce tau phosphorylation at Y18 and to indirectly regulate tau phosphorylation at multiple epitopes (S396/404, S202) as well as tau misfolding (MC1, TOC1).\", \"key\": \"5bac1664b48611562a0a26b251b7ea2e089be484f4a9890b165826166bf434cd4e9afef6b50d82b57f024e376521b0ef8962454fb6016749135956fccde7fd92\", \"line\": 221, \"relation\": \"increases\", \"source\": 366, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 305}, {\"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Mouzon B\", \"Mullan M\", \"Paris D\", \"Schweig JE\", \"Yao H\"], \"date\": \"2017-09-06\", \"first\": \"Schweig JE\", \"last\": \"Paris D\", \"name\": \"Acta neuropathologica communications\", \"pages\": \"69\", \"reference\": \"28877763\", \"title\": \"Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \" Interestingly, Syk up- regulation in SH-SY5Y cells leads to a significant in- crease (1.7-fold) in phosphorylated tau at Y18 (Fig. 14c, p < 0.01) and at S396/404 (Fig. 14d, 3-fold, p < 0.0001) compared to control cells.\", \"key\": \"31fc909f7abf86970d1404a1e8b53898acb32e3a18829c953a86f8707ea0f5c235e4b9bc557e83efb06a341bfb47920bd67788eaaa635ed73f9f12b01f4b7ade\", \"line\": 231, \"relation\": \"increases\", \"source\": 366, \"target\": 305}, {\"annotations\": {\"Species\": {\"6239\": true}}, \"citation\": {\"authors\": [\"Choudhary B\", \"Mandelkow E\", \"Pir GJ\"], \"date\": \"2017-12-01\", \"first\": \"Pir GJ\", \"last\": \"Mandelkow E\", \"name\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\", \"pages\": \"5137-5148\", \"reference\": \"29191965\", \"title\": \"&lt;i&gt;Caenorhabditis elegans&lt;/i&gt; models of tauopathy.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"The responsible kinases include 1) proline-directed protein kinases (PDPKs) targeting SP or TP motifs [e.g., GSK3b, cyclindependent kinase (CDK)-5, and MAPKs]; 2) nonproline directed protein kinases targeting KXGS-motifs [e.g., PKA, microtubule affinity-regulating kinase and synapses of the amphid defective (SADK)]; 3) protein kinases specific for tyrosines (e.g., Src, Lck, Syk, Fyn, and c-Abl kinase) (91).\", \"key\": \"5c2da1caf7819028e72691cdfc0ff3653b7483887a1b3107a44f3b0dc10cb1fec569711dab17be17e561260f518905564068d1cae71bb8df1d743487510ad778\", \"line\": 251, \"relation\": \"directlyIncreases\", \"source\": 366, \"target\": 317}, {\"annotations\": {\"Cell_Line\": {\"HEK293T\": true}}, \"citation\": {\"authors\": [\"Cho SH\", \"Cole PA\", \"Gan L\", \"Haroutunian V\", \"Huang EJ\", \"Masliah E\", \"Meyers D\", \"Min SW\", \"Mukherjee C\", \"Ott M\", \"Schroeder S\", \"Seeley WW\", \"Shen Y\", \"Zhou Y\"], \"date\": \"2010-09-23\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"Neuron\", \"pages\": \"953-66\", \"reference\": \"20869593\", \"title\": \"Acetylation of tau inhibits its degradation and contributes to tauopathy.\", \"type\": \"PubMed\", \"volume\": \"67\"}, \"evidence\": \"Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. \", \"key\": \"3b35863f4f51ae2e7e05ec50c41d928cf4d3c64ba041781a3836bd139a86a755d05d5a9eb5f06d7ddcfb09b4921df212ecce70f54bf12f52d3241fe882ea0f1a\", \"line\": 3305, \"relation\": \"increases\", \"source\": 227, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 268}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Tau can be acetylated by the P300 acetyltransferase or by CREB-binding protein at several Lys residues in the flanking region or the repeat domain, and deacetylated at these sites by sirtuin 1 (SIRT1) and histone deacetylase 6 (HDAC6), respectively\", \"key\": \"3fec8db64a3b59b072848106e46373a6e88d68998de72343e8c14480f5b22319c29401523245b1b0312692636bbc6e6be245d8a41fa06d4f1c5c9cecae0550f6\", \"line\": 251, \"relation\": \"increases\", \"source\": 227, \"target\": 248}, {\"annotations\": {\"Cell_Line\": {\"HEK293T\": true}}, \"citation\": {\"authors\": [\"Cho SH\", \"Cole PA\", \"Gan L\", \"Haroutunian V\", \"Huang EJ\", \"Masliah E\", \"Meyers D\", \"Min SW\", \"Mukherjee C\", \"Ott M\", \"Schroeder S\", \"Seeley WW\", \"Shen Y\", \"Zhou Y\"], \"date\": \"2010-09-23\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"Neuron\", \"pages\": \"953-66\", \"reference\": \"20869593\", \"title\": \"Acetylation of tau inhibits its degradation and contributes to tauopathy.\", \"type\": \"PubMed\", \"volume\": \"67\"}, \"evidence\": \"Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. \", \"key\": \"66a1ec04b82f828b4985e036fa95e0317978b5790e33f1e288e0d200993f24dc83e776ca40e4c6170918a6bbf2d3256de286aed7e9bf708006e63e1c710e494a\", \"line\": 3294, \"relation\": \"increases\", \"source\": 227, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 253}, {\"annotations\": {\"Cell_Line\": {\"HEK293T\": true}}, \"citation\": {\"authors\": [\"Cho SH\", \"Cole PA\", \"Gan L\", \"Haroutunian V\", \"Huang EJ\", \"Masliah E\", \"Meyers D\", \"Min SW\", \"Mukherjee C\", \"Ott M\", \"Schroeder S\", \"Seeley WW\", \"Shen Y\", \"Zhou Y\"], \"date\": \"2010-09-23\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"Neuron\", \"pages\": \"953-66\", \"reference\": \"20869593\", \"title\": \"Acetylation of tau inhibits its degradation and contributes to tauopathy.\", \"type\": \"PubMed\", \"volume\": \"67\"}, \"evidence\": \"Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. \", \"key\": \"00c422d823026805af769935d041e4239a9d72ae4d30175bf423c0d1cbff3697e86340873eba017b4460a3a3afc1f2672b25b0015f15fafdeff68ec3b4dbb326\", \"line\": 3304, \"relation\": \"increases\", \"source\": 227, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 267}, {\"annotations\": {\"Cell_Line\": {\"HEK293T\": true}}, \"citation\": {\"authors\": [\"Cho SH\", \"Cole PA\", \"Gan L\", \"Haroutunian V\", \"Huang EJ\", \"Masliah E\", \"Meyers D\", \"Min SW\", \"Mukherjee C\", \"Ott M\", \"Schroeder S\", \"Seeley WW\", \"Shen Y\", \"Zhou Y\"], \"date\": \"2010-09-23\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"Neuron\", \"pages\": \"953-66\", \"reference\": \"20869593\", \"title\": \"Acetylation of tau inhibits its degradation and contributes to tauopathy.\", \"type\": \"PubMed\", \"volume\": \"67\"}, \"evidence\": \"Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. \", \"key\": \"9b568dc2e67c71e799de6a12e50608e9ac935b1be4610cbd73272304c4f4eb0b1d01679b6ebdf4b88b2dff7b305947a59ef5109ddbd8ddfc2fe9326e6dfdd055\", \"line\": 3307, \"relation\": \"increases\", \"source\": 227, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 270}, {\"annotations\": {\"Cell_Line\": {\"HEK293T\": true}}, \"citation\": {\"authors\": [\"Cho SH\", \"Cole PA\", \"Gan L\", \"Haroutunian V\", \"Huang EJ\", \"Masliah E\", \"Meyers D\", \"Min SW\", \"Mukherjee C\", \"Ott M\", \"Schroeder S\", \"Seeley WW\", \"Shen Y\", \"Zhou Y\"], \"date\": \"2010-09-23\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"Neuron\", \"pages\": \"953-66\", \"reference\": \"20869593\", \"title\": \"Acetylation of tau inhibits its degradation and contributes to tauopathy.\", \"type\": \"PubMed\", \"volume\": \"67\"}, \"evidence\": \"Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. \", \"key\": \"f85ae5c97a2e6ac6751c3ccdf85c7115c4975c0d9312de8569dcd3dfc06adaf2c35fa37a702d736335a540837cc9c0e3c569e97006f7d05ce139e4b30e9292a2\", \"line\": 3295, \"relation\": \"increases\", \"source\": 227, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 255}, {\"annotations\": {\"Cell_Line\": {\"HEK293T\": true}}, \"citation\": {\"authors\": [\"Cho SH\", \"Cole PA\", \"Gan L\", \"Haroutunian V\", \"Huang EJ\", \"Masliah E\", \"Meyers D\", \"Min SW\", \"Mukherjee C\", \"Ott M\", \"Schroeder S\", \"Seeley WW\", \"Shen Y\", \"Zhou Y\"], \"date\": \"2010-09-23\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"Neuron\", \"pages\": \"953-66\", \"reference\": \"20869593\", \"title\": \"Acetylation of tau inhibits its degradation and contributes to tauopathy.\", \"type\": \"PubMed\", \"volume\": \"67\"}, \"evidence\": \"Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. \", \"key\": \"c83c9e114c3c3437a5070000eed9f6ee3760777b59247b363205acbc1045ce55c54242bebca03c7a4bf689579f3f5be4d4f1b3dfc328e503d3ed4cee6bad28a4\", \"line\": 3298, \"relation\": \"increases\", \"source\": 227, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 258}, {\"annotations\": {\"Cell_Line\": {\"HEK293T\": true}}, \"citation\": {\"authors\": [\"Cho SH\", \"Cole PA\", \"Gan L\", \"Haroutunian V\", \"Huang EJ\", \"Masliah E\", \"Meyers D\", \"Min SW\", \"Mukherjee C\", \"Ott M\", \"Schroeder S\", \"Seeley WW\", \"Shen Y\", \"Zhou Y\"], \"date\": \"2010-09-23\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"Neuron\", \"pages\": \"953-66\", \"reference\": \"20869593\", \"title\": \"Acetylation of tau inhibits its degradation and contributes to tauopathy.\", \"type\": \"PubMed\", \"volume\": \"67\"}, \"evidence\": \"Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. \", \"key\": \"c98145cdd2513a793a8d149c4a72d8bb623d4b1465f770a001f51b10e7422fa35a3ce7526c27c1d1b8000ab8566705f91d89535455e07726858ccc78a378f3f4\", \"line\": 3303, \"relation\": \"increases\", \"source\": 227, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 265}, {\"annotations\": {\"Cell_Line\": {\"HEK293T\": true}}, \"citation\": {\"authors\": [\"Cho SH\", \"Cole PA\", \"Gan L\", \"Haroutunian V\", \"Huang EJ\", \"Masliah E\", \"Meyers D\", \"Min SW\", \"Mukherjee C\", \"Ott M\", \"Schroeder S\", \"Seeley WW\", \"Shen Y\", \"Zhou Y\"], \"date\": \"2010-09-23\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"Neuron\", \"pages\": \"953-66\", \"reference\": \"20869593\", \"title\": \"Acetylation of tau inhibits its degradation and contributes to tauopathy.\", \"type\": \"PubMed\", \"volume\": \"67\"}, \"evidence\": \"Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. \", \"key\": \"6a7c3b78ed6df47c8db54df8421be7071dd372e7f07e53c85206986ed7417979e64a434ce7184450d848cf1e264d519d82d232df6fc5eaf3774be1353a438eb3\", \"line\": 3299, \"relation\": \"increases\", \"source\": 227, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 259}, {\"annotations\": {\"Cell_Line\": {\"HEK293T\": true}}, \"citation\": {\"authors\": [\"Cho SH\", \"Cole PA\", \"Gan L\", \"Haroutunian V\", \"Huang EJ\", \"Masliah E\", \"Meyers D\", \"Min SW\", \"Mukherjee C\", \"Ott M\", \"Schroeder S\", \"Seeley WW\", \"Shen Y\", \"Zhou Y\"], \"date\": \"2010-09-23\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"Neuron\", \"pages\": \"953-66\", \"reference\": \"20869593\", \"title\": \"Acetylation of tau inhibits its degradation and contributes to tauopathy.\", \"type\": \"PubMed\", \"volume\": \"67\"}, \"evidence\": \"Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. \", \"key\": \"603b0cfc225e3b54758b1e73e4a0479bd1584b86b77ff6e80b9eb934c89be0982c42bd80fbe090cbf41979f71058ab8595fefb25191a8c1e2d9bb9450fd04f35\", \"line\": 3291, \"relation\": \"increases\", \"source\": 227, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 249}, {\"annotations\": {\"Cell_Line\": {\"HEK293T\": true}}, \"citation\": {\"authors\": [\"Cho SH\", \"Cole PA\", \"Gan L\", \"Haroutunian V\", \"Huang EJ\", \"Masliah E\", \"Meyers D\", \"Min SW\", \"Mukherjee C\", \"Ott M\", \"Schroeder S\", \"Seeley WW\", \"Shen Y\", \"Zhou Y\"], \"date\": \"2010-09-23\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"Neuron\", \"pages\": \"953-66\", \"reference\": \"20869593\", \"title\": \"Acetylation of tau inhibits its degradation and contributes to tauopathy.\", \"type\": \"PubMed\", \"volume\": \"67\"}, \"evidence\": \"Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. \", \"key\": \"b2ce82c03b4b94276bab63f6669e1df98e9a89627f684d93143cda4d4c8864ca879bbe4103374cf9f7eda8c61f7c2407ad3e7551f30a16a799686608c9c1e84d\", \"line\": 3301, \"relation\": \"increases\", \"source\": 227, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 261}, {\"annotations\": {\"Cell_Line\": {\"HEK293T\": true}}, \"citation\": {\"authors\": [\"Cho SH\", \"Cole PA\", \"Gan L\", \"Haroutunian V\", \"Huang EJ\", \"Masliah E\", \"Meyers D\", \"Min SW\", \"Mukherjee C\", \"Ott M\", \"Schroeder S\", \"Seeley WW\", \"Shen Y\", \"Zhou Y\"], \"date\": \"2010-09-23\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"Neuron\", \"pages\": \"953-66\", \"reference\": \"20869593\", \"title\": \"Acetylation of tau inhibits its degradation and contributes to tauopathy.\", \"type\": \"PubMed\", \"volume\": \"67\"}, \"evidence\": \"Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. \", \"key\": \"eb9c88d1b95a8e06cf711e81b01468dfe9e35cd5b104817eac5c191083a6c6ba161c460e0f8490214a339ace59b2ce01dd28e4dae8733bf57c1356301385a0b8\", \"line\": 3292, \"relation\": \"increases\", \"source\": 227, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 250}, {\"annotations\": {\"Cell_Line\": {\"HEK293T\": true}}, \"citation\": {\"authors\": [\"Cho SH\", \"Cole PA\", \"Gan L\", \"Haroutunian V\", \"Huang EJ\", \"Masliah E\", \"Meyers D\", \"Min SW\", \"Mukherjee C\", \"Ott M\", \"Schroeder S\", \"Seeley WW\", \"Shen Y\", \"Zhou Y\"], \"date\": \"2010-09-23\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"Neuron\", \"pages\": \"953-66\", \"reference\": \"20869593\", \"title\": \"Acetylation of tau inhibits its degradation and contributes to tauopathy.\", \"type\": \"PubMed\", \"volume\": \"67\"}, \"evidence\": \"Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. \", \"key\": \"46d6f59ae7a5af54ddc317511c6ddf7f4afb800aecbc0daab18d13dd3de8bf0c9be02b0bda26c63ad8a2c6d00906e458322ff9bc68fd8a6ea66d1b517c4c052c\", \"line\": 3293, \"relation\": \"increases\", \"source\": 227, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 251}, {\"annotations\": {\"Cell_Line\": {\"HEK293T\": true}}, \"citation\": {\"authors\": [\"Cho SH\", \"Cole PA\", \"Gan L\", \"Haroutunian V\", \"Huang EJ\", \"Masliah E\", \"Meyers D\", \"Min SW\", \"Mukherjee C\", \"Ott M\", \"Schroeder S\", \"Seeley WW\", \"Shen Y\", \"Zhou Y\"], \"date\": \"2010-09-23\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"Neuron\", \"pages\": \"953-66\", \"reference\": \"20869593\", \"title\": \"Acetylation of tau inhibits its degradation and contributes to tauopathy.\", \"type\": \"PubMed\", \"volume\": \"67\"}, \"evidence\": \"Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. \", \"key\": \"e9ae26bcf0ee9c02328007fc616b3bcbfc7ae5d9c75166f44dff875c13bc2c57d6c845128b15ff90b64c98ce9c011dd0e26208277161fd0b24979aba73d8adbc\", \"line\": 3297, \"relation\": \"increases\", \"source\": 227, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 257}, {\"annotations\": {\"Cell_Line\": {\"HEK293T\": true}}, \"citation\": {\"authors\": [\"Cho SH\", \"Cole PA\", \"Gan L\", \"Haroutunian V\", \"Huang EJ\", \"Masliah E\", \"Meyers D\", \"Min SW\", \"Mukherjee C\", \"Ott M\", \"Schroeder S\", \"Seeley WW\", \"Shen Y\", \"Zhou Y\"], \"date\": \"2010-09-23\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"Neuron\", \"pages\": \"953-66\", \"reference\": \"20869593\", \"title\": \"Acetylation of tau inhibits its degradation and contributes to tauopathy.\", \"type\": \"PubMed\", \"volume\": \"67\"}, \"evidence\": \"Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. \", \"key\": \"93acbe1ff2baaa4dccb747c7724fd86a32df3ec0ec749dddb57558ad2830b8fc61ac87347a8cf0848b607c91fdf7421a99b2d69d5b7e3c066600cdf7815d797d\", \"line\": 3306, \"relation\": \"increases\", \"source\": 227, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 269}, {\"annotations\": {\"Cell_Line\": {\"HEK293T\": true}}, \"citation\": {\"authors\": [\"Cho SH\", \"Cole PA\", \"Gan L\", \"Haroutunian V\", \"Huang EJ\", \"Masliah E\", \"Meyers D\", \"Min SW\", \"Mukherjee C\", \"Ott M\", \"Schroeder S\", \"Seeley WW\", \"Shen Y\", \"Zhou Y\"], \"date\": \"2010-09-23\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"Neuron\", \"pages\": \"953-66\", \"reference\": \"20869593\", \"title\": \"Acetylation of tau inhibits its degradation and contributes to tauopathy.\", \"type\": \"PubMed\", \"volume\": \"67\"}, \"evidence\": \"Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. \", \"key\": \"f62780514d7da8609e4b3a5c9ba1a6920938a7c3913185f25916bc30c001f22a78de324b9947592b0bc9b1f8ac50f3af325681187b546ade99c56e43144df49e\", \"line\": 3300, \"relation\": \"increases\", \"source\": 227, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 260}, {\"annotations\": {\"Cell_Line\": {\"HEK293T\": true}}, \"citation\": {\"authors\": [\"Cho SH\", \"Cole PA\", \"Gan L\", \"Haroutunian V\", \"Huang EJ\", \"Masliah E\", \"Meyers D\", \"Min SW\", \"Mukherjee C\", \"Ott M\", \"Schroeder S\", \"Seeley WW\", \"Shen Y\", \"Zhou Y\"], \"date\": \"2010-09-23\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"Neuron\", \"pages\": \"953-66\", \"reference\": \"20869593\", \"title\": \"Acetylation of tau inhibits its degradation and contributes to tauopathy.\", \"type\": \"PubMed\", \"volume\": \"67\"}, \"evidence\": \"Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. \", \"key\": \"8d96bac0ce03f250aa93ee71459dd5c5f11d3133e32e85b3f0d0394020e11940c310436010be2f00fc7aa1e03190896b25914df6e53b4afe10820fc1e15687ae\", \"line\": 3308, \"relation\": \"increases\", \"source\": 227, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 271}, {\"annotations\": {\"Cell_Line\": {\"HEK293T\": true}}, \"citation\": {\"authors\": [\"Cho SH\", \"Cole PA\", \"Gan L\", \"Haroutunian V\", \"Huang EJ\", \"Masliah E\", \"Meyers D\", \"Min SW\", \"Mukherjee C\", \"Ott M\", \"Schroeder S\", \"Seeley WW\", \"Shen Y\", \"Zhou Y\"], \"date\": \"2010-09-23\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"Neuron\", \"pages\": \"953-66\", \"reference\": \"20869593\", \"title\": \"Acetylation of tau inhibits its degradation and contributes to tauopathy.\", \"type\": \"PubMed\", \"volume\": \"67\"}, \"evidence\": \"Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. \", \"key\": \"4df1fa3853cf97d97a957faf49078a0dd17bcc86b0f49a9df1aed533cb7ad73f1bebd01755bed2b940726e9e9eeeaf24c9d09a89ae1eced3ed3f72e00bd0760a\", \"line\": 3296, \"relation\": \"increases\", \"source\": 227, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 256}, {\"annotations\": {\"Cell_Line\": {\"HEK293T\": true}}, \"citation\": {\"authors\": [\"Cho SH\", \"Cole PA\", \"Gan L\", \"Haroutunian V\", \"Huang EJ\", \"Masliah E\", \"Meyers D\", \"Min SW\", \"Mukherjee C\", \"Ott M\", \"Schroeder S\", \"Seeley WW\", \"Shen Y\", \"Zhou Y\"], \"date\": \"2010-09-23\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"Neuron\", \"pages\": \"953-66\", \"reference\": \"20869593\", \"title\": \"Acetylation of tau inhibits its degradation and contributes to tauopathy.\", \"type\": \"PubMed\", \"volume\": \"67\"}, \"evidence\": \"Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. \", \"key\": \"7379af73190ec7731796c7dcf86ecaa848577c04256be5bf1c66822cd256cc369da8b4d0b427f66893ae20f8773ca229bdafcb93a307b195553f9e3826ceba18\", \"line\": 3302, \"relation\": \"increases\", \"source\": 227, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 262}, {\"annotations\": {\"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Hyman BT\", \"Kay KR\", \"Mandelkow EM\", \"Polydoro M\", \"Saidi LJ\", \"Sanchez L\", \"Spires-Jones TL\"], \"date\": \"2015-01-01\", \"first\": \"Saidi LJ\", \"last\": \"Spires-Jones TL\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"937-47\", \"reference\": \"25374103\", \"title\": \"Carboxy terminus heat shock protein 70 interacting protein reduces tau-associated degenerative changes.\", \"type\": \"PubMed\", \"volume\": \"44\"}, \"evidence\": \"In the pathological case of Alzheimers disease (AD) tau becomes hyperphosphorylated, detaches from the microtubules, misfolds, and mislocalizes to the somatodendritic compartment where it aggregates into neurofibrillary tangles.\", \"key\": \"689cea584f9bf8332f72e1bc12ac0721c8df5cd4563d690f0389d26a0f35ea5f543abc84fae2e4e99f57922e192efcf1686ad697ac7eb872dd7ab73305147d2a\", \"line\": 92, \"relation\": \"decreases\", \"source\": 111, \"target\": 277}, {\"annotations\": {\"CellStructure\": {\"Neurites\": true}, \"MeSHAnatomy\": {\"Brain\": true}, \"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Mouzon B\", \"Mullan M\", \"Paris D\", \"Schweig JE\", \"Yao H\"], \"date\": \"2017-09-06\", \"first\": \"Schweig JE\", \"last\": \"Paris D\", \"name\": \"Acta neuropathologica communications\", \"pages\": \"69\", \"reference\": \"28877763\", \"title\": \"Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \" We found an increase in Syk activation in DNs surrounding A  deposits as well as in neurons displaying an accumu- lation of phosphorylated Tau at Y18 and elevated levels of MC1 pathogenic tau conformers in AD brain sections whereas only weak immunoreactivity for pSyk was ob- served in brain sections from a non-demented control (Figs. 15, 16 and 17).\", \"key\": \"ddfe624b94ffa098b1d4d98753cca6090bf2c460348a662fe43a649a556ceb2f3980cd6784643a8c25d1b4de17efc085ba921049c819a455382f05e6a28f4657\", \"line\": 259, \"object\": {\"modifier\": \"Activity\"}, \"relation\": \"positiveCorrelation\", \"source\": 277, \"target\": 366}, {\"citation\": {\"authors\": [\"Hyman BT\", \"Kay KR\", \"Mandelkow EM\", \"Polydoro M\", \"Saidi LJ\", \"Sanchez L\", \"Spires-Jones TL\"], \"date\": \"2015-01-01\", \"first\": \"Saidi LJ\", \"last\": \"Spires-Jones TL\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"937-47\", \"reference\": \"25374103\", \"title\": \"Carboxy terminus heat shock protein 70 interacting protein reduces tau-associated degenerative changes.\", \"type\": \"PubMed\", \"volume\": \"44\"}, \"evidence\": \"Misfolded tau proteins, like other natively unfolded molecules, can be detected and cleared by chaperone assisted mechanisms [13].\", \"key\": \"88e0b5abd3147a375bb4174ff74f4d3fa42090e813d00b03483a6257fe869ee243f5667370972e78b6bb1aab9885de8b2837b787df62f4774b3173384562d592\", \"line\": 124, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 81, \"target\": 277}, {\"citation\": {\"authors\": [\"Hyman BT\", \"Kay KR\", \"Mandelkow EM\", \"Polydoro M\", \"Saidi LJ\", \"Sanchez L\", \"Spires-Jones TL\"], \"date\": \"2015-01-01\", \"first\": \"Saidi LJ\", \"last\": \"Spires-Jones TL\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"937-47\", \"reference\": \"25374103\", \"title\": \"Carboxy terminus heat shock protein 70 interacting protein reduces tau-associated degenerative changes.\", \"type\": \"PubMed\", \"volume\": \"44\"}, \"evidence\": \"Several publications suggest that molecular chaperones, e.g., heat shock protein 70 and 90 (Hsp70, Hsp90) play a fundamental role in the clearance of misfolded proteins including tau [12].\", \"key\": \"fe14773353a90ccaac6a2189e2603ed33f424f11213e97ef1d586dad1546b05ea50668580c62ebd63da7176af1c709b3ef8d335d6f11286dfe60cb94d94e1055\", \"line\": 169, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 66, \"target\": 277}, {\"annotations\": {\"Method\": {\"Electron Microscopy, Transmission\": true, \"NMR Spectroscopy\": true, \"Thioflavin T Assay\": true}, \"Tau_Epitope\": {\"AT8\": true}}, \"citation\": {\"authors\": [\"Baulieu EE\", \"Byrne C\", \"Cantrelle FX\", \"Chambraud B\", \"Despres C\", \"Huvent I\", \"Jacquot Y\", \"Landrieu I\", \"Lippens G\", \"Qi H\", \"Smet-Nocca C\"], \"date\": \"2017-08-22\", \"first\": \"Despres C\", \"last\": \"Smet-Nocca C\", \"name\": \"Proceedings of the National Academy of Sciences of the United States of America\", \"pages\": \"9080-9085\", \"reference\": \"28784767\", \"title\": \"Identification of the Tau phosphorylation pattern that drives its aggregation.\", \"type\": \"PubMed\", \"volume\": \"114\"}, \"evidence\": \"Phosphorylation at Ser208 might be catalyzed by Casein kinase 1 (44), and its identification as a potential site for O-GlcNacylation (45) points to the important role of this residue.\", \"key\": \"625f47fbcaf24ed885eac7cc97b9351735a9696d5c758c7214b3b7528db09f934cfb558b236c4db770150cbe7112e40323178c40edbcbfc49ab100dc7648ca7f\", \"line\": 96, \"relation\": \"increases\", \"source\": 158, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 292}, {\"annotations\": {\"Method\": {\"Electron Microscopy, Transmission\": true, \"NMR Spectroscopy\": true, \"Thioflavin T Assay\": true}, \"Tau_Epitope\": {\"AT8\": true}}, \"citation\": {\"authors\": [\"Baulieu EE\", \"Byrne C\", \"Cantrelle FX\", \"Chambraud B\", \"Despres C\", \"Huvent I\", \"Jacquot Y\", \"Landrieu I\", \"Lippens G\", \"Qi H\", \"Smet-Nocca C\"], \"date\": \"2017-08-22\", \"first\": \"Despres C\", \"last\": \"Smet-Nocca C\", \"name\": \"Proceedings of the National Academy of Sciences of the United States of America\", \"pages\": \"9080-9085\", \"reference\": \"28784767\", \"title\": \"Identification of the Tau phosphorylation pattern that drives its aggregation.\", \"type\": \"PubMed\", \"volume\": \"114\"}, \"evidence\": \"Only very recently has the crystal structure of its fragment antigen body (Fab) with different phosphorylated peptides suggested that a third phosphorylation event at position Ser208 might lead to an epitope with an even better affinity (15).\", \"key\": \"f5607d24357c6c3442aa230f6bb46f876aa2360bdf3bc69a37e2cd6751715496aeac93dcc269b6d6f4a3b13a8f7fee9a31b3e42a86c1b342e12b048188c29739\", \"line\": 77, \"relation\": \"partOf\", \"source\": 292, \"target\": 187}, {\"annotations\": {\"Method\": {\"Electron Microscopy, Transmission\": true, \"NMR Spectroscopy\": true, \"Thioflavin T Assay\": true}, \"Tau_Epitope\": {\"AT8\": true}}, \"citation\": {\"authors\": [\"Baulieu EE\", \"Byrne C\", \"Cantrelle FX\", \"Chambraud B\", \"Despres C\", \"Huvent I\", \"Jacquot Y\", \"Landrieu I\", \"Lippens G\", \"Qi H\", \"Smet-Nocca C\"], \"date\": \"2017-08-22\", \"first\": \"Despres C\", \"last\": \"Smet-Nocca C\", \"name\": \"Proceedings of the National Academy of Sciences of the United States of America\", \"pages\": \"9080-9085\", \"reference\": \"28784767\", \"title\": \"Identification of the Tau phosphorylation pattern that drives its aggregation.\", \"type\": \"PubMed\", \"volume\": \"114\"}, \"evidence\": \"Indeed, Tau phosphorylation at the three positions, Ser202/Thr205/Ser208, while not at Ser262, is sufficient to induce aggregation without the addition of any exogenous aggregation inducer.\", \"key\": \"43b1df51eeaab6fe1a2e2e826450bb5c3b4ab1662fe851cac2e7117c508e91e70fbe6e0d077aee454b4a5bbdc66ea8913a604d963482235355dfe9d511c84a1d\", \"line\": 102, \"relation\": \"decreases\", \"source\": 292, \"target\": 38}, {\"citation\": {\"authors\": [\"Kato R\", \"Kitano-Takahashi M\", \"Kohno T\", \"Kondo S\", \"Morita H\", \"Shirota Y\", \"Sugio S\", \"Takahashi H\", \"Tanio M\", \"Tomizawa K\"], \"date\": \"2007-07-01\", \"first\": \"Kitano-Takahashi M\", \"last\": \"Kohno T\", \"name\": \"Acta crystallographica. Section F, Structural biology and crystallization communications\", \"pages\": \"602-4\", \"reference\": \"17620722\", \"title\": \"Expression, purification and crystallization of a human tau-tubulin kinase 2 that phosphorylates tau protein.\", \"type\": \"PubMed\", \"volume\": \"63\"}, \"evidence\": \"Tau-tubulin kinase 2 (TTBK2) is a Ser/Thr kinase that putatively phosphorylates residues Ser208 and Ser210 (numbered according to a 441-residue human tau isoform) in tau protein.\", \"key\": \"cd1efb588035e6ca4af5a6954271ab102ffa2cee64763ef79353d49045d67eecf7be4239b87e04e269e280d4d0a5c615a0b70f37c61e069f2383e11eeb057393\", \"line\": 1338, \"relation\": \"increases\", \"source\": 375, \"target\": 292}, {\"citation\": {\"authors\": [\"Kato R\", \"Kitano-Takahashi M\", \"Kohno T\", \"Kondo S\", \"Morita H\", \"Shirota Y\", \"Sugio S\", \"Takahashi H\", \"Tanio M\", \"Tomizawa K\"], \"date\": \"2007-07-01\", \"first\": \"Kitano-Takahashi M\", \"last\": \"Kohno T\", \"name\": \"Acta crystallographica. Section F, Structural biology and crystallization communications\", \"pages\": \"602-4\", \"reference\": \"17620722\", \"title\": \"Expression, purification and crystallization of a human tau-tubulin kinase 2 that phosphorylates tau protein.\", \"type\": \"PubMed\", \"volume\": \"63\"}, \"evidence\": \"Tau-tubulin kinase 2 (TTBK2) is a Ser/Thr kinase that putatively phosphorylates residues Ser208 and Ser210 (numbered according to a 441-residue human tau isoform) in tau protein.\", \"key\": \"f71162a8faa774aa988b16326c376a7c914770919d060da2b8e9c1c7819fa0cf8629e1e2309fcf4d5b3f5a8e672b1fff34c092c4f0e68020253272e228d15ab6\", \"line\": 1339, \"relation\": \"increases\", \"source\": 375, \"target\": 293}, {\"annotations\": {\"Cell_Line\": {\"COS7\": true}, \"Method\": {\"Deglycosylation Assay\": true, \"Dephosphorylation Assay\": true, \"Immunoblotting\": true, \"Immunocytochemistry\": true, \"Phosphorylation Assay\": true, \"Pull-down Assay, His-tagged\": true, \"SDS-PAGE\": true, \"Ubiquitination Assay\": true}}, \"citation\": {\"authors\": [\"Gygi SP\", \"Kosik KS\", \"Schwartz D\", \"Shimura H\"], \"date\": \"2004-02-06\", \"first\": \"Shimura H\", \"last\": \"Kosik KS\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"4869-76\", \"reference\": \"14612456\", \"title\": \"CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival.\", \"type\": \"PubMed\", \"volume\": \"279\"}, \"evidence\": \"These data indicated that phosphorylation of PP2A dephosphorylation sites is an important recognition signal for ubiquitination. We used 200 g of amino-terminal His-tagged full-length recombinant human tau in an in vitro phosphorylation reaction with GSK-3Beta. When phosphorylated, the tau protein reacted on immunoblots with PHF1 (25, 26) and AT8 (24), indicating that at least sites Ser202, Thr205, Ser396, and Ser404 were phosphorylated. Following GSK-3Beta incubation, this tau served as an excellent substrate for in vitro ubiquitination using UbcH5B and the cofactor fraction from AD tau immunoprecipitates (Fig. 2a). This finding suggested that GSK-3Beta can place phosphates on tau that create recognition sites for an E3 Ub ligase.\", \"key\": \"729a05db20fe1a68cccf207da70f02397d0fe969b6d088234e632fb56800ab53e293febb2edf8fcbd1f68d61fe66b5e51981559f704179c753e7ebc60c774c69\", \"line\": 395, \"relation\": \"isA\", \"source\": 304, \"target\": 286}, {\"annotations\": {\"Method\": {\"Chromatography, Gel filtration\": true, \"Chromatography, Ni-NTA-Sepharose\": true, \"Chymotrypsin Assay\": true, \"Co-Immunoprecipitation\": true, \"Immunofluorescence\": true, \"Immunohistochemistry\": true, \"Microtubule polzmerization Assay\": true, \"Protease-coupled Assay\": true, \"RNA Interference, siRNA\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Blair LJ\", \"Borysov SI\", \"Buchner J\", \"Cox MB\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"O'Leary JC 3rd\", \"Schmid AB\", \"Shults CL\"], \"date\": \"2010-01-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"591-9\", \"reference\": \"20071522\", \"title\": \"The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules.\", \"type\": \"PubMed\", \"volume\": \"30\"}, \"evidence\": \"We found that FKBP51 indeed could interact with tau from both AD patients and control cases (Fig. 3D), further suggesting a functionally relevant relationship between FKBP51 and tau. We then investigated whether FKBP51 would preferentially interact with phosphorylated tau species. We increased the number of samples per group (4 for AD and 4 for normal) and again co-immunoprecipitated FKBP51. After gel electrophoresis, immunoblotting showed increased association of pS396 and pS199-S202 tau species with FKBP51 in AD tissue (Fig S1). Indeed, we found that FKBP51 over-expression increased phospho- and total tau levels (by 80%) in HeLa cells stably expressing normal human tau, while FKBP52 over-expression had no affect (Fig.4A). These experiments were repeated multiple times and Student t-test of these replicates demonstrated that FKBP51 significantly increased total tau levels (p= 0.0104).\", \"key\": \"bbf45ba10c7fa01df406bfe929b01bff1b1f424a0d7a32bbda3d15469465485289bb0d39fe26cf49c6bcf7577a1947409dcf7882a95ac2bb54bbe627ac2637b4\", \"line\": 589, \"relation\": \"isA\", \"source\": 304, \"target\": 204}, {\"annotations\": {\"Method\": {\"Chromatography, Gel filtration\": true, \"Chromatography, Ni-NTA-Sepharose\": true, \"Chymotrypsin Assay\": true, \"Co-Immunoprecipitation\": true, \"Immunofluorescence\": true, \"Immunohistochemistry\": true, \"Microtubule polzmerization Assay\": true, \"Protease-coupled Assay\": true, \"RNA Interference, siRNA\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Blair LJ\", \"Borysov SI\", \"Buchner J\", \"Cox MB\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"O'Leary JC 3rd\", \"Schmid AB\", \"Shults CL\"], \"date\": \"2010-01-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"591-9\", \"reference\": \"20071522\", \"title\": \"The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules.\", \"type\": \"PubMed\", \"volume\": \"30\"}, \"evidence\": \"We found that FKBP51 indeed could interact with tau from both AD patients and control cases (Fig. 3D), further suggesting a functionally relevant relationship between FKBP51 and tau. We then investigated whether FKBP51 would preferentially interact with phosphorylated tau species. We increased the number of samples per group (4 for AD and 4 for normal) and again co-immunoprecipitated FKBP51. After gel electrophoresis, immunoblotting showed increased association of pS396 and pS199-S202 tau species with FKBP51 in AD tissue (Fig S1). Indeed, we found that FKBP51 over-expression increased phospho- and total tau levels (by 80%) in HeLa cells stably expressing normal human tau, while FKBP52 over-expression had no affect (Fig.4A). These experiments were repeated multiple times and Student t-test of these replicates demonstrated that FKBP51 significantly increased total tau levels (p= 0.0104).\", \"key\": \"ecb2d050aaccc88554cb28968b3c10ab08574e4e52a7d83378b5e0dea3cacdd924ccf08bda41ea2c945f6379764a8fe03080578c48dcd31c8e8554608e33ddc4\", \"line\": 592, \"relation\": \"association\", \"source\": 304, \"target\": 122}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"ec72dd4057b841bebbf154a0c23ad149a53c85e56ccbc22df8e4a62097adc7714175e59253868e69ebafcceae24fa047f7307e23c784ebbbe028c32dce190861\", \"line\": 1127, \"relation\": \"positiveCorrelation\", \"source\": 304, \"target\": 164}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"bcb537382746ba29bfd5a68f4fd1078d5b9bcec7d4f6b22b66646d424598ac5800b41fc03fcda60dfc02e5c2164a87480d064cdf15acbb811b29e193792538a3\", \"line\": 1156, \"relation\": \"partOf\", \"source\": 304, \"target\": 118}, {\"citation\": {\"authors\": [\"Lu B\", \"Malenka R\", \"Polepalli J\", \"Rajadas J\", \"Wagh D\", \"Yu W\"], \"date\": \"2012-03-15\", \"first\": \"Yu W\", \"last\": \"Lu B\", \"name\": \"Human molecular genetics\", \"pages\": \"1384-90\", \"reference\": \"22156579\", \"title\": \"A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of A on synapses and dendritic spines.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"We first confirmed that expression of an MKI-GFP fusion protein in rat hippocampal neurons effectively attenuated MARK4-mediated phosphorylation of both endogenous tau (Fig. 3A) and transfected human tau at the 12E8 sites (Fig. 3B). Phosphorylation of tau at the PHF-1 site was also reduced by MKI (Fig. 3A). It is possible that the PHF-1 site is also targeted by PAR-1/MARKs in vivo, or that the phosphorylation of tau at the 12E8 sites is a prerequisite for PHF-1 site phosphorylation, as the 12E8 sites were previously shown to be required for tau phosphorylation at other sites\", \"key\": \"42ed9b4958f344cd28187ee13b5f59b7707cfc831da6651338b979896d3c0d991437feb12eaf4894fb440c3c1f98eb3b3ca645368a660265231308d12e85b8b2\", \"line\": 1806, \"relation\": \"positiveCorrelation\", \"source\": 304, \"target\": 45}, {\"citation\": {\"authors\": [\"Chai GS\", \"Chen NN\", \"Cheng XS\", \"Duan DX\", \"Hu Y\", \"Liu GP\", \"Luo Y\", \"Ni ZF\", \"Wang JZ\"], \"date\": \"2013-01-01\", \"first\": \"Duan DX\", \"last\": \"Liu GP\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"795-808\", \"reference\": \"23948915\", \"title\": \"Phosphorylation of tau by death-associated protein kinase 1 antagonizes the kinase-induced cell apoptosis.\", \"type\": \"PubMed\", \"volume\": \"37\"}, \"evidence\": \"These data suggest that tau hyperphosphorylation at Thr231, Ser262, and Ser396 by DAPK1 renders the cells more resistant to the kinase-induced apoptotic cell death, providing new insights into the tau-involved apoptotic abortion in the course of chronic neurodegeneration.\", \"key\": \"6ed14b0a081f69b5c9bb76ce77de1d1a16df74683e5717bda842e943b80a6a9b7bdc915ec346aa2c409bd68ab3bade8dcebb1bf97b45e634b455a498856c6cbd\", \"line\": 2001, \"relation\": \"negativeCorrelation\", \"source\": 304, \"target\": 78}, {\"citation\": {\"authors\": [\"Cavallaro RA\", \"Ciraci V\", \"Ferrer I\", \"Fuso A\", \"Nicolia V\", \"Scarpa S\"], \"date\": \"2017-01-01\", \"first\": \"Nicolia V\", \"last\": \"Fuso A\", \"name\": \"Current Alzheimer research\", \"pages\": \"753-759\", \"reference\": \"28176663\", \"title\": \"GSK3 5'-flanking DNA Methylation and Expression in Alzheimer's Disease Patients.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \"Here, we show for the first time that the administration of D-ribose, the most active glycator among monosaccharides, produces high levels of advanced glycation end products (AGEs) and, importantly, triggers hyperphosphorylation of Tau in the brain of C57BL/6 mouse and neuroblastoma N2a cells.\", \"key\": \"8f170e83d0b2e206b16b6a9b90be553e3677dd5ded1919ae3d5a108b4588e8b85f4835cc9436959b24af590dd98d111f8e9b7f59de8e6f463a7019a5db7562fb\", \"line\": 2293, \"relation\": \"positiveCorrelation\", \"source\": 304, \"target\": 3}, {\"annotations\": {\"Research_Model\": {\"rTg4510 mice\": true}}, \"citation\": {\"authors\": [\"Boehm J\", \"Bourgeois C\", \"Dudilot A\", \"Lauzon M\", \"Leclerc N\", \"Mondragn-Rodrguez S\", \"Trillaud-Doppia E\"], \"date\": \"2012-09-14\", \"first\": \"Mondragn-Rodrguez S\", \"last\": \"Boehm J\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"32040-53\", \"reference\": \"22833681\", \"title\": \"Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.\", \"type\": \"PubMed\", \"volume\": \"287\"}, \"evidence\": \"Acute treatment of rTg4510 mice with an O-GlcNAcase inhibitor transiently reduced tau phosphorylation at epitopes implicated in tau pathology. More importantly, long-term inhibitor treatment strongly increased tau O-GlcNAcylation, reduced the number of dystrophic neurons, and protected against the formation of pathological tau species without altering the phosphorylation of non-pathological tau.\", \"key\": \"93061d0c48394bdd5635c18c131dc69dec6ed2ff9e829ebca485d6ae64560bb60b7a4dc7e2d8b1f2f292c00952051ee4947bc79ab4553d543002f1f1db00953d\", \"line\": 2510, \"relation\": \"positiveCorrelation\", \"source\": 304, \"target\": 272}, {\"annotations\": {\"Method\": {\"Immunocytochemistry\": true, \"RNA Interference, siRNA\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"Lawson LY\", \"Li Q\", \"O'Leary JC 3rd\", \"Trotter JH\", \"Vestal GD\", \"Weeber EJ\"], \"date\": \"2011-05-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"16976-83\", \"reference\": \"21367866\", \"title\": \"The Hsp90 kinase co-chaperone Cdc37 regulates tau stability and phosphorylation dynamics.\", \"type\": \"PubMed\", \"volume\": \"286\"}, \"evidence\": \"Quantification of the Western blot showed that Cdc37 knockdown reduced phospho-Thr-231, phospho-Ser-199/Ser-202, phospho-Ser-396/Ser-404, and phospho-Ser-262/Ser-356 tau.\", \"key\": \"04f5396d0282e495fad62ab6beb1d0c07a3b436c9a7789fc04ad7e57f67cd5a90a0ff80a1574d4e2d89d5ac2f0968489825c19b71acbac425a5cd66686c0c051\", \"line\": 633, \"relation\": \"positiveCorrelation\", \"source\": 304, \"target\": 214}, {\"annotations\": {\"Method\": {\"Chromatography, Gel filtration\": true, \"Chromatography, Ni-NTA-Sepharose\": true, \"Chymotrypsin Assay\": true, \"Co-Immunoprecipitation\": true, \"Immunofluorescence\": true, \"Immunohistochemistry\": true, \"Microtubule polzmerization Assay\": true, \"Protease-coupled Assay\": true, \"RNA Interference, siRNA\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Blair LJ\", \"Borysov SI\", \"Buchner J\", \"Cox MB\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"O'Leary JC 3rd\", \"Schmid AB\", \"Shults CL\"], \"date\": \"2010-01-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"591-9\", \"reference\": \"20071522\", \"title\": \"The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules.\", \"type\": \"PubMed\", \"volume\": \"30\"}, \"evidence\": \"We found that FKBP51 indeed could interact with tau from both AD patients and control cases (Fig. 3D), further suggesting a functionally relevant relationship between FKBP51 and tau. We then investigated whether FKBP51 would preferentially interact with phosphorylated tau species. We increased the number of samples per group (4 for AD and 4 for normal) and again co-immunoprecipitated FKBP51. After gel electrophoresis, immunoblotting showed increased association of pS396 and pS199-S202 tau species with FKBP51 in AD tissue (Fig S1). Indeed, we found that FKBP51 over-expression increased phospho- and total tau levels (by 80%) in HeLa cells stably expressing normal human tau, while FKBP52 over-expression had no affect (Fig.4A). These experiments were repeated multiple times and Student t-test of these replicates demonstrated that FKBP51 significantly increased total tau levels (p= 0.0104).\", \"key\": \"8bc1c679aaffd16efeb1e10c73292b8b9d36f763f9eeceacd84bf27d052de0c9c2044feabca50ef707f18d52c3151c53a98f950b41fb77a89e0a8006afad1676\", \"line\": 595, \"relation\": \"positiveCorrelation\", \"source\": 304, \"target\": 229}, {\"annotations\": {\"Cell_Line\": {\"N2a\": true, \"SH-SY5Y\": true}}, \"citation\": {\"authors\": [\"Fan SJ\", \"Huang FI\", \"Liou JP\", \"Yang CR\"], \"date\": \"2018-05-29\", \"first\": \"Fan SJ\", \"last\": \"Yang CR\", \"name\": \"Cell death &amp; disease\", \"pages\": \"655\", \"reference\": \"29844403\", \"title\": \"The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.\", \"type\": \"PubMed\", \"volume\": \"9\"}, \"evidence\": \"This study aimed to investigate the protective effects and mechanism of the novel HDAC6 inhibitor, MPT0G211, using an AD model. Our results indicated that MPT0G211 significantly reduced tau phosphorylation and aggregation, the processes highly correlated with the formation of NFTs. This HDAC6 inhibitory activity resulted in an increase in acetylated Hsp90, which decreased Hsp90 and HDAC6 binding, causing ubiquitination of phosphorylated tau proteins. In addition, a significant increase of phospho-glycogen synthase kinase-3 (phospho-GSK3) on Ser9 (the inactive form) through Akt phosphorylation was associated with the inhibition of phospho-tau Ser396 in response to MPT0G211 treatment.\", \"key\": \"f13ed02ecfd16d298f503f40f452d143e2bde0c75526ddd3bd22ab908459e6667f80c28fe96bf8816714d109e9819d6e431a83b73a75f3d7c9cea199c0e10858\", \"line\": 3395, \"object\": {\"modifier\": \"Activity\"}, \"relation\": \"positiveCorrelation\", \"source\": 304, \"target\": 232}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"The reaction with the diagnostic antibodies (Fig. 4) is similar to the examples shown previously for cdk2 (Fig. 2), MAP kinase [8], or GSK-3 [26], indicating the phosphorylation of the SP motifs for which these antibodies are sensitive (serines 199, 202, 235, 396, 404; see Fig. 1)\", \"key\": \"0544bcc857112ee6204e0a0e2b8c7f715dfa5f78f3e9c6471e41d22a75ada814fe0de2c09c973ac4c140d7ab6960d0a07a31689e260f52abcb80d1054b9dbf5a\", \"line\": 132, \"relation\": \"directlyIncreases\", \"source\": 159, \"target\": 304}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"The reaction with the diagnostic antibodies (Fig. 4) is similar to the examples shown previously for cdk2 (Fig. 2), MAP kinase [8], or GSK-3 [26], indicating the phosphorylation of the SP motifs for which these antibodies are sensitive (serines 199, 202, 235, 396, 404; see Fig. 1)\", \"key\": \"529c2d160ac78564d300742e7846f4121176e2ff67673a03536431e6931aa8db67f52a3c6b7ef64ca4a9e4263b04bc5356b84d8e09098a901c80d55cf4c1af43\", \"line\": 129, \"relation\": \"directlyIncreases\", \"source\": 159, \"target\": 289}, {\"citation\": {\"authors\": [\"Dewachter I\", \"Terwel D\", \"Van Leuven F\"], \"date\": \"2002-01-01\", \"first\": \"Terwel D\", \"last\": \"Van Leuven F\", \"name\": \"Neuromolecular medicine\", \"pages\": \"151-65\", \"reference\": \"12428809\", \"title\": \"Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"2\"}, \"evidence\": \" Among the specific proline-dependent kinases that can phosphorylate protein tau at dif- ferent sites in vitro, special attention is dedicated to glycogen-synthase kinase-3 (GSK-3) (Michel et al., 1998), mitogen-activated protein kinase (MAPK) (Drewes et al., 1992), stress-activated protein kinases (SAPKs) (Goedert et al., 1997) and cyclin-dependent kinases (CDKs) including cdc2 and cdk5 (Baumann et al., 1993; Patrick et al., 1999).\", \"key\": \"f1abacfabe14e908730495eb48f09acf8208a41735d31e21d276205d47315f3d58ab2ea9ce1db8233a5a5b0fd01ac295bce310437348ec73080ebc6116074831\", \"line\": 112, \"relation\": \"increases\", \"source\": 159, \"target\": 286}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"The Mr shifts up with time in several stages, very similar to our earlier observations with the brain kinase activity, MAP kinase and GSK3 (Fig. 2,)\", \"key\": \"9bbfeae0d349acc4db616bfe82904a2babb657908a79ca7d4049e1b525b77a0702c6749a599bf0c11f61284de5d9bd6bd6827ea842bc487e3fe2dfe8d083cbc7\", \"line\": 71, \"relation\": \"directlyIncreases\", \"source\": 159, \"target\": 286}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"The reaction with the diagnostic antibodies (Fig. 4) is similar to the examples shown previously for cdk2 (Fig. 2), MAP kinase [8], or GSK-3 [26], indicating the phosphorylation of the SP motifs for which these antibodies are sensitive (serines 199, 202, 235, 396, 404; see Fig. 1)\", \"key\": \"6319d747103bd577c16136c6fd3484e3c1703796e75f542928586ff07ece30edc8a5fd85694a20ee0edf02093e663976eda1b209710f60a3f5d71c08ac0351e5\", \"line\": 130, \"relation\": \"directlyIncreases\", \"source\": 159, \"target\": 290}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"The reaction with the diagnostic antibodies (Fig. 4) is similar to the examples shown previously for cdk2 (Fig. 2), MAP kinase [8], or GSK-3 [26], indicating the phosphorylation of the SP motifs for which these antibodies are sensitive (serines 199, 202, 235, 396, 404; see Fig. 1)\", \"key\": \"2d9032cb7b47f53a87212c2a636780759eefb695e6c74fc70a42d563d884d0af7bbef2851ffa19cbe026298c0e8ac365f2b2bf6116fbd55c505391c682e55788\", \"line\": 133, \"relation\": \"directlyIncreases\", \"source\": 159, \"target\": 306}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"The reaction with the diagnostic antibodies (Fig. 4) is similar to the examples shown previously for cdk2 (Fig. 2), MAP kinase [8], or GSK-3 [26], indicating the phosphorylation of the SP motifs for which these antibodies are sensitive (serines 199, 202, 235, 396, 404; see Fig. 1)\", \"key\": \"fbf94ba6b37a7a52c3822de30a1e8253ccbd53fb167f37187328c2f9c7c41adabffcaeafb2092e973a3e6a4a80fbe0c4c2dfe5d9ecc77200b1e48f0f06675591\", \"line\": 131, \"relation\": \"directlyIncreases\", \"source\": 159, \"target\": 295}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"The reaction with the diagnostic antibodies (Fig. 4) is similar to the examples shown previously for cdk2 (Fig. 2), MAP kinase [8], or GSK-3 [26], indicating the phosphorylation of the SP motifs for which these antibodies are sensitive (serines 199, 202, 235, 396, 404; see Fig. 1)\", \"key\": \"1d73eb884925934e859d505d8eba9e1e7410dd76516d342e8af680c550f29d49a4f4dae400afd24b17d96e53f54e2964ba7680916f2252e8060ae7e728b1aaba\", \"line\": 137, \"relation\": \"directlyIncreases\", \"source\": 160, \"target\": 304}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"The reaction with the diagnostic antibodies (Fig. 4) is similar to the examples shown previously for cdk2 (Fig. 2), MAP kinase [8], or GSK-3 [26], indicating the phosphorylation of the SP motifs for which these antibodies are sensitive (serines 199, 202, 235, 396, 404; see Fig. 1)\", \"key\": \"7bb41a4db24503616b18ac0672c14935dfcb142abdd9664c7b420e0af8017c76c0b91b1a883ddf873d9125211ea863d33edbdd5ed5389a368cb1f4ecc5a97979\", \"line\": 134, \"relation\": \"directlyIncreases\", \"source\": 160, \"target\": 289}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"The Mr shifts up with time in several stages, very similar to our earlier observations with the brain kinase activity, MAP kinase and GSK3 (Fig. 2,)\", \"key\": \"8232496d7f63728909d8955058c68a906c064d3c043dc25a34ec4ce203b67b9f14107a118b6882c2dce6bd3cb0ca94c1b8c61d96894da2c205ac1de12a9a70e7\", \"line\": 72, \"relation\": \"directlyIncreases\", \"source\": 160, \"target\": 286}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"The reaction with the diagnostic antibodies (Fig. 4) is similar to the examples shown previously for cdk2 (Fig. 2), MAP kinase [8], or GSK-3 [26], indicating the phosphorylation of the SP motifs for which these antibodies are sensitive (serines 199, 202, 235, 396, 404; see Fig. 1)\", \"key\": \"839a3e42a2f1291ad8b4aaa94e32211a86993ae798666660cd40296c80006811fcbfeaf0da1fd35918da224f1e60b13f04aa73dd4646166b457bd3d216f0393a\", \"line\": 135, \"relation\": \"directlyIncreases\", \"source\": 160, \"target\": 290}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"The reaction with the diagnostic antibodies (Fig. 4) is similar to the examples shown previously for cdk2 (Fig. 2), MAP kinase [8], or GSK-3 [26], indicating the phosphorylation of the SP motifs for which these antibodies are sensitive (serines 199, 202, 235, 396, 404; see Fig. 1)\", \"key\": \"89fb960a881d5e91e16b47885186a1384b086638c65c56691692da648acd4ee3df8c43e70603360d592435a25330f32acd695b5c07f28ae5590528c50584870f\", \"line\": 138, \"relation\": \"directlyIncreases\", \"source\": 160, \"target\": 306}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"The reaction with the diagnostic antibodies (Fig. 4) is similar to the examples shown previously for cdk2 (Fig. 2), MAP kinase [8], or GSK-3 [26], indicating the phosphorylation of the SP motifs for which these antibodies are sensitive (serines 199, 202, 235, 396, 404; see Fig. 1)\", \"key\": \"1e3d4b2f530ecb526a700be419d19fa03afc9a2ae9f40ac407b4447f9ff5b8dbdb86b6d23e040a19f4494d0ce9eb06381fe71772c9a1928340cdf3132490a1ac\", \"line\": 136, \"relation\": \"directlyIncreases\", \"source\": 160, \"target\": 295}, {\"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Bachmeier C\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Jin C\", \"Laco G\", \"Lin Y\", \"Mullan M\", \"Paris D\"], \"date\": \"2014-12-05\", \"first\": \"Paris D\", \"last\": \"Mullan M\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"33927-44\", \"reference\": \"25331948\", \"title\": \"The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid- production and Tau hyperphosphorylation.\", \"type\": \"PubMed\", \"volume\": \"289\"}, \"evidence\": \"We further confirmed that possibility by showing that Tau phosphorylation at the typical GSK3 sites (PHF-1 and CP13) is reduced following treatment of SH-SY5Y cells with BAY61-3606, whereas Tau phosphorylation at the RZ3 site was not significantly impacted in SH-SY5Y cells (Fig. 9C).\", \"key\": \"239eec64f4b5b53084e3d96a9f011162ff207c9798a78d6fa35884254474e32a57b1905c25fdbc9afe50e78ad47ec7c1df19151653471335ac4f657b2ce1a1cb\", \"line\": 309, \"relation\": \"decreases\", \"source\": 2, \"target\": 304}, {\"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Bachmeier C\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Jin C\", \"Laco G\", \"Lin Y\", \"Mullan M\", \"Paris D\"], \"date\": \"2014-12-05\", \"first\": \"Paris D\", \"last\": \"Mullan M\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"33927-44\", \"reference\": \"25331948\", \"title\": \"The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid- production and Tau hyperphosphorylation.\", \"type\": \"PubMed\", \"volume\": \"289\"}, \"evidence\": \"We further confirmed that possibility by showing that Tau phosphorylation at the typical GSK3 sites (PHF-1 and CP13) is reduced following treatment of SH-SY5Y cells with BAY61-3606, whereas Tau phosphorylation at the RZ3 site was not significantly impacted in SH-SY5Y cells (Fig. 9C).\", \"key\": \"d3986c740609e67b9a0c7ad70a2d3d4d0fc42a602f6eb758eea2c785778291625059c1dcfa22f5c96776c77da099bcdf6a9d0be91d53fbddc6ca1905ff85c474\", \"line\": 311, \"relation\": \"decreases\", \"source\": 2, \"target\": 290}, {\"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Bachmeier C\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Jin C\", \"Laco G\", \"Lin Y\", \"Mullan M\", \"Paris D\"], \"date\": \"2014-12-05\", \"first\": \"Paris D\", \"last\": \"Mullan M\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"33927-44\", \"reference\": \"25331948\", \"title\": \"The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid- production and Tau hyperphosphorylation.\", \"type\": \"PubMed\", \"volume\": \"289\"}, \"evidence\": \"We further confirmed that possibility by showing that Tau phosphorylation at the typical GSK3 sites (PHF-1 and CP13) is reduced following treatment of SH-SY5Y cells with BAY61-3606, whereas Tau phosphorylation at the RZ3 site was not significantly impacted in SH-SY5Y cells (Fig. 9C).\", \"key\": \"d69fd62735f47bc55d044f7081b279ff593421305f056cc9ec619b6e3da668ce76f4474ceb3327bd15af8d468f20014143911c18823d2acafbaf848b4f39ef0e\", \"line\": 310, \"relation\": \"decreases\", \"source\": 2, \"target\": 306}, {\"citation\": {\"authors\": [\"Choi H\", \"Gwon Y\", \"Jung YK\", \"Kam TI\", \"Kim C\", \"Kim Y\", \"Koh JY\", \"Park H\"], \"date\": \"2012-06-15\", \"first\": \"Park H\", \"last\": \"Jung YK\", \"name\": \"Human molecular genetics\", \"pages\": \"2725-37\", \"reference\": \"22419736\", \"title\": \"Neuropathogenic role of adenylate kinase-1 in A-mediated tau phosphorylation via AMPK and GSK3.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"Interestingly, tau phosphor- ylation, which was detected by PHF-1 (Ser 396/404), CP13 (Ser 202) and 12E8 (Ser 262) antibodies, was also increased by Ab42 \", \"key\": \"0e34b65a21882ee15563b39f246deeba4a9e30e5286c5745a111c018680221becbcb3c608150fd8ccc3adc48b7b62fbc9ecebaf03fe66b6869ff5a61898f19dc\", \"line\": 92, \"relation\": \"increases\", \"source\": 6, \"target\": 304}, {\"citation\": {\"authors\": [\"Choi H\", \"Gwon Y\", \"Jung YK\", \"Kam TI\", \"Kim C\", \"Kim Y\", \"Koh JY\", \"Park H\"], \"date\": \"2012-06-15\", \"first\": \"Park H\", \"last\": \"Jung YK\", \"name\": \"Human molecular genetics\", \"pages\": \"2725-37\", \"reference\": \"22419736\", \"title\": \"Neuropathogenic role of adenylate kinase-1 in A-mediated tau phosphorylation via AMPK and GSK3.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"Compared with control neurons, the effects of Ab42 on tau phosphorylation at CP13, PHF-1 and AT180 epitopes were significantly ameliorated in AK1 knockdown cortical neurons \", \"key\": \"96d684906812fd7a8aeacb69882f0f8c6f002bbe0ae19e15c94e94ef83224207aeb2066a0ba4604a643f32992f6ac8c7ad412a4b3413d4c6577a3d46640e7b82\", \"line\": 110, \"relation\": \"increases\", \"source\": 6, \"target\": 286}, {\"citation\": {\"authors\": [\"Choi H\", \"Gwon Y\", \"Jung YK\", \"Kam TI\", \"Kim C\", \"Kim Y\", \"Koh JY\", \"Park H\"], \"date\": \"2012-06-15\", \"first\": \"Park H\", \"last\": \"Jung YK\", \"name\": \"Human molecular genetics\", \"pages\": \"2725-37\", \"reference\": \"22419736\", \"title\": \"Neuropathogenic role of adenylate kinase-1 in A-mediated tau phosphorylation via AMPK and GSK3.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"Interestingly, tau phosphor- ylation, which was detected by PHF-1 (Ser 396/404), CP13 (Ser 202) and 12E8 (Ser 262) antibodies, was also increased by Ab42 \", \"key\": \"47312296411e74afa246dcdfb80eaecd667284190c81c12c96ac7f5c69c750d0f544285d8099321fcdba3ac2ac76428dd914be17ddb7d05c10632c806e3c7fab\", \"line\": 91, \"relation\": \"increases\", \"source\": 6, \"target\": 290}, {\"citation\": {\"authors\": [\"Choi H\", \"Gwon Y\", \"Jung YK\", \"Kam TI\", \"Kim C\", \"Kim Y\", \"Koh JY\", \"Park H\"], \"date\": \"2012-06-15\", \"first\": \"Park H\", \"last\": \"Jung YK\", \"name\": \"Human molecular genetics\", \"pages\": \"2725-37\", \"reference\": \"22419736\", \"title\": \"Neuropathogenic role of adenylate kinase-1 in A-mediated tau phosphorylation via AMPK and GSK3.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"Interestingly, tau phosphor- ylation, which was detected by PHF-1 (Ser 396/404), CP13 (Ser 202) and 12E8 (Ser 262) antibodies, was also increased by Ab42 \", \"key\": \"4c882428f8c4f57f1409f2a46ccbcf34aae640c2bfbd0044eec11f4ee12b9b3aba656afdc985348c548aab601300283abf865bed74534bf2bc1bace0d30524d6\", \"line\": 93, \"relation\": \"increases\", \"source\": 6, \"target\": 306}, {\"citation\": {\"authors\": [\"Choi H\", \"Gwon Y\", \"Jung YK\", \"Kam TI\", \"Kim C\", \"Kim Y\", \"Koh JY\", \"Park H\"], \"date\": \"2012-06-15\", \"first\": \"Park H\", \"last\": \"Jung YK\", \"name\": \"Human molecular genetics\", \"pages\": \"2725-37\", \"reference\": \"22419736\", \"title\": \"Neuropathogenic role of adenylate kinase-1 in A-mediated tau phosphorylation via AMPK and GSK3.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"Interestingly, tau phosphor- ylation, which was detected by PHF-1 (Ser 396/404), CP13 (Ser 202) and 12E8 (Ser 262) antibodies, was also increased by Ab42 \", \"key\": \"fd2b2bb4da816385233bfc2de5d1fd08fb940e9ad5c31da1dde2c59b3abb01c17f337bc5ec5ca3012ed3a11a68f9bedd43e3c453ee59f61d705ebeac1e9eec3a\", \"line\": 94, \"relation\": \"increases\", \"source\": 6, \"target\": 297}, {\"annotations\": {\"Method\": {\"Chromatography, Gel filtration\": true, \"Chromatography, Ni-NTA-Sepharose\": true, \"Chymotrypsin Assay\": true, \"Co-Immunoprecipitation\": true, \"Immunofluorescence\": true, \"Immunohistochemistry\": true, \"Microtubule polzmerization Assay\": true, \"Protease-coupled Assay\": true, \"RNA Interference, siRNA\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Blair LJ\", \"Borysov SI\", \"Buchner J\", \"Cox MB\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"O'Leary JC 3rd\", \"Schmid AB\", \"Shults CL\"], \"date\": \"2010-01-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"591-9\", \"reference\": \"20071522\", \"title\": \"The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules.\", \"type\": \"PubMed\", \"volume\": \"30\"}, \"evidence\": \"We found that FKBP51 indeed could interact with tau from both AD patients and control cases (Fig. 3D), further suggesting a functionally relevant relationship between FKBP51 and tau. We then investigated whether FKBP51 would preferentially interact with phosphorylated tau species. We increased the number of samples per group (4 for AD and 4 for normal) and again co-immunoprecipitated FKBP51. After gel electrophoresis, immunoblotting showed increased association of pS396 and pS199-S202 tau species with FKBP51 in AD tissue (Fig S1). Indeed, we found that FKBP51 over-expression increased phospho- and total tau levels (by 80%) in HeLa cells stably expressing normal human tau, while FKBP52 over-expression had no affect (Fig.4A). These experiments were repeated multiple times and Student t-test of these replicates demonstrated that FKBP51 significantly increased total tau levels (p= 0.0104).\", \"key\": \"11c2db509de7c9017ee075a55caafd4e3ef662739e05683d8dfeeaebedd6aeee5e8a0b3b7493610f37a3fb656605f4ef44b74ad90c03942046bfc1c2d6b7b871\", \"line\": 592, \"relation\": \"association\", \"source\": 122, \"target\": 304}, {\"annotations\": {\"Method\": {\"Chromatography, Gel filtration\": true, \"Chromatography, Ni-NTA-Sepharose\": true, \"Chymotrypsin Assay\": true, \"Co-Immunoprecipitation\": true, \"Immunofluorescence\": true, \"Immunohistochemistry\": true, \"Microtubule polzmerization Assay\": true, \"Protease-coupled Assay\": true, \"RNA Interference, siRNA\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Blair LJ\", \"Borysov SI\", \"Buchner J\", \"Cox MB\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"O'Leary JC 3rd\", \"Schmid AB\", \"Shults CL\"], \"date\": \"2010-01-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"591-9\", \"reference\": \"20071522\", \"title\": \"The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules.\", \"type\": \"PubMed\", \"volume\": \"30\"}, \"evidence\": \"We found that FKBP51 indeed could interact with tau from both AD patients and control cases (Fig. 3D), further suggesting a functionally relevant relationship between FKBP51 and tau. We then investigated whether FKBP51 would preferentially interact with phosphorylated tau species. We increased the number of samples per group (4 for AD and 4 for normal) and again co-immunoprecipitated FKBP51. After gel electrophoresis, immunoblotting showed increased association of pS396 and pS199-S202 tau species with FKBP51 in AD tissue (Fig S1). Indeed, we found that FKBP51 over-expression increased phospho- and total tau levels (by 80%) in HeLa cells stably expressing normal human tau, while FKBP52 over-expression had no affect (Fig.4A). These experiments were repeated multiple times and Student t-test of these replicates demonstrated that FKBP51 significantly increased total tau levels (p= 0.0104).\", \"key\": \"9a86e0b7e8b929aaa580d7102c2669e18c9fdc605095ff987dc3084d7ef6382f434703041dd9fa838977bbbb488e8994810c453c9ec34c6d6b993fb3cb6858af\", \"line\": 593, \"relation\": \"association\", \"source\": 122, \"target\": 289}, {\"annotations\": {\"Method\": {\"Chromatography, Gel filtration\": true, \"Chromatography, Ni-NTA-Sepharose\": true, \"Chymotrypsin Assay\": true, \"Co-Immunoprecipitation\": true, \"Immunofluorescence\": true, \"Immunohistochemistry\": true, \"Microtubule polzmerization Assay\": true, \"Protease-coupled Assay\": true, \"RNA Interference, siRNA\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Blair LJ\", \"Borysov SI\", \"Buchner J\", \"Cox MB\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"O'Leary JC 3rd\", \"Schmid AB\", \"Shults CL\"], \"date\": \"2010-01-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"591-9\", \"reference\": \"20071522\", \"title\": \"The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules.\", \"type\": \"PubMed\", \"volume\": \"30\"}, \"evidence\": \"We found that FKBP51 indeed could interact with tau from both AD patients and control cases (Fig. 3D), further suggesting a functionally relevant relationship between FKBP51 and tau. We then investigated whether FKBP51 would preferentially interact with phosphorylated tau species. We increased the number of samples per group (4 for AD and 4 for normal) and again co-immunoprecipitated FKBP51. After gel electrophoresis, immunoblotting showed increased association of pS396 and pS199-S202 tau species with FKBP51 in AD tissue (Fig S1). Indeed, we found that FKBP51 over-expression increased phospho- and total tau levels (by 80%) in HeLa cells stably expressing normal human tau, while FKBP52 over-expression had no affect (Fig.4A). These experiments were repeated multiple times and Student t-test of these replicates demonstrated that FKBP51 significantly increased total tau levels (p= 0.0104).\", \"key\": \"7b0b22eb577709082ab0ccd39608064a9da708b0cb466bb30d70ec65ce301a9bd61bf06b6ecaf5b57fd97c32844da8640c57b13256cc683e303e3a6583bcf3ee\", \"line\": 594, \"relation\": \"association\", \"source\": 122, \"target\": 290}, {\"annotations\": {\"Method\": {\"Confocal Microscopy, Laser Scanning\": true, \"Immunocytochemistry\": true, \"Mass Spectrometry\": true, \"Pull-down Assay, GFP\": true, \"RNA Interference, shRNA\": true, \"Tandem Affinity Purification, TAP\": true}}, \"citation\": {\"authors\": [\"Brandt R\", \"Drewes G\", \"Gauthier-Kemper A\", \"Gerke V\", \"Golovyashkina N\", \"Heinisch JJ\", \"Seb-Lemke Z\", \"Weissmann C\"], \"date\": \"2011-02-21\", \"first\": \"Gauthier-Kemper A\", \"last\": \"Brandt R\", \"name\": \"The Journal of cell biology\", \"pages\": \"647-61\", \"reference\": \"21339331\", \"title\": \"The frontotemporal dementia mutation R406W blocks tau's interaction with the membrane in an annexin A2-dependent manner.\", \"type\": \"PubMed\", \"volume\": \"192\"}, \"evidence\": \"The quantification of all immunoreactive bands revealed that the R406W mutation exhibits a decreased phosphorylation at T205, T212, and the PHF1 epitope (S396/S404; reductions of 4065%) as compared with wt tau, whereas other sites were not affected or only slightly affected (T181, S199, S214, and S262).\", \"key\": \"dda54b057f735421f370e34b88a3eee190a3bab6f69ef88ebd03c29df1a39c76c0cd5f66cc3918b94235086b602b5bc68b1907be02e0bbfd33ff6cac83b2a666\", \"line\": 802, \"relation\": \"decreases\", \"source\": 189, \"target\": 304}, {\"annotations\": {\"Method\": {\"Confocal Microscopy, Laser Scanning\": true, \"Immunocytochemistry\": true, \"Mass Spectrometry\": true, \"Pull-down Assay, GFP\": true, \"RNA Interference, shRNA\": true, \"Tandem Affinity Purification, TAP\": true}}, \"citation\": {\"authors\": [\"Brandt R\", \"Drewes G\", \"Gauthier-Kemper A\", \"Gerke V\", \"Golovyashkina N\", \"Heinisch JJ\", \"Seb-Lemke Z\", \"Weissmann C\"], \"date\": \"2011-02-21\", \"first\": \"Gauthier-Kemper A\", \"last\": \"Brandt R\", \"name\": \"The Journal of cell biology\", \"pages\": \"647-61\", \"reference\": \"21339331\", \"title\": \"The frontotemporal dementia mutation R406W blocks tau's interaction with the membrane in an annexin A2-dependent manner.\", \"type\": \"PubMed\", \"volume\": \"192\"}, \"evidence\": \"The quantification of all immunoreactive bands revealed that the R406W mutation exhibits a decreased phosphorylation at T205, T212, and the PHF1 epitope (S396/S404; reductions of 4065%) as compared with wt tau, whereas other sites were not affected or only slightly affected (T181, S199, S214, and S262).\", \"key\": \"a0cbc225cc12669d917f54ca94e03e2c63d1d9a1a53fa38a84b0f34452efdf59ece5808a5fb1ce6579aaf5807c3d9ea1279525a7b24540c8eefe9560101a8120\", \"line\": 800, \"relation\": \"decreases\", \"source\": 189, \"target\": 312}, {\"annotations\": {\"Method\": {\"Confocal Microscopy, Laser Scanning\": true, \"Immunocytochemistry\": true, \"Mass Spectrometry\": true, \"Pull-down Assay, GFP\": true, \"RNA Interference, shRNA\": true, \"Tandem Affinity Purification, TAP\": true}}, \"citation\": {\"authors\": [\"Brandt R\", \"Drewes G\", \"Gauthier-Kemper A\", \"Gerke V\", \"Golovyashkina N\", \"Heinisch JJ\", \"Seb-Lemke Z\", \"Weissmann C\"], \"date\": \"2011-02-21\", \"first\": \"Gauthier-Kemper A\", \"last\": \"Brandt R\", \"name\": \"The Journal of cell biology\", \"pages\": \"647-61\", \"reference\": \"21339331\", \"title\": \"The frontotemporal dementia mutation R406W blocks tau's interaction with the membrane in an annexin A2-dependent manner.\", \"type\": \"PubMed\", \"volume\": \"192\"}, \"evidence\": \"The quantification of all immunoreactive bands revealed that the R406W mutation exhibits a decreased phosphorylation at T205, T212, and the PHF1 epitope (S396/S404; reductions of 4065%) as compared with wt tau, whereas other sites were not affected or only slightly affected (T181, S199, S214, and S262).\", \"key\": \"a61688cc8256384637d6879eb2972c0961846fd400704ec2a208bf7b370cd3da881ac52102938aac8e20d0153b6e6d430e6b075df254b60f9ec0084765a21396\", \"line\": 801, \"relation\": \"decreases\", \"source\": 189, \"target\": 313}, {\"annotations\": {\"Method\": {\"Confocal Microscopy, Laser Scanning\": true, \"Immunocytochemistry\": true, \"Mass Spectrometry\": true, \"Pull-down Assay, GFP\": true, \"RNA Interference, shRNA\": true, \"Tandem Affinity Purification, TAP\": true}}, \"citation\": {\"authors\": [\"Brandt R\", \"Drewes G\", \"Gauthier-Kemper A\", \"Gerke V\", \"Golovyashkina N\", \"Heinisch JJ\", \"Seb-Lemke Z\", \"Weissmann C\"], \"date\": \"2011-02-21\", \"first\": \"Gauthier-Kemper A\", \"last\": \"Brandt R\", \"name\": \"The Journal of cell biology\", \"pages\": \"647-61\", \"reference\": \"21339331\", \"title\": \"The frontotemporal dementia mutation R406W blocks tau's interaction with the membrane in an annexin A2-dependent manner.\", \"type\": \"PubMed\", \"volume\": \"192\"}, \"evidence\": \"The quantification of all immunoreactive bands revealed that the R406W mutation exhibits a decreased phosphorylation at T205, T212, and the PHF1 epitope (S396/S404; reductions of 4065%) as compared with wt tau, whereas other sites were not affected or only slightly affected (T181, S199, S214, and S262).\", \"key\": \"1e9a2563d0d5b3399a2a18fccc738096e97007826c8d135cd630395d55e4560ae6e4b9154cf357de5fc59c0e69fb12fe0bcf99240c12642a3c5050b9585d245f\", \"line\": 803, \"relation\": \"decreases\", \"source\": 189, \"target\": 306}, {\"citation\": {\"authors\": [\"Lu B\", \"Malenka R\", \"Polepalli J\", \"Rajadas J\", \"Wagh D\", \"Yu W\"], \"date\": \"2012-03-15\", \"first\": \"Yu W\", \"last\": \"Lu B\", \"name\": \"Human molecular genetics\", \"pages\": \"1384-90\", \"reference\": \"22156579\", \"title\": \"A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of A on synapses and dendritic spines.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"We first confirmed that expression of an MKI-GFP fusion protein in rat hippocampal neurons effectively attenuated MARK4-mediated phosphorylation of both endogenous tau (Fig. 3A) and transfected human tau at the 12E8 sites (Fig. 3B). Phosphorylation of tau at the PHF-1 site was also reduced by MKI (Fig. 3A). It is possible that the PHF-1 site is also targeted by PAR-1/MARKs in vivo, or that the phosphorylation of tau at the 12E8 sites is a prerequisite for PHF-1 site phosphorylation, as the 12E8 sites were previously shown to be required for tau phosphorylation at other sites\", \"key\": \"ff548ca67b04fb5573817eaa257c76a78d88de8c2cfc947c65d8b7cc52b7af85e54f16abfdec9fa75f770bfaadcd7e4dc3aff65e1a23bd38a186f5b97dde3e9e\", \"line\": 1806, \"relation\": \"positiveCorrelation\", \"source\": 45, \"target\": 304}, {\"citation\": {\"authors\": [\"Lu B\", \"Malenka R\", \"Polepalli J\", \"Rajadas J\", \"Wagh D\", \"Yu W\"], \"date\": \"2012-03-15\", \"first\": \"Yu W\", \"last\": \"Lu B\", \"name\": \"Human molecular genetics\", \"pages\": \"1384-90\", \"reference\": \"22156579\", \"title\": \"A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of A on synapses and dendritic spines.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"We first confirmed that expression of an MKI-GFP fusion protein in rat hippocampal neurons effectively attenuated MARK4-mediated phosphorylation of both endogenous tau (Fig. 3A) and transfected human tau at the 12E8 sites (Fig. 3B). Phosphorylation of tau at the PHF-1 site was also reduced by MKI (Fig. 3A). It is possible that the PHF-1 site is also targeted by PAR-1/MARKs in vivo, or that the phosphorylation of tau at the 12E8 sites is a prerequisite for PHF-1 site phosphorylation, as the 12E8 sites were previously shown to be required for tau phosphorylation at other sites\", \"key\": \"d621af086784aeac0a05ee47c16e4b242ded3f8e68326bd6b0eb4fff01f4262a414718ea84df97f3f1fa13cbf430195d32db5c04bb29cc26c8cca58bec49152c\", \"line\": 1807, \"relation\": \"positiveCorrelation\", \"source\": 45, \"target\": 306}, {\"citation\": {\"authors\": [\"Chai GS\", \"Chen NN\", \"Cheng XS\", \"Duan DX\", \"Hu Y\", \"Liu GP\", \"Luo Y\", \"Ni ZF\", \"Wang JZ\"], \"date\": \"2013-01-01\", \"first\": \"Duan DX\", \"last\": \"Liu GP\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"795-808\", \"reference\": \"23948915\", \"title\": \"Phosphorylation of tau by death-associated protein kinase 1 antagonizes the kinase-induced cell apoptosis.\", \"type\": \"PubMed\", \"volume\": \"37\"}, \"evidence\": \"These data suggest that tau hyperphosphorylation at Thr231, Ser262, and Ser396 by DAPK1 renders the cells more resistant to the kinase-induced apoptotic cell death, providing new insights into the tau-involved apoptotic abortion in the course of chronic neurodegeneration.\", \"key\": \"0e875531a526b51c13b1de4917a7684776ef214f46341a2e5be0431bbba302727a24d6e34ce610a8f7970b4b975f4451470b9adf0df3a581505c23887d82e4b1\", \"line\": 2001, \"relation\": \"negativeCorrelation\", \"source\": 78, \"target\": 304}, {\"citation\": {\"authors\": [\"Chai GS\", \"Chen NN\", \"Cheng XS\", \"Duan DX\", \"Hu Y\", \"Liu GP\", \"Luo Y\", \"Ni ZF\", \"Wang JZ\"], \"date\": \"2013-01-01\", \"first\": \"Duan DX\", \"last\": \"Liu GP\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"795-808\", \"reference\": \"23948915\", \"title\": \"Phosphorylation of tau by death-associated protein kinase 1 antagonizes the kinase-induced cell apoptosis.\", \"type\": \"PubMed\", \"volume\": \"37\"}, \"evidence\": \"These data suggest that tau hyperphosphorylation at Thr231, Ser262, and Ser396 by DAPK1 renders the cells more resistant to the kinase-induced apoptotic cell death, providing new insights into the tau-involved apoptotic abortion in the course of chronic neurodegeneration.\", \"key\": \"79dc7520fefbfe877149bea0ba8a606ffcb3796c1a7677e7f16a1ae05ebf4b754cb5724ed034f80d7611f86e24d5a3d0ab20412f4f32b1412bb2b665e7e2a1ac\", \"line\": 2002, \"relation\": \"negativeCorrelation\", \"source\": 78, \"target\": 315}, {\"citation\": {\"authors\": [\"Chai GS\", \"Chen NN\", \"Cheng XS\", \"Duan DX\", \"Hu Y\", \"Liu GP\", \"Luo Y\", \"Ni ZF\", \"Wang JZ\"], \"date\": \"2013-01-01\", \"first\": \"Duan DX\", \"last\": \"Liu GP\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"795-808\", \"reference\": \"23948915\", \"title\": \"Phosphorylation of tau by death-associated protein kinase 1 antagonizes the kinase-induced cell apoptosis.\", \"type\": \"PubMed\", \"volume\": \"37\"}, \"evidence\": \"These data suggest that tau hyperphosphorylation at Thr231, Ser262, and Ser396 by DAPK1 renders the cells more resistant to the kinase-induced apoptotic cell death, providing new insights into the tau-involved apoptotic abortion in the course of chronic neurodegeneration.\", \"key\": \"3f1104694d0497b00b8a253d39404c19a7c8fd780dde35ccde2c37b1ae266e1a04278440820c3eaf9fec85604df25db767ad115efdfe9f648f8bee1afc856c4d\", \"line\": 2000, \"relation\": \"negativeCorrelation\", \"source\": 78, \"target\": 297}, {\"annotations\": {\"Cell_Line\": {\"N2a\": true}, \"Method\": {\"Immunofluorescence\": true, \"Immunohistochemistry\": true, \"Western Blot\": true}, \"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Han C\", \"He R\", \"Liu Y\", \"Su T\", \"Wang Y\", \"Wei Y\", \"Wu B\"], \"date\": \"2015-10-01\", \"first\": \"Wei Y\", \"last\": \"He R\", \"name\": \"Aging cell\", \"pages\": \"754-63\", \"reference\": \"26095350\", \"title\": \"Ribosylation triggering Alzheimer's disease-like Tau hyperphosphorylation via activation of CaMKII.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \"Here, we show for the first time that the administration of D-ribose, the most active glycator among monosaccharides, produces high levels of advanced glycation end products (AGEs) and, importantly, triggers hyperphosphorylation of Tau in the brain of C57BL/6 mouse and neuroblastoma N2a cells.\", \"key\": \"f844fcbd9f93fc4da1463f8779c6f4a95c32519f9fabfa5fba74778b79b49845ad621b7cc8b1064ee394a94f242f2a5ac713e7098ec8da3851a74716d9729f5c\", \"line\": 528, \"relation\": \"increases\", \"source\": 3, \"target\": 304}, {\"citation\": {\"authors\": [\"Cavallaro RA\", \"Ciraci V\", \"Ferrer I\", \"Fuso A\", \"Nicolia V\", \"Scarpa S\"], \"date\": \"2017-01-01\", \"first\": \"Nicolia V\", \"last\": \"Fuso A\", \"name\": \"Current Alzheimer research\", \"pages\": \"753-759\", \"reference\": \"28176663\", \"title\": \"GSK3 5'-flanking DNA Methylation and Expression in Alzheimer's Disease Patients.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \"Here, we show for the first time that the administration of D-ribose, the most active glycator among monosaccharides, produces high levels of advanced glycation end products (AGEs) and, importantly, triggers hyperphosphorylation of Tau in the brain of C57BL/6 mouse and neuroblastoma N2a cells.\", \"key\": \"7ed3682047cd0ed4f6fe864921ed782634b17f9624bd402151305878037696e912521ee76f03ad9e04d18d939c0895eb68e8969c92f2127620d7d0ca2a0a71a8\", \"line\": 2293, \"relation\": \"positiveCorrelation\", \"source\": 3, \"target\": 304}, {\"annotations\": {\"Cell_Line\": {\"N2a\": true}, \"Method\": {\"Immunofluorescence\": true, \"Immunohistochemistry\": true, \"Western Blot\": true}, \"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Han C\", \"He R\", \"Liu Y\", \"Su T\", \"Wang Y\", \"Wei Y\", \"Wu B\"], \"date\": \"2015-10-01\", \"first\": \"Wei Y\", \"last\": \"He R\", \"name\": \"Aging cell\", \"pages\": \"754-63\", \"reference\": \"26095350\", \"title\": \"Ribosylation triggering Alzheimer's disease-like Tau hyperphosphorylation via activation of CaMKII.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \"Here, we show for the first time that the administration of D-ribose, the most active glycator among monosaccharides, produces high levels of advanced glycation end products (AGEs) and, importantly, triggers hyperphosphorylation of Tau in the brain of C57BL/6 mouse and neuroblastoma N2a cells.\", \"key\": \"b2b60e1ab117a5a5f9a4a1b27f4917e69e00975bea30fdb721017b2e9fe59563462d4500676d1113545955370ece046d176e061a6165c96bc0c6419bd58e0d00\", \"line\": 529, \"relation\": \"increases\", \"source\": 3, \"target\": 311}, {\"citation\": {\"authors\": [\"Cavallaro RA\", \"Ciraci V\", \"Ferrer I\", \"Fuso A\", \"Nicolia V\", \"Scarpa S\"], \"date\": \"2017-01-01\", \"first\": \"Nicolia V\", \"last\": \"Fuso A\", \"name\": \"Current Alzheimer research\", \"pages\": \"753-759\", \"reference\": \"28176663\", \"title\": \"GSK3 5'-flanking DNA Methylation and Expression in Alzheimer's Disease Patients.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \"Here, we show for the first time that the administration of D-ribose, the most active glycator among monosaccharides, produces high levels of advanced glycation end products (AGEs) and, importantly, triggers hyperphosphorylation of Tau in the brain of C57BL/6 mouse and neuroblastoma N2a cells.\", \"key\": \"feaafdb6592cbb31f99e3b3d886486d35ca88bf6b11cf760a98ea8bf75894a5080a8a0b031c5c80d41d921d84800f53069d133fff851d5fc4cfc1e6b3827afc5\", \"line\": 2291, \"relation\": \"positiveCorrelation\", \"source\": 3, \"target\": 311}, {\"annotations\": {\"Cell_Line\": {\"SH-SY5Y\": true}, \"Method\": {\"Atomic Force Microscopy\": true, \"Cell Viability Assay, MTT\": true, \"Flow Cytometry\": true, \"Fluorescence Spectrophotometry\": true, \"NBT colorimetric fructosamine assay\": true}}, \"citation\": {\"authors\": [\"Chen L\", \"He R\", \"Wang X\", \"Wei Y\"], \"date\": \"2009-08-01\", \"first\": \"Chen L\", \"last\": \"He R\", \"name\": \"Cellular and molecular life sciences : CMLS\", \"pages\": \"2559-71\", \"reference\": \"19517062\", \"title\": \"D-Ribosylated Tau forms globular aggregates with high cytotoxicity.\", \"type\": \"PubMed\", \"volume\": \"66\"}, \"evidence\": \"Tau is rapidly glycated in the presence of D-ribose, resulting in oligomerization and polymerization with Glycated derivatives appearing after 24 h. Advanced glycation end-products (AGEs) were formed during initial stages of glycation. Thioflavin T-positive (ThT-positive) aggregations (day 4) indicated the globular-like features. Atomic force microscopy revealed that the surface morphology of ribosylated Tau40 was globular-like.\", \"key\": \"7d36188026e1f6be80bdd5ede417e74eba89083299ec9961aabf35643ca85bf6fbf408048f8fe50ba4a01d73730690cbe24e08cde92333852204de473606e6d6\", \"line\": 590, \"relation\": \"increases\", \"source\": 3, \"target\": 275}, {\"annotations\": {\"Cell_Line\": {\"N2a\": true}, \"Method\": {\"Immunofluorescence\": true, \"Immunohistochemistry\": true, \"Western Blot\": true}, \"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Han C\", \"He R\", \"Liu Y\", \"Su T\", \"Wang Y\", \"Wei Y\", \"Wu B\"], \"date\": \"2015-10-01\", \"first\": \"Wei Y\", \"last\": \"He R\", \"name\": \"Aging cell\", \"pages\": \"754-63\", \"reference\": \"26095350\", \"title\": \"Ribosylation triggering Alzheimer's disease-like Tau hyperphosphorylation via activation of CaMKII.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \"Here, we show for the first time that the administration of D-ribose, the most active glycator among monosaccharides, produces high levels of advanced glycation end products (AGEs) and, importantly, triggers hyperphosphorylation of Tau in the brain of C57BL/6 mouse and neuroblastoma N2a cells.\", \"key\": \"a205065644165fe29aca5162709653f635e355828f77b1b5f8fac37fffb0695f167bb1cba68b38930901c17698ec71b362cda98fb0d2fff35071a749bebeb1c3\", \"line\": 527, \"relation\": \"increases\", \"source\": 3, \"target\": 294}, {\"citation\": {\"authors\": [\"Cavallaro RA\", \"Ciraci V\", \"Ferrer I\", \"Fuso A\", \"Nicolia V\", \"Scarpa S\"], \"date\": \"2017-01-01\", \"first\": \"Nicolia V\", \"last\": \"Fuso A\", \"name\": \"Current Alzheimer research\", \"pages\": \"753-759\", \"reference\": \"28176663\", \"title\": \"GSK3 5'-flanking DNA Methylation and Expression in Alzheimer's Disease Patients.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \"Here, we show for the first time that the administration of D-ribose, the most active glycator among monosaccharides, produces high levels of advanced glycation end products (AGEs) and, importantly, triggers hyperphosphorylation of Tau in the brain of C57BL/6 mouse and neuroblastoma N2a cells.\", \"key\": \"d51c5e9a78a6da4cfd873b9b2cd28bbb6e791278e8b59de1001b4931e6387c695e0c2d99321e064355b4496459be2bbca84e65d0a1ce4fd63849ded24bc45a94\", \"line\": 2292, \"relation\": \"positiveCorrelation\", \"source\": 3, \"target\": 294}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"ccfc0863cec88d79860dada598685c155129e44d21d3c671a29e9cefe15647c262c8fb3b58f73de1e9ebcb4a0e3b999aa01c10c60ed8236e5e9d633aebd5daa9\", \"line\": 1127, \"relation\": \"positiveCorrelation\", \"source\": 164, \"target\": 304}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"d153ea06f4c6df9733c87afdb60004ac3cadb0efd29f58105dece37838a4df2673cfb0bdf3466ceb14ecee4e89dee669a4fdc9d3cafe3d98215b161a04a11051\", \"line\": 1121, \"relation\": \"positiveCorrelation\", \"source\": 164, \"target\": 311}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"a1c098b95e2f2eeee1ac1f9f55a158107278e288f6f8babdf409a18429a1bae6328cbcbd929cc69b8bc461c0a7cd882da2df143b7023f7c1f240bdddacd17f60\", \"line\": 1124, \"relation\": \"positiveCorrelation\", \"source\": 164, \"target\": 312}, {\"annotations\": {\"Anatomy\": {\"brain\": true}, \"Species\": {\"9606\": true}, \"TauIsoform\": {\"Isoform F (441 aa)\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"von Bergen M\"], \"date\": \"2007-01-01\", \"first\": \"Mandelkow E\", \"last\": \"Mandelkow EM\", \"name\": \"Brain pathology (Zurich, Switzerland)\", \"pages\": \"83-90\", \"reference\": \"17493042\", \"title\": \"Structural principles of tau and the paired helical filaments of Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"A further potent detaching site is phosphoS214, which can be phosphorylated by PKA and other kinases of the AGC group (PKA/PKG/PKC group of protein kinases), and is up-regulated during mitosis (16, 63). Tau contains one or two cysteines in the repeat domain (C291 in R2, present in 4R isoforms, and C322 in R3), which can be engaged in intra- or intermolecular cross-linking affecting conformation, dimerization and aggregation (108).\", \"key\": \"612f58bf95a4214c9e736f0c1ba9929fc236de4d4d77606393d90caabd3ff5c3e760e3ede980f1aa01b3133cb479718d012cdfa202998baec8c1a5a74108307e\", \"line\": 167, \"relation\": \"increases\", \"source\": 164, \"target\": 294}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"fc20f93223c632cdd85c258e064a212c5850e8f4e93950345172df87275472b0cddb20e5a06bf49b1b93be7d35ad78bbd8de37ddae0245e8442d2b9c24aa85c0\", \"line\": 1128, \"relation\": \"positiveCorrelation\", \"source\": 164, \"target\": 309}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"425359abea24117743d444b9cd84363204db192ac95e7fa1c35b977e49b45d1fc04c9854d83cded8dd753e4c045d80357c64bd1f9842afe4ed241a38f82bdf75\", \"line\": 1126, \"relation\": \"positiveCorrelation\", \"source\": 164, \"target\": 315}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"c73a425975f01439588d929cff9609b9b9ef92f3b662678d8561557ebe47e6b6797dc6b12989e6387836fa1f0e8f80aa6b6c3f028691ff58dcd8207a2b4e4145\", \"line\": 1125, \"relation\": \"positiveCorrelation\", \"source\": 164, \"target\": 314}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"bd402e9ec39a225e573d4a3a54267a05a4f60f749b7157c4c2ffb37bed41fd8128c6edac0133eeb75a8283c34feac4afe59ad7b1b1a765866b402ee5f2f963d7\", \"line\": 1131, \"relation\": \"negativeCorrelation\", \"source\": 164, \"target\": 313}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"395166322fbf93a54b115c73c336bddd97ec407abb202ca40c2ce45f8a910f59f998cbe0fa78e5df2005a1cf50df23ea8f4e724595de24b39a4c6e8f350b782d\", \"line\": 1122, \"relation\": \"positiveCorrelation\", \"source\": 164, \"target\": 289}, {\"citation\": {\"authors\": [\"Dewachter I\", \"Terwel D\", \"Van Leuven F\"], \"date\": \"2002-01-01\", \"first\": \"Terwel D\", \"last\": \"Van Leuven F\", \"name\": \"Neuromolecular medicine\", \"pages\": \"151-65\", \"reference\": \"12428809\", \"title\": \"Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"2\"}, \"evidence\": \"Other serine and threonine residues, not followed by proline, are phosphorylated by other protein kinases, including microtubule-affinity-regulating kinase (MARK) (Drewes et al., 1993), calcium/ calmodulin kinase II (CAMKII), cAMP-dependent kinase (PKA) (Johnson et al., 1992), and casein kinase II (Greenwood et al., 1994).\", \"key\": \"78cf70468d140b2b9a8fffe0d9d039e7d01328c68db54dc585081c1428c4c2cd20742c80730bc792e647a9e0f20cb371b52e6224259ba364c368973882f1fb3d\", \"line\": 126, \"relation\": \"increases\", \"source\": 164, \"target\": 286}, {\"annotations\": {\"Species\": {\"6239\": true}}, \"citation\": {\"authors\": [\"Choudhary B\", \"Mandelkow E\", \"Pir GJ\"], \"date\": \"2017-12-01\", \"first\": \"Pir GJ\", \"last\": \"Mandelkow E\", \"name\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\", \"pages\": \"5137-5148\", \"reference\": \"29191965\", \"title\": \"&lt;i&gt;Caenorhabditis elegans&lt;/i&gt; models of tauopathy.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"The responsible kinases include 1) proline-directed protein kinases (PDPKs) targeting SP or TP motifs [e.g., GSK3b, cyclindependent kinase (CDK)-5, and MAPKs]; 2) nonproline directed protein kinases targeting KXGS-motifs [e.g., PKA, microtubule affinity-regulating kinase and synapses of the amphid defective (SADK)]; 3) protein kinases specific for tyrosines (e.g., Src, Lck, Syk, Fyn, and c-Abl kinase) (91).\", \"key\": \"9ace71a58f82f95507c45259df97aeee7885e7e82ec3e40b2030e674403bd86636f09187e57a48a03d9999c812abb4963adf085a7e799a8949926249712889be\", \"line\": 248, \"relation\": \"directlyIncreases\", \"source\": 164, \"target\": 286}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Other phosphorylation sites in or near the repeat domain are phosphorylated by microtubule affinity-regulating kinases (MARKs; also known as PAR1 kinases), cyclic AMP-dependent protein kinase (PKA) and Ca2+- or calmodulin-dependent protein kinase II (CaMKII), among others\", \"key\": \"0560db37d53b562490a6ccfc43e6e823baefaeb873c5d5096cc0063b6da9829f635ec933cd64174f8aa6e1cd9c28d020e712a8cb4f29078b717ee6c795cf3842\", \"line\": 166, \"relation\": \"directlyIncreases\", \"source\": 164, \"target\": 286}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"102bb970967ce9aa2b3b524963874120455a08919f4b62f44ad75ffbd8cd82fabf35ea828e42d637c25a390d21e442919f9ddbf3d47465f0ed5c4cc2001c371f\", \"line\": 1123, \"relation\": \"positiveCorrelation\", \"source\": 164, \"target\": 290}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"b25b68c0ec646133490c99f0755805f18cff5eb0a5e6107949a9660f1c86dfe0b2081e6d2f17a16b76e172dff768dc100604c60a36058f65a24719c53fb026e9\", \"line\": 1130, \"relation\": \"negativeCorrelation\", \"source\": 164, \"target\": 306}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"For example,the phosphorylation of KXGS motifs (particularly Ser262) in the repeat domain of tau by MARK, PKA or CaMKII can reduce the affinity of tau to microtubules\", \"key\": \"522d125e22b494f907f4cc981ecf626995cbf96d7230d20b9cdff6d25d9af458961d130c8d4e4618b72e9c5f68a3bed593ac1c2dbebabee014c336e27b56fd5a\", \"line\": 206, \"relation\": \"directlyIncreases\", \"source\": 164, \"target\": 297}, {\"citation\": {\"authors\": [\"Agerman K\", \"Eckersley S\", \"Gu GJ\", \"Kamali-Moghaddam M\", \"Kvist AJ\", \"Landegren U\", \"Lund H\", \"Milner R\", \"Nilsson LN\", \"Sunnemark D\", \"Wu D\"], \"date\": \"2013-01-01\", \"first\": \"Gu GJ\", \"last\": \"Kamali-Moghaddam M\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"699-713\", \"reference\": \"23001711\", \"title\": \"Elevated MARK2-dependent phosphorylation of Tau in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"33\"}, \"evidence\": \"Several kinases such as microtubule-affinity regulating kinase (MARK), protein kinase A, calcium calmodulin kinase II, and checkpoint kinase 2 are known to phosphorylate tau on Ser(262) in vitro. In this study, we took advantage of the in situ proximity ligation assay to investigate the role of MARK2, one of the four MARK isoforms, in AD. We demonstrate that MARK2 interacts with tau and phosphorylates tau at Ser(262) in stably transfected NIH/3T3 cells expressing human recombinant tau. Staurosporine, a protein kinase inhibitor, significantly reduced the interaction between MARK2 and tau, and also phosphorylation of tau at Ser(262).\", \"key\": \"dfea10e94bade9f0886239fcb8f49e16b951cd1195212f2b86fe34cc5ea98ca9ad4b4496fa5a177874059771dccfb3e0a64b2579426c4b71afbd4ce075451bcf\", \"line\": 2771, \"relation\": \"directlyIncreases\", \"source\": 164, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 297}, {\"key\": \"e697e93998c4f010e8119c813ee3817a7d9d666aee7b8c341410fea7a7f96c689412f0df412dad8ca37a0d878377f23cddde0d43a5a1ce69537c2f4e24350d3d\", \"relation\": \"hasComponent\", \"source\": 118, \"target\": 304}, {\"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Bachmeier C\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Jin C\", \"Laco G\", \"Lin Y\", \"Mullan M\", \"Paris D\"], \"date\": \"2014-12-05\", \"first\": \"Paris D\", \"last\": \"Mullan M\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"33927-44\", \"reference\": \"25331948\", \"title\": \"The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid- production and Tau hyperphosphorylation.\", \"type\": \"PubMed\", \"volume\": \"289\"}, \"evidence\": \"Western blot analyses of brain homogenates show that ()-nilvadipine significantly reduces Tau phosphorylation in AT8 (phosphorylated Ser-199/Ser-202/Thr-205) and PHF-1 (phosphorylated Ser-396/Ser-404) epitopes\", \"key\": \"bd76cbea1355fecd15a81a8dfc16f75b73c2c9cbffc502e4fe436e7589f1922e3e55fa34c5c2572e792d2b7d7a7a6456a221e39988a2f17eee555d609654ac9e\", \"line\": 2250, \"relation\": \"decreases\", \"source\": 15, \"target\": 304}, {\"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Bachmeier C\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Jin C\", \"Laco G\", \"Lin Y\", \"Mullan M\", \"Paris D\"], \"date\": \"2014-12-05\", \"first\": \"Paris D\", \"last\": \"Mullan M\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"33927-44\", \"reference\": \"25331948\", \"title\": \"The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid- production and Tau hyperphosphorylation.\", \"type\": \"PubMed\", \"volume\": \"289\"}, \"evidence\": \"Western blot analyses of brain homogenates show that ()-nilvadipine significantly reduces Tau phosphorylation in AT8 (phosphorylated Ser-199/Ser-202/Thr-205) and PHF-1 (phosphorylated Ser-396/Ser-404) epitopes\", \"key\": \"75d1fbcd1b2bc39de1cb1d3307a162149df49ea784a52b3dc31379c002a7c54c1d837fb965d5a67824502d5c8cea51dbfa980e4bb3f24bd5c01ca77e5314fc1d\", \"line\": 2248, \"relation\": \"decreases\", \"source\": 15, \"target\": 312}, {\"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Bachmeier C\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Jin C\", \"Laco G\", \"Lin Y\", \"Mullan M\", \"Paris D\"], \"date\": \"2014-12-05\", \"first\": \"Paris D\", \"last\": \"Mullan M\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"33927-44\", \"reference\": \"25331948\", \"title\": \"The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid- production and Tau hyperphosphorylation.\", \"type\": \"PubMed\", \"volume\": \"289\"}, \"evidence\": \"Western blot analyses of brain homogenates show that ()-nilvadipine significantly reduces Tau phosphorylation in AT8 (phosphorylated Ser-199/Ser-202/Thr-205) and PHF-1 (phosphorylated Ser-396/Ser-404) epitopes\", \"key\": \"c5dee2ad31d4f4cd82ed1196f12e67a7b289e27590db58c3cede82fbcd9fa1125bfe54807c8a5758c6047fd5d8dcf9979a1a80da008fc88eec6b278e6e35080e\", \"line\": 2246, \"relation\": \"decreases\", \"source\": 15, \"target\": 289}, {\"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Bachmeier C\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Jin C\", \"Laco G\", \"Lin Y\", \"Mullan M\", \"Paris D\"], \"date\": \"2014-12-05\", \"first\": \"Paris D\", \"last\": \"Mullan M\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"33927-44\", \"reference\": \"25331948\", \"title\": \"The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid- production and Tau hyperphosphorylation.\", \"type\": \"PubMed\", \"volume\": \"289\"}, \"evidence\": \"Western blot analyses of brain homogenates show that ()-nilvadipine significantly reduces Tau phosphorylation in AT8 (phosphorylated Ser-199/Ser-202/Thr-205) and PHF-1 (phosphorylated Ser-396/Ser-404) epitopes\", \"key\": \"5a4bf22b6aa1a194f5388bb32649c26ea379d53815aeeb2bb5b9b9ae566b28aaf7d59090626fb774f81e66862af02c7122fde642d7103fd68db4cdd5649ab167\", \"line\": 2247, \"relation\": \"decreases\", \"source\": 15, \"target\": 290}, {\"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Bachmeier C\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Jin C\", \"Laco G\", \"Lin Y\", \"Mullan M\", \"Paris D\"], \"date\": \"2014-12-05\", \"first\": \"Paris D\", \"last\": \"Mullan M\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"33927-44\", \"reference\": \"25331948\", \"title\": \"The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid- production and Tau hyperphosphorylation.\", \"type\": \"PubMed\", \"volume\": \"289\"}, \"evidence\": \"Western blot analyses of brain homogenates show that ()-nilvadipine significantly reduces Tau phosphorylation in AT8 (phosphorylated Ser-199/Ser-202/Thr-205) and PHF-1 (phosphorylated Ser-396/Ser-404) epitopes\", \"key\": \"18fb5f26f63cdad1c351be093b3760bcf5fc8121cc49c82ddf742a788b6ee68a61fe517a40ed9d3cd5f31e8356579da64a60dbaf20fe1b363065978e3a2d4dc2\", \"line\": 2251, \"relation\": \"decreases\", \"source\": 15, \"target\": 306}, {\"annotations\": {\"Cell_Line\": {\"N2a\": true, \"SH-SY5Y\": true}}, \"citation\": {\"authors\": [\"Fan SJ\", \"Huang FI\", \"Liou JP\", \"Yang CR\"], \"date\": \"2018-05-29\", \"first\": \"Fan SJ\", \"last\": \"Yang CR\", \"name\": \"Cell death &amp; disease\", \"pages\": \"655\", \"reference\": \"29844403\", \"title\": \"The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.\", \"type\": \"PubMed\", \"volume\": \"9\"}, \"evidence\": \"This study aimed to investigate the protective effects and mechanism of the novel HDAC6 inhibitor, MPT0G211, using an AD model. Our results indicated that MPT0G211 significantly reduced tau phosphorylation and aggregation, the processes highly correlated with the formation of NFTs. This HDAC6 inhibitory activity resulted in an increase in acetylated Hsp90, which decreased Hsp90 and HDAC6 binding, causing ubiquitination of phosphorylated tau proteins. In addition, a significant increase of phospho-glycogen synthase kinase-3 (phospho-GSK3) on Ser9 (the inactive form) through Akt phosphorylation was associated with the inhibition of phospho-tau Ser396 in response to MPT0G211 treatment.\", \"key\": \"5665f3aff6c5198c9ae5fc920d6e025667631bbf7e651f46f41acab3a8c540dd82167d52b9bbecbc58908c7f72e8114cb87394ddee36eb61dd2dd6fedbfb705a\", \"line\": 3396, \"relation\": \"decreases\", \"source\": 61, \"target\": 304}, {\"annotations\": {\"Research_Model\": {\"APPswe x P301L transgenic mice\": true}, \"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Fan SJ\", \"Huang FI\", \"Liou JP\", \"Yang CR\"], \"date\": \"2018-05-29\", \"first\": \"Fan SJ\", \"last\": \"Yang CR\", \"name\": \"Cell death &amp; disease\", \"pages\": \"655\", \"reference\": \"29844403\", \"title\": \"The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.\", \"type\": \"PubMed\", \"volume\": \"9\"}, \"evidence\": \"This study aimed to investigate the protective effects and mechanism of the novel HDAC6 inhibitor, MPT0G211, using an AD model. Our results indicated that MPT0G211 significantly reduced tau phosphorylation and aggregation, the processes highly correlated with the formation of NFTs. This HDAC6 inhibitory activity resulted in an increase in acetylated Hsp90, which decreased Hsp90 and HDAC6 binding, causing ubiquitination of phosphorylated tau proteins. In addition, a significant increase of phospho-glycogen synthase kinase-3 (phospho-GSK3) on Ser9 (the inactive form) through Akt phosphorylation was associated with the inhibition of phospho-tau Ser396 in response to MPT0G211 treatment.\", \"key\": \"7778c99d4e5472cc76aade98173127244a1d8d7fa524b8e36a6b6bb2b70aaef3e5ba419752c226765eb64bf69ad4fa09a43a73fe01d8982910d9d9083c752f31\", \"line\": 3401, \"relation\": \"decreases\", \"source\": 61, \"target\": 306}, {\"annotations\": {\"Cell_Line\": {\"HeLa\": true}}, \"citation\": {\"authors\": [\"Chen CH\", \"Hong Y\", \"Kim BM\", \"Kimchi A\", \"Lee S\", \"Lee TH\", \"You MH\", \"Zhou XZ\"], \"date\": \"2014-05-22\", \"first\": \"Kim BM\", \"last\": \"Lee TH\", \"name\": \"Cell death &amp; disease\", \"pages\": \"e1237\", \"reference\": \"24853415\", \"title\": \"Death-associated protein kinase 1 has a critical role in aberrant tau protein regulation and function.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \"As shown in Figure 7a, compared with the vector control, DAPK1, but not DAPK1K42A, increased the phosphorylation of exogenous tau protein in HeLa cells, as detected by Thr231-specific (AT180), Ser262-specific, and Ser396-specific (PHF-13) antibodies that recognize specific tau phosphoepitopes and/or abnormal conformations specific to AD NFT.\", \"key\": \"b778ce5ada409f05c2df5a93b102b2a46a301685e557ffe9cc886ff27191b8bedde8aa683e9374514336441a6d178e6276a36dad7e6b196f35531521f107eb7e\", \"line\": 1985, \"relation\": \"increases\", \"source\": 226, \"target\": 304}, {\"citation\": {\"authors\": [\"Chai GS\", \"Chen NN\", \"Cheng XS\", \"Duan DX\", \"Hu Y\", \"Liu GP\", \"Luo Y\", \"Ni ZF\", \"Wang JZ\"], \"date\": \"2013-01-01\", \"first\": \"Duan DX\", \"last\": \"Liu GP\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"795-808\", \"reference\": \"23948915\", \"title\": \"Phosphorylation of tau by death-associated protein kinase 1 antagonizes the kinase-induced cell apoptosis.\", \"type\": \"PubMed\", \"volume\": \"37\"}, \"evidence\": \"These data suggest that tau hyperphosphorylation at Thr231, Ser262, and Ser396 by DAPK1 renders the cells more resistant to the kinase-induced apoptotic cell death, providing new insights into the tau-involved apoptotic abortion in the course of chronic neurodegeneration.\", \"key\": \"7842925c8ccf8813dc14827dc5289fef01490dc26f46eca00e2b7defcf2081e3214edbb9dadbb0dbfe4be53f8435b91772668f2957b5dabbb35950d99640ca7c\", \"line\": 1998, \"relation\": \"increases\", \"source\": 226, \"target\": 304}, {\"annotations\": {\"Cell_Line\": {\"HeLa\": true}}, \"citation\": {\"authors\": [\"Chen CH\", \"Hong Y\", \"Kim BM\", \"Kimchi A\", \"Lee S\", \"Lee TH\", \"You MH\", \"Zhou XZ\"], \"date\": \"2014-05-22\", \"first\": \"Kim BM\", \"last\": \"Lee TH\", \"name\": \"Cell death &amp; disease\", \"pages\": \"e1237\", \"reference\": \"24853415\", \"title\": \"Death-associated protein kinase 1 has a critical role in aberrant tau protein regulation and function.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \"As shown in Figure 7a, compared with the vector control, DAPK1, but not DAPK1K42A, increased the phosphorylation of exogenous tau protein in HeLa cells, as detected by Thr231-specific (AT180), Ser262-specific, and Ser396-specific (PHF-13) antibodies that recognize specific tau phosphoepitopes and/or abnormal conformations specific to AD NFT.\", \"key\": \"d2af464f204d0506eaaccf27cfefad6f9db6382cc8220a29b3a866b084bdb3083202d5c40517696a669976d01ace7a0c7e0ae26834d3764fe1e1f46d4a6c41a4\", \"line\": 1986, \"relation\": \"increases\", \"source\": 226, \"target\": 315}, {\"citation\": {\"authors\": [\"Chai GS\", \"Chen NN\", \"Cheng XS\", \"Duan DX\", \"Hu Y\", \"Liu GP\", \"Luo Y\", \"Ni ZF\", \"Wang JZ\"], \"date\": \"2013-01-01\", \"first\": \"Duan DX\", \"last\": \"Liu GP\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"795-808\", \"reference\": \"23948915\", \"title\": \"Phosphorylation of tau by death-associated protein kinase 1 antagonizes the kinase-induced cell apoptosis.\", \"type\": \"PubMed\", \"volume\": \"37\"}, \"evidence\": \"These data suggest that tau hyperphosphorylation at Thr231, Ser262, and Ser396 by DAPK1 renders the cells more resistant to the kinase-induced apoptotic cell death, providing new insights into the tau-involved apoptotic abortion in the course of chronic neurodegeneration.\", \"key\": \"2633e76ef10708a61df37511010d9dfb4d7e91d614c07dfda750cc40ce870c51e3c65634cca3bc8e28dc1027bb232b358d784e93349829d03488117ec9b36bb9\", \"line\": 1999, \"relation\": \"increases\", \"source\": 226, \"target\": 315}, {\"annotations\": {\"Cell_Line\": {\"HeLa\": true}}, \"citation\": {\"authors\": [\"Chen CH\", \"Hong Y\", \"Kim BM\", \"Kimchi A\", \"Lee S\", \"Lee TH\", \"You MH\", \"Zhou XZ\"], \"date\": \"2014-05-22\", \"first\": \"Kim BM\", \"last\": \"Lee TH\", \"name\": \"Cell death &amp; disease\", \"pages\": \"e1237\", \"reference\": \"24853415\", \"title\": \"Death-associated protein kinase 1 has a critical role in aberrant tau protein regulation and function.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \"As shown in Figure 7a, compared with the vector control, DAPK1, but not DAPK1K42A, increased the phosphorylation of exogenous tau protein in HeLa cells, as detected by Thr231-specific (AT180), Ser262-specific, and Ser396-specific (PHF-13) antibodies that recognize specific tau phosphoepitopes and/or abnormal conformations specific to AD NFT.\", \"key\": \"52f1e0ee2cca86dfdd29de508d322f610009bde9be241fa47b1467e407a73a86a0ed4199c5162af1fa23723b897d767b216238368b8ea2473699ba2b53d38118\", \"line\": 1984, \"relation\": \"increases\", \"source\": 226, \"target\": 297}, {\"citation\": {\"authors\": [\"Chai GS\", \"Chen NN\", \"Cheng XS\", \"Duan DX\", \"Hu Y\", \"Liu GP\", \"Luo Y\", \"Ni ZF\", \"Wang JZ\"], \"date\": \"2013-01-01\", \"first\": \"Duan DX\", \"last\": \"Liu GP\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"795-808\", \"reference\": \"23948915\", \"title\": \"Phosphorylation of tau by death-associated protein kinase 1 antagonizes the kinase-induced cell apoptosis.\", \"type\": \"PubMed\", \"volume\": \"37\"}, \"evidence\": \"These data suggest that tau hyperphosphorylation at Thr231, Ser262, and Ser396 by DAPK1 renders the cells more resistant to the kinase-induced apoptotic cell death, providing new insights into the tau-involved apoptotic abortion in the course of chronic neurodegeneration.\", \"key\": \"181cb7511e74d578fce8c3d9d9c8a8e75342fc1c55c338a960a5d8afa2e0b0c50e976e7f21966fd4773574674dafd564c97331630707ff9e217c68c84661b74b\", \"line\": 1997, \"relation\": \"increases\", \"source\": 226, \"target\": 297}, {\"annotations\": {\"Method\": {\"Immunocytochemistry\": true, \"RNA Interference, siRNA\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"Lawson LY\", \"Li Q\", \"O'Leary JC 3rd\", \"Trotter JH\", \"Vestal GD\", \"Weeber EJ\"], \"date\": \"2011-05-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"16976-83\", \"reference\": \"21367866\", \"title\": \"The Hsp90 kinase co-chaperone Cdc37 regulates tau stability and phosphorylation dynamics.\", \"type\": \"PubMed\", \"volume\": \"286\"}, \"evidence\": \"Quantification of the Western blot showed that Cdc37 knockdown reduced phospho-Thr-231, phospho-Ser-199/Ser-202, phospho-Ser-396/Ser-404, and phospho-Ser-262/Ser-356 tau.\", \"key\": \"690491c61b91c802bd03449bc1d3c94c2665542f76c5a44b54477282490b0db29942136efdc99a91b2c0e768b9b551246a5b0f0cfd808a47431655ac33636d37\", \"line\": 633, \"relation\": \"positiveCorrelation\", \"source\": 214, \"target\": 304}, {\"annotations\": {\"Method\": {\"Immunocytochemistry\": true, \"RNA Interference, siRNA\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"Lawson LY\", \"Li Q\", \"O'Leary JC 3rd\", \"Trotter JH\", \"Vestal GD\", \"Weeber EJ\"], \"date\": \"2011-05-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"16976-83\", \"reference\": \"21367866\", \"title\": \"The Hsp90 kinase co-chaperone Cdc37 regulates tau stability and phosphorylation dynamics.\", \"type\": \"PubMed\", \"volume\": \"286\"}, \"evidence\": \"Quantification of the Western blot showed that Cdc37 knockdown reduced phospho-Thr-231, phospho-Ser-199/Ser-202, phospho-Ser-396/Ser-404, and phospho-Ser-262/Ser-356 tau.\", \"key\": \"d271d3592416c842ad0ef9acbd865daff1f10aa195785798575320ce9f06e076810b20b49ed5ea0ed80b3bd51c509d9533391aec580d961e5b171fadfdf9317e\", \"line\": 630, \"relation\": \"positiveCorrelation\", \"source\": 214, \"target\": 315}, {\"annotations\": {\"Method\": {\"Immunocytochemistry\": true, \"RNA Interference, siRNA\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"Lawson LY\", \"Li Q\", \"O'Leary JC 3rd\", \"Trotter JH\", \"Vestal GD\", \"Weeber EJ\"], \"date\": \"2011-05-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"16976-83\", \"reference\": \"21367866\", \"title\": \"The Hsp90 kinase co-chaperone Cdc37 regulates tau stability and phosphorylation dynamics.\", \"type\": \"PubMed\", \"volume\": \"286\"}, \"evidence\": \"Quantification of the Western blot showed that Cdc37 knockdown reduced phospho-Thr-231, phospho-Ser-199/Ser-202, phospho-Ser-396/Ser-404, and phospho-Ser-262/Ser-356 tau.\", \"key\": \"3422a1c4caa2cb8071f0db85e4a818d4241098c9c4dd8d5c7fc0d70b551fe62309e704cc82b98cf59de5fab87dfd0b621770647b4b69a2c63fdded21380a17d1\", \"line\": 631, \"relation\": \"positiveCorrelation\", \"source\": 214, \"target\": 289}, {\"annotations\": {\"Method\": {\"Immunocytochemistry\": true, \"RNA Interference, siRNA\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"Lawson LY\", \"Li Q\", \"O'Leary JC 3rd\", \"Trotter JH\", \"Vestal GD\", \"Weeber EJ\"], \"date\": \"2011-05-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"16976-83\", \"reference\": \"21367866\", \"title\": \"The Hsp90 kinase co-chaperone Cdc37 regulates tau stability and phosphorylation dynamics.\", \"type\": \"PubMed\", \"volume\": \"286\"}, \"evidence\": \"Quantification of the Western blot showed that Cdc37 knockdown reduced phospho-Thr-231, phospho-Ser-199/Ser-202, phospho-Ser-396/Ser-404, and phospho-Ser-262/Ser-356 tau.\", \"key\": \"84053cb1fae3d7c1722923a4baea3a3cd7920e2920862e5b29823423e9470eafd792d271ffe0786daec26c4ebe7a0e820fc4e4e5895f2940f4db1a06456441a7\", \"line\": 632, \"relation\": \"positiveCorrelation\", \"source\": 214, \"target\": 290}, {\"annotations\": {\"Method\": {\"Immunocytochemistry\": true, \"RNA Interference, siRNA\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"Lawson LY\", \"Li Q\", \"O'Leary JC 3rd\", \"Trotter JH\", \"Vestal GD\", \"Weeber EJ\"], \"date\": \"2011-05-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"16976-83\", \"reference\": \"21367866\", \"title\": \"The Hsp90 kinase co-chaperone Cdc37 regulates tau stability and phosphorylation dynamics.\", \"type\": \"PubMed\", \"volume\": \"286\"}, \"evidence\": \"Quantification of the Western blot showed that Cdc37 knockdown reduced phospho-Thr-231, phospho-Ser-199/Ser-202, phospho-Ser-396/Ser-404, and phospho-Ser-262/Ser-356 tau.\", \"key\": \"e66ff33d7b78b5cd0a977b581dde870bdb960769f3d63530847b37ba2875bffe9c0a3d6bfd7ab82d1eb3e32bdddff14fc49bb9d99c2f3e6ccac8bc1785bbf3a0\", \"line\": 636, \"relation\": \"positiveCorrelation\", \"source\": 214, \"target\": 303}, {\"annotations\": {\"Method\": {\"Immunocytochemistry\": true, \"RNA Interference, siRNA\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"Lawson LY\", \"Li Q\", \"O'Leary JC 3rd\", \"Trotter JH\", \"Vestal GD\", \"Weeber EJ\"], \"date\": \"2011-05-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"16976-83\", \"reference\": \"21367866\", \"title\": \"The Hsp90 kinase co-chaperone Cdc37 regulates tau stability and phosphorylation dynamics.\", \"type\": \"PubMed\", \"volume\": \"286\"}, \"evidence\": \"Quantification of the Western blot showed that Cdc37 knockdown reduced phospho-Thr-231, phospho-Ser-199/Ser-202, phospho-Ser-396/Ser-404, and phospho-Ser-262/Ser-356 tau.\", \"key\": \"f5ae2ba0892dab4656926ed0aa5879287014e2613f048ce18e16c17594d5e7a263140ec48ec47b640c6682aa84a6ce110f7af55746e8d5c9460d0cda2d28fbb0\", \"line\": 634, \"relation\": \"positiveCorrelation\", \"source\": 214, \"target\": 306}, {\"annotations\": {\"Method\": {\"Immunocytochemistry\": true, \"RNA Interference, siRNA\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"Lawson LY\", \"Li Q\", \"O'Leary JC 3rd\", \"Trotter JH\", \"Vestal GD\", \"Weeber EJ\"], \"date\": \"2011-05-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"16976-83\", \"reference\": \"21367866\", \"title\": \"The Hsp90 kinase co-chaperone Cdc37 regulates tau stability and phosphorylation dynamics.\", \"type\": \"PubMed\", \"volume\": \"286\"}, \"evidence\": \"Quantification of the Western blot showed that Cdc37 knockdown reduced phospho-Thr-231, phospho-Ser-199/Ser-202, phospho-Ser-396/Ser-404, and phospho-Ser-262/Ser-356 tau.\", \"key\": \"c5926f8765339ee4c61b755ab84a0dfd4344a04bcb61d73ebe6e91d282e143a72db115d180528d9385f6486411238a9b2f0adbd8d6c098210fa998424fee494f\", \"line\": 635, \"relation\": \"positiveCorrelation\", \"source\": 214, \"target\": 297}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"The diagnostic antibodies AT8, TAU-1, SM131, SM134, and SM133 react to phosphorylation similarly as with MAPK and GSK-3, indicating that SP motifs before the repeat region (S199 and/or S202, S235) and after the repeats (S396, S404) become phosphorylated (Fig. 2,-2,); note that AT8, SMUl, and SM134 react with PHFs where the epitopes containing SP motifs are phosphorylated, while TAU-1 and SM133 react with normal tau where the epitopes are not phosphorylated\", \"key\": \"33864912de465d13801db132d2fdf917d03ac8454252e5a669ed8b1ff9bc68774ee8998c643b008b6aa53b70d4c06d1116a86ae1734e1a5dc80f359d0e4ffd6c\", \"line\": 84, \"relation\": \"directlyIncreases\", \"source\": 216, \"target\": 304}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"The reaction with the diagnostic antibodies (Fig. 4) is similar to the examples shown previously for cdk2 (Fig. 2), MAP kinase [8], or GSK-3 [26], indicating the phosphorylation of the SP motifs for which these antibodies are sensitive (serines 199, 202, 235, 396, 404; see Fig. 1)\", \"key\": \"9b443ad95d24a6661f210448c4ccab644d9ee520e838d88b3e793f6d607636c30a99c70be72a5d97be5b76e6e8a3c358ce0320886a7feab6176eddfd323c7322\", \"line\": 122, \"relation\": \"directlyIncreases\", \"source\": 216, \"target\": 304}, {\"citation\": {\"authors\": [\"Amniai L\", \"Fauquant C\", \"Huvent I\", \"Landrieu I\", \"Leroy A\", \"Lippens G\", \"Sibille N\", \"Verdegem D\", \"Wieruszeski JM\"], \"date\": \"2012-02-01\", \"first\": \"Sibille N\", \"last\": \"Landrieu I\", \"name\": \"Proteins\", \"pages\": \"454-62\", \"reference\": \"22072628\", \"title\": \"Structural characterization by nuclear magnetic resonance of the impact of phosphorylation in the proline-rich region of the disordered Tau protein.\", \"type\": \"PubMed\", \"volume\": \"80\"}, \"evidence\": \"In this study, we address the structural impact of phosphorylation of the Tau protein by Nuclear Magnetic Resonance (NMR) spectroscopy on a functional fragment of Tau (Tau[Ser208-Ser324] = TauF4). TauF4 was phosphorylated by the proline-directed CDK2/CycA3 kinase on Thr231 (generating the AT180 epitope), Ser235, and equally on Thr212 and Thr217 in the Proline-rich region (Tau[Ser208-Gln244] or PRR). These modifications strongly decrease the capacity of TauF4 to polymerize tubulin into microtubules. While all the NMR parameters are consistent with a globally disordered Tau protein fragment, local clusters of structuration can be defined. The most salient result of our NMR analysis is that phosphorylation in the PRR stabilizes a short -helix that runs from pSer235 till the very beginning of the microtubule-binding region (Tau[Thr245-Ser324] or MTBR of TauF4).\", \"key\": \"9d2c09e35d38cc5c920182f36133594626635ea094706867d88109175b78cdc1b4aa816596222581ba9d8a635e3f6b3baa208d3229a8d72b121c152e8667fdf6\", \"line\": 2789, \"relation\": \"directlyIncreases\", \"source\": 216, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 314}, {\"citation\": {\"authors\": [\"Amniai L\", \"Fauquant C\", \"Huvent I\", \"Landrieu I\", \"Leroy A\", \"Lippens G\", \"Sibille N\", \"Verdegem D\", \"Wieruszeski JM\"], \"date\": \"2012-02-01\", \"first\": \"Sibille N\", \"last\": \"Landrieu I\", \"name\": \"Proteins\", \"pages\": \"454-62\", \"reference\": \"22072628\", \"title\": \"Structural characterization by nuclear magnetic resonance of the impact of phosphorylation in the proline-rich region of the disordered Tau protein.\", \"type\": \"PubMed\", \"volume\": \"80\"}, \"evidence\": \"In this study, we address the structural impact of phosphorylation of the Tau protein by Nuclear Magnetic Resonance (NMR) spectroscopy on a functional fragment of Tau (Tau[Ser208-Ser324] = TauF4). TauF4 was phosphorylated by the proline-directed CDK2/CycA3 kinase on Thr231 (generating the AT180 epitope), Ser235, and equally on Thr212 and Thr217 in the Proline-rich region (Tau[Ser208-Gln244] or PRR). These modifications strongly decrease the capacity of TauF4 to polymerize tubulin into microtubules. While all the NMR parameters are consistent with a globally disordered Tau protein fragment, local clusters of structuration can be defined. The most salient result of our NMR analysis is that phosphorylation in the PRR stabilizes a short -helix that runs from pSer235 till the very beginning of the microtubule-binding region (Tau[Thr245-Ser324] or MTBR of TauF4).\", \"key\": \"203c3dc3b8038385f994acaadec1947689e96f42e896b92afa4092906e2ba20126c207821caa371b6b8ade86f6afbccd9ac045d16803bb8613143c8427515f7e\", \"line\": 2788, \"relation\": \"directlyIncreases\", \"source\": 216, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 313}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"The diagnostic antibodies AT8, TAU-1, SM131, SM134, and SM133 react to phosphorylation similarly as with MAPK and GSK-3, indicating that SP motifs before the repeat region (S199 and/or S202, S235) and after the repeats (S396, S404) become phosphorylated (Fig. 2,-2,); note that AT8, SMUl, and SM134 react with PHFs where the epitopes containing SP motifs are phosphorylated, while TAU-1 and SM133 react with normal tau where the epitopes are not phosphorylated\", \"key\": \"496e3374babfbd24dfca507d6512f78d0066a2b743c301b59d049e1c19a4684d23013cfdfb4c831bb68eeb5a3cac22650eed4d52eb7ad72d6254be426f5ad9fd\", \"line\": 81, \"relation\": \"directlyIncreases\", \"source\": 216, \"target\": 289}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"The reaction with the diagnostic antibodies (Fig. 4) is similar to the examples shown previously for cdk2 (Fig. 2), MAP kinase [8], or GSK-3 [26], indicating the phosphorylation of the SP motifs for which these antibodies are sensitive (serines 199, 202, 235, 396, 404; see Fig. 1)\", \"key\": \"50c7fd98a771d7c981681021bdbca5e2b1f15432c6e731e696e454f1d202c90deb9135c446eb8f9e6d46c0078ad810a6693717594fcbe9aa6d0175072eb7c82d\", \"line\": 119, \"relation\": \"directlyIncreases\", \"source\": 216, \"target\": 289}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"The Mr shifts up with time in several stages, very similar to our earlier observations with the brain kinase activity, MAP kinase and GSK3 (Fig. 2,)\", \"key\": \"2e9f37caff30fcb0616a59c6655b54ca0d4d706abfeb377906050f31d7eec4dfbbba3783fdb0b88feb493df9b948caa5727c492a5d99474c409a703e52873937\", \"line\": 70, \"relation\": \"directlyIncreases\", \"source\": 216, \"target\": 286}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"The diagnostic antibodies AT8, TAU-1, SM131, SM134, and SM133 react to phosphorylation similarly as with MAPK and GSK-3, indicating that SP motifs before the repeat region (S199 and/or S202, S235) and after the repeats (S396, S404) become phosphorylated (Fig. 2,-2,); note that AT8, SMUl, and SM134 react with PHFs where the epitopes containing SP motifs are phosphorylated, while TAU-1 and SM133 react with normal tau where the epitopes are not phosphorylated\", \"key\": \"257f067956576b8ded8fc4ddeeb27b016fcebb7ceda364be72e6004724f2ac1cc6942f9c43ab595fcff800e100e0d6ff13f6c24b96764d12a0f4b0a6a040f0bb\", \"line\": 82, \"relation\": \"directlyIncreases\", \"source\": 216, \"target\": 290}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"The reaction with the diagnostic antibodies (Fig. 4) is similar to the examples shown previously for cdk2 (Fig. 2), MAP kinase [8], or GSK-3 [26], indicating the phosphorylation of the SP motifs for which these antibodies are sensitive (serines 199, 202, 235, 396, 404; see Fig. 1)\", \"key\": \"46fa72122021ce71931d18159538f6097eca464edae1080f4aac055bded004c20d70a361ab177d4c77580d828e4eaa85aeed991efb2120e8cce80cb11a8c4202\", \"line\": 120, \"relation\": \"directlyIncreases\", \"source\": 216, \"target\": 290}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"The diagnostic antibodies AT8, TAU-1, SM131, SM134, and SM133 react to phosphorylation similarly as with MAPK and GSK-3, indicating that SP motifs before the repeat region (S199 and/or S202, S235) and after the repeats (S396, S404) become phosphorylated (Fig. 2,-2,); note that AT8, SMUl, and SM134 react with PHFs where the epitopes containing SP motifs are phosphorylated, while TAU-1 and SM133 react with normal tau where the epitopes are not phosphorylated\", \"key\": \"57c09bf062fa090778d134842ac3478f1f2e3ca1a394ef9390b847b8d930f095eacd299c45f73a4e5d326382b3ce1f6d28a4f43f5239a5e92c5db59310a117b3\", \"line\": 85, \"relation\": \"directlyIncreases\", \"source\": 216, \"target\": 306}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"The reaction with the diagnostic antibodies (Fig. 4) is similar to the examples shown previously for cdk2 (Fig. 2), MAP kinase [8], or GSK-3 [26], indicating the phosphorylation of the SP motifs for which these antibodies are sensitive (serines 199, 202, 235, 396, 404; see Fig. 1)\", \"key\": \"74e43a8ccf0a0c79ac29b4b40a082b58c50fd4dc1046f9e6e5d1b51dc493f4ad98194fb5fe96fa46bc537cb2d023b20d9c7da4cb8450a20732643b97209980fb\", \"line\": 123, \"relation\": \"directlyIncreases\", \"source\": 216, \"target\": 306}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"The diagnostic antibodies AT8, TAU-1, SM131, SM134, and SM133 react to phosphorylation similarly as with MAPK and GSK-3, indicating that SP motifs before the repeat region (S199 and/or S202, S235) and after the repeats (S396, S404) become phosphorylated (Fig. 2,-2,); note that AT8, SMUl, and SM134 react with PHFs where the epitopes containing SP motifs are phosphorylated, while TAU-1 and SM133 react with normal tau where the epitopes are not phosphorylated\", \"key\": \"83e7db45e12eca5c7d31885124bdb869e3b20aec06da67e36c0deab40d19e74df00da563c050e20a933717cef933b5bc79ef91b6901e7ea14955ad3703d995ae\", \"line\": 83, \"relation\": \"directlyIncreases\", \"source\": 216, \"target\": 295}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"The reaction with the diagnostic antibodies (Fig. 4) is similar to the examples shown previously for cdk2 (Fig. 2), MAP kinase [8], or GSK-3 [26], indicating the phosphorylation of the SP motifs for which these antibodies are sensitive (serines 199, 202, 235, 396, 404; see Fig. 1)\", \"key\": \"67e02c065f8636eb15c108f39c0543517f1375a47350181e35eab24b8a900511c1d3fca325c554981c4526520b26fba565ccc89aa270b5a8fe502fe85c6175bf\", \"line\": 121, \"relation\": \"directlyIncreases\", \"source\": 216, \"target\": 295}, {\"citation\": {\"authors\": [\"Amniai L\", \"Fauquant C\", \"Huvent I\", \"Landrieu I\", \"Leroy A\", \"Lippens G\", \"Sibille N\", \"Verdegem D\", \"Wieruszeski JM\"], \"date\": \"2012-02-01\", \"first\": \"Sibille N\", \"last\": \"Landrieu I\", \"name\": \"Proteins\", \"pages\": \"454-62\", \"reference\": \"22072628\", \"title\": \"Structural characterization by nuclear magnetic resonance of the impact of phosphorylation in the proline-rich region of the disordered Tau protein.\", \"type\": \"PubMed\", \"volume\": \"80\"}, \"evidence\": \"In this study, we address the structural impact of phosphorylation of the Tau protein by Nuclear Magnetic Resonance (NMR) spectroscopy on a functional fragment of Tau (Tau[Ser208-Ser324] = TauF4). TauF4 was phosphorylated by the proline-directed CDK2/CycA3 kinase on Thr231 (generating the AT180 epitope), Ser235, and equally on Thr212 and Thr217 in the Proline-rich region (Tau[Ser208-Gln244] or PRR). These modifications strongly decrease the capacity of TauF4 to polymerize tubulin into microtubules. While all the NMR parameters are consistent with a globally disordered Tau protein fragment, local clusters of structuration can be defined. The most salient result of our NMR analysis is that phosphorylation in the PRR stabilizes a short -helix that runs from pSer235 till the very beginning of the microtubule-binding region (Tau[Thr245-Ser324] or MTBR of TauF4).\", \"key\": \"d0b1e72524904b6c505c4f9284a5bd3bfc06186bc4f108e81bda4c857a9895f6788247822ad4c282a6ff38b717c4fdc65e456f245ea446f3f07e7f6fe3005a9c\", \"line\": 2787, \"relation\": \"directlyIncreases\", \"source\": 216, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 295}, {\"annotations\": {\"Species\": {\"6239\": true}}, \"citation\": {\"authors\": [\"Baumeister R\", \"Biernat J\", \"Fatouros C\", \"Koushika SP\", \"Mandelkow E\", \"Mandelkow EM\", \"Pir GJ\", \"Schmidt E\"], \"date\": \"2012-08-15\", \"first\": \"Fatouros C\", \"last\": \"Baumeister R\", \"name\": \"Human molecular genetics\", \"pages\": \"3587-603\", \"reference\": \"22611162\", \"title\": \"Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"In add- ition, only FL Tau V337M was phosphorylated at the KXGS motif (Fig. 2A, mid panel, 12E8), S396 and S404 (PHF-1 epitope) (Fig. 2A, lower panel, PHF-1).\", \"key\": \"05fa84bd2e897668af0494432410555a297270585822363daae6152a373d2169bf5b8e146b2e674cb6028d948f4b0bf058421c432465bf3ca8571c270d9e4ec6\", \"line\": 107, \"relation\": \"increases\", \"source\": 331, \"target\": 304}, {\"annotations\": {\"Species\": {\"6239\": true}}, \"citation\": {\"authors\": [\"Baumeister R\", \"Biernat J\", \"Fatouros C\", \"Koushika SP\", \"Mandelkow E\", \"Mandelkow EM\", \"Pir GJ\", \"Schmidt E\"], \"date\": \"2012-08-15\", \"first\": \"Fatouros C\", \"last\": \"Baumeister R\", \"name\": \"Human molecular genetics\", \"pages\": \"3587-603\", \"reference\": \"22611162\", \"title\": \"Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"In add- ition, only FL Tau V337M was phosphorylated at the KXGS motif (Fig. 2A, mid panel, 12E8), S396 and S404 (PHF-1 epitope) (Fig. 2A, lower panel, PHF-1).\", \"key\": \"7489d04a925a83c8e34752ecd3e701aec6e37e917895515a81118ddf2ec9b2250831152e5d011f8fda4256c0b9bdefb66258225f4c51441307d6658494d6a90a\", \"line\": 108, \"relation\": \"increases\", \"source\": 331, \"target\": 306}, {\"annotations\": {\"Method\": {\"Chromatography, Gel filtration\": true, \"Chromatography, Ni-NTA-Sepharose\": true, \"Chymotrypsin Assay\": true, \"Co-Immunoprecipitation\": true, \"Immunofluorescence\": true, \"Immunohistochemistry\": true, \"Microtubule polzmerization Assay\": true, \"Protease-coupled Assay\": true, \"RNA Interference, siRNA\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Blair LJ\", \"Borysov SI\", \"Buchner J\", \"Cox MB\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"O'Leary JC 3rd\", \"Schmid AB\", \"Shults CL\"], \"date\": \"2010-01-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"591-9\", \"reference\": \"20071522\", \"title\": \"The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules.\", \"type\": \"PubMed\", \"volume\": \"30\"}, \"evidence\": \"We found that FKBP51 indeed could interact with tau from both AD patients and control cases (Fig. 3D), further suggesting a functionally relevant relationship between FKBP51 and tau. We then investigated whether FKBP51 would preferentially interact with phosphorylated tau species. We increased the number of samples per group (4 for AD and 4 for normal) and again co-immunoprecipitated FKBP51. After gel electrophoresis, immunoblotting showed increased association of pS396 and pS199-S202 tau species with FKBP51 in AD tissue (Fig S1). Indeed, we found that FKBP51 over-expression increased phospho- and total tau levels (by 80%) in HeLa cells stably expressing normal human tau, while FKBP52 over-expression had no affect (Fig.4A). These experiments were repeated multiple times and Student t-test of these replicates demonstrated that FKBP51 significantly increased total tau levels (p= 0.0104).\", \"key\": \"6ea2f2a92695e6faa0832294192f9287089ed34c822e27772d53b9ce0363ee56d92709230c9dbb7d1a7eda3cf9fb129ac1d97873b46da3a7e46da3ec511081d9\", \"line\": 595, \"relation\": \"positiveCorrelation\", \"source\": 229, \"target\": 304}, {\"annotations\": {\"Method\": {\"Chromatography, Gel filtration\": true, \"Chromatography, Ni-NTA-Sepharose\": true, \"Chymotrypsin Assay\": true, \"Co-Immunoprecipitation\": true, \"Immunofluorescence\": true, \"Immunohistochemistry\": true, \"Microtubule polzmerization Assay\": true, \"Protease-coupled Assay\": true, \"RNA Interference, siRNA\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Blair LJ\", \"Borysov SI\", \"Buchner J\", \"Cox MB\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"O'Leary JC 3rd\", \"Schmid AB\", \"Shults CL\"], \"date\": \"2010-01-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"591-9\", \"reference\": \"20071522\", \"title\": \"The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules.\", \"type\": \"PubMed\", \"volume\": \"30\"}, \"evidence\": \"We found that FKBP51 indeed could interact with tau from both AD patients and control cases (Fig. 3D), further suggesting a functionally relevant relationship between FKBP51 and tau. We then investigated whether FKBP51 would preferentially interact with phosphorylated tau species. We increased the number of samples per group (4 for AD and 4 for normal) and again co-immunoprecipitated FKBP51. After gel electrophoresis, immunoblotting showed increased association of pS396 and pS199-S202 tau species with FKBP51 in AD tissue (Fig S1). Indeed, we found that FKBP51 over-expression increased phospho- and total tau levels (by 80%) in HeLa cells stably expressing normal human tau, while FKBP52 over-expression had no affect (Fig.4A). These experiments were repeated multiple times and Student t-test of these replicates demonstrated that FKBP51 significantly increased total tau levels (p= 0.0104).\", \"key\": \"026baabf3bbc0d93e9996bcbdec38525c54a382c5594af59b4670b8a9aa89e1221808cfc28d75f28bbb733520e0179de5d5b02e222a75b6c46e148923b4a1d25\", \"line\": 596, \"relation\": \"positiveCorrelation\", \"source\": 229, \"target\": 289}, {\"citation\": {\"authors\": [\"Dickey CA\", \"Gestwicki JE\", \"Kiray J\", \"Koren J\", \"Miyata Y\"], \"date\": \"2011-09-01\", \"first\": \"Miyata Y\", \"last\": \"Gestwicki JE\", \"name\": \"Future medicinal chemistry\", \"pages\": \"1523-37\", \"reference\": \"21882945\", \"title\": \"Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.\", \"type\": \"PubMed\", \"volume\": \"3\"}, \"evidence\": \"These interactions may be functionally important because silencing FKBP51 reduces tau and phosphorylated-tau levels [136].\", \"key\": \"e544fd98cdb6314d5579d443680d8fdcf69debd35f512f4ac154c6d5017fbf487a50b59c08140e59adf5fcf1f5d5df2cb6b469d3ffb0942b84c5b9df907f683e\", \"line\": 408, \"relation\": \"increases\", \"source\": 229, \"target\": 286}, {\"annotations\": {\"Method\": {\"Chromatography, Gel filtration\": true, \"Chromatography, Ni-NTA-Sepharose\": true, \"Chymotrypsin Assay\": true, \"Co-Immunoprecipitation\": true, \"Immunofluorescence\": true, \"Immunohistochemistry\": true, \"Microtubule polzmerization Assay\": true, \"Protease-coupled Assay\": true, \"RNA Interference, siRNA\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Blair LJ\", \"Borysov SI\", \"Buchner J\", \"Cox MB\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"O'Leary JC 3rd\", \"Schmid AB\", \"Shults CL\"], \"date\": \"2010-01-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"591-9\", \"reference\": \"20071522\", \"title\": \"The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules.\", \"type\": \"PubMed\", \"volume\": \"30\"}, \"evidence\": \"We found that FKBP51 indeed could interact with tau from both AD patients and control cases (Fig. 3D), further suggesting a functionally relevant relationship between FKBP51 and tau. We then investigated whether FKBP51 would preferentially interact with phosphorylated tau species. We increased the number of samples per group (4 for AD and 4 for normal) and again co-immunoprecipitated FKBP51. After gel electrophoresis, immunoblotting showed increased association of pS396 and pS199-S202 tau species with FKBP51 in AD tissue (Fig S1). Indeed, we found that FKBP51 over-expression increased phospho- and total tau levels (by 80%) in HeLa cells stably expressing normal human tau, while FKBP52 over-expression had no affect (Fig.4A). These experiments were repeated multiple times and Student t-test of these replicates demonstrated that FKBP51 significantly increased total tau levels (p= 0.0104).\", \"key\": \"ccdfcded8bf96af2882d482e915fcdd2cd458a00ed4c9c37b1511ba4eb7a14f1b25dd8dccb5f0fcb6a451f86e4c7924156973f0d9ca1162595a5a2858f421c75\", \"line\": 597, \"relation\": \"positiveCorrelation\", \"source\": 229, \"target\": 290}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Tau phosphorylated at Ser262 or Ser356 cannot be recognized by the C terminus of HSP70interacting proteinheat shock protein 90 (CHIPHSP90) complex and is thus spared from proteasomal degradation\", \"key\": \"fb1685e6ce7e672ec9ddc18e43a99243598a9c296d0c90b0aa2f13c8981e9d78ed2b0042343bbdcceea0b897c6e3b48a37b585ccb705ec97c66f79b69de03907\", \"line\": 230, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"decreases\", \"source\": 298, \"target\": 298}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Tau phosphorylated at Ser262 or Ser356 cannot be recognized by the C terminus of HSP70interacting proteinheat shock protein 90 (CHIPHSP90) complex and is thus spared from proteasomal degradation\", \"key\": \"a7ee9305d5781856b3f79ef04c1f95c88c665c17bd5dcdfd366579661ffa7e96eb4eed4f9c35f4253bf21f63e370fee388eeb93b087a9e5b91760affc53d7c46\", \"line\": 229, \"relation\": \"decreases\", \"source\": 298, \"target\": 136}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Tau phosphorylated at Ser262 or Ser356 cannot be recognized by the C terminus of HSP70interacting proteinheat shock protein 90 (CHIPHSP90) complex and is thus spared from proteasomal degradation\", \"key\": \"6598970f02a1519abd772300329f77b22896212beaf0fe66456657751d1cbcfbf7f4a5d34a0f2ed9fa7331275e327c3465b9c741b460d633da0d804acd5bdb85\", \"line\": 232, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"decreases\", \"source\": 90, \"target\": 298}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Tau is known to be ubiquitylated through Lys48 linkages by CHIP for proteasomal degradation\", \"key\": \"df905490fed298117494ba41864df6d68394550dcdc4fa599a68f955675aa90f50543bf72552cfb6ab0c36c348cae83c5e73fe69387aac1237e81f8f37968bda\", \"line\": 360, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 90, \"target\": 323}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Notably, one study demonstrated that tau can also be ubiquitylated through Lys63 linkages by TNF receptor-associated factor 6 (TRAF6)  again, for proteasomal degradation\", \"key\": \"1d0306965b222abcb031ecfb8405cf4ba25edb0b40925eed8190056da517cc6c548a77af1ffc7f069843ca20ea9ad20a257b6b08d0e8d6cfcef5b1a3251b1ffc\", \"line\": 365, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 90, \"target\": 325}, {\"annotations\": {\"Tau_Antibody\": {\"Tau-12\": true, \"Tau-13\": true}}, \"citation\": {\"authors\": [\"Blum D\", \"Bue L\", \"Bue-Scherrer V\", \"Carrier S\", \"Chiappetta G\", \"Demeyer D\", \"Derisbourg M\", \"Fernandez-Gomez FJ\", \"Hamdane M\", \"Laurent C\", \"Leghay C\", \"Sergeant N\", \"Verdier Y\", \"Vinh J\"], \"date\": \"2015-05-14\", \"first\": \"Derisbourg M\", \"last\": \"Hamdane M\", \"name\": \"Scientific reports\", \"pages\": \"9659\", \"reference\": \"25974414\", \"title\": \"Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \"Hyperphosphorylation with Prostate-derived sterile 20-like kinase 1 alpha/beta (PSK1/TAOK2), Prostate-derived sterile 20-like kinase 2 (PSK2/TAOK1), CK1.\", \"key\": \"b1ea162f0b6267f62cfa008a44dc4cb9b8535b605c8970b65ef7a72fc8328655e8d0741da04ef76298f6af4dadd685c4b183e25f6e4199e307df210fcb798e39\", \"line\": 189, \"relation\": \"directlyIncreases\", \"source\": 369, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 310}, {\"annotations\": {\"Tau_Antibody\": {\"Tau-12\": true, \"Tau-13\": true}}, \"citation\": {\"authors\": [\"Blum D\", \"Bue L\", \"Bue-Scherrer V\", \"Carrier S\", \"Chiappetta G\", \"Demeyer D\", \"Derisbourg M\", \"Fernandez-Gomez FJ\", \"Hamdane M\", \"Laurent C\", \"Leghay C\", \"Sergeant N\", \"Verdier Y\", \"Vinh J\"], \"date\": \"2015-05-14\", \"first\": \"Derisbourg M\", \"last\": \"Hamdane M\", \"name\": \"Scientific reports\", \"pages\": \"9659\", \"reference\": \"25974414\", \"title\": \"Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \"Hyperphosphorylation with Prostate-derived sterile 20-like kinase 1 alpha/beta (PSK1/TAOK2), Prostate-derived sterile 20-like kinase 2 (PSK2/TAOK1), CK1.\", \"key\": \"7fffd8e3c05d1021c0c6c5cf2e79aafa89a8b4efa419faed36a2c46ac76d6c980ccc5487af1bbab3fc610a694db2a69649d148ba2269e7fc07b259d92d5038b4\", \"line\": 191, \"relation\": \"isA\", \"source\": 310, \"target\": 244}, {\"annotations\": {\"Tau_Antibody\": {\"Tau-12\": true, \"Tau-13\": true}}, \"citation\": {\"authors\": [\"Blum D\", \"Bue L\", \"Bue-Scherrer V\", \"Carrier S\", \"Chiappetta G\", \"Demeyer D\", \"Derisbourg M\", \"Fernandez-Gomez FJ\", \"Hamdane M\", \"Laurent C\", \"Leghay C\", \"Sergeant N\", \"Verdier Y\", \"Vinh J\"], \"date\": \"2015-05-14\", \"first\": \"Derisbourg M\", \"last\": \"Hamdane M\", \"name\": \"Scientific reports\", \"pages\": \"9659\", \"reference\": \"25974414\", \"title\": \"Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \"Hyperphosphorylation with Prostate-derived sterile 20-like kinase 1 alpha/beta (PSK1/TAOK2), Prostate-derived sterile 20-like kinase 2 (PSK2/TAOK1), CK1.\", \"key\": \"9d7443d5fa99fdf28a4943fd160be3f8d9b1860ec3613e18af0d8c8e131e45ef367bba542c8e6c8597c8595124abc63fc82a8b71c099aaa5212337d881ebd5c7\", \"line\": 188, \"relation\": \"directlyIncreases\", \"source\": 368, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 310}, {\"annotations\": {\"Tau_Antibody\": {\"Tau-12\": true, \"Tau-13\": true}}, \"citation\": {\"authors\": [\"Blum D\", \"Bue L\", \"Bue-Scherrer V\", \"Carrier S\", \"Chiappetta G\", \"Demeyer D\", \"Derisbourg M\", \"Fernandez-Gomez FJ\", \"Hamdane M\", \"Laurent C\", \"Leghay C\", \"Sergeant N\", \"Verdier Y\", \"Vinh J\"], \"date\": \"2015-05-14\", \"first\": \"Derisbourg M\", \"last\": \"Hamdane M\", \"name\": \"Scientific reports\", \"pages\": \"9659\", \"reference\": \"25974414\", \"title\": \"Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \"Hyperphosphorylation with Prostate-derived sterile 20-like kinase 1 alpha/beta (PSK1/TAOK2), Prostate-derived sterile 20-like kinase 2 (PSK2/TAOK1), CK1.\", \"key\": \"382c4691e87773235c74ced0a6600a42fa5d90c522e8ab70fc5294c71bc48cc6e6776acbde20d0d163020ca629b79f2731fb90916d31c1f7a4abb145573998a9\", \"line\": 190, \"relation\": \"directlyIncreases\", \"source\": 223, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 310}, {\"annotations\": {\"MeSHAnatomy\": {\"Neurons\": true}}, \"citation\": {\"authors\": [\"Morsy A\", \"Trippier PC\"], \"date\": \"2018-11-30\", \"first\": \"Morsy A\", \"last\": \"Trippier PC\", \"name\": \"Journal of medicinal chemistry\", \"reference\": \"30444369\", \"title\": \"Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.\", \"type\": \"PubMed\"}, \"evidence\": \" Isoforms  of  CK1  are  responsible  for  tau phosphorylation. 129   The  enzyme  can  modulate  the  activity  of  -secretase  and  consequently  the production of A.\", \"key\": \"0be3804fede56aeb8b237991efee62a6827d9345e5b009f534e0262c177596c2a2a7b2db4fb3159f34a191fade6f40e54eb6097d084c70a096aa242e5a1f0df7\", \"line\": 279, \"relation\": \"increases\", \"source\": 223, \"target\": 286}, {\"citation\": {\"authors\": [\"Carlomagno Y\", \"Castanedes-Casey M\", \"Chung DC\", \"Cook C\", \"DeTure M\", \"Dickson DW\", \"Dunmore J\", \"Madden BJ\", \"Petrucelli L\", \"Tong J\", \"Yue M\"], \"date\": \"2017-09-15\", \"first\": \"Carlomagno Y\", \"last\": \"Cook C\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"15277-15286\", \"reference\": \"28760828\", \"title\": \"An acetylation-phosphorylation switch that regulates tau aggregation propensity and function.\", \"type\": \"PubMed\", \"volume\": \"292\"}, \"evidence\": \"Our findings indicate that several acetylation sites in tau are responsive to HDAC6 and that acetylation on Lys-321 (within a KCGS motif) is both essential for acetylation-mediated inhibition of tau aggregation in vitro and a molecular tactic for preventing phosphorylation on the downstream Ser-324 residue. Tau phosphorylation of Ser-324 (pSer-324) has not previously been evaluated in the context of tauopathy, and here we observed increased deposition of pSer-324-positive tau both in mouse models of tauopathy and in patients with Alzheimer's disease. These findings uncover a novel acetylation-phosphorylation switch at Lys-321/Ser-324 that coordinately regulates tau polymerization and function.\", \"key\": \"64dc368457911aa66449d9dc2b348d57d8602d88c1835c5b6117908e2eac0eb2c0631a041db1f670726bdd695225ef53a3f90b2fa8fc46deb511dca0c1c4eda7\", \"line\": 3361, \"relation\": \"positiveCorrelation\", \"source\": 178, \"target\": 301}, {\"citation\": {\"authors\": [\"Babi Leko M\", \"Baadona D\", \"Bue L\", \"Delalle I\", \"Di Giovanni G\", \"Harrington C\", \"Hof PR\", \"Jovanov-Miloevi N\", \"Wischik C\", \"Wray S\", \"de Silva R\", \"imi G\"], \"date\": \"2016-01-06\", \"first\": \"imi G\", \"last\": \"Hof PR\", \"name\": \"Biomolecules\", \"pages\": \"6\", \"reference\": \"26751493\", \"title\": \"Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.\", \"type\": \"PubMed\", \"volume\": \"6\"}, \"evidence\": \"Recently, it has been proposed that tau protein acetylation may be responsible for tau aggregation in AD. Grinberg and collaborators detected tau acetylation at Lys274 in all tauopathies (both primary and secondary), except in AgD\", \"key\": \"cbcd85a7f7322c600d736f64343f92b5c352ea380ac781aeba3fd25c981157d243acd5c28371488bba04e53782aa6bbc7e7a11f14edfbf697e700bba5333e6e3\", \"line\": 243, \"relation\": \"positiveCorrelation\", \"source\": 178, \"target\": 255}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Cabrales Fontela Y\", \"Kadavath H\", \"Mandelkow E\", \"Riedel D\", \"Zweckstetter M\"], \"date\": \"2017-12-07\", \"first\": \"Cabrales Fontela Y\", \"last\": \"Zweckstetter M\", \"name\": \"Nature communications\", \"pages\": \"1981\", \"reference\": \"29215007\", \"title\": \"Multivalent cross-linking of actin filaments and microtubules through the microtubule-associated protein Tau.\", \"type\": \"PubMed\", \"volume\": \"8\"}, \"evidence\": \"The NMR experiments demonstrate that MARK2- phosphorylation of Tau attenuates its binding to F-actin. Consistent with a reduced affinity, MARK2-phosphorylated Tau failed in bundling actin filaments (Fig. 4e)\", \"key\": \"0ba45899d849f5a84fd7417c84cc261fc59402416b539fe3d4ed76f5edb8643830d1883b501e96efe732c1eaec0f27592ba468ac5c8dc25ce7816fa6e3cc3157\", \"line\": 265, \"relation\": \"decreases\", \"source\": 301, \"target\": 107}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Cabrales Fontela Y\", \"Kadavath H\", \"Mandelkow E\", \"Riedel D\", \"Zweckstetter M\"], \"date\": \"2017-12-07\", \"first\": \"Cabrales Fontela Y\", \"last\": \"Zweckstetter M\", \"name\": \"Nature communications\", \"pages\": \"1981\", \"reference\": \"29215007\", \"title\": \"Multivalent cross-linking of actin filaments and microtubules through the microtubule-associated protein Tau.\", \"type\": \"PubMed\", \"volume\": \"8\"}, \"evidence\": \"The NMR experiments demonstrate that MARK2- phosphorylation of Tau attenuates its binding to F-actin. Consistent with a reduced affinity, MARK2-phosphorylated Tau failed in bundling actin filaments (Fig. 4e)\", \"key\": \"1a198eb6282136b1c2775d46792b5445a93f7d62b7072127745744dee58c545e545d86b87f2f07746529a3b026312ca6179bd34fbeea15e9864bfc65cf4b3503\", \"line\": 271, \"relation\": \"decreases\", \"source\": 301, \"target\": 75}, {\"annotations\": {\"Anatomy\": {\"brain\": true}, \"Species\": {\"9606\": true}, \"TauIsoform\": {\"Isoform F (441 aa)\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"von Bergen M\"], \"date\": \"2007-01-01\", \"first\": \"Mandelkow E\", \"last\": \"Mandelkow EM\", \"name\": \"Brain pathology (Zurich, Switzerland)\", \"pages\": \"83-90\", \"reference\": \"17493042\", \"title\": \"Structural principles of tau and the paired helical filaments of Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"The lysine-isoleucine-glycineserine motif (KIGS) or lysine-cysteineglycine-serine motif (KCGS) motifs in the repeat domain (S262, S293, S324, S356) can be phosphorylated by MARK, PKA, SAD kinases, CaMKII and p70S6K, which strongly reduces the tau microtubule interactions (36, 74, 96), [note that phosphorylation at these sites also inhibits tau aggregation, illustrating an analogous role for the repeat domain in the physiological and pathological functions of tau (106)].\", \"key\": \"c6d67d7b810b8322272c6ed94281e0bfb8bc946e232bda191f146ee433c669f3c13a0c8a6dbe9d6d5fb789bd7448c38029e89beb6b7f505a342eb4a43d95a7b4\", \"line\": 155, \"relation\": \"decreases\", \"source\": 301, \"target\": 137}, {\"annotations\": {\"Anatomy\": {\"brain\": true}, \"Species\": {\"9606\": true}, \"TauIsoform\": {\"Isoform F (441 aa)\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"von Bergen M\"], \"date\": \"2007-01-01\", \"first\": \"Mandelkow E\", \"last\": \"Mandelkow EM\", \"name\": \"Brain pathology (Zurich, Switzerland)\", \"pages\": \"83-90\", \"reference\": \"17493042\", \"title\": \"Structural principles of tau and the paired helical filaments of Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"The lysine-isoleucine-glycineserine motif (KIGS) or lysine-cysteineglycine-serine motif (KCGS) motifs in the repeat domain (S262, S293, S324, S356) can be phosphorylated by MARK, PKA, SAD kinases, CaMKII and p70S6K, which strongly reduces the tau microtubule interactions (36, 74, 96), [note that phosphorylation at these sites also inhibits tau aggregation, illustrating an analogous role for the repeat domain in the physiological and pathological functions of tau (106)].\", \"key\": \"981d6e255cf09ec922b13ff31d342018761e0d8d31edfacfd1aa48487ad5f0fa279cf6e3d312e6af4654bc53c5f7572bea72a7ed30b09d440e1330437ebbff68\", \"line\": 160, \"relation\": \"decreases\", \"source\": 301, \"target\": 86}, {\"citation\": {\"authors\": [\"Carlomagno Y\", \"Castanedes-Casey M\", \"Chung DC\", \"Cook C\", \"DeTure M\", \"Dickson DW\", \"Dunmore J\", \"Madden BJ\", \"Petrucelli L\", \"Tong J\", \"Yue M\"], \"date\": \"2017-09-15\", \"first\": \"Carlomagno Y\", \"last\": \"Cook C\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"15277-15286\", \"reference\": \"28760828\", \"title\": \"An acetylation-phosphorylation switch that regulates tau aggregation propensity and function.\", \"type\": \"PubMed\", \"volume\": \"292\"}, \"evidence\": \"Our findings indicate that several acetylation sites in tau are responsive to HDAC6 and that acetylation on Lys-321 (within a KCGS motif) is both essential for acetylation-mediated inhibition of tau aggregation in vitro and a molecular tactic for preventing phosphorylation on the downstream Ser-324 residue. Tau phosphorylation of Ser-324 (pSer-324) has not previously been evaluated in the context of tauopathy, and here we observed increased deposition of pSer-324-positive tau both in mouse models of tauopathy and in patients with Alzheimer's disease. These findings uncover a novel acetylation-phosphorylation switch at Lys-321/Ser-324 that coordinately regulates tau polymerization and function.\", \"key\": \"9b13786fb0f95e29472fe78b3fdb152663be80279e0e124ce9c6e04a9a8fc0a8fd1cc9a4c08443424d78f11d2f31fe8ee8062310a34104caebc197ad1597f0fb\", \"line\": 3361, \"relation\": \"positiveCorrelation\", \"source\": 301, \"target\": 178}, {\"citation\": {\"authors\": [\"Carlomagno Y\", \"Castanedes-Casey M\", \"Chung DC\", \"Cook C\", \"DeTure M\", \"Dickson DW\", \"Dunmore J\", \"Madden BJ\", \"Petrucelli L\", \"Tong J\", \"Yue M\"], \"date\": \"2017-09-15\", \"first\": \"Carlomagno Y\", \"last\": \"Cook C\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"15277-15286\", \"reference\": \"28760828\", \"title\": \"An acetylation-phosphorylation switch that regulates tau aggregation propensity and function.\", \"type\": \"PubMed\", \"volume\": \"292\"}, \"evidence\": \"HDAC6 inhibition leads to a significant reduction in tau levels as detected by the human tau-specific antibody E1 (Fig. 6 (a and c) and supplemental Fig. S6). We also observed a striking decrease in phosphorylation at Ser-324, which was statistically significant even when normalizing to E1 to control for the reduction in tau levels (Fig. 6 (a and b) and supplemental Fig. S6).\", \"key\": \"a6dd483c84969d4fa8fabe79b0bf77f90a1d90330635606d8d07c021ddf743de17d664035ea7914dbe4689155f08629ddc0863c267c2d7f5af9461eca47ec73a\", \"line\": 3366, \"relation\": \"positiveCorrelation\", \"source\": 301, \"target\": 233}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Cabrales Fontela Y\", \"Kadavath H\", \"Mandelkow E\", \"Riedel D\", \"Zweckstetter M\"], \"date\": \"2017-12-07\", \"first\": \"Cabrales Fontela Y\", \"last\": \"Zweckstetter M\", \"name\": \"Nature communications\", \"pages\": \"1981\", \"reference\": \"29215007\", \"title\": \"Multivalent cross-linking of actin filaments and microtubules through the microtubule-associated protein Tau.\", \"type\": \"PubMed\", \"volume\": \"8\"}, \"evidence\": \"We therefore phosphorylated full-length Tau by MARK2. The downfield chemical shift of phosphorylated residues (Fig. 4a) is in agreement with previous reports and confirms phosphorylation at S262, S293, S305, S324, S356, and S416\", \"key\": \"1639b68062bfc4f8dc95c6c110988e53015520e33b4007e6258e32d104e82237d21316e70ec628d0080d3e0faecc89f15cad8b52ec0815225bbfd03b9675c279\", \"line\": 253, \"relation\": \"increases\", \"source\": 334, \"target\": 301}, {\"citation\": {\"authors\": [\"Bibow S\", \"Biernat J\", \"Blackledge M\", \"Jensen MR\", \"Kadavath H\", \"Mandelkow E\", \"Ozenne V\", \"Schwalbe M\", \"Zweckstetter M\"], \"date\": \"2013-12-17\", \"first\": \"Schwalbe M\", \"last\": \"Zweckstetter M\", \"name\": \"Biochemistry\", \"pages\": \"9068-79\", \"reference\": \"24251416\", \"title\": \"Phosphorylation of human Tau protein by microtubule affinity-regulating kinase 2.\", \"type\": \"PubMed\", \"volume\": \"52\"}, \"evidence\": \"While residues Ser-262, Ser-324, and Ser-356 were completely phosphorylated, Ser-293 in the second repeat was only 84% phosphorylated (Table 1). Furthermore, four non-KXGS phosphorylation sites were detected, two within the repeat domain (Ser-305 in R2 and Ser-352 in R4) and two more at the C-terminus (Ser-413 and Ser-416) (Figure 1B,C). Of these, Ser-305 was 66% phosphorylated and Ser-352, Ser-413, and Ser-416 were 4558% phosphorylated (Table 1). Using wild-type MARK2cat at 25 C and pH 6.8, the same phosphorylation sites were observed. The three primary sites, Ser-262, Ser-324, and Ser-356, were still completely phosphorylated.\", \"key\": \"959e3f3379bf4f7a4bfddbbede623489e84925651a5c56137030932c755d115b8d14b6d3d8c1dc39d6919cd5f7bdb024927e15b6e076c71dc5f7aa6060eceea1\", \"line\": 2644, \"relation\": \"directlyIncreases\", \"source\": 334, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 301}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Cabrales Fontela Y\", \"Kadavath H\", \"Mandelkow E\", \"Riedel D\", \"Zweckstetter M\"], \"date\": \"2017-12-07\", \"first\": \"Cabrales Fontela Y\", \"last\": \"Zweckstetter M\", \"name\": \"Nature communications\", \"pages\": \"1981\", \"reference\": \"29215007\", \"title\": \"Multivalent cross-linking of actin filaments and microtubules through the microtubule-associated protein Tau.\", \"type\": \"PubMed\", \"volume\": \"8\"}, \"evidence\": \"We therefore phosphorylated full-length Tau by MARK2. The downfield chemical shift of phosphorylated residues (Fig. 4a) is in agreement with previous reports and confirms phosphorylation at S262, S293, S305, S324, S356, and S416\", \"key\": \"cdfb746f3c7ac3dabbcfa2725fef4820e9a4c2c2cced500eb3ccf638a573a4d745780cf4f00a1ef502d690b3f3500683510e91af7863fbc35439eaf455fc40b3\", \"line\": 255, \"relation\": \"increases\", \"source\": 334, \"target\": 308}, {\"citation\": {\"authors\": [\"Bibow S\", \"Biernat J\", \"Blackledge M\", \"Jensen MR\", \"Kadavath H\", \"Mandelkow E\", \"Ozenne V\", \"Schwalbe M\", \"Zweckstetter M\"], \"date\": \"2013-12-17\", \"first\": \"Schwalbe M\", \"last\": \"Zweckstetter M\", \"name\": \"Biochemistry\", \"pages\": \"9068-79\", \"reference\": \"24251416\", \"title\": \"Phosphorylation of human Tau protein by microtubule affinity-regulating kinase 2.\", \"type\": \"PubMed\", \"volume\": \"52\"}, \"evidence\": \"While residues Ser-262, Ser-324, and Ser-356 were completely phosphorylated, Ser-293 in the second repeat was only 84% phosphorylated (Table 1). Furthermore, four non-KXGS phosphorylation sites were detected, two within the repeat domain (Ser-305 in R2 and Ser-352 in R4) and two more at the C-terminus (Ser-413 and Ser-416) (Figure 1B,C). Of these, Ser-305 was 66% phosphorylated and Ser-352, Ser-413, and Ser-416 were 4558% phosphorylated (Table 1). Using wild-type MARK2cat at 25 C and pH 6.8, the same phosphorylation sites were observed. The three primary sites, Ser-262, Ser-324, and Ser-356, were still completely phosphorylated.\", \"key\": \"4fff548b198ec5f7524dc87112abf42629822e5f0cbcb5e48f31b5b75aeba3bbf16d27e0189ec78927db1083787fc5c397438beb2021f655c240f242abdc1f3e\", \"line\": 2653, \"relation\": \"directlyIncreases\", \"source\": 334, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 308}, {\"citation\": {\"authors\": [\"Bibow S\", \"Biernat J\", \"Blackledge M\", \"Jensen MR\", \"Kadavath H\", \"Mandelkow E\", \"Ozenne V\", \"Schwalbe M\", \"Zweckstetter M\"], \"date\": \"2013-12-17\", \"first\": \"Schwalbe M\", \"last\": \"Zweckstetter M\", \"name\": \"Biochemistry\", \"pages\": \"9068-79\", \"reference\": \"24251416\", \"title\": \"Phosphorylation of human Tau protein by microtubule affinity-regulating kinase 2.\", \"type\": \"PubMed\", \"volume\": \"52\"}, \"evidence\": \"While residues Ser-262, Ser-324, and Ser-356 were completely phosphorylated, Ser-293 in the second repeat was only 84% phosphorylated (Table 1). Furthermore, four non-KXGS phosphorylation sites were detected, two within the repeat domain (Ser-305 in R2 and Ser-352 in R4) and two more at the C-terminus (Ser-413 and Ser-416) (Figure 1B,C). Of these, Ser-305 was 66% phosphorylated and Ser-352, Ser-413, and Ser-416 were 4558% phosphorylated (Table 1). Using wild-type MARK2cat at 25 C and pH 6.8, the same phosphorylation sites were observed. The three primary sites, Ser-262, Ser-324, and Ser-356, were still completely phosphorylated.\", \"key\": \"49ae11c4a271fff31a75f67c1bd30cf7857f13ada2e5cb2b18fedbf1419cc942a783ac44f25ecfd99b0edbcfa0f82c4aa6630ba100684164b61e51c0f8d8cead\", \"line\": 2650, \"relation\": \"directlyIncreases\", \"source\": 334, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 302}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Cabrales Fontela Y\", \"Kadavath H\", \"Mandelkow E\", \"Riedel D\", \"Zweckstetter M\"], \"date\": \"2017-12-07\", \"first\": \"Cabrales Fontela Y\", \"last\": \"Zweckstetter M\", \"name\": \"Nature communications\", \"pages\": \"1981\", \"reference\": \"29215007\", \"title\": \"Multivalent cross-linking of actin filaments and microtubules through the microtubule-associated protein Tau.\", \"type\": \"PubMed\", \"volume\": \"8\"}, \"evidence\": \"We therefore phosphorylated full-length Tau by MARK2. The downfield chemical shift of phosphorylated residues (Fig. 4a) is in agreement with previous reports and confirms phosphorylation at S262, S293, S305, S324, S356, and S416\", \"key\": \"38ef69f5a688cbca1c0e2539e5c04948f3b0a234963f85550ab821c46dafd84c4258da45d1cf1b729e85b0ea995ad2112b2ed7b2f00bc21533ef0fd17dc5e2b5\", \"line\": 252, \"relation\": \"increases\", \"source\": 334, \"target\": 300}, {\"citation\": {\"authors\": [\"Bibow S\", \"Biernat J\", \"Blackledge M\", \"Jensen MR\", \"Kadavath H\", \"Mandelkow E\", \"Ozenne V\", \"Schwalbe M\", \"Zweckstetter M\"], \"date\": \"2013-12-17\", \"first\": \"Schwalbe M\", \"last\": \"Zweckstetter M\", \"name\": \"Biochemistry\", \"pages\": \"9068-79\", \"reference\": \"24251416\", \"title\": \"Phosphorylation of human Tau protein by microtubule affinity-regulating kinase 2.\", \"type\": \"PubMed\", \"volume\": \"52\"}, \"evidence\": \"While residues Ser-262, Ser-324, and Ser-356 were completely phosphorylated, Ser-293 in the second repeat was only 84% phosphorylated (Table 1). Furthermore, four non-KXGS phosphorylation sites were detected, two within the repeat domain (Ser-305 in R2 and Ser-352 in R4) and two more at the C-terminus (Ser-413 and Ser-416) (Figure 1B,C). Of these, Ser-305 was 66% phosphorylated and Ser-352, Ser-413, and Ser-416 were 4558% phosphorylated (Table 1). Using wild-type MARK2cat at 25 C and pH 6.8, the same phosphorylation sites were observed. The three primary sites, Ser-262, Ser-324, and Ser-356, were still completely phosphorylated.\", \"key\": \"afbc0cd779781b3e970d4f1d2c9a6e4b7f7275c56b6592a8171ca641b311f82c729cf6c1fd4cac2d2b6a1233fc560b8a33b2e0def7be8474f67c1e66623b0d8c\", \"line\": 2648, \"relation\": \"directlyIncreases\", \"source\": 334, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 300}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Cabrales Fontela Y\", \"Kadavath H\", \"Mandelkow E\", \"Riedel D\", \"Zweckstetter M\"], \"date\": \"2017-12-07\", \"first\": \"Cabrales Fontela Y\", \"last\": \"Zweckstetter M\", \"name\": \"Nature communications\", \"pages\": \"1981\", \"reference\": \"29215007\", \"title\": \"Multivalent cross-linking of actin filaments and microtubules through the microtubule-associated protein Tau.\", \"type\": \"PubMed\", \"volume\": \"8\"}, \"evidence\": \"We therefore phosphorylated full-length Tau by MARK2. The downfield chemical shift of phosphorylated residues (Fig. 4a) is in agreement with previous reports and confirms phosphorylation at S262, S293, S305, S324, S356, and S416\", \"key\": \"37aa0742fd1ab064a44a0cb7cc6d4c4fe21f6792de9e744cac06fe927f68bd808b031fa93c3cf408b47b17823d1ea5e0c034b611e331d293659565b24509dec4\", \"line\": 251, \"relation\": \"increases\", \"source\": 334, \"target\": 299}, {\"citation\": {\"authors\": [\"Bibow S\", \"Biernat J\", \"Blackledge M\", \"Jensen MR\", \"Kadavath H\", \"Mandelkow E\", \"Ozenne V\", \"Schwalbe M\", \"Zweckstetter M\"], \"date\": \"2013-12-17\", \"first\": \"Schwalbe M\", \"last\": \"Zweckstetter M\", \"name\": \"Biochemistry\", \"pages\": \"9068-79\", \"reference\": \"24251416\", \"title\": \"Phosphorylation of human Tau protein by microtubule affinity-regulating kinase 2.\", \"type\": \"PubMed\", \"volume\": \"52\"}, \"evidence\": \"While residues Ser-262, Ser-324, and Ser-356 were completely phosphorylated, Ser-293 in the second repeat was only 84% phosphorylated (Table 1). Furthermore, four non-KXGS phosphorylation sites were detected, two within the repeat domain (Ser-305 in R2 and Ser-352 in R4) and two more at the C-terminus (Ser-413 and Ser-416) (Figure 1B,C). Of these, Ser-305 was 66% phosphorylated and Ser-352, Ser-413, and Ser-416 were 4558% phosphorylated (Table 1). Using wild-type MARK2cat at 25 C and pH 6.8, the same phosphorylation sites were observed. The three primary sites, Ser-262, Ser-324, and Ser-356, were still completely phosphorylated.\", \"key\": \"2534d690bce73f21e487135b3c9c208a0b816cfc4626af8a82afeb582d74dc6139c93a01fa0d043fc68bc2c6af2d066505153ffe73063752c7a8cd6362eedbe4\", \"line\": 2646, \"relation\": \"directlyIncreases\", \"source\": 334, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 299}, {\"citation\": {\"authors\": [\"Dickey CA\", \"Gestwicki JE\", \"Kiray J\", \"Koren J\", \"Miyata Y\"], \"date\": \"2011-09-01\", \"first\": \"Miyata Y\", \"last\": \"Gestwicki JE\", \"name\": \"Future medicinal chemistry\", \"pages\": \"1523-37\", \"reference\": \"21882945\", \"title\": \"Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.\", \"type\": \"PubMed\", \"volume\": \"3\"}, \"evidence\": \"Phosphorylation of tau by the kinases GSK3b, Cdk5 and MARK2 is a major regulator of its microtubule interactions\", \"key\": \"a074cedddfad5e065d3f96324604315e3889d958aebcce4a1a60153747433a06a04c62beac66e2b6604d832f863a963b1044d71ea20e545dbf04b35b20fdacf7\", \"line\": 97, \"relation\": \"directlyIncreases\", \"source\": 334, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 286}, {\"citation\": {\"authors\": [\"Dickey CA\", \"Gestwicki JE\", \"Kiray J\", \"Koren J\", \"Miyata Y\"], \"date\": \"2011-09-01\", \"first\": \"Miyata Y\", \"last\": \"Gestwicki JE\", \"name\": \"Future medicinal chemistry\", \"pages\": \"1523-37\", \"reference\": \"21882945\", \"title\": \"Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.\", \"type\": \"PubMed\", \"volume\": \"3\"}, \"evidence\": \"Importantly, MARK2-based phosphorylation of tau is accelerated by the priming activity of either Cdk5 or GSK3b [29], suggesting that tau phosphorylation involves a series of ordered kinase events.\", \"key\": \"52cb80d7b576a0013c18eb04c90e0a33eb58fe2ab97d028e62fd60ac3e6d34e60a46ba288041bb873b2871dc5fcbceffb91ebccb353fc77309704c00a8224b58\", \"line\": 103, \"relation\": \"directlyIncreases\", \"source\": 334, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 286}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Cabrales Fontela Y\", \"Kadavath H\", \"Mandelkow E\", \"Riedel D\", \"Zweckstetter M\"], \"date\": \"2017-12-07\", \"first\": \"Cabrales Fontela Y\", \"last\": \"Zweckstetter M\", \"name\": \"Nature communications\", \"pages\": \"1981\", \"reference\": \"29215007\", \"title\": \"Multivalent cross-linking of actin filaments and microtubules through the microtubule-associated protein Tau.\", \"type\": \"PubMed\", \"volume\": \"8\"}, \"evidence\": \"We therefore phosphorylated full-length Tau by MARK2. The downfield chemical shift of phosphorylated residues (Fig. 4a) is in agreement with previous reports and confirms phosphorylation at S262, S293, S305, S324, S356, and S416\", \"key\": \"f1fa4eb42b7ec6f089cfacd68577c528e511a18cfb9c9d230711e1c72ecd289e40d6e6d258b5d2c680eea2502a8dea398878bd052441df127bec6cd9e672cac2\", \"line\": 254, \"relation\": \"increases\", \"source\": 334, \"target\": 303}, {\"citation\": {\"authors\": [\"Bibow S\", \"Biernat J\", \"Blackledge M\", \"Jensen MR\", \"Kadavath H\", \"Mandelkow E\", \"Ozenne V\", \"Schwalbe M\", \"Zweckstetter M\"], \"date\": \"2013-12-17\", \"first\": \"Schwalbe M\", \"last\": \"Zweckstetter M\", \"name\": \"Biochemistry\", \"pages\": \"9068-79\", \"reference\": \"24251416\", \"title\": \"Phosphorylation of human Tau protein by microtubule affinity-regulating kinase 2.\", \"type\": \"PubMed\", \"volume\": \"52\"}, \"evidence\": \"While residues Ser-262, Ser-324, and Ser-356 were completely phosphorylated, Ser-293 in the second repeat was only 84% phosphorylated (Table 1). Furthermore, four non-KXGS phosphorylation sites were detected, two within the repeat domain (Ser-305 in R2 and Ser-352 in R4) and two more at the C-terminus (Ser-413 and Ser-416) (Figure 1B,C). Of these, Ser-305 was 66% phosphorylated and Ser-352, Ser-413, and Ser-416 were 4558% phosphorylated (Table 1). Using wild-type MARK2cat at 25 C and pH 6.8, the same phosphorylation sites were observed. The three primary sites, Ser-262, Ser-324, and Ser-356, were still completely phosphorylated.\", \"key\": \"717715808a9a2abeae10cb041263b5fd0f66219a4a9cfe12756c624362133abce5be2d0611aba6af2f79063e847ce93e24e24929adc00b5a36ffeea05dc647f3\", \"line\": 2645, \"relation\": \"directlyIncreases\", \"source\": 334, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 303}, {\"annotations\": {\"Confidence\": {\"Medium\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Cabrales Fontela Y\", \"Kadavath H\", \"Mandelkow E\", \"Riedel D\", \"Zweckstetter M\"], \"date\": \"2017-12-07\", \"first\": \"Cabrales Fontela Y\", \"last\": \"Zweckstetter M\", \"name\": \"Nature communications\", \"pages\": \"1981\", \"reference\": \"29215007\", \"title\": \"Multivalent cross-linking of actin filaments and microtubules through the microtubule-associated protein Tau.\", \"type\": \"PubMed\", \"volume\": \"8\"}, \"evidence\": \"An important class of kinases that phosphorylate Tau at S262 and the other KXGS motifs in the repeat domain are the microtubule-associated protein/microtubule affinity-regulating kinases (MARKs)\", \"key\": \"abbe62dba04a326c5701d5147b6e11eea5916d354af2d1c534f91018783e5ad8d5ce949eb6bbb5c79fff300f5aa1d16f3951df5065cf4f7782f70a2cf08f5474\", \"line\": 242, \"relation\": \"increases\", \"source\": 334, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 297}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Cabrales Fontela Y\", \"Kadavath H\", \"Mandelkow E\", \"Riedel D\", \"Zweckstetter M\"], \"date\": \"2017-12-07\", \"first\": \"Cabrales Fontela Y\", \"last\": \"Zweckstetter M\", \"name\": \"Nature communications\", \"pages\": \"1981\", \"reference\": \"29215007\", \"title\": \"Multivalent cross-linking of actin filaments and microtubules through the microtubule-associated protein Tau.\", \"type\": \"PubMed\", \"volume\": \"8\"}, \"evidence\": \"We therefore phosphorylated full-length Tau by MARK2. The downfield chemical shift of phosphorylated residues (Fig. 4a) is in agreement with previous reports and confirms phosphorylation at S262, S293, S305, S324, S356, and S416\", \"key\": \"67de8b9e90defd7214a09fd77e167fa8f3b47227f8f9d2a4e04c8f3f43df5403133d3585afc846d52506f550f1538ebccc979390b64b6f4f117b09e52bae0bb0\", \"line\": 250, \"relation\": \"increases\", \"source\": 334, \"target\": 297}, {\"citation\": {\"authors\": [\"Chen GC\", \"Chen RH\", \"Chen YH\", \"Chien CT\", \"Chou HJ\", \"Huang YP\", \"Kimchi A\", \"Lin MY\", \"Tsai PI\", \"Wu PR\"], \"date\": \"2011-09-01\", \"first\": \"Wu PR\", \"last\": \"Chen RH\", \"name\": \"Cell death and differentiation\", \"pages\": \"1507-20\", \"reference\": \"21311567\", \"title\": \"DAPK activates MARK1/2 to regulate microtubule assembly, neuronal differentiation, and tau toxicity.\", \"type\": \"PubMed\", \"volume\": \"18\"}, \"evidence\": \"Furthermore, silencing of both MARK1 and MARK2 blocked DAPK-induced tau S262 phosphorylation (Figure 3e). More importantly, a decrease of pS262 tau, but not total tau, was observed in brain extracts derived from DAPK/ mice, compared with that from DAPK+/+ mice (Figure 3f). These results strongly suggest a role of endogenous DAPK in stimulating the activity of endogenous MARK, which in turn phosphorylates tau in neurons.\", \"key\": \"a254e1bd51ba7e87c7692a935fe73aa24ca5f2fdc4dabcf8853adb62435ac11dcde48d6c35ef71df3353f9a1170f87d1893c72a84ecfa78907c5739fd35176a8\", \"line\": 2011, \"relation\": \"increases\", \"source\": 334, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 297}, {\"citation\": {\"authors\": [\"Bibow S\", \"Biernat J\", \"Blackledge M\", \"Jensen MR\", \"Kadavath H\", \"Mandelkow E\", \"Ozenne V\", \"Schwalbe M\", \"Zweckstetter M\"], \"date\": \"2013-12-17\", \"first\": \"Schwalbe M\", \"last\": \"Zweckstetter M\", \"name\": \"Biochemistry\", \"pages\": \"9068-79\", \"reference\": \"24251416\", \"title\": \"Phosphorylation of human Tau protein by microtubule affinity-regulating kinase 2.\", \"type\": \"PubMed\", \"volume\": \"52\"}, \"evidence\": \"While residues Ser-262, Ser-324, and Ser-356 were completely phosphorylated, Ser-293 in the second repeat was only 84% phosphorylated (Table 1). Furthermore, four non-KXGS phosphorylation sites were detected, two within the repeat domain (Ser-305 in R2 and Ser-352 in R4) and two more at the C-terminus (Ser-413 and Ser-416) (Figure 1B,C). Of these, Ser-305 was 66% phosphorylated and Ser-352, Ser-413, and Ser-416 were 4558% phosphorylated (Table 1). Using wild-type MARK2cat at 25 C and pH 6.8, the same phosphorylation sites were observed. The three primary sites, Ser-262, Ser-324, and Ser-356, were still completely phosphorylated.\", \"key\": \"469028357db820a1612d3ad7d3a522a0c6fa7f952dc2353d78c13e68fd5025ceeb3406cd6a43a5d75ea154845f358851b3294877061f18a5f7a5850cf7a51c5c\", \"line\": 2643, \"relation\": \"directlyIncreases\", \"source\": 334, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 297}, {\"annotations\": {\"Cell_Line\": {\"NIH/3T3\": true}}, \"citation\": {\"authors\": [\"Agerman K\", \"Eckersley S\", \"Gu GJ\", \"Kamali-Moghaddam M\", \"Kvist AJ\", \"Landegren U\", \"Lund H\", \"Milner R\", \"Nilsson LN\", \"Sunnemark D\", \"Wu D\"], \"date\": \"2013-01-01\", \"first\": \"Gu GJ\", \"last\": \"Kamali-Moghaddam M\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"699-713\", \"reference\": \"23001711\", \"title\": \"Elevated MARK2-dependent phosphorylation of Tau in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"33\"}, \"evidence\": \"Several kinases such as microtubule-affinity regulating kinase (MARK), protein kinase A, calcium calmodulin kinase II, and checkpoint kinase 2 are known to phosphorylate tau on Ser(262) in vitro. In this study, we took advantage of the in situ proximity ligation assay to investigate the role of MARK2, one of the four MARK isoforms, in AD. We demonstrate that MARK2 interacts with tau and phosphorylates tau at Ser(262) in stably transfected NIH/3T3 cells expressing human recombinant tau. Staurosporine, a protein kinase inhibitor, significantly reduced the interaction between MARK2 and tau, and also phosphorylation of tau at Ser(262).\", \"key\": \"d08804d93f72158abf47d778e49e122ea2233dfbaec9696de12c13549b3067887cc860739a29d368a767a2b078f4508f00d413b389487d305a02d0b42e0f77ca\", \"line\": 2775, \"relation\": \"directlyIncreases\", \"source\": 334, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 297}, {\"citation\": {\"authors\": [\"Bibow S\", \"Biernat J\", \"Blackledge M\", \"Jensen MR\", \"Kadavath H\", \"Mandelkow E\", \"Ozenne V\", \"Schwalbe M\", \"Zweckstetter M\"], \"date\": \"2013-12-17\", \"first\": \"Schwalbe M\", \"last\": \"Zweckstetter M\", \"name\": \"Biochemistry\", \"pages\": \"9068-79\", \"reference\": \"24251416\", \"title\": \"Phosphorylation of human Tau protein by microtubule affinity-regulating kinase 2.\", \"type\": \"PubMed\", \"volume\": \"52\"}, \"evidence\": \"While residues Ser-262, Ser-324, and Ser-356 were completely phosphorylated, Ser-293 in the second repeat was only 84% phosphorylated (Table 1). Furthermore, four non-KXGS phosphorylation sites were detected, two within the repeat domain (Ser-305 in R2 and Ser-352 in R4) and two more at the C-terminus (Ser-413 and Ser-416) (Figure 1B,C). Of these, Ser-305 was 66% phosphorylated and Ser-352, Ser-413, and Ser-416 were 4558% phosphorylated (Table 1). Using wild-type MARK2cat at 25 C and pH 6.8, the same phosphorylation sites were observed. The three primary sites, Ser-262, Ser-324, and Ser-356, were still completely phosphorylated.\", \"key\": \"16644673d63fc779f15ffa63830ffd1393b9755989ffe9f13991dc88c4d560c45b7a061b26a6d195ad551d31c7ab46365c30a20dde538006f59cdfd7471f6649\", \"line\": 2652, \"relation\": \"directlyIncreases\", \"source\": 334, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 307}, {\"citation\": {\"authors\": [\"Carlomagno Y\", \"Castanedes-Casey M\", \"Chung DC\", \"Cook C\", \"DeTure M\", \"Dickson DW\", \"Dunmore J\", \"Madden BJ\", \"Petrucelli L\", \"Tong J\", \"Yue M\"], \"date\": \"2017-09-15\", \"first\": \"Carlomagno Y\", \"last\": \"Cook C\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"15277-15286\", \"reference\": \"28760828\", \"title\": \"An acetylation-phosphorylation switch that regulates tau aggregation propensity and function.\", \"type\": \"PubMed\", \"volume\": \"292\"}, \"evidence\": \"HDAC6 inhibition leads to a significant reduction in tau levels as detected by the human tau-specific antibody E1 (Fig. 6 (a and c) and supplemental Fig. S6). We also observed a striking decrease in phosphorylation at Ser-324, which was statistically significant even when normalizing to E1 to control for the reduction in tau levels (Fig. 6 (a and b) and supplemental Fig. S6).\", \"key\": \"629987366b04c82a2159841db71a4539954fa36208e90aae8843b13ee3068a302dcc6b4632367f20939448e2658b4db983b970dcbec7f074fa888fb171a08e17\", \"line\": 3366, \"relation\": \"positiveCorrelation\", \"source\": 233, \"target\": 301}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Tau can be acetylated by the P300 acetyltransferase or by CREB-binding protein at several Lys residues in the flanking region or the repeat domain, and deacetylated at these sites by sirtuin 1 (SIRT1) and histone deacetylase 6 (HDAC6), respectively\", \"key\": \"e0bacbf99c5fc123044bbdd52837c715831351eb2fb97b55c41bb5bddc9f122ad18af14e610b8ff772c10e57eb5ce9606064c00983b25931c9c91b07997c340c\", \"line\": 254, \"relation\": \"decreases\", \"source\": 233, \"target\": 248}, {\"citation\": {\"authors\": [\"Carlomagno Y\", \"Castanedes-Casey M\", \"Chung DC\", \"Cook C\", \"DeTure M\", \"Dickson DW\", \"Dunmore J\", \"Madden BJ\", \"Petrucelli L\", \"Tong J\", \"Yue M\"], \"date\": \"2017-09-15\", \"first\": \"Carlomagno Y\", \"last\": \"Cook C\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"15277-15286\", \"reference\": \"28760828\", \"title\": \"An acetylation-phosphorylation switch that regulates tau aggregation propensity and function.\", \"type\": \"PubMed\", \"volume\": \"292\"}, \"evidence\": \"Our findings indicate that several acetylation sites in tau are responsive to HDAC6 and that acetylation on Lys-321 (within a KCGS motif) is both essential for acetylation-mediated inhibition of tau aggregation in vitro and a molecular tactic for preventing phosphorylation on the downstream Ser-324 residue. Tau phosphorylation of Ser-324 (pSer-324) has not previously been evaluated in the context of tauopathy, and here we observed increased deposition of pSer-324-positive tau both in mouse models of tauopathy and in patients with Alzheimer's disease. These findings uncover a novel acetylation-phosphorylation switch at Lys-321/Ser-324 that coordinately regulates tau polymerization and function.\", \"key\": \"440886efff5af6d594c58aa886fd00cd4da3d8703cad377e5099b233e62e9e84206892d13641010b4108e8dc0a079c730ceb2fb664dfa948f19b84fc14d24fb1\", \"line\": 3360, \"relation\": \"decreases\", \"source\": 261, \"target\": 301}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Depending on the sites, the acetylation of tau could inhibit its degradation (for example, when at Lys163, Lys280, Lys281 or Lys369) or, by contrast, facilitate its degradation and suppress its phosphorylation and aggregation (for example, when at Lys259, Lys290, Lys321 or Lys353)\", \"key\": \"e2cc87399bf8b654356a7f447aaf8d44ff1d837f4c67e36b27b897e3d12ba20bbb14b1d7aecc994b7dbe3cb3edb82b634761a50701cce90e48cbe82d05104e7b\", \"line\": 274, \"relation\": \"decreases\", \"source\": 261, \"target\": 286}, {\"citation\": {\"authors\": [\"Burlingame AL\", \"Ioanoviciu A\", \"Knudsen GM\", \"Maeda S\", \"Morris M\", \"Mucke L\", \"Trinidad JC\"], \"date\": \"2015-08-01\", \"first\": \"Morris M\", \"last\": \"Mucke L\", \"name\": \"Nature neuroscience\", \"pages\": \"1183-9\", \"reference\": \"26192747\", \"title\": \"Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"18\"}, \"evidence\": \"Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.\", \"key\": \"381c002c75e9d9ae207dce399d9361a8114d24570d0b9bfdd66d623a0947e3c8bbbebbab47efddf6e166869d836d4701724096a28f717c1d8dbd287a9577b546\", \"line\": 3221, \"relation\": \"isA\", \"source\": 261, \"target\": 247}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Depending on the sites, the acetylation of tau could inhibit its degradation (for example, when at Lys163, Lys280, Lys281 or Lys369) or, by contrast, facilitate its degradation and suppress its phosphorylation and aggregation (for example, when at Lys259, Lys290, Lys321 or Lys353)\", \"key\": \"427476175372a8575631acdf27615428aee043afcd0290d61b827eb980127a1c973d4bab5da0ab5e1e04149478e031a8e86c5a47121940b94c2f59b70bb9612f\", \"line\": 273, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 261, \"target\": 261}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Depending on the sites, the acetylation of tau could inhibit its degradation (for example, when at Lys163, Lys280, Lys281 or Lys369) or, by contrast, facilitate its degradation and suppress its phosphorylation and aggregation (for example, when at Lys259, Lys290, Lys321 or Lys353)\", \"key\": \"acfb3d1a58e1cb2fcf5cec60741b20dde800518fab27d9463deaeaf641e465ad71f668c06385df796fe68a0479eca0dad075c96cc402fefc2e6dca05cf0468a7\", \"line\": 275, \"relation\": \"decreases\", \"source\": 261, \"target\": 39}, {\"citation\": {\"authors\": [\"Burlingame AL\", \"Ioanoviciu A\", \"Knudsen GM\", \"Maeda S\", \"Morris M\", \"Mucke L\", \"Trinidad JC\"], \"date\": \"2015-08-01\", \"first\": \"Morris M\", \"last\": \"Mucke L\", \"name\": \"Nature neuroscience\", \"pages\": \"1183-9\", \"reference\": \"26192747\", \"title\": \"Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"18\"}, \"evidence\": \"Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.\", \"key\": \"e9b298b9ae8c06a77c7dd5dccf2f703c200d1e03160c8778e08aa5a9cb4f69561637f05e06d3d53d11a193f1bc9c8e327ba6ea4c17f699874ff8fe67b8e87773\", \"line\": 3231, \"relation\": \"partOf\", \"source\": 261, \"target\": 55}, {\"citation\": {\"authors\": [\"Carlomagno Y\", \"Castanedes-Casey M\", \"Chung DC\", \"Cook C\", \"DeTure M\", \"Dickson DW\", \"Dunmore J\", \"Madden BJ\", \"Petrucelli L\", \"Tong J\", \"Yue M\"], \"date\": \"2017-09-15\", \"first\": \"Carlomagno Y\", \"last\": \"Cook C\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"15277-15286\", \"reference\": \"28760828\", \"title\": \"An acetylation-phosphorylation switch that regulates tau aggregation propensity and function.\", \"type\": \"PubMed\", \"volume\": \"292\"}, \"evidence\": \"Our findings indicate that several acetylation sites in tau are responsive to HDAC6 and that acetylation on Lys-321 (within a KCGS motif) is both essential for acetylation-mediated inhibition of tau aggregation in vitro and a molecular tactic for preventing phosphorylation on the downstream Ser-324 residue. Tau phosphorylation of Ser-324 (pSer-324) has not previously been evaluated in the context of tauopathy, and here we observed increased deposition of pSer-324-positive tau both in mouse models of tauopathy and in patients with Alzheimer's disease. These findings uncover a novel acetylation-phosphorylation switch at Lys-321/Ser-324 that coordinately regulates tau polymerization and function.\", \"key\": \"1f66ba0856ff2b67409694253748e21463024514533ef274773c23bdffd5c99648b06246391b6f541f2be84a213433e5bec7987d5f76048e895c47eb8d4be138\", \"line\": 3359, \"relation\": \"decreases\", \"source\": 261, \"target\": 178}, {\"citation\": {\"authors\": [\"Berry RW\", \"Binder LI\", \"Lukas TJ\", \"Reynolds MR\"], \"date\": \"2006-04-04\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"Biochemistry\", \"pages\": \"4314-26\", \"reference\": \"16566606\", \"title\": \"Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.\", \"type\": \"PubMed\", \"volume\": \"45\"}, \"evidence\": \"Previously, we showed that peroxynitrite (ONOO-) induces the oxidative 3,3- dityrosine (3,3-DT) cross-linking and site-selective nitration of tau monomers [Reynolds et al. (2005)\", \"key\": \"fbce9f7a8556b360405b1a6d06a0f4b35480951ded0b641d8ddfc0d862c9bee9a03f65528c841bb585ba09d9019b55bb53cfa0301f8e2b755be56b5bddb61cd3\", \"line\": 200, \"relation\": \"increases\", \"source\": 28, \"target\": 279}, {\"citation\": {\"authors\": [\"Berry RW\", \"Binder LI\", \"Lukas TJ\", \"Reynolds MR\"], \"date\": \"2006-04-04\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"Biochemistry\", \"pages\": \"4314-26\", \"reference\": \"16566606\", \"title\": \"Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.\", \"type\": \"PubMed\", \"volume\": \"45\"}, \"evidence\": \"Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.\", \"key\": \"4063eed223b51628a0048a7b8615b114f3f55154d5f1456feab40ae55a0aa49eb191c19b373f2ddfd299caf3465a7d505774404fd5563480fb1248262b2fd915\", \"line\": 919, \"relation\": \"increases\", \"source\": 28, \"target\": 283}, {\"citation\": {\"authors\": [\"Binder LI\", \"Hakala K\", \"Kanaan NM\", \"Vana L\", \"Weintraub ST\"], \"date\": \"2011-02-22\", \"first\": \"Vana L\", \"last\": \"Binder LI\", \"name\": \"Biochemistry\", \"pages\": \"1203-12\", \"reference\": \"21210655\", \"title\": \"Peroxynitrite-induced nitrative and oxidative modifications alter tau filament formation.\", \"type\": \"PubMed\", \"volume\": \"50\"}, \"evidence\": \"PN-treated wild-type tau and 5XYF tau consistently displayed lysine formylation throughout tau in a non-sequence specific distribution. Lysine formylation likely results from reactive free radical exposure caused by PN treatment.\", \"key\": \"c4fc6ac0631313a4424478885c9279ff670b45ad6b4d3c353732c0644f3658f782fb7da25aaffda52ddf65a2316d5b989f229e05ddc74f68668b70e676229005\", \"line\": 859, \"relation\": \"increases\", \"source\": 28, \"target\": 274}, {\"citation\": {\"authors\": [\"Berry RW\", \"Binder LI\", \"Lukas TJ\", \"Reynolds MR\"], \"date\": \"2006-04-04\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"Biochemistry\", \"pages\": \"4314-26\", \"reference\": \"16566606\", \"title\": \"Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.\", \"type\": \"PubMed\", \"volume\": \"45\"}, \"evidence\": \"Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.\", \"key\": \"f555c3e1d6d7df9eb409d1413f38d4c8357ad709e76359f79f5edb79f275b874d4b64099291ffa7f3924806bb2cccc4880057815df7a75f8fde0065b045eaa32\", \"line\": 917, \"relation\": \"increases\", \"source\": 28, \"target\": 282}, {\"citation\": {\"authors\": [\"Berry RW\", \"Binder LI\", \"Lukas TJ\", \"Reynolds MR\"], \"date\": \"2006-04-04\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"Biochemistry\", \"pages\": \"4314-26\", \"reference\": \"16566606\", \"title\": \"Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.\", \"type\": \"PubMed\", \"volume\": \"45\"}, \"evidence\": \"Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.\", \"key\": \"77b650d4399cecb6a899730ac18178fbeaf891cf0dbe65dd4be6ba3ccd4d67e533fbebc290fedbdecc7cd9b8ea0f46ced8c1694e1d02eb039ec7f6546b878e22\", \"line\": 918, \"relation\": \"increases\", \"source\": 28, \"target\": 281}, {\"citation\": {\"authors\": [\"Berry RW\", \"Binder LI\", \"Lukas TJ\", \"Reynolds MR\"], \"date\": \"2006-04-04\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"Biochemistry\", \"pages\": \"4314-26\", \"reference\": \"16566606\", \"title\": \"Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.\", \"type\": \"PubMed\", \"volume\": \"45\"}, \"evidence\": \"Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.\", \"key\": \"8cad963e9628d76d481251e15129c3a31ef3bf1f71bd4530f08c92d5059898bd88a07f5eb0fd7bed3ed39473d9b3a7b483c2befa76e2dc8c0f5eaf8a1c40296e\", \"line\": 916, \"relation\": \"increases\", \"source\": 28, \"target\": 280}, {\"annotations\": {\"Disease\": {\"Alzheimer's disease\": true}}, \"citation\": {\"authors\": [\"Berry RW\", \"Bigio EH\", \"Binder LI\", \"Fu Y\", \"Guillozet-Bongaarts AL\", \"Reyes JF\", \"Reynolds MR\"], \"date\": \"2006-10-18\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"10636-45\", \"reference\": \"17050703\", \"title\": \"Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies.\", \"type\": \"PubMed\", \"volume\": \"26\"}, \"evidence\": \"Tau-nY29 detects soluble tau and paired helical filament tau from severely affected Alzheimer's brain but fails to recognize tau from normal aged brain. This observation suggests that nitration at Tyr29 is a disease-related event that may alter the intrinsic ability of tau to self-polymerize. In Alzheimer's brain, Tau-nY29 labels the fibrillar triad of tau lesions, including neurofibrillary tangles, neuritic plaques, and, to a lesser extent, neuropil threads. Intriguingly, although Tau-nY29 stains both the neuronal and glial tau pathology of Pick disease, it detects only the neuronal pathology in corticobasal degeneration and progressive supranuclear palsy without labeling the predominant glial pathology.\", \"key\": \"82c99dd51869786c5c411b621cff843b74ed417a5c9eaf62baab88228ff6be79e8f38b30adaa0b590520a0d818b5cc7691c0bf71d8176028ea14f980a9a57caa\", \"line\": 852, \"relation\": \"isA\", \"source\": 280, \"target\": 279}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"The nitration of these Tyr residues alters the conformation of tau, reduces its binding to microtubules and, depending on the nitration sites, can promote or inhibit aggregation\", \"key\": \"040d2ec29e4a9a8b90695e765c56135334c66222b4e7a2d6f321d503a708b54882b343b15571a564b4e4704b64e7db412bff8034b5a4e221c1ebba5dfb445a06\", \"line\": 346, \"relation\": \"decreases\", \"source\": 280, \"target\": 111}, {\"annotations\": {\"Tau_Antibody\": {\"9G3\": true, \"Tau-12\": true, \"Tau-13\": true, \"pY18\": true}}, \"citation\": {\"authors\": [\"Berry RW\", \"Binder LI\", \"Lukas TJ\", \"Reynolds MR\"], \"date\": \"2006-04-04\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"Biochemistry\", \"pages\": \"4314-26\", \"reference\": \"16566606\", \"title\": \"Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.\", \"type\": \"PubMed\", \"volume\": \"45\"}, \"evidence\": \"Further, select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation [Reynolds et al. (2005) Biochemistry 44, 13997-14009], inhibits the ability of monomeric tau to promote tubulin assembly.\", \"key\": \"a0b8d65a4979863448591ce784d3774a93f5d10fa5b04b8372b78eef1ee5f830485c16609b85e992878452ad56ef2e273a017ff061d12094ea84cb0ad4abf1e7\", \"line\": 205, \"relation\": \"decreases\", \"source\": 280, \"target\": 92}, {\"citation\": {\"authors\": [\"Berry R\", \"Binder LI\", \"Fu Y\", \"Guillozet-Bongaarts AL\", \"Horowitz PM\", \"Reyes JF\", \"Reynolds MR\"], \"date\": \"2008-08-01\", \"first\": \"Reyes JF\", \"last\": \"Binder LI\", \"name\": \"Neurobiology of disease\", \"pages\": \"198-208\", \"reference\": \"18562203\", \"title\": \"A possible link between astrocyte activation and tau nitration in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"This antibody detects nitrated tau in soluble preparations from both severe AD brains (Braak stage V, VI) and age-matched controls, suggesting that nitration at Tyr 18 may be linked to astrocyte activation, an early event associated with amyloid plaque formation\", \"key\": \"987d76f3c622459496b175366ca225f5a5ec40589ab50ea5cfc781568240a7cbe12ee3503b626ce0d384474d74447fe1faab24de1c33293eee847541b7e421e7\", \"line\": 835, \"object\": {\"modifier\": \"Activity\"}, \"relation\": \"association\", \"source\": 280, \"target\": 0}, {\"citation\": {\"authors\": [\"Berry RW\", \"Binder LI\", \"Lukas TJ\", \"Reynolds MR\"], \"date\": \"2006-04-04\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"Biochemistry\", \"pages\": \"4314-26\", \"reference\": \"16566606\", \"title\": \"Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.\", \"type\": \"PubMed\", \"volume\": \"45\"}, \"evidence\": \"Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.\", \"key\": \"d34ac7d64f772364679c712fd70b35903a5c5132c248e01d9bc5f91e50dc59afd02200f02bee02eb86b5c9bc369d1a9f0feab5cf6cf43e0b3b97632a65189037\", \"line\": 920, \"relation\": \"positiveCorrelation\", \"source\": 280, \"target\": 56}, {\"citation\": {\"authors\": [\"Berry RW\", \"Binder LI\", \"Lukas TJ\", \"Reynolds MR\"], \"date\": \"2006-04-04\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"Biochemistry\", \"pages\": \"4314-26\", \"reference\": \"16566606\", \"title\": \"Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.\", \"type\": \"PubMed\", \"volume\": \"45\"}, \"evidence\": \"Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.\", \"key\": \"6b4d4bdba26ede32390656af16ca6d2e7b1fbd836c420201b6e3eefc1776798190517f08b98b4f03662ddb4bfddbcd7570b53fd5e4131a8c29ae6fd9b60f3128\", \"line\": 924, \"object\": {\"modifier\": \"Activity\"}, \"relation\": \"negativeCorrelation\", \"source\": 280, \"target\": 244}, {\"annotations\": {\"Disease\": {\"Alzheimer's disease\": true}}, \"citation\": {\"authors\": [\"Berry RW\", \"Bigio EH\", \"Binder LI\", \"Fu Y\", \"Guillozet-Bongaarts AL\", \"Reyes JF\", \"Reynolds MR\"], \"date\": \"2006-10-18\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"10636-45\", \"reference\": \"17050703\", \"title\": \"Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies.\", \"type\": \"PubMed\", \"volume\": \"26\"}, \"evidence\": \"Tau-nY29 detects soluble tau and paired helical filament tau from severely affected Alzheimer's brain but fails to recognize tau from normal aged brain. This observation suggests that nitration at Tyr29 is a disease-related event that may alter the intrinsic ability of tau to self-polymerize. In Alzheimer's brain, Tau-nY29 labels the fibrillar triad of tau lesions, including neurofibrillary tangles, neuritic plaques, and, to a lesser extent, neuropil threads. Intriguingly, although Tau-nY29 stains both the neuronal and glial tau pathology of Pick disease, it detects only the neuronal pathology in corticobasal degeneration and progressive supranuclear palsy without labeling the predominant glial pathology.\", \"key\": \"e765a2458b366a23eb60865ca8a04414489b79ac5c037505930e135ddf5d38b2b29c8c0b344eb06b63243e5703e6106c16cea63529190dd41ff2e43594d6abda\", \"line\": 851, \"relation\": \"isA\", \"source\": 282, \"target\": 279}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"The nitration of these Tyr residues alters the conformation of tau, reduces its binding to microtubules and, depending on the nitration sites, can promote or inhibit aggregation\", \"key\": \"c49a82a66c8ae57adc663ee4a1ae0bb755556cb956e01010ea7cac9c076771bd1910f7273a38460598ff56319058709bdf56d8be4c52115c0002e2072d709ea9\", \"line\": 347, \"relation\": \"decreases\", \"source\": 282, \"target\": 111}, {\"annotations\": {\"Tau_Antibody\": {\"9G3\": true, \"Tau-12\": true, \"Tau-13\": true, \"pY18\": true}}, \"citation\": {\"authors\": [\"Berry RW\", \"Binder LI\", \"Lukas TJ\", \"Reynolds MR\"], \"date\": \"2006-04-04\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"Biochemistry\", \"pages\": \"4314-26\", \"reference\": \"16566606\", \"title\": \"Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.\", \"type\": \"PubMed\", \"volume\": \"45\"}, \"evidence\": \"Further, select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation [Reynolds et al. (2005) Biochemistry 44, 13997-14009], inhibits the ability of monomeric tau to promote tubulin assembly.\", \"key\": \"a7e51f902aeb9135948916005b96a054364fde51423401da5a8a4beb9b4294f1590d31b02f55c60a31d98bc3780a7bae8f298e11e9fdcec0c9522f2c2bd6c81e\", \"line\": 206, \"relation\": \"decreases\", \"source\": 282, \"target\": 92}, {\"annotations\": {\"Disease\": {\"Alzheimer's disease\": true}}, \"citation\": {\"authors\": [\"Berry RW\", \"Bigio EH\", \"Binder LI\", \"Fu Y\", \"Guillozet-Bongaarts AL\", \"Reyes JF\", \"Reynolds MR\"], \"date\": \"2006-10-18\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"10636-45\", \"reference\": \"17050703\", \"title\": \"Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies.\", \"type\": \"PubMed\", \"volume\": \"26\"}, \"evidence\": \"Tau-nY29 detects soluble tau and paired helical filament tau from severely affected Alzheimer's brain but fails to recognize tau from normal aged brain. This observation suggests that nitration at Tyr29 is a disease-related event that may alter the intrinsic ability of tau to self-polymerize. In Alzheimer's brain, Tau-nY29 labels the fibrillar triad of tau lesions, including neurofibrillary tangles, neuritic plaques, and, to a lesser extent, neuropil threads. Intriguingly, although Tau-nY29 stains both the neuronal and glial tau pathology of Pick disease, it detects only the neuronal pathology in corticobasal degeneration and progressive supranuclear palsy without labeling the predominant glial pathology.\", \"key\": \"89272b582582372b5ac7ff3bdcb4d4bae5f6da3bc6daf156b03f3fba4aee043e07fae281969d7a458d6684f54d6408e6af00513c91d578380ff828a459c5d4c5\", \"line\": 845, \"relation\": \"positiveCorrelation\", \"source\": 282, \"target\": 86}, {\"annotations\": {\"Disease\": {\"Alzheimer's disease\": true}}, \"citation\": {\"authors\": [\"Berry RW\", \"Bigio EH\", \"Binder LI\", \"Fu Y\", \"Guillozet-Bongaarts AL\", \"Reyes JF\", \"Reynolds MR\"], \"date\": \"2006-10-18\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"10636-45\", \"reference\": \"17050703\", \"title\": \"Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies.\", \"type\": \"PubMed\", \"volume\": \"26\"}, \"evidence\": \"Tau-nY29 detects soluble tau and paired helical filament tau from severely affected Alzheimer's brain but fails to recognize tau from normal aged brain. This observation suggests that nitration at Tyr29 is a disease-related event that may alter the intrinsic ability of tau to self-polymerize. In Alzheimer's brain, Tau-nY29 labels the fibrillar triad of tau lesions, including neurofibrillary tangles, neuritic plaques, and, to a lesser extent, neuropil threads. Intriguingly, although Tau-nY29 stains both the neuronal and glial tau pathology of Pick disease, it detects only the neuronal pathology in corticobasal degeneration and progressive supranuclear palsy without labeling the predominant glial pathology.\", \"key\": \"a6245dde0df148aa5a37e9ba37dc38d1c0e17cd5d3d1dc82bf8ab609a5f1ff4bb259a257ec3a897a12afe3051c838514439943cc2f8d6d478bdb9c833e020118\", \"line\": 846, \"relation\": \"partOf\", \"source\": 282, \"target\": 35}, {\"citation\": {\"authors\": [\"Berry RW\", \"Binder LI\", \"Lukas TJ\", \"Reynolds MR\"], \"date\": \"2006-04-04\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"Biochemistry\", \"pages\": \"4314-26\", \"reference\": \"16566606\", \"title\": \"Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.\", \"type\": \"PubMed\", \"volume\": \"45\"}, \"evidence\": \"Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.\", \"key\": \"7041afeea5424eee7a83db182fc1e9c83cc5b804739bab32407c0883a6381766915ae3c7131905ce2ef6802acb7bd759e377504818e8b2827632512f47224795\", \"line\": 921, \"relation\": \"positiveCorrelation\", \"source\": 282, \"target\": 56}, {\"citation\": {\"authors\": [\"Berry RW\", \"Binder LI\", \"Lukas TJ\", \"Reynolds MR\"], \"date\": \"2006-04-04\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"Biochemistry\", \"pages\": \"4314-26\", \"reference\": \"16566606\", \"title\": \"Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.\", \"type\": \"PubMed\", \"volume\": \"45\"}, \"evidence\": \"Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.\", \"key\": \"f768fdf8a3364181747379f852016dd8135101122255dea43112f223b86830fc228af76f4a378264c4c1e540b24425e171aaf9d98d296b6c9214e19f17fab5fb\", \"line\": 925, \"object\": {\"modifier\": \"Activity\"}, \"relation\": \"negativeCorrelation\", \"source\": 282, \"target\": 244}, {\"annotations\": {\"Disease\": {\"Alzheimer's disease\": true}}, \"citation\": {\"authors\": [\"Berry RW\", \"Bigio EH\", \"Binder LI\", \"Fu Y\", \"Guillozet-Bongaarts AL\", \"Reyes JF\", \"Reynolds MR\"], \"date\": \"2006-10-18\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"10636-45\", \"reference\": \"17050703\", \"title\": \"Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies.\", \"type\": \"PubMed\", \"volume\": \"26\"}, \"evidence\": \"Tau-nY29 detects soluble tau and paired helical filament tau from severely affected Alzheimer's brain but fails to recognize tau from normal aged brain. This observation suggests that nitration at Tyr29 is a disease-related event that may alter the intrinsic ability of tau to self-polymerize. In Alzheimer's brain, Tau-nY29 labels the fibrillar triad of tau lesions, including neurofibrillary tangles, neuritic plaques, and, to a lesser extent, neuropil threads. Intriguingly, although Tau-nY29 stains both the neuronal and glial tau pathology of Pick disease, it detects only the neuronal pathology in corticobasal degeneration and progressive supranuclear palsy without labeling the predominant glial pathology.\", \"key\": \"a99455abd4a1597ed5537d1143fc823baad89c8269ab921090641fce8d5d2539a49abe8783644c59cd2c13136c8f8555f8e11dffd5482d7837fa18f39397b398\", \"line\": 853, \"relation\": \"isA\", \"source\": 281, \"target\": 279}, {\"annotations\": {\"Tau_Antibody\": {\"9G3\": true, \"Tau-12\": true, \"Tau-13\": true, \"pY18\": true}}, \"citation\": {\"authors\": [\"Berry RW\", \"Binder LI\", \"Lukas TJ\", \"Reynolds MR\"], \"date\": \"2006-04-04\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"Biochemistry\", \"pages\": \"4314-26\", \"reference\": \"16566606\", \"title\": \"Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.\", \"type\": \"PubMed\", \"volume\": \"45\"}, \"evidence\": \"Further, select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation [Reynolds et al. (2005) Biochemistry 44, 13997-14009], inhibits the ability of monomeric tau to promote tubulin assembly.\", \"key\": \"e5816fb96c70ea0d6e9dfa48d7d80651adc36e44d5acd3dd813c2cea775180501b7efa0689764d9240f1cb7d0aeda4b41a4de81a776c0ebbb8f11880c3eaeeaf\", \"line\": 207, \"relation\": \"decreases\", \"source\": 281, \"target\": 92}, {\"annotations\": {\"Anatomy\": {\"neuropil\": true}, \"Disease\": {\"progressive supranuclear palsy\": true}, \"HBP_Disease\": {\"Corticobasal Degeneration\": true}}, \"citation\": {\"authors\": [\"Binder LI\", \"Geula C\", \"Reyes JF\", \"Vana L\"], \"date\": \"2012-01-01\", \"first\": \"Reyes JF\", \"last\": \"Binder LI\", \"name\": \"Acta neuropathologica\", \"pages\": \"119-32\", \"reference\": \"22057784\", \"title\": \"Selective tau tyrosine nitration in non-AD tauopathies.\", \"type\": \"PubMed\", \"volume\": \"123\"}, \"evidence\": \"Tau-nY18 did not label the classical pathological lesions of CBD or PSP but did label the neuronal lesions associated with PiD. Tau-nY29 revealed some, but not all classes of tau inclusions associated with both CBD and PSP but did label numerous Pick body inclusions in PiD. Tau-nY197 was restricted to the neuropil threads in both CBD and PSP; however, similar to Tau-nY29, extensive Pick body pathology was clearly labeled. Tau-nY394 did not detect any of the lesions associated with these disorders.\", \"key\": \"6640ce46438bf2c93d1a32c4e01a85d861d0074c730ece2bfdcf4b3ce4cc037132d867e4bd0f67e47294d38e877a13c252a65ba9f7acaf89f27b5374c40c8ea6\", \"line\": 825, \"relation\": \"partOf\", \"source\": 281, \"target\": 68}, {\"citation\": {\"authors\": [\"Berry RW\", \"Binder LI\", \"Lukas TJ\", \"Reynolds MR\"], \"date\": \"2006-04-04\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"Biochemistry\", \"pages\": \"4314-26\", \"reference\": \"16566606\", \"title\": \"Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.\", \"type\": \"PubMed\", \"volume\": \"45\"}, \"evidence\": \"Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.\", \"key\": \"b58b9e4b904db062d88720ca57e7cfc3e953ce103dd2cafebe7818e0f2a2d33b79fbb42dde4acfa5b746be544c40f99f3df84911288c9793f74e8d852f71759f\", \"line\": 922, \"relation\": \"positiveCorrelation\", \"source\": 281, \"target\": 56}, {\"citation\": {\"authors\": [\"Berry RW\", \"Binder LI\", \"Lukas TJ\", \"Reynolds MR\"], \"date\": \"2006-04-04\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"Biochemistry\", \"pages\": \"4314-26\", \"reference\": \"16566606\", \"title\": \"Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.\", \"type\": \"PubMed\", \"volume\": \"45\"}, \"evidence\": \"Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.\", \"key\": \"4e16f293f3b06f43e51885c62e26c438e34c06b95b3394bf8f821a18cf3361d97a906c8cfe05cf277be7f715474c29db1cf03a489fc8b2f50d0806c4a1452340\", \"line\": 926, \"object\": {\"modifier\": \"Activity\"}, \"relation\": \"negativeCorrelation\", \"source\": 281, \"target\": 244}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"The nitration of these Tyr residues alters the conformation of tau, reduces its binding to microtubules and, depending on the nitration sites, can promote or inhibit aggregation\", \"key\": \"4bb152de6a1a7a2a8da4a1b131a0cb702498b4c3826eddf3605d41b930c35f6d927a55ff86b281afdcced7c1896a93f5ab1130c8d4d4d135d444207a0f232d2a\", \"line\": 348, \"relation\": \"decreases\", \"source\": 283, \"target\": 111}, {\"annotations\": {\"Tau_Antibody\": {\"9G3\": true, \"Tau-12\": true, \"Tau-13\": true, \"pY18\": true}}, \"citation\": {\"authors\": [\"Berry RW\", \"Binder LI\", \"Lukas TJ\", \"Reynolds MR\"], \"date\": \"2006-04-04\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"Biochemistry\", \"pages\": \"4314-26\", \"reference\": \"16566606\", \"title\": \"Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.\", \"type\": \"PubMed\", \"volume\": \"45\"}, \"evidence\": \"Further, select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation [Reynolds et al. (2005) Biochemistry 44, 13997-14009], inhibits the ability of monomeric tau to promote tubulin assembly.\", \"key\": \"b1db221de8f98f39c5201bd24b7adbf394534546fad60553adbfbe426ca292a3718801b3c645515ce6cb4d6dba209f218bbfbefc653f2066ce2d6034c0274f4a\", \"line\": 208, \"relation\": \"decreases\", \"source\": 283, \"target\": 92}, {\"citation\": {\"authors\": [\"Berry RW\", \"Binder LI\", \"Lukas TJ\", \"Reynolds MR\"], \"date\": \"2006-04-04\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"Biochemistry\", \"pages\": \"4314-26\", \"reference\": \"16566606\", \"title\": \"Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.\", \"type\": \"PubMed\", \"volume\": \"45\"}, \"evidence\": \"Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.\", \"key\": \"f625dbbd91dd27ecce84c743830bbb84f9a5b4096257f02b248d67c47b72ec1d163bbfc9b881e72944b5803c7a0af667f17b74e657c137d08baa0882dc167eaa\", \"line\": 923, \"relation\": \"positiveCorrelation\", \"source\": 283, \"target\": 56}, {\"citation\": {\"authors\": [\"Berry RW\", \"Binder LI\", \"Lukas TJ\", \"Reynolds MR\"], \"date\": \"2006-04-04\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"Biochemistry\", \"pages\": \"4314-26\", \"reference\": \"16566606\", \"title\": \"Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.\", \"type\": \"PubMed\", \"volume\": \"45\"}, \"evidence\": \"Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.\", \"key\": \"b04e0bd96f54d673523593a02b39183c1abaac54fbe89808579eae71f36bb14a7ae71d354d45f4022b83e4ffd0ea38d7e8827c9c2681d5cafb24041637df7aed\", \"line\": 927, \"object\": {\"modifier\": \"Activity\"}, \"relation\": \"negativeCorrelation\", \"source\": 283, \"target\": 244}, {\"citation\": {\"authors\": [\"Berry RW\", \"Binder LI\", \"Lukas TJ\", \"Reynolds MR\"], \"date\": \"2006-04-04\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"Biochemistry\", \"pages\": \"4314-26\", \"reference\": \"16566606\", \"title\": \"Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.\", \"type\": \"PubMed\", \"volume\": \"45\"}, \"evidence\": \"Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.\", \"key\": \"469248073c9e6dec273cf73c33da1eeaae50bc17b04b9309be2a135c8893355151011439077c53cc74c6f1e6433a13bba692f2937f295f84f0b4e217581dadde\", \"line\": 923, \"relation\": \"positiveCorrelation\", \"source\": 56, \"target\": 283}, {\"citation\": {\"authors\": [\"Berry RW\", \"Binder LI\", \"Lukas TJ\", \"Reynolds MR\"], \"date\": \"2006-04-04\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"Biochemistry\", \"pages\": \"4314-26\", \"reference\": \"16566606\", \"title\": \"Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.\", \"type\": \"PubMed\", \"volume\": \"45\"}, \"evidence\": \"Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.\", \"key\": \"dd830ffeacbcfab4fd4973197bd3b71c5037f612306121e0fef890ab34b792bad06c33cac3572cef431dfc8c21e005d6a862f81ca5910dbf8c690f740d861705\", \"line\": 921, \"relation\": \"positiveCorrelation\", \"source\": 56, \"target\": 282}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"The phosphorylation of tau at Tyr394 and Tyr18 is present in PHFs in the brains of individuals with AD.\", \"key\": \"8277bf313bbe1d0d5c1c2cc52320339c6c9f38ee0cda6556768215eefdf97585073a18d99b190c4b7f4b11de15c28490889535667eb8581b5bc0f61d2ac115c5\", \"line\": 181, \"relation\": \"association\", \"source\": 56, \"target\": 318}, {\"citation\": {\"authors\": [\"Berry RW\", \"Binder LI\", \"Lukas TJ\", \"Reynolds MR\"], \"date\": \"2006-04-04\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"Biochemistry\", \"pages\": \"4314-26\", \"reference\": \"16566606\", \"title\": \"Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.\", \"type\": \"PubMed\", \"volume\": \"45\"}, \"evidence\": \"Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.\", \"key\": \"399fe5e756e4d08847f337abb5ed4911291c4878f043ed8f1e130ef1bcc6882cde293beb9da73f9f0bbed7a27a0399f7535564a4e2d595454e605ca414b565a8\", \"line\": 922, \"relation\": \"positiveCorrelation\", \"source\": 56, \"target\": 281}, {\"citation\": {\"authors\": [\"Berry RW\", \"Binder LI\", \"Lukas TJ\", \"Reynolds MR\"], \"date\": \"2006-04-04\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"Biochemistry\", \"pages\": \"4314-26\", \"reference\": \"16566606\", \"title\": \"Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.\", \"type\": \"PubMed\", \"volume\": \"45\"}, \"evidence\": \"Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.\", \"key\": \"6e2b5369717c8f28489cdf71fbe551d1b2f2778589820fc6e282577fb3c2f9230feea873ac0186cd4e3bf38fe2eadd4e40cd9046e2e2db723bc823dbbd801553\", \"line\": 920, \"relation\": \"positiveCorrelation\", \"source\": 56, \"target\": 280}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"The phosphorylation of tau at Tyr394 and Tyr18 is present in PHFs in the brains of individuals with AD.\", \"key\": \"41afe546cb492ed2c1cc9d6e62ff053690d47ba1ca8b42169be699db964284d33a98bfb76b6a42f3b3cb15e8937e22f4019a76aba9db25a081891f76f9c96352\", \"line\": 183, \"relation\": \"association\", \"source\": 56, \"target\": 321}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Tau can be acetylated by the P300 acetyltransferase or by CREB-binding protein at several Lys residues in the flanking region or the repeat domain, and deacetylated at these sites by sirtuin 1 (SIRT1) and histone deacetylase 6 (HDAC6), respectively\", \"key\": \"711d67f3a90715233740afc8451b416dd14458374e2c27af6ee0f665c08eb781764d701d94b395bcf1f392390bfa73bf2b9fd98a096a80ec0d70fae8235e143e\", \"line\": 253, \"relation\": \"decreases\", \"source\": 361, \"target\": 248}, {\"citation\": {\"authors\": [\"Cho SH\", \"Cole PA\", \"Gan L\", \"Haroutunian V\", \"Huang EJ\", \"Masliah E\", \"Meyers D\", \"Min SW\", \"Mukherjee C\", \"Ott M\", \"Schroeder S\", \"Seeley WW\", \"Shen Y\", \"Zhou Y\"], \"date\": \"2010-09-23\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"Neuron\", \"pages\": \"953-66\", \"reference\": \"20869593\", \"title\": \"Acetylation of tau inhibits its degradation and contributes to tauopathy.\", \"type\": \"PubMed\", \"volume\": \"67\"}, \"evidence\": \"Thus, the increase in ac-tau induced by SIRT1 deficiency is accompanied by accumulation of pathogenic p-tau in primary neurons. In mouse brains, deleting SIRT1, which elevated ac-tau, also increased AT8-positive p-tau.\", \"key\": \"544c071ddf1852f5300bd1e8b980d2ccf40dc350be3b9defd649e6e45ff5437ba6c13067c88085009b08acb9c12ea2ac4aa24d60a0bf044623a2bfdf8804b957\", \"line\": 3319, \"relation\": \"negativeCorrelation\", \"source\": 361, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 247}, {\"annotations\": {\"Anatomy\": {\"hippocampal formation\": true}, \"Research_Model\": {\"P301S mice\": true}, \"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Devidze N\", \"Gan L\", \"Gestwicki JE\", \"Johnson JR\", \"Krogan NJ\", \"Li Y\", \"Masliah E\", \"Min SW\", \"Mok SA\", \"Sohn PD\"], \"date\": \"2018-04-11\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"3680-3688\", \"reference\": \"29540553\", \"title\": \"SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.\", \"type\": \"PubMed\", \"volume\": \"38\"}, \"evidence\": \"SIRT1 deficiency exacerbates premature mortality, synapse loss, and behavioral disinhibition in tauP301S TG mice of both sexes. SIRT1 overexpression into the hippocampus reduces acetylated K174 tau and significantly attenuates the spread of tau pathology into anatomically connected brain regions of tauP301S transgenic mice of both sexes.\", \"key\": \"f23835a2d600115d98a7002aa20bf2f172f2472e63297b338c02657d7d9b44d5a73b1bc2cd0877f06437f943898d963def8c74b610fdbd0c0540913adc3d5f44\", \"line\": 3332, \"relation\": \"negativeCorrelation\", \"source\": 361, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 250}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Tau can be acetylated by the P300 acetyltransferase or by CREB-binding protein at several Lys residues in the flanking region or the repeat domain, and deacetylated at these sites by sirtuin 1 (SIRT1) and histone deacetylase 6 (HDAC6), respectively\", \"key\": \"4312393317f3da2610b56edeec42cd478c6f42a444d575c7b5bde708aa1cb5e32fc9a68ffebf135a2488147d838a2bcb231746b4050e92d1689ccdf8306df8bf\", \"line\": 252, \"relation\": \"increases\", \"source\": 222, \"target\": 248}, {\"annotations\": {\"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Acton PJ\", \"Bigio EH\", \"Chen-Dodson E\", \"De Felice FG\", \"Fernandez SJ\", \"Jerecic J\", \"Kinney GG\", \"Klein WL\", \"Lacor PN\", \"Lambert MP\", \"Shughrue PJ\", \"Velasco PT\", \"Wu D\"], \"date\": \"2008-09-01\", \"first\": \"De Felice FG\", \"last\": \"Klein WL\", \"name\": \"Neurobiology of aging\", \"pages\": \"1334-47\", \"reference\": \"17403556\", \"title\": \"Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"29\"}, \"evidence\": \"Verification of the findings from immunofluorescence microscopy was provided by Western blot analysis of hippocampal neuronal lysates with P404, P231 and P181 antiphosphotau antibodies. A 4 h exposure to 500nM ADDLs resulted in a significant increase in tau phosphorylated at the three epitopes, to levels similar to those observed after exposure to 10 \\u0003M Abeta fibrils (Fig. 4AD).\", \"key\": \"a53269b73f212b1f730d967ef62be2db16511891c1479b236a625e6d2f648155a085ec5a5ae796e9eceb4de46fb1687edf6080ea2d239c9db056ccc53c536aba\", \"line\": 190, \"relation\": \"increases\", \"source\": 50, \"target\": 311}, {\"annotations\": {\"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Acton PJ\", \"Bigio EH\", \"Chen-Dodson E\", \"De Felice FG\", \"Fernandez SJ\", \"Jerecic J\", \"Kinney GG\", \"Klein WL\", \"Lacor PN\", \"Lambert MP\", \"Shughrue PJ\", \"Velasco PT\", \"Wu D\"], \"date\": \"2008-09-01\", \"first\": \"De Felice FG\", \"last\": \"Klein WL\", \"name\": \"Neurobiology of aging\", \"pages\": \"1334-47\", \"reference\": \"17403556\", \"title\": \"Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"29\"}, \"evidence\": \"Following exposure to ADDLs, double-label immunofluorescence microscopy showed high levels of tau phosphorylated at Thr231, which discriminates among AD and non-AD subjects and patients with other forms of dementia (Hampel et al., 2004, 2003), in neurons with prominent dendritic ADDL binding (detected with NU1, Fig. 2KM). ADDL binding to synaptic hot-spots in hippocampal neurons is evident in images at highermagnification (60objective, PanelsLand M).\", \"key\": \"bf0981345576e41154409d42cd8cfd44fc4184379a66b25f7fbb1cda08cdf69b3617b6b024c1d454ffdf4831e2453a6070a4cfd82a5c5b669d502bf8d3647a28\", \"line\": 127, \"relation\": \"increases\", \"source\": 50, \"target\": 315}, {\"annotations\": {\"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Acton PJ\", \"Bigio EH\", \"Chen-Dodson E\", \"De Felice FG\", \"Fernandez SJ\", \"Jerecic J\", \"Kinney GG\", \"Klein WL\", \"Lacor PN\", \"Lambert MP\", \"Shughrue PJ\", \"Velasco PT\", \"Wu D\"], \"date\": \"2008-09-01\", \"first\": \"De Felice FG\", \"last\": \"Klein WL\", \"name\": \"Neurobiology of aging\", \"pages\": \"1334-47\", \"reference\": \"17403556\", \"title\": \"Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"29\"}, \"evidence\": \"Vehicle-treated neurons (Fig. 3A and E) exhibited very low phosphotau immunofluorescence, but neurons treated for 4 h with 500nM ADDLs showed significantly higher levels in immunofluorescence of P-Ser404 and P-Thr231 tau (Fig. 3B and F, respectively). Neurons treated for 4 h with 10\\u0003M Abeta fibrils also showed an increase in immunofluorescence of P-Ser404 and P-Thr231 tau (Fig. 3C and G, respectively).\", \"key\": \"0f18a1df583638d89f5ff6f7c85b29127d600789b3ed6f6d8f5f508aba63ec5a79779c43275e713efa62469db1b572be549069558f19efc8e0374f3604e8a498\", \"line\": 154, \"relation\": \"increases\", \"source\": 50, \"target\": 315}, {\"annotations\": {\"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Acton PJ\", \"Bigio EH\", \"Chen-Dodson E\", \"De Felice FG\", \"Fernandez SJ\", \"Jerecic J\", \"Kinney GG\", \"Klein WL\", \"Lacor PN\", \"Lambert MP\", \"Shughrue PJ\", \"Velasco PT\", \"Wu D\"], \"date\": \"2008-09-01\", \"first\": \"De Felice FG\", \"last\": \"Klein WL\", \"name\": \"Neurobiology of aging\", \"pages\": \"1334-47\", \"reference\": \"17403556\", \"title\": \"Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"29\"}, \"evidence\": \"Verification of the findings from immunofluorescence microscopy was provided by Western blot analysis of hippocampal neuronal lysates with P404, P231 and P181 antiphosphotau antibodies. A 4 h exposure to 500nM ADDLs resulted in a significant increase in tau phosphorylated at the three epitopes, to levels similar to those observed after exposure to 10 \\u0003M Abeta fibrils (Fig. 4AD).\", \"key\": \"91054ea23c9c265fd7ab636a81d0ee4a475ccca92b389d51f0b2f28d838abd26838ddaa1805ae198cd0cfb45b5e80fd34a1a8af104139bce9854496960d30a80\", \"line\": 188, \"relation\": \"increases\", \"source\": 50, \"target\": 315}, {\"annotations\": {\"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Acton PJ\", \"Bigio EH\", \"Chen-Dodson E\", \"De Felice FG\", \"Fernandez SJ\", \"Jerecic J\", \"Kinney GG\", \"Klein WL\", \"Lacor PN\", \"Lambert MP\", \"Shughrue PJ\", \"Velasco PT\", \"Wu D\"], \"date\": \"2008-09-01\", \"first\": \"De Felice FG\", \"last\": \"Klein WL\", \"name\": \"Neurobiology of aging\", \"pages\": \"1334-47\", \"reference\": \"17403556\", \"title\": \"Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"29\"}, \"evidence\": \"While vehicle treated cells (Fig. 2A and B) exhibited low phosphotau immunofluorescence, cells treated with 1 microM biotinylated ADDLs (bADDLs) for 6 h (Fig. 2C and D) showed a significant increase in P-tau immunofluorescence (Fig. 2D).\", \"key\": \"27550a8bbd22585883ad46d3b1ab603e9546a1f5dbff8c510112dd47ce57b4ff05d4b0238b1eac406d61361e9f34d5c7d625fa8f15c238b04bebf31708f9c697\", \"line\": 97, \"relation\": \"increases\", \"source\": 50, \"target\": 286}, {\"annotations\": {\"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Acton PJ\", \"Bigio EH\", \"Chen-Dodson E\", \"De Felice FG\", \"Fernandez SJ\", \"Jerecic J\", \"Kinney GG\", \"Klein WL\", \"Lacor PN\", \"Lambert MP\", \"Shughrue PJ\", \"Velasco PT\", \"Wu D\"], \"date\": \"2008-09-01\", \"first\": \"De Felice FG\", \"last\": \"Klein WL\", \"name\": \"Neurobiology of aging\", \"pages\": \"1334-47\", \"reference\": \"17403556\", \"title\": \"Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"29\"}, \"evidence\": \"Vehicle-treated neurons (Fig. 3A and E) exhibited very low phosphotau immunofluorescence, but neurons treated for 4 h with 500nM ADDLs showed significantly higher levels in immunofluorescence of P-Ser404 and P-Thr231 tau (Fig. 3B and F, respectively). Neurons treated for 4 h with 10\\u0003M Abeta fibrils also showed an increase in immunofluorescence of P-Ser404 and P-Thr231 tau (Fig. 3C and G, respectively).\", \"key\": \"695fdc419674b27587af742857a27d2c3c2c85e249aa1660c0c84e9c69c4af10f5330b09be650bf625549b69614a81d8659ae05d3446e867b9fdb747a5703122\", \"line\": 155, \"relation\": \"increases\", \"source\": 50, \"target\": 306}, {\"annotations\": {\"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Acton PJ\", \"Bigio EH\", \"Chen-Dodson E\", \"De Felice FG\", \"Fernandez SJ\", \"Jerecic J\", \"Kinney GG\", \"Klein WL\", \"Lacor PN\", \"Lambert MP\", \"Shughrue PJ\", \"Velasco PT\", \"Wu D\"], \"date\": \"2008-09-01\", \"first\": \"De Felice FG\", \"last\": \"Klein WL\", \"name\": \"Neurobiology of aging\", \"pages\": \"1334-47\", \"reference\": \"17403556\", \"title\": \"Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"29\"}, \"evidence\": \"Verification of the findings from immunofluorescence microscopy was provided by Western blot analysis of hippocampal neuronal lysates with P404, P231 and P181 antiphosphotau antibodies. A 4 h exposure to 500nM ADDLs resulted in a significant increase in tau phosphorylated at the three epitopes, to levels similar to those observed after exposure to 10 \\u0003M Abeta fibrils (Fig. 4AD).\", \"key\": \"a9d7f4f0fa0bd522c0d3ec991f4bcedaf82529386b97eb60b09c846e4f3414712a829547554b6946a298681180c37574a46ec63bd933a65f6834cbce83f9246c\", \"line\": 189, \"relation\": \"increases\", \"source\": 50, \"target\": 306}, {\"annotations\": {\"Confidence\": {\"High\": true}, \"MeSHAnatomy\": {\"Cerebrospinal Fluid\": true}, \"MeSHDisease\": {\"Alzheimer Disease\": true}, \"PublicationType\": {\"Review\": true}}, \"citation\": {\"authors\": [\"Castillo-Carranza DL\", \"Guerrero-Muoz MJ\", \"Shafiei SS\"], \"date\": \"2017-01-01\", \"first\": \"Shafiei SS\", \"last\": \"Castillo-Carranza DL\", \"name\": \"Frontiers in aging neuroscience\", \"pages\": \"83\", \"reference\": \"28420982\", \"title\": \"Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage.\", \"type\": \"PubMed\", \"volume\": \"9\"}, \"evidence\": \"In support, tau associated with exosomes and phosphorylated at Thr-181 (AT270+ tau) has been identified in human CSF samples of AD patients\", \"key\": \"61a268a152e8a38986e983af56da2e4e4459746a1071d8740a1069e740da760ad85a63936ffa41b84263096247246d3e7c1fc2411629b67725114c95a3ae2e4c\", \"line\": 264, \"relation\": \"association\", \"source\": 311, \"target\": 71}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"ebb0e638d191a5340a58a02bed9f63b150f1dfbf88b3404bdc0fc881d34af4015041d6d698895efd2467859f4376e7727a4e92fa7f8940678a294637145c6fdd\", \"line\": 1121, \"relation\": \"positiveCorrelation\", \"source\": 311, \"target\": 164}, {\"annotations\": {\"Enzyme_Acitvity\": {\"1 U/ml\": true}}, \"citation\": {\"authors\": [\"Bue-Scherrer V\", \"Goedert M\"], \"date\": \"2002-03-27\", \"first\": \"Bue-Scherrer V\", \"last\": \"Goedert M\", \"name\": \"FEBS letters\", \"pages\": \"151-4\", \"reference\": \"11943212\", \"title\": \"Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.\", \"type\": \"PubMed\", \"volume\": \"515\"}, \"evidence\": \"All five SAP kinases generated the AT270 epitope, indicative of phosphorylation of T181 in tau.\", \"key\": \"45cd108e2b8d6e8d3594de5c74b8dbdf274265f38696f522cccaa24d16f778962d3a383d09f23149e65c3963d7142850bddf1f903b74412cf5ddd0d6236d8119\", \"line\": 1508, \"relation\": \"partOf\", \"source\": 311, \"target\": 186}, {\"citation\": {\"authors\": [\"Cavallaro RA\", \"Ciraci V\", \"Ferrer I\", \"Fuso A\", \"Nicolia V\", \"Scarpa S\"], \"date\": \"2017-01-01\", \"first\": \"Nicolia V\", \"last\": \"Fuso A\", \"name\": \"Current Alzheimer research\", \"pages\": \"753-759\", \"reference\": \"28176663\", \"title\": \"GSK3 5'-flanking DNA Methylation and Expression in Alzheimer's Disease Patients.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \"Here, we show for the first time that the administration of D-ribose, the most active glycator among monosaccharides, produces high levels of advanced glycation end products (AGEs) and, importantly, triggers hyperphosphorylation of Tau in the brain of C57BL/6 mouse and neuroblastoma N2a cells.\", \"key\": \"16da206b51775b8652fadd993d9dbaf952071c38ba9bfa01024155d0180133c5dbaa81cddaff3ee7a78ab754b6714c3abfc64f387ff749a2be0738d37e9e8b9e\", \"line\": 2291, \"relation\": \"positiveCorrelation\", \"source\": 311, \"target\": 3}, {\"annotations\": {\"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Acton PJ\", \"Bigio EH\", \"Chen-Dodson E\", \"De Felice FG\", \"Fernandez SJ\", \"Jerecic J\", \"Kinney GG\", \"Klein WL\", \"Lacor PN\", \"Lambert MP\", \"Shughrue PJ\", \"Velasco PT\", \"Wu D\"], \"date\": \"2008-09-01\", \"first\": \"De Felice FG\", \"last\": \"Klein WL\", \"name\": \"Neurobiology of aging\", \"pages\": \"1334-47\", \"reference\": \"17403556\", \"title\": \"Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"29\"}, \"evidence\": \"Verification of the findings from immunofluorescence microscopy was provided by Western blot analysis of hippocampal neuronal lysates with P404, P231 and P181 antiphosphotau antibodies. A 4 h exposure to 500nM ADDLs resulted in a significant increase in tau phosphorylated at the three epitopes, to levels similar to those observed after exposure to 10 \\u0003M Abeta fibrils (Fig. 4AD).\", \"key\": \"607c099b2577079b5723f06b4533fb6357e2d3466a48256caf9e0227bd82317b0a19b355b4956be0bd6e0b58532cb7249aa936e486f28f3ec3a803e81988fef3\", \"line\": 193, \"relation\": \"increases\", \"source\": 51, \"target\": 311}, {\"annotations\": {\"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Acton PJ\", \"Bigio EH\", \"Chen-Dodson E\", \"De Felice FG\", \"Fernandez SJ\", \"Jerecic J\", \"Kinney GG\", \"Klein WL\", \"Lacor PN\", \"Lambert MP\", \"Shughrue PJ\", \"Velasco PT\", \"Wu D\"], \"date\": \"2008-09-01\", \"first\": \"De Felice FG\", \"last\": \"Klein WL\", \"name\": \"Neurobiology of aging\", \"pages\": \"1334-47\", \"reference\": \"17403556\", \"title\": \"Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"29\"}, \"evidence\": \"Vehicle-treated neurons (Fig. 3A and E) exhibited very low phosphotau immunofluorescence, but neurons treated for 4 h with 500nM ADDLs showed significantly higher levels in immunofluorescence of P-Ser404 and P-Thr231 tau (Fig. 3B and F, respectively). Neurons treated for 4 h with 10\\u0003M Abeta fibrils also showed an increase in immunofluorescence of P-Ser404 and P-Thr231 tau (Fig. 3C and G, respectively).\", \"key\": \"7d860ed464d603bc944230707787337fdd42371a23b3b3908b1bec51b70ebd1a536bb91617626c8d1a356c35a2d97952e7a095239e5490a0dabf2cfec0a0adef\", \"line\": 156, \"relation\": \"increases\", \"source\": 51, \"target\": 315}, {\"annotations\": {\"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Acton PJ\", \"Bigio EH\", \"Chen-Dodson E\", \"De Felice FG\", \"Fernandez SJ\", \"Jerecic J\", \"Kinney GG\", \"Klein WL\", \"Lacor PN\", \"Lambert MP\", \"Shughrue PJ\", \"Velasco PT\", \"Wu D\"], \"date\": \"2008-09-01\", \"first\": \"De Felice FG\", \"last\": \"Klein WL\", \"name\": \"Neurobiology of aging\", \"pages\": \"1334-47\", \"reference\": \"17403556\", \"title\": \"Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"29\"}, \"evidence\": \"Verification of the findings from immunofluorescence microscopy was provided by Western blot analysis of hippocampal neuronal lysates with P404, P231 and P181 antiphosphotau antibodies. A 4 h exposure to 500nM ADDLs resulted in a significant increase in tau phosphorylated at the three epitopes, to levels similar to those observed after exposure to 10 \\u0003M Abeta fibrils (Fig. 4AD).\", \"key\": \"a691f353a5d769f9a96b0a6a47a1d03d173d28c1aa68abdf8b1dc5d04370429fd95bc3c9e9877b1276edcbf72771b8d0e45fe4a1d103a8d344f6404ea72f129d\", \"line\": 191, \"relation\": \"increases\", \"source\": 51, \"target\": 315}, {\"annotations\": {\"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Acton PJ\", \"Bigio EH\", \"Chen-Dodson E\", \"De Felice FG\", \"Fernandez SJ\", \"Jerecic J\", \"Kinney GG\", \"Klein WL\", \"Lacor PN\", \"Lambert MP\", \"Shughrue PJ\", \"Velasco PT\", \"Wu D\"], \"date\": \"2008-09-01\", \"first\": \"De Felice FG\", \"last\": \"Klein WL\", \"name\": \"Neurobiology of aging\", \"pages\": \"1334-47\", \"reference\": \"17403556\", \"title\": \"Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"29\"}, \"evidence\": \"Hippocampal neurons exposed to Abeta fibrils rather than oligomers also showed elevated P-tau immunofluorescence (Fig. 2NP) However, although fibrils could be seen attached to neurons, they did not bind in the synaptic pattern observed for ADDLs (Fig. 2O and P).\", \"key\": \"e1a6ebe4b701ee0273d2384537c58f63458499f2730e5f6de505e026793225cd5472384301ac46ba59b23b35def551b0876102e9a2e4325c29080b4c16581708\", \"line\": 143, \"relation\": \"increases\", \"source\": 51, \"target\": 286}, {\"annotations\": {\"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Acton PJ\", \"Bigio EH\", \"Chen-Dodson E\", \"De Felice FG\", \"Fernandez SJ\", \"Jerecic J\", \"Kinney GG\", \"Klein WL\", \"Lacor PN\", \"Lambert MP\", \"Shughrue PJ\", \"Velasco PT\", \"Wu D\"], \"date\": \"2008-09-01\", \"first\": \"De Felice FG\", \"last\": \"Klein WL\", \"name\": \"Neurobiology of aging\", \"pages\": \"1334-47\", \"reference\": \"17403556\", \"title\": \"Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"29\"}, \"evidence\": \"Vehicle-treated neurons (Fig. 3A and E) exhibited very low phosphotau immunofluorescence, but neurons treated for 4 h with 500nM ADDLs showed significantly higher levels in immunofluorescence of P-Ser404 and P-Thr231 tau (Fig. 3B and F, respectively). Neurons treated for 4 h with 10\\u0003M Abeta fibrils also showed an increase in immunofluorescence of P-Ser404 and P-Thr231 tau (Fig. 3C and G, respectively).\", \"key\": \"dcd49f472ad3a2c296e43448b6f2aff1cb28c9d5ecca1e4dbbb9dab1401a10c9367055532352f08155620e7aee447c029f1cd253ccb02bae3bf7fc332b905132\", \"line\": 157, \"relation\": \"increases\", \"source\": 51, \"target\": 306}, {\"annotations\": {\"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Acton PJ\", \"Bigio EH\", \"Chen-Dodson E\", \"De Felice FG\", \"Fernandez SJ\", \"Jerecic J\", \"Kinney GG\", \"Klein WL\", \"Lacor PN\", \"Lambert MP\", \"Shughrue PJ\", \"Velasco PT\", \"Wu D\"], \"date\": \"2008-09-01\", \"first\": \"De Felice FG\", \"last\": \"Klein WL\", \"name\": \"Neurobiology of aging\", \"pages\": \"1334-47\", \"reference\": \"17403556\", \"title\": \"Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"29\"}, \"evidence\": \"Verification of the findings from immunofluorescence microscopy was provided by Western blot analysis of hippocampal neuronal lysates with P404, P231 and P181 antiphosphotau antibodies. A 4 h exposure to 500nM ADDLs resulted in a significant increase in tau phosphorylated at the three epitopes, to levels similar to those observed after exposure to 10 \\u0003M Abeta fibrils (Fig. 4AD).\", \"key\": \"b01efaccf7505dbc2b07e0b4b17c7838a12ef7500c633242bdd21711eae65f3b12d41067fb6624b7ae36de74f845e872e0bda2fbdec9d154bf3dac1ccdbab3ee\", \"line\": 192, \"relation\": \"increases\", \"source\": 51, \"target\": 306}, {\"annotations\": {\"Confidence\": {\"High\": true}, \"MeSHAnatomy\": {\"Cerebrospinal Fluid\": true}, \"MeSHDisease\": {\"Alzheimer Disease\": true}, \"PublicationType\": {\"Review\": true}}, \"citation\": {\"authors\": [\"Castillo-Carranza DL\", \"Guerrero-Muoz MJ\", \"Shafiei SS\"], \"date\": \"2017-01-01\", \"first\": \"Shafiei SS\", \"last\": \"Castillo-Carranza DL\", \"name\": \"Frontiers in aging neuroscience\", \"pages\": \"83\", \"reference\": \"28420982\", \"title\": \"Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage.\", \"type\": \"PubMed\", \"volume\": \"9\"}, \"evidence\": \"In support, tau associated with exosomes and phosphorylated at Thr-181 (AT270+ tau) has been identified in human CSF samples of AD patients\", \"key\": \"73ba1c4af614abc06b8446803e10765fe6a68f8670f27122ce078326d756b9aadfdccf7e4cc31a137dff16314d787739c7b9576373303928fb0e8a6d07c9f766\", \"line\": 264, \"relation\": \"association\", \"source\": 71, \"target\": 311}, {\"annotations\": {\"Cell_Line\": {\"SH-SY5Y\": true}, \"Method\": {\"Bradford Assay\": true, \"Fluorescence Microscopy\": true, \"Immunoblotting\": true, \"RT-PCR\": true}}, \"citation\": {\"authors\": [\"Furukawa A\", \"Koriyama Y\", \"Muramatsu M\", \"Takeuchi M\", \"Takino J\"], \"date\": \"2015-08-25\", \"first\": \"Koriyama Y\", \"last\": \"Takeuchi M\", \"name\": \"Scientific reports\", \"pages\": \"13313\", \"reference\": \"26304819\", \"title\": \"Glyceraldehyde caused Alzheimer's disease-like alterations in diagnostic marker levels in SH-SY5Y human neuroblastoma cells.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \"A 42 in the medium decreased in a GA dose-dependent manner (Fig. 3a). In contrast, GA significantly increased tau and its phosphorylated form, p-tauT181 (Fig. 3b,c) in the medium. In addition, VEGF (Fig. 3e) and TGF- (Fig. 3f), which are also AD biomarkers,  were increased when the concentration of GA added was greater than 0.7 mM.\", \"key\": \"a65a1d1ecc997eff875bfda6f92d795ecbe647e70517d5eb4809489e20b296014224c4001f87ba3f4da9f56060ad7e0b5df6f71d4736d4516ba1a9a23d83e289\", \"line\": 506, \"relation\": \"increases\", \"source\": 25, \"target\": 311}, {\"annotations\": {\"Enzyme_Acitvity\": {\"1 U/ml\": true}}, \"citation\": {\"authors\": [\"Bue-Scherrer V\", \"Goedert M\"], \"date\": \"2002-03-27\", \"first\": \"Bue-Scherrer V\", \"last\": \"Goedert M\", \"name\": \"FEBS letters\", \"pages\": \"151-4\", \"reference\": \"11943212\", \"title\": \"Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.\", \"type\": \"PubMed\", \"volume\": \"515\"}, \"evidence\": \"All five SAP kinases generated the AT270 epitope, indicative of phosphorylation of T181 in tau.\", \"key\": \"c3a27a8a5dce4447b1fb34503f8b3072f70b2919af7dfc88a1c18d7b13c0ad9ff7f15131e27f3d81aea7ef2bcd8552189f739c41c1a387f2b73fc61058dc37f2\", \"line\": 1506, \"relation\": \"increases\", \"source\": 242, \"target\": 311}, {\"annotations\": {\"Enzyme_Acitvity\": {\"1 U/ml\": true}}, \"citation\": {\"authors\": [\"Bue-Scherrer V\", \"Goedert M\"], \"date\": \"2002-03-27\", \"first\": \"Bue-Scherrer V\", \"last\": \"Goedert M\", \"name\": \"FEBS letters\", \"pages\": \"151-4\", \"reference\": \"11943212\", \"title\": \"Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.\", \"type\": \"PubMed\", \"volume\": \"515\"}, \"evidence\": \"All five SAP kinases generated the AT270 epitope, indicative of phosphorylation of T181 in tau.\", \"key\": \"6b4cc366d38a989515631339fc7c3ca84cf63651a05dd6e1f27899c9f946a2355dff3eeff995e087aa4417b1d2303910a828d6b0070bbf96bc3c31c660c03930\", \"line\": 1504, \"relation\": \"increases\", \"source\": 239, \"target\": 311}, {\"annotations\": {\"Enzyme_Acitvity\": {\"1 U/ml\": true}}, \"citation\": {\"authors\": [\"Bue-Scherrer V\", \"Goedert M\"], \"date\": \"2002-03-27\", \"first\": \"Bue-Scherrer V\", \"last\": \"Goedert M\", \"name\": \"FEBS letters\", \"pages\": \"151-4\", \"reference\": \"11943212\", \"title\": \"Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.\", \"type\": \"PubMed\", \"volume\": \"515\"}, \"evidence\": \"For AT8, which recognises phosphorylated S202 and T205 in tau, SAPK3/p38gamma gave the strongest labelling\", \"key\": \"9131e45be113d63b85fc7292dbd98e39b3d8079971ff61b03ff89b32868fa35dfcbb90a5f0f3f7144752abdc8136b0f9f48efabd7ae3ea5a31fab434f5cd5f36\", \"line\": 1512, \"relation\": \"increases\", \"source\": 239, \"target\": 312}, {\"annotations\": {\"Enzyme_Acitvity\": {\"1 U/ml\": true}}, \"citation\": {\"authors\": [\"Bue-Scherrer V\", \"Goedert M\"], \"date\": \"2002-03-27\", \"first\": \"Bue-Scherrer V\", \"last\": \"Goedert M\", \"name\": \"FEBS letters\", \"pages\": \"151-4\", \"reference\": \"11943212\", \"title\": \"Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.\", \"type\": \"PubMed\", \"volume\": \"515\"}, \"evidence\": \"Finally, phosphorylation of S422 in tau, as recognisedby antibody AP422, was generated most eciently by SAPK3/p38gamma, SAPK4/p38delta and SAPK2b/p38beta\", \"key\": \"9c2220eeb260a65c7e9cb6cbc10da895ff3aff40ad395c63c8cec65cca29577efa8d81376f255818715f07e1b161a498f8e1efc936175de41ae4ad23def6da5d\", \"line\": 1525, \"relation\": \"increases\", \"source\": 239, \"target\": 309}, {\"annotations\": {\"Enzyme_Acitvity\": {\"1 U/ml\": true}}, \"citation\": {\"authors\": [\"Bue-Scherrer V\", \"Goedert M\"], \"date\": \"2002-03-27\", \"first\": \"Bue-Scherrer V\", \"last\": \"Goedert M\", \"name\": \"FEBS letters\", \"pages\": \"151-4\", \"reference\": \"11943212\", \"title\": \"Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.\", \"type\": \"PubMed\", \"volume\": \"515\"}, \"evidence\": \"The AD2 epitope, which corresponds to phosphorylated S396 and S404 in tau, was generated most effectively by SAPK3/p38gamma and SAPK4/p38delta\", \"key\": \"cb95886d29a20b1ff589748f23c04bbf5fe807b7223b91a99317f8da715fa6cd8f1019afc6b37e3044fa7d27432bd280cb84adc9da7b23d7576acc32897d5627\", \"line\": 1516, \"relation\": \"increases\", \"source\": 239, \"target\": 316}, {\"annotations\": {\"Enzyme_Acitvity\": {\"1 U/ml\": true}}, \"citation\": {\"authors\": [\"Bue-Scherrer V\", \"Goedert M\"], \"date\": \"2002-03-27\", \"first\": \"Bue-Scherrer V\", \"last\": \"Goedert M\", \"name\": \"FEBS letters\", \"pages\": \"151-4\", \"reference\": \"11943212\", \"title\": \"Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.\", \"type\": \"PubMed\", \"volume\": \"515\"}, \"evidence\": \"For AT8, which recognises phosphorylated S202 and T205 in tau, SAPK3/p38gamma gave the strongest labelling\", \"key\": \"3166caa25bdfc6fbd3a3453eaae3f4fab7978ed12208b3328be49a6051e255358bdba4d3cd9a3dcca30ca41b821a4b4cadc1d1edeeb4957c000dfc9d2653ce96\", \"line\": 1513, \"relation\": \"increases\", \"source\": 239, \"target\": 290}, {\"annotations\": {\"Enzyme_Acitvity\": {\"1 U/ml\": true}}, \"citation\": {\"authors\": [\"Bue-Scherrer V\", \"Goedert M\"], \"date\": \"2002-03-27\", \"first\": \"Bue-Scherrer V\", \"last\": \"Goedert M\", \"name\": \"FEBS letters\", \"pages\": \"151-4\", \"reference\": \"11943212\", \"title\": \"Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.\", \"type\": \"PubMed\", \"volume\": \"515\"}, \"evidence\": \"The AD2 epitope, which corresponds to phosphorylated S396 and S404 in tau, was generated most effectively by SAPK3/p38gamma and SAPK4/p38delta\", \"key\": \"554c9658ce2cb3793af052048e055d18354638b26119d399672d897e8224059bbf3b0391ec674d676aa2b407091c39e58db567dff353169c41e3efd5b44fb488\", \"line\": 1517, \"relation\": \"increases\", \"source\": 239, \"target\": 306}, {\"annotations\": {\"Enzyme_Acitvity\": {\"1 U/ml\": true}}, \"citation\": {\"authors\": [\"Bue-Scherrer V\", \"Goedert M\"], \"date\": \"2002-03-27\", \"first\": \"Bue-Scherrer V\", \"last\": \"Goedert M\", \"name\": \"FEBS letters\", \"pages\": \"151-4\", \"reference\": \"11943212\", \"title\": \"Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.\", \"type\": \"PubMed\", \"volume\": \"515\"}, \"evidence\": \"All five SAP kinases generated the AT270 epitope, indicative of phosphorylation of T181 in tau.\", \"key\": \"a73ee3186ddd23e0225f55a237bf9e6f1a397f866c4d75984bd691355d71a3b44e0a0906bfadd3ecdb93a3f9688171210cd133dcdbfed0144724a4681cd6f44f\", \"line\": 1505, \"relation\": \"increases\", \"source\": 240, \"target\": 311}, {\"annotations\": {\"Enzyme_Acitvity\": {\"1 U/ml\": true}}, \"citation\": {\"authors\": [\"Bue-Scherrer V\", \"Goedert M\"], \"date\": \"2002-03-27\", \"first\": \"Bue-Scherrer V\", \"last\": \"Goedert M\", \"name\": \"FEBS letters\", \"pages\": \"151-4\", \"reference\": \"11943212\", \"title\": \"Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.\", \"type\": \"PubMed\", \"volume\": \"515\"}, \"evidence\": \"Finally, phosphorylation of S422 in tau, as recognisedby antibody AP422, was generated most eciently by SAPK3/p38gamma, SAPK4/p38delta and SAPK2b/p38beta\", \"key\": \"10370b563c0f86a01f9263da7d0b836dd373fc755fed7bd923a37a88bf5ad5132929ab5dedef47f74aee2d34ab3b595c0194c7fcc0abe4c05c39a1eb418ccac0\", \"line\": 1526, \"relation\": \"increases\", \"source\": 240, \"target\": 309}, {\"annotations\": {\"Enzyme_Acitvity\": {\"1 U/ml\": true}}, \"citation\": {\"authors\": [\"Bue-Scherrer V\", \"Goedert M\"], \"date\": \"2002-03-27\", \"first\": \"Bue-Scherrer V\", \"last\": \"Goedert M\", \"name\": \"FEBS letters\", \"pages\": \"151-4\", \"reference\": \"11943212\", \"title\": \"Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.\", \"type\": \"PubMed\", \"volume\": \"515\"}, \"evidence\": \"The AD2 epitope, which corresponds to phosphorylated S396 and S404 in tau, was generated most effectively by SAPK3/p38gamma and SAPK4/p38delta\", \"key\": \"9b5d4d89e1e8f08c5e3bf88a63fe3cf26c729afd5ea776c646a15377ce422874a0ff1c0c2fb1ffc7af2ce830fdfa979b9a16ba4560beea3984e167f341a9e69d\", \"line\": 1518, \"relation\": \"increases\", \"source\": 240, \"target\": 316}, {\"annotations\": {\"MeSHAnatomy\": {\"Cerebral Cortex\": true}}, \"citation\": {\"authors\": [\"Blair LJ\", \"Koren J 3rd\", \"Shelton LB\"], \"date\": \"2017-01-01\", \"first\": \"Shelton LB\", \"last\": \"Blair LJ\", \"name\": \"Frontiers in neuroscience\", \"pages\": \"724\", \"reference\": \"29311797\", \"title\": \"Imbalances in the Hsp90 Chaperone Machinery: Implications for Tauopathies.\", \"type\": \"PubMed\", \"volume\": \"11\"}, \"evidence\": \"Cdc37 is also required for the stable folding of protein kinases in coordination with Hsp90 (Calderwood, 2015). Many of these kinases are known to phosphorylate tau at sites associated with AD, such as GSK3 and MAPK13 (Taipale et al., 2012; Jin et al., 2016).\", \"key\": \"272711ec5f1a646f7b98ce48809a771644ca12c95efd7828c338bb80928599b77dfb03dd9a3353809ca00e05dca3dd950647e9ff5207ca634668d1e407ec0cea\", \"line\": 295, \"relation\": \"increases\", \"source\": 240, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 286}, {\"annotations\": {\"Enzyme_Acitvity\": {\"1 U/ml\": true}}, \"citation\": {\"authors\": [\"Bue-Scherrer V\", \"Goedert M\"], \"date\": \"2002-03-27\", \"first\": \"Bue-Scherrer V\", \"last\": \"Goedert M\", \"name\": \"FEBS letters\", \"pages\": \"151-4\", \"reference\": \"11943212\", \"title\": \"Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.\", \"type\": \"PubMed\", \"volume\": \"515\"}, \"evidence\": \"The AD2 epitope, which corresponds to phosphorylated S396 and S404 in tau, was generated most effectively by SAPK3/p38gamma and SAPK4/p38delta\", \"key\": \"ac8a1e6395b425d5fa24fb60066bea0b783e046cc6301b870ae598d11cc07bac118da045d947ef033cfd3da8033c2f4431fbfb88d846b24b86eddba1659e8011\", \"line\": 1519, \"relation\": \"increases\", \"source\": 240, \"target\": 306}, {\"annotations\": {\"Enzyme_Acitvity\": {\"1 U/ml\": true}}, \"citation\": {\"authors\": [\"Bue-Scherrer V\", \"Goedert M\"], \"date\": \"2002-03-27\", \"first\": \"Bue-Scherrer V\", \"last\": \"Goedert M\", \"name\": \"FEBS letters\", \"pages\": \"151-4\", \"reference\": \"11943212\", \"title\": \"Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.\", \"type\": \"PubMed\", \"volume\": \"515\"}, \"evidence\": \"All five SAP kinases generated the AT270 epitope, indicative of phosphorylation of T181 in tau.\", \"key\": \"08f31f7460094a3224bada0a1f09b9324a581dbd72b80bbcedbd5390e4979dc57b7154cf30b765e3bb59331030e09b125a1d3d433dbef84c54533f4a92720bad\", \"line\": 1503, \"relation\": \"increases\", \"source\": 238, \"target\": 311}, {\"annotations\": {\"Enzyme_Acitvity\": {\"1 U/ml\": true}}, \"citation\": {\"authors\": [\"Bue-Scherrer V\", \"Goedert M\"], \"date\": \"2002-03-27\", \"first\": \"Bue-Scherrer V\", \"last\": \"Goedert M\", \"name\": \"FEBS letters\", \"pages\": \"151-4\", \"reference\": \"11943212\", \"title\": \"Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.\", \"type\": \"PubMed\", \"volume\": \"515\"}, \"evidence\": \"Finally, phosphorylation of S422 in tau, as recognisedby antibody AP422, was generated most eciently by SAPK3/p38gamma, SAPK4/p38delta and SAPK2b/p38beta\", \"key\": \"0987d2dc91067267dd89ef62cdbafe88fe459fade6848cfe413d642fcbb53b31bd00c67faed44c68cd43ec816bc8080697d782c9d7c38f13c21d7495acd02034\", \"line\": 1527, \"relation\": \"increases\", \"source\": 238, \"target\": 309}, {\"annotations\": {\"Enzyme_Acitvity\": {\"1 U/ml\": true}}, \"citation\": {\"authors\": [\"Bue-Scherrer V\", \"Goedert M\"], \"date\": \"2002-03-27\", \"first\": \"Bue-Scherrer V\", \"last\": \"Goedert M\", \"name\": \"FEBS letters\", \"pages\": \"151-4\", \"reference\": \"11943212\", \"title\": \"Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.\", \"type\": \"PubMed\", \"volume\": \"515\"}, \"evidence\": \"All five SAP kinases generated the AT270 epitope, indicative of phosphorylation of T181 in tau.\", \"key\": \"e9158e7abaf9c0159cfd335fc9ce2fee4bcab6d68823013d972494b978402bba28e1d5d8d2dd067e768fff3a62bfbbc7e28cbe05ace9f7e83cada5f4694f463e\", \"line\": 1502, \"relation\": \"increases\", \"source\": 241, \"target\": 311}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Depending on the sites, the acetylation of tau could inhibit its degradation (for example, when at Lys163, Lys280, Lys281 or Lys369) or, by contrast, facilitate its degradation and suppress its phosphorylation and aggregation (for example, when at Lys259, Lys290, Lys321 or Lys353)\", \"key\": \"dfac284bb2ff57f3f8312c2573d285465e4da283687421fc9215affa9a36c280320acfadd16b6902f9eb46e5cfbb8d6ff2dc3ac780406b564af638795845dc30\", \"line\": 276, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 266, \"target\": 266}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Depending on the sites, the acetylation of tau could inhibit its degradation (for example, when at Lys163, Lys280, Lys281 or Lys369) or, by contrast, facilitate its degradation and suppress its phosphorylation and aggregation (for example, when at Lys259, Lys290, Lys321 or Lys353)\", \"key\": \"2696009d230d6c23c8a9e16bc5fab7ef256d7017534df039eb8a1346c7134802cf987fcbbcd3e186a25db3ce9e2cf8f7013dd121685d693b94d3ea8a13d159d9\", \"line\": 277, \"relation\": \"decreases\", \"source\": 266, \"target\": 286}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Depending on the sites, the acetylation of tau could inhibit its degradation (for example, when at Lys163, Lys280, Lys281 or Lys369) or, by contrast, facilitate its degradation and suppress its phosphorylation and aggregation (for example, when at Lys259, Lys290, Lys321 or Lys353)\", \"key\": \"e0274a228b32e4b7ff6599d89819efb664ce750a7b27bcfafb1f58f393e52e31bca39be0ea8de7f82f35924e216b4e23949082ae642262959bf68300d6ecd8e9\", \"line\": 278, \"relation\": \"decreases\", \"source\": 266, \"target\": 39}, {\"annotations\": {\"TextLocation\": {\"Review\": true}}, \"citation\": {\"authors\": [\"Chesser AS\", \"Johnson GV\", \"Pritchard SM\"], \"date\": \"2013-09-03\", \"first\": \"Chesser AS\", \"last\": \"Johnson GV\", \"name\": \"Frontiers in neurology\", \"pages\": \"122\", \"reference\": \"24027553\", \"title\": \"Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"4\"}, \"evidence\": \"Not surprisingly, if recombinant tau is incubated with isolated 20S proteasomal complexes, degradation occurs (65). In this system proteolysis is bidirectional. Also, if tau is first ubiquitylated in an in vitro reaction and then incubated with isolated 26S proteasomes supplemented with MgCl2 and ATP, degradation proceeds (66). These data indicate tau can be a substrate for both forms of the proteasome. \", \"key\": \"f2cd00569694e5b0430dc1c246bdeae44c3c5b3b66bfb44df112a1e0bdb33424cdbdc1f2df6e504163157a27a8ba96cbae3e2dceb7e9c5a280de23518a258d27\", \"line\": 603, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 197, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 323}, {\"annotations\": {\"TextLocation\": {\"Review\": true}}, \"citation\": {\"authors\": [\"Chesser AS\", \"Johnson GV\", \"Pritchard SM\"], \"date\": \"2013-09-03\", \"first\": \"Chesser AS\", \"last\": \"Johnson GV\", \"name\": \"Frontiers in neurology\", \"pages\": \"122\", \"reference\": \"24027553\", \"title\": \"Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"4\"}, \"evidence\": \"For example, if HEK cells are transfected with tau and ubiquitin, tau is readily ubiquitylated and degraded by the proteasome (66).\", \"key\": \"b71205706dbeb2d1bba31613a17e4867c50d4df1ed37aa11932b7970e3f8f2f2058031ceda6dd8a4d253e844ca86f9be4a170695e854f9b2ce023c5f0b142f86\", \"line\": 856, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 197, \"target\": 323}, {\"annotations\": {\"TextLocation\": {\"Review\": true}}, \"citation\": {\"authors\": [\"Chesser AS\", \"Johnson GV\", \"Pritchard SM\"], \"date\": \"2013-09-03\", \"first\": \"Chesser AS\", \"last\": \"Johnson GV\", \"name\": \"Frontiers in neurology\", \"pages\": \"122\", \"reference\": \"24027553\", \"title\": \"Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"4\"}, \"evidence\": \"In CHO cells overexpressing P301L mutant tau, treatment with the Hsp90 inhibitor geldanamycin led to a more pronounced proteasome-mediated reduction in tau phosphorylated at proline-directed S/T sites compared to total tau (67).\", \"key\": \"8e2bb36f0ca702a5988f0afec2ea15076f3e45681b87caddd90d7272426f573dacd54984d254106caa799290cb0517eba3fda7a9d54d8f29300c6e37681a5871\", \"line\": 894, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 197, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 286}, {\"annotations\": {\"Cell_Line\": {\"COS7\": true}, \"Method\": {\"Deglycosylation Assay\": true, \"Dephosphorylation Assay\": true, \"Immunoblotting\": true, \"Immunocytochemistry\": true, \"Phosphorylation Assay\": true, \"Pull-down Assay, His-tagged\": true, \"SDS-PAGE\": true, \"Ubiquitination Assay\": true}}, \"citation\": {\"authors\": [\"Gygi SP\", \"Kosik KS\", \"Schwartz D\", \"Shimura H\"], \"date\": \"2004-02-06\", \"first\": \"Shimura H\", \"last\": \"Kosik KS\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"4869-76\", \"reference\": \"14612456\", \"title\": \"CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival.\", \"type\": \"PubMed\", \"volume\": \"279\"}, \"evidence\": \"These data indicated that phosphorylation of PP2A dephosphorylation sites is an important recognition signal for ubiquitination. We used 200 g of amino-terminal His-tagged full-length recombinant human tau in an in vitro phosphorylation reaction with GSK-3Beta. When phosphorylated, the tau protein reacted on immunoblots with PHF1 (25, 26) and AT8 (24), indicating that at least sites Ser202, Thr205, Ser396, and Ser404 were phosphorylated. Following GSK-3Beta incubation, this tau served as an excellent substrate for in vitro ubiquitination using UbcH5B and the cofactor fraction from AD tau immunoprecipitates (Fig. 2a). This finding suggested that GSK-3Beta can place phosphates on tau that create recognition sites for an E3 Ub ligase.\", \"key\": \"48a67657a6a581f991525b65b63fa638bbec4221fa364af36fcc1762e4e6dff5e739662728add2877198e27bc8974ca8c43538611d4a9e4879f1f58af4c70631\", \"line\": 397, \"relation\": \"positiveCorrelation\", \"source\": 323, \"target\": 286}, {\"annotations\": {\"Method\": {\"Immunoblotting\": true, \"Mass Spectrometry\": true, \"RP HPLC\": true, \"SDS-PAGE\": true}}, \"citation\": {\"authors\": [\"Hasegawa M\", \"Ihara Y\", \"Morishima-Kawashima M\", \"Suzuki M\", \"Takio K\", \"Titani K\"], \"date\": \"1993-06-01\", \"first\": \"Morishima-Kawashima M\", \"last\": \"Ihara Y\", \"name\": \"Neuron\", \"pages\": \"1151-60\", \"reference\": \"8391280\", \"title\": \"Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments.\", \"type\": \"PubMed\", \"volume\": \"10\"}, \"evidence\": \"The ubiquitin-targeted protein was identified as tau in paired helical filaments, and the conjugation sites were localized to the microtubule-binding region.\", \"key\": \"8256bb83dbcbe30e37cad205c6de7b02da1a7f0afc107a51a9d51a67e2e22f818b9f2a384c97c34f933e299df86323c8f3624f9c6a4af234267eb86d90c7152c\", \"line\": 443, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 323, \"target\": 244}, {\"citation\": {\"authors\": [\"Feng Y\", \"Jiang J\", \"Liu XH\", \"Liu ZC\", \"Luo HB\", \"Shu XJ\", \"Wang JZ\", \"Wang XC\", \"Xia YY\", \"Xiong YS\", \"Ye K\", \"Yin G\", \"Yu G\", \"Zeng K\"], \"date\": \"2014-11-18\", \"first\": \"Luo HB\", \"last\": \"Wang JZ\", \"name\": \"Proceedings of the National Academy of Sciences of the United States of America\", \"pages\": \"16586-91\", \"reference\": \"25378699\", \"title\": \"SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination.\", \"type\": \"PubMed\", \"volume\": \"111\"}, \"evidence\": \"Furthermore, the enhanced SUMO-immunoreactivity, costained with the hyperphosphorylated tau, is detected in cerebral cortex of the AD brains, and -amyloid exposure of rat primary hippocampal neurons induces a dose-dependent SUMOylation of the hyperphosphorylated tau. Our findings suggest that tau SUMOylation reciprocally stimulates its phosphorylation and inhibits the ubiquitination-mediated tau degradation, which provides a new insight into the AD-like tau accumulation.\", \"key\": \"9e4d3c4bcd315653c697776c6f6eeab5de5da3d40f6297ed7de3ad458ed7b65e583f50f28f668aca75d005304ffa6de9f8dad48bddb315c935ed32f1cf27f4f9\", \"line\": 3487, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"positiveCorrelation\", \"source\": 323, \"target\": 244}, {\"citation\": {\"authors\": [\"Albrecht F\", \"Arendt T\", \"Arsalan-Werner A\", \"Flach K\", \"Goedert M\", \"Herrmann L\", \"Hilbrich I\", \"Holzer M\", \"Ramminger E\"], \"date\": \"2014-09-01\", \"first\": \"Flach K\", \"last\": \"Holzer M\", \"name\": \"Biochimica et biophysica acta\", \"pages\": \"1527-38\", \"reference\": \"24905733\", \"title\": \"Axotrophin/MARCH7 acts as an E3 ubiquitin ligase and ubiquitinates tau protein in vitro impairing microtubule binding.\", \"type\": \"PubMed\", \"volume\": \"1842\"}, \"evidence\": \"We show that axotrophin/MARCH7, a RING-variant domain containing protein with similarity to E3 ubiquitin ligases interacts with tau. We find here that tau becomes mono-ubiquitinated by recombinant tau-interacting RING-variant domain, which diminishes its microtubule-binding. Tau becomes mono-ubiquitinated by recombinant tau-interacting RING-variant domain reducing microtubule-binding.\", \"key\": \"e856eff13673c13b561a538ba6599f372fc27b64faac2957fd2e55761679d129a87502b4099bc308ee5f269a33d9a80984624881d2a08a480bc4d1c848d39fa9\", \"line\": 3513, \"object\": {\"modifier\": \"Activity\"}, \"relation\": \"negativeCorrelation\", \"source\": 323, \"target\": 244}, {\"annotations\": {\"Cell_Line\": {\"COS7\": true}, \"Method\": {\"Deglycosylation Assay\": true, \"Dephosphorylation Assay\": true, \"Immunoblotting\": true, \"Immunocytochemistry\": true, \"Phosphorylation Assay\": true, \"Pull-down Assay, His-tagged\": true, \"SDS-PAGE\": true, \"Ubiquitination Assay\": true}}, \"citation\": {\"authors\": [\"Gygi SP\", \"Kosik KS\", \"Schwartz D\", \"Shimura H\"], \"date\": \"2004-02-06\", \"first\": \"Shimura H\", \"last\": \"Kosik KS\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"4869-76\", \"reference\": \"14612456\", \"title\": \"CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival.\", \"type\": \"PubMed\", \"volume\": \"279\"}, \"evidence\": \"This result strongly suggested that the E2 conjugating enzyme for tau ubiquitination is UbcH5B.\", \"key\": \"490cb5c28797c79da84e9e0c978e5f9c81d41fd571d80236e1f61a8af2457899b423c01e45971d4533bbba0ee958a3e562186681c4b3a69b383cdcdc430b80ae\", \"line\": 378, \"relation\": \"positiveCorrelation\", \"source\": 323, \"target\": 376}, {\"annotations\": {\"TextLocation\": {\"Review\": true}}, \"citation\": {\"authors\": [\"Chesser AS\", \"Johnson GV\", \"Pritchard SM\"], \"date\": \"2013-09-03\", \"first\": \"Chesser AS\", \"last\": \"Johnson GV\", \"name\": \"Frontiers in neurology\", \"pages\": \"122\", \"reference\": \"24027553\", \"title\": \"Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"4\"}, \"evidence\": \"For example, if HEK cells are transfected with tau and ubiquitin, tau is readily ubiquitylated and degraded by the proteasome (66).\", \"key\": \"24b2bace4a8f72637b58e3d700f39874c15bc17cd92c14516283f644623a320e7df01a8d6af2274ff622224e81e3eb14f02a41f8d5768b25beac44a890c62f69\", \"line\": 855, \"relation\": \"increases\", \"source\": 147, \"target\": 323}, {\"key\": \"eee92426c540af02f98f2518d202fb15e6d219c17faff21ff1a45217a9568d93f9638a18764e7474b6d3691318756c4617dda8e40d6998d026d8037c0d4c93a7\", \"relation\": \"hasComponent\", \"source\": 126, \"target\": 323}, {\"annotations\": {\"Cell_Line\": {\"COS7\": true}, \"Method\": {\"Deglycosylation Assay\": true, \"Dephosphorylation Assay\": true, \"Immunoblotting\": true, \"Immunocytochemistry\": true, \"Phosphorylation Assay\": true, \"Pull-down Assay, His-tagged\": true, \"SDS-PAGE\": true, \"Ubiquitination Assay\": true}}, \"citation\": {\"authors\": [\"Gygi SP\", \"Kosik KS\", \"Schwartz D\", \"Shimura H\"], \"date\": \"2004-02-06\", \"first\": \"Shimura H\", \"last\": \"Kosik KS\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"4869-76\", \"reference\": \"14612456\", \"title\": \"CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival.\", \"type\": \"PubMed\", \"volume\": \"279\"}, \"evidence\": \"These data suggest a model by which phosphorylated tau is bound to a chaperone and the complex is recognized by the E3 Ub ligase CHIP. We further examined whether recombinant GST-CHIP ubiquitinates phosphorylated tau in vitro in the presence of UbcH5B and Hsc70. Ubiquitination of phosphorylated tau was detected as high molecular weight bands by immunoblotting with 5E2 in the presence of UbcH5B and Hsc70 (Fig. 2e).\", \"key\": \"43de0603d6885662d9b67393205724804152d075b9e579c21afb270e6af8eef6746e4522c84ed9cbe8edb660ccc6c907d97817ab0df35bed7be1c91fbd49f34b\", \"line\": 407, \"relation\": \"directlyIncreases\", \"source\": 140, \"target\": 323}, {\"key\": \"ccf586eab03e1ce2fa604e78823a8b515729caf8bac4d94ccf73c07be2e8d519d0a1af24adde8a303623bfdc3c08b6f640ca41f3e63bb7cdd8f2914e85a7945a\", \"relation\": \"hasComponent\", \"source\": 140, \"target\": 286}, {\"annotations\": {\"Method\": {\"Immunoblotting\": true, \"Mass Spectrometry\": true, \"RP HPLC\": true, \"SDS-PAGE\": true}}, \"citation\": {\"authors\": [\"Hasegawa M\", \"Ihara Y\", \"Morishima-Kawashima M\", \"Suzuki M\", \"Takio K\", \"Titani K\"], \"date\": \"1993-06-01\", \"first\": \"Morishima-Kawashima M\", \"last\": \"Ihara Y\", \"name\": \"Neuron\", \"pages\": \"1151-60\", \"reference\": \"8391280\", \"title\": \"Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments.\", \"type\": \"PubMed\", \"volume\": \"10\"}, \"evidence\": \"The ubiquitin-targeted protein was identified as tau in paired helical filaments, and the conjugation sites were localized to the microtubule-binding region.\", \"key\": \"6a8b5f12aa68a828774c5afa66190bfeb80644910fb8a9018df2de2878ef1ab6ba32d9059cf52bb6dad9b3bb81cff8e27087af8aab66a2f10ec3ec44df8d0068\", \"line\": 445, \"relation\": \"directlyIncreases\", \"source\": 173, \"target\": 323}, {\"citation\": {\"authors\": [\"D'Adamio L\", \"Del Prete D\", \"Rajadhyaksha AM\", \"Rice RC\"], \"date\": \"2016-08-12\", \"first\": \"Del Prete D\", \"last\": \"D'Adamio L\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"17209-27\", \"reference\": \"27325702\", \"title\": \"Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration.\", \"type\": \"PubMed\", \"volume\": \"291\"}, \"evidence\": \"As reported in Table 6, several brain-derived proteins associated with the ACR bait were ubiquitinated. These proteins can be separated into four groups as follows: (a) group 1, proteins of the ubiquitin-conjugating system; (b) group 2, presynaptic proteins; (c) group 3, other proteins implicated in AD; and (d) group 4, phosphorylation-dependent ACR interactors.\", \"key\": \"749ef901396fb5a387086ee3e4b5fef20816430e64472cc9512f9786c959c6070063b266a6ceaedac6be76e60af342b15e23c4da2eb310980b01635439d8c7ed\", \"line\": 3476, \"relation\": \"increases\", \"source\": 175, \"target\": 323}, {\"citation\": {\"authors\": [\"Feng Y\", \"Jiang J\", \"Liu XH\", \"Liu ZC\", \"Luo HB\", \"Shu XJ\", \"Wang JZ\", \"Wang XC\", \"Xia YY\", \"Xiong YS\", \"Ye K\", \"Yin G\", \"Yu G\", \"Zeng K\"], \"date\": \"2014-11-18\", \"first\": \"Luo HB\", \"last\": \"Wang JZ\", \"name\": \"Proceedings of the National Academy of Sciences of the United States of America\", \"pages\": \"16586-91\", \"reference\": \"25378699\", \"title\": \"SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination.\", \"type\": \"PubMed\", \"volume\": \"111\"}, \"evidence\": \"Furthermore, the enhanced SUMO-immunoreactivity, costained with the hyperphosphorylated tau, is detected in cerebral cortex of the AD brains, and -amyloid exposure of rat primary hippocampal neurons induces a dose-dependent SUMOylation of the hyperphosphorylated tau. Our findings suggest that tau SUMOylation reciprocally stimulates its phosphorylation and inhibits the ubiquitination-mediated tau degradation, which provides a new insight into the AD-like tau accumulation.\", \"key\": \"353f6339606ec8f998c04350b264c18175356f2025d7c39fa88df12b2fe45215b88172286617849babda6b67afa773c4df3088afdade5ef8066c897a38c191fb\", \"line\": 3486, \"relation\": \"decreases\", \"source\": 322, \"target\": 323}, {\"citation\": {\"authors\": [\"Feng Y\", \"Jiang J\", \"Liu XH\", \"Liu ZC\", \"Luo HB\", \"Shu XJ\", \"Wang JZ\", \"Wang XC\", \"Xia YY\", \"Xiong YS\", \"Ye K\", \"Yin G\", \"Yu G\", \"Zeng K\"], \"date\": \"2014-11-18\", \"first\": \"Luo HB\", \"last\": \"Wang JZ\", \"name\": \"Proceedings of the National Academy of Sciences of the United States of America\", \"pages\": \"16586-91\", \"reference\": \"25378699\", \"title\": \"SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination.\", \"type\": \"PubMed\", \"volume\": \"111\"}, \"evidence\": \"Furthermore, the enhanced SUMO-immunoreactivity, costained with the hyperphosphorylated tau, is detected in cerebral cortex of the AD brains, and -amyloid exposure of rat primary hippocampal neurons induces a dose-dependent SUMOylation of the hyperphosphorylated tau. Our findings suggest that tau SUMOylation reciprocally stimulates its phosphorylation and inhibits the ubiquitination-mediated tau degradation, which provides a new insight into the AD-like tau accumulation.\", \"key\": \"29d94a87b4add5e994406f9967fdf1e605847ad45998f23505400315335f6c00c91c2f5b2894973ec25a71944e5b3b99b6d64c2985b6b5a75bc2a52ddf47b042\", \"line\": 3485, \"relation\": \"positiveCorrelation\", \"source\": 322, \"target\": 286}, {\"citation\": {\"authors\": [\"Dorval V\", \"Fraser PE\"], \"date\": \"2006-04-14\", \"first\": \"Dorval V\", \"last\": \"Fraser PE\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"9919-24\", \"reference\": \"16464864\", \"title\": \"Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein.\", \"type\": \"PubMed\", \"volume\": \"281\"}, \"evidence\": \"Both brain proteins were preferentially modified by SUMO1, as compared with SUMO2 or SUMO3. Tau contains two SUMO consensus sequences with Lys(340) as the major sumoylation site. Although both tau and alpha-synuclein are targets for proteasomal degradation, only tau sumoylation was affected by inhibitors of the proteasome pathway. Treatment with the phosphatase inhibitor, okadaic acid, or the microtubule depolymerizing drug, colchicine, up-regulated tau sumoylation.\", \"key\": \"4d352ba5efc18c1eb450a2b6ef80da33dd5705ef9f3ab56c7186cfa4f81fab3c0b14d64c24609d6b4127156a4f7a7d051e8c98c43b107364f4ab2f433f23ead8\", \"line\": 3718, \"relation\": \"positiveCorrelation\", \"source\": 322, \"target\": 290}, {\"annotations\": {\"Cell_Line\": {\"COS7\": true}, \"Method\": {\"Deglycosylation Assay\": true, \"Dephosphorylation Assay\": true, \"Immunoblotting\": true, \"Immunocytochemistry\": true, \"Phosphorylation Assay\": true, \"Pull-down Assay, His-tagged\": true, \"SDS-PAGE\": true, \"Ubiquitination Assay\": true}}, \"citation\": {\"authors\": [\"Gygi SP\", \"Kosik KS\", \"Schwartz D\", \"Shimura H\"], \"date\": \"2004-02-06\", \"first\": \"Shimura H\", \"last\": \"Kosik KS\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"4869-76\", \"reference\": \"14612456\", \"title\": \"CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival.\", \"type\": \"PubMed\", \"volume\": \"279\"}, \"evidence\": \"These data indicated that phosphorylation of PP2A dephosphorylation sites is an important recognition signal for ubiquitination. We used 200 g of amino-terminal His-tagged full-length recombinant human tau in an in vitro phosphorylation reaction with GSK-3Beta. When phosphorylated, the tau protein reacted on immunoblots with PHF1 (25, 26) and AT8 (24), indicating that at least sites Ser202, Thr205, Ser396, and Ser404 were phosphorylated. Following GSK-3Beta incubation, this tau served as an excellent substrate for in vitro ubiquitination using UbcH5B and the cofactor fraction from AD tau immunoprecipitates (Fig. 2a). This finding suggested that GSK-3Beta can place phosphates on tau that create recognition sites for an E3 Ub ligase.\", \"key\": \"0ffd727ad2e79fe29e83feb86da3bcea5851aa538662ae0b2276f3e2137f7705dfd93648baad121743b72e0d9863a51741d88242a7c0abc8b47071c47d92b1f8\", \"line\": 397, \"relation\": \"positiveCorrelation\", \"source\": 286, \"target\": 323}, {\"citation\": {\"authors\": [\"Feng Y\", \"Jiang J\", \"Liu XH\", \"Liu ZC\", \"Luo HB\", \"Shu XJ\", \"Wang JZ\", \"Wang XC\", \"Xia YY\", \"Xiong YS\", \"Ye K\", \"Yin G\", \"Yu G\", \"Zeng K\"], \"date\": \"2014-11-18\", \"first\": \"Luo HB\", \"last\": \"Wang JZ\", \"name\": \"Proceedings of the National Academy of Sciences of the United States of America\", \"pages\": \"16586-91\", \"reference\": \"25378699\", \"title\": \"SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination.\", \"type\": \"PubMed\", \"volume\": \"111\"}, \"evidence\": \"Furthermore, the enhanced SUMO-immunoreactivity, costained with the hyperphosphorylated tau, is detected in cerebral cortex of the AD brains, and -amyloid exposure of rat primary hippocampal neurons induces a dose-dependent SUMOylation of the hyperphosphorylated tau. Our findings suggest that tau SUMOylation reciprocally stimulates its phosphorylation and inhibits the ubiquitination-mediated tau degradation, which provides a new insight into the AD-like tau accumulation.\", \"key\": \"dc49d915c8f6dfe77ae5770897d21fea066dba25cb7c249ea842c0c2f62cc63c2f1e9c7ce5c80d1f3e234ae7ba7f980b66fc7acd9d5c4fbf655af622dbef522e\", \"line\": 3485, \"relation\": \"positiveCorrelation\", \"source\": 286, \"target\": 322}, {\"annotations\": {\"Confidence\": {\"High\": true}, \"PublicationType\": {\"Review\": true}}, \"citation\": {\"authors\": [\"Thompson R\", \"Xu H\", \"Zhang H\", \"Zhang YW\"], \"date\": \"2011-01-07\", \"first\": \"Zhang YW\", \"last\": \"Xu H\", \"name\": \"Molecular brain\", \"pages\": \"3\", \"reference\": \"21214928\", \"title\": \"APP processing in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"4\"}, \"evidence\": \"The neurofibrillary tangles (NFTs) consist largely of hyperphosphorylated twisted filaments of the microtubule-associated protein tau [4,5]\", \"key\": \"4ba70d2b01c70d37e34ffc1657c34d2447ee6b5e68ac946eb9e5c6e843aec37254acf34c83dd73f28a78aa58fbe44664429355dac53edf4baaf2f3598619aee3\", \"line\": 65, \"relation\": \"increases\", \"source\": 286, \"target\": 35}, {\"annotations\": {\"Confidence\": {\"High\": true}, \"MeSHAnatomy\": {\"Cerebral Cortex\": true}, \"PublicationType\": {\"Review\": true}}, \"citation\": {\"authors\": [\"Castillo-Carranza DL\", \"Guerrero-Muoz MJ\", \"Shafiei SS\"], \"date\": \"2017-01-01\", \"first\": \"Shafiei SS\", \"last\": \"Castillo-Carranza DL\", \"name\": \"Frontiers in aging neuroscience\", \"pages\": \"83\", \"reference\": \"28420982\", \"title\": \"Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage.\", \"type\": \"PubMed\", \"volume\": \"9\"}, \"evidence\": \"Hyper-phosphorylated tau assembles into small aggregates known as tau oligomers in route of NFT formation\", \"key\": \"534df3c1cfc59b9bd1fd1dd964bdeeeeedfe18260ddec65e00e46ccd63cea1edc248bbe074458c29d7b82564063ee5e2cbf9b9109a2023b379f20d1bb36c7f02\", \"line\": 103, \"relation\": \"increases\", \"source\": 286, \"target\": 35}, {\"annotations\": {\"Confidence\": {\"High\": true}, \"PublicationType\": {\"Review\": true}}, \"citation\": {\"authors\": [\"Ma Q\", \"Xu H\", \"Zhang H\", \"Zhang YW\"], \"date\": \"2012-01-01\", \"first\": \"Zhang H\", \"last\": \"Xu H\", \"name\": \"Journal of neurochemistry\", \"pages\": \"9-21\", \"reference\": \"22122372\", \"title\": \"Proteolytic processing of Alzheimer's -amyloid precursor protein.\", \"type\": \"PubMed\", \"volume\": \"120 Suppl 1\"}, \"evidence\": \"Plaques consisting of beta-amyloid (Abeta) peptide (Selkoe 1998), neurofibrillary tangles consisting largely of hyperphosphorylated microtubule-associated tau protein (Buee et al. 2000; Gendron and Petrucelli 2009) and neuron loss in the hippocampus and cortex regions are the major pathological hallmarks of Alzheimers disease.\", \"key\": \"2a2bfbba4b55eeee3123b74fcd531eb47297888f3e50df1d3943e10cd63cee47d8be332229749b873bf92f908466e753b034132117a1e5daaa41ff43dcc02167\", \"line\": 85, \"relation\": \"association\", \"source\": 286, \"target\": 86}, {\"annotations\": {\"MeSHAnatomy\": {\"Neurons\": true}, \"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Lastly, increased phosphorylation of PP2A at Tyr-307 has been found in P-tau-rich, tangle-bearing neurons from post-mortem brain (Liu et al.,2008b).\", \"key\": \"0e9358d5e271281d7cfdaefad2dc28631da1f1f6d507d005f5ae25089774ef59dbf02ccc79b1127cbd3408f89b6c0f7bc1874752deceabb3037fc4368dfbaa8f\", \"line\": 288, \"relation\": \"association\", \"source\": 286, \"target\": 169}, {\"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Notably, tau missense mutations found in frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17; Goedert et al.,2000) and AD-mimicking tau phosphorylation in proline-rich motifs (Eidenmuller et al.,2001) inhibit the association of tau with PP2A (Figure3B).\", \"key\": \"dbb6182ba0befe598a58bb85d5dc98256973edf502641f84a75d8151c56887cb65f967ba8f4be7b77193eb2f659d8767bf99e9725c12ca41383002cee74b1e83\", \"line\": 464, \"relation\": \"decreases\", \"source\": 286, \"target\": 110}, {\"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Dietary folate and B-vitamin deficiency (Sontag et al.,2008; Nicolia et al.,2010) and elevated homocysteine levels (Sontag et al.,2007, 2013; Zhang et al.,2008) lead to down-regulation of PP2A methylation and concomitant phosphorylation of tau and/or APP in vivo\", \"key\": \"0e42a8ea352cb0575f7ae9277295b779668318d6747fe0ef3e84f3e73c5c9823590b55ea5a4201b1adda21e4ec0933ede4cc66dee8bf60c4d7b0025ae8ecc5fe\", \"line\": 523, \"relation\": \"positiveCorrelation\", \"source\": 286, \"target\": 26}, {\"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Dietary folate and B-vitamin deficiency (Sontag et al.,2008; Nicolia et al.,2010) and elevated homocysteine levels (Sontag et al.,2007, 2013; Zhang et al.,2008) lead to down-regulation of PP2A methylation and concomitant phosphorylation of tau and/or APP in vivo\", \"key\": \"6a4ae7ad407b138169ff850a9ebeb75a00f9c3ba841846f862d0caadd005334069a9739a697c5336a7a3ae37064ea819f07ce36eb7a36f17068b4b64ec02d375\", \"line\": 525, \"relation\": \"negativeCorrelation\", \"source\": 286, \"target\": 168}, {\"citation\": {\"authors\": [\"Chung KM\", \"Hernndez N\", \"Sproul AA\", \"Yu WH\"], \"date\": \"2018-05-18\", \"first\": \"Chung KM\", \"last\": \"Yu WH\", \"name\": \"Neuroscience letters\", \"reference\": \"29758300\", \"title\": \"Alzheimer's disease and the autophagic-lysosomal system.\", \"type\": \"PubMed\"}, \"evidence\": \"For instance, phosphorylated insoluble tau proteins dampen 26S proteasome activity, while activation of the UPS attenuates tauopathy [27]\", \"key\": \"7a8ce255d21a23cc16542502a4de834c0d8ef86f0e6daa2a5f8d85e2f00f538e5cd5e31ddac10b706059f1aea36ea37af672134eb9ad84bd720939746fd34d72\", \"line\": 184, \"object\": {\"modifier\": \"Activity\"}, \"relation\": \"decreases\", \"source\": 286, \"target\": 104}, {\"citation\": {\"authors\": [\"Chung KM\", \"Hernndez N\", \"Sproul AA\", \"Yu WH\"], \"date\": \"2018-05-18\", \"first\": \"Chung KM\", \"last\": \"Yu WH\", \"name\": \"Neuroscience letters\", \"reference\": \"29758300\", \"title\": \"Alzheimer's disease and the autophagic-lysosomal system.\", \"type\": \"PubMed\"}, \"evidence\": \"Abnormal phosphorylation and truncation of tau are hallmarks of AD pathology and are targets of proteasome and autophagy pathways [27,44,45].\", \"key\": \"ebbeb18c4bdd12c05d819f17138290f7334187a31703a3e5d4729368842a35286f08a5d72a59bf4b3d514c8e484946ecb5d0bd2a72aa47e439da3ec668e35675\", \"line\": 294, \"relation\": \"association\", \"source\": 286, \"target\": 104}, {\"citation\": {\"authors\": [\"Chung KM\", \"Hernndez N\", \"Sproul AA\", \"Yu WH\"], \"date\": \"2018-05-18\", \"first\": \"Chung KM\", \"last\": \"Yu WH\", \"name\": \"Neuroscience letters\", \"reference\": \"29758300\", \"title\": \"Alzheimer's disease and the autophagic-lysosomal system.\", \"type\": \"PubMed\"}, \"evidence\": \"Abnormal phosphorylation and truncation of tau are hallmarks of AD pathology and are targets of proteasome and autophagy pathways [27,44,45].\", \"key\": \"df1bcda1ac75c2dcfd2982c1ac081edf11d275940c5b6e936c16bd85831dc580a773b27d7ba7bf5fc7185d8e23c4541a48f7ae6be838222ae4e35c913da414b8\", \"line\": 295, \"relation\": \"association\", \"source\": 286, \"target\": 93}, {\"citation\": {\"authors\": [\"Chung KM\", \"Hernndez N\", \"Sproul AA\", \"Yu WH\"], \"date\": \"2018-05-18\", \"first\": \"Chung KM\", \"last\": \"Yu WH\", \"name\": \"Neuroscience letters\", \"reference\": \"29758300\", \"title\": \"Alzheimer's disease and the autophagic-lysosomal system.\", \"type\": \"PubMed\"}, \"evidence\": \"TFEB has been shown to effectively clear phosphorylated tau proteins through A-LS, resulting in ameliorated neuronal loss and neuroinflammation, as well as improved cognitive performance [89].\", \"key\": \"f4cff9bf27c3ddbca922b094340bcd1516033ae77a0d5fb7cc32b3fa97d85b38ac4e52d6d6fd8020665034e5f750256ba72644c491ce480f67281743e32bd5db\", \"line\": 506, \"relation\": \"decreases\", \"source\": 286, \"subject\": {\"modifier\": \"Degradation\"}, \"target\": 88}, {\"citation\": {\"authors\": [\"Chung KM\", \"Hernndez N\", \"Sproul AA\", \"Yu WH\"], \"date\": \"2018-05-18\", \"first\": \"Chung KM\", \"last\": \"Yu WH\", \"name\": \"Neuroscience letters\", \"reference\": \"29758300\", \"title\": \"Alzheimer's disease and the autophagic-lysosomal system.\", \"type\": \"PubMed\"}, \"evidence\": \"TFEB has been shown to effectively clear phosphorylated tau proteins through A-LS, resulting in ameliorated neuronal loss and neuroinflammation, as well as improved cognitive performance [89].\", \"key\": \"986a000fe50b296c2c8e85d641260006a77c71ba585c94f00eff3c9d62ccd1d54a712c02a55baafce64c61f7e9764de63e2ff3dbfe6940700f6711db5cd1080a\", \"line\": 508, \"relation\": \"increases\", \"source\": 286, \"subject\": {\"modifier\": \"Degradation\"}, \"target\": 94}, {\"annotations\": {\"TextLocation\": {\"Review\": true}}, \"citation\": {\"authors\": [\"Chesser AS\", \"Johnson GV\", \"Pritchard SM\"], \"date\": \"2013-09-03\", \"first\": \"Chesser AS\", \"last\": \"Johnson GV\", \"name\": \"Frontiers in neurology\", \"pages\": \"122\", \"reference\": \"24027553\", \"title\": \"Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"4\"}, \"evidence\": \"Interestingly, phosphorylation of tau also appears to disrupt some thrombin cleavage sites, changing the pattern of cleavage without impeding the thrombin-mediated proteolysis (14, 28).\", \"key\": \"b978898725593dbcc652bfea06d8d3411ec3b9b44f403c3416afdf95cc9376425f3693e0112e75e34061fadfc2e33ddadfa042fdf3b9ddbd8282d0c51c111471\", \"line\": 324, \"object\": {\"modifier\": \"Activity\"}, \"relation\": \"decreases\", \"source\": 286, \"target\": 17}, {\"citation\": {\"authors\": [\"Andreadis A\", \"Binder LI\", \"Brady ST\", \"Fu Y\", \"Kanaan NM\", \"LaPointe NE\", \"Morfini GA\", \"Patterson KR\", \"Pigino GF\", \"Song Y\"], \"date\": \"2011-07-06\", \"first\": \"Kanaan NM\", \"last\": \"Binder LI\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"9858-68\", \"reference\": \"21734277\", \"title\": \"Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"Soluble AT8 tau monomers inhibited anterograde FAT (Fig. 6 A, C), while retrograde trans- port was unaffected (Fig. 6 A, D). These data indicate that phos- phorylation of tau at the AT8 epitope, which is associated with hyperphosphorylation of tau in AD and other tauopathies, renders soluble monomeric tau capable of inhibiting antero- grade FAT.\", \"key\": \"3285489ccae1d46058954f043ab2031a50abac0592e4f7a78b21f603b59da25517af8516b16743d3dff0c135d49312095bd7bb4bde192f6fa807fe1aacf11f8e\", \"line\": 121, \"relation\": \"association\", \"source\": 286, \"target\": 176}, {\"citation\": {\"authors\": [\"Dickey CA\", \"Gestwicki JE\", \"Kiray J\", \"Koren J\", \"Miyata Y\"], \"date\": \"2011-09-01\", \"first\": \"Miyata Y\", \"last\": \"Gestwicki JE\", \"name\": \"Future medicinal chemistry\", \"pages\": \"1523-37\", \"reference\": \"21882945\", \"title\": \"Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.\", \"type\": \"PubMed\", \"volume\": \"3\"}, \"evidence\": \"Phosphorylation of tau by the kinases GSK3b, Cdk5 and MARK2 is a major regulator of its microtubule interactions\", \"key\": \"40890a54019dceccc5affd56194eb21488bd073586472697433b011acce00af1f0795c21e415134704f8bd31e196aa672b3ce5cb1036b562c685648a10ab183c\", \"line\": 98, \"relation\": \"regulates\", \"source\": 286, \"target\": 111}, {\"citation\": {\"authors\": [\"Dickey CA\", \"Gestwicki JE\", \"Kiray J\", \"Koren J\", \"Miyata Y\"], \"date\": \"2011-09-01\", \"first\": \"Miyata Y\", \"last\": \"Gestwicki JE\", \"name\": \"Future medicinal chemistry\", \"pages\": \"1523-37\", \"reference\": \"21882945\", \"title\": \"Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.\", \"type\": \"PubMed\", \"volume\": \"3\"}, \"evidence\": \"In general, phosphorylation of tau reduces its affinity for microtubules [30], while dephosphorylation via enzymes such as PP2A and PP5 restores binding\", \"key\": \"cbf561278aaf8af2f2bf0b5bf1a666bb70c93404b734debda088a3a7cc13e4a6548d29bd168937d230ffdfba609940c1867e5f637bba7da273860830118e83dc\", \"line\": 110, \"relation\": \"decreases\", \"source\": 286, \"target\": 111}, {\"annotations\": {\"MeSHAnatomy\": {\"Brain\": true}, \"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Thus, it is possible that unknown cofactors trigger tau aggregation in the AD brain, whereas phosphorylation may accelerate aggregation indirectly: for example, by detaching tau from microtubules\", \"key\": \"43aebe4924811bc67b22b505013d06529b755c31f5bafe2b7ec5ac977081a63491cd19ac4805ec03699e36f6ca3e9014f181b2fa7e8bdd274cc4608c60c2622c\", \"line\": 610, \"relation\": \"decreases\", \"source\": 286, \"target\": 111}, {\"citation\": {\"authors\": [\"Choi H\", \"Gwon Y\", \"Jung YK\", \"Kam TI\", \"Kim C\", \"Kim Y\", \"Koh JY\", \"Park H\"], \"date\": \"2012-06-15\", \"first\": \"Park H\", \"last\": \"Jung YK\", \"name\": \"Human molecular genetics\", \"pages\": \"2725-37\", \"reference\": \"22419736\", \"title\": \"Neuropathogenic role of adenylate kinase-1 in A-mediated tau phosphorylation via AMPK and GSK3.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"These results indicate that AMPK activity is impaired by Ab42 in the neuronal cells in which tau phosphor- ylation increased. \", \"key\": \"9e8a726b4e5389e059731fd7697b69b13831c058f3147536fb13532dd51d67e831bf4c5ee466377b2267176466577fa00c095534a688782f28467fce0acf7b4a\", \"line\": 135, \"object\": {\"modifier\": \"Activity\"}, \"relation\": \"negativeCorrelation\", \"source\": 286, \"target\": 154}, {\"annotations\": {\"Species\": {\"6239\": true}}, \"citation\": {\"authors\": [\"Choudhary B\", \"Mandelkow E\", \"Pir GJ\"], \"date\": \"2017-12-01\", \"first\": \"Pir GJ\", \"last\": \"Mandelkow E\", \"name\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\", \"pages\": \"5137-5148\", \"reference\": \"29191965\", \"title\": \"&lt;i&gt;Caenorhabditis elegans&lt;/i&gt; models of tauopathy.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"Nonetheless, it is assumed that tau aggregation may be driven by phosphorylation at certain sites (95), whereas phosphorylation at other sites may inhibit aggregation (96).\", \"key\": \"cce3981761ae5addce757c73c0445d3111eebd51590569d8786ec340b3006c349eeda3ea42fe58f577721b6a43df7c44315902ddcd05fb898b16492ecff4b780\", \"line\": 267, \"relation\": \"positiveCorrelation\", \"source\": 286, \"target\": 39}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Third, the phosphorylation of tau is often considered to enhance tau aggregation, as hyperphosphorylation and aggregation are both increased in AD\", \"key\": \"7a896f49bbb0e258ed7769f0bf7601d34fac97b50cf4e80bf6cb24e0cbc24b6dc45103a62dce398a45c0861c3861dadb839e11db1de562978c57b281b6e01ca8\", \"line\": 236, \"relation\": \"increases\", \"source\": 286, \"target\": 39}, {\"annotations\": {\"MeSHAnatomy\": {\"Brain\": true}, \"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Thus, it is possible that unknown cofactors trigger tau aggregation in the AD brain, whereas phosphorylation may accelerate aggregation indirectly: for example, by detaching tau from microtubules\", \"key\": \"a6bcfb2fa1936c4b06a5a9e2e7f38d856d5863e9ad1d0621b869128495c14d5d8a107fd8fc4819083448fec38f55b067b988a3f28785d68429db73fbd57608ec\", \"line\": 609, \"relation\": \"increases\", \"source\": 286, \"target\": 39}, {\"annotations\": {\"Confidence\": {\"High\": true}, \"MeSHAnatomy\": {\"Intracellular Space\": true}, \"PublicationType\": {\"Review\": true}}, \"citation\": {\"authors\": [\"Binder LI\", \"Himmelstein DS\", \"Lancia JK\", \"Ward SM\"], \"date\": \"2012-08-01\", \"first\": \"Ward SM\", \"last\": \"Binder LI\", \"name\": \"Biochemical Society transactions\", \"pages\": \"667-71\", \"reference\": \"22817713\", \"title\": \"Tau oligomers and tau toxicity in neurodegenerative disease.\", \"type\": \"PubMed\", \"volume\": \"40\"}, \"evidence\": \"The tau protein becomes highly phosphorylated in AD and this is likely to induce a conformational change causing its detachment from microtubules and its accumulation in aggregates [3]\", \"key\": \"2cd608348fd6b4b31d522364ceb4fbab3450b74ca4934035f3a906d67ec869f64b77e90f506f371fca8705f3d1d4fe7645747f418845888b611888c475a96ec3\", \"line\": 99, \"relation\": \"increases\", \"source\": 286, \"target\": 39}, {\"annotations\": {\"Confidence\": {\"High\": true}, \"MeSHAnatomy\": {\"Cerebral Cortex\": true}, \"PublicationType\": {\"Review\": true}}, \"citation\": {\"authors\": [\"Castillo-Carranza DL\", \"Guerrero-Muoz MJ\", \"Shafiei SS\"], \"date\": \"2017-01-01\", \"first\": \"Shafiei SS\", \"last\": \"Castillo-Carranza DL\", \"name\": \"Frontiers in aging neuroscience\", \"pages\": \"83\", \"reference\": \"28420982\", \"title\": \"Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage.\", \"type\": \"PubMed\", \"volume\": \"9\"}, \"evidence\": \"Hyper-phosphorylated tau assembles into small aggregates known as tau oligomers in route of NFT formation\", \"key\": \"6ef9891466ef495b4cefbb56662d7f171e6302008a4aeaa71a75ad5462ecbb918411ce6483cf127078623f527e90ee035067f976cbf885b5da5c434e0fcfc4aa\", \"line\": 102, \"relation\": \"increases\", \"source\": 286, \"target\": 46}, {\"annotations\": {\"Confidence\": {\"High\": true}, \"MeSHAnatomy\": {\"Cerebral Cortex\": true}, \"PublicationType\": {\"Review\": true}}, \"citation\": {\"authors\": [\"Castillo-Carranza DL\", \"Guerrero-Muoz MJ\", \"Shafiei SS\"], \"date\": \"2017-01-01\", \"first\": \"Shafiei SS\", \"last\": \"Castillo-Carranza DL\", \"name\": \"Frontiers in aging neuroscience\", \"pages\": \"83\", \"reference\": \"28420982\", \"title\": \"Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage.\", \"type\": \"PubMed\", \"volume\": \"9\"}, \"evidence\": \"As hyperphosphorylated tau dislodges from microtubules, its affinity for other tau monomers leads individual tau to bind each other, forming oligomeric tau, a detergent-soluble aggregate\", \"key\": \"eded8ee7f98b3f5218783be1aacc9f3b72da77b3d2632cedf9c6fa0bae3663e51729b9006e83a79440c7e221cd02a0df1793b392d5d2788b726a1e3fcb17f710\", \"line\": 110, \"relation\": \"increases\", \"source\": 286, \"target\": 46}, {\"annotations\": {\"MeSHAnatomy\": {\"Choroid Plexus\": true}}, \"citation\": {\"authors\": [\"Axel L\", \"Blennow K\", \"Butler T\", \"Carare RO\", \"Fieremans E\", \"Frangione B\", \"Glodzik L\", \"Mnard J\", \"Nicholson C\", \"Osorio RS\", \"Rusinek H\", \"Tarasoff-Conway JM\", \"Wisniewski T\", \"Zetterberg H\", \"Zlokovic BV\", \"de Leon MJ\"], \"date\": \"2015-08-01\", \"first\": \"Tarasoff-Conway JM\", \"last\": \"de Leon MJ\", \"name\": \"Nature reviews. Neurology\", \"pages\": \"457-70\", \"reference\": \"26195256\", \"title\": \"Clearance systems in the brain-implications for Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"11\"}, \"evidence\": \"Phosphorylation of tau by protein kinase A increases its resistance to degradation by calpain\", \"key\": \"7e1cc6f7d7860baee923208524956d64e73629db36eeef21cd9559dcbd963c91f6f90b90e5e6d9c0d83250fbc0a46a40ad0edc106edde4d27b687d2353ee5dbe\", \"line\": 270, \"object\": {\"modifier\": \"Activity\"}, \"relation\": \"decreases\", \"source\": 286, \"target\": 201}, {\"citation\": {\"authors\": [\"Brady ST\", \"Combs B\", \"Counts SE\", \"Cox K\", \"Kanaan NM\", \"Morfini G\", \"Tiernan CT\"], \"date\": \"2016-09-01\", \"first\": \"Tiernan CT\", \"last\": \"Kanaan NM\", \"name\": \"Experimental neurology\", \"pages\": \"318-29\", \"reference\": \"27373205\", \"title\": \"Pseudophosphorylation of tau at S422 enhances SDS-stable dimer formation and impairs both anterograde and retrograde fast axonal transport.\", \"type\": \"PubMed\", \"volume\": \"283\"}, \"evidence\": \"Staining in fixed tissue sections confirmed several previous reports (Kanaan et al., 2016; Mufson et al., 2014; Patterson et al., 2011a) that pS422 (Fig. 7A) extensively colocalizes with TNT1 (Fig. 7B) and TOC1 (Fig. 7C) in both control and AD brains, despite the relatively sparse appearance of tau pathology in the temporal cortices of control cases (data not shown).\", \"key\": \"b82a5acf9c4a67b78d27cbc27d88fe7f7f5c5c94353ca57f6ea81a164ac00287d3688c7bea0eced53b273766c374d6c37bdba611824af335c315f86ab48078d1\", \"line\": 157, \"object\": {\"location\": {\"name\": \"Brain\", \"namespace\": \"MESH\"}}, \"relation\": \"increases\", \"source\": 286, \"target\": 146}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"The phosphorylation of tau appears to alter its association with actin, as tau phosphorylated at the KXGS motifs tends to colocalize with actin filaments in growth cones during development and in rod-like inclusions of cofilin and actin\", \"key\": \"4605e0ca0a74fe26b0946fa9397a3e9c26c98e9f72dbf315b4730afa33305aa180038d24ff2161a7119b850113e83f4310eae86b6702028a22c2725f63f61983\", \"line\": 513, \"relation\": \"decreases\", \"source\": 286, \"target\": 114}, {\"annotations\": {\"Disease\": {\"Alzheimer's disease\": true, \"Down syndrome\": true}, \"Method\": {\"Immunohistochemistry\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Ando K\", \"Authelet M\", \"Belkouch M\", \"Brion JP\", \"Duyckaerts C\", \"Ndjim M\", \"Potier MC\", \"Sazdovitch V\", \"Suain V\", \"Tomimura K\", \"Vergara C\", \"Yilmaz Z\"], \"date\": \"2016-10-01\", \"first\": \"Ando K\", \"last\": \"Brion JP\", \"name\": \"Neurobiology of disease\", \"pages\": \"32-43\", \"reference\": \"27260836\", \"title\": \"Level of PICALM, a key component of clathrin-mediated endocytosis, is correlated with levels of phosphotau and autophagy-related proteins and is associated with tau inclusions in AD, PSP and Pick disease.\", \"type\": \"PubMed\", \"volume\": \"94\"}, \"evidence\": \"Phosphatidylinositol binding clathrin assembly protein, PICALM (aka CALM) assembles adaptor protein-2 (AP-2) to clathrin, thus participating in clathrin-mediated endocytosis. We have previously reported that the level of full-length PICALM is decreased in AD brains; PICALM was co-localised with phosphorylated tau in NFTs and in granulovacuolar degenerations (GVDs) in the brains of AD patients and of individuals with Down syndrome but was not observed in amyloid plaques (Ando et al., 2013).\", \"key\": \"39117463caa3e8e857475330cf604cf9d6fb4ec5ac5bd18f103be795e7b5f0901754cc67566387a45b8604aaaedaff9d16aba884c5fa6aa647e8982158d8511c\", \"line\": 226, \"relation\": \"partOf\", \"source\": 286, \"target\": 103}, {\"annotations\": {\"Anatomy\": {\"striatum\": true}, \"Disease\": {\"progressive supranuclear palsy\": true}, \"Method\": {\"Immunohistochemistry\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Ando K\", \"Authelet M\", \"Belkouch M\", \"Brion JP\", \"Duyckaerts C\", \"Ndjim M\", \"Potier MC\", \"Sazdovitch V\", \"Suain V\", \"Tomimura K\", \"Vergara C\", \"Yilmaz Z\"], \"date\": \"2016-10-01\", \"first\": \"Ando K\", \"last\": \"Brion JP\", \"name\": \"Neurobiology of disease\", \"pages\": \"32-43\", \"reference\": \"27260836\", \"title\": \"Level of PICALM, a key component of clathrin-mediated endocytosis, is correlated with levels of phosphotau and autophagy-related proteins and is associated with tau inclusions in AD, PSP and Pick disease.\", \"type\": \"PubMed\", \"volume\": \"94\"}, \"evidence\": \"In PSP cases, both coiled bodies (Fig. 2 D-F) and NFTs (Fig. 2G-I) in the striatum showed a complete co-localisation of PICALM and phosphotau immunoreactivies.\", \"key\": \"0a54d4fdccbacbdad4d97a31299580aac7e10a4ebf207422c15a0460a8276ae460a652005c336a7f098939e323d26a0eff12a9c94dea8deb3700b9590f215343\", \"line\": 244, \"relation\": \"partOf\", \"source\": 286, \"target\": 103}, {\"annotations\": {\"Disease\": {\"Pick's disease\": true}, \"Method\": {\"Immunohistochemistry\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Ando K\", \"Authelet M\", \"Belkouch M\", \"Brion JP\", \"Duyckaerts C\", \"Ndjim M\", \"Potier MC\", \"Sazdovitch V\", \"Suain V\", \"Tomimura K\", \"Vergara C\", \"Yilmaz Z\"], \"date\": \"2016-10-01\", \"first\": \"Ando K\", \"last\": \"Brion JP\", \"name\": \"Neurobiology of disease\", \"pages\": \"32-43\", \"reference\": \"27260836\", \"title\": \"Level of PICALM, a key component of clathrin-mediated endocytosis, is correlated with levels of phosphotau and autophagy-related proteins and is associated with tau inclusions in AD, PSP and Pick disease.\", \"type\": \"PubMed\", \"volume\": \"94\"}, \"evidence\": \"Double immunostaining for PICALM and anti-phosphotau antibodies (AT8 and PHF1) showed a co-localisation of PICALM and phosphotau in Pick bodies of Pick disease\", \"key\": \"a829732ad8ddd1ac5413c72f71ce69c89268e7fd9b68bfd5111e1a37d4384431a89c6f6b6aa70ee28fc78a80ff66cb55852e4c3f6d570e3388253ac0325453c1\", \"line\": 235, \"relation\": \"partOf\", \"source\": 286, \"target\": 101}, {\"annotations\": {\"Anatomy\": {\"striatum\": true}, \"Disease\": {\"progressive supranuclear palsy\": true}, \"Method\": {\"Immunohistochemistry\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Ando K\", \"Authelet M\", \"Belkouch M\", \"Brion JP\", \"Duyckaerts C\", \"Ndjim M\", \"Potier MC\", \"Sazdovitch V\", \"Suain V\", \"Tomimura K\", \"Vergara C\", \"Yilmaz Z\"], \"date\": \"2016-10-01\", \"first\": \"Ando K\", \"last\": \"Brion JP\", \"name\": \"Neurobiology of disease\", \"pages\": \"32-43\", \"reference\": \"27260836\", \"title\": \"Level of PICALM, a key component of clathrin-mediated endocytosis, is correlated with levels of phosphotau and autophagy-related proteins and is associated with tau inclusions in AD, PSP and Pick disease.\", \"type\": \"PubMed\", \"volume\": \"94\"}, \"evidence\": \"In PSP cases, both coiled bodies (Fig. 2 D-F) and NFTs (Fig. 2G-I) in the striatum showed a complete co-localisation of PICALM and phosphotau immunoreactivies.\", \"key\": \"9b8e8ec9d4959f34adead22628ecfe75e178537aef5413f7f7ae38bfb48faadbe340de25cafb056fc2487efa6c126d3000b46cade37225e0933127f1ede392d8\", \"line\": 247, \"relation\": \"partOf\", \"source\": 286, \"target\": 100}, {\"annotations\": {\"Method\": {\"Chromatography\": true, \"Enhanced Chemioluminescence visualization (ECL)\": true, \"Immunofluorescence Imaging\": true, \"Mass Spectrometry\": true, \"Pull-down assay, GST\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Anderton BH\", \"Garwood CJ\", \"Hanger DP\", \"Kellie S\", \"Perera T\", \"Price C\", \"Reynolds CH\", \"Sheppard PW\", \"Varndell IM\", \"Wray S\", \"Yang A\", \"Zvelebil M\"], \"date\": \"2008-06-27\", \"first\": \"Reynolds CH\", \"last\": \"Anderton BH\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"18177-86\", \"reference\": \"18467332\", \"title\": \"Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases.\", \"type\": \"PubMed\", \"volume\": \"283\"}, \"evidence\": \"The binding of all four SH3 domains tested (from Fyn, p85alpha, PLCgamma1, and the N-terminal SH3 of Grb2) was considerably decreased by phosphorylation.\", \"key\": \"3642081a9299f906f547588b05ffaaf73f3894c8ee842ee64c05c39260d1569f23ef529d0294e084ec40e9479056bed41c96585f7333aa9760e529f58224693c\", \"line\": 227, \"relation\": \"decreases\", \"source\": 286, \"target\": 135}, {\"annotations\": {\"Method\": {\"Chromatography\": true, \"Enhanced Chemioluminescence visualization (ECL)\": true, \"Immunofluorescence Imaging\": true, \"Mass Spectrometry\": true, \"Pull-down assay, GST\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Anderton BH\", \"Garwood CJ\", \"Hanger DP\", \"Kellie S\", \"Perera T\", \"Price C\", \"Reynolds CH\", \"Sheppard PW\", \"Varndell IM\", \"Wray S\", \"Yang A\", \"Zvelebil M\"], \"date\": \"2008-06-27\", \"first\": \"Reynolds CH\", \"last\": \"Anderton BH\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"18177-86\", \"reference\": \"18467332\", \"title\": \"Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases.\", \"type\": \"PubMed\", \"volume\": \"283\"}, \"evidence\": \"The binding of all four SH3 domains tested (from Fyn, p85alpha, PLCgamma1, and the N-terminal SH3 of Grb2) was considerably decreased by phosphorylation.\", \"key\": \"4446dd7183a4a840f8606c6a7f7b2e0c4e078faff3a369840eab6b2017224cb3a95ac3c3d6728c75668f88d956ed842d33d267b9916306bbfecc53dfa7e2b9fa\", \"line\": 228, \"relation\": \"decreases\", \"source\": 286, \"target\": 132}, {\"annotations\": {\"Method\": {\"Chromatography\": true, \"Enhanced Chemioluminescence visualization (ECL)\": true, \"Immunofluorescence Imaging\": true, \"Mass Spectrometry\": true, \"Pull-down assay, GST\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Anderton BH\", \"Garwood CJ\", \"Hanger DP\", \"Kellie S\", \"Perera T\", \"Price C\", \"Reynolds CH\", \"Sheppard PW\", \"Varndell IM\", \"Wray S\", \"Yang A\", \"Zvelebil M\"], \"date\": \"2008-06-27\", \"first\": \"Reynolds CH\", \"last\": \"Anderton BH\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"18177-86\", \"reference\": \"18467332\", \"title\": \"Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases.\", \"type\": \"PubMed\", \"volume\": \"283\"}, \"evidence\": \"The binding of all four SH3 domains tested (from Fyn, p85alpha, PLCgamma1, and the N-terminal SH3 of Grb2) was considerably decreased by phosphorylation.\", \"key\": \"d6e4bdf85f0c9af4988290f35e4ee2ca50675ed7ab6644f6b734387e78bbae5d9cb3cbf5934234fb248ff534852b9f03be5da5bb5e2f14a3d4f0705befc1a1d5\", \"line\": 229, \"relation\": \"decreases\", \"source\": 286, \"target\": 124}, {\"annotations\": {\"Method\": {\"Chromatography\": true, \"Enhanced Chemioluminescence visualization (ECL)\": true, \"Immunofluorescence Imaging\": true, \"Mass Spectrometry\": true, \"Pull-down assay, GST\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Anderton BH\", \"Garwood CJ\", \"Hanger DP\", \"Kellie S\", \"Perera T\", \"Price C\", \"Reynolds CH\", \"Sheppard PW\", \"Varndell IM\", \"Wray S\", \"Yang A\", \"Zvelebil M\"], \"date\": \"2008-06-27\", \"first\": \"Reynolds CH\", \"last\": \"Anderton BH\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"18177-86\", \"reference\": \"18467332\", \"title\": \"Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases.\", \"type\": \"PubMed\", \"volume\": \"283\"}, \"evidence\": \"The binding of all four SH3 domains tested (from Fyn, p85alpha, PLCgamma1, and the N-terminal SH3 of Grb2) was considerably decreased by phosphorylation.\", \"key\": \"107afda12ddc6b8f6012aae244e6b166af04b1c6c488cca6550f29c797e129d554a1936b01d34c73b64d2a7241de342af88f6c4897d73e4fd6f7fb7f18bd4b91\", \"line\": 230, \"relation\": \"decreases\", \"source\": 286, \"target\": 131}, {\"annotations\": {\"Method\": {\"Dephosphorylation Assay, Colorimetric\": true, \"Enhanced Chemioluminescence visualization (ECL)\": true, \"Microtubule Co-Sedimentation Assay\": true, \"SDS-PAGE\": true, \"Western Blot\": true}, \"TauIsoform\": {\"Isoform F (441 aa)\": true}}, \"citation\": {\"authors\": [\"Bloom GS\", \"Brandt R\", \"Kamibayashi C\", \"Kuret J\", \"Lee G\", \"Mumby MC\", \"Nunbhakdi-Craig V\", \"Sontag E\", \"White CL 3rd\"], \"date\": \"1999-09-03\", \"first\": \"Sontag E\", \"last\": \"Bloom GS\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"25490-8\", \"reference\": \"10464280\", \"title\": \"Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies.\", \"type\": \"PubMed\", \"volume\": \"274\"}, \"evidence\": \"Thus, MTs inhibited the rate of tau dephosphorylation by ABaC.\", \"key\": \"3912e3e00c19cbdf11147fe1106e6ca921aae21478de1e4a8be078e4b61c03ce67a8de7b1be895fbaed2c6a9c0a88efe75475277391600394f7f459b37f07a4f\", \"line\": 288, \"relation\": \"negativeCorrelation\", \"source\": 286, \"target\": 381}, {\"annotations\": {\"Method\": {\"Dot Blot\": true, \"Immunoprecipitation\": true, \"SDS-PAGE\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Avila J\", \"Lim F\", \"Moreno F\", \"Perez M\", \"Santa-Maria I\", \"Tortosa E\"], \"date\": \"2009-01-01\", \"first\": \"Tortosa E\", \"last\": \"Avila J\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"319-25\", \"reference\": \"19363271\", \"title\": \"Binding of Hsp90 to tau promotes a conformational change and aggregation of tau protein.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"To test the effect of Hsp90 on tau phosphorylation, this protein was mixed with tau protein in the presence of GSK-3 and ATP. Figure 4 shows that tau phosphorylation increases in the presence of increased added amounts of Hsp90.\", \"key\": \"1dd853c4405b54cfdee2ca0462395323ff6c4a98b288a1575a34d485e4999564b0ead9370ddbf04eadc41ef86ec56e964f82e58f8a68fcdd10d149d5bf531670\", \"line\": 331, \"relation\": \"positiveCorrelation\", \"source\": 286, \"target\": 206}, {\"annotations\": {\"Anatomy\": {\"temporal cortex\": true}, \"Cell_Line\": {\"HCN2A\": true}, \"Method\": {\"Pull-down Assay, His-tagged\": true, \"SDS-PAGE\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Kosik KS\", \"Miura-Shimura Y\", \"Shimura H\"], \"date\": \"2004-04-23\", \"first\": \"Shimura H\", \"last\": \"Kosik KS\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"17957-62\", \"reference\": \"14963027\", \"title\": \"Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival.\", \"type\": \"PubMed\", \"volume\": \"279\"}, \"evidence\": \"Here we show that heat shock protein 27 (Hsp27) preferentially binds pathological hyperphosphorylated tau and paired helical filaments tau directly but not non-phosphorylated tau. The formation of this complex altered the conformation of pathological hyperphosphorylated tau and reduced its concentration by facilitating its degradation and dephosphorylation.\", \"key\": \"fdf26b659e4e2008b27fd7fd933ce17109240bb705178be2145807eaee23689bc5369d1c2a43f2caa67d1c6bf89f8dba701158b0425002ff9a4419c390953a04\", \"line\": 357, \"relation\": \"increases\", \"source\": 286, \"target\": 128}, {\"annotations\": {\"Anatomy\": {\"temporal cortex\": true}, \"Cell_Line\": {\"HCN2A\": true}, \"Method\": {\"Pull-down Assay, His-tagged\": true, \"SDS-PAGE\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Kosik KS\", \"Miura-Shimura Y\", \"Shimura H\"], \"date\": \"2004-04-23\", \"first\": \"Shimura H\", \"last\": \"Kosik KS\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"17957-62\", \"reference\": \"14963027\", \"title\": \"Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival.\", \"type\": \"PubMed\", \"volume\": \"279\"}, \"evidence\": \"Taken together, pathological hyperphosphorylated tau caused cell death, and Hsp27 attenuated the cell toxicity of pathological hyperphosphorylated tau.\", \"key\": \"f8e8a84ea3a5dff06e5996e9ac186a328c27e76277a8eb90e93d36f676e766f2ccda59721b1410d468f1b0371d3d68e6dfc185c48c38d26c2d6271feec68acf6\", \"line\": 364, \"relation\": \"increases\", \"source\": 286, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 87}, {\"annotations\": {\"Cell_Line\": {\"COS7\": true}, \"Method\": {\"Deglycosylation Assay\": true, \"Dephosphorylation Assay\": true, \"Immunoblotting\": true, \"Immunocytochemistry\": true, \"Phosphorylation Assay\": true, \"Pull-down Assay, His-tagged\": true, \"SDS-PAGE\": true, \"Ubiquitination Assay\": true}}, \"citation\": {\"authors\": [\"Gygi SP\", \"Kosik KS\", \"Schwartz D\", \"Shimura H\"], \"date\": \"2004-02-06\", \"first\": \"Shimura H\", \"last\": \"Kosik KS\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"4869-76\", \"reference\": \"14612456\", \"title\": \"CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival.\", \"type\": \"PubMed\", \"volume\": \"279\"}, \"evidence\": \"These data suggest a model by which phosphorylated tau is bound to a chaperone and the complex is recognized by the E3 Ub ligase CHIP. We further examined whether recombinant GST-CHIP ubiquitinates phosphorylated tau in vitro in the presence of UbcH5B and Hsc70. Ubiquitination of phosphorylated tau was detected as high molecular weight bands by immunoblotting with 5E2 in the presence of UbcH5B and Hsc70 (Fig. 2e).\", \"key\": \"601886b931e39a3e5a21005e4e2d1fc39a0e05b0eb7e8e0617ec967f5d0a10975822148100e5ed7d529ce6c22367a86c7aa1d3f8ad11823ead23cb0b1dbf2349\", \"line\": 406, \"relation\": \"isA\", \"source\": 286, \"target\": 140}, {\"annotations\": {\"Cell_Line\": {\"N2a\": true}, \"Disease\": {\"Alzheimer's disease\": true}, \"Method\": {\"Western Blot\": true}}, \"citation\": {\"authors\": [\"Nunbhakdi-Craig V\", \"Sontag E\", \"Sontag JM\"], \"date\": \"2013-09-20\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"27396-405\", \"reference\": \"23943618\", \"title\": \"Leucine carboxyl methyltransferase 1 (LCMT1)-dependent methylation regulates the association of protein phosphatase 2A and Tau protein with plasma membrane microdomains in neuroblastoma cells.\", \"type\": \"PubMed\", \"volume\": \"288\"}, \"evidence\": \"Notably, methylation of PP2A catalytic C subunit on the Leu- 309 residue by leucine carboxyl methyltransferase 1 (LCMT1) promotes the biogenesis and stabilization of PP2A/B\\u0001 enzymes (20). We have shown that decreased LCMT1 activity and/or expression levels correlate with down-regulation of PP2A methylation and PP2A/B\\u0001 expression levels and with concomitant accumulation of phospho-Tau in AD-affected brain regions (21), in cultured N2a neuroblastoma cells and in vivo\", \"key\": \"ab35d46ca4e5b9f5e42dac8b6791477bfb683da215b3560f0b9a20e23d45a368ec78494131ad0ff3afd3dbb087402817d5d59efcd71acbe299d09fb5c11846ff\", \"line\": 328, \"relation\": \"negativeCorrelation\", \"source\": 286, \"target\": 116}, {\"citation\": {\"authors\": [\"Asada A\", \"Hasegawa M\", \"Hisanaga S\", \"Ishiguro K\", \"Kimura T\", \"Oikawa T\", \"Saito T\", \"Uchida C\", \"Uchida T\", \"Yotsumoto K\"], \"date\": \"2009-06-19\", \"first\": \"Yotsumoto K\", \"last\": \"Hisanaga S\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"16840-7\", \"reference\": \"19401603\", \"title\": \"Effect of Pin1 or microtubule binding on dephosphorylation of FTDP-17 mutant Tau.\", \"type\": \"PubMed\", \"volume\": \"284\"}, \"evidence\": \"Taken together, these results indicate that the binding of P-Tau to microtubules suppresses its dephosphorylation.\", \"key\": \"0c378ec5dd8a4e8a7d55ea01b08fb50a80f87f80647a032816d6a42dabc78559d732e21ef027fe24d23f3da215d340496450b580e402074a6fe79ad705923ae9\", \"line\": 4015, \"relation\": \"positiveCorrelation\", \"source\": 286, \"target\": 106}, {\"citation\": {\"authors\": [\"Chung KM\", \"Hernndez N\", \"Sproul AA\", \"Yu WH\"], \"date\": \"2018-05-18\", \"first\": \"Chung KM\", \"last\": \"Yu WH\", \"name\": \"Neuroscience letters\", \"reference\": \"29758300\", \"title\": \"Alzheimer's disease and the autophagic-lysosomal system.\", \"type\": \"PubMed\"}, \"evidence\": \"For example, in tau A152T iPSC-derived cortical neurons, total and phosphorylated Tau levels are elevated, particularly the insoluble forms [133], which is associated with decreases in UPS function as measured by total polyubiquitinated proteins and an upregulation of macroautophagy markers.\", \"key\": \"fe1104fd993867cbf2abf30e8e82d0dd76f092784b40c866ebe898f85554fcc2d65d6be678a32e6e0a63f72d5a0dd5d899b7601b421225d922bf96d62d8babb1\", \"line\": 682, \"relation\": \"positiveCorrelation\", \"source\": 286, \"target\": 326}, {\"annotations\": {\"Anatomy\": {\"temporal cortex\": true}, \"Cell_Line\": {\"HCN2A\": true}, \"Method\": {\"Pull-down Assay, His-tagged\": true, \"SDS-PAGE\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Kosik KS\", \"Miura-Shimura Y\", \"Shimura H\"], \"date\": \"2004-04-23\", \"first\": \"Shimura H\", \"last\": \"Kosik KS\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"17957-62\", \"reference\": \"14963027\", \"title\": \"Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival.\", \"type\": \"PubMed\", \"volume\": \"279\"}, \"evidence\": \"Here we show that heat shock protein 27 (Hsp27) preferentially binds pathological hyperphosphorylated tau and paired helical filaments tau directly but not non-phosphorylated tau. The formation of this complex altered the conformation of pathological hyperphosphorylated tau and reduced its concentration by facilitating its degradation and dephosphorylation.\", \"key\": \"dbc23d108fd42ae2ef028d73a504694b255ae53315f5728af51f40b35a90a229b2b6a93036099e18fbd2611ce67834c8da65e85f9429775ff7fd1b07ee1532c5\", \"line\": 354, \"relation\": \"association\", \"source\": 286, \"target\": 234}, {\"citation\": {\"authors\": [\"Gong CX\", \"Li X\", \"Lu F\", \"Wang JZ\"], \"date\": \"2006-04-01\", \"first\": \"Li X\", \"last\": \"Gong CX\", \"name\": \"The European journal of neuroscience\", \"pages\": \"2078-86\", \"reference\": \"16630055\", \"title\": \"Concurrent alterations of O-GlcNAcylation and phosphorylation of tau in mouse brains during fasting.\", \"type\": \"PubMed\", \"volume\": \"23\"}, \"evidence\": \"We recently discovered that the human brain tau is also modified by O-GlcNAcylation in addition to phosphorylation and that O-GlcNAcylation modulates phosphorylation of tau inversely (Liu et al.,2004a). We found that fasting induced a time-dependent decrease in tau O-GlcNAcylation and concurrent hyperphosphorylation of tau at most of the phosphorylation sites studied.\", \"key\": \"5dc2dd20fc77f1f77246619f0e1d4d62c1e1c2a5100ac84a2a2b01b091758dfe3fa0b6d68bb3e4e08deacaf685f8c217b8fea9a653ff4bd663c96c4294f8cb50\", \"line\": 690, \"relation\": \"negativeCorrelation\", \"source\": 286, \"target\": 272}, {\"citation\": {\"authors\": [\"Ehninger D\", \"Hettich MM\", \"Kickstein E\", \"Krau S\", \"Matthes F\", \"Pfurtscheller S\", \"Posey K\", \"Schneider R\", \"Schweiger S\", \"Weber S\"], \"date\": \"2017-10-23\", \"first\": \"Schweiger S\", \"last\": \"Krau S\", \"name\": \"Scientific reports\", \"pages\": \"13753\", \"reference\": \"29062069\", \"title\": \"Resveratrol induces dephosphorylation of Tau by interfering with the MID1-PP2A complex.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Here we show that resveratrol treatment directly interferes with the MID1-4-PP2A degradation complex by reducing MID1 protein expression in vitro and in vivo. This leads to an increase of microtubule-associated PP2A activity and a time- and dose-dependent dephosphorylation of Tau. Interestingly, we further show that MID1 expression is elevated in AD tissue.\", \"key\": \"2277cd03464270ef55b3d8cfac97e44880056fdfebabe9e97dd261d82085c5b8b975c19d1d78149544aba6f2207506f7ca0fab16712219269dc30d5148c8e712\", \"line\": 3792, \"object\": {\"modifier\": \"Activity\"}, \"relation\": \"negativeCorrelation\", \"source\": 286, \"target\": 347}, {\"annotations\": {\"Disease\": {\"Alzheimer's disease\": true, \"Down syndrome\": true}, \"Method\": {\"Immunohistochemistry\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Ando K\", \"Authelet M\", \"Belkouch M\", \"Brion JP\", \"Duyckaerts C\", \"Ndjim M\", \"Potier MC\", \"Sazdovitch V\", \"Suain V\", \"Tomimura K\", \"Vergara C\", \"Yilmaz Z\"], \"date\": \"2016-10-01\", \"first\": \"Ando K\", \"last\": \"Brion JP\", \"name\": \"Neurobiology of disease\", \"pages\": \"32-43\", \"reference\": \"27260836\", \"title\": \"Level of PICALM, a key component of clathrin-mediated endocytosis, is correlated with levels of phosphotau and autophagy-related proteins and is associated with tau inclusions in AD, PSP and Pick disease.\", \"type\": \"PubMed\", \"volume\": \"94\"}, \"evidence\": \"Phosphatidylinositol binding clathrin assembly protein, PICALM (aka CALM) assembles adaptor protein-2 (AP-2) to clathrin, thus participating in clathrin-mediated endocytosis. We have previously reported that the level of full-length PICALM is decreased in AD brains; PICALM was co-localised with phosphorylated tau in NFTs and in granulovacuolar degenerations (GVDs) in the brains of AD patients and of individuals with Down syndrome but was not observed in amyloid plaques (Ando et al., 2013).\", \"key\": \"984c0e30d40958c82cc727bd7e5f36a21bfe07466c1c39735c95ff022e6d084e646376e2cfc800b1e58bc5880245e53f5c0254726f269978c39e35740dc68051\", \"line\": 227, \"relation\": \"association\", \"source\": 286, \"target\": 341}, {\"annotations\": {\"Anatomy\": {\"striatum\": true}, \"Disease\": {\"progressive supranuclear palsy\": true}, \"Method\": {\"Immunohistochemistry\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Ando K\", \"Authelet M\", \"Belkouch M\", \"Brion JP\", \"Duyckaerts C\", \"Ndjim M\", \"Potier MC\", \"Sazdovitch V\", \"Suain V\", \"Tomimura K\", \"Vergara C\", \"Yilmaz Z\"], \"date\": \"2016-10-01\", \"first\": \"Ando K\", \"last\": \"Brion JP\", \"name\": \"Neurobiology of disease\", \"pages\": \"32-43\", \"reference\": \"27260836\", \"title\": \"Level of PICALM, a key component of clathrin-mediated endocytosis, is correlated with levels of phosphotau and autophagy-related proteins and is associated with tau inclusions in AD, PSP and Pick disease.\", \"type\": \"PubMed\", \"volume\": \"94\"}, \"evidence\": \"In PSP cases, both coiled bodies (Fig. 2 D-F) and NFTs (Fig. 2G-I) in the striatum showed a complete co-localisation of PICALM and phosphotau immunoreactivies.\", \"key\": \"7f14bafef49dafbdfdd4634402951abcff4ab7deb05d657c91dfe542d497394d46f09ae7cc80cd15e0d6c084c2668f53e57f5816a90c66000e9603810365fef0\", \"line\": 245, \"relation\": \"association\", \"source\": 286, \"target\": 341}, {\"citation\": {\"authors\": [\"Chung KM\", \"Hernndez N\", \"Sproul AA\", \"Yu WH\"], \"date\": \"2018-05-18\", \"first\": \"Chung KM\", \"last\": \"Yu WH\", \"name\": \"Neuroscience letters\", \"reference\": \"29758300\", \"title\": \"Alzheimer's disease and the autophagic-lysosomal system.\", \"type\": \"PubMed\"}, \"evidence\": \"Modulation of mTOR can influence the levels of tau, with upregulation increasing tau phosphorylation and accumulation by reducing autophagic clearance [87], and conversely, pharmacological treatment with rapamycin reducing tau levels and rescuing motor deficits in the Tau P301S mice [53]\", \"key\": \"bc13e5b33e28c63e33bcd0ef83530b6991236e1d37a7e3532c17b0055e78d9764e327638467f69de57ad1ae0161d20525b8f328c117d623770f42749ba914b02\", \"line\": 462, \"relation\": \"positiveCorrelation\", \"source\": 286, \"target\": 336}, {\"annotations\": {\"MeSHAnatomy\": {\"Cerebrospinal Fluid\": true}, \"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Chung KM\", \"Hernndez N\", \"Sproul AA\", \"Yu WH\"], \"date\": \"2018-05-18\", \"first\": \"Chung KM\", \"last\": \"Yu WH\", \"name\": \"Neuroscience letters\", \"reference\": \"29758300\", \"title\": \"Alzheimer's disease and the autophagic-lysosomal system.\", \"type\": \"PubMed\"}, \"evidence\": \"In a more recent GWAS investigation, TREM2 (triggering receptor expressed on myeloid cells 2) was identified as one of the markers strongly associated with increased levels of tau and phosphorylated tau in cerebrospinal fluid from AD patients [91].\", \"key\": \"be1c64af802c7580221e9dab486fe67729224e9435fe4ede50eadcd63fcfd2e1c33e928051739f91762ca303cf3350dbff0795a125ff565924005b14343a456b\", \"line\": 571, \"relation\": \"positiveCorrelation\", \"source\": 286, \"target\": 373}, {\"citation\": {\"authors\": [\"Brown LA\", \"Buckingham SD\", \"Jones AK\", \"Sattelle DB\"], \"date\": \"2009-03-01\", \"first\": \"Buckingham SD\", \"last\": \"Sattelle DB\", \"name\": \"Pharmacological reviews\", \"pages\": \"39-61\", \"reference\": \"19293145\", \"title\": \"Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection.\", \"type\": \"PubMed\", \"volume\": \"61\"}, \"evidence\": \"FYN expression is increased in brains from patients with AD, specifically in a subset of neurons with elevated hyperphosphorylated tau protein (Shirazi and Wood, 1993), but it is not known whether this increase in FYN contributes to hyperphosphorylation of tau or is a protective response to it. In extracts of human brains from patients with AD, soluble FYN increases with cognitive score and synaptophysin levels and inversely with the tangle count, suggestive of a pro-cognitive role for FYN (Ho et al., 2005).\", \"key\": \"1b41491d2608eec21a3c82ecae6867e542f4d35db066320b4119cdd023bd12a9eed7094de8fd353113a62a54d845542f7e77e047a16c3de3e181889200d583f6\", \"line\": 642, \"relation\": \"association\", \"source\": 286, \"target\": 230}, {\"citation\": {\"authors\": [\"Dickey CA\", \"Gestwicki JE\", \"Kiray J\", \"Koren J\", \"Miyata Y\"], \"date\": \"2011-09-01\", \"first\": \"Miyata Y\", \"last\": \"Gestwicki JE\", \"name\": \"Future medicinal chemistry\", \"pages\": \"1523-37\", \"reference\": \"21882945\", \"title\": \"Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.\", \"type\": \"PubMed\", \"volume\": \"3\"}, \"evidence\": \"However, another related BAG family member, BAG2, interacts with Hsp70 and tau but, unlike BAG1, assists clearance of phosphorylated tau [132]\", \"key\": \"44e155a2952486509896ac2fe83bcbc25e78d40f3d60b8894cbf02ce078d9503b40b6b162c8164ab3cccf8721b8f2b809f44bda646de529a8c56e8a841f50606\", \"line\": 381, \"relation\": \"association\", \"source\": 286, \"subject\": {\"modifier\": \"Degradation\"}, \"target\": 211}, {\"annotations\": {\"MeSHAnatomy\": {\"Post-Synaptic Density\": true}, \"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Arnal I\", \"Borel E\", \"Buisson A\", \"De Seranno S\", \"Elie A\", \"Frandemiche ML\", \"Lant F\", \"Rush T\"], \"date\": \"2014-04-23\", \"first\": \"Frandemiche ML\", \"last\": \"Buisson A\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"6084-97\", \"reference\": \"24760868\", \"title\": \"Activity-dependent tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"34\"}, \"evidence\": \"Conversely, only Abetao exposure promoted significant tau phosphorylation on Ser 404 (**p\\u00050.05, 1-way ANOVA; control 15.67\\u00042.418 vs Abetao 32.65 \\u0004 3.76 vs Bic/4-AP 26.75 \\u0004 1.17 vs Abetao         Bic/4-AP 24.97 \\u0004 4.48, N \\u0003 4). These results revealed that, although synaptic activation or Abetao promote tau translocation to PSD fractions, the synaptic tau displays a different phosphorylation profile that may be responsible for the conditional tau properties observed.\", \"key\": \"3f1a1aaeb80166ea083628c24c68b73b0829c921df8f3fd4de705f477ad8357213329f0a7f6279982ec2180bf551930860ae85367e96c29fd7173ea810bed3e2\", \"line\": 308, \"object\": {\"modifier\": \"Activity\"}, \"relation\": \"association\", \"source\": 286, \"target\": 244}, {\"annotations\": {\"CellLine\": {\"HEK293\": true}, \"MeSHAnatomy\": {\"Hippocampus\": true}, \"Method\": {\"Degradation Assay, 20S Proteasomal\": true, \"Immunohistochemistry\": true, \"Immunoprecipitation\": true, \"Pull-down Assay, GST\": true, \"SDS-PAGE\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Elliott E\", \"Ginzburg I\", \"Tsvetkov P\"], \"date\": \"2007-12-21\", \"first\": \"Elliott E\", \"last\": \"Ginzburg I\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"37276-84\", \"reference\": \"17954934\", \"title\": \"BAG-1 associates with Hsc70.Tau complex and regulates the proteasomal degradation of Tau protein.\", \"type\": \"PubMed\", \"volume\": \"282\"}, \"evidence\": \"We further show that BAG-1 can inhibit the degradation of Tau protein by the 20 S proteasome but does not affect the ubiquitination of Tau protein.RNA-me- diated interference depletion of BAG-1 leads to a decrease in total Tau protein levels as well as promoting hyperphosphorylation of the remaining protein.\", \"key\": \"aac5bc1f26827da492c090fa5df74e0dbc7dbc0250584680f3055bd8f0e8c42b804d07f0cf45c2610919c7e725040f731c662e05b2add9998ad26f769eca5220\", \"line\": 432, \"relation\": \"negativeCorrelation\", \"source\": 286, \"target\": 210}, {\"citation\": {\"authors\": [\"Albrecht F\", \"Arendt T\", \"Arsalan-Werner A\", \"Flach K\", \"Goedert M\", \"Herrmann L\", \"Hilbrich I\", \"Holzer M\", \"Ramminger E\"], \"date\": \"2014-09-01\", \"first\": \"Flach K\", \"last\": \"Holzer M\", \"name\": \"Biochimica et biophysica acta\", \"pages\": \"1527-38\", \"reference\": \"24905733\", \"title\": \"Axotrophin/MARCH7 acts as an E3 ubiquitin ligase and ubiquitinates tau protein in vitro impairing microtubule binding.\", \"type\": \"PubMed\", \"volume\": \"1842\"}, \"evidence\": \"We show that axotrophin/MARCH7, a RING-variant domain containing protein with similarity to E3 ubiquitin ligases interacts with tau. We find here that tau becomes mono-ubiquitinated by recombinant tau-interacting RING-variant domain, which diminishes its microtubule-binding. Tau becomes mono-ubiquitinated by recombinant tau-interacting RING-variant domain reducing microtubule-binding.\", \"key\": \"a2f18073d1f52db51b4e28b2a3188ef221b32fc5abb5890a9a07e0f311cae6cd7400a2e370f7be9ffcee719542f2bc69a6b71a061e6aeb04f98e5a9bcf674fbc\", \"line\": 3512, \"relation\": \"increases\", \"source\": 332, \"target\": 323}, {\"citation\": {\"authors\": [\"Bantscheff M\", \"Buist A\", \"Dewachter I\", \"Drewes G\", \"Faelth-Savitski M\", \"Joberty G\", \"Kienlen-Campard P\", \"Moechars D\", \"Octave JN\", \"Pierrot N\", \"Stancu IC\", \"Vanoosthuyse A\", \"Vasconcelos B\", \"Wang P\"], \"date\": \"2017-05-01\", \"first\": \"Wang P\", \"last\": \"Dewachter I\", \"name\": \"Acta neuropathologica\", \"pages\": \"731-749\", \"reference\": \"28083634\", \"title\": \"Tau interactome mappingbased identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo.\", \"type\": \"PubMed\", \"volume\": \"133\"}, \"evidence\": \"We focused particularly on Tau deubiquitination and identified three major candidate deubiquitinating enzymes, including Otub1, USP5, and USP9x, with Otub1 as the strongest Tau interactor according to statistical analysis\", \"key\": \"9e544660cb32a6d34804c99ce7e698ec277288fd18bf58d6ba11402c38ac5167c30b9bb987d4f2bb975b42983ba7ec27358edf4bf6215364f7719bdd4504a225\", \"line\": 78, \"relation\": \"decreases\", \"source\": 338, \"target\": 323}, {\"citation\": {\"authors\": [\"Bantscheff M\", \"Buist A\", \"Dewachter I\", \"Drewes G\", \"Faelth-Savitski M\", \"Joberty G\", \"Kienlen-Campard P\", \"Moechars D\", \"Octave JN\", \"Pierrot N\", \"Stancu IC\", \"Vanoosthuyse A\", \"Vasconcelos B\", \"Wang P\"], \"date\": \"2017-05-01\", \"first\": \"Wang P\", \"last\": \"Dewachter I\", \"name\": \"Acta neuropathologica\", \"pages\": \"731-749\", \"reference\": \"28083634\", \"title\": \"Tau interactome mappingbased identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo.\", \"type\": \"PubMed\", \"volume\": \"133\"}, \"evidence\": \"Otub1 displayed strong preference for disassembling Lys48-linked polyubiquitin chains, while leaving Lys63-linked polyubiquitin chains unaffected (Fig. 5a).\", \"key\": \"98714de2ef490afafa860b340e174282f526a01af577db58bd69adc46b33adf948dbd254b2a0c93ae175e556b4e57a8d65da2675d9db45a9885d2426a04d941f\", \"line\": 143, \"relation\": \"causesNoChange\", \"source\": 338, \"target\": 325}, {\"citation\": {\"authors\": [\"Bantscheff M\", \"Buist A\", \"Dewachter I\", \"Drewes G\", \"Faelth-Savitski M\", \"Joberty G\", \"Kienlen-Campard P\", \"Moechars D\", \"Octave JN\", \"Pierrot N\", \"Stancu IC\", \"Vanoosthuyse A\", \"Vasconcelos B\", \"Wang P\"], \"date\": \"2017-05-01\", \"first\": \"Wang P\", \"last\": \"Dewachter I\", \"name\": \"Acta neuropathologica\", \"pages\": \"731-749\", \"reference\": \"28083634\", \"title\": \"Tau interactome mappingbased identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo.\", \"type\": \"PubMed\", \"volume\": \"133\"}, \"evidence\": \"Otub1 displayed strong preference for disassembling Lys48-linked polyubiquitin chains, while leaving Lys63-linked polyubiquitin chains unaffected (Fig. 5a).\", \"key\": \"c4ac5a534ab5d6fc521afdc212c5a06e2aafc7816045d9a9872ed6dc1f6691b8f9b6d96cb95cae08b7d11634671cb20402570d19192238eba52e9c5d6b9dc7fa\", \"line\": 142, \"relation\": \"decreases\", \"source\": 338, \"target\": 324}, {\"annotations\": {\"MeSHAnatomy\": {\"Neurons\": true}}, \"citation\": {\"authors\": [\"Bantscheff M\", \"Buist A\", \"Dewachter I\", \"Drewes G\", \"Faelth-Savitski M\", \"Joberty G\", \"Kienlen-Campard P\", \"Moechars D\", \"Octave JN\", \"Pierrot N\", \"Stancu IC\", \"Vanoosthuyse A\", \"Vasconcelos B\", \"Wang P\"], \"date\": \"2017-05-01\", \"first\": \"Wang P\", \"last\": \"Dewachter I\", \"name\": \"Acta neuropathologica\", \"pages\": \"731-749\", \"reference\": \"28083634\", \"title\": \"Tau interactome mappingbased identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo.\", \"type\": \"PubMed\", \"volume\": \"133\"}, \"evidence\": \"Immunocytological analysis with AT8 antibody against phosphorylated Tau (Ser202/Thr205) demonstrated that Otub1 expression drastically increased phospho-Tau (p-Tau Ser202/Thr205) in primary neurons compared with GFP expression (Fig. 3a).\", \"key\": \"1a2aa3d71759a035b77c219e2120589c1e35ae0b4797eea3561b729e88f3e8c5e0b62049d00495cd7e64c667fc2a31cf69b401b21acd1f3c4a25f68862879363\", \"line\": 104, \"relation\": \"decreases\", \"source\": 338, \"target\": 291}, {\"annotations\": {\"MeSHAnatomy\": {\"Neurons\": true}}, \"citation\": {\"authors\": [\"Bantscheff M\", \"Buist A\", \"Dewachter I\", \"Drewes G\", \"Faelth-Savitski M\", \"Joberty G\", \"Kienlen-Campard P\", \"Moechars D\", \"Octave JN\", \"Pierrot N\", \"Stancu IC\", \"Vanoosthuyse A\", \"Vasconcelos B\", \"Wang P\"], \"date\": \"2017-05-01\", \"first\": \"Wang P\", \"last\": \"Dewachter I\", \"name\": \"Acta neuropathologica\", \"pages\": \"731-749\", \"reference\": \"28083634\", \"title\": \"Tau interactome mappingbased identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo.\", \"type\": \"PubMed\", \"volume\": \"133\"}, \"evidence\": \"Biochemical analysis confirmed a sharp increase of phosphorylated Tau at Ser202/Thr205 in Otub1-infected primary neurons (Fig. 3b).\", \"key\": \"779cb338ecc3efd64b32f9d1cee0118ba803f756977dc52bb99ab04ccae28e531dc62446d9efa84f2c60ad69fcd0161250c11d02d4114e113aada281a8650419\", \"line\": 110, \"relation\": \"decreases\", \"source\": 338, \"target\": 291}, {\"citation\": {\"authors\": [\"Bantscheff M\", \"Buist A\", \"Dewachter I\", \"Drewes G\", \"Faelth-Savitski M\", \"Joberty G\", \"Kienlen-Campard P\", \"Moechars D\", \"Octave JN\", \"Pierrot N\", \"Stancu IC\", \"Vanoosthuyse A\", \"Vasconcelos B\", \"Wang P\"], \"date\": \"2017-05-01\", \"first\": \"Wang P\", \"last\": \"Dewachter I\", \"name\": \"Acta neuropathologica\", \"pages\": \"731-749\", \"reference\": \"28083634\", \"title\": \"Tau interactome mappingbased identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo.\", \"type\": \"PubMed\", \"volume\": \"133\"}, \"evidence\": \"AAV-driven expression of Otub1-C91A did not increase AT8-positive Tau, in contrast to expression of wild-type Otub1 and the N-terminally truncated form of Otub1. This was demonstrated by immunofluorescence staining (Fig. 6a) and confirmed by biochemical analysis (Fig. 6b).\", \"key\": \"267d5eeac71f5e18e7a4d7377bddf834d405961e90754ef63525b3a426fe44dfb6b942179f43c126e399b3a133934e4b51868de78d124e4f1e07d64480226d2e\", \"line\": 167, \"relation\": \"increases\", \"source\": 338, \"target\": 291}, {\"citation\": {\"authors\": [\"Bantscheff M\", \"Buist A\", \"Dewachter I\", \"Drewes G\", \"Faelth-Savitski M\", \"Joberty G\", \"Kienlen-Campard P\", \"Moechars D\", \"Octave JN\", \"Pierrot N\", \"Stancu IC\", \"Vanoosthuyse A\", \"Vasconcelos B\", \"Wang P\"], \"date\": \"2017-05-01\", \"first\": \"Wang P\", \"last\": \"Dewachter I\", \"name\": \"Acta neuropathologica\", \"pages\": \"731-749\", \"reference\": \"28083634\", \"title\": \"Tau interactome mappingbased identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo.\", \"type\": \"PubMed\", \"volume\": \"133\"}, \"evidence\": \"We focused particularly on Tau deubiquitination and identified three major candidate deubiquitinating enzymes, including Otub1, USP5, and USP9x, with Otub1 as the strongest Tau interactor according to statistical analysis\", \"key\": \"c06ac94bc5fb2c2570ded93603dc68f09f4fe28c4a602e6e361755c1369ea972b71c0baf707ebc4cabff5e0a17d8ad126634027efe126d4b6c00b138bde9e9ba\", \"line\": 82, \"relation\": \"decreases\", \"source\": 378, \"target\": 323}, {\"citation\": {\"authors\": [\"Bantscheff M\", \"Buist A\", \"Dewachter I\", \"Drewes G\", \"Faelth-Savitski M\", \"Joberty G\", \"Kienlen-Campard P\", \"Moechars D\", \"Octave JN\", \"Pierrot N\", \"Stancu IC\", \"Vanoosthuyse A\", \"Vasconcelos B\", \"Wang P\"], \"date\": \"2017-05-01\", \"first\": \"Wang P\", \"last\": \"Dewachter I\", \"name\": \"Acta neuropathologica\", \"pages\": \"731-749\", \"reference\": \"28083634\", \"title\": \"Tau interactome mappingbased identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo.\", \"type\": \"PubMed\", \"volume\": \"133\"}, \"evidence\": \"We focused particularly on Tau deubiquitination and identified three major candidate deubiquitinating enzymes, including Otub1, USP5, and USP9x, with Otub1 as the strongest Tau interactor according to statistical analysis\", \"key\": \"a8742a67406b381f5947b5c5a63fb19a8a25b8b2092fae4e67464f3ae1f97bab72cdfb4bfef226b27624211603ce326326a28569471c030ae478005f29d45079\", \"line\": 80, \"relation\": \"decreases\", \"source\": 377, \"target\": 323}, {\"annotations\": {\"Cell_Line\": {\"COS7\": true}, \"Method\": {\"Deglycosylation Assay\": true, \"Dephosphorylation Assay\": true, \"Immunoblotting\": true, \"Immunocytochemistry\": true, \"Phosphorylation Assay\": true, \"Pull-down Assay, His-tagged\": true, \"SDS-PAGE\": true, \"Ubiquitination Assay\": true}}, \"citation\": {\"authors\": [\"Gygi SP\", \"Kosik KS\", \"Schwartz D\", \"Shimura H\"], \"date\": \"2004-02-06\", \"first\": \"Shimura H\", \"last\": \"Kosik KS\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"4869-76\", \"reference\": \"14612456\", \"title\": \"CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival.\", \"type\": \"PubMed\", \"volume\": \"279\"}, \"evidence\": \"This result strongly suggested that the E2 conjugating enzyme for tau ubiquitination is UbcH5B.\", \"key\": \"a699f18c7acef6482dd8a77645f77f2a0998ea108196cdfa3e089ce334ca0fe7e79bd374995257ee8fcd32b2e85de67ea67b0200c4c1571b5efb407e3d36f1be\", \"line\": 378, \"relation\": \"positiveCorrelation\", \"source\": 376, \"target\": 323}, {\"annotations\": {\"MeSHAnatomy\": {\"Dendrites\": true}}, \"citation\": {\"authors\": [\"Balaji V\", \"Kaniyappan S\", \"Mandelkow E\", \"Mandelkow EM\", \"Wang Y\"], \"date\": \"2018-01-01\", \"first\": \"Balaji V\", \"last\": \"Mandelkow EM\", \"name\": \"Autophagy\", \"pages\": \"2139-2154\", \"reference\": \"30145931\", \"title\": \"Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \" Missorted dendritic MAPT showed phosphorylation mainly at the 12E8 sites upon treatment with either the autophagy inhibitor wortmannin (Fig. 4B; 57.29.4% dendrites) or the proteasomal inhibitor epoxomicin (Fig. 4C, 62.97.4% dendrites) (Fig. 4A-C, quantification in Fig. 4D), but not at the AT8 and the PHF1 (p-S396/p-S404) sites (Fig. S5, Fig 4D).\", \"key\": \"3fc75b8f257c6d3876e5919e02d25cf6f6de5ac355e1cf5fb79fc5f26a7155081f87cf14cca0240c105562db1fb5d0f3d995606d9333493c605bf4ad9f8a6898\", \"line\": 161, \"relation\": \"causesNoChange\", \"source\": 34, \"target\": 312}, {\"annotations\": {\"MeSHAnatomy\": {\"Dendrites\": true}}, \"citation\": {\"authors\": [\"Balaji V\", \"Kaniyappan S\", \"Mandelkow E\", \"Mandelkow EM\", \"Wang Y\"], \"date\": \"2018-01-01\", \"first\": \"Balaji V\", \"last\": \"Mandelkow EM\", \"name\": \"Autophagy\", \"pages\": \"2139-2154\", \"reference\": \"30145931\", \"title\": \"Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \" Missorted dendritic MAPT showed phosphorylation mainly at the 12E8 sites upon treatment with either the autophagy inhibitor wortmannin (Fig. 4B; 57.29.4% dendrites) or the proteasomal inhibitor epoxomicin (Fig. 4C, 62.97.4% dendrites) (Fig. 4A-C, quantification in Fig. 4D), but not at the AT8 and the PHF1 (p-S396/p-S404) sites (Fig. S5, Fig 4D).\", \"key\": \"a57a2b13ceeb6fc8a1dac38c6d1c585b76159832e37f7617123239cc09ec1f00dd75e54ddf5985d1dbb3cf6b26c2e5e917e124c72de34590880b48d7c14f6beb\", \"line\": 160, \"relation\": \"causesNoChange\", \"source\": 34, \"target\": 290}, {\"annotations\": {\"MeSHAnatomy\": {\"Dendrites\": true}}, \"citation\": {\"authors\": [\"Balaji V\", \"Kaniyappan S\", \"Mandelkow E\", \"Mandelkow EM\", \"Wang Y\"], \"date\": \"2018-01-01\", \"first\": \"Balaji V\", \"last\": \"Mandelkow EM\", \"name\": \"Autophagy\", \"pages\": \"2139-2154\", \"reference\": \"30145931\", \"title\": \"Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \" Missorted dendritic MAPT showed phosphorylation mainly at the 12E8 sites upon treatment with either the autophagy inhibitor wortmannin (Fig. 4B; 57.29.4% dendrites) or the proteasomal inhibitor epoxomicin (Fig. 4C, 62.97.4% dendrites) (Fig. 4A-C, quantification in Fig. 4D), but not at the AT8 and the PHF1 (p-S396/p-S404) sites (Fig. S5, Fig 4D).\", \"key\": \"6a55ae4a93c4cafffde86a92c9f5db3509a0a19dba4b682691f73e638eecf1219995e2e17b447eaaaae4e33dfe3ce517098aeeaed9f677bbd3e0ae6194c6afe0\", \"line\": 157, \"relation\": \"positiveCorrelation\", \"source\": 34, \"target\": 303}, {\"annotations\": {\"MeSHAnatomy\": {\"Dendrites\": true}}, \"citation\": {\"authors\": [\"Balaji V\", \"Kaniyappan S\", \"Mandelkow E\", \"Mandelkow EM\", \"Wang Y\"], \"date\": \"2018-01-01\", \"first\": \"Balaji V\", \"last\": \"Mandelkow EM\", \"name\": \"Autophagy\", \"pages\": \"2139-2154\", \"reference\": \"30145931\", \"title\": \"Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \" Missorted dendritic MAPT showed phosphorylation mainly at the 12E8 sites upon treatment with either the autophagy inhibitor wortmannin (Fig. 4B; 57.29.4% dendrites) or the proteasomal inhibitor epoxomicin (Fig. 4C, 62.97.4% dendrites) (Fig. 4A-C, quantification in Fig. 4D), but not at the AT8 and the PHF1 (p-S396/p-S404) sites (Fig. S5, Fig 4D).\", \"key\": \"405e510efa911cfd296e32ae6c508fc35a13a5e756c722a19040f3c747a09b7c6b9ce41e03c09767c1a42827122be8836e2c0f6bd8c92915d7051f1525174cff\", \"line\": 156, \"relation\": \"positiveCorrelation\", \"source\": 34, \"target\": 297}, {\"annotations\": {\"Cell_Line\": {\"COS7\": true}, \"Method\": {\"Deglycosylation Assay\": true, \"Dephosphorylation Assay\": true, \"Immunoblotting\": true, \"Immunocytochemistry\": true, \"Phosphorylation Assay\": true, \"Pull-down Assay, His-tagged\": true, \"SDS-PAGE\": true, \"Ubiquitination Assay\": true}}, \"citation\": {\"authors\": [\"Gygi SP\", \"Kosik KS\", \"Schwartz D\", \"Shimura H\"], \"date\": \"2004-02-06\", \"first\": \"Shimura H\", \"last\": \"Kosik KS\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"4869-76\", \"reference\": \"14612456\", \"title\": \"CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival.\", \"type\": \"PubMed\", \"volume\": \"279\"}, \"evidence\": \"These data indicated that phosphorylation of PP2A dephosphorylation sites is an important recognition signal for ubiquitination. We used 200 g of amino-terminal His-tagged full-length recombinant human tau in an in vitro phosphorylation reaction with GSK-3Beta. When phosphorylated, the tau protein reacted on immunoblots with PHF1 (25, 26) and AT8 (24), indicating that at least sites Ser202, Thr205, Ser396, and Ser404 were phosphorylated. Following GSK-3Beta incubation, this tau served as an excellent substrate for in vitro ubiquitination using UbcH5B and the cofactor fraction from AD tau immunoprecipitates (Fig. 2a). This finding suggested that GSK-3Beta can place phosphates on tau that create recognition sites for an E3 Ub ligase.\", \"key\": \"e4866c9e2a49470a9dede75c8e33f3e828b7d03beb2813119857f85b97ff7cd3fff15e7ef42be01f17d827eb152e5df99e1f4cdd4a7bda76819647415e30961a\", \"line\": 394, \"relation\": \"isA\", \"source\": 312, \"target\": 286}, {\"annotations\": {\"MeSHAnatomy\": {\"Dendrites\": true}}, \"citation\": {\"authors\": [\"Balaji V\", \"Kaniyappan S\", \"Mandelkow E\", \"Mandelkow EM\", \"Wang Y\"], \"date\": \"2018-01-01\", \"first\": \"Balaji V\", \"last\": \"Mandelkow EM\", \"name\": \"Autophagy\", \"pages\": \"2139-2154\", \"reference\": \"30145931\", \"title\": \"Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \"In addition, it has been reported that in cultured neurons, A oligomers induce MAPT missorting into the somatodendritic compartment, and the missorted MAPT is phosphorylated mainly at the 12E8 (p-S262/p-S356) and AT8 (p-S202/p-T205) sites [6].\", \"key\": \"f8c8b03871dcc9d4107a607c0f3ba0769cb791eee7cadf3f09e6da5de69add7cdad9b41ebf54fab924bdf1928c99402e4cb22a86fb232dcfc2092247dce9041e\", \"line\": 147, \"relation\": \"positiveCorrelation\", \"source\": 312, \"target\": 52}, {\"annotations\": {\"Method\": {\"Electron Microscopy, Transmission\": true, \"NMR Spectroscopy\": true, \"Thioflavin T Assay\": true}, \"Tau_Epitope\": {\"AT8\": true}}, \"citation\": {\"authors\": [\"Baulieu EE\", \"Byrne C\", \"Cantrelle FX\", \"Chambraud B\", \"Despres C\", \"Huvent I\", \"Jacquot Y\", \"Landrieu I\", \"Lippens G\", \"Qi H\", \"Smet-Nocca C\"], \"date\": \"2017-08-22\", \"first\": \"Despres C\", \"last\": \"Smet-Nocca C\", \"name\": \"Proceedings of the National Academy of Sciences of the United States of America\", \"pages\": \"9080-9085\", \"reference\": \"28784767\", \"title\": \"Identification of the Tau phosphorylation pattern that drives its aggregation.\", \"type\": \"PubMed\", \"volume\": \"114\"}, \"evidence\": \"When combined with ERK2 catalyzed phosphorylation, the turn-like disrupting G207V mutation in TauF8 hence leads to fast aggregation that already occurs during the phosphorylation reaction.\", \"key\": \"0c83d70bf47e9e3595fead70044117c5e45686cee8a349e68fd457be9cadb043d207eece9c0ec187643959a2c1bce6b065dbbf5fc8efd3977e83a51b200f2657\", \"line\": 84, \"relation\": \"partOf\", \"source\": 312, \"target\": 187}, {\"citation\": {\"authors\": [\"Kawakami F\", \"Ohtsuki K\", \"Suzuki K\"], \"date\": \"2008-02-01\", \"first\": \"Kawakami F\", \"last\": \"Ohtsuki K\", \"name\": \"Biological &amp; pharmaceutical bulletin\", \"pages\": \"193-200\", \"reference\": \"18239272\", \"title\": \"A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"Epitopes S198, S199, S202, T205, S422 (Lund 2013)\", \"key\": \"da9ede1f3f483b4c032f1f194cbaaa93e4445a44aaf84bed6b503af83b3285e85d397851f726b5a75c2b6c41e11600bc16551f5a7ed947645ce25f49f712a3ef\", \"line\": 1295, \"relation\": \"partOf\", \"source\": 312, \"target\": 187}, {\"annotations\": {\"Confidence\": {\"High\": true}, \"MeSHAnatomy\": {\"Intracellular Space\": true}, \"PublicationType\": {\"Review\": true}}, \"citation\": {\"authors\": [\"Binder LI\", \"Himmelstein DS\", \"Lancia JK\", \"Ward SM\"], \"date\": \"2012-08-01\", \"first\": \"Ward SM\", \"last\": \"Binder LI\", \"name\": \"Biochemical Society transactions\", \"pages\": \"667-71\", \"reference\": \"22817713\", \"title\": \"Tau oligomers and tau toxicity in neurodegenerative disease.\", \"type\": \"PubMed\", \"volume\": \"40\"}, \"evidence\": \"TNT1 also co-localizes in tissue with the phospho-epitope defined by the AT8 antibody, indicating that PAD exposure represents an early event in AD pathology\", \"key\": \"6f4e67d55ba3bfb012ad3682cc1da90ad571b5ca35859e208271a031feea12cab2f02ef4f79f4ce647840bd23874d24031e383b5e0794386600ea5b38794ad5e\", \"line\": 171, \"relation\": \"association\", \"source\": 312, \"target\": 39}, {\"annotations\": {\"Confidence\": {\"High\": true}, \"MeSHAnatomy\": {\"Intracellular Space\": true}, \"PublicationType\": {\"Review\": true}}, \"citation\": {\"authors\": [\"Binder LI\", \"Himmelstein DS\", \"Lancia JK\", \"Ward SM\"], \"date\": \"2012-08-01\", \"first\": \"Ward SM\", \"last\": \"Binder LI\", \"name\": \"Biochemical Society transactions\", \"pages\": \"667-71\", \"reference\": \"22817713\", \"title\": \"Tau oligomers and tau toxicity in neurodegenerative disease.\", \"type\": \"PubMed\", \"volume\": \"40\"}, \"evidence\": \"TNT1 also co-localizes in tissue with the phospho-epitope defined by the AT8 antibody, indicating that PAD exposure represents an early event in AD pathology\", \"key\": \"22da4976c0ae7f583c2dfb0fd720b0232d3dcd20bf11bc67da6351e226eb90d3d550d5b169f56344c19447a271fed9ccfe0a7187f1a69b06ff08cc05eb6a063a\", \"line\": 173, \"relation\": \"association\", \"source\": 312, \"target\": 46}, {\"annotations\": {\"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Cornwell LB\", \"Gylys KH\", \"Henkins KM\", \"Miller CA\", \"Poon WW\", \"Saing T\", \"Sokolow S\", \"Vinters HV\"], \"date\": \"2012-11-01\", \"first\": \"Henkins KM\", \"last\": \"Gylys KH\", \"name\": \"Brain pathology (Zurich, Switzerland)\", \"pages\": \"826-33\", \"reference\": \"22486774\", \"title\": \"Extensive p-tau pathology and SDS-stable p-tau oligomers in Alzheimer's cortical synapses.\", \"type\": \"PubMed\", \"volume\": \"22\"}, \"evidence\": \"Oligomers positive for pS202/pT205 accumulate at synapses in AD\", \"key\": \"8b221d2ec935d3e90753d4c572a368642d568f80d7fcb3bac2a79a37eb69094e252532d4848de377a42898561a9f4d5a60cb68828c99ea94e02e2a9e670d27c7\", \"line\": 2631, \"relation\": \"partOf\", \"source\": 312, \"target\": 46}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"e0743fe9706d8f6353d08e0e5712599e5626d402f85b9f41cd4f167b9a4b69fb3a048c0fe2055ec5c1a9a43a3306f9a901a7b261c084faf8edaaf364242e533f\", \"line\": 1124, \"relation\": \"positiveCorrelation\", \"source\": 312, \"target\": 164}, {\"annotations\": {\"Species\": {\"10116\": true}}, \"citation\": {\"authors\": [\"Ai J\", \"Ban T\", \"Bao YN\", \"Chen QX\", \"Hu XL\", \"Jiang XM\", \"Liu CD\", \"Pei SC\", \"Su XL\", \"Sun LH\", \"Sun LL\", \"Wang X\", \"Yan ML\", \"Zhao LJ\", \"Zong DK\"], \"date\": \"2015-09-01\", \"first\": \"Sun LH\", \"last\": \"Ai J\", \"name\": \"Journal of neurochemistry\", \"pages\": \"1139-51\", \"reference\": \"26118667\", \"title\": \"Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.\", \"type\": \"PubMed\", \"volume\": \"134\"}, \"evidence\": \"Endogenous miR-195 was knocked down using over-expression of its antisense molecule (pre-AMO-miR-195) via a lentivirus (lenti-pre-AMO-miR-195); this knockdown increased the tau phosphorylation at Ser202/Thr205, Ser262, Thr231, Ser422, and the Cdk5/p25 activation, but over-expression of miR-195 using lenti-pre-miR-195 decreased the tau phosphorylation and Cdk5/p25 activation.\", \"key\": \"28ed2f012fd38c4d64f9e1b5a58444f4b769c1abc99c5a1eb8ba70a708a5332f56ccd55d21d71da20681792b9e9cffdec7a0daff48c48fefb8dea5151c346b56\", \"line\": 2332, \"relation\": \"negativeCorrelation\", \"source\": 312, \"target\": 153}, {\"annotations\": {\"Disease_Progression\": {\"Late Stage\": true}, \"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Castillo-Carranza DL\", \"Jackson GR\", \"Kayed R\", \"Lasagna-Reeves CA\", \"Sarmiento J\", \"Sengupta U\", \"Troncoso J\"], \"date\": \"2012-05-01\", \"first\": \"Lasagna-Reeves CA\", \"last\": \"Kayed R\", \"name\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\", \"pages\": \"1946-59\", \"reference\": \"22253473\", \"title\": \"Identification of oligomers at early stages of tau aggregation in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"26\"}, \"evidence\": \"Phosphorylation at the epitope Ser202/Thr205 is regarded as a good marker for late-stage NFTs (5, 72). Hyman and colleagues (5) demonstrated that AT8 immunoreactivity is present primarily in eNFTs and in certain cases in iNFTs. These investigators also found that AT8 revealed dense neuropil thread staining.\", \"key\": \"bceba1f946ae45359442accdc9326e92a831ddf1c228fea3605d1ba39320032d707c0cb869f996ad4fc5cb53327d68d7db8c8df595b4f3b2a12a3e5c7b1ff51d\", \"line\": 2621, \"relation\": \"partOf\", \"source\": 312, \"target\": 35}, {\"annotations\": {\"Research_Model\": {\"rTg4510 mice\": true}}, \"citation\": {\"authors\": [\"Boehm J\", \"Bourgeois C\", \"Dudilot A\", \"Lauzon M\", \"Leclerc N\", \"Mondragn-Rodrguez S\", \"Trillaud-Doppia E\"], \"date\": \"2012-09-14\", \"first\": \"Mondragn-Rodrguez S\", \"last\": \"Boehm J\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"32040-53\", \"reference\": \"22833681\", \"title\": \"Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.\", \"type\": \"PubMed\", \"volume\": \"287\"}, \"evidence\": \"Acute treatment of rTg4510 mice with an O-GlcNAcase inhibitor transiently reduced tau phosphorylation at epitopes implicated in tau pathology. More importantly, long-term inhibitor treatment strongly increased tau O-GlcNAcylation, reduced the number of dystrophic neurons, and protected against the formation of pathological tau species without altering the phosphorylation of non-pathological tau.\", \"key\": \"72ccf29ee9c3cc799684ea8327d4a6bd0eb8fc2cefc231da60372fb4a396602b8edd56ab5cfb239df577d2b3508a4fabfb4dde3e8562581a8386c5499518374d\", \"line\": 2507, \"relation\": \"positiveCorrelation\", \"source\": 312, \"target\": 272}, {\"annotations\": {\"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Arnal I\", \"Borel E\", \"Buisson A\", \"De Seranno S\", \"Elie A\", \"Frandemiche ML\", \"Lant F\", \"Rush T\"], \"date\": \"2014-04-23\", \"first\": \"Frandemiche ML\", \"last\": \"Buisson A\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"6084-97\", \"reference\": \"24760868\", \"title\": \"Activity-dependent tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"34\"}, \"evidence\": \"We observed that synaptic activation promoted EGFP-Tau T205A translocation to the spine but FRAP experiments revealed a shorter tau turnover time in the spine (Fig. 9B), whereas Abetao driven translocation to the spine was no longer observable in EGFP-Tau S404A-transfected neurons (Fig. 9F,G). These experiments highlight the pivotal role of these phosphorylations in tau translocation features to the spine.\", \"key\": \"db3f3fa392828f4fb262bd100257e6ddb10845bf011845062cdca7ca14e118009b70eb653ae805e3a6c16a59b6a6dc4c0d1193aa10b66d75385ced92a6486a02\", \"line\": 323, \"object\": {\"location\": {\"name\": \"Dendritic Spines\", \"namespace\": \"MESH\"}}, \"relation\": \"increases\", \"source\": 312, \"target\": 244}, {\"annotations\": {\"Research_Model\": {\"pR5 mice\": true}, \"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Dinekov M\", \"Gtz J\", \"Khler C\"], \"date\": \"2013-05-01\", \"first\": \"Khler C\", \"last\": \"Gtz J\", \"name\": \"Neurobiology of aging\", \"pages\": \"1369-79\", \"reference\": \"23294633\", \"title\": \"Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"34\"}, \"evidence\": \"We studied underlying pathomechanisms in tauopathies using pR5 mice that express the P301L tau mutation found in familial forms of frontotemporal dementia. In a longitudinal study we investigated the functional status of glycogen synthase kinase-3 and correlated it with the appearance of distinct tau phospho-epitopes. Neurons displaying increases in activating phosphorylation of glycogen synthase kinase-3/ at tyrosine 279/216 also showed an intense rather than moderate AT8 (phospho-Ser202/Thr205 tau) immunoreactivity, and immunoreactivity for AT100 (phospho-Ser212/Thr214 tau) and phosphorylated Ser422, phospho-epitopes associated with fibrillar tau pathology.\", \"key\": \"70b72ae48c0bebbe333f00dbc56158176696f6f3be8d9719b3d99d8098ae68dba4424ac101eb98ed85b7b3c7e94891da2b031b8ef2bbb3446136446b6628ad9d\", \"line\": 2543, \"relation\": \"positiveCorrelation\", \"source\": 312, \"target\": 329}, {\"annotations\": {\"Research_Model\": {\"TPR50 mice\": true}, \"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Hattori M\", \"Horiguchi T\", \"Iwashita H\", \"Matsumoto Y\", \"Nakamura K\", \"Obayashi Y\", \"Onishi T\", \"Yano T\"], \"date\": \"2014-03-01\", \"first\": \"Onishi T\", \"last\": \"Iwashita H\", \"name\": \"Neuroscience research\", \"pages\": \"76-85\", \"reference\": \"24406748\", \"title\": \"Early-onset cognitive deficits and axonal transport dysfunction in P301S mutant tau transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"80\"}, \"evidence\": \"We developed a transgenic mouse, named TPR50, harboring human P301S tau. Tau phosphorylation in the hippocampus of TPR50 mice increased with age, particularly at S202/T205. Therefore, cognitive dysfunction in TPR50 mice may result from early MT dysfunction and impaired axonal transport rather than accumulation of insoluble tau and neurodegeneration.\", \"key\": \"8c2c2cd46b7a9db97539888ede19e19bfc6902e15a00ca8c825320dab915b9e5a361cbb959b99808ebe3829eb0db5791cbd1fb65e7b3fa5e29688a4016a93e26\", \"line\": 2524, \"relation\": \"positiveCorrelation\", \"source\": 312, \"target\": 330}, {\"annotations\": {\"MeSHAnatomy\": {\"Dendrites\": true}}, \"citation\": {\"authors\": [\"Balaji V\", \"Kaniyappan S\", \"Mandelkow E\", \"Mandelkow EM\", \"Wang Y\"], \"date\": \"2018-01-01\", \"first\": \"Balaji V\", \"last\": \"Mandelkow EM\", \"name\": \"Autophagy\", \"pages\": \"2139-2154\", \"reference\": \"30145931\", \"title\": \"Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \" Missorted dendritic MAPT showed phosphorylation mainly at the 12E8 sites upon treatment with either the autophagy inhibitor wortmannin (Fig. 4B; 57.29.4% dendrites) or the proteasomal inhibitor epoxomicin (Fig. 4C, 62.97.4% dendrites) (Fig. 4A-C, quantification in Fig. 4D), but not at the AT8 and the PHF1 (p-S396/p-S404) sites (Fig. S5, Fig 4D).\", \"key\": \"d949feadb01f1131da9b57904c7843b7dc2f54347a46d44e8b21314e492bc8e5ce79feb0badc3e7adb7c8a7f29c311e63ea9d7e8ad997ad77a320ea1c23773cb\", \"line\": 163, \"relation\": \"causesNoChange\", \"source\": 21, \"target\": 312}, {\"annotations\": {\"MeSHAnatomy\": {\"Dendrites\": true}}, \"citation\": {\"authors\": [\"Balaji V\", \"Kaniyappan S\", \"Mandelkow E\", \"Mandelkow EM\", \"Wang Y\"], \"date\": \"2018-01-01\", \"first\": \"Balaji V\", \"last\": \"Mandelkow EM\", \"name\": \"Autophagy\", \"pages\": \"2139-2154\", \"reference\": \"30145931\", \"title\": \"Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \" Missorted dendritic MAPT showed phosphorylation mainly at the 12E8 sites upon treatment with either the autophagy inhibitor wortmannin (Fig. 4B; 57.29.4% dendrites) or the proteasomal inhibitor epoxomicin (Fig. 4C, 62.97.4% dendrites) (Fig. 4A-C, quantification in Fig. 4D), but not at the AT8 and the PHF1 (p-S396/p-S404) sites (Fig. S5, Fig 4D).\", \"key\": \"5d6ddd9a36cfbf5a98d2371f30c35436364d7d3f8290b0de9dcab9ef954a40d2062fb38d9a774e8110ac5db3f33ebe482e18176321e0f1d82940c375e595a1f2\", \"line\": 162, \"relation\": \"causesNoChange\", \"source\": 21, \"target\": 290}, {\"annotations\": {\"MeSHAnatomy\": {\"Dendrites\": true}}, \"citation\": {\"authors\": [\"Balaji V\", \"Kaniyappan S\", \"Mandelkow E\", \"Mandelkow EM\", \"Wang Y\"], \"date\": \"2018-01-01\", \"first\": \"Balaji V\", \"last\": \"Mandelkow EM\", \"name\": \"Autophagy\", \"pages\": \"2139-2154\", \"reference\": \"30145931\", \"title\": \"Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \" Missorted dendritic MAPT showed phosphorylation mainly at the 12E8 sites upon treatment with either the autophagy inhibitor wortmannin (Fig. 4B; 57.29.4% dendrites) or the proteasomal inhibitor epoxomicin (Fig. 4C, 62.97.4% dendrites) (Fig. 4A-C, quantification in Fig. 4D), but not at the AT8 and the PHF1 (p-S396/p-S404) sites (Fig. S5, Fig 4D).\", \"key\": \"57216ecdce51c4e73f3471a4cb7bf58b24039370fc172ccfd22eb9dcdcc766fb43ad96716ecfaeb7899cddc1b6e2364ba49ca30cd556ff4c35d5234e48579241\", \"line\": 159, \"relation\": \"positiveCorrelation\", \"source\": 21, \"target\": 303}, {\"annotations\": {\"MeSHAnatomy\": {\"Dendrites\": true}}, \"citation\": {\"authors\": [\"Balaji V\", \"Kaniyappan S\", \"Mandelkow E\", \"Mandelkow EM\", \"Wang Y\"], \"date\": \"2018-01-01\", \"first\": \"Balaji V\", \"last\": \"Mandelkow EM\", \"name\": \"Autophagy\", \"pages\": \"2139-2154\", \"reference\": \"30145931\", \"title\": \"Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \" Missorted dendritic MAPT showed phosphorylation mainly at the 12E8 sites upon treatment with either the autophagy inhibitor wortmannin (Fig. 4B; 57.29.4% dendrites) or the proteasomal inhibitor epoxomicin (Fig. 4C, 62.97.4% dendrites) (Fig. 4A-C, quantification in Fig. 4D), but not at the AT8 and the PHF1 (p-S396/p-S404) sites (Fig. S5, Fig 4D).\", \"key\": \"e47e768af19e239997ab9c470d42a11ef7ab6fbcf21095be7082c75b5b78b9a3ee80338c357cad0a6cca65085370d5019f5fd98025498c5ba70c79ec2f045e7d\", \"line\": 158, \"relation\": \"positiveCorrelation\", \"source\": 21, \"target\": 297}, {\"annotations\": {\"MeSHAnatomy\": {\"Post-Synaptic Density\": true}, \"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Arnal I\", \"Borel E\", \"Buisson A\", \"De Seranno S\", \"Elie A\", \"Frandemiche ML\", \"Lant F\", \"Rush T\"], \"date\": \"2014-04-23\", \"first\": \"Frandemiche ML\", \"last\": \"Buisson A\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"6084-97\", \"reference\": \"24760868\", \"title\": \"Activity-dependent tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"34\"}, \"evidence\": \"Thr-205 phosphorylated tau was only increased under synaptic activation in the PSD fraction (control 24.57 \\u0004 0.9754 vs Bic/4-AP 38.90 \\u0004 1.936; Fig. 9E), whereas it was decreased after Abetao treatment (control 24.57 \\u0004 0.9754 vs Abeta 13.64 \\u0004 2.416). Synaptic activation after Abetao exposure did not produce any significant Thr-205 phosphorylation of tau (Abeta          Bic/4-AP 22.89\\u00042.796 vs Bic/ 4-AP 38.90 \\u0004 1.93 vs Abeta 13.64\\u00042.50).\", \"key\": \"6deca66b37652c3daa84b557fd132e7311b60ae5750466e06be1ce5a427aa82bd10a5f9102c472ec4626a2936ada3d8e465f64a60a9dc9736d4fd5ee4e576a59\", \"line\": 289, \"relation\": \"increases\", \"source\": 82, \"target\": 312}, {\"citation\": {\"authors\": [\"Chandupatla RR\", \"Kaniyappan S\", \"Mandelkow E\", \"Mandelkow EM\"], \"date\": \"2017-11-01\", \"first\": \"Kaniyappan S\", \"last\": \"Mandelkow E\", \"name\": \"Alzheimer's &amp; dementia : the journal of the Alzheimer's Association\", \"pages\": \"1270-1291\", \"reference\": \"28528849\", \"title\": \"Extracellular low-n oligomers of tau cause selective synaptotoxicity without affecting cell viability.\", \"type\": \"PubMed\", \"volume\": \"13\"}, \"evidence\": \"We also checked the phosphorylation of tau at other sites (e.g., using the antibody AT8, reacting only with the endogenous tau) and did not observe an increase in the phosphorylation.\", \"key\": \"e14c6d5342c4605d012536d103bf28474dacd8220dea4ad4b2e78b223789ef07fc1fe63ef91c4029dba4de3a31c39e9202230b6073e39db37d493b95fc012f61\", \"line\": 245, \"relation\": \"causesNoChange\", \"source\": 190, \"target\": 312}, {\"citation\": {\"authors\": [\"Chandupatla RR\", \"Kaniyappan S\", \"Mandelkow E\", \"Mandelkow EM\"], \"date\": \"2017-11-01\", \"first\": \"Kaniyappan S\", \"last\": \"Mandelkow E\", \"name\": \"Alzheimer's &amp; dementia : the journal of the Alzheimer's Association\", \"pages\": \"1270-1291\", \"reference\": \"28528849\", \"title\": \"Extracellular low-n oligomers of tau cause selective synaptotoxicity without affecting cell viability.\", \"type\": \"PubMed\", \"volume\": \"13\"}, \"evidence\": \"We also checked the phosphorylation of tau at other sites (e.g., using the antibody AT8, reacting only with the endogenous tau) and did not observe an increase in the phosphorylation.\", \"key\": \"65516470ae69cc978a110d9bcb8ded044bd5ea39630b6ebb477cf61e7d68411cae9f8a6de1936047c1b15c04d3c4cc8409c720f72f3b531715cd36e633ffdb9c\", \"line\": 244, \"relation\": \"causesNoChange\", \"source\": 190, \"target\": 290}, {\"citation\": {\"authors\": [\"Chandupatla RR\", \"Kaniyappan S\", \"Mandelkow E\", \"Mandelkow EM\"], \"date\": \"2017-11-01\", \"first\": \"Kaniyappan S\", \"last\": \"Mandelkow E\", \"name\": \"Alzheimer's &amp; dementia : the journal of the Alzheimer's Association\", \"pages\": \"1270-1291\", \"reference\": \"28528849\", \"title\": \"Extracellular low-n oligomers of tau cause selective synaptotoxicity without affecting cell viability.\", \"type\": \"PubMed\", \"volume\": \"13\"}, \"evidence\": \"We did not observe any increase in the phosphorylation of the tau repeat domain (as seen by the antibody 12E8) after treating the neurons with TauRDK oligomers.\", \"key\": \"eed11b8dc5b9c9faef6f7504fa292bbc7c0ac6c015a1541a547c93699d8555dff1ce9d7ae2bb927d61a9497d47d618d40a383d6bbf407e0e6d432e315ead4647\", \"line\": 240, \"relation\": \"causesNoChange\", \"source\": 190, \"target\": 297}, {\"annotations\": {\"Confidence\": {\"High\": true}, \"MeSHAnatomy\": {\"Intracellular Space\": true}, \"PublicationType\": {\"Review\": true}}, \"citation\": {\"authors\": [\"Binder LI\", \"Himmelstein DS\", \"Lancia JK\", \"Ward SM\"], \"date\": \"2012-08-01\", \"first\": \"Ward SM\", \"last\": \"Binder LI\", \"name\": \"Biochemical Society transactions\", \"pages\": \"667-71\", \"reference\": \"22817713\", \"title\": \"Tau oligomers and tau toxicity in neurodegenerative disease.\", \"type\": \"PubMed\", \"volume\": \"40\"}, \"evidence\": \"TNT1 also co-localizes in tissue with the phospho-epitope defined by the AT8 antibody, indicating that PAD exposure represents an early event in AD pathology\", \"key\": \"7c2c1a2600459b8bd2ddc117941bf94e3793a941ebddce53f975f2c0c94328fc5c5750aac0a9f1ec2083df2025c9c4579929f3c8c52706dd66ef3acfce3d46fd\", \"line\": 173, \"relation\": \"association\", \"source\": 46, \"target\": 312}, {\"annotations\": {\"Confidence\": {\"Medium\": true}, \"MeSHAnatomy\": {\"Intracellular Space\": true}, \"PublicationType\": {\"Review\": true}}, \"citation\": {\"authors\": [\"Binder LI\", \"Himmelstein DS\", \"Lancia JK\", \"Ward SM\"], \"date\": \"2012-08-01\", \"first\": \"Ward SM\", \"last\": \"Binder LI\", \"name\": \"Biochemical Society transactions\", \"pages\": \"667-71\", \"reference\": \"22817713\", \"title\": \"Tau oligomers and tau toxicity in neurodegenerative disease.\", \"type\": \"PubMed\", \"volume\": \"40\"}, \"evidence\": \"TOC1s immunoreactivity is greatly elevated in AD brains compared with healthy controls, but co-localizes best with early-stage markers for AD pathogenesis such as pS422 [16]\", \"key\": \"713c77db1ad4f48cb65b567d26c84c3ce9576a76c6e62b0604f31cd8cd6fe067cbfba82079a117675ddf5b4dc6eeac1b473ec4553c0862bb0333970c55b138d9\", \"line\": 124, \"relation\": \"association\", \"source\": 46, \"target\": 309}, {\"annotations\": {\"Confidence\": {\"High\": true}, \"MeSHAnatomy\": {\"Intracellular Space\": true}, \"PublicationType\": {\"Review\": true}}, \"citation\": {\"authors\": [\"Binder LI\", \"Himmelstein DS\", \"Lancia JK\", \"Ward SM\"], \"date\": \"2012-08-01\", \"first\": \"Ward SM\", \"last\": \"Binder LI\", \"name\": \"Biochemical Society transactions\", \"pages\": \"667-71\", \"reference\": \"22817713\", \"title\": \"Tau oligomers and tau toxicity in neurodegenerative disease.\", \"type\": \"PubMed\", \"volume\": \"40\"}, \"evidence\": \"TNT1 also co-localizes in tissue with the phospho-epitope defined by the AT8 antibody, indicating that PAD exposure represents an early event in AD pathology\", \"key\": \"66d55f6841e232ba387f43121d7cc5e457f1eda2570f3c09657ec46e5c79f2192a4ab6c78b7b0ef35108c230a2192ed41b4ffce0791eeb67a074d9620cf1fbe1\", \"line\": 172, \"relation\": \"association\", \"source\": 46, \"target\": 290}, {\"annotations\": {\"Anatomy\": {\"hippocampal formation\": true}, \"Method\": {\"Cell Viability Assay, MTT\": true, \"Confocal Laser Microscopy\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"An FM\", \"Chen S\", \"Gao XD\", \"Liu AR\", \"Yao WB\", \"Yin DK\", \"Yin L\"], \"date\": \"2014-01-03\", \"first\": \"Chen S\", \"last\": \"Gao XD\", \"name\": \"Neuroscience\", \"pages\": \"137-46\", \"reference\": \"24183963\", \"title\": \"Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation.\", \"type\": \"PubMed\", \"volume\": \"256\"}, \"evidence\": \"Primary hippocampal neuron cells at different concentrations (0, 50, 100, 200 lg/ml) of glucoseBSA were incubated together for 24 h, and then thr205- phosphorylated tau was estimated by the western immunoblotting method. Western blot analysis of each experimental group showed that glucoseBSA promoted tau thr205-phosphorylation in a concentration-dependent manner (Fig. 3(a)). In the present study, it was also shown that 100 nM GLP-1 or Ex-4 treatment reduced tau hyperphosphorylation induced by glucoseBSA (Fig. 3(b, c)).\", \"key\": \"87da64a6b0bf13bce5b61644707574bb114224a0354b84e9f56a7a5a65ba4363190a8be5f61ee2e571e96b6415dbb94df2b85471d1f8edf077609f8f6ec975c2\", \"line\": 397, \"relation\": \"increases\", \"source\": 24, \"target\": 312}, {\"annotations\": {\"Species\": {\"10116\": true}}, \"citation\": {\"authors\": [\"Ai J\", \"Ban T\", \"Bao YN\", \"Chen QX\", \"Hu XL\", \"Jiang XM\", \"Liu CD\", \"Pei SC\", \"Su XL\", \"Sun LH\", \"Sun LL\", \"Wang X\", \"Yan ML\", \"Zhao LJ\", \"Zong DK\"], \"date\": \"2015-09-01\", \"first\": \"Sun LH\", \"last\": \"Ai J\", \"name\": \"Journal of neurochemistry\", \"pages\": \"1139-51\", \"reference\": \"26118667\", \"title\": \"Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.\", \"type\": \"PubMed\", \"volume\": \"134\"}, \"evidence\": \"Endogenous miR-195 was knocked down using over-expression of its antisense molecule (pre-AMO-miR-195) via a lentivirus (lenti-pre-AMO-miR-195); this knockdown increased the tau phosphorylation at Ser202/Thr205, Ser262, Thr231, Ser422, and the Cdk5/p25 activation, but over-expression of miR-195 using lenti-pre-miR-195 decreased the tau phosphorylation and Cdk5/p25 activation.\", \"key\": \"5becf7fd9cac5ea97cd9009be8b958157e89e4779b317a6774de8c471521b346eb6111643c3dac5b0893e5bdf25dacdf5d95edf526119eb165d85256ef52439f\", \"line\": 2332, \"relation\": \"negativeCorrelation\", \"source\": 153, \"target\": 312}, {\"annotations\": {\"Species\": {\"10116\": true}}, \"citation\": {\"authors\": [\"Ai J\", \"Ban T\", \"Bao YN\", \"Chen QX\", \"Hu XL\", \"Jiang XM\", \"Liu CD\", \"Pei SC\", \"Su XL\", \"Sun LH\", \"Sun LL\", \"Wang X\", \"Yan ML\", \"Zhao LJ\", \"Zong DK\"], \"date\": \"2015-09-01\", \"first\": \"Sun LH\", \"last\": \"Ai J\", \"name\": \"Journal of neurochemistry\", \"pages\": \"1139-51\", \"reference\": \"26118667\", \"title\": \"Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.\", \"type\": \"PubMed\", \"volume\": \"134\"}, \"evidence\": \"Endogenous miR-195 was knocked down using over-expression of its antisense molecule (pre-AMO-miR-195) via a lentivirus (lenti-pre-AMO-miR-195); this knockdown increased the tau phosphorylation at Ser202/Thr205, Ser262, Thr231, Ser422, and the Cdk5/p25 activation, but over-expression of miR-195 using lenti-pre-miR-195 decreased the tau phosphorylation and Cdk5/p25 activation.\", \"key\": \"14c01558cbfe80920b50df2a0caaa88ab37a84d848a901987bf1042596e2fff982e2cc6aeca13e23a6c3c44972cb387ba7a35d3984618dd0ad884d777c02d055\", \"line\": 2335, \"relation\": \"negativeCorrelation\", \"source\": 153, \"target\": 309}, {\"annotations\": {\"Species\": {\"10116\": true}}, \"citation\": {\"authors\": [\"Ai J\", \"Ban T\", \"Bao YN\", \"Chen QX\", \"Hu XL\", \"Jiang XM\", \"Liu CD\", \"Pei SC\", \"Su XL\", \"Sun LH\", \"Sun LL\", \"Wang X\", \"Yan ML\", \"Zhao LJ\", \"Zong DK\"], \"date\": \"2015-09-01\", \"first\": \"Sun LH\", \"last\": \"Ai J\", \"name\": \"Journal of neurochemistry\", \"pages\": \"1139-51\", \"reference\": \"26118667\", \"title\": \"Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.\", \"type\": \"PubMed\", \"volume\": \"134\"}, \"evidence\": \"Endogenous miR-195 was knocked down using over-expression of its antisense molecule (pre-AMO-miR-195) via a lentivirus (lenti-pre-AMO-miR-195); this knockdown increased the tau phosphorylation at Ser202/Thr205, Ser262, Thr231, Ser422, and the Cdk5/p25 activation, but over-expression of miR-195 using lenti-pre-miR-195 decreased the tau phosphorylation and Cdk5/p25 activation.\", \"key\": \"a8012c8ab22fd90e123abfbe69843e6aa3d5afd3f59064110437f6f613a18429ff1393146f528dfa692e44c01e7eefb0efd6b1f213d61f3888ab07d8e92dd49e\", \"line\": 2334, \"relation\": \"negativeCorrelation\", \"source\": 153, \"target\": 315}, {\"annotations\": {\"Species\": {\"10116\": true}}, \"citation\": {\"authors\": [\"Ai J\", \"Ban T\", \"Bao YN\", \"Chen QX\", \"Hu XL\", \"Jiang XM\", \"Liu CD\", \"Pei SC\", \"Su XL\", \"Sun LH\", \"Sun LL\", \"Wang X\", \"Yan ML\", \"Zhao LJ\", \"Zong DK\"], \"date\": \"2015-09-01\", \"first\": \"Sun LH\", \"last\": \"Ai J\", \"name\": \"Journal of neurochemistry\", \"pages\": \"1139-51\", \"reference\": \"26118667\", \"title\": \"Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.\", \"type\": \"PubMed\", \"volume\": \"134\"}, \"evidence\": \"Endogenous miR-195 was knocked down using over-expression of its antisense molecule (pre-AMO-miR-195) via a lentivirus (lenti-pre-AMO-miR-195); this knockdown increased the tau phosphorylation at Ser202/Thr205, Ser262, Thr231, Ser422, and the Cdk5/p25 activation, but over-expression of miR-195 using lenti-pre-miR-195 decreased the tau phosphorylation and Cdk5/p25 activation.\", \"key\": \"b91650ea7e1a167a0bc0db540dfac489a546d7dc6c7a8b46af41baaab11844e2b658ec8b751883f4a1044cf81df89aba5f836f26db7e614dd60e8e7d5c63865b\", \"line\": 2331, \"relation\": \"negativeCorrelation\", \"source\": 153, \"target\": 290}, {\"annotations\": {\"Species\": {\"10116\": true}}, \"citation\": {\"authors\": [\"Ai J\", \"Ban T\", \"Bao YN\", \"Chen QX\", \"Hu XL\", \"Jiang XM\", \"Liu CD\", \"Pei SC\", \"Su XL\", \"Sun LH\", \"Sun LL\", \"Wang X\", \"Yan ML\", \"Zhao LJ\", \"Zong DK\"], \"date\": \"2015-09-01\", \"first\": \"Sun LH\", \"last\": \"Ai J\", \"name\": \"Journal of neurochemistry\", \"pages\": \"1139-51\", \"reference\": \"26118667\", \"title\": \"Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.\", \"type\": \"PubMed\", \"volume\": \"134\"}, \"evidence\": \"Endogenous miR-195 was knocked down using over-expression of its antisense molecule (pre-AMO-miR-195) via a lentivirus (lenti-pre-AMO-miR-195); this knockdown increased the tau phosphorylation at Ser202/Thr205, Ser262, Thr231, Ser422, and the Cdk5/p25 activation, but over-expression of miR-195 using lenti-pre-miR-195 decreased the tau phosphorylation and Cdk5/p25 activation.\", \"key\": \"081ad2edd10c2f6f09483e3921dc15b9777f94cad03326346b6d84a10e30d1e296fba07be50fd5b544e86c88639135a00d06c004978fb712daef6b081528c2ce\", \"line\": 2333, \"relation\": \"negativeCorrelation\", \"source\": 153, \"target\": 297}, {\"annotations\": {\"Method\": {\"Electron Microscopy, Transmission\": true, \"NMR Spectroscopy\": true, \"Thioflavin T Assay\": true}, \"Tau_Epitope\": {\"AT8\": true}}, \"citation\": {\"authors\": [\"Baulieu EE\", \"Byrne C\", \"Cantrelle FX\", \"Chambraud B\", \"Despres C\", \"Huvent I\", \"Jacquot Y\", \"Landrieu I\", \"Lippens G\", \"Qi H\", \"Smet-Nocca C\"], \"date\": \"2017-08-22\", \"first\": \"Despres C\", \"last\": \"Smet-Nocca C\", \"name\": \"Proceedings of the National Academy of Sciences of the United States of America\", \"pages\": \"9080-9085\", \"reference\": \"28784767\", \"title\": \"Identification of the Tau phosphorylation pattern that drives its aggregation.\", \"type\": \"PubMed\", \"volume\": \"114\"}, \"evidence\": \"When combined with ERK2 catalyzed phosphorylation, the turn-like disrupting G207V mutation in TauF8 hence leads to fast aggregation that already occurs during the phosphorylation reaction.\", \"key\": \"3416d6868046f661b2d2434dc727cd801dc8172498170f7d6cd4443f1355bd5cffb015ba9efbe7a0b60e7112454c45bc95245c211c83697cbf595b4ecaff71e3\", \"line\": 82, \"relation\": \"increases\", \"source\": 237, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 312}, {\"annotations\": {\"Method\": {\"Electron Microscopy, Transmission\": true, \"NMR Spectroscopy\": true, \"Thioflavin T Assay\": true}, \"Tau_Epitope\": {\"AT8\": true}}, \"citation\": {\"authors\": [\"Baulieu EE\", \"Byrne C\", \"Cantrelle FX\", \"Chambraud B\", \"Despres C\", \"Huvent I\", \"Jacquot Y\", \"Landrieu I\", \"Lippens G\", \"Qi H\", \"Smet-Nocca C\"], \"date\": \"2017-08-22\", \"first\": \"Despres C\", \"last\": \"Smet-Nocca C\", \"name\": \"Proceedings of the National Academy of Sciences of the United States of America\", \"pages\": \"9080-9085\", \"reference\": \"28784767\", \"title\": \"Identification of the Tau phosphorylation pattern that drives its aggregation.\", \"type\": \"PubMed\", \"volume\": \"114\"}, \"evidence\": \"When combined with ERK2 catalyzed phosphorylation, the turn-like disrupting G207V mutation in TauF8 hence leads to fast aggregation that already occurs during the phosphorylation reaction.\", \"key\": \"fdb700850b99f2eca859e532b98019d3c5a9e9c91471c77facc5c205bda85e182154ed4ed8ce6e64b8cf67633489b2c1064f48a8bdf5d2ac5813297e1e3cdd5c\", \"line\": 81, \"relation\": \"increases\", \"source\": 237, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 290}, {\"citation\": {\"authors\": [\"Cohen TJ\", \"Madden V\", \"Tripathy A\", \"Trzeciakiewicz H\", \"Tseng JH\", \"Wander CM\", \"Yuan CX\"], \"date\": \"2017-03-13\", \"first\": \"Trzeciakiewicz H\", \"last\": \"Cohen TJ\", \"name\": \"Scientific reports\", \"pages\": \"44102\", \"reference\": \"28287136\", \"title\": \"A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Surprisingly, we show that tau acetylation alters phosphorylation at residues S202/T205 (comprising the AT8 epitope), indicating acetylation-dephosphorylation cross-talk. Using a series of biochemical approaches, we found that K280/K281 acetylation impaired tau-mediated MT assembly function and also significantly enhanced tau aggregation. We also demonstrate that methylene blue, a reported tau aggregation inhibitor, modulates tau acetylation, a novel mechanism of action for this class of compounds\", \"key\": \"1597cb3fb12e88db6b38a86eeac26394a26cd5cb3f564ea3c9c7194fdcb973ed716141de3595d3535cac75e9c1c36d63c590362a55761643d0b0726d2ac5aed8\", \"line\": 3137, \"relation\": \"decreases\", \"source\": 257, \"target\": 312}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Depending on the sites, the acetylation of tau could inhibit its degradation (for example, when at Lys163, Lys280, Lys281 or Lys369) or, by contrast, facilitate its degradation and suppress its phosphorylation and aggregation (for example, when at Lys259, Lys290, Lys321 or Lys353)\", \"key\": \"8f56b265c5b0d0d8daa037ff158f8c8c37c921519b181c89ecdb7d07f329ff5fdd1ce1bbb1189045bacd7124de090b0b3a0b3727866be6e92d3ed393f038b873\", \"line\": 265, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"decreases\", \"source\": 257, \"target\": 257}, {\"annotations\": {\"Species\": {\"7227\": true}}, \"citation\": {\"authors\": [\"Augustin H\", \"Burnouf S\", \"Dols J\", \"Gorsky MK\", \"Grnke S\", \"Partridge L\", \"Sofola-Adesakin O\", \"Weigelt CM\"], \"date\": \"2017-08-30\", \"first\": \"Gorsky MK\", \"last\": \"Partridge L\", \"name\": \"Scientific reports\", \"pages\": \"9984\", \"reference\": \"28855586\", \"title\": \"Pseudo-acetylation of multiple sites on human Tau proteins alters Tau phosphorylation and microtubule binding, and ameliorates amyloid beta toxicity.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"We have used a knock-out/knock-in strategy in Drosophila to generate a strain with hTau inserted into the endogenous fly tau locus and expressed under the control of the endogenous fly tau promoter, thus avoiding potential toxicity due to genetic over-expression. hTau knock-in (KI) proteins were expressed at normal, endogenous levels, bound to fly microtubules and were post-translationally modified, hence displaying physiological properties. We used this new model to investigate the effects of acetylation on hTau toxicity in vivo. The simultaneous pseudo-acetylation of hTau at lysines 163, 280, 281 and 369 drastically decreased hTau phosphorylation and significantly reduced its binding to microtubules in vivo. These molecular alterations were associated with ameliorated amyloid beta toxicity. Our results indicate acetylation of hTau on multiple sites regulates its biology and ameliorates amyloid beta toxicity in vivo.\", \"key\": \"64a90cd1fd344e72379564cdde6a6196f88b149dceb8c7c64cfced50945cd353b5b2e685a9b7df87a3f2e0d99682c12248f0c6acacbdc1c5207de702c593cdac\", \"line\": 3124, \"relation\": \"association\", \"source\": 257, \"target\": 152}, {\"citation\": {\"authors\": [\"Cohen TJ\", \"Madden V\", \"Tripathy A\", \"Trzeciakiewicz H\", \"Tseng JH\", \"Wander CM\", \"Yuan CX\"], \"date\": \"2017-03-13\", \"first\": \"Trzeciakiewicz H\", \"last\": \"Cohen TJ\", \"name\": \"Scientific reports\", \"pages\": \"44102\", \"reference\": \"28287136\", \"title\": \"A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Surprisingly, we show that tau acetylation alters phosphorylation at residues S202/T205 (comprising the AT8 epitope), indicating acetylation-dephosphorylation cross-talk. Using a series of biochemical approaches, we found that K280/K281 acetylation impaired tau-mediated MT assembly function and also significantly enhanced tau aggregation. We also demonstrate that methylene blue, a reported tau aggregation inhibitor, modulates tau acetylation, a novel mechanism of action for this class of compounds\", \"key\": \"2313ae45db20d4da05662228cadea95838f4e6921caab6738a4c6c0c7433a7d25b2e847b302e08331c002d07f284c298ca230d3522d6efc2580ffdb14611c4f8\", \"line\": 3139, \"relation\": \"increases\", \"source\": 257, \"target\": 39}, {\"citation\": {\"authors\": [\"Cohen TJ\", \"Madden V\", \"Tripathy A\", \"Trzeciakiewicz H\", \"Tseng JH\", \"Wander CM\", \"Yuan CX\"], \"date\": \"2017-03-13\", \"first\": \"Trzeciakiewicz H\", \"last\": \"Cohen TJ\", \"name\": \"Scientific reports\", \"pages\": \"44102\", \"reference\": \"28287136\", \"title\": \"A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Surprisingly, we show that tau acetylation alters phosphorylation at residues S202/T205 (comprising the AT8 epitope), indicating acetylation-dephosphorylation cross-talk. Using a series of biochemical approaches, we found that K280/K281 acetylation impaired tau-mediated MT assembly function and also significantly enhanced tau aggregation. We also demonstrate that methylene blue, a reported tau aggregation inhibitor, modulates tau acetylation, a novel mechanism of action for this class of compounds\", \"key\": \"36c49e45e7f2ff4dbc89480bb14c901d618c467fd6a577a0a0f3463b2fad35ecf64274a2b1f6e8108f47f1e95b5158a3da4c9f71f0397b86c473f9db0d03e9e5\", \"line\": 3140, \"relation\": \"partOf\", \"source\": 257, \"target\": 191}, {\"annotations\": {\"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Cong X\", \"Ellerby LM\", \"Gan L\", \"Huganir RL\", \"Le D\", \"Li Y\", \"Lo I\", \"Min SW\", \"Minami SS\", \"Ponnusamy R\", \"Schilling B\", \"Sohn PD\", \"Tracy TE\", \"Wang C\", \"Zhou Y\"], \"date\": \"2016-04-20\", \"first\": \"Tracy TE\", \"last\": \"Gan L\", \"name\": \"Neuron\", \"pages\": \"245-60\", \"reference\": \"27041503\", \"title\": \"Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss.\", \"type\": \"PubMed\", \"volume\": \"90\"}, \"evidence\": \"Here we report abnormal acetylation of K274 and K281 on tau, identified in AD brains, promotes memory loss and disrupts synaptic plasticity by reducing postsynaptic KIdney/BRAin (KIBRA) protein, a memory-associated protein.Transgenic mice expressing human tau with lysine-to-glutamine mutations to mimic K274 and K281 acetylation (tauKQ) exhibit AD-related memory deficits and impaired hippocampal long-term potentiation (LTP). TauKQ reduces synaptic KIBRA levels and disrupts activity-induced postsynaptic actin remodeling and AMPA receptor insertion. The LTP deficit was rescued by promoting actin polymerization or by KIBRA expression. In AD patients with dementia, we found enhanced tau acetylation is linked to loss of KIBRA.\", \"key\": \"00b8762bee3364b5c965b20a61f450c828f9bd5384ed69d106daa5f63421b85c1fcefb504aa289095d4db120ecd5e1a90d0f9d7759ca2741604a2d37bd64422a\", \"line\": 3176, \"relation\": \"decreases\", \"source\": 257, \"target\": 76}, {\"annotations\": {\"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Cong X\", \"Ellerby LM\", \"Gan L\", \"Huganir RL\", \"Le D\", \"Li Y\", \"Lo I\", \"Min SW\", \"Minami SS\", \"Ponnusamy R\", \"Schilling B\", \"Sohn PD\", \"Tracy TE\", \"Wang C\", \"Zhou Y\"], \"date\": \"2016-04-20\", \"first\": \"Tracy TE\", \"last\": \"Gan L\", \"name\": \"Neuron\", \"pages\": \"245-60\", \"reference\": \"27041503\", \"title\": \"Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss.\", \"type\": \"PubMed\", \"volume\": \"90\"}, \"evidence\": \"Here we report abnormal acetylation of K274 and K281 on tau, identified in AD brains, promotes memory loss and disrupts synaptic plasticity by reducing postsynaptic KIdney/BRAin (KIBRA) protein, a memory-associated protein.Transgenic mice expressing human tau with lysine-to-glutamine mutations to mimic K274 and K281 acetylation (tauKQ) exhibit AD-related memory deficits and impaired hippocampal long-term potentiation (LTP). TauKQ reduces synaptic KIBRA levels and disrupts activity-induced postsynaptic actin remodeling and AMPA receptor insertion. The LTP deficit was rescued by promoting actin polymerization or by KIBRA expression. In AD patients with dementia, we found enhanced tau acetylation is linked to loss of KIBRA.\", \"key\": \"d4c2bf0f5fd6403266c0955d0b76ed9c684e1fdc7fc622998f4a2f13bbda323fe75d6e1e0d4b31a040375056de8f47088e7726886459094a3d3813f9ec5ec346\", \"line\": 3174, \"relation\": \"decreases\", \"source\": 257, \"target\": 379}, {\"annotations\": {\"Research_Model\": {\"pR5 mice\": true}, \"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Dinekov M\", \"Gtz J\", \"Khler C\"], \"date\": \"2013-05-01\", \"first\": \"Khler C\", \"last\": \"Gtz J\", \"name\": \"Neurobiology of aging\", \"pages\": \"1369-79\", \"reference\": \"23294633\", \"title\": \"Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"34\"}, \"evidence\": \"We studied underlying pathomechanisms in tauopathies using pR5 mice that express the P301L tau mutation found in familial forms of frontotemporal dementia. In a longitudinal study we investigated the functional status of glycogen synthase kinase-3 and correlated it with the appearance of distinct tau phospho-epitopes. Neurons displaying increases in activating phosphorylation of glycogen synthase kinase-3/ at tyrosine 279/216 also showed an intense rather than moderate AT8 (phospho-Ser202/Thr205 tau) immunoreactivity, and immunoreactivity for AT100 (phospho-Ser212/Thr214 tau) and phosphorylated Ser422, phospho-epitopes associated with fibrillar tau pathology.\", \"key\": \"ea89fe42e3e1276474e5013f44647efc80cdd8ca89fb0fe074afb8046c0c14d103da4a1a8333f6a2d95645ae83d2c45ad60539e8bcf1fbe59aefc8c31501df35\", \"line\": 2543, \"relation\": \"positiveCorrelation\", \"source\": 329, \"target\": 312}, {\"annotations\": {\"Research_Model\": {\"pR5 mice\": true}, \"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Dinekov M\", \"Gtz J\", \"Khler C\"], \"date\": \"2013-05-01\", \"first\": \"Khler C\", \"last\": \"Gtz J\", \"name\": \"Neurobiology of aging\", \"pages\": \"1369-79\", \"reference\": \"23294633\", \"title\": \"Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"34\"}, \"evidence\": \"We studied underlying pathomechanisms in tauopathies using pR5 mice that express the P301L tau mutation found in familial forms of frontotemporal dementia. In a longitudinal study we investigated the functional status of glycogen synthase kinase-3 and correlated it with the appearance of distinct tau phospho-epitopes. Neurons displaying increases in activating phosphorylation of glycogen synthase kinase-3/ at tyrosine 279/216 also showed an intense rather than moderate AT8 (phospho-Ser202/Thr205 tau) immunoreactivity, and immunoreactivity for AT100 (phospho-Ser212/Thr214 tau) and phosphorylated Ser422, phospho-epitopes associated with fibrillar tau pathology.\", \"key\": \"65326b5831e91a7cfca3baf17626bfa04452988a2645350f0ee7d716edd5b3e177ad9bba5c3594e8fcd0c88668172beba0c6a32b9800b9caeb67e05b68e4e508\", \"line\": 2545, \"relation\": \"positiveCorrelation\", \"source\": 329, \"target\": 309}, {\"annotations\": {\"Research_Model\": {\"pR5 mice\": true}, \"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Dinekov M\", \"Gtz J\", \"Khler C\"], \"date\": \"2013-05-01\", \"first\": \"Khler C\", \"last\": \"Gtz J\", \"name\": \"Neurobiology of aging\", \"pages\": \"1369-79\", \"reference\": \"23294633\", \"title\": \"Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"34\"}, \"evidence\": \"We studied underlying pathomechanisms in tauopathies using pR5 mice that express the P301L tau mutation found in familial forms of frontotemporal dementia. In a longitudinal study we investigated the functional status of glycogen synthase kinase-3 and correlated it with the appearance of distinct tau phospho-epitopes. Neurons displaying increases in activating phosphorylation of glycogen synthase kinase-3/ at tyrosine 279/216 also showed an intense rather than moderate AT8 (phospho-Ser202/Thr205 tau) immunoreactivity, and immunoreactivity for AT100 (phospho-Ser212/Thr214 tau) and phosphorylated Ser422, phospho-epitopes associated with fibrillar tau pathology.\", \"key\": \"c4769a870fc1dea47e665b0513b4bd446df2f81b1912b7dcb313ac3bab83c0f051d57a88be71e9aa9d3ac6001313919f966ed435a6c9b94c2fef3bdf6f48adfe\", \"line\": 2542, \"relation\": \"positiveCorrelation\", \"source\": 329, \"target\": 290}, {\"citation\": {\"authors\": [\"Kawakami F\", \"Ohtsuki K\", \"Suzuki K\"], \"date\": \"2008-02-01\", \"first\": \"Kawakami F\", \"last\": \"Ohtsuki K\", \"name\": \"Biological &amp; pharmaceutical bulletin\", \"pages\": \"193-200\", \"reference\": \"18239272\", \"title\": \"A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"Epitopes S198, S199, S202, T205, S422 (Lund 2013)\", \"key\": \"cd9c7822ba93e017ca611cd105687ec3f441dc77d7d8d14ef7abe80e886dbf1e2a6a43b6ff0e9e0ab4d15bb284de4d27aa5391692cc6ffe50acf9850fb62a585\", \"line\": 1291, \"relation\": \"increases\", \"source\": 374, \"target\": 312}, {\"citation\": {\"authors\": [\"Kawakami F\", \"Ohtsuki K\", \"Suzuki K\"], \"date\": \"2008-02-01\", \"first\": \"Kawakami F\", \"last\": \"Ohtsuki K\", \"name\": \"Biological &amp; pharmaceutical bulletin\", \"pages\": \"193-200\", \"reference\": \"18239272\", \"title\": \"A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"Epitopes S198, S199, S202, T205, S422 (Lund 2013)\", \"key\": \"1be45af82688542840eba27e735233ecf859ec94a843f06d82aabc8f8df9919a346044101ca2f78013066cfe484501c12d86a3a9529ec6e7bbad5702d85ca58a\", \"line\": 1292, \"relation\": \"increases\", \"source\": 374, \"target\": 309}, {\"citation\": {\"authors\": [\"Kawakami F\", \"Ohtsuki K\", \"Suzuki K\"], \"date\": \"2008-02-01\", \"first\": \"Kawakami F\", \"last\": \"Ohtsuki K\", \"name\": \"Biological &amp; pharmaceutical bulletin\", \"pages\": \"193-200\", \"reference\": \"18239272\", \"title\": \"A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"Epitopes S198, S199, S202, T205, S422 (Lund 2013)\", \"key\": \"b45370f48dc13b644f6914f349f84912b54b5a8f479c4c08f3d6de0558f82c32c34971f2b43788d0e607d96afa8f862b5d07cbc8da7a2747c988a57489ddded1\", \"line\": 1289, \"relation\": \"increases\", \"source\": 374, \"target\": 289}, {\"citation\": {\"authors\": [\"Freeman D\", \"Kraatz HB\", \"Marti S\", \"Rains MK\"], \"date\": \"2013-08-21\", \"first\": \"Rains MK\", \"last\": \"Kraatz HB\", \"name\": \"ACS chemical neuroscience\", \"pages\": \"1194-203\", \"reference\": \"23687953\", \"title\": \"Electrochemical investigations into kinase-catalyzed transformations of tau protein.\", \"type\": \"PubMed\", \"volume\": \"4\"}, \"evidence\": \"The single kinase and sequential kinase-catalyzed Fc-phosphorylations points to dramatic changes around the Fc group in the Fc-phosphorylated tau films. Additional surface characterization of the Fc-tau films by time-of-flight secondary ion-mass spectrometry and X-ray photoelectron spectroscopy revealed that Fc-phosphorylations influence the tau orientation and conformation on surfaces.\", \"key\": \"6c3f40d1261b265a61909de689d156b1d5ba96845a17b33a6ce8673b5bf2c7596afb25ee637caa52196e8406b37f12f0d1033e70a1e757e0b6ae001f8e7213a4\", \"line\": 2451, \"relation\": \"directlyIncreases\", \"source\": 374, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 319}, {\"citation\": {\"authors\": [\"Kawakami F\", \"Ohtsuki K\", \"Suzuki K\"], \"date\": \"2008-02-01\", \"first\": \"Kawakami F\", \"last\": \"Ohtsuki K\", \"name\": \"Biological &amp; pharmaceutical bulletin\", \"pages\": \"193-200\", \"reference\": \"18239272\", \"title\": \"A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"Epitopes S198, S199, S202, T205, S422 (Lund 2013)\", \"key\": \"e754a8e2fee6698aed215f3ace31d79aded0c6785be00b799bcc39241b7512a3ff6d50ecc1e03f13eba6caef26203bca40c5be8aaf4c43faafe2d0120b8db5d0\", \"line\": 1290, \"relation\": \"increases\", \"source\": 374, \"target\": 290}, {\"citation\": {\"authors\": [\"Kawakami F\", \"Ohtsuki K\", \"Suzuki K\"], \"date\": \"2008-02-01\", \"first\": \"Kawakami F\", \"last\": \"Ohtsuki K\", \"name\": \"Biological &amp; pharmaceutical bulletin\", \"pages\": \"193-200\", \"reference\": \"18239272\", \"title\": \"A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"Epitopes S198, S199, S202, T205, S422 (Lund 2013)\", \"key\": \"5508ba1bdd36522fe015cc7ca4b0d8dbb9119530065ee42cbb571c0dc7fd43e15b2df3dd04cd64fd9f2a0c0655381139de88bdaef484cadd52cc5a7679d49fc3\", \"line\": 1288, \"relation\": \"increases\", \"source\": 374, \"target\": 288}, {\"annotations\": {\"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Chen X\", \"Cong X\", \"Defensor E\", \"Ellerby L\", \"Gan L\", \"Gestwicki J\", \"Gibson BW\", \"Johnson J\", \"Krogan N\", \"Li Y\", \"Masliah E\", \"Min SW\", \"Minami SS\", \"Mok SA\", \"Schilling B\", \"Shamloo M\", \"Shirakawa K\", \"Sohn PD\", \"Tracy TE\", \"Verdin E\", \"Wang C\", \"Zhou Y\"], \"date\": \"2015-10-01\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"Nature medicine\", \"pages\": \"1154-62\", \"reference\": \"26390242\", \"title\": \"Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"The acetyl-mimicking mutant K174Q slows tau turnover and induces cognitive deficits in vivo. Acetyltransferase p300-induced tau acetylation is inhibited by salsalate and salicylate, which enhance tau turnover and reduce tau levels. In the PS19 transgenic mouse model of FTD, administration of salsalate after disease onset inhibited p300 activity, lowered levels of total tau and tau acetylated at K174, rescued tau-induced memory deficits and prevented hippocampal atrophy.\", \"key\": \"9fab3599e18f4733772f14f8a0772e78d65261b6e75898946892894314a5e8e6c1d64fe3500980758c18f791446f75e77acf94a721eb0e1ae4af7e04bc2d4b57\", \"line\": 3201, \"relation\": \"increases\", \"source\": 250, \"target\": 312}, {\"annotations\": {\"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Chen X\", \"Cong X\", \"Defensor E\", \"Ellerby L\", \"Gan L\", \"Gestwicki J\", \"Gibson BW\", \"Johnson J\", \"Krogan N\", \"Li Y\", \"Masliah E\", \"Min SW\", \"Minami SS\", \"Mok SA\", \"Schilling B\", \"Shamloo M\", \"Shirakawa K\", \"Sohn PD\", \"Tracy TE\", \"Verdin E\", \"Wang C\", \"Zhou Y\"], \"date\": \"2015-10-01\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"Nature medicine\", \"pages\": \"1154-62\", \"reference\": \"26390242\", \"title\": \"Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"The acetyl-mimicking mutant K174Q slows tau turnover and induces cognitive deficits in vivo. Acetyltransferase p300-induced tau acetylation is inhibited by salsalate and salicylate, which enhance tau turnover and reduce tau levels. In the PS19 transgenic mouse model of FTD, administration of salsalate after disease onset inhibited p300 activity, lowered levels of total tau and tau acetylated at K174, rescued tau-induced memory deficits and prevented hippocampal atrophy.\", \"key\": \"f6cf7049af1ced4dc4ffc96ac48006d7a63f113a25659d13ea7846631515a82785534df0b04aba6f002fd5c84f7fdb577f02ac797748193ce447003c86a78826\", \"line\": 3200, \"relation\": \"increases\", \"source\": 250, \"target\": 290}, {\"annotations\": {\"Anatomy\": {\"hippocampal formation\": true}, \"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Chen X\", \"Cong X\", \"Defensor E\", \"Ellerby L\", \"Gan L\", \"Gestwicki J\", \"Gibson BW\", \"Johnson J\", \"Krogan N\", \"Li Y\", \"Masliah E\", \"Min SW\", \"Minami SS\", \"Mok SA\", \"Schilling B\", \"Shamloo M\", \"Shirakawa K\", \"Sohn PD\", \"Tracy TE\", \"Verdin E\", \"Wang C\", \"Zhou Y\"], \"date\": \"2015-10-01\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"Nature medicine\", \"pages\": \"1154-62\", \"reference\": \"26390242\", \"title\": \"Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"The acetyl-mimicking mutant K174Q slows tau turnover and induces cognitive deficits in vivo. Acetyltransferase p300-induced tau acetylation is inhibited by salsalate and salicylate, which enhance tau turnover and reduce tau levels. In the PS19 transgenic mouse model of FTD, administration of salsalate after disease onset inhibited p300 activity, lowered levels of total tau and tau acetylated at K174, rescued tau-induced memory deficits and prevented hippocampal atrophy.\", \"key\": \"88284293f31c0416df1ba45713f0d71bb4b04fd6f664c3ce8c422034d34a98f04f90c9ffdf84cc2e5b004dd45aba40c05ebb1adc4eb057dc8f803156b298d933\", \"line\": 3203, \"relation\": \"increases\", \"source\": 250, \"target\": 62}, {\"annotations\": {\"Anatomy\": {\"hippocampal formation\": true}, \"Research_Model\": {\"P301S mice\": true}, \"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Devidze N\", \"Gan L\", \"Gestwicki JE\", \"Johnson JR\", \"Krogan NJ\", \"Li Y\", \"Masliah E\", \"Min SW\", \"Mok SA\", \"Sohn PD\"], \"date\": \"2018-04-11\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"3680-3688\", \"reference\": \"29540553\", \"title\": \"SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.\", \"type\": \"PubMed\", \"volume\": \"38\"}, \"evidence\": \"SIRT1 deficiency exacerbates premature mortality, synapse loss, and behavioral disinhibition in tauP301S TG mice of both sexes. SIRT1 overexpression into the hippocampus reduces acetylated K174 tau and significantly attenuates the spread of tau pathology into anatomically connected brain regions of tauP301S transgenic mice of both sexes.\", \"key\": \"2c2b7e2ef3aa8ebbd39affffb227a679903704f4e012a2d740b713aee948f5f2dad3faf8c592295a2f246354da68b45ef91f167789681a42c2c51d2e4d414b50\", \"line\": 3332, \"object\": {\"modifier\": \"Activity\"}, \"relation\": \"negativeCorrelation\", \"source\": 250, \"target\": 361}, {\"annotations\": {\"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Chen X\", \"Cong X\", \"Defensor E\", \"Ellerby L\", \"Gan L\", \"Gestwicki J\", \"Gibson BW\", \"Johnson J\", \"Krogan N\", \"Li Y\", \"Masliah E\", \"Min SW\", \"Minami SS\", \"Mok SA\", \"Schilling B\", \"Shamloo M\", \"Shirakawa K\", \"Sohn PD\", \"Tracy TE\", \"Verdin E\", \"Wang C\", \"Zhou Y\"], \"date\": \"2015-10-01\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"Nature medicine\", \"pages\": \"1154-62\", \"reference\": \"26390242\", \"title\": \"Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"The acetyl-mimicking mutant K174Q slows tau turnover and induces cognitive deficits in vivo. Acetyltransferase p300-induced tau acetylation is inhibited by salsalate and salicylate, which enhance tau turnover and reduce tau levels. In the PS19 transgenic mouse model of FTD, administration of salsalate after disease onset inhibited p300 activity, lowered levels of total tau and tau acetylated at K174, rescued tau-induced memory deficits and prevented hippocampal atrophy.\", \"key\": \"4cb39a5da24649d2aadcc901128d28aa79b7c3f04bd47f5db2e29ca0cdafa381a0edf631ef2f269fa41c97316dcab06216dd2cdd1902f194e9da6106b3357446\", \"line\": 3199, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"decreases\", \"source\": 250, \"target\": 244}, {\"annotations\": {\"Anatomy\": {\"hippocampal formation\": true}, \"Method\": {\"Cell Viability Assay, MTT\": true, \"Confocal Laser Microscopy\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"An FM\", \"Chen S\", \"Gao XD\", \"Liu AR\", \"Yao WB\", \"Yin DK\", \"Yin L\"], \"date\": \"2014-01-03\", \"first\": \"Chen S\", \"last\": \"Gao XD\", \"name\": \"Neuroscience\", \"pages\": \"137-46\", \"reference\": \"24183963\", \"title\": \"Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation.\", \"type\": \"PubMed\", \"volume\": \"256\"}, \"evidence\": \"Primary hippocampal neuron cells at different concentrations (0, 50, 100, 200 lg/ml) of glucoseBSA were incubated together for 24 h, and then thr205- phosphorylated tau was estimated by the western immunoblotting method. Western blot analysis of each experimental group showed that glucoseBSA promoted tau thr205-phosphorylation in a concentration-dependent manner (Fig. 3(a)). In the present study, it was also shown that 100 nM GLP-1 or Ex-4 treatment reduced tau hyperphosphorylation induced by glucoseBSA (Fig. 3(b, c)).\", \"key\": \"1a583d10191f79b3519cc88092362d5d8f68a0b1f874d0b1de045930432bf39f42affa19c21ab132c0937ca19cd955af0270cdf7043bf881141785a3c15fee5e\", \"line\": 398, \"relation\": \"decreases\", \"source\": 231, \"target\": 312}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Non-enzymatic post-translational modifications, including glycation, deamidation and isomerization, are detected in PHF-tau but not in normal tau. All of these modifications may facilitate tau aggregation\", \"key\": \"5570c3242e90ca038b6710afe1125e5aa9a3a7dcbb3945c64c16e55bb03547783697ee954ce9e8d8d09637c1b49a0e9fedfa144a0b5a35750c67daf90330a5a1\", \"line\": 327, \"relation\": \"increases\", \"source\": 275, \"target\": 39}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"In addition, glycation of tau may reduce the binding of tau to microtubules\", \"key\": \"305afa0ff14c2fa38d1cd2043aab8c6ced18206c75872e76e8970ed9020d4fab45e007c3fea91fff4b5faf61fbace245ebb068a0823217c33b1435474968343b\", \"line\": 331, \"relation\": \"decreases\", \"source\": 275, \"target\": 111}, {\"annotations\": {\"Cell_Line\": {\"SH-SY5Y\": true}, \"Method\": {\"Atomic Force Microscopy\": true, \"Cell Viability Assay, MTT\": true, \"Flow Cytometry\": true, \"Fluorescence Spectrophotometry\": true, \"NBT colorimetric fructosamine assay\": true}}, \"citation\": {\"authors\": [\"Chen L\", \"He R\", \"Wang X\", \"Wei Y\"], \"date\": \"2009-08-01\", \"first\": \"Chen L\", \"last\": \"He R\", \"name\": \"Cellular and molecular life sciences : CMLS\", \"pages\": \"2559-71\", \"reference\": \"19517062\", \"title\": \"D-Ribosylated Tau forms globular aggregates with high cytotoxicity.\", \"type\": \"PubMed\", \"volume\": \"66\"}, \"evidence\": \"Tau is rapidly glycated in the presence of D-ribose, resulting in oligomerization and polymerization with Glycated derivatives appearing after 24 h. Advanced glycation end-products (AGEs) were formed during initial stages of glycation. Thioflavin T-positive (ThT-positive) aggregations (day 4) indicated the globular-like features. Atomic force microscopy revealed that the surface morphology of ribosylated Tau40 was globular-like.\", \"key\": \"abb42fe6d9759934007ab404e6a2b42f4fe14f8b742ac5f61174c1a3bdc97bd9d857c35463877c245908f950fadd0648c8305493a0e8283729f14344ac0d7fd3\", \"line\": 591, \"relation\": \"increases\", \"source\": 275, \"target\": 4}, {\"annotations\": {\"Cell_Line\": {\"SH-SY5Y\": true}, \"Method\": {\"Atomic Force Microscopy\": true, \"Cell Viability Assay, MTT\": true, \"Flow Cytometry\": true, \"Fluorescence Spectrophotometry\": true, \"NBT colorimetric fructosamine assay\": true}}, \"citation\": {\"authors\": [\"Chen L\", \"He R\", \"Wang X\", \"Wei Y\"], \"date\": \"2009-08-01\", \"first\": \"Chen L\", \"last\": \"He R\", \"name\": \"Cellular and molecular life sciences : CMLS\", \"pages\": \"2559-71\", \"reference\": \"19517062\", \"title\": \"D-Ribosylated Tau forms globular aggregates with high cytotoxicity.\", \"type\": \"PubMed\", \"volume\": \"66\"}, \"evidence\": \"Tau is rapidly glycated in the presence of D-ribose, resulting in oligomerization and polymerization with Glycated derivatives appearing after 24 h. Advanced glycation end-products (AGEs) were formed during initial stages of glycation. Thioflavin T-positive (ThT-positive) aggregations (day 4) indicated the globular-like features. Atomic force microscopy revealed that the surface morphology of ribosylated Tau40 was globular-like.\", \"key\": \"8e66c274a84dd773033a1eb19c798b7b31d46e38e2b8cefbde2a7ab2ebfe115a580675e2d0abbe02567ae14e5fcf10be052e0cb0c30ea2c114554d922f17c390\", \"line\": 592, \"relation\": \"partOf\", \"source\": 275, \"target\": 178}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Cabrales Fontela Y\", \"Kadavath H\", \"Mandelkow E\", \"Riedel D\", \"Zweckstetter M\"], \"date\": \"2017-12-07\", \"first\": \"Cabrales Fontela Y\", \"last\": \"Zweckstetter M\", \"name\": \"Nature communications\", \"pages\": \"1981\", \"reference\": \"29215007\", \"title\": \"Multivalent cross-linking of actin filaments and microtubules through the microtubule-associated protein Tau.\", \"type\": \"PubMed\", \"volume\": \"8\"}, \"evidence\": \"The NMR experiments demonstrate that MARK2- phosphorylation of Tau attenuates its binding to F-actin. Consistent with a reduced affinity, MARK2-phosphorylated Tau failed in bundling actin filaments (Fig. 4e)\", \"key\": \"6eb3c849a890381313b40617f052da0c66d47bf05d5862c507382c0bba0ddbabe9fa056406697b4e6d2dadb4bfd9e06cc4a9f24de5bc09603d10bc54b779176f\", \"line\": 267, \"relation\": \"decreases\", \"source\": 308, \"target\": 107}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Cabrales Fontela Y\", \"Kadavath H\", \"Mandelkow E\", \"Riedel D\", \"Zweckstetter M\"], \"date\": \"2017-12-07\", \"first\": \"Cabrales Fontela Y\", \"last\": \"Zweckstetter M\", \"name\": \"Nature communications\", \"pages\": \"1981\", \"reference\": \"29215007\", \"title\": \"Multivalent cross-linking of actin filaments and microtubules through the microtubule-associated protein Tau.\", \"type\": \"PubMed\", \"volume\": \"8\"}, \"evidence\": \"The NMR experiments demonstrate that MARK2- phosphorylation of Tau attenuates its binding to F-actin. Consistent with a reduced affinity, MARK2-phosphorylated Tau failed in bundling actin filaments (Fig. 4e)\", \"key\": \"ad2d1081cb7ab3d2deb9f1442b1cfb044e26b590d102fd5bdc123e98efc1ae3865865c676126677c7a0642add3f884998fc2a27bb815855365a8c68ff7d22d64\", \"line\": 273, \"relation\": \"decreases\", \"source\": 308, \"target\": 75}, {\"citation\": {\"authors\": [\"Cavallaro RA\", \"Ciraci V\", \"Ferrer I\", \"Fuso A\", \"Nicolia V\", \"Scarpa S\"], \"date\": \"2017-01-01\", \"first\": \"Nicolia V\", \"last\": \"Fuso A\", \"name\": \"Current Alzheimer research\", \"pages\": \"753-759\", \"reference\": \"28176663\", \"title\": \"GSK3 5'-flanking DNA Methylation and Expression in Alzheimer's Disease Patients.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \"Here, we show for the first time that the administration of D-ribose, the most active glycator among monosaccharides, produces high levels of advanced glycation end products (AGEs) and, importantly, triggers hyperphosphorylation of Tau in the brain of C57BL/6 mouse and neuroblastoma N2a cells.\", \"key\": \"62b463e645753461c61e68f52a4d12f1f658ce229dfb4636e843b73f22007947944815c6ec04b99dd0c54b19dca3ff4ac4c811577c8525fee4eeb034bd173140\", \"line\": 2292, \"relation\": \"positiveCorrelation\", \"source\": 294, \"target\": 3}, {\"citation\": {\"authors\": [\"Alonso AC\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Kpke E\", \"Shaikh S\", \"Tung YC\"], \"date\": \"1993-11-15\", \"first\": \"Kpke E\", \"last\": \"Grundke-Iqbal I\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"24374-84\", \"reference\": \"8226987\", \"title\": \"Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"268\"}, \"evidence\": \">8 phosphates per tau molecules (vs 2 in adult healthy brain); can also be increased during development, hibernation and temperature, heat and oxydative stress These phosphorylated states are detected by specific antibodies and are targets of proline-directed kinases (SP motifs), non-proline kinases (KXGS motif) Weakens tau-MT interaction especially S261 in R1 and S214 in proline-rich domain\", \"key\": \"d74becbda417c30061c58ee349991e9a230ba27ee2d352775590224c774ead5a93ca70328388d1cdfbe2f61deeadec495ebfff344b57cb69779cc13ebcae4430\", \"line\": 2821, \"object\": {\"modifier\": \"Activity\"}, \"relation\": \"decreases\", \"source\": 294, \"target\": 244}, {\"annotations\": {\"Anatomy\": {\"brain\": true}, \"Species\": {\"9606\": true}, \"TauIsoform\": {\"Isoform F (441 aa)\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"von Bergen M\"], \"date\": \"2007-01-01\", \"first\": \"Mandelkow E\", \"last\": \"Mandelkow EM\", \"name\": \"Brain pathology (Zurich, Switzerland)\", \"pages\": \"83-90\", \"reference\": \"17493042\", \"title\": \"Structural principles of tau and the paired helical filaments of Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"A further potent detaching site is phosphoS214, which can be phosphorylated by PKA and other kinases of the AGC group (PKA/PKG/PKC group of protein kinases), and is up-regulated during mitosis (16, 63). Tau contains one or two cysteines in the repeat domain (C291 in R2, present in 4R isoforms, and C322 in R3), which can be engaged in intra- or intermolecular cross-linking affecting conformation, dimerization and aggregation (108).\", \"key\": \"0734383837ae4fe3be8773345837b63d7c68e6b45b1b7f986aaba96576b95a1ebf8bcade05aa7e798a77a0bfa4196559bcb5ecf6c7238f053e763310181d4a93\", \"line\": 168, \"relation\": \"increases\", \"source\": 165, \"target\": 294}, {\"annotations\": {\"Anatomy\": {\"brain\": true}, \"Species\": {\"9606\": true}, \"TauIsoform\": {\"Isoform F (441 aa)\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"von Bergen M\"], \"date\": \"2007-01-01\", \"first\": \"Mandelkow E\", \"last\": \"Mandelkow EM\", \"name\": \"Brain pathology (Zurich, Switzerland)\", \"pages\": \"83-90\", \"reference\": \"17493042\", \"title\": \"Structural principles of tau and the paired helical filaments of Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"A further potent detaching site is phosphoS214, which can be phosphorylated by PKA and other kinases of the AGC group (PKA/PKG/PKC group of protein kinases), and is up-regulated during mitosis (16, 63). Tau contains one or two cysteines in the repeat domain (C291 in R2, present in 4R isoforms, and C322 in R3), which can be engaged in intra- or intermolecular cross-linking affecting conformation, dimerization and aggregation (108).\", \"key\": \"e6f6a3f19b32dd67ceef5c93793f11f1884db5c721334256efa533d859fd1945fb2bfce59652cd30a755f68f09d2c68933110be3d16fa04c6f7b4e4aac057591\", \"line\": 169, \"relation\": \"increases\", \"source\": 171, \"target\": 294}, {\"annotations\": {\"Anatomy\": {\"brain\": true}, \"Species\": {\"9606\": true}, \"TauIsoform\": {\"Isoform F (441 aa)\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"von Bergen M\"], \"date\": \"2007-01-01\", \"first\": \"Mandelkow E\", \"last\": \"Mandelkow EM\", \"name\": \"Brain pathology (Zurich, Switzerland)\", \"pages\": \"83-90\", \"reference\": \"17493042\", \"title\": \"Structural principles of tau and the paired helical filaments of Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"A further potent detaching site is phosphoS214, which can be phosphorylated by PKA and other kinases of the AGC group (PKA/PKG/PKC group of protein kinases), and is up-regulated during mitosis (16, 63). Tau contains one or two cysteines in the repeat domain (C291 in R2, present in 4R isoforms, and C322 in R3), which can be engaged in intra- or intermolecular cross-linking affecting conformation, dimerization and aggregation (108).\", \"key\": \"aef4ce5e8e184e720d508f62da3d7c9394a5d88d4fad4dc4423784d8cd98ac1118bb9360732904c822d3484424218e46996fd3f03de40d8150536acac7ca91b8\", \"line\": 170, \"relation\": \"increases\", \"source\": 99, \"target\": 294}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Depending on the sites, the acetylation of tau could inhibit its degradation (for example, when at Lys163, Lys280, Lys281 or Lys369) or, by contrast, facilitate its degradation and suppress its phosphorylation and aggregation (for example, when at Lys259, Lys290, Lys321 or Lys353)\", \"key\": \"e9e7bfd5e94b54f41a7c48290cbc24378882b0a3c341c46915cbc8cda6161bcfedb0f05cf5667322b075f6ddc0a85ca20e47659b16145ab284d520e56409982d\", \"line\": 266, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"decreases\", \"source\": 267, \"target\": 267}, {\"citation\": {\"authors\": [\"Burlingame AL\", \"Ioanoviciu A\", \"Knudsen GM\", \"Maeda S\", \"Morris M\", \"Mucke L\", \"Trinidad JC\"], \"date\": \"2015-08-01\", \"first\": \"Morris M\", \"last\": \"Mucke L\", \"name\": \"Nature neuroscience\", \"pages\": \"1183-9\", \"reference\": \"26192747\", \"title\": \"Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"18\"}, \"evidence\": \"Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.\", \"key\": \"f2f25f25a2b51ff8189775dbf1c8f599338d9ffcb4d6e5beb2df0c27717ae5428e16df29ac84b200b2e069bb1479b92da75c0065682a1a16045fae5c79e0875f\", \"line\": 3225, \"relation\": \"isA\", \"source\": 267, \"target\": 247}, {\"annotations\": {\"Species\": {\"7227\": true}}, \"citation\": {\"authors\": [\"Augustin H\", \"Burnouf S\", \"Dols J\", \"Gorsky MK\", \"Grnke S\", \"Partridge L\", \"Sofola-Adesakin O\", \"Weigelt CM\"], \"date\": \"2017-08-30\", \"first\": \"Gorsky MK\", \"last\": \"Partridge L\", \"name\": \"Scientific reports\", \"pages\": \"9984\", \"reference\": \"28855586\", \"title\": \"Pseudo-acetylation of multiple sites on human Tau proteins alters Tau phosphorylation and microtubule binding, and ameliorates amyloid beta toxicity.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"We have used a knock-out/knock-in strategy in Drosophila to generate a strain with hTau inserted into the endogenous fly tau locus and expressed under the control of the endogenous fly tau promoter, thus avoiding potential toxicity due to genetic over-expression. hTau knock-in (KI) proteins were expressed at normal, endogenous levels, bound to fly microtubules and were post-translationally modified, hence displaying physiological properties. We used this new model to investigate the effects of acetylation on hTau toxicity in vivo. The simultaneous pseudo-acetylation of hTau at lysines 163, 280, 281 and 369 drastically decreased hTau phosphorylation and significantly reduced its binding to microtubules in vivo. These molecular alterations were associated with ameliorated amyloid beta toxicity. Our results indicate acetylation of hTau on multiple sites regulates its biology and ameliorates amyloid beta toxicity in vivo.\", \"key\": \"c827935fa0a49ae5325be8be029ad2e8ee1980c50c0013cd7219816ca5fbaa77488af1c0de3a5cf95cdcc872d5fd430c4c78f91e2d6f15ce89f8fed6f88da10c\", \"line\": 3125, \"relation\": \"association\", \"source\": 267, \"target\": 152}, {\"citation\": {\"authors\": [\"Burlingame AL\", \"Ioanoviciu A\", \"Knudsen GM\", \"Maeda S\", \"Morris M\", \"Mucke L\", \"Trinidad JC\"], \"date\": \"2015-08-01\", \"first\": \"Morris M\", \"last\": \"Mucke L\", \"name\": \"Nature neuroscience\", \"pages\": \"1183-9\", \"reference\": \"26192747\", \"title\": \"Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"18\"}, \"evidence\": \"Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.\", \"key\": \"81f73f71932dd80d0160f666aaa8b295087eca4b45605f2e0fcf2339c9e1f18b69a1d5f0faf70726036e2a6a6be7f3799f1ccf19e0e12a0c4a40097cb62a7370\", \"line\": 3235, \"relation\": \"partOf\", \"source\": 267, \"target\": 55}, {\"key\": \"d0fb3105e939189ddaa93591906857820e832e46f0281feb34f0f53f328bb65aaea7f5c2e3215c649ebfb57f0072c48723782359527cc4e77f5e64dfab754057\", \"relation\": \"hasComponent\", \"source\": 152, \"target\": 267}, {\"annotations\": {\"Species\": {\"7227\": true}}, \"citation\": {\"authors\": [\"Augustin H\", \"Burnouf S\", \"Dols J\", \"Gorsky MK\", \"Grnke S\", \"Partridge L\", \"Sofola-Adesakin O\", \"Weigelt CM\"], \"date\": \"2017-08-30\", \"first\": \"Gorsky MK\", \"last\": \"Partridge L\", \"name\": \"Scientific reports\", \"pages\": \"9984\", \"reference\": \"28855586\", \"title\": \"Pseudo-acetylation of multiple sites on human Tau proteins alters Tau phosphorylation and microtubule binding, and ameliorates amyloid beta toxicity.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"We have used a knock-out/knock-in strategy in Drosophila to generate a strain with hTau inserted into the endogenous fly tau locus and expressed under the control of the endogenous fly tau promoter, thus avoiding potential toxicity due to genetic over-expression. hTau knock-in (KI) proteins were expressed at normal, endogenous levels, bound to fly microtubules and were post-translationally modified, hence displaying physiological properties. We used this new model to investigate the effects of acetylation on hTau toxicity in vivo. The simultaneous pseudo-acetylation of hTau at lysines 163, 280, 281 and 369 drastically decreased hTau phosphorylation and significantly reduced its binding to microtubules in vivo. These molecular alterations were associated with ameliorated amyloid beta toxicity. Our results indicate acetylation of hTau on multiple sites regulates its biology and ameliorates amyloid beta toxicity in vivo.\", \"key\": \"52959ea83a45f2f3413867050450cad9264613716399cf5c38f84269c107ac025b47e713a914538e2d55a91fd914294512f4091ebced75b93c5b4097918d192b\", \"line\": 3125, \"relation\": \"association\", \"source\": 152, \"target\": 267}, {\"annotations\": {\"Species\": {\"7227\": true}}, \"citation\": {\"authors\": [\"Augustin H\", \"Burnouf S\", \"Dols J\", \"Gorsky MK\", \"Grnke S\", \"Partridge L\", \"Sofola-Adesakin O\", \"Weigelt CM\"], \"date\": \"2017-08-30\", \"first\": \"Gorsky MK\", \"last\": \"Partridge L\", \"name\": \"Scientific reports\", \"pages\": \"9984\", \"reference\": \"28855586\", \"title\": \"Pseudo-acetylation of multiple sites on human Tau proteins alters Tau phosphorylation and microtubule binding, and ameliorates amyloid beta toxicity.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"We have used a knock-out/knock-in strategy in Drosophila to generate a strain with hTau inserted into the endogenous fly tau locus and expressed under the control of the endogenous fly tau promoter, thus avoiding potential toxicity due to genetic over-expression. hTau knock-in (KI) proteins were expressed at normal, endogenous levels, bound to fly microtubules and were post-translationally modified, hence displaying physiological properties. We used this new model to investigate the effects of acetylation on hTau toxicity in vivo. The simultaneous pseudo-acetylation of hTau at lysines 163, 280, 281 and 369 drastically decreased hTau phosphorylation and significantly reduced its binding to microtubules in vivo. These molecular alterations were associated with ameliorated amyloid beta toxicity. Our results indicate acetylation of hTau on multiple sites regulates its biology and ameliorates amyloid beta toxicity in vivo.\", \"key\": \"eff4f6c14ac63a085ef6f7672cc22995fe32bb4a093427a76a769f3c5d77a268e43241635572800584ff60153061a6ed4abcc97ff8c5cd8b617720d97b8ff568\", \"line\": 3126, \"relation\": \"decreases\", \"source\": 152, \"target\": 286}, {\"key\": \"972d0c8a05927bf97b0a5eb2c011126a25145c1f4db0a2c52d7b464b9b00276d13aed48579d91b3842c590413d0c97d1603d58a39dc42937305b94e0f456e680\", \"relation\": \"hasComponent\", \"source\": 152, \"target\": 249}, {\"annotations\": {\"Species\": {\"7227\": true}}, \"citation\": {\"authors\": [\"Augustin H\", \"Burnouf S\", \"Dols J\", \"Gorsky MK\", \"Grnke S\", \"Partridge L\", \"Sofola-Adesakin O\", \"Weigelt CM\"], \"date\": \"2017-08-30\", \"first\": \"Gorsky MK\", \"last\": \"Partridge L\", \"name\": \"Scientific reports\", \"pages\": \"9984\", \"reference\": \"28855586\", \"title\": \"Pseudo-acetylation of multiple sites on human Tau proteins alters Tau phosphorylation and microtubule binding, and ameliorates amyloid beta toxicity.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"We have used a knock-out/knock-in strategy in Drosophila to generate a strain with hTau inserted into the endogenous fly tau locus and expressed under the control of the endogenous fly tau promoter, thus avoiding potential toxicity due to genetic over-expression. hTau knock-in (KI) proteins were expressed at normal, endogenous levels, bound to fly microtubules and were post-translationally modified, hence displaying physiological properties. We used this new model to investigate the effects of acetylation on hTau toxicity in vivo. The simultaneous pseudo-acetylation of hTau at lysines 163, 280, 281 and 369 drastically decreased hTau phosphorylation and significantly reduced its binding to microtubules in vivo. These molecular alterations were associated with ameliorated amyloid beta toxicity. Our results indicate acetylation of hTau on multiple sites regulates its biology and ameliorates amyloid beta toxicity in vivo.\", \"key\": \"6b03f4ae0ebed5bb8c2f7c5d67e7a8505bce61393f825525b59efe37f8b1957dc27ffdab4b99d344239c2be87eb84fa16897a3954c289ebd0b82b7a2d44f3b0f\", \"line\": 3122, \"relation\": \"association\", \"source\": 152, \"target\": 249}, {\"key\": \"7714a6a3ce31d8b3df2a54fb3e821a3f1b8c61b547d8a2e53ffc2d5aae7a535487f95b5298996f69471e90e01328d6e4e03377ad695a80349580c470f5acba91\", \"relation\": \"hasComponent\", \"source\": 152, \"target\": 257}, {\"annotations\": {\"Species\": {\"7227\": true}}, \"citation\": {\"authors\": [\"Augustin H\", \"Burnouf S\", \"Dols J\", \"Gorsky MK\", \"Grnke S\", \"Partridge L\", \"Sofola-Adesakin O\", \"Weigelt CM\"], \"date\": \"2017-08-30\", \"first\": \"Gorsky MK\", \"last\": \"Partridge L\", \"name\": \"Scientific reports\", \"pages\": \"9984\", \"reference\": \"28855586\", \"title\": \"Pseudo-acetylation of multiple sites on human Tau proteins alters Tau phosphorylation and microtubule binding, and ameliorates amyloid beta toxicity.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"We have used a knock-out/knock-in strategy in Drosophila to generate a strain with hTau inserted into the endogenous fly tau locus and expressed under the control of the endogenous fly tau promoter, thus avoiding potential toxicity due to genetic over-expression. hTau knock-in (KI) proteins were expressed at normal, endogenous levels, bound to fly microtubules and were post-translationally modified, hence displaying physiological properties. We used this new model to investigate the effects of acetylation on hTau toxicity in vivo. The simultaneous pseudo-acetylation of hTau at lysines 163, 280, 281 and 369 drastically decreased hTau phosphorylation and significantly reduced its binding to microtubules in vivo. These molecular alterations were associated with ameliorated amyloid beta toxicity. Our results indicate acetylation of hTau on multiple sites regulates its biology and ameliorates amyloid beta toxicity in vivo.\", \"key\": \"7fea6503700b9f900854104dcab68139d85231dcd00c6dd02605ab9105f4a7105e77429ff0616e8d47d971aba9b686c267d5a69c2d5633a8ef15e08f7118b629\", \"line\": 3124, \"relation\": \"association\", \"source\": 152, \"target\": 257}, {\"key\": \"94c8b4e238fabee7ab89369035c4e095e7beebac6a99996d92c8f4e995023950ce07b50697b8262b2c10d49ae0d2f8b3dbcd4b2acaa79e959809d03cedfec1a4\", \"relation\": \"hasComponent\", \"source\": 152, \"target\": 256}, {\"annotations\": {\"Species\": {\"7227\": true}}, \"citation\": {\"authors\": [\"Augustin H\", \"Burnouf S\", \"Dols J\", \"Gorsky MK\", \"Grnke S\", \"Partridge L\", \"Sofola-Adesakin O\", \"Weigelt CM\"], \"date\": \"2017-08-30\", \"first\": \"Gorsky MK\", \"last\": \"Partridge L\", \"name\": \"Scientific reports\", \"pages\": \"9984\", \"reference\": \"28855586\", \"title\": \"Pseudo-acetylation of multiple sites on human Tau proteins alters Tau phosphorylation and microtubule binding, and ameliorates amyloid beta toxicity.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"We have used a knock-out/knock-in strategy in Drosophila to generate a strain with hTau inserted into the endogenous fly tau locus and expressed under the control of the endogenous fly tau promoter, thus avoiding potential toxicity due to genetic over-expression. hTau knock-in (KI) proteins were expressed at normal, endogenous levels, bound to fly microtubules and were post-translationally modified, hence displaying physiological properties. We used this new model to investigate the effects of acetylation on hTau toxicity in vivo. The simultaneous pseudo-acetylation of hTau at lysines 163, 280, 281 and 369 drastically decreased hTau phosphorylation and significantly reduced its binding to microtubules in vivo. These molecular alterations were associated with ameliorated amyloid beta toxicity. Our results indicate acetylation of hTau on multiple sites regulates its biology and ameliorates amyloid beta toxicity in vivo.\", \"key\": \"c51573f93e899a994987860fe42d68671622e940a68919c1cde72503e41bfbd7c612d0117a923960aeb396411dea906c64931e983f2e73b860337899d88eaf7d\", \"line\": 3123, \"relation\": \"association\", \"source\": 152, \"target\": 256}, {\"citation\": {\"authors\": [\"Bibow S\", \"Biernat J\", \"Blackledge M\", \"Jensen MR\", \"Kadavath H\", \"Mandelkow E\", \"Ozenne V\", \"Schwalbe M\", \"Zweckstetter M\"], \"date\": \"2013-12-17\", \"first\": \"Schwalbe M\", \"last\": \"Zweckstetter M\", \"name\": \"Biochemistry\", \"pages\": \"9068-79\", \"reference\": \"24251416\", \"title\": \"Phosphorylation of human Tau protein by microtubule affinity-regulating kinase 2.\", \"type\": \"PubMed\", \"volume\": \"52\"}, \"evidence\": \"While residues Ser-262, Ser-324, and Ser-356 were completely phosphorylated, Ser-293 in the second repeat was only 84% phosphorylated (Table 1). Furthermore, four non-KXGS phosphorylation sites were detected, two within the repeat domain (Ser-305 in R2 and Ser-352 in R4) and two more at the C-terminus (Ser-413 and Ser-416) (Figure 1B,C). Of these, Ser-305 was 66% phosphorylated and Ser-352, Ser-413, and Ser-416 were 4558% phosphorylated (Table 1). Using wild-type MARK2cat at 25 C and pH 6.8, the same phosphorylation sites were observed. The three primary sites, Ser-262, Ser-324, and Ser-356, were still completely phosphorylated.\", \"key\": \"3fd4272075259da867ce23863c15b28f8f7b67334058ba026c73627e6ccdd5fe1b2cb71d1081594edacb205ed07096a7adfb93135fda2805d98da717aa0672ef\", \"line\": 2651, \"relation\": \"partOf\", \"source\": 302, \"target\": 195}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Cabrales Fontela Y\", \"Kadavath H\", \"Mandelkow E\", \"Riedel D\", \"Zweckstetter M\"], \"date\": \"2017-12-07\", \"first\": \"Cabrales Fontela Y\", \"last\": \"Zweckstetter M\", \"name\": \"Nature communications\", \"pages\": \"1981\", \"reference\": \"29215007\", \"title\": \"Multivalent cross-linking of actin filaments and microtubules through the microtubule-associated protein Tau.\", \"type\": \"PubMed\", \"volume\": \"8\"}, \"evidence\": \"The NMR experiments demonstrate that MARK2- phosphorylation of Tau attenuates its binding to F-actin. Consistent with a reduced affinity, MARK2-phosphorylated Tau failed in bundling actin filaments (Fig. 4e)\", \"key\": \"5bb57765c07630bc8770bba147abe5a9fb476b38182580976df98afd95c3a69301b24c3a1f459d725e1aceaea1b4463c2948ec7ad6e0d33742f0f49e489c038e\", \"line\": 264, \"relation\": \"decreases\", \"source\": 300, \"target\": 107}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Cabrales Fontela Y\", \"Kadavath H\", \"Mandelkow E\", \"Riedel D\", \"Zweckstetter M\"], \"date\": \"2017-12-07\", \"first\": \"Cabrales Fontela Y\", \"last\": \"Zweckstetter M\", \"name\": \"Nature communications\", \"pages\": \"1981\", \"reference\": \"29215007\", \"title\": \"Multivalent cross-linking of actin filaments and microtubules through the microtubule-associated protein Tau.\", \"type\": \"PubMed\", \"volume\": \"8\"}, \"evidence\": \"The NMR experiments demonstrate that MARK2- phosphorylation of Tau attenuates its binding to F-actin. Consistent with a reduced affinity, MARK2-phosphorylated Tau failed in bundling actin filaments (Fig. 4e)\", \"key\": \"272fb962caa4ed937134ea6eeef7a6f0efc3c20cd84032799127faba1e5790e1fe71c1c8b12b9fa6482971e28fc7c1408ed3e0802383d68343c6d11beb33392d\", \"line\": 270, \"relation\": \"decreases\", \"source\": 300, \"target\": 75}, {\"citation\": {\"authors\": [\"Bibow S\", \"Biernat J\", \"Blackledge M\", \"Jensen MR\", \"Kadavath H\", \"Mandelkow E\", \"Ozenne V\", \"Schwalbe M\", \"Zweckstetter M\"], \"date\": \"2013-12-17\", \"first\": \"Schwalbe M\", \"last\": \"Zweckstetter M\", \"name\": \"Biochemistry\", \"pages\": \"9068-79\", \"reference\": \"24251416\", \"title\": \"Phosphorylation of human Tau protein by microtubule affinity-regulating kinase 2.\", \"type\": \"PubMed\", \"volume\": \"52\"}, \"evidence\": \"While residues Ser-262, Ser-324, and Ser-356 were completely phosphorylated, Ser-293 in the second repeat was only 84% phosphorylated (Table 1). Furthermore, four non-KXGS phosphorylation sites were detected, two within the repeat domain (Ser-305 in R2 and Ser-352 in R4) and two more at the C-terminus (Ser-413 and Ser-416) (Figure 1B,C). Of these, Ser-305 was 66% phosphorylated and Ser-352, Ser-413, and Ser-416 were 4558% phosphorylated (Table 1). Using wild-type MARK2cat at 25 C and pH 6.8, the same phosphorylation sites were observed. The three primary sites, Ser-262, Ser-324, and Ser-356, were still completely phosphorylated.\", \"key\": \"080988a692a49149f14e5ee55dfbeec948ee519b46215350ac14683bb8b810bc1d09a0a58388bac22398ac0418faec1219c93f43b68f57b0e67ef30763ed1422\", \"line\": 2649, \"relation\": \"partOf\", \"source\": 300, \"target\": 194}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Notably, one study demonstrated that tau can also be ubiquitylated through Lys63 linkages by TNF receptor-associated factor 6 (TRAF6)  again, for proteasomal degradation\", \"key\": \"8aae2404a2e403fef212cff3e52328d2c3326cd35ce0f2eabacdc9e4b88108878c2b4387c277042eb7e9cc5d7a7229e14b62a7c56215667f20219aba4c67c180\", \"line\": 364, \"relation\": \"increases\", \"source\": 371, \"target\": 325}, {\"citation\": {\"authors\": [\"Babi Leko M\", \"Baadona D\", \"Bue L\", \"Delalle I\", \"Di Giovanni G\", \"Harrington C\", \"Hof PR\", \"Jovanov-Miloevi N\", \"Wischik C\", \"Wray S\", \"de Silva R\", \"imi G\"], \"date\": \"2016-01-06\", \"first\": \"imi G\", \"last\": \"Hof PR\", \"name\": \"Biomolecules\", \"pages\": \"6\", \"reference\": \"26751493\", \"title\": \"Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.\", \"type\": \"PubMed\", \"volume\": \"6\"}, \"evidence\": \"A quite different strategy is to target tau clearancee.g., by rapamycin that induces macroautophagy [175], inhibitors of Hsp90 chaperone protein that binds to misfolded proteins or by immunotherapeutic approaches [176].\", \"key\": \"13a4ee00013a50b8ec6c291ef3fb12911cd74881e19359c16342c18bc9f831ffd5706571cfab135256baffa9729f4f6d69acc3e2ededf06369d45b604f95c99d\", \"line\": 233, \"relation\": \"partOf\", \"source\": 309, \"target\": 178}, {\"annotations\": {\"Confidence\": {\"Medium\": true}, \"MeSHAnatomy\": {\"Intracellular Space\": true}, \"PublicationType\": {\"Review\": true}}, \"citation\": {\"authors\": [\"Binder LI\", \"Himmelstein DS\", \"Lancia JK\", \"Ward SM\"], \"date\": \"2012-08-01\", \"first\": \"Ward SM\", \"last\": \"Binder LI\", \"name\": \"Biochemical Society transactions\", \"pages\": \"667-71\", \"reference\": \"22817713\", \"title\": \"Tau oligomers and tau toxicity in neurodegenerative disease.\", \"type\": \"PubMed\", \"volume\": \"40\"}, \"evidence\": \"TOC1s immunoreactivity is greatly elevated in AD brains compared with healthy controls, but co-localizes best with early-stage markers for AD pathogenesis such as pS422 [16]\", \"key\": \"f38cb69356ba9f68cb00fbe06dd86c55f42d0c6d9e08f1d20e828c191e23012124350782f7f9320f32c9c93356be1814cb0df904914b039e932057d703769b30\", \"line\": 124, \"relation\": \"association\", \"source\": 309, \"target\": 46}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"44cf457f153eae95954d19878dbe72dd693db6d8c23ce76b1ab8157ad05970d9281d04ca47fce63d8b97708210ccac3710687d192ea0055395cc0f6d576e46a9\", \"line\": 1128, \"relation\": \"positiveCorrelation\", \"source\": 309, \"target\": 164}, {\"citation\": {\"authors\": [\"Kawakami F\", \"Ohtsuki K\", \"Suzuki K\"], \"date\": \"2008-02-01\", \"first\": \"Kawakami F\", \"last\": \"Ohtsuki K\", \"name\": \"Biological &amp; pharmaceutical bulletin\", \"pages\": \"193-200\", \"reference\": \"18239272\", \"title\": \"A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"The pSer422 antibody displayed an almost identical pattern to that of AT8, in that it stained NFTs (Figure 5AD), neuropil threads and neuritic plaques (Figure 5EH)\", \"key\": \"07f95dfb27e1a3bbb590863f851d532bc565da71862e0ca64365a19edb0902b4948be5739b6ca88acf7e5b3021130eeb070f984bb819270f8d50c8dc00187b5a\", \"line\": 1302, \"relation\": \"partOf\", \"source\": 309, \"target\": 35}, {\"citation\": {\"authors\": [\"Kawakami F\", \"Ohtsuki K\", \"Suzuki K\"], \"date\": \"2008-02-01\", \"first\": \"Kawakami F\", \"last\": \"Ohtsuki K\", \"name\": \"Biological &amp; pharmaceutical bulletin\", \"pages\": \"193-200\", \"reference\": \"18239272\", \"title\": \"A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"The pSer422 antibody displayed an almost identical pattern to that of AT8, in that it stained NFTs (Figure 5AD), neuropil threads and neuritic plaques (Figure 5EH)\", \"key\": \"a2b8deda46608ce11055808b455c1be7c5f5d75c2e1dfd052ea209395381eae0ae982afa1e8dc3311b9a716fe92930ec399b2c2b8737aa39e7db2799b57526ae\", \"line\": 1303, \"relation\": \"partOf\", \"source\": 309, \"target\": 68}, {\"citation\": {\"authors\": [\"Kawakami F\", \"Ohtsuki K\", \"Suzuki K\"], \"date\": \"2008-02-01\", \"first\": \"Kawakami F\", \"last\": \"Ohtsuki K\", \"name\": \"Biological &amp; pharmaceutical bulletin\", \"pages\": \"193-200\", \"reference\": \"18239272\", \"title\": \"A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"These data suggest a role for TTBK1 in pre-tangle formation prior to the formation of fibrillar tau and strengthen the idea that tau is phosphorylated at Ser422 at an early intermediate stage in NFT formation.\", \"key\": \"6c1d77628f70c7e470ba8482f2fbf005528e92e05272b3da401e034a2108486264b573bdbc7b907853e3b0a89c0ed5d36fdb53a29013f39add7cf7b966ae638a\", \"line\": 1310, \"relation\": \"association\", \"source\": 309, \"target\": 63}, {\"annotations\": {\"Enzyme_Acitvity\": {\"1 U/ml\": true}}, \"citation\": {\"authors\": [\"Bue-Scherrer V\", \"Goedert M\"], \"date\": \"2002-03-27\", \"first\": \"Bue-Scherrer V\", \"last\": \"Goedert M\", \"name\": \"FEBS letters\", \"pages\": \"151-4\", \"reference\": \"11943212\", \"title\": \"Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.\", \"type\": \"PubMed\", \"volume\": \"515\"}, \"evidence\": \"Finally, phosphorylation of S422 in tau, as recognisedby antibody AP422, was generated most eciently by SAPK3/p38gamma, SAPK4/p38delta and SAPK2b/p38beta\", \"key\": \"dd494c25575b9771b75a1f81990f411a5313410632f67b5db4738a1925ba9de701eafc737bdad7e14133229d4e2f1b8d2e9c3c17cdbd4636f43006553c2f1282\", \"line\": 1529, \"relation\": \"partOf\", \"source\": 309, \"target\": 184}, {\"annotations\": {\"Species\": {\"10116\": true}}, \"citation\": {\"authors\": [\"Ai J\", \"Ban T\", \"Bao YN\", \"Chen QX\", \"Hu XL\", \"Jiang XM\", \"Liu CD\", \"Pei SC\", \"Su XL\", \"Sun LH\", \"Sun LL\", \"Wang X\", \"Yan ML\", \"Zhao LJ\", \"Zong DK\"], \"date\": \"2015-09-01\", \"first\": \"Sun LH\", \"last\": \"Ai J\", \"name\": \"Journal of neurochemistry\", \"pages\": \"1139-51\", \"reference\": \"26118667\", \"title\": \"Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.\", \"type\": \"PubMed\", \"volume\": \"134\"}, \"evidence\": \"Endogenous miR-195 was knocked down using over-expression of its antisense molecule (pre-AMO-miR-195) via a lentivirus (lenti-pre-AMO-miR-195); this knockdown increased the tau phosphorylation at Ser202/Thr205, Ser262, Thr231, Ser422, and the Cdk5/p25 activation, but over-expression of miR-195 using lenti-pre-miR-195 decreased the tau phosphorylation and Cdk5/p25 activation.\", \"key\": \"56c571bbfb9fb0366ac6435e74450fa9d07e07de3087c68a44b0367fde318a380a9c08096e0720885ad964b5d8e192b4fdd09d949241384cf246a71a294ae835\", \"line\": 2335, \"relation\": \"negativeCorrelation\", \"source\": 309, \"target\": 153}, {\"citation\": {\"authors\": [\"Brady ST\", \"Combs B\", \"Counts SE\", \"Cox K\", \"Kanaan NM\", \"Morfini G\", \"Tiernan CT\"], \"date\": \"2016-09-01\", \"first\": \"Tiernan CT\", \"last\": \"Kanaan NM\", \"name\": \"Experimental neurology\", \"pages\": \"318-29\", \"reference\": \"27373205\", \"title\": \"Pseudophosphorylation of tau at S422 enhances SDS-stable dimer formation and impairs both anterograde and retrograde fast axonal transport.\", \"type\": \"PubMed\", \"volume\": \"283\"}, \"evidence\": \"Highlighting the relevance of these findings to human disease, pS422 tau was found to colocalize with tau oligomers and with a fraction of tau showing increased PAD exposure in the human AD brain. This study identifies novel effects of pS422 on tau biochemical properties, including prolonged nucleation and enhanced dimer formation, which correlate with a distinct inhibitory effect on FAT.\", \"key\": \"4b955247f0af27016a5951a47f30424c4f403f539b12e12ca73d4e5134da12c8515b3aa8c7d87f62979aeb7fa513a0a2dd5a538fdb0d197efeace023ceffe3cd\", \"line\": 3567, \"relation\": \"positiveCorrelation\", \"source\": 309, \"target\": 192}, {\"citation\": {\"authors\": [\"Brady ST\", \"Combs B\", \"Counts SE\", \"Cox K\", \"Kanaan NM\", \"Morfini G\", \"Tiernan CT\"], \"date\": \"2016-09-01\", \"first\": \"Tiernan CT\", \"last\": \"Kanaan NM\", \"name\": \"Experimental neurology\", \"pages\": \"318-29\", \"reference\": \"27373205\", \"title\": \"Pseudophosphorylation of tau at S422 enhances SDS-stable dimer formation and impairs both anterograde and retrograde fast axonal transport.\", \"type\": \"PubMed\", \"volume\": \"283\"}, \"evidence\": \"Highlighting the relevance of these findings to human disease, pS422 tau was found to colocalize with tau oligomers and with a fraction of tau showing increased PAD exposure in the human AD brain. This study identifies novel effects of pS422 on tau biochemical properties, including prolonged nucleation and enhanced dimer formation, which correlate with a distinct inhibitory effect on FAT.\", \"key\": \"8276b038ad71accc311e20d2c183a54192f264ef09f80a1ec0e26b8cd55bb328b467090b94b73d64082bac51fe8174c203633c3d960624596c017b677495de4a\", \"line\": 3568, \"relation\": \"positiveCorrelation\", \"source\": 309, \"target\": 182}, {\"citation\": {\"authors\": [\"Brady ST\", \"Combs B\", \"Counts SE\", \"Cox K\", \"Kanaan NM\", \"Morfini G\", \"Tiernan CT\"], \"date\": \"2016-09-01\", \"first\": \"Tiernan CT\", \"last\": \"Kanaan NM\", \"name\": \"Experimental neurology\", \"pages\": \"318-29\", \"reference\": \"27373205\", \"title\": \"Pseudophosphorylation of tau at S422 enhances SDS-stable dimer formation and impairs both anterograde and retrograde fast axonal transport.\", \"type\": \"PubMed\", \"volume\": \"283\"}, \"evidence\": \"Highlighting the relevance of these findings to human disease, pS422 tau was found to colocalize with tau oligomers and with a fraction of tau showing increased PAD exposure in the human AD brain. This study identifies novel effects of pS422 on tau biochemical properties, including prolonged nucleation and enhanced dimer formation, which correlate with a distinct inhibitory effect on FAT.\", \"key\": \"5ba5f4ef4fc652d96acf484323444dadb4e11de1cca01d34543bdfa01c5337090f0536cf275abf6f09f5f2301f5181576923d0302fce9017e9964aed3baf7b93\", \"line\": 3569, \"relation\": \"decreases\", \"source\": 309, \"target\": 77}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"For instance, the phosphorylation of tau at Ser422 inhibits the cleavage of tau by caspase 3 at Asp421\", \"key\": \"8abf6a4d9ba9bd3fa825733cf1aed677ee599e7f9312621ba878b36428be55ba0e4048f6598c9bfbe9b6d81403a7a88e54d94434f9484a9e18e9d980fc10c1b9\", \"line\": 223, \"relation\": \"decreases\", \"source\": 309, \"target\": 245}, {\"annotations\": {\"Research_Model\": {\"pR5 mice\": true}, \"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Dinekov M\", \"Gtz J\", \"Khler C\"], \"date\": \"2013-05-01\", \"first\": \"Khler C\", \"last\": \"Gtz J\", \"name\": \"Neurobiology of aging\", \"pages\": \"1369-79\", \"reference\": \"23294633\", \"title\": \"Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"34\"}, \"evidence\": \"We studied underlying pathomechanisms in tauopathies using pR5 mice that express the P301L tau mutation found in familial forms of frontotemporal dementia. In a longitudinal study we investigated the functional status of glycogen synthase kinase-3 and correlated it with the appearance of distinct tau phospho-epitopes. Neurons displaying increases in activating phosphorylation of glycogen synthase kinase-3/ at tyrosine 279/216 also showed an intense rather than moderate AT8 (phospho-Ser202/Thr205 tau) immunoreactivity, and immunoreactivity for AT100 (phospho-Ser212/Thr214 tau) and phosphorylated Ser422, phospho-epitopes associated with fibrillar tau pathology.\", \"key\": \"bfef79ea31f1dd48fa4674691fca6b9bed57032242d344960cf93a45ebcee3af1bcba0ec962c90e5f1105e1b40d57baf6c64338338e9848504c34a175f312940\", \"line\": 2545, \"relation\": \"positiveCorrelation\", \"source\": 309, \"target\": 329}, {\"citation\": {\"authors\": [\"Babi Leko M\", \"Baadona D\", \"Bue L\", \"Delalle I\", \"Di Giovanni G\", \"Harrington C\", \"Hof PR\", \"Jovanov-Miloevi N\", \"Wischik C\", \"Wray S\", \"de Silva R\", \"imi G\"], \"date\": \"2016-01-06\", \"first\": \"imi G\", \"last\": \"Hof PR\", \"name\": \"Biomolecules\", \"pages\": \"6\", \"reference\": \"26751493\", \"title\": \"Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.\", \"type\": \"PubMed\", \"volume\": \"6\"}, \"evidence\": \"A quite different strategy is to target tau clearancee.g., by rapamycin that induces macroautophagy [175], inhibitors of Hsp90 chaperone protein that binds to misfolded proteins or by immunotherapeutic approaches [176].\", \"key\": \"05e15921a83678f7cb401857c8c9a3a636012d1b6bd730461197d46cf4a397ab101829aeac70adee18966686b298653b047f6c6504ca9cd9217ba49e3624a4c8\", \"line\": 232, \"relation\": \"decreases\", \"source\": 180, \"target\": 309}, {\"citation\": {\"authors\": [\"Brady ST\", \"Combs B\", \"Counts SE\", \"Cox K\", \"Kanaan NM\", \"Morfini G\", \"Tiernan CT\"], \"date\": \"2016-09-01\", \"first\": \"Tiernan CT\", \"last\": \"Kanaan NM\", \"name\": \"Experimental neurology\", \"pages\": \"318-29\", \"reference\": \"27373205\", \"title\": \"Pseudophosphorylation of tau at S422 enhances SDS-stable dimer formation and impairs both anterograde and retrograde fast axonal transport.\", \"type\": \"PubMed\", \"volume\": \"283\"}, \"evidence\": \"Highlighting the relevance of these findings to human disease, pS422 tau was found to colocalize with tau oligomers and with a fraction of tau showing increased PAD exposure in the human AD brain. This study identifies novel effects of pS422 on tau biochemical properties, including prolonged nucleation and enhanced dimer formation, which correlate with a distinct inhibitory effect on FAT.\", \"key\": \"0365bac2d8b1bacec58891ffa7d1a4ce15f96b9b9d324fb4a8569b9472452737a693b9b233c0a7a62780f3d4271d072b43170f8cf83a2da89cf3281927da2cea\", \"line\": 3567, \"relation\": \"positiveCorrelation\", \"source\": 192, \"target\": 309}, {\"citation\": {\"authors\": [\"Kawakami F\", \"Ohtsuki K\", \"Suzuki K\"], \"date\": \"2008-02-01\", \"first\": \"Kawakami F\", \"last\": \"Ohtsuki K\", \"name\": \"Biological &amp; pharmaceutical bulletin\", \"pages\": \"193-200\", \"reference\": \"18239272\", \"title\": \"A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"These data suggest a role for TTBK1 in pre-tangle formation prior to the formation of fibrillar tau and strengthen the idea that tau is phosphorylated at Ser422 at an early intermediate stage in NFT formation.\", \"key\": \"908dbaa5781441c65427b88cb9766c6b17a79259b0d4ac09bdcbb79f083fd6f1e0d2358fefb450a72e353d82510b6b0366e6e0aa2b90af2159625c456b4ceac5\", \"line\": 1310, \"relation\": \"association\", \"source\": 63, \"target\": 309}, {\"citation\": {\"authors\": [\"Brady ST\", \"Combs B\", \"Counts SE\", \"Cox K\", \"Kanaan NM\", \"Morfini G\", \"Tiernan CT\"], \"date\": \"2016-09-01\", \"first\": \"Tiernan CT\", \"last\": \"Kanaan NM\", \"name\": \"Experimental neurology\", \"pages\": \"318-29\", \"reference\": \"27373205\", \"title\": \"Pseudophosphorylation of tau at S422 enhances SDS-stable dimer formation and impairs both anterograde and retrograde fast axonal transport.\", \"type\": \"PubMed\", \"volume\": \"283\"}, \"evidence\": \"Highlighting the relevance of these findings to human disease, pS422 tau was found to colocalize with tau oligomers and with a fraction of tau showing increased PAD exposure in the human AD brain. This study identifies novel effects of pS422 on tau biochemical properties, including prolonged nucleation and enhanced dimer formation, which correlate with a distinct inhibitory effect on FAT.\", \"key\": \"6eea12dea54e5271d8900b88e645db9aa4afde646001c69aac9a46138abb4ffa5efc78a6b604ae3edb81e357b808de5c39910a62cfa12150cf542346751250d8\", \"line\": 3568, \"relation\": \"positiveCorrelation\", \"source\": 182, \"target\": 309}, {\"citation\": {\"authors\": [\"Bantscheff M\", \"Buist A\", \"Dewachter I\", \"Drewes G\", \"Faelth-Savitski M\", \"Joberty G\", \"Kienlen-Campard P\", \"Moechars D\", \"Octave JN\", \"Pierrot N\", \"Stancu IC\", \"Vanoosthuyse A\", \"Vasconcelos B\", \"Wang P\"], \"date\": \"2017-05-01\", \"first\": \"Wang P\", \"last\": \"Dewachter I\", \"name\": \"Acta neuropathologica\", \"pages\": \"731-749\", \"reference\": \"28083634\", \"title\": \"Tau interactome mappingbased identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo.\", \"type\": \"PubMed\", \"volume\": \"133\"}, \"evidence\": \"Analysis of a catalytically dead mutant with a C91A mutation revealed no effect on Lys48-linked polyubiquitination of Tau\", \"key\": \"3051fce170256609db3a80d186cd87aa25c8dc9afd9fc49cf6d5c1dd7b3cee35e7487dd23af83c72b04433507ffa9a72fa973b7a7d43b82a8b38dcc804bbb7cf\", \"line\": 148, \"relation\": \"causesNoChange\", \"source\": 340, \"target\": 324}, {\"citation\": {\"authors\": [\"Bantscheff M\", \"Buist A\", \"Dewachter I\", \"Drewes G\", \"Faelth-Savitski M\", \"Joberty G\", \"Kienlen-Campard P\", \"Moechars D\", \"Octave JN\", \"Pierrot N\", \"Stancu IC\", \"Vanoosthuyse A\", \"Vasconcelos B\", \"Wang P\"], \"date\": \"2017-05-01\", \"first\": \"Wang P\", \"last\": \"Dewachter I\", \"name\": \"Acta neuropathologica\", \"pages\": \"731-749\", \"reference\": \"28083634\", \"title\": \"Tau interactome mappingbased identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo.\", \"type\": \"PubMed\", \"volume\": \"133\"}, \"evidence\": \"AAV-driven expression of Otub1-C91A did not increase AT8-positive Tau, in contrast to expression of wild-type Otub1 and the N-terminally truncated form of Otub1. This was demonstrated by immunofluorescence staining (Fig. 6a) and confirmed by biochemical analysis (Fig. 6b).\", \"key\": \"5681a02c4c510d99b0872ed652ec06da77e9cef122e627fec4f2c2422333d165af379006e35122f1dfc5167a2df0fca53a0a21d7213641426280156ca838a430\", \"line\": 166, \"relation\": \"causesNoChange\", \"source\": 340, \"target\": 291}, {\"citation\": {\"authors\": [\"Bantscheff M\", \"Buist A\", \"Dewachter I\", \"Drewes G\", \"Faelth-Savitski M\", \"Joberty G\", \"Kienlen-Campard P\", \"Moechars D\", \"Octave JN\", \"Pierrot N\", \"Stancu IC\", \"Vanoosthuyse A\", \"Vasconcelos B\", \"Wang P\"], \"date\": \"2017-05-01\", \"first\": \"Wang P\", \"last\": \"Dewachter I\", \"name\": \"Acta neuropathologica\", \"pages\": \"731-749\", \"reference\": \"28083634\", \"title\": \"Tau interactome mappingbased identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo.\", \"type\": \"PubMed\", \"volume\": \"133\"}, \"evidence\": \"Conversely, AAV-driven expression of N-terminally truncated Otub1 significantly decreased Lys48-linked polyubiquitin chains of Tau (Fig. 5b), demonstrating that the N-terminal domain of Otub1, which is crucial for its noncanonical role, is not involved in regulation of Tau ubiquitination.\", \"key\": \"c98d03d07f6f3f946606f1e20c1653c7264ad950727226e6ddcbcda4b1301f7a2774ac462b010c9e11d67ef8ad6862a287e2ae8fdfbc061d3d72e3f67f05d72e\", \"line\": 153, \"relation\": \"decreases\", \"source\": 339, \"target\": 324}, {\"citation\": {\"authors\": [\"Bantscheff M\", \"Buist A\", \"Dewachter I\", \"Drewes G\", \"Faelth-Savitski M\", \"Joberty G\", \"Kienlen-Campard P\", \"Moechars D\", \"Octave JN\", \"Pierrot N\", \"Stancu IC\", \"Vanoosthuyse A\", \"Vasconcelos B\", \"Wang P\"], \"date\": \"2017-05-01\", \"first\": \"Wang P\", \"last\": \"Dewachter I\", \"name\": \"Acta neuropathologica\", \"pages\": \"731-749\", \"reference\": \"28083634\", \"title\": \"Tau interactome mappingbased identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo.\", \"type\": \"PubMed\", \"volume\": \"133\"}, \"evidence\": \"AAV-driven expression of Otub1-C91A did not increase AT8-positive Tau, in contrast to expression of wild-type Otub1 and the N-terminally truncated form of Otub1. This was demonstrated by immunofluorescence staining (Fig. 6a) and confirmed by biochemical analysis (Fig. 6b).\", \"key\": \"77f1217527304b1c4a1c83ebf3186dd5743b8d8314ace6bc2bb39321882a59fa2a3191cbe445ccc04bb48a2ce1f332be9e41eb2b4a4f35097d1c398f9e7c0954\", \"line\": 168, \"relation\": \"increases\", \"source\": 339, \"target\": 291}, {\"annotations\": {\"Enzyme_Acitvity\": {\"1 U/ml\": true}}, \"citation\": {\"authors\": [\"Bue-Scherrer V\", \"Goedert M\"], \"date\": \"2002-03-27\", \"first\": \"Bue-Scherrer V\", \"last\": \"Goedert M\", \"name\": \"FEBS letters\", \"pages\": \"151-4\", \"reference\": \"11943212\", \"title\": \"Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.\", \"type\": \"PubMed\", \"volume\": \"515\"}, \"evidence\": \"The AD2 epitope, which corresponds to phosphorylated S396 and S404 in tau, was generated most effectively by SAPK3/p38gamma and SAPK4/p38delta\", \"key\": \"96674bbcca4194854ba431a1c45c14a904ce7acc134cebd2d0ce73075c13a812a6f4676ff2bd78dd7d4db3857935f1b2fe51d9a0d03b92329f551cce745b815b\", \"line\": 1521, \"relation\": \"partOf\", \"source\": 316, \"target\": 183}, {\"citation\": {\"authors\": [\"Burlingame AL\", \"Ioanoviciu A\", \"Knudsen GM\", \"Maeda S\", \"Morris M\", \"Mucke L\", \"Trinidad JC\"], \"date\": \"2015-08-01\", \"first\": \"Morris M\", \"last\": \"Mucke L\", \"name\": \"Nature neuroscience\", \"pages\": \"1183-9\", \"reference\": \"26192747\", \"title\": \"Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"18\"}, \"evidence\": \"Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.\", \"key\": \"7688085b61602419f0d96caac5ec2a3706a813d8dc05dfab1e34e92241cf3103003298079b03e7bb365d4b8d231f56beb03ba73d2e89bffc75cdd76a7eba9e98\", \"line\": 3226, \"relation\": \"isA\", \"source\": 270, \"target\": 247}, {\"annotations\": {\"MeSHAnatomy\": {\"Brain\": true, \"Spinal Cord\": true}}, \"citation\": {\"reference\": \"10.4172/2168-975X.1000126\", \"type\": \"DOI\"}, \"evidence\": \"In both the detergent soluble and insoluble fractions of the brain and spinal cord homogenates of Tg Tau P301S mice, we found that tau phosphorylation was significantly reduced (T-tests, P<0.05) by the anatabine treatment for all the AD phosphorylated epitopes tested (Figure 6)\", \"key\": \"f7b088de7beb169f9d8dd8a9e16875c2d4ee5588a48c6c436fb3551d0a8cf8a87cdcb85488bdbfef9215308d001db5ef5c450d6fd50526fdb2fdc0a29bac2f6a\", \"line\": 116, \"relation\": \"decreases\", \"source\": 13, \"target\": 315}, {\"annotations\": {\"MeSHDisease\": {\"Tauopathies\": true}, \"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Li R\", \"Mullan M\", \"Paris D\", \"Verma M\"], \"date\": \"2015-01-01\", \"first\": \"Verma M\", \"last\": \"Paris D\", \"name\": \"PloS one\", \"pages\": \"e0128224\", \"reference\": \"26010758\", \"title\": \"Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.\", \"type\": \"PubMed\", \"volume\": \"10\"}, \"evidence\": \" We have shown previously that anatabine displays some anti-inflammatory properties and reduces microgliosis and tau phosphorylation in a pure mouse model of tauopathy.\", \"key\": \"feceac31ac30b111adf077d83d7f7b12b1175b909e3093972bdeb77b63b18575da61bd9bedd73beb37f008293c573e71b8255b102c9133be343de0c63f79774f\", \"line\": 83, \"relation\": \"decreases\", \"source\": 13, \"target\": 286}, {\"annotations\": {\"MeSHAnatomy\": {\"Brain\": true, \"Spinal Cord\": true}}, \"citation\": {\"reference\": \"10.4172/2168-975X.1000126\", \"type\": \"DOI\"}, \"evidence\": \"In both the detergent soluble and insoluble fractions of the brain and spinal cord homogenates of Tg Tau P301S mice, we found that tau phosphorylation was significantly reduced (T-tests, P<0.05) by the anatabine treatment for all the AD phosphorylated epitopes tested (Figure 6)\", \"key\": \"188eda61f3c3153e0ca4c526a00ba3b55458063536bb9f127672cfedce289bb47863d1935e714efad396ea6d6a3726ff285619ca52d9590ea4c14a4fb3d65598\", \"line\": 115, \"relation\": \"decreases\", \"source\": 13, \"target\": 290}, {\"annotations\": {\"MeSHAnatomy\": {\"Brain\": true, \"Spinal Cord\": true}}, \"citation\": {\"reference\": \"10.4172/2168-975X.1000126\", \"type\": \"DOI\"}, \"evidence\": \"In both the detergent soluble and insoluble fractions of the brain and spinal cord homogenates of Tg Tau P301S mice, we found that tau phosphorylation was significantly reduced (T-tests, P<0.05) by the anatabine treatment for all the AD phosphorylated epitopes tested (Figure 6)\", \"key\": \"3fb75b54eefecb665e36982268506387a1c1f1d85a2d58eb57a73684095f6f8be12325e9908477d3b8ef05f5f846dfde45ef28c3df6ede2c6af1e3ae2d12a2fb\", \"line\": 114, \"relation\": \"decreases\", \"source\": 13, \"target\": 305}, {\"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Phosphorylation of the Thr-231 residue in this motif markedly decreases the affinity of tau for PP2A.\", \"key\": \"3fc78171439cc074a02c52db90dcaa9bab4eca2e13b11bfc2b82f55418ff0dc9a4eb71b632ec3f4c68d03c3abbfd4071051c47231c6be34144ea4184dea5952e\", \"line\": 468, \"relation\": \"decreases\", \"source\": 315, \"target\": 110}, {\"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"This is potentially physiologically significant since phosphorylation of tau at Thr-231, a target site for ERK2, GSK3, and cdk5, occurs early in AD and can further inhibit the ability of PP2A/B to dephosphorylate other major AD-tau phosphoepitopes (Landrieu et al.,2011).\", \"key\": \"aa8669d8ab115df62b2fd39f86248a153fe5ee32b08fe885d7a764191d675793c5755a2ed6cd19a154b6589458848c8e78a95158e7b28ad989db1fd9eb576f33\", \"line\": 474, \"object\": {\"modifier\": \"Activity\"}, \"relation\": \"decreases\", \"source\": 315, \"target\": 143}, {\"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"This is potentially physiologically significant since phosphorylation of tau at Thr-231, a target site for ERK2, GSK3, and cdk5, occurs early in AD and can further inhibit the ability of PP2A/B to dephosphorylate other major AD-tau phosphoepitopes (Landrieu et al.,2011).\", \"key\": \"691c4f967b06862198cb1a227fec1c682180af95e146fb5a526b266bf8c1bb8e38d8971c732391270358cd31986b10004a742f7b30c95161a8eb18519a4fc404\", \"line\": 475, \"object\": {\"modifier\": \"Activity\"}, \"relation\": \"decreases\", \"source\": 315, \"target\": 145}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"a22d71720bf042cae00452bfe6cda72faf20cd60de111ba94acb03adebd2244eec268a0e85039c5ff9aef8f8666f123331ca4e3578688e263aa5d4dc289271d0\", \"line\": 1126, \"relation\": \"positiveCorrelation\", \"source\": 315, \"target\": 164}, {\"citation\": {\"authors\": [\"Chai GS\", \"Chen NN\", \"Cheng XS\", \"Duan DX\", \"Hu Y\", \"Liu GP\", \"Luo Y\", \"Ni ZF\", \"Wang JZ\"], \"date\": \"2013-01-01\", \"first\": \"Duan DX\", \"last\": \"Liu GP\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"795-808\", \"reference\": \"23948915\", \"title\": \"Phosphorylation of tau by death-associated protein kinase 1 antagonizes the kinase-induced cell apoptosis.\", \"type\": \"PubMed\", \"volume\": \"37\"}, \"evidence\": \"These data suggest that tau hyperphosphorylation at Thr231, Ser262, and Ser396 by DAPK1 renders the cells more resistant to the kinase-induced apoptotic cell death, providing new insights into the tau-involved apoptotic abortion in the course of chronic neurodegeneration.\", \"key\": \"a1ba7daa2d6be9f3cd5701f7d2548779703809c942a91b0f343e54702c56a0d5b8d104ea6398248f118bf8c1e78add5198a923b0214960f8e45b4ab50ec8031c\", \"line\": 2002, \"relation\": \"negativeCorrelation\", \"source\": 315, \"target\": 78}, {\"annotations\": {\"Species\": {\"10116\": true}}, \"citation\": {\"authors\": [\"Ai J\", \"Ban T\", \"Bao YN\", \"Chen QX\", \"Hu XL\", \"Jiang XM\", \"Liu CD\", \"Pei SC\", \"Su XL\", \"Sun LH\", \"Sun LL\", \"Wang X\", \"Yan ML\", \"Zhao LJ\", \"Zong DK\"], \"date\": \"2015-09-01\", \"first\": \"Sun LH\", \"last\": \"Ai J\", \"name\": \"Journal of neurochemistry\", \"pages\": \"1139-51\", \"reference\": \"26118667\", \"title\": \"Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.\", \"type\": \"PubMed\", \"volume\": \"134\"}, \"evidence\": \"Endogenous miR-195 was knocked down using over-expression of its antisense molecule (pre-AMO-miR-195) via a lentivirus (lenti-pre-AMO-miR-195); this knockdown increased the tau phosphorylation at Ser202/Thr205, Ser262, Thr231, Ser422, and the Cdk5/p25 activation, but over-expression of miR-195 using lenti-pre-miR-195 decreased the tau phosphorylation and Cdk5/p25 activation.\", \"key\": \"cfdaf1f6fbb176df9c97070b4eca8fda6518cd785eeebb8139f2a4c29db478f03407e5505e8c704b7ee944781064bc91748a1165dd0332513b3f3942f943a0bd\", \"line\": 2334, \"relation\": \"negativeCorrelation\", \"source\": 315, \"target\": 153}, {\"annotations\": {\"Anatomy\": {\"hippocampal formation\": true}, \"Species\": {\"10116\": true}}, \"citation\": {\"authors\": [\"Boehm J\", \"Bourgeois C\", \"Dudilot A\", \"Lauzon M\", \"Leclerc N\", \"Mondragn-Rodrguez S\", \"Trillaud-Doppia E\"], \"date\": \"2012-09-14\", \"first\": \"Mondragn-Rodrguez S\", \"last\": \"Boehm J\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"32040-53\", \"reference\": \"22833681\", \"title\": \"Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.\", \"type\": \"PubMed\", \"volume\": \"287\"}, \"evidence\": \"Hence, LTD-inducing NMDA receptor activation leads to an increase in tau phosphorylation at sites PHF-1, AT180, as well as AT8 and to a reduction at AT100.\", \"key\": \"f1d1296823801a00921bcf85193e8f9c7f2c10d1a04b177a41fd269cf2bdf83e3d0f87bcbbc3e046386f337eb620dae20f5159f0a0ed89fd5221f3033a81a5e9\", \"line\": 2482, \"relation\": \"equivalentTo\", \"source\": 315, \"target\": 43}, {\"citation\": {\"authors\": [\"Braidy N\", \"Brew BJ\", \"Cullen KM\", \"Guillemin GJ\", \"Rahman A\", \"Ting K\"], \"date\": \"2009-07-22\", \"first\": \"Rahman A\", \"last\": \"Guillemin GJ\", \"name\": \"PloS one\", \"pages\": \"e6344\", \"reference\": \"19623258\", \"title\": \"The excitotoxin quinolinic acid induces tau phosphorylation in human neurons.\", \"type\": \"PubMed\", \"volume\": \"4\"}, \"evidence\": \"QA appears to act through NMDA receptor activation similar to other agonists, glutamate and NMDA and was abrogated by the NMDAR antagonist memantine. NMDA receptor agonists, glutamate and NMDA at equimolar concentrations (500 nM) increased tau phosphorylation at serine 199/202 (AT8) and threonine 231 (AT-180), similar to QA.\", \"key\": \"a659f67d51f3b5dd7d6d5b8759f3852ad3f7f4b7bd0e3612c4ec9815e9354c0c70181cced3ba836805fa38ac165bc6c44ef0c5ed388ec2762979f64bfc9c8332\", \"line\": 3881, \"relation\": \"equivalentTo\", \"source\": 315, \"target\": 185}, {\"citation\": {\"authors\": [\"Ando K\", \"Blum D\", \"Bretteville A\", \"Bue L\", \"Bgard S\", \"Blarbi K\", \"Caillet-Boudin ML\", \"Demey-Thomas E\", \"Dourlen P\", \"Drobecq H\", \"Eddarkaoui S\", \"Galas MC\", \"Ghestem A\", \"Hamdane M\", \"Landrieu I\", \"Lippens G\", \"Maurage CA\", \"Melnyk P\", \"Sambo AV\", \"Sergeant N\", \"Smet C\", \"Verdier Y\", \"Vingtdeux V\", \"Vinh J\"], \"date\": \"2013-03-01\", \"first\": \"Ando K\", \"last\": \"Bue L\", \"name\": \"Neurobiology of aging\", \"pages\": \"757-69\", \"reference\": \"22926167\", \"title\": \"Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker.\", \"type\": \"PubMed\", \"volume\": \"34\"}, \"evidence\": \"Pin1 binds to phosphorylated Thr231 of tau and facilitates the dephosphorylation of phosphoThr231 through isomerization (Galas et al., 2006; Hamdane et al., 2006; Lu et al., 1999a). Phosphorylation at Thr231 on tau is associated with the early events of tau aggregation and NFT (Augustinack et al., 2002). Pin1 binds and isomerizes the proline imidic peptide bond following the phosphothreonine 231\", \"key\": \"3f1dd4af034d1901ae8a40914f2a717b0cc92aef4da51726ae16a21868362ec8779cc4529dca862ab9db7b38b160123db14735c5dd59df55b1ba09c4b2fe09a0\", \"line\": 3996, \"relation\": \"increases\", \"source\": 315, \"target\": 39}, {\"annotations\": {\"Method\": {\"ELISA\": true, \"Immunocytochemistry\": true, \"Microtubule-binding Assay\": true, \"Pull-down Assay, GST\": true, \"Pull-down Assay, His-tagged\": true}}, \"citation\": {\"authors\": [\"Davies P\", \"Lu KP\", \"Lu PJ\", \"Wulf G\", \"Zhou XZ\"], \"date\": \"1999-06-24\", \"first\": \"Lu PJ\", \"last\": \"Lu KP\", \"name\": \"Nature\", \"pages\": \"784-8\", \"reference\": \"10391244\", \"title\": \"The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein.\", \"type\": \"PubMed\", \"volume\": \"399\"}, \"evidence\": \"In contrast, no binding was observed between Pin1 and the nonphosphorylated tau (Fig. 4a), demonstrating that T231 phosphorylation is required for Pin1 binding of tau. To determine whether the WW domain of Pin1 is responsible for binding, the mutant Pin1Y23A was used, which contains a single alanine substitution at the critical Tyr 23 in theWWdomain, resulting in a loss of the phosphoserine-binding activity13. Pin1Y23A showed much less binding to pT231 peptide (Table 1). The residual binding might be due to binding of the pT231 peptide to the much lower affinity isomerase domain of Pin113. These results indicate that the WW domain mediates Pin1 binding to the pT231 sequence of tau.\", \"key\": \"7d46fe40dadcdf33e1503b5c7f4a846354df52d9dd78ab04302dddb1b24b813eecf3306ed614b7388df9f89e2e4b8a5e8f6584ff9d084f489fb80ec74087b45b\", \"line\": 513, \"relation\": \"association\", \"source\": 315, \"target\": 343}, {\"annotations\": {\"Method\": {\"ELISA\": true, \"Immunocytochemistry\": true, \"Microtubule-binding Assay\": true, \"Pull-down Assay, GST\": true, \"Pull-down Assay, His-tagged\": true}}, \"citation\": {\"authors\": [\"Davies P\", \"Lu KP\", \"Lu PJ\", \"Wulf G\", \"Zhou XZ\"], \"date\": \"1999-06-24\", \"first\": \"Lu PJ\", \"last\": \"Lu KP\", \"name\": \"Nature\", \"pages\": \"784-8\", \"reference\": \"10391244\", \"title\": \"The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein.\", \"type\": \"PubMed\", \"volume\": \"399\"}, \"evidence\": \"To examine whether Pin1 affects the ability of pTau to bind microtubules, we generated pTau in vitro using purified Cdc2 (refs 17, 18), and determined its ability to bind Taxol-stabilized microtubules with or without Pin1. Although Cdc2 phosphorylation disrupted the ability of tau to bind microtubules; the binding was fully restored by preincubation with Pin1 (Fig. 5a). Furthermore, Pin1 was detected in the fraction of tau-bound microtubules (Fig. 5a). However, no Pin1 was detected in the microtubule fraction if pTau was not added (Fig. 5a), indicating that Pin1 does not bind microtubules directly. Thus, Pin1 binds pTau and restores its ability to bind microtubules.\", \"key\": \"3a96b14fa3907562b028cd5c85a489f3fe0061ac616ed425a06d7f6eb71b831ee7e1535e66b258d8b6a1ae665b92389b131af84f86295d903bfa82e67bdc26c0\", \"line\": 530, \"object\": {\"modifier\": \"Activity\"}, \"relation\": \"negativeCorrelation\", \"source\": 315, \"target\": 244}, {\"annotations\": {\"Method\": {\"Immunocytochemistry\": true, \"RNA Interference, siRNA\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"Lawson LY\", \"Li Q\", \"O'Leary JC 3rd\", \"Trotter JH\", \"Vestal GD\", \"Weeber EJ\"], \"date\": \"2011-05-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"16976-83\", \"reference\": \"21367866\", \"title\": \"The Hsp90 kinase co-chaperone Cdc37 regulates tau stability and phosphorylation dynamics.\", \"type\": \"PubMed\", \"volume\": \"286\"}, \"evidence\": \"Quantification of the Western blot showed that Cdc37 knockdown reduced phospho-Thr-231, phospho-Ser-199/Ser-202, phospho-Ser-396/Ser-404, and phospho-Ser-262/Ser-356 tau.\", \"key\": \"77b23c857ce571188bd0f74725ae867bfce490880f0b1ac4b51d1d9ff09c15e7ad5af623820a511148c05b3415c5b1a1ec05d521fc0db781448cae941db0d4d1\", \"line\": 630, \"relation\": \"positiveCorrelation\", \"source\": 315, \"target\": 214}, {\"annotations\": {\"MeSHDisease\": {\"Alzheimer Disease\": true}, \"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Acton PJ\", \"Bigio EH\", \"Chen-Dodson E\", \"De Felice FG\", \"Fernandez SJ\", \"Jerecic J\", \"Kinney GG\", \"Klein WL\", \"Lacor PN\", \"Lambert MP\", \"Shughrue PJ\", \"Velasco PT\", \"Wu D\"], \"date\": \"2008-09-01\", \"first\": \"De Felice FG\", \"last\": \"Klein WL\", \"name\": \"Neurobiology of aging\", \"pages\": \"1334-47\", \"reference\": \"17403556\", \"title\": \"Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"29\"}, \"evidence\": \"Importantly, pre-incubation of AD brain extracts with NU1 significantly blocked the increase in Thr231 phosphotau immunofluorescence (Fig. 6G), establishing the tau hyperphosphorylation was induced by Abeta oligomers in the AD brain extracts. NU1 also prevented the binding of brain-derived ADDLs to synaptic hot-spots (Fig. 6H and I). In NU1-treated cultures, the presence of large extracellular aggregates indicates that the antibody sequesters ADDLs and prevents their interactions with neurons (Fig. 6I).\", \"key\": \"d2b00bda20e82aa93d1e5fb1793af717277bcf887ced574edc41646a3a6b899b53c465bc62eda5c2cccc41c53f3af14e3dc39da36d821a64ce07e6785536e7a7\", \"line\": 252, \"relation\": \"decreases\", \"source\": 49, \"target\": 315}, {\"key\": \"df42210588c8f0e38df091924843c8147e18793cfd3463d9ca6789c22587d9c564f67f3e8c89c05d4d42a6ee52ce28226a1788c2704eb9c32a6c67a4e96a36fc\", \"relation\": \"hasComponent\", \"source\": 141, \"target\": 315}, {\"annotations\": {\"Anatomy\": {\"hippocampal formation\": true}, \"Species\": {\"10116\": true}}, \"citation\": {\"authors\": [\"Boehm J\", \"Bourgeois C\", \"Dudilot A\", \"Lauzon M\", \"Leclerc N\", \"Mondragn-Rodrguez S\", \"Trillaud-Doppia E\"], \"date\": \"2012-09-14\", \"first\": \"Mondragn-Rodrguez S\", \"last\": \"Boehm J\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"32040-53\", \"reference\": \"22833681\", \"title\": \"Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.\", \"type\": \"PubMed\", \"volume\": \"287\"}, \"evidence\": \"Hence, LTD-inducing NMDA receptor activation leads to an increase in tau phosphorylation at sites PHF-1, AT180, as well as AT8 and to a reduction at AT100.\", \"key\": \"a769955d9abae84ee3004af2bfde1c888a32cc62a1228a962e9bbe347525f71623be38329f6d9f9fafa65dbbc5d06ea3ca1266ba6a27b5ac89e7cdb380e6cf9c\", \"line\": 2482, \"relation\": \"equivalentTo\", \"source\": 43, \"target\": 315}, {\"citation\": {\"authors\": [\"Braidy N\", \"Brew BJ\", \"Cullen KM\", \"Guillemin GJ\", \"Rahman A\", \"Ting K\"], \"date\": \"2009-07-22\", \"first\": \"Rahman A\", \"last\": \"Guillemin GJ\", \"name\": \"PloS one\", \"pages\": \"e6344\", \"reference\": \"19623258\", \"title\": \"The excitotoxin quinolinic acid induces tau phosphorylation in human neurons.\", \"type\": \"PubMed\", \"volume\": \"4\"}, \"evidence\": \"QA appears to act through NMDA receptor activation similar to other agonists, glutamate and NMDA and was abrogated by the NMDAR antagonist memantine. NMDA receptor agonists, glutamate and NMDA at equimolar concentrations (500 nM) increased tau phosphorylation at serine 199/202 (AT8) and threonine 231 (AT-180), similar to QA.\", \"key\": \"ebdb6623b7dacad975429a499b738e83d1895202850c4d5fddd51553002f8e47bc162c1a2be58378e01a0d40b4186532d7de8621ce77a091b0b42f527a1cdb97\", \"line\": 3881, \"relation\": \"equivalentTo\", \"source\": 185, \"target\": 315}, {\"citation\": {\"authors\": [\"Asada A\", \"Hasegawa M\", \"Hisanaga S\", \"Ishiguro K\", \"Kimura T\", \"Oikawa T\", \"Saito T\", \"Uchida C\", \"Uchida T\", \"Yotsumoto K\"], \"date\": \"2009-06-19\", \"first\": \"Yotsumoto K\", \"last\": \"Hisanaga S\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"16840-7\", \"reference\": \"19401603\", \"title\": \"Effect of Pin1 or microtubule binding on dephosphorylation of FTDP-17 mutant Tau.\", \"type\": \"PubMed\", \"volume\": \"284\"}, \"evidence\": \"Pin1 is indicated to facilitate Tau dephosphorylation via PP2A by binding to the phospho-Thr-231-Pro or phospho-Thr-212-Pro site\", \"key\": \"e89e56af73894bcc51cae512775388697aa640ee7d1342856cb3e68aa7a58aed4070f2dcf45174bababd6f2b4b8a32095d9aa9f3dfcf2c405b694528ab80708f\", \"line\": 4009, \"relation\": \"directlyDecreases\", \"source\": 347, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 315}, {\"citation\": {\"authors\": [\"Asada A\", \"Hasegawa M\", \"Hisanaga S\", \"Ishiguro K\", \"Kimura T\", \"Oikawa T\", \"Saito T\", \"Uchida C\", \"Uchida T\", \"Yotsumoto K\"], \"date\": \"2009-06-19\", \"first\": \"Yotsumoto K\", \"last\": \"Hisanaga S\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"16840-7\", \"reference\": \"19401603\", \"title\": \"Effect of Pin1 or microtubule binding on dephosphorylation of FTDP-17 mutant Tau.\", \"type\": \"PubMed\", \"volume\": \"284\"}, \"evidence\": \"Pin1 is indicated to facilitate Tau dephosphorylation via PP2A by binding to the phospho-Thr-231-Pro or phospho-Thr-212-Pro site\", \"key\": \"2db9a78ebdad1f9d809fd1333e798274d6431e57d0e7e94d2628f3dcf08d3261f87a69086933d86d7e44938983d76a3123f7d13c95e7bc28118c1654a5cef549\", \"line\": 4010, \"relation\": \"directlyDecreases\", \"source\": 347, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 313}, {\"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Knock-down of PP2A catalytic subunit (Kins et al.,2001) or PP2A B (or PPP2R5D) regulatory subunit (Louis et al.,2011), and expression of the methylation-site L309A C subunit mutant (Schild et al.,2006) all induce AD-like tau phosphorylation in transgenic mice\", \"key\": \"9658e8d30520fef1de2f2aaeeeb23e85b2f2b1f3d3d055f44ce8706be81aee6b8ff8f47c75a878910c6b0bfc124e09da5a3303010dd2b609ca301012d3a0e8fa\", \"line\": 354, \"relation\": \"decreases\", \"source\": 347, \"target\": 286}, {\"annotations\": {\"Species\": {\"6239\": true}}, \"citation\": {\"authors\": [\"Choudhary B\", \"Mandelkow E\", \"Pir GJ\"], \"date\": \"2017-12-01\", \"first\": \"Pir GJ\", \"last\": \"Mandelkow E\", \"name\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\", \"pages\": \"5137-5148\", \"reference\": \"29191965\", \"title\": \"&lt;i&gt;Caenorhabditis elegans&lt;/i&gt; models of tauopathy.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"Dephosphorylation of tau is achieved mainly by protein phosphatase (PP)2A, PP2B (calcineurin), and PP-1 (92).\", \"key\": \"6dea363c9e8f66afdce0b92a758dc23130896b48962186cb021b770a06e6a6fc9096139fd9452adf5e1a89d38ca47505b949f01396125cd1eadfd5d42d71539b\", \"line\": 257, \"relation\": \"directlyDecreases\", \"source\": 347, \"target\": 286}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Protein phosphatase 1 (PP1), PP2A, PP2B, PP2C and PP5 have all been implicated in the dephosphorylation of tau\", \"key\": \"1573e9e856d752d755b4df906b23d2bbbcc871fd2bf9b796e3d65beacaa4bcbc671234ca80179a2a44628d610605ace095d5b29fd82bb5cacdf454e76626553d\", \"line\": 192, \"relation\": \"directlyDecreases\", \"source\": 347, \"target\": 286}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Among them, PP2A is the main phosphatase:it accounts for ~70% of the human brain tau phosphatase activity, and its activity is reduced in the AD brain (by ~20% and ~40% in the grey and white matter, respectively)\", \"key\": \"c7a55fbb31a6e39f5896043a3296a8830993af70835623b107599c9e849c34f2324106a51f4fb18809a0aa2230d986e45e0cddcb3ed70608e4586adadf74259e\", \"line\": 201, \"relation\": \"directlyDecreases\", \"source\": 347, \"target\": 286}, {\"citation\": {\"authors\": [\"Ehninger D\", \"Hettich MM\", \"Kickstein E\", \"Krau S\", \"Matthes F\", \"Pfurtscheller S\", \"Posey K\", \"Schneider R\", \"Schweiger S\", \"Weber S\"], \"date\": \"2017-10-23\", \"first\": \"Schweiger S\", \"last\": \"Krau S\", \"name\": \"Scientific reports\", \"pages\": \"13753\", \"reference\": \"29062069\", \"title\": \"Resveratrol induces dephosphorylation of Tau by interfering with the MID1-PP2A complex.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Here we show that resveratrol treatment directly interferes with the MID1-4-PP2A degradation complex by reducing MID1 protein expression in vitro and in vivo. This leads to an increase of microtubule-associated PP2A activity and a time- and dose-dependent dephosphorylation of Tau. Interestingly, we further show that MID1 expression is elevated in AD tissue.\", \"key\": \"ed17c97f2de5a6de0b20ba50235aeec8b9f0e691997c2bfc56f2c43273381d9af3d51a75e182f81f53c3eb61be9d45c57d761af34b46ba14a9167ae261137f6c\", \"line\": 3792, \"relation\": \"negativeCorrelation\", \"source\": 347, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 286}, {\"annotations\": {\"Method\": {\"ELISA\": true, \"Immunocytochemistry\": true, \"Microtubule-binding Assay\": true, \"Pull-down Assay, GST\": true, \"Pull-down Assay, His-tagged\": true}}, \"citation\": {\"authors\": [\"Davies P\", \"Lu KP\", \"Lu PJ\", \"Wulf G\", \"Zhou XZ\"], \"date\": \"1999-06-24\", \"first\": \"Lu PJ\", \"last\": \"Lu KP\", \"name\": \"Nature\", \"pages\": \"784-8\", \"reference\": \"10391244\", \"title\": \"The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein.\", \"type\": \"PubMed\", \"volume\": \"399\"}, \"evidence\": \"In contrast, no binding was observed between Pin1 and the nonphosphorylated tau (Fig. 4a), demonstrating that T231 phosphorylation is required for Pin1 binding of tau. To determine whether the WW domain of Pin1 is responsible for binding, the mutant Pin1Y23A was used, which contains a single alanine substitution at the critical Tyr 23 in theWWdomain, resulting in a loss of the phosphoserine-binding activity13. Pin1Y23A showed much less binding to pT231 peptide (Table 1). The residual binding might be due to binding of the pT231 peptide to the much lower affinity isomerase domain of Pin113. These results indicate that the WW domain mediates Pin1 binding to the pT231 sequence of tau.\", \"key\": \"d46a5a1521deb861317d8351ee73a997b48ac9c9003102b6d8592194fb2b7754dd9443a85d4f0065c2d72ea65ed48cd94a35f98dfaba337201ba435b70d8efd8\", \"line\": 513, \"relation\": \"association\", \"source\": 343, \"target\": 315}, {\"annotations\": {\"Method\": {\"ELISA\": true, \"Immunocytochemistry\": true, \"Microtubule-binding Assay\": true, \"Pull-down Assay, GST\": true, \"Pull-down Assay, His-tagged\": true}}, \"citation\": {\"authors\": [\"Davies P\", \"Lu KP\", \"Lu PJ\", \"Wulf G\", \"Zhou XZ\"], \"date\": \"1999-06-24\", \"first\": \"Lu PJ\", \"last\": \"Lu KP\", \"name\": \"Nature\", \"pages\": \"784-8\", \"reference\": \"10391244\", \"title\": \"The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein.\", \"type\": \"PubMed\", \"volume\": \"399\"}, \"evidence\": \"This result confirms previous findings that T231 is an important Cdc2 phosphorylation site in tau, and is also consistent with Pin1 binding mitotically pTau (Fig. 1a) and being sequestered on to PHFs in AD brains, where Cdc2 is upregulated (Fig. 3).\", \"key\": \"65cd36e61fdfdca12bcba300ab335f776d2ceac0541b2658ddb903da431ac634f866bd09136623c998c1e50c08b690586b3f40b962703b1841a24aaef960fdfc\", \"line\": 520, \"relation\": \"increases\", \"source\": 215, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 315}, {\"citation\": {\"authors\": [\"Dewachter I\", \"Terwel D\", \"Van Leuven F\"], \"date\": \"2002-01-01\", \"first\": \"Terwel D\", \"last\": \"Van Leuven F\", \"name\": \"Neuromolecular medicine\", \"pages\": \"151-65\", \"reference\": \"12428809\", \"title\": \"Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"2\"}, \"evidence\": \" Among the specific proline-dependent kinases that can phosphorylate protein tau at dif- ferent sites in vitro, special attention is dedicated to glycogen-synthase kinase-3 (GSK-3) (Michel et al., 1998), mitogen-activated protein kinase (MAPK) (Drewes et al., 1992), stress-activated protein kinases (SAPKs) (Goedert et al., 1997) and cyclin-dependent kinases (CDKs) including cdc2 and cdk5 (Baumann et al., 1993; Patrick et al., 1999).\", \"key\": \"50dddaf1ebd49d5dc0d2bbc0d439755326e169412fa7a403ebed7af10edf18762fa7664c4c6b1037710bfb849d1b937fa7c08d4e8dd10b19018ece6f268d57e4\", \"line\": 114, \"relation\": \"increases\", \"source\": 215, \"target\": 286}, {\"citation\": {\"authors\": [\"Ando K\", \"Blum D\", \"Bretteville A\", \"Bue L\", \"Bgard S\", \"Blarbi K\", \"Caillet-Boudin ML\", \"Demey-Thomas E\", \"Dourlen P\", \"Drobecq H\", \"Eddarkaoui S\", \"Galas MC\", \"Ghestem A\", \"Hamdane M\", \"Landrieu I\", \"Lippens G\", \"Maurage CA\", \"Melnyk P\", \"Sambo AV\", \"Sergeant N\", \"Smet C\", \"Verdier Y\", \"Vingtdeux V\", \"Vinh J\"], \"date\": \"2013-03-01\", \"first\": \"Ando K\", \"last\": \"Bue L\", \"name\": \"Neurobiology of aging\", \"pages\": \"757-69\", \"reference\": \"22926167\", \"title\": \"Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker.\", \"type\": \"PubMed\", \"volume\": \"34\"}, \"evidence\": \"Pin1 binds to phosphorylated Thr231 of tau and facilitates the dephosphorylation of phosphoThr231 through isomerization (Galas et al., 2006; Hamdane et al., 2006; Lu et al., 1999a). Phosphorylation at Thr231 on tau is associated with the early events of tau aggregation and NFT (Augustinack et al., 2002). Pin1 binds and isomerizes the proline imidic peptide bond following the phosphothreonine 231\", \"key\": \"a989a4d3e3e442ead366d998eec2cdaac43b0a8be4178578eea415f489b72007c3afcf902bcb1ff2ba6f68c9a691da3b81543ba9233c8239226a8a5cb0f62623\", \"line\": 3995, \"relation\": \"directlyDecreases\", \"source\": 342, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 315}, {\"citation\": {\"authors\": [\"Asada A\", \"Hasegawa M\", \"Hisanaga S\", \"Ishiguro K\", \"Kimura T\", \"Oikawa T\", \"Saito T\", \"Uchida C\", \"Uchida T\", \"Yotsumoto K\"], \"date\": \"2009-06-19\", \"first\": \"Yotsumoto K\", \"last\": \"Hisanaga S\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"16840-7\", \"reference\": \"19401603\", \"title\": \"Effect of Pin1 or microtubule binding on dephosphorylation of FTDP-17 mutant Tau.\", \"type\": \"PubMed\", \"volume\": \"284\"}, \"evidence\": \"Pin1 is indicated to facilitate Tau dephosphorylation via PP2A by binding to the phospho-Thr-231-Pro or phospho-Thr-212-Pro site\", \"key\": \"7eb58488904cc93690145388b630a9eb6a31e9ef0917bcadd42c1fdda2496f99765784acd4bc21900aad1f44930a32e62310f0d0f55310b155f532628a1ac3e6\", \"line\": 4011, \"relation\": \"directlyDecreases\", \"source\": 342, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 313}, {\"citation\": {\"authors\": [\"Buosi V\", \"Eichner T\", \"Kern D\", \"Kutter S\", \"Labeikovsky W\"], \"date\": \"2016-05-08\", \"first\": \"Eichner T\", \"last\": \"Kern D\", \"name\": \"Journal of molecular biology\", \"pages\": \"1760-75\", \"reference\": \"26996941\", \"title\": \"Molecular Mechanism of Pin1-Tau Recognition and Catalysis.\", \"type\": \"PubMed\", \"volume\": \"428\"}, \"evidence\": \"We find that phosphorylated (p-) SER235-PRO, but not pTHR231-PRO, is exclusively catalyzed by full-length Pin1 and isolated PPIase domain.\", \"key\": \"8e42b7ac3588cfeb5c65aa536f8dfdd0e92c80166eca698066035b25f0c5022c0181f61199c5e53f2a9b2c38a32fb28306664a3e08ad341e7eee337a1d585e7a\", \"line\": 3967, \"relation\": \"association\", \"source\": 342, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 295}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"4980742f27b19a5a74470c115046235d667a83cc1713c00fc3c79c9f2d96356a77a57a9ebeb2eb65a8b40dd45782ad87825c5f541733260dcbef517349218480\", \"line\": 1125, \"relation\": \"positiveCorrelation\", \"source\": 314, \"target\": 164}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"ca37ddf9f3d90be500afb7e3b1267abe27dad11ed05d9831ffdf1c0c72fd6d544aacb415ebb96c0835d3787210846e14b336a74daa5701f3fe8af4ecbb94d517\", \"line\": 1152, \"relation\": \"partOf\", \"source\": 314, \"target\": 121}, {\"citation\": {\"authors\": [\"Amniai L\", \"Fauquant C\", \"Huvent I\", \"Landrieu I\", \"Leroy A\", \"Lippens G\", \"Sibille N\", \"Verdegem D\", \"Wieruszeski JM\"], \"date\": \"2012-02-01\", \"first\": \"Sibille N\", \"last\": \"Landrieu I\", \"name\": \"Proteins\", \"pages\": \"454-62\", \"reference\": \"22072628\", \"title\": \"Structural characterization by nuclear magnetic resonance of the impact of phosphorylation in the proline-rich region of the disordered Tau protein.\", \"type\": \"PubMed\", \"volume\": \"80\"}, \"evidence\": \"In this study, we address the structural impact of phosphorylation of the Tau protein by Nuclear Magnetic Resonance (NMR) spectroscopy on a functional fragment of Tau (Tau[Ser208-Ser324] = TauF4). TauF4 was phosphorylated by the proline-directed CDK2/CycA3 kinase on Thr231 (generating the AT180 epitope), Ser235, and equally on Thr212 and Thr217 in the Proline-rich region (Tau[Ser208-Gln244] or PRR). These modifications strongly decrease the capacity of TauF4 to polymerize tubulin into microtubules. While all the NMR parameters are consistent with a globally disordered Tau protein fragment, local clusters of structuration can be defined. The most salient result of our NMR analysis is that phosphorylation in the PRR stabilizes a short -helix that runs from pSer235 till the very beginning of the microtubule-binding region (Tau[Thr245-Ser324] or MTBR of TauF4).\", \"key\": \"d4bc0f406d860c51e6eefad6453085d8e65f00672cdc1966e59b81537046721d823e6e399051b292626f6e57c622ff45ed94feba0151e7aa791ea6759ae6d8d3\", \"line\": 2792, \"relation\": \"partOf\", \"source\": 314, \"target\": 193}, {\"key\": \"2000e3000581bfba648a2557212f95214a47c3ecbb3dcf7f8736d895cdd4f76b183de17c2eb230f9a4a60bc48ef4e5fe799886f241f99f482f3b9cfb136b4b83\", \"relation\": \"hasComponent\", \"source\": 121, \"target\": 314}, {\"citation\": {\"authors\": [\"Babi Leko M\", \"Baadona D\", \"Bue L\", \"Delalle I\", \"Di Giovanni G\", \"Harrington C\", \"Hof PR\", \"Jovanov-Miloevi N\", \"Wischik C\", \"Wray S\", \"de Silva R\", \"imi G\"], \"date\": \"2016-01-06\", \"first\": \"imi G\", \"last\": \"Hof PR\", \"name\": \"Biomolecules\", \"pages\": \"6\", \"reference\": \"26751493\", \"title\": \"Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.\", \"type\": \"PubMed\", \"volume\": \"6\"}, \"evidence\": \"Recently, it has been proposed that tau protein acetylation may be responsible for tau aggregation in AD. Grinberg and collaborators detected tau acetylation at Lys274 in all tauopathies (both primary and secondary), except in AgD\", \"key\": \"88acffc56c792aaaa763b4815b7c1f0764eb3a8806e80cb17568902ad0fab9ac79f161c4f4737760c64a1291e44b53a1a413dd5a5eda002ab6b8370a6b4f38aa\", \"line\": 243, \"relation\": \"positiveCorrelation\", \"source\": 255, \"target\": 178}, {\"annotations\": {\"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Cong X\", \"Ellerby LM\", \"Gan L\", \"Huganir RL\", \"Le D\", \"Li Y\", \"Lo I\", \"Min SW\", \"Minami SS\", \"Ponnusamy R\", \"Schilling B\", \"Sohn PD\", \"Tracy TE\", \"Wang C\", \"Zhou Y\"], \"date\": \"2016-04-20\", \"first\": \"Tracy TE\", \"last\": \"Gan L\", \"name\": \"Neuron\", \"pages\": \"245-60\", \"reference\": \"27041503\", \"title\": \"Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss.\", \"type\": \"PubMed\", \"volume\": \"90\"}, \"evidence\": \"Here we report abnormal acetylation of K274 and K281 on tau, identified in AD brains, promotes memory loss and disrupts synaptic plasticity by reducing postsynaptic KIdney/BRAin (KIBRA) protein, a memory-associated protein.Transgenic mice expressing human tau with lysine-to-glutamine mutations to mimic K274 and K281 acetylation (tauKQ) exhibit AD-related memory deficits and impaired hippocampal long-term potentiation (LTP). TauKQ reduces synaptic KIBRA levels and disrupts activity-induced postsynaptic actin remodeling and AMPA receptor insertion. The LTP deficit was rescued by promoting actin polymerization or by KIBRA expression. In AD patients with dementia, we found enhanced tau acetylation is linked to loss of KIBRA.\", \"key\": \"6782ed703270b5e321c277b5b8298a0c5d2ab8a76cf9fd69cc6fde54d038781de5325f432ad670b8335f9ff612ebd237acd7430404eaac1ee0c2d4092ba74791\", \"line\": 3175, \"relation\": \"decreases\", \"source\": 255, \"target\": 76}, {\"annotations\": {\"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Cong X\", \"Ellerby LM\", \"Gan L\", \"Huganir RL\", \"Le D\", \"Li Y\", \"Lo I\", \"Min SW\", \"Minami SS\", \"Ponnusamy R\", \"Schilling B\", \"Sohn PD\", \"Tracy TE\", \"Wang C\", \"Zhou Y\"], \"date\": \"2016-04-20\", \"first\": \"Tracy TE\", \"last\": \"Gan L\", \"name\": \"Neuron\", \"pages\": \"245-60\", \"reference\": \"27041503\", \"title\": \"Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss.\", \"type\": \"PubMed\", \"volume\": \"90\"}, \"evidence\": \"Here we report abnormal acetylation of K274 and K281 on tau, identified in AD brains, promotes memory loss and disrupts synaptic plasticity by reducing postsynaptic KIdney/BRAin (KIBRA) protein, a memory-associated protein.Transgenic mice expressing human tau with lysine-to-glutamine mutations to mimic K274 and K281 acetylation (tauKQ) exhibit AD-related memory deficits and impaired hippocampal long-term potentiation (LTP). TauKQ reduces synaptic KIBRA levels and disrupts activity-induced postsynaptic actin remodeling and AMPA receptor insertion. The LTP deficit was rescued by promoting actin polymerization or by KIBRA expression. In AD patients with dementia, we found enhanced tau acetylation is linked to loss of KIBRA.\", \"key\": \"42730380f09c90c46dc990a50236daf7a9dc46bbffa7b431c4b85f3455a6778713bed406ac998e9791ee508dd169330f6689f76a0990904f65d05ac135b41171\", \"line\": 3173, \"relation\": \"decreases\", \"source\": 255, \"target\": 379}, {\"citation\": {\"authors\": [\"Chung KM\", \"Hernndez N\", \"Sproul AA\", \"Yu WH\"], \"date\": \"2018-05-18\", \"first\": \"Chung KM\", \"last\": \"Yu WH\", \"name\": \"Neuroscience letters\", \"reference\": \"29758300\", \"title\": \"Alzheimer's disease and the autophagic-lysosomal system.\", \"type\": \"PubMed\"}, \"evidence\": \"Methylene blue, a contrast agent that can reduce tau misfolding, has also been shown to induce macroautophagy, as indicated by elevated Beclin 1 and LC3-II levels and reduced tau and p62 levels in organotypic neuronal cultures and a mouse model of FTD [159]\", \"key\": \"085d39f49e3b8d1b80c4305460c15ac0043166540458cdad4878d678aa1f2da1ffe235539f953b6e83ec7a3b3a15da7e15a36f0da111bde734f954ebea436733\", \"line\": 718, \"relation\": \"decreases\", \"source\": 9, \"target\": 278}, {\"citation\": {\"authors\": [\"Lee JH\", \"Lee MJ\", \"Rubinsztein DC\"], \"date\": \"2013-06-01\", \"first\": \"Lee MJ\", \"last\": \"Rubinsztein DC\", \"name\": \"Progress in neurobiology\", \"pages\": \"49-59\", \"reference\": \"23528736\", \"title\": \"Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system.\", \"type\": \"PubMed\", \"volume\": \"105\"}, \"evidence\": \"Methylene blue, which has been known to directly inhibit tau aggregation, is also capable to induce autophagy and reduce total and phospho-tau levels with improved cognitive performance in tau transgenic mice by oral administration (Congdon et al., 2012).\", \"key\": \"01e4de5fef26347d343ce984de8c37ae897f52997b3a10c448cdf07be30e9c3418088ece6164b015e441e7ee074f7a73f1a3953619237ba057e801d838423217\", \"line\": 259, \"relation\": \"decreases\", \"source\": 9, \"target\": 286}, {\"citation\": {\"authors\": [\"Cohen TJ\", \"Madden V\", \"Tripathy A\", \"Trzeciakiewicz H\", \"Tseng JH\", \"Wander CM\", \"Yuan CX\"], \"date\": \"2017-03-13\", \"first\": \"Trzeciakiewicz H\", \"last\": \"Cohen TJ\", \"name\": \"Scientific reports\", \"pages\": \"44102\", \"reference\": \"28287136\", \"title\": \"A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Thus, KQ substitutions within the critical PHF6* motif, in the apparent absence of other tau PTMs, appears sufficient to accelerate tau aggregation in vitro.\", \"key\": \"3cb320490b43c578d6434007272863c3d172915e7b12b60dfd2ff4c73b6144cc8f42d776610ed588f11ddef83d38542ab12c077253674c3a45aa049ab0b239ad\", \"line\": 3146, \"relation\": \"decreases\", \"source\": 9, \"target\": 247}, {\"citation\": {\"authors\": [\"Blair LJ\", \"Koren J 3rd\", \"Shelton LB\"], \"date\": \"2017-01-01\", \"first\": \"Shelton LB\", \"last\": \"Blair LJ\", \"name\": \"Frontiers in neuroscience\", \"pages\": \"724\", \"reference\": \"29311797\", \"title\": \"Imbalances in the Hsp90 Chaperone Machinery: Implications for Tauopathies.\", \"type\": \"PubMed\", \"volume\": \"11\"}, \"evidence\": \"p23 also plays an important role in preventing endoplasmic reticulum (ER) stress-induced cell death, which can be triggered by misfolded proteins, like tau (Rao et al., 2006; Abisambra et al., 2013).\", \"key\": \"5a25af4500e158ce4dab065865ab7e90370f45942f566e07ec39775a9fad4ccf1b416235795ad0cfe9de4ed6576c477d41bf88fda699d00a9fc3bfed6b9f08fa\", \"line\": 355, \"relation\": \"increases\", \"source\": 278, \"target\": 80}, {\"citation\": {\"authors\": [\"Freeman D\", \"Kraatz HB\", \"Marti S\", \"Rains MK\"], \"date\": \"2013-08-21\", \"first\": \"Rains MK\", \"last\": \"Kraatz HB\", \"name\": \"ACS chemical neuroscience\", \"pages\": \"1194-203\", \"reference\": \"23687953\", \"title\": \"Electrochemical investigations into kinase-catalyzed transformations of tau protein.\", \"type\": \"PubMed\", \"volume\": \"4\"}, \"evidence\": \"The single kinase and sequential kinase-catalyzed Fc-phosphorylations points to dramatic changes around the Fc group in the Fc-phosphorylated tau films. Additional surface characterization of the Fc-tau films by time-of-flight secondary ion-mass spectrometry and X-ray photoelectron spectroscopy revealed that Fc-phosphorylations influence the tau orientation and conformation on surfaces.\", \"key\": \"c4d6fc3fede337b336413eb4dbdbfec018f29d22edbe3ead5c9e64bae57e66bb78658d441c5b6383e26ca915f40120d650bedd33f18e72d6f675cc59c0250bc9\", \"line\": 2452, \"relation\": \"directlyIncreases\", \"source\": 207, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 320}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"In addition, tau can be phosphorylated by tyrosine kinases such as the SRC family members LCK, SYK and FYN at Tyr18, and the ABL family members ARG and ABL1 at Tyr394 (REF. 45).\", \"key\": \"68fc0939bbc28240e10e23456a1df8ae144d46d169d073ba225b1c85b396def00bd55ef1d1baf84d72f41720585d57402ce214c55972b635210fc4fa586637cf\", \"line\": 175, \"relation\": \"directlyIncreases\", \"source\": 207, \"target\": 321}, {\"annotations\": {\"Anatomy\": {\"brain\": true}, \"Species\": {\"9606\": true}, \"TauIsoform\": {\"Isoform F (441 aa)\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"von Bergen M\"], \"date\": \"2007-01-01\", \"first\": \"Mandelkow E\", \"last\": \"Mandelkow EM\", \"name\": \"Brain pathology (Zurich, Switzerland)\", \"pages\": \"83-90\", \"reference\": \"17493042\", \"title\": \"Structural principles of tau and the paired helical filaments of Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Tyrosine kinases target Y18 [fyn, (79)] and Y394 [abl, (31)].\", \"key\": \"0e556a6dbe2bc51c8928a0f5f622d5f275ca13aed29c05aaba9e10d474f490f5df1b3b70dfad92fdb2b9097da92a50db4e8faf2afe31a786c571a87cce9e8a9b\", \"line\": 146, \"relation\": \"increases\", \"source\": 207, \"target\": 321}, {\"annotations\": {\"Species\": {\"6239\": true}}, \"citation\": {\"authors\": [\"Choudhary B\", \"Mandelkow E\", \"Pir GJ\"], \"date\": \"2017-12-01\", \"first\": \"Pir GJ\", \"last\": \"Mandelkow E\", \"name\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\", \"pages\": \"5137-5148\", \"reference\": \"29191965\", \"title\": \"&lt;i&gt;Caenorhabditis elegans&lt;/i&gt; models of tauopathy.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"The responsible kinases include 1) proline-directed protein kinases (PDPKs) targeting SP or TP motifs [e.g., GSK3b, cyclindependent kinase (CDK)-5, and MAPKs]; 2) nonproline directed protein kinases targeting KXGS-motifs [e.g., PKA, microtubule affinity-regulating kinase and synapses of the amphid defective (SADK)]; 3) protein kinases specific for tyrosines (e.g., Src, Lck, Syk, Fyn, and c-Abl kinase) (91).\", \"key\": \"2d7d78579ce28b03a83900570bd7aeeeab343e4a78d0b3451ee5db1b8807d8be56b274430c41a0ed8bf4494fa000786b1a5d0229a7f7f82ed7d021e6cf30abb8\", \"line\": 253, \"relation\": \"directlyIncreases\", \"source\": 207, \"target\": 317}, {\"annotations\": {\"Disease\": {\"Alzheimer's disease\": true}}, \"citation\": {\"authors\": [\"Berry RW\", \"Bigio EH\", \"Binder LI\", \"Fu Y\", \"Guillozet-Bongaarts AL\", \"Reyes JF\", \"Reynolds MR\"], \"date\": \"2006-10-18\", \"first\": \"Reynolds MR\", \"last\": \"Binder LI\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"10636-45\", \"reference\": \"17050703\", \"title\": \"Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies.\", \"type\": \"PubMed\", \"volume\": \"26\"}, \"evidence\": \"Tau-nY29 detects soluble tau and paired helical filament tau from severely affected Alzheimer's brain but fails to recognize tau from normal aged brain. This observation suggests that nitration at Tyr29 is a disease-related event that may alter the intrinsic ability of tau to self-polymerize. In Alzheimer's brain, Tau-nY29 labels the fibrillar triad of tau lesions, including neurofibrillary tangles, neuritic plaques, and, to a lesser extent, neuropil threads. Intriguingly, although Tau-nY29 stains both the neuronal and glial tau pathology of Pick disease, it detects only the neuronal pathology in corticobasal degeneration and progressive supranuclear palsy without labeling the predominant glial pathology.\", \"key\": \"6662a14847e1a6845486d06219e752c863de6316cf6342acaba5b624523ef12cfbbbb3cacda92f138a3d2a59483ae83eb9945599020503166fb6d36534ab6dde\", \"line\": 845, \"relation\": \"positiveCorrelation\", \"source\": 86, \"target\": 282}, {\"annotations\": {\"Confidence\": {\"High\": true}, \"PublicationType\": {\"Review\": true}}, \"citation\": {\"authors\": [\"Ma Q\", \"Xu H\", \"Zhang H\", \"Zhang YW\"], \"date\": \"2012-01-01\", \"first\": \"Zhang H\", \"last\": \"Xu H\", \"name\": \"Journal of neurochemistry\", \"pages\": \"9-21\", \"reference\": \"22122372\", \"title\": \"Proteolytic processing of Alzheimer's -amyloid precursor protein.\", \"type\": \"PubMed\", \"volume\": \"120 Suppl 1\"}, \"evidence\": \"Plaques consisting of beta-amyloid (Abeta) peptide (Selkoe 1998), neurofibrillary tangles consisting largely of hyperphosphorylated microtubule-associated tau protein (Buee et al. 2000; Gendron and Petrucelli 2009) and neuron loss in the hippocampus and cortex regions are the major pathological hallmarks of Alzheimers disease.\", \"key\": \"cd146a49d47d4ff69cca901165488e6d4a822e7eeec367bd065a4406557c62bc391d0184d7af3d2a0bc82b26aaa89648751e3c0546f606c5f786d643406bc309\", \"line\": 85, \"relation\": \"association\", \"source\": 86, \"target\": 286}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"c7e2d8a226012f214176cab21fe7ace67c63726033f393159552a6632373ab88975780fb571d1b053e3d6a6dda87a8d67cf8d8e217ce09e258a0cbdaa5e11b44\", \"line\": 1131, \"relation\": \"negativeCorrelation\", \"source\": 313, \"target\": 164}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"1cd23cb529681e1839241594913fbe2de79e55b503b1b07bfdc6e49a80d3ff860c6e32d6aff0f485b2f26be215ca9df3278da25104d91fab25c6efbca9de8f01\", \"line\": 1150, \"relation\": \"partOf\", \"source\": 313, \"target\": 120}, {\"citation\": {\"authors\": [\"Amniai L\", \"Fauquant C\", \"Huvent I\", \"Landrieu I\", \"Leroy A\", \"Lippens G\", \"Sibille N\", \"Verdegem D\", \"Wieruszeski JM\"], \"date\": \"2012-02-01\", \"first\": \"Sibille N\", \"last\": \"Landrieu I\", \"name\": \"Proteins\", \"pages\": \"454-62\", \"reference\": \"22072628\", \"title\": \"Structural characterization by nuclear magnetic resonance of the impact of phosphorylation in the proline-rich region of the disordered Tau protein.\", \"type\": \"PubMed\", \"volume\": \"80\"}, \"evidence\": \"In this study, we address the structural impact of phosphorylation of the Tau protein by Nuclear Magnetic Resonance (NMR) spectroscopy on a functional fragment of Tau (Tau[Ser208-Ser324] = TauF4). TauF4 was phosphorylated by the proline-directed CDK2/CycA3 kinase on Thr231 (generating the AT180 epitope), Ser235, and equally on Thr212 and Thr217 in the Proline-rich region (Tau[Ser208-Gln244] or PRR). These modifications strongly decrease the capacity of TauF4 to polymerize tubulin into microtubules. While all the NMR parameters are consistent with a globally disordered Tau protein fragment, local clusters of structuration can be defined. The most salient result of our NMR analysis is that phosphorylation in the PRR stabilizes a short -helix that runs from pSer235 till the very beginning of the microtubule-binding region (Tau[Thr245-Ser324] or MTBR of TauF4).\", \"key\": \"0437791b0113d2a1ee8966c1d57cd65f0a7c30ab84c089895def24193da0c037f9d91fc71ad8b638170916cc5a34be45a70aa1d3714ba362446b45bc45a1f24a\", \"line\": 2791, \"relation\": \"partOf\", \"source\": 313, \"target\": 193}, {\"key\": \"3067e4d861e43a3ba0acaa9becd2ea4d959d8a5bd1b6f4615412c53599d3546c19d3971f66441d237eb9b440fc7628a3d88447676d586f839a1beff26e4ae8b0\", \"relation\": \"hasComponent\", \"source\": 120, \"target\": 313}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"The phosphorylation of tau at Tyr394 and Tyr18 is present in PHFs in the brains of individuals with AD.\", \"key\": \"b75a4d090ab0deb1b8fe953be813d8aa7442e116b9572cac45ac2105a6ced08287a24038fe42d0c3847727bd781dce1c68a6a237849fb5a3c83e0df095585f17\", \"line\": 181, \"relation\": \"association\", \"source\": 318, \"target\": 56}, {\"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Mouzon B\", \"Mullan M\", \"Paris D\", \"Schweig JE\", \"Yao H\"], \"date\": \"2017-09-06\", \"first\": \"Schweig JE\", \"last\": \"Paris D\", \"name\": \"Acta neuropathologica communications\", \"pages\": \"69\", \"reference\": \"28877763\", \"title\": \"Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \"We found an increase in Syk activation in DNs surrounding A deposits as well as in neurons displaying an accumulation of phosphorylated Tau at Y18 and elevated levels of MC1 pathogenic tau conformers in AD brain sections whereas only weak immunoreactivity for pSyk was observed in brain sections from a non-demented control\", \"key\": \"0a876ed8bbd11ff76e5f9977d9e6979f66af5e5bd9d7b0402f685b2136fd3d907cf7b322d667ac454eaf6346a248d7c01cd4e4ceed473fc7eff4d370648b4a7e\", \"line\": 2208, \"relation\": \"positiveCorrelation\", \"source\": 318, \"target\": 367}, {\"annotations\": {\"MeSHAnatomy\": {\"Neurons\": true}}, \"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Mouzon B\", \"Mullan M\", \"Paris D\", \"Schweig JE\", \"Yao H\"], \"date\": \"2017-09-06\", \"first\": \"Schweig JE\", \"last\": \"Paris D\", \"name\": \"Acta neuropathologica communications\", \"pages\": \"69\", \"reference\": \"28877763\", \"title\": \"Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \" We found that tau phosphorylation at Y18 is significantly increased in neurons that are also immunopositive for pSyk (Fig. 10d, p < 0.05) which is consistent with previous data showing that in vitro Syk can phosphorylates tau at Y18.\", \"key\": \"1dbf0efbd9586c48473878ea48d06203ba7754fa33b3f79669dd10981ede791120bdaac7e747256b756aa5d39a92d2660bbddd4139dada5539ee2f2eeca5da48\", \"line\": 204, \"relation\": \"positiveCorrelation\", \"source\": 318, \"target\": 366}, {\"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Mouzon B\", \"Mullan M\", \"Paris D\", \"Schweig JE\", \"Yao H\"], \"date\": \"2017-09-06\", \"first\": \"Schweig JE\", \"last\": \"Paris D\", \"name\": \"Acta neuropathologica communications\", \"pages\": \"69\", \"reference\": \"28877763\", \"title\": \"Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \"Altogether, these data suggest that only certain pathogenic forms of tau (MC1, Y18) promote Syk activation, whereas Syk activation appears to directly in- duce tau phosphorylation at Y18 and to indirectly regulate tau phosphorylation at multiple epitopes (S396/404, S202) as well as tau misfolding (MC1, TOC1).\", \"key\": \"38fc59b21e08f8ec22559e5dba39d006d65a4595aaed737ba5a76be6d5d9966710c2d8296829c830717b0438e937490fb55213f4835f07addb0cbb6e89a3afdd\", \"line\": 219, \"object\": {\"modifier\": \"Activity\"}, \"relation\": \"increases\", \"source\": 318, \"target\": 366}, {\"annotations\": {\"CellStructure\": {\"Neurites\": true}, \"MeSHAnatomy\": {\"Brain\": true}, \"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Mouzon B\", \"Mullan M\", \"Paris D\", \"Schweig JE\", \"Yao H\"], \"date\": \"2017-09-06\", \"first\": \"Schweig JE\", \"last\": \"Paris D\", \"name\": \"Acta neuropathologica communications\", \"pages\": \"69\", \"reference\": \"28877763\", \"title\": \"Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \" We found an increase in Syk activation in DNs surrounding A  deposits as well as in neurons displaying an accumu- lation of phosphorylated Tau at Y18 and elevated levels of MC1 pathogenic tau conformers in AD brain sections whereas only weak immunoreactivity for pSyk was ob- served in brain sections from a non-demented control (Figs. 15, 16 and 17).\", \"key\": \"695a07776a2368aab89f0ddb2a0e6a38955325bc3296cd8c22a7140af434f0560c6de5a3707750b4e36c17c82b7ca140f08af8cc16c9308992e0e7d0a64fc30b\", \"line\": 258, \"object\": {\"modifier\": \"Activity\"}, \"relation\": \"positiveCorrelation\", \"source\": 318, \"target\": 366}, {\"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Mouzon B\", \"Mullan M\", \"Paris D\", \"Schweig JE\", \"Yao H\"], \"date\": \"2017-09-06\", \"first\": \"Schweig JE\", \"last\": \"Paris D\", \"name\": \"Acta neuropathologica communications\", \"pages\": \"69\", \"reference\": \"28877763\", \"title\": \"Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.\", \"type\": \"PubMed\", \"volume\": \"5\"}, \"evidence\": \"We found an increase in Syk activation in DNs surrounding A deposits as well as in neurons displaying an accumulation of phosphorylated Tau at Y18 and elevated levels of MC1 pathogenic tau conformers in AD brain sections whereas only weak immunoreactivity for pSyk was observed in brain sections from a non-demented control\", \"key\": \"13028f270de3cf808cc1b5bf07c2de00ab2cd5342da04564474be0578b37b96b313d30731f74f143c211940ffbe0ec9e7a5e121bee0e921c2f67312f6bbc97cd\", \"line\": 2208, \"relation\": \"positiveCorrelation\", \"source\": 367, \"target\": 318}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"In addition, tau can be phosphorylated by tyrosine kinases such as the SRC family members LCK, SYK and FYN at Tyr18, and the ABL family members ARG and ABL1 at Tyr394 (REF. 45).\", \"key\": \"415894a2bcc7b7fe9f25912c19b4688a5a80d44f89e880f209f7bc5a819c87ce31adaf6d3aa61f7217568c425e25586578afb5fbf0372346392a2af92c8c4d7c\", \"line\": 172, \"relation\": \"directlyIncreases\", \"source\": 236, \"target\": 318}, {\"annotations\": {\"Species\": {\"6239\": true}}, \"citation\": {\"authors\": [\"Choudhary B\", \"Mandelkow E\", \"Pir GJ\"], \"date\": \"2017-12-01\", \"first\": \"Pir GJ\", \"last\": \"Mandelkow E\", \"name\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\", \"pages\": \"5137-5148\", \"reference\": \"29191965\", \"title\": \"&lt;i&gt;Caenorhabditis elegans&lt;/i&gt; models of tauopathy.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"The responsible kinases include 1) proline-directed protein kinases (PDPKs) targeting SP or TP motifs [e.g., GSK3b, cyclindependent kinase (CDK)-5, and MAPKs]; 2) nonproline directed protein kinases targeting KXGS-motifs [e.g., PKA, microtubule affinity-regulating kinase and synapses of the amphid defective (SADK)]; 3) protein kinases specific for tyrosines (e.g., Src, Lck, Syk, Fyn, and c-Abl kinase) (91).\", \"key\": \"0f4a56aecbc33cada3af952332358e11a28f00ad356142639f576ef8ade78857394710a78e853bc36ba92c908552bea2d45843fcf5023e158e5032627238c121\", \"line\": 250, \"relation\": \"directlyIncreases\", \"source\": 236, \"target\": 317}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"In addition, tau can be phosphorylated by tyrosine kinases such as the SRC family members LCK, SYK and FYN at Tyr18, and the ABL family members ARG and ABL1 at Tyr394 (REF. 45).\", \"key\": \"13ad5c8b1017739490b208e1e4ea78802445aba09bb570a6e1bec5d265dedac17d1bcd0195036b593eb526b21e0137ef8dbf0c4f71d3c8d58b0f360230a66ee4\", \"line\": 174, \"relation\": \"directlyIncreases\", \"source\": 230, \"target\": 318}, {\"annotations\": {\"Anatomy\": {\"brain\": true}, \"Species\": {\"9606\": true}, \"TauIsoform\": {\"Isoform F (441 aa)\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"von Bergen M\"], \"date\": \"2007-01-01\", \"first\": \"Mandelkow E\", \"last\": \"Mandelkow EM\", \"name\": \"Brain pathology (Zurich, Switzerland)\", \"pages\": \"83-90\", \"reference\": \"17493042\", \"title\": \"Structural principles of tau and the paired helical filaments of Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Tyrosine kinases target Y18 [fyn, (79)] and Y394 [abl, (31)].\", \"key\": \"b55925102d00b69de2fe07e1c9951c2231689d06db837ef7f130e1c29a65ff36d4f355e22b003e4a9152ca1608180a5607aa4304f650504ba512abfe7e7b110a\", \"line\": 145, \"relation\": \"increases\", \"source\": 230, \"target\": 318}, {\"citation\": {\"authors\": [\"Brown LA\", \"Buckingham SD\", \"Jones AK\", \"Sattelle DB\"], \"date\": \"2009-03-01\", \"first\": \"Buckingham SD\", \"last\": \"Sattelle DB\", \"name\": \"Pharmacological reviews\", \"pages\": \"39-61\", \"reference\": \"19293145\", \"title\": \"Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection.\", \"type\": \"PubMed\", \"volume\": \"61\"}, \"evidence\": \"FYN expression is increased in brains from patients with AD, specifically in a subset of neurons with elevated hyperphosphorylated tau protein (Shirazi and Wood, 1993), but it is not known whether this increase in FYN contributes to hyperphosphorylation of tau or is a protective response to it. In extracts of human brains from patients with AD, soluble FYN increases with cognitive score and synaptophysin levels and inversely with the tangle count, suggestive of a pro-cognitive role for FYN (Ho et al., 2005).\", \"key\": \"71a080acb1d93f1fba6a8ca9557909b192259fbdbf748b721a63452911899515b40213f4d6aa10d97c2e833f1ff3825425923456163f482c74a45cb92de40d95\", \"line\": 642, \"relation\": \"association\", \"source\": 230, \"target\": 286}, {\"annotations\": {\"Cell\": {\"neuron\": true}, \"Cell_Line\": {\"CG-4\": true}, \"Method\": {\"Confocal Microscopy\": true, \"Immunohistochemistry\": true, \"Imunofluorescence\": true}}, \"citation\": {\"authors\": [\"Belkadi A\", \"LoPresti P\"], \"date\": \"2008-10-01\", \"first\": \"Belkadi A\", \"last\": \"LoPresti P\", \"name\": \"Journal of neurochemistry\", \"pages\": \"351-60\", \"reference\": \"18680553\", \"title\": \"Truncated Tau with the Fyn-binding domain and without the microtubule-binding domain hinders the myelinating capacity of an oligodendrocyte cell line.\", \"type\": \"PubMed\", \"volume\": \"107\"}, \"evidence\": \"Furthermore, Tau binds Fyn both in neuronal and oligodendroglial cells (Brandt et al. 1995; Klein et al.2002), and Fyn phosphorylates Tau in neuronal cells (Lee et al. 2004). The main Fyn SH3 domain-binding PXXP motif (Pro, Lys, Ser, Pro) in adult rat Tau is at the residues 223-226 (Kosik et al. 1989; Lee et al. 1998).\", \"key\": \"a9d9712bf31a3a685380bca34acd0ba34a11825ccd662ae1f4866c278c044b20858545ab6b08dbab6f621e84a121e4f7ae0be077c9a4885af27e00acef562dbf\", \"line\": 174, \"relation\": \"increases\", \"source\": 230, \"target\": 286}, {\"annotations\": {\"Species\": {\"6239\": true}}, \"citation\": {\"authors\": [\"Choudhary B\", \"Mandelkow E\", \"Pir GJ\"], \"date\": \"2017-12-01\", \"first\": \"Pir GJ\", \"last\": \"Mandelkow E\", \"name\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\", \"pages\": \"5137-5148\", \"reference\": \"29191965\", \"title\": \"&lt;i&gt;Caenorhabditis elegans&lt;/i&gt; models of tauopathy.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"The responsible kinases include 1) proline-directed protein kinases (PDPKs) targeting SP or TP motifs [e.g., GSK3b, cyclindependent kinase (CDK)-5, and MAPKs]; 2) nonproline directed protein kinases targeting KXGS-motifs [e.g., PKA, microtubule affinity-regulating kinase and synapses of the amphid defective (SADK)]; 3) protein kinases specific for tyrosines (e.g., Src, Lck, Syk, Fyn, and c-Abl kinase) (91).\", \"key\": \"43cb97c2a63903b2ca6f3527d206a7557870431fa61df8b862eadbd2bb18135f3ffa4af8a811927ec231026991a7a69824e45181854076f371c74e19ee3c7094\", \"line\": 252, \"relation\": \"directlyIncreases\", \"source\": 230, \"target\": 317}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Depending on the sites, the acetylation of tau could inhibit its degradation (for example, when at Lys163, Lys280, Lys281 or Lys369) or, by contrast, facilitate its degradation and suppress its phosphorylation and aggregation (for example, when at Lys259, Lys290, Lys321 or Lys353)\", \"key\": \"c6d5d42b38c4deef78b892cc0660877480faacd5a677a2dc3a299e9245ab0d2a67f3ba1da3e09bab87e7ac798614682944d4a14a97bf020959b7a6ec6484ab30\", \"line\": 270, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 258, \"target\": 258}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Depending on the sites, the acetylation of tau could inhibit its degradation (for example, when at Lys163, Lys280, Lys281 or Lys369) or, by contrast, facilitate its degradation and suppress its phosphorylation and aggregation (for example, when at Lys259, Lys290, Lys321 or Lys353)\", \"key\": \"1da1dcfdb7e4561896fa164cb9a50fe4c64a51c25f6165b052e23e63c4207ff353cdd8a796b69556b9cd6194ca27a4b1550dc8375171fb554f23f150f93c6cde\", \"line\": 271, \"relation\": \"decreases\", \"source\": 258, \"target\": 286}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Depending on the sites, the acetylation of tau could inhibit its degradation (for example, when at Lys163, Lys280, Lys281 or Lys369) or, by contrast, facilitate its degradation and suppress its phosphorylation and aggregation (for example, when at Lys259, Lys290, Lys321 or Lys353)\", \"key\": \"1093d4d5f0f94a16cc4cb7a06054e4d79fb63a810db7f237ef895351864b3e3727099d3247ef6ecbf6c4f7440a213cb8dbb49b1a3fe7de9c9302a3463ac77fd1\", \"line\": 272, \"relation\": \"decreases\", \"source\": 258, \"target\": 39}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Cabrales Fontela Y\", \"Kadavath H\", \"Mandelkow E\", \"Riedel D\", \"Zweckstetter M\"], \"date\": \"2017-12-07\", \"first\": \"Cabrales Fontela Y\", \"last\": \"Zweckstetter M\", \"name\": \"Nature communications\", \"pages\": \"1981\", \"reference\": \"29215007\", \"title\": \"Multivalent cross-linking of actin filaments and microtubules through the microtubule-associated protein Tau.\", \"type\": \"PubMed\", \"volume\": \"8\"}, \"evidence\": \"The NMR experiments demonstrate that MARK2- phosphorylation of Tau attenuates its binding to F-actin. Consistent with a reduced affinity, MARK2-phosphorylated Tau failed in bundling actin filaments (Fig. 4e)\", \"key\": \"92a01b9858031d4fe932ef3111d3d353a5053b94bf3cda3db2fc6a73b52d16c525ea0c63c5c5501b41d2f75050702671d6f1c190c7910442d113e3bc951554c8\", \"line\": 263, \"relation\": \"decreases\", \"source\": 299, \"target\": 107}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Cabrales Fontela Y\", \"Kadavath H\", \"Mandelkow E\", \"Riedel D\", \"Zweckstetter M\"], \"date\": \"2017-12-07\", \"first\": \"Cabrales Fontela Y\", \"last\": \"Zweckstetter M\", \"name\": \"Nature communications\", \"pages\": \"1981\", \"reference\": \"29215007\", \"title\": \"Multivalent cross-linking of actin filaments and microtubules through the microtubule-associated protein Tau.\", \"type\": \"PubMed\", \"volume\": \"8\"}, \"evidence\": \"The NMR experiments demonstrate that MARK2- phosphorylation of Tau attenuates its binding to F-actin. Consistent with a reduced affinity, MARK2-phosphorylated Tau failed in bundling actin filaments (Fig. 4e)\", \"key\": \"30f725180dd6ca1dc977c5b4efc07024fed4ddcd5ca825dd0822b93cba09187bf90bd4061c12d732ea0b6d9f23c5e3f4b5dc4f4f95adaae715485165c721896c\", \"line\": 269, \"relation\": \"decreases\", \"source\": 299, \"target\": 75}, {\"annotations\": {\"Anatomy\": {\"brain\": true}, \"Species\": {\"9606\": true}, \"TauIsoform\": {\"Isoform F (441 aa)\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"von Bergen M\"], \"date\": \"2007-01-01\", \"first\": \"Mandelkow E\", \"last\": \"Mandelkow EM\", \"name\": \"Brain pathology (Zurich, Switzerland)\", \"pages\": \"83-90\", \"reference\": \"17493042\", \"title\": \"Structural principles of tau and the paired helical filaments of Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"The lysine-isoleucine-glycineserine motif (KIGS) or lysine-cysteineglycine-serine motif (KCGS) motifs in the repeat domain (S262, S293, S324, S356) can be phosphorylated by MARK, PKA, SAD kinases, CaMKII and p70S6K, which strongly reduces the tau microtubule interactions (36, 74, 96), [note that phosphorylation at these sites also inhibits tau aggregation, illustrating an analogous role for the repeat domain in the physiological and pathological functions of tau (106)].\", \"key\": \"1fd355929513fbca23e2c739fe0afb5aa23491456a693f157b7c732999de36ffa614878a5c9ada731056fad264150824f36ef1cac637a758c71578fc19b0ae70\", \"line\": 154, \"relation\": \"decreases\", \"source\": 299, \"target\": 137}, {\"annotations\": {\"Anatomy\": {\"brain\": true}, \"Species\": {\"9606\": true}, \"TauIsoform\": {\"Isoform F (441 aa)\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"von Bergen M\"], \"date\": \"2007-01-01\", \"first\": \"Mandelkow E\", \"last\": \"Mandelkow EM\", \"name\": \"Brain pathology (Zurich, Switzerland)\", \"pages\": \"83-90\", \"reference\": \"17493042\", \"title\": \"Structural principles of tau and the paired helical filaments of Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"The lysine-isoleucine-glycineserine motif (KIGS) or lysine-cysteineglycine-serine motif (KCGS) motifs in the repeat domain (S262, S293, S324, S356) can be phosphorylated by MARK, PKA, SAD kinases, CaMKII and p70S6K, which strongly reduces the tau microtubule interactions (36, 74, 96), [note that phosphorylation at these sites also inhibits tau aggregation, illustrating an analogous role for the repeat domain in the physiological and pathological functions of tau (106)].\", \"key\": \"e4ebbd16d908fe96238827d4d6182a5eac7f261ee88c25fe805928b2309788e9d63924657a97233610fbf305b508d6da4866049bf1b6a69db6c6f0d80406c045\", \"line\": 159, \"relation\": \"decreases\", \"source\": 299, \"target\": 86}, {\"citation\": {\"authors\": [\"Bibow S\", \"Biernat J\", \"Blackledge M\", \"Jensen MR\", \"Kadavath H\", \"Mandelkow E\", \"Ozenne V\", \"Schwalbe M\", \"Zweckstetter M\"], \"date\": \"2013-12-17\", \"first\": \"Schwalbe M\", \"last\": \"Zweckstetter M\", \"name\": \"Biochemistry\", \"pages\": \"9068-79\", \"reference\": \"24251416\", \"title\": \"Phosphorylation of human Tau protein by microtubule affinity-regulating kinase 2.\", \"type\": \"PubMed\", \"volume\": \"52\"}, \"evidence\": \"While residues Ser-262, Ser-324, and Ser-356 were completely phosphorylated, Ser-293 in the second repeat was only 84% phosphorylated (Table 1). Furthermore, four non-KXGS phosphorylation sites were detected, two within the repeat domain (Ser-305 in R2 and Ser-352 in R4) and two more at the C-terminus (Ser-413 and Ser-416) (Figure 1B,C). Of these, Ser-305 was 66% phosphorylated and Ser-352, Ser-413, and Ser-416 were 4558% phosphorylated (Table 1). Using wild-type MARK2cat at 25 C and pH 6.8, the same phosphorylation sites were observed. The three primary sites, Ser-262, Ser-324, and Ser-356, were still completely phosphorylated.\", \"key\": \"4c66fa5f88028e166d91fdfd92e15b37141153d1025b30903d40414f5610afd2502d98417b45bc59b41037b2302f1622683e9457e7578e7e28919c28a639744e\", \"line\": 2647, \"relation\": \"partOf\", \"source\": 299, \"target\": 194}, {\"annotations\": {\"Method\": {\"Chromatography, Gel filtration\": true, \"Chromatography, Ni-NTA-Sepharose\": true, \"Chymotrypsin Assay\": true, \"Co-Immunoprecipitation\": true, \"Immunofluorescence\": true, \"Immunohistochemistry\": true, \"Microtubule polzmerization Assay\": true, \"Protease-coupled Assay\": true, \"RNA Interference, siRNA\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Blair LJ\", \"Borysov SI\", \"Buchner J\", \"Cox MB\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"O'Leary JC 3rd\", \"Schmid AB\", \"Shults CL\"], \"date\": \"2010-01-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"591-9\", \"reference\": \"20071522\", \"title\": \"The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules.\", \"type\": \"PubMed\", \"volume\": \"30\"}, \"evidence\": \"We found that FKBP51 indeed could interact with tau from both AD patients and control cases (Fig. 3D), further suggesting a functionally relevant relationship between FKBP51 and tau. We then investigated whether FKBP51 would preferentially interact with phosphorylated tau species. We increased the number of samples per group (4 for AD and 4 for normal) and again co-immunoprecipitated FKBP51. After gel electrophoresis, immunoblotting showed increased association of pS396 and pS199-S202 tau species with FKBP51 in AD tissue (Fig S1). Indeed, we found that FKBP51 over-expression increased phospho- and total tau levels (by 80%) in HeLa cells stably expressing normal human tau, while FKBP52 over-expression had no affect (Fig.4A). These experiments were repeated multiple times and Student t-test of these replicates demonstrated that FKBP51 significantly increased total tau levels (p= 0.0104).\", \"key\": \"bf6f1c17d2adc09859a7cf48e3d6acfd0a23fc9e4c0b28753d85961acbf581826d28a5c39795ac8f3c8d046e1fcff848037a3926a1600f718424ab5f63f71e7c\", \"line\": 590, \"relation\": \"isA\", \"source\": 289, \"target\": 204}, {\"annotations\": {\"Method\": {\"Chromatography, Gel filtration\": true, \"Chromatography, Ni-NTA-Sepharose\": true, \"Chymotrypsin Assay\": true, \"Co-Immunoprecipitation\": true, \"Immunofluorescence\": true, \"Immunohistochemistry\": true, \"Microtubule polzmerization Assay\": true, \"Protease-coupled Assay\": true, \"RNA Interference, siRNA\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Blair LJ\", \"Borysov SI\", \"Buchner J\", \"Cox MB\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"O'Leary JC 3rd\", \"Schmid AB\", \"Shults CL\"], \"date\": \"2010-01-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"591-9\", \"reference\": \"20071522\", \"title\": \"The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules.\", \"type\": \"PubMed\", \"volume\": \"30\"}, \"evidence\": \"We found that FKBP51 indeed could interact with tau from both AD patients and control cases (Fig. 3D), further suggesting a functionally relevant relationship between FKBP51 and tau. We then investigated whether FKBP51 would preferentially interact with phosphorylated tau species. We increased the number of samples per group (4 for AD and 4 for normal) and again co-immunoprecipitated FKBP51. After gel electrophoresis, immunoblotting showed increased association of pS396 and pS199-S202 tau species with FKBP51 in AD tissue (Fig S1). Indeed, we found that FKBP51 over-expression increased phospho- and total tau levels (by 80%) in HeLa cells stably expressing normal human tau, while FKBP52 over-expression had no affect (Fig.4A). These experiments were repeated multiple times and Student t-test of these replicates demonstrated that FKBP51 significantly increased total tau levels (p= 0.0104).\", \"key\": \"6ff61a9c4db99768b6fd8d844200b3576f73816f40e4237eab30417bd22c0f2a39bcde21f5531d477e95b870709813ad6e9b431b60205bc7cd39bf50d3d6d171\", \"line\": 593, \"relation\": \"association\", \"source\": 289, \"target\": 122}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"a9b08c60d07f2a396b6141c803afcc9bb526653a4939060372e3a9a8503e19a41a652d2a5fb8a1cbca4d04b784ca4f3ee5d90af9dc68edcafcb70dded9eb0b38\", \"line\": 1122, \"relation\": \"positiveCorrelation\", \"source\": 289, \"target\": 164}, {\"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Bachmeier C\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Jin C\", \"Laco G\", \"Lin Y\", \"Mullan M\", \"Paris D\"], \"date\": \"2014-12-05\", \"first\": \"Paris D\", \"last\": \"Mullan M\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"33927-44\", \"reference\": \"25331948\", \"title\": \"The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid- production and Tau hyperphosphorylation.\", \"type\": \"PubMed\", \"volume\": \"289\"}, \"evidence\": \"Western blot analyses of brain homogenates show that ()-nilvadipine significantly reduces Tau phosphorylation in AT8 (phosphorylated Ser-199/Ser-202/Thr-205) and PHF-1 (phosphorylated Ser-396/Ser-404) epitopes\", \"key\": \"ed62f7f7f1c4759d7b30c9c414672d3708d58eaf66aa2b1c45579d2c42a2c4f5c87cd0d25b83b79f3237df0b57faf8b4858eec41594c47720d86261eaa1ac742\", \"line\": 2249, \"relation\": \"partOf\", \"source\": 289, \"target\": 187}, {\"citation\": {\"authors\": [\"Gamblin TC\", \"Sun Q\"], \"date\": \"2009-06-30\", \"first\": \"Sun Q\", \"last\": \"Gamblin TC\", \"name\": \"Biochemistry\", \"pages\": \"6002-11\", \"reference\": \"19459590\", \"title\": \"Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization.\", \"type\": \"PubMed\", \"volume\": \"48\"}, \"evidence\": \"Because S199/S202/T205E, S396/S404E, 6-Phos and 7-Phos all demonstrated an AD-like shift in mobility as a result of phosphorylation-like changes, we conclude that they have the characteristics of hyperphosphorylated tau. These mutants will therefore be referred to as pseudo-hyperphosphorylated tau throughout the manuscript. On the basis of the observations that pseudohyperphosphorylated tau has decreased affinity for microtubules and reduced inducer-initiated rates of nucleation and polymerization, we propose that this combination could be the cause of the increased cytotoxicity of hyperphosphorylated tau in Alzheimer's disease and also explain the potentially beneficial role of tau polymerization and NFT formation.\", \"key\": \"9e7ad898d3b9c3457252cc95e1e82616c6c4b932ff9cca5cb9ee7395128fea0a32af25d0f0b83e400e1eef54a5265ac013672d7c01dbe75afa2b1bb624f006d0\", \"line\": 2467, \"relation\": \"partOf\", \"source\": 289, \"target\": 187}, {\"annotations\": {\"Method\": {\"Immunocytochemistry\": true, \"RNA Interference, siRNA\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"Lawson LY\", \"Li Q\", \"O'Leary JC 3rd\", \"Trotter JH\", \"Vestal GD\", \"Weeber EJ\"], \"date\": \"2011-05-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"16976-83\", \"reference\": \"21367866\", \"title\": \"The Hsp90 kinase co-chaperone Cdc37 regulates tau stability and phosphorylation dynamics.\", \"type\": \"PubMed\", \"volume\": \"286\"}, \"evidence\": \"Quantification of the Western blot showed that Cdc37 knockdown reduced phospho-Thr-231, phospho-Ser-199/Ser-202, phospho-Ser-396/Ser-404, and phospho-Ser-262/Ser-356 tau.\", \"key\": \"cd847569cea6079d71f9b9ffe383067c8241282392c0e6d439b7af66f639e7f489e0ef3a9655f1648c5a117e103b8a552184fba4c8a5fe050115ec28870e421b\", \"line\": 631, \"relation\": \"positiveCorrelation\", \"source\": 289, \"target\": 214}, {\"annotations\": {\"Method\": {\"Chromatography, Gel filtration\": true, \"Chromatography, Ni-NTA-Sepharose\": true, \"Chymotrypsin Assay\": true, \"Co-Immunoprecipitation\": true, \"Immunofluorescence\": true, \"Immunohistochemistry\": true, \"Microtubule polzmerization Assay\": true, \"Protease-coupled Assay\": true, \"RNA Interference, siRNA\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Blair LJ\", \"Borysov SI\", \"Buchner J\", \"Cox MB\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"O'Leary JC 3rd\", \"Schmid AB\", \"Shults CL\"], \"date\": \"2010-01-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"591-9\", \"reference\": \"20071522\", \"title\": \"The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules.\", \"type\": \"PubMed\", \"volume\": \"30\"}, \"evidence\": \"We found that FKBP51 indeed could interact with tau from both AD patients and control cases (Fig. 3D), further suggesting a functionally relevant relationship between FKBP51 and tau. We then investigated whether FKBP51 would preferentially interact with phosphorylated tau species. We increased the number of samples per group (4 for AD and 4 for normal) and again co-immunoprecipitated FKBP51. After gel electrophoresis, immunoblotting showed increased association of pS396 and pS199-S202 tau species with FKBP51 in AD tissue (Fig S1). Indeed, we found that FKBP51 over-expression increased phospho- and total tau levels (by 80%) in HeLa cells stably expressing normal human tau, while FKBP52 over-expression had no affect (Fig.4A). These experiments were repeated multiple times and Student t-test of these replicates demonstrated that FKBP51 significantly increased total tau levels (p= 0.0104).\", \"key\": \"acc22a1994d04ef803fa3f581b0dd2028eb5acf6880d8d1034fac4d50e95598b8fbd3d39f1296edd94e89d5f19ce55d7d7cb261e413f5e91b39ea0d66863c953\", \"line\": 596, \"relation\": \"positiveCorrelation\", \"source\": 289, \"target\": 229}, {\"annotations\": {\"ArticleCompoundNumber\": {\"1\": true}, \"Page\": {\"899\": true}}, \"citation\": {\"authors\": [\"Chang MY\", \"Greig NH\", \"John V\", \"Maccecchini ML\", \"Pan C\", \"Zetterberg H\"], \"date\": \"2012-09-01\", \"first\": \"Maccecchini ML\", \"last\": \"Greig NH\", \"name\": \"Journal of neurology, neurosurgery, and psychiatry\", \"pages\": \"894-902\", \"reference\": \"22791904\", \"title\": \"Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid- peptide and  levels: target engagement, tolerability and pharmacokinetics in humans.\", \"type\": \"PubMed\", \"volume\": \"83\"}, \"evidence\": \"In addition, Posiphen significantly reduced levels of t-s (\\u000174.1%, as assessed by the Innogenetics assay and \\u000146.2%, as assessed by the AlphaLisa assay) and p-s (\\u000161%, as assessed by the Innogenetics assay).\", \"key\": \"76410f1fa7b0c23262df00c6da0c23643a246d36c2a5c988fb9616438586c6a2eb08c401d1d2549d0d7a0ac86d0fdca99f96f88fe4ef93fa98ce4a73e7d4a708\", \"line\": 124, \"relation\": \"decreases\", \"source\": 73, \"target\": 286}, {\"annotations\": {\"CellLine\": {\"PC12\": true}}, \"citation\": {\"authors\": [\"Brown LA\", \"Buckingham SD\", \"Jones AK\", \"Sattelle DB\"], \"date\": \"2009-03-01\", \"first\": \"Buckingham SD\", \"last\": \"Sattelle DB\", \"name\": \"Pharmacological reviews\", \"pages\": \"39-61\", \"reference\": \"19293145\", \"title\": \"Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection.\", \"type\": \"PubMed\", \"volume\": \"61\"}, \"evidence\": \"It is also noteworthy that Abeta-induced tau protein phosphorylation in PC12 cells is inhibited not only by alpha7 agonists, as would be predicted from the role of alpha7 nAChRs in neuroprotection, but also by alpha-bungarotoxin (Hu et al., 2008), as might be predicted if the competition by alpha-bungarotoxin for the Abeta site blocked a direct action of Abeta on nAChRs. It is therefore possible that the toxicity of Abeta is mediated, at least in part, through a direct physical interaction between Abeta and nAChRs.\", \"key\": \"e915501f429fb575621a69a57de5be004a10562222bf5fcf90cafe94606e6960097dfe9196734e4195616d2792b1bf57890fef66cfbdc7829e63ad88af71e6a3\", \"line\": 1323, \"relation\": \"decreases\", \"source\": 196, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 286}, {\"annotations\": {\"CellLine\": {\"PC12\": true}}, \"citation\": {\"authors\": [\"Brown LA\", \"Buckingham SD\", \"Jones AK\", \"Sattelle DB\"], \"date\": \"2009-03-01\", \"first\": \"Buckingham SD\", \"last\": \"Sattelle DB\", \"name\": \"Pharmacological reviews\", \"pages\": \"39-61\", \"reference\": \"19293145\", \"title\": \"Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection.\", \"type\": \"PubMed\", \"volume\": \"61\"}, \"evidence\": \"It is also noteworthy that Abeta-induced tau protein phosphorylation in PC12 cells is inhibited not only by alpha7 agonists, as would be predicted from the role of alpha7 nAChRs in neuroprotection, but also by alpha-bungarotoxin (Hu et al., 2008), as might be predicted if the competition by alpha-bungarotoxin for the Abeta site blocked a direct action of Abeta on nAChRs. It is therefore possible that the toxicity of Abeta is mediated, at least in part, through a direct physical interaction between Abeta and nAChRs.\", \"key\": \"e6c8b9bc5411853a1b36244bb559c0327b2ae8c31e763d3f786649d76842dd3c22b00f0bcb020ca2cbc356454124cedbdf352daa33f6d5da8dcfb93906ef7dae\", \"line\": 1322, \"relation\": \"increases\", \"source\": 7, \"target\": 286}, {\"annotations\": {\"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Ferreira-Vieira TH\", \"Guimaraes IM\", \"Ribeiro FM\", \"Silva FR\"], \"date\": \"2016-01-01\", \"first\": \"Ferreira-Vieira TH\", \"last\": \"Ribeiro FM\", \"name\": \"Current neuropharmacology\", \"pages\": \"101-15\", \"reference\": \"26813123\", \"title\": \"Alzheimer's disease: Targeting the Cholinergic System.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \"However, further studies have demonstrated that nicotinic receptor activation can lead to an increase in A-mediated tau phosphorylation\", \"key\": \"cf59c400bbac3d4faec345393d5367df28327b7633bb637cdbcb8aeb6989f2e5db4d64ebdac8ab79d42fd648d05f086bf47a57cc663991f1b0152020de491827\", \"line\": 703, \"relation\": \"regulates\", \"source\": 7, \"target\": 286}, {\"citation\": {\"authors\": [\"Brown LA\", \"Buckingham SD\", \"Jones AK\", \"Sattelle DB\"], \"date\": \"2009-03-01\", \"first\": \"Buckingham SD\", \"last\": \"Sattelle DB\", \"name\": \"Pharmacological reviews\", \"pages\": \"39-61\", \"reference\": \"19293145\", \"title\": \"Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection.\", \"type\": \"PubMed\", \"volume\": \"61\"}, \"evidence\": \"FYN physically interacts with and phosphorylates tau protein, and the affinity of this physical interaction is enhanced in AD-associated mutations in tau protein (Bhaskar et al., 2005). Abeta rapidly induces tyrosine phosphorylation of many proteins (including tau protein) in human and cultured rat cortical neurons (Williamson et al., 2002). This phosphorylation is concomitant with phosphorylation and inactivation of focal adhesion kinase 1 (FADK1, a major downstream target of FYN), is blocked by inhibitors of SRC kinases and PI3K, and involves FYN associating physically with FADK1 (Williamson et al., 2002).\", \"key\": \"65b0b3c6b655e74dedf70b2907f033f58659334abd0271522246a90dc67e39460edce52c93104ca674ae15472e379a134342478485bae74a38fd73037d2a30db\", \"line\": 713, \"relation\": \"increases\", \"source\": 7, \"target\": 317}, {\"annotations\": {\"CellLine\": {\"PC12\": true}}, \"citation\": {\"authors\": [\"Brown LA\", \"Buckingham SD\", \"Jones AK\", \"Sattelle DB\"], \"date\": \"2009-03-01\", \"first\": \"Buckingham SD\", \"last\": \"Sattelle DB\", \"name\": \"Pharmacological reviews\", \"pages\": \"39-61\", \"reference\": \"19293145\", \"title\": \"Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection.\", \"type\": \"PubMed\", \"volume\": \"61\"}, \"evidence\": \"It is also noteworthy that Abeta-induced tau protein phosphorylation in PC12 cells is inhibited not only by alpha7 agonists, as would be predicted from the role of alpha7 nAChRs in neuroprotection, but also by alpha-bungarotoxin (Hu et al., 2008), as might be predicted if the competition by alpha-bungarotoxin for the Abeta site blocked a direct action of Abeta on nAChRs. It is therefore possible that the toxicity of Abeta is mediated, at least in part, through a direct physical interaction between Abeta and nAChRs.\", \"key\": \"2d44f690fb7f591ea347749a0cffc0868ae28c2bc52e9f7913e3638e9916a1b07be3c3f3b437b4312f26534cedfb9da7e6d91a4355f8029763bb4d8aa2919bbe\", \"line\": 1324, \"relation\": \"decreases\", \"source\": 70, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 286}, {\"citation\": {\"authors\": [\"Brown LA\", \"Buckingham SD\", \"Jones AK\", \"Sattelle DB\"], \"date\": \"2009-03-01\", \"first\": \"Buckingham SD\", \"last\": \"Sattelle DB\", \"name\": \"Pharmacological reviews\", \"pages\": \"39-61\", \"reference\": \"19293145\", \"title\": \"Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection.\", \"type\": \"PubMed\", \"volume\": \"61\"}, \"evidence\": \"FYN physically interacts with and phosphorylates tau protein, and the affinity of this physical interaction is enhanced in AD-associated mutations in tau protein (Bhaskar et al., 2005). Abeta rapidly induces tyrosine phosphorylation of many proteins (including tau protein) in human and cultured rat cortical neurons (Williamson et al., 2002). This phosphorylation is concomitant with phosphorylation and inactivation of focal adhesion kinase 1 (FADK1, a major downstream target of FYN), is blocked by inhibitors of SRC kinases and PI3K, and involves FYN associating physically with FADK1 (Williamson et al., 2002).\", \"key\": \"3ff454acd90fdab134996968d5acbea48b49addb08b22f8b62f3b35ff38ee352a7a0d8c6eba26034b9ddac0bc7a205fd9faef363db082356bfc298f13b1bcf66\", \"line\": 711, \"relation\": \"increases\", \"source\": 123, \"target\": 286}, {\"citation\": {\"authors\": [\"Brown LA\", \"Buckingham SD\", \"Jones AK\", \"Sattelle DB\"], \"date\": \"2009-03-01\", \"first\": \"Buckingham SD\", \"last\": \"Sattelle DB\", \"name\": \"Pharmacological reviews\", \"pages\": \"39-61\", \"reference\": \"19293145\", \"title\": \"Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection.\", \"type\": \"PubMed\", \"volume\": \"61\"}, \"evidence\": \"In neuroblastoma cells, as well as cultured hippocampal neurons, Abeta activates JNK and ERK, and blocking these prevents Abeta hyperphosphorylating tau protein, as does alpha7 antisense oligonucleotides or alpha7 antagonists, suggesting that Abeta may trigger tau protein phosphorylation through ERK and JNK via alpha7 receptors (Wang et al., 2003b). Abeta leads to phosphorylation of AKT in cultured mouse neurons through a mechanism that requires alpha7 nAChRs (Abbott et al., 2008), AKT phosphorylation levels returning to baseline upon prolonged application of Abeta.\", \"key\": \"0cccf3d1a4ede9d3d4619770a5fe36164244d6192769187d6ef9219a936434a5f2a60400d27735c36bcaeb180d55ac96bfad4262863d647d7a28fa076e6060f0\", \"line\": 1375, \"relation\": \"increases\", \"source\": 148, \"target\": 286}, {\"citation\": {\"authors\": [\"Brown LA\", \"Buckingham SD\", \"Jones AK\", \"Sattelle DB\"], \"date\": \"2009-03-01\", \"first\": \"Buckingham SD\", \"last\": \"Sattelle DB\", \"name\": \"Pharmacological reviews\", \"pages\": \"39-61\", \"reference\": \"19293145\", \"title\": \"Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection.\", \"type\": \"PubMed\", \"volume\": \"61\"}, \"evidence\": \"In neuroblastoma cells, as well as cultured hippocampal neurons, Abeta activates JNK and ERK, and blocking these prevents Abeta hyperphosphorylating tau protein, as does alpha7 antisense oligonucleotides or alpha7 antagonists, suggesting that Abeta may trigger tau protein phosphorylation through ERK and JNK via alpha7 receptors (Wang et al., 2003b). Abeta leads to phosphorylation of AKT in cultured mouse neurons through a mechanism that requires alpha7 nAChRs (Abbott et al., 2008), AKT phosphorylation levels returning to baseline upon prolonged application of Abeta.\", \"key\": \"3d6c21fccb5f0d9282dd21a7605647c7a6c628ff3ff38fe922b9ba0d7aebcc97f886594d11666a96809ac9462185cb65eed8b572d841ddd3971c2ae870cdde13\", \"line\": 1376, \"relation\": \"increases\", \"source\": 149, \"target\": 286}, {\"annotations\": {\"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Ferreira-Vieira TH\", \"Guimaraes IM\", \"Ribeiro FM\", \"Silva FR\"], \"date\": \"2016-01-01\", \"first\": \"Ferreira-Vieira TH\", \"last\": \"Ribeiro FM\", \"name\": \"Current neuropharmacology\", \"pages\": \"101-15\", \"reference\": \"26813123\", \"title\": \"Alzheimer's disease: Targeting the Cholinergic System.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \"However, further studies have demonstrated that nicotinic receptor activation can lead to an increase in A-mediated tau phosphorylation\", \"key\": \"cf9ed63847a7e2cee5766e18ac202f917c844346552ea0b906774c259d0cb5475a12a3e076633fead30790cb79fb11cd28f2646d5f40383ec2f16f030eddbe9e\", \"line\": 702, \"relation\": \"increases\", \"source\": 69, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 286}, {\"annotations\": {\"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Bu G\", \"Jiang S\", \"Li Y\", \"Xu H\", \"Zhang C\", \"Zhang YW\", \"Zhao Y\"], \"date\": \"2014-04-01\", \"first\": \"Jiang S\", \"last\": \"Zhang YW\", \"name\": \"Neuroscience bulletin\", \"pages\": \"295-307\", \"reference\": \"24590577\", \"title\": \"M1 muscarinic acetylcholine receptor in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"30\"}, \"evidence\": \"Stimulation of M1 mAChR by two agonists, carbachol and AF102B, time- and dose-dependently decreases tau phosphorylation in PC12 cells[81]. Chronic treatment with AF267B also alleviates tau pathology in 3Tg AD mice, possibly by activating PKC and inhibiting GSK-3beta\", \"key\": \"d3544c7b05ef35a817a6b364e1bb6bf15b10b81fa508c2f71d1efde896af628887c8e9ab53698cbac66b3ff08e15c0f884a79bd5b9665b6ce9e9236fcad315d4\", \"line\": 469, \"relation\": \"decreases\", \"source\": 64, \"target\": 286}, {\"annotations\": {\"MeSHDisease\": {\"Alzheimer Disease\": true}, \"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Bu G\", \"Jiang S\", \"Li Y\", \"Xu H\", \"Zhang C\", \"Zhang YW\", \"Zhao Y\"], \"date\": \"2014-04-01\", \"first\": \"Jiang S\", \"last\": \"Zhang YW\", \"name\": \"Neuroscience bulletin\", \"pages\": \"295-307\", \"reference\": \"24590577\", \"title\": \"M1 muscarinic acetylcholine receptor in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"30\"}, \"evidence\": \"Chronic treatment with AF267B reduces Abeta plaques and tau hyperphosphorylation and rescues learning and memory impairments in 3Tg AD mice\", \"key\": \"177ac309c0b2e64c466936d4b8ca5099ee7f4aa28d54cf0ac2a64936881cc0e56b493a1201799b17a4b80b3a54f65d7445006177c686953e88030f58b013ae95\", \"line\": 550, \"relation\": \"decreases\", \"source\": 64, \"target\": 286}, {\"annotations\": {\"Confidence\": {\"Medium\": true}}, \"citation\": {\"authors\": [\"Landreth GE\", \"Mandrekar-Colucci S\"], \"date\": \"2011-09-01\", \"first\": \"Mandrekar-Colucci S\", \"last\": \"Landreth GE\", \"name\": \"Expert opinion on therapeutic targets\", \"pages\": \"1085-97\", \"reference\": \"21718217\", \"title\": \"Nuclear receptors as therapeutic targets for Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"15\"}, \"evidence\": \" Treatment of 5-month-old APP/PS1 mice for 8 weeks with ATRA (20 mg/kg/day) resulted in significant decreases in Ab deposition and tau phosphorylation in these mice. Additionally, it attenuated memory deficits seen in the Morris water maze [77]. \", \"key\": \"d5f5618fd53b399630eafa5dc006debe445d56d59a8690f17360a5cfb3732a3645aef32d52465f2199e113255295aab77f0058f68d23522dbd9a42330eb56213\", \"line\": 321, \"relation\": \"decreases\", \"source\": 5, \"target\": 286}, {\"annotations\": {\"Disease\": {\"Alzheimer's disease\": true}, \"MeSHAnatomy\": {\"Cholinergic Neurons\": true}, \"MeSHDisease\": {\"Cognitive Dysfunction\": true}}, \"citation\": {\"authors\": [\"Counts SE\", \"Ginsberg SD\", \"Mufson EJ\", \"Perez SE\"], \"date\": \"2008-11-01\", \"first\": \"Mufson EJ\", \"last\": \"Ginsberg SD\", \"name\": \"Expert review of neurotherapeutics\", \"pages\": \"1703-18\", \"reference\": \"18986241\", \"title\": \"Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.\", \"type\": \"PubMed\", \"volume\": \"8\"}, \"evidence\": \"In addition, subunits of protein phosphatase PP1 (Unigene-NCBI annotation PPP1CA and PPP1CC) mRNAs were downregulated in CBF neurons in AD [135]. This observation is interesting in light of the observation that PP1 can phosphorylate tau on several serine/threonine residues and experimental downregulation of PP1 activity leads to increased tau hyperphosphorylation [137,138], which may affect NFT formation in CBF neurons.\", \"key\": \"94b24e0eb1ab02f79da75d886730b5b1b896adf70a2bbbe44eedb08384e0c89fd272a827387f3f3bc3c1985093e854e570f70e6c0a7d64a79afc75df1390850a\", \"line\": 788, \"relation\": \"increases\", \"source\": 174, \"target\": 286}, {\"citation\": {\"authors\": [\"Shi Y\"], \"date\": \"2009-02-01\", \"first\": \"Shi Y\", \"last\": \"Shi Y\", \"name\": \"Science in China. Series C, Life sciences\", \"pages\": \"135-46\", \"reference\": \"19277525\", \"title\": \"Assembly and structure of protein phosphatase 2A.\", \"type\": \"PubMed\", \"volume\": \"52\"}, \"evidence\": \"The specificity in this in vitro system is quite robust, as evidenced by the observation that the PP2A core enzyme exhibited a lower activity to dephosphorylate the Tau protein than the PP2A holoenzyme involving the B subunit, but a higher activity than the holoenzyme involving the B subunit\", \"key\": \"b5e8a15e9bed0c761323101d9ba9735f55674d2ec5ad8b3c4a8c20fc74e072a7d32f5d019d45201a791c86b8f7cd52911fe912efe5e045ba838ce16ee1da233a\", \"line\": 246, \"relation\": \"decreases\", \"source\": 142, \"target\": 286}, {\"citation\": {\"authors\": [\"Shi Y\"], \"date\": \"2009-02-01\", \"first\": \"Shi Y\", \"last\": \"Shi Y\", \"name\": \"Science in China. Series C, Life sciences\", \"pages\": \"135-46\", \"reference\": \"19277525\", \"title\": \"Assembly and structure of protein phosphatase 2A.\", \"type\": \"PubMed\", \"volume\": \"52\"}, \"evidence\": \"The specificity in this in vitro system is quite robust, as evidenced by the observation that the PP2A core enzyme exhibited a lower activity to dephosphorylate the Tau protein than the PP2A holoenzyme involving the B subunit, but a higher activity than the holoenzyme involving the B subunit\", \"key\": \"2f9380dcb10a7fe3ffd9b3fccf24b8b341e885af1d7ce744c13a6d525ed9c97d957199039c2531091241d9245505e8c7ac3dde84c77092c829e531c8b753b442\", \"line\": 247, \"relation\": \"decreases\", \"source\": 143, \"target\": 286}, {\"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"While many PP2A holoenzymes have the potential to indirectly affect tau phosphorylation by modulating key tau protein kinases (For example see Louis et al., 2011), biochemical and structural studies have demonstrated that PP2A/B is the primary PP2A isoform that mediates tau dephosphorylation (Sontag et al.,1996, 1999; Xu et al.,2008).\", \"key\": \"4ff4dbce90d82921a597a9b40759184948dc29e403775182f3fc31d9e189871bad94d8d352ae90c8aab8289dddd7244b19265e20d21762c49db3e59a75e7229b\", \"line\": 429, \"relation\": \"decreases\", \"source\": 143, \"target\": 286}, {\"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Specific inhibition of PP2A/B is associated with enhanced tau phosphorylation at many AD-like phospho epitopes, and subsequent inability of tau to bind to and stabilize microtubules (Sontag et al., 1996).\", \"key\": \"f381ac4e2b4b1c23b6c11fb3b51e8781ec40a1d5f0bdca152a92add31a51674f5578709abaa799a7c535c3d2063f4023ff25c5da0f43259c6af490a2584efa69\", \"line\": 435, \"relation\": \"decreases\", \"source\": 143, \"target\": 286}, {\"citation\": {\"authors\": [\"Shi Y\"], \"date\": \"2009-02-01\", \"first\": \"Shi Y\", \"last\": \"Shi Y\", \"name\": \"Science in China. Series C, Life sciences\", \"pages\": \"135-46\", \"reference\": \"19277525\", \"title\": \"Assembly and structure of protein phosphatase 2A.\", \"type\": \"PubMed\", \"volume\": \"52\"}, \"evidence\": \"The specificity in this in vitro system is quite robust, as evidenced by the observation that the PP2A core enzyme exhibited a lower activity to dephosphorylate the Tau protein than the PP2A holoenzyme involving the B subunit, but a higher activity than the holoenzyme involving the B subunit\", \"key\": \"a9b0cc137269aa230d85a6e180a2ab65344a3f0028dca905bab4e2663e8695014e1ebd7f838d6558e692259e3dca72bfed4a3e8f5138bbc09bced531ca8dba9f\", \"line\": 248, \"relation\": \"decreases\", \"source\": 144, \"target\": 286}, {\"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Dietary folate and B-vitamin deficiency (Sontag et al.,2008; Nicolia et al.,2010) and elevated homocysteine levels (Sontag et al.,2007, 2013; Zhang et al.,2008) lead to down-regulation of PP2A methylation and concomitant phosphorylation of tau and/or APP in vivo\", \"key\": \"5b12f77aa3c7e72c107e4acc63d45b41c299144510051f1e70d09cea85a7af619e273acd54ddeb38bde117053bce72be9def091584579fc6483a05b0993fd9c1\", \"line\": 517, \"relation\": \"increases\", \"source\": 22, \"target\": 286}, {\"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Dietary folate and B-vitamin deficiency (Sontag et al.,2008; Nicolia et al.,2010) and elevated homocysteine levels (Sontag et al.,2007, 2013; Zhang et al.,2008) lead to down-regulation of PP2A methylation and concomitant phosphorylation of tau and/or APP in vivo\", \"key\": \"4297f7a8cf9382aa46491bd4641dee21cfd65c5fe825a4b681361cf73f3bc57ab49ad2c0054a662b0c92f400e9fe5927514ba8aea617f77ecd5e61ea6a0b1751\", \"line\": 523, \"relation\": \"positiveCorrelation\", \"source\": 26, \"target\": 286}, {\"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Remarkably, impairment of one-carbon metabolism in animal models can reproduce AD-like pathological features: accumulation of P-tau (Sontag et al.,2007; Zhang et al.,2008; Wei et al.,2011); enhanced amyloidogenesis (Pacheco-Quinto et al.,2006; Zhang et al.,2009; Zhuo et al.,2010; Zhuo and Pratico,2010); increased phosphorylation of APP at the regulatory Thr-668 site (Sontag et al.,2007; Zhang et al.,2009); increased sensitivity to amyloid toxicity (Kruman et al.,2002); and cognitive impairment (Bernardo et al.,2007; Wei et al.,2011; Rhodehouse et al., 2013).\", \"key\": \"80890cf4b3f722d562d29236bf83d4f6c047c4b3c4cfb95dce6ac5156d89df8d31c41aea56b34ac4af97594537342cde12b3f48f81b2e06c4992b2c04441d844\", \"line\": 507, \"relation\": \"decreases\", \"source\": 89, \"target\": 286}, {\"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"It is noteworthy that PP2A/B can directly bind to tau via a domain encompassing the microtubule-binding of tau; this interaction maximizes the efficiency of tau dephosphorylation by PP2A (Sontag et al.,1999; Xu et al.,2008; Figure 3A).\", \"key\": \"30f07f69100b28d7703a218d59f59a63077ea0ff6e6c4d3d495f0097cd2a66e46bfc35ad9b49f14add43064237b9143d45be0aca0bf4cfb6818530f40338a9a5\", \"line\": 456, \"relation\": \"decreases\", \"source\": 133, \"target\": 286}, {\"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Conversely, decreased PP2A methylation and PP2A/B levels in AD will disrupt normal PP2A-tau interactions (Sontag et al., 2007), thereby preventing PP2A-mediated tau dephosphorylation while allowing for enhanced binding of Fyn kinase or other regulators to the tau proteins.\", \"key\": \"8ce94eb3f5fbf050dd1723897f47ffe856b2ff58af7993c2174e3cd41baaeebdbe221bfd097d4e1d61fa10f62f138506cb8a030eeedb24af1af37427fad246e9\", \"line\": 487, \"relation\": \"decreases\", \"source\": 133, \"target\": 286}, {\"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"It is noteworthy that PP2A/B can directly bind to tau via a domain encompassing the microtubule-binding of tau; this interaction maximizes the efficiency of tau dephosphorylation by PP2A (Sontag et al.,1999; Xu et al.,2008; Figure 3A).\", \"key\": \"8b4f816a55c764e0abf7328b037cf469b0a179ba7d4319c926e4c4544395bd968b23cf2c4c0144ec00becbf39008e7c599d726618e0c5f8e0a3d29df68d889a1\", \"line\": 458, \"relation\": \"decreases\", \"source\": 134, \"target\": 286}, {\"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Conversely, decreased PP2A methylation and PP2A/B levels in AD will disrupt normal PP2A-tau interactions (Sontag et al., 2007), thereby preventing PP2A-mediated tau dephosphorylation while allowing for enhanced binding of Fyn kinase or other regulators to the tau proteins.\", \"key\": \"d993516fb986d57e3204804e32936f055c6b08906e28bf2c8b15833140946f4f550fc2fb5f2640ac2b04b6315dded6a9fb01a5bc89a516563dde5e7f04f3df0f\", \"line\": 488, \"relation\": \"decreases\", \"source\": 134, \"target\": 286}, {\"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"While many PP2A holoenzymes have the potential to indirectly affect tau phosphorylation by modulating key tau protein kinases (For example see Louis et al., 2011), biochemical and structural studies have demonstrated that PP2A/B is the primary PP2A isoform that mediates tau dephosphorylation (Sontag et al.,1996, 1999; Xu et al.,2008).\", \"key\": \"686adadb8e4f263adacb4dabba62ecf2e44064834f1587e884f3e5d8fc9985f89877e531cb4239f2e26b7f562341c92e2dca7ca83ea2d1eba3021bdf88b289c1\", \"line\": 430, \"relation\": \"decreases\", \"source\": 145, \"target\": 286}, {\"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Specific inhibition of PP2A/B is associated with enhanced tau phosphorylation at many AD-like phospho epitopes, and subsequent inability of tau to bind to and stabilize microtubules (Sontag et al., 1996).\", \"key\": \"124acf93594a70374ee41223faabdc1300b1cbbe2ba93adeb437e36e9ab885d44b9f69db2b3c9017ec229cea66ab764064060f154404706b459ceea32fb246c1\", \"line\": 437, \"relation\": \"decreases\", \"source\": 145, \"target\": 286}, {\"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Dietary folate and B-vitamin deficiency (Sontag et al.,2008; Nicolia et al.,2010) and elevated homocysteine levels (Sontag et al.,2007, 2013; Zhang et al.,2008) lead to down-regulation of PP2A methylation and concomitant phosphorylation of tau and/or APP in vivo\", \"key\": \"eb4f8619cc13caa321d4e8dbc1bde54bbc8eaa714ae115eb90b359eb744b4852d88a2c020d77e658d477c535c98e2704e7733f51b3e137f8542066aa5ebd16da\", \"line\": 525, \"relation\": \"negativeCorrelation\", \"source\": 168, \"target\": 286}, {\"annotations\": {\"MeSHAnatomy\": {\"Neurons\": true}, \"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Lastly, increased phosphorylation of PP2A at Tyr-307 has been found in P-tau-rich, tangle-bearing neurons from post-mortem brain (Liu et al.,2008b).\", \"key\": \"1d4c110d4cb1824d5a44594941d78b496e4a3b8e7066c6cc03b3b6bae767292903e5b0d301b0a58d75959cde186397ff12714dfbd6b8a09fba2796356ed95a5a\", \"line\": 288, \"relation\": \"association\", \"source\": 169, \"target\": 286}, {\"citation\": {\"authors\": [\"Dewachter I\", \"Terwel D\", \"Van Leuven F\"], \"date\": \"2002-01-01\", \"first\": \"Terwel D\", \"last\": \"Van Leuven F\", \"name\": \"Neuromolecular medicine\", \"pages\": \"151-65\", \"reference\": \"12428809\", \"title\": \"Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"2\"}, \"evidence\": \"Other serine and threonine residues, not followed by proline, are phosphorylated by other protein kinases, including microtubule-affinity-regulating kinase (MARK) (Drewes et al., 1993), calcium/ calmodulin kinase II (CAMKII), cAMP-dependent kinase (PKA) (Johnson et al., 1992), and casein kinase II (Greenwood et al., 1994).\", \"key\": \"0aa372bb7be4451ddc8e6b123445ce67f8289d723862b322006bdc81b6277a5171b6b96474232776ea8e18e88550f97bfda85cd596bc09af26954615ef4bc194\", \"line\": 127, \"relation\": \"increases\", \"source\": 157, \"target\": 286}, {\"citation\": {\"authors\": [\"Dewachter I\", \"Terwel D\", \"Van Leuven F\"], \"date\": \"2002-01-01\", \"first\": \"Terwel D\", \"last\": \"Van Leuven F\", \"name\": \"Neuromolecular medicine\", \"pages\": \"151-65\", \"reference\": \"12428809\", \"title\": \"Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"2\"}, \"evidence\": \" Tau protein is rapidly dephosphorylated by endogenous phosphatases such as protein phosphatases 1, 2A, and 2B (cal- cineurin) that are all present in the brain, and effec- tively dephosphorylate tau protein in vitro. \", \"key\": \"db2ad8a759836c34933fffac4b55aed2dad4a4e54986a7478de906cd18ee7c95cbde1ce7f2c6bd1e678816c6867d251e723c55f3dbb2ef13d7ad212a589cf351\", \"line\": 134, \"relation\": \"decreases\", \"source\": 166, \"target\": 286}, {\"citation\": {\"authors\": [\"Dewachter I\", \"Terwel D\", \"Van Leuven F\"], \"date\": \"2002-01-01\", \"first\": \"Terwel D\", \"last\": \"Van Leuven F\", \"name\": \"Neuromolecular medicine\", \"pages\": \"151-65\", \"reference\": \"12428809\", \"title\": \"Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"2\"}, \"evidence\": \" Tau protein is rapidly dephosphorylated by endogenous phosphatases such as protein phosphatases 1, 2A, and 2B (cal- cineurin) that are all present in the brain, and effec- tively dephosphorylate tau protein in vitro. \", \"key\": \"db038cee51dbf704991ad3af31c247947fdf5a4488f88e21315c3e9ab94acf9fdda9ba62389a719f23946a26e33fa73f8494b87930c2564812cb6825765dac5a\", \"line\": 136, \"relation\": \"decreases\", \"source\": 170, \"target\": 286}, {\"citation\": {\"authors\": [\"Bantscheff M\", \"Buist A\", \"Dewachter I\", \"Drewes G\", \"Faelth-Savitski M\", \"Joberty G\", \"Kienlen-Campard P\", \"Moechars D\", \"Octave JN\", \"Pierrot N\", \"Stancu IC\", \"Vanoosthuyse A\", \"Vasconcelos B\", \"Wang P\"], \"date\": \"2017-05-01\", \"first\": \"Wang P\", \"last\": \"Dewachter I\", \"name\": \"Acta neuropathologica\", \"pages\": \"731-749\", \"reference\": \"28083634\", \"title\": \"Tau interactome mappingbased identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo.\", \"type\": \"PubMed\", \"volume\": \"133\"}, \"evidence\": \"Since Otub1 interacts with Tau and promotes phosphorylated and aggregated Tau levels in primary neurons, we hypothesized that Otub1 could act as a Tau deubiquitinase, interfering with pathological Tau degradation and hence Tau aggregation.\", \"key\": \"08f3ff0722cf6e28fa0d7798e934f11ef96106d5030bbd7ad4217dc0eb4d522d8ec7711ff65b35328a1f8f5abaedd932cc06b84d0fbb9f874ac3d92b212154c8\", \"line\": 137, \"relation\": \"increases\", \"source\": 130, \"target\": 286}, {\"citation\": {\"authors\": [\"Chung KM\", \"Hernndez N\", \"Sproul AA\", \"Yu WH\"], \"date\": \"2018-05-18\", \"first\": \"Chung KM\", \"last\": \"Yu WH\", \"name\": \"Neuroscience letters\", \"reference\": \"29758300\", \"title\": \"Alzheimer's disease and the autophagic-lysosomal system.\", \"type\": \"PubMed\"}, \"evidence\": \"Abnormal phosphorylation and truncation of tau are hallmarks of AD pathology and are targets of proteasome and autophagy pathways [27,44,45].\", \"key\": \"ed5320abbceb0aeb5cb9798df70b93deafe3d6027b50c546c2f9a91170939e19d7471eedbc114dfddbe0a60b9cc6338f8adeedfed1099bb9a454c4e98ef9d907\", \"line\": 295, \"relation\": \"association\", \"source\": 93, \"target\": 286}, {\"citation\": {\"authors\": [\"Chung KM\", \"Hernndez N\", \"Sproul AA\", \"Yu WH\"], \"date\": \"2018-05-18\", \"first\": \"Chung KM\", \"last\": \"Yu WH\", \"name\": \"Neuroscience letters\", \"reference\": \"29758300\", \"title\": \"Alzheimer's disease and the autophagic-lysosomal system.\", \"type\": \"PubMed\"}, \"evidence\": \"TFEB has been shown to effectively clear phosphorylated tau proteins through A-LS, resulting in ameliorated neuronal loss and neuroinflammation, as well as improved cognitive performance [89].\", \"key\": \"84314faa90bc0076bb6e69a1af3eec224393d4a7360b80d6ad2904bfe172d8283d36c6a27c834e278c9b642ca86466e929e56d0a07357f690b4e43c4a9ea681a\", \"line\": 505, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 93, \"target\": 286}, {\"citation\": {\"authors\": [\"Cao X\", \"Tan L\", \"Xin SH\", \"Yu JT\"], \"date\": \"2018-10-01\", \"first\": \"Xin SH\", \"last\": \"Tan L\", \"name\": \"Neurotoxicity research\", \"pages\": \"733-748\", \"reference\": \"29626319\", \"title\": \"Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.\", \"type\": \"PubMed\", \"volume\": \"34\"}, \"evidence\": \"Neuronal PAS domain protein 4 has been found to facilitate the autophagic clearance of endogenous total and phosphorylated tau in cortical neurons of rats\", \"key\": \"88f2556cda92b2052b0db01782d798eeeb8d1b0d96befb0714473ba4d71a068c8996425909747c7f6d6b4b08a3d0b8b118f4e022176d838d98f05722ec09fd54\", \"line\": 701, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 93, \"target\": 286}, {\"annotations\": {\"MeSHAnatomy\": {\"Dendrites\": true}}, \"citation\": {\"authors\": [\"Balaji V\", \"Kaniyappan S\", \"Mandelkow E\", \"Mandelkow EM\", \"Wang Y\"], \"date\": \"2018-01-01\", \"first\": \"Balaji V\", \"last\": \"Mandelkow EM\", \"name\": \"Autophagy\", \"pages\": \"2139-2154\", \"reference\": \"30145931\", \"title\": \"Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \" Thus, the dendritic and axonal MAPT are differentially phosphorylated. Based on this observation, we can conclude that the dendritic MAPT degraded by autophagy or proteasomal pathways is phosphorylated mainly at the 12E8 site. \", \"key\": \"2d17993183ba9de1939d47ecb61f3a4cad0e4053a978ab3315927d2fe2932d136a11c33374f7b11eac791569a8a3993fd35ed4da1fc9b5dc939ce61ecb5ff84f\", \"line\": 171, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 93, \"target\": 303}, {\"annotations\": {\"MeSHAnatomy\": {\"Dendrites\": true}}, \"citation\": {\"authors\": [\"Balaji V\", \"Kaniyappan S\", \"Mandelkow E\", \"Mandelkow EM\", \"Wang Y\"], \"date\": \"2018-01-01\", \"first\": \"Balaji V\", \"last\": \"Mandelkow EM\", \"name\": \"Autophagy\", \"pages\": \"2139-2154\", \"reference\": \"30145931\", \"title\": \"Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \" Thus, the dendritic and axonal MAPT are differentially phosphorylated. Based on this observation, we can conclude that the dendritic MAPT degraded by autophagy or proteasomal pathways is phosphorylated mainly at the 12E8 site. \", \"key\": \"12a6c36c443a01bcb438e21db11b0a93bea6e00a23dba18bdfad699710b2480ff89d412bbf71b7d712cff76314ec22e382fa804945d64c1bfa9ed9be3dd83fe6\", \"line\": 170, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 93, \"target\": 297}, {\"citation\": {\"authors\": [\"Chung KM\", \"Hernndez N\", \"Sproul AA\", \"Yu WH\"], \"date\": \"2018-05-18\", \"first\": \"Chung KM\", \"last\": \"Yu WH\", \"name\": \"Neuroscience letters\", \"reference\": \"29758300\", \"title\": \"Alzheimer's disease and the autophagic-lysosomal system.\", \"type\": \"PubMed\"}, \"evidence\": \"Abnormal phosphorylation and truncation of tau are hallmarks of AD pathology and are targets of proteasome and autophagy pathways [27,44,45].\", \"key\": \"3bae426265cfd64f5b426fac78e900d7fd1266ffad32e897a9cd6b3d787505eb4c37af0f38d0075916b7610eff2d1edfbc443411d927676a783fe5970d7d7f03\", \"line\": 294, \"relation\": \"association\", \"source\": 104, \"target\": 286}, {\"citation\": {\"authors\": [\"Chung KM\", \"Hernndez N\", \"Sproul AA\", \"Yu WH\"], \"date\": \"2018-05-18\", \"first\": \"Chung KM\", \"last\": \"Yu WH\", \"name\": \"Neuroscience letters\", \"reference\": \"29758300\", \"title\": \"Alzheimer's disease and the autophagic-lysosomal system.\", \"type\": \"PubMed\"}, \"evidence\": \"Tau phosphorylation, the major disease-related post-translational modification, is highly regulated by glycogen synthase kinase-3 (GSK-3), cyclin-dependent kinase 5 (CDK5), mitogen-activated protein kinase (MAPK) and other kinases.\", \"key\": \"2cea764a47f4f922347210854769155f9c6eecd0f1407a774618cc4ef50b9aa4322756c0c2c046ad959debafef652e2e4bc6c0072e9d5448e01bb7a1e00a7540\", \"line\": 289, \"relation\": \"increases\", \"source\": 163, \"target\": 286}, {\"annotations\": {\"Species\": {\"6239\": true}}, \"citation\": {\"authors\": [\"Choudhary B\", \"Mandelkow E\", \"Pir GJ\"], \"date\": \"2017-12-01\", \"first\": \"Pir GJ\", \"last\": \"Mandelkow E\", \"name\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\", \"pages\": \"5137-5148\", \"reference\": \"29191965\", \"title\": \"&lt;i&gt;Caenorhabditis elegans&lt;/i&gt; models of tauopathy.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"The responsible kinases include 1) proline-directed protein kinases (PDPKs) targeting SP or TP motifs [e.g., GSK3b, cyclindependent kinase (CDK)-5, and MAPKs]; 2) nonproline directed protein kinases targeting KXGS-motifs [e.g., PKA, microtubule affinity-regulating kinase and synapses of the amphid defective (SADK)]; 3) protein kinases specific for tyrosines (e.g., Src, Lck, Syk, Fyn, and c-Abl kinase) (91).\", \"key\": \"e492ef46b176546e4eba0adcc58324c70a79386f12e3307521a7cd8a62246ee8b68e69cdc9ebffabe62a49c620bb58cca50d2f1908806ffecff63e8238d0cac1\", \"line\": 247, \"relation\": \"directlyIncreases\", \"source\": 163, \"target\": 286}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Baumann K\", \"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"Piwnica-Worms H\"], \"date\": \"1993-12-28\", \"first\": \"Baumann K\", \"last\": \"Mandelkow E\", \"name\": \"FEBS letters\", \"pages\": \"417-24\", \"reference\": \"8282104\", \"title\": \"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.\", \"type\": \"PubMed\", \"volume\": \"336\"}, \"evidence\": \"We find that this kinase shows good activity towards tau only when complexed with another protein of Mr 25 kDa, presumably a regulatory subunit analogous to one of the cyclins\", \"key\": \"2d611abafa97fcbac7d7fe89fea067284ca89694bb5f1b11a52d3e8aa7dccd2a5365415b6d4675cb45ee4da8e081fcd98de3af242569f7b23b337ff79f177ab2\", \"line\": 111, \"relation\": \"increases\", \"source\": 113, \"target\": 286}, {\"key\": \"562e9e67c936ec93a32dc9546298ad408ec8c717fdb5dcbf04b07b7aeb410d1a9593bc1aa2f56c9513169f60d04e4d273a420f8f467bae1e2b349f1f11c4ddc1\", \"relation\": \"hasProduct\", \"source\": 380, \"target\": 286}, {\"annotations\": {\"MeSHAnatomy\": {\"Hippocampus\": true}, \"TextLocation\": {\"Review\": true}}, \"citation\": {\"authors\": [\"Chesser AS\", \"Johnson GV\", \"Pritchard SM\"], \"date\": \"2013-09-03\", \"first\": \"Chesser AS\", \"last\": \"Johnson GV\", \"name\": \"Frontiers in neurology\", \"pages\": \"122\", \"reference\": \"24027553\", \"title\": \"Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"4\"}, \"evidence\": \"Directly activating autophagy through a variety of mechanisms leads consistently to enhanced tau clearance  either pathological forms or total tau. In a hippocampal slice preparation methylene blue was used to induce autophagy, which resulted in a decrease in phosphorylated tau and insoluble tau, specifically (95). \", \"key\": \"eb39ad2698a16e6585438e62a55ca6629a95df1954389d6f08b1fcd0cc2d45a28c78e32a64001eab09a4757589d7506e9232ee611b307d3cfe80a095aa926952\", \"line\": 776, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 98, \"target\": 286}, {\"annotations\": {\"MeSHAnatomy\": {\"Hippocampus\": true}, \"TextLocation\": {\"Review\": true}}, \"citation\": {\"authors\": [\"Chesser AS\", \"Johnson GV\", \"Pritchard SM\"], \"date\": \"2013-09-03\", \"first\": \"Chesser AS\", \"last\": \"Johnson GV\", \"name\": \"Frontiers in neurology\", \"pages\": \"122\", \"reference\": \"24027553\", \"title\": \"Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"4\"}, \"evidence\": \"Additionally, in a hippocampal slice preparation, induction of autophagy by treatment with methylene blue led to a decrease in phosphorylated tau and insoluble tau without an effect on total tau (95).\", \"key\": \"9f9cdbbfb4540f39636887b8c344598aeb5cc1cb44980d2fcc011a0eaa3080fa89d819e8fee8103d9da4d3be79435a90d25738a5d4756eddadb9b3a59226e351\", \"line\": 903, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 98, \"target\": 286}, {\"citation\": {\"authors\": [\"Andreadis A\", \"Binder LI\", \"Brady ST\", \"Fu Y\", \"Kanaan NM\", \"LaPointe NE\", \"Morfini GA\", \"Patterson KR\", \"Pigino GF\", \"Song Y\"], \"date\": \"2011-07-06\", \"first\": \"Kanaan NM\", \"last\": \"Binder LI\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"9858-68\", \"reference\": \"21734277\", \"title\": \"Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"Soluble AT8 tau monomers inhibited anterograde FAT (Fig. 6 A, C), while retrograde trans- port was unaffected (Fig. 6 A, D). These data indicate that phos- phorylation of tau at the AT8 epitope, which is associated with hyperphosphorylation of tau in AD and other tauopathies, renders soluble monomeric tau capable of inhibiting antero- grade FAT.\", \"key\": \"0b3d48a51d8a5f848292a78c3970118d0a817acd00be3c898c5de2a099079450716f7dd47a60232bac5a164006824d221f4f4904dfc97d6d0d800fa891d9b132\", \"line\": 121, \"relation\": \"association\", \"source\": 176, \"target\": 286}, {\"key\": \"8ea6c8b6cea6db487bddf1933a8b15258d2462521adf2efba56661c61431f89c7af8483be7ddb11e1534bab18a30169dc0f80da0b6ff65925fe9a4911023c43f\", \"relation\": \"hasComponent\", \"source\": 128, \"target\": 286}, {\"citation\": {\"authors\": [\"Dickey CA\", \"Gestwicki JE\", \"Kiray J\", \"Koren J\", \"Miyata Y\"], \"date\": \"2011-09-01\", \"first\": \"Miyata Y\", \"last\": \"Gestwicki JE\", \"name\": \"Future medicinal chemistry\", \"pages\": \"1523-37\", \"reference\": \"21882945\", \"title\": \"Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.\", \"type\": \"PubMed\", \"volume\": \"3\"}, \"evidence\": \"Hsp27 has emerged as a potential target for tau regulation based on early findings that it preferentially binds to phosphorylated and hyperphosphorylated tau and promotes their clearance [125,126]\", \"key\": \"c34c33c3730726e0beef211682e47ce2630aa90de81f253e71dd0c2e39570b362633c46756d5431b2525d43f31debe1570f731fc83fe3020f6b0fffd3f0f082b\", \"line\": 347, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 128, \"target\": 286}, {\"annotations\": {\"Anatomy\": {\"temporal cortex\": true}, \"Cell_Line\": {\"HCN2A\": true}, \"Method\": {\"Pull-down Assay, His-tagged\": true, \"SDS-PAGE\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Kosik KS\", \"Miura-Shimura Y\", \"Shimura H\"], \"date\": \"2004-04-23\", \"first\": \"Shimura H\", \"last\": \"Kosik KS\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"17957-62\", \"reference\": \"14963027\", \"title\": \"Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival.\", \"type\": \"PubMed\", \"volume\": \"279\"}, \"evidence\": \"Here we show that heat shock protein 27 (Hsp27) preferentially binds pathological hyperphosphorylated tau and paired helical filaments tau directly but not non-phosphorylated tau. The formation of this complex altered the conformation of pathological hyperphosphorylated tau and reduced its concentration by facilitating its degradation and dephosphorylation.\", \"key\": \"8a181dca80bf2592e77d48f4fc3f882a3934dcd6b3bfc188596f2df40a81b2ddafb73c4219c6a912090c76998928a6ed010f7d79d62a87e4a81571faaaa1f7c2\", \"line\": 359, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 128, \"target\": 286}, {\"annotations\": {\"MeSHDisease\": {\"Alzheimer Disease\": true}, \"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Bussiere T\", \"Carlson GA\", \"Cheung AE\", \"Commins C\", \"Costantino I\", \"DeVos SL\", \"Dunah AW\", \"Frosch MP\", \"Grimm J\", \"Hock C\", \"Hyman BT\", \"Montrasio F\", \"Moore BD\", \"Nitsch RM\", \"Nobuhara CK\", \"Pitstick R\", \"Roe AD\", \"Takeda S\", \"Wegmann S\", \"Weinreb PH\", \"Wittmann M\"], \"date\": \"2017-06-01\", \"first\": \"Nobuhara CK\", \"last\": \"Takeda S\", \"name\": \"The American journal of pathology\", \"pages\": \"1399-1412\", \"reference\": \"28408124\", \"title\": \"Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau inVitro.\", \"type\": \"PubMed\", \"volume\": \"187\"}, \"evidence\": \"for example, the two phosphorylation dependent tau antibodies (40E8 and p396) were the most efficient in the human AD case with the highest level of phosphorylated tau (1266). Both 6C5 and 40E8, shown to be most effective at reducing uptake from HMW human AD brainederived tau species (Figure 3, B and C), immunostained NFTs and neuritic plaques in postmortem human AD frontal cortex sections (Figure 6); 40E8 was somewhat more reactive to neuropil threads under the conditions used.\", \"key\": \"d59e3b0e59d5b6267c7184505a384c6b17a1cadcb5bcd45f5cab5545a0fed42c1e3ec8ada74f6bac5e82d312eb0f85ce9ab1a35d84b7d3ad8f5da64b9d8d6e8c\", \"line\": 202, \"relation\": \"decreases\", \"source\": 40, \"target\": 286}, {\"annotations\": {\"MeSHDisease\": {\"Alzheimer Disease\": true}, \"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Bussiere T\", \"Carlson GA\", \"Cheung AE\", \"Commins C\", \"Costantino I\", \"DeVos SL\", \"Dunah AW\", \"Frosch MP\", \"Grimm J\", \"Hock C\", \"Hyman BT\", \"Montrasio F\", \"Moore BD\", \"Nitsch RM\", \"Nobuhara CK\", \"Pitstick R\", \"Roe AD\", \"Takeda S\", \"Wegmann S\", \"Weinreb PH\", \"Wittmann M\"], \"date\": \"2017-06-01\", \"first\": \"Nobuhara CK\", \"last\": \"Takeda S\", \"name\": \"The American journal of pathology\", \"pages\": \"1399-1412\", \"reference\": \"28408124\", \"title\": \"Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau inVitro.\", \"type\": \"PubMed\", \"volume\": \"187\"}, \"evidence\": \"for example, the two phosphorylation dependent tau antibodies (40E8 and p396) were the most efficient in the human AD case with the highest level of phosphorylated tau (1266). Both 6C5 and 40E8, shown to be most effective at reducing uptake from HMW human AD brainederived tau species (Figure 3, B and C), immunostained NFTs and neuritic plaques in postmortem human AD frontal cortex sections (Figure 6); 40E8 was somewhat more reactive to neuropil threads under the conditions used.\", \"key\": \"0ef5beeec898d0a5f847460daf93587894c8fcd007a53292a469cc113cfe32e9de0fb26989146093fd46682d1da103f97f2fa75bcf8ff0c5daf276391b189718\", \"line\": 203, \"relation\": \"decreases\", \"source\": 41, \"target\": 286}, {\"citation\": {\"authors\": [\"Choi H\", \"Gwon Y\", \"Jung YK\", \"Kam TI\", \"Kim C\", \"Kim Y\", \"Koh JY\", \"Park H\"], \"date\": \"2012-06-15\", \"first\": \"Park H\", \"last\": \"Jung YK\", \"name\": \"Human molecular genetics\", \"pages\": \"2725-37\", \"reference\": \"22419736\", \"title\": \"Neuropathogenic role of adenylate kinase-1 in A-mediated tau phosphorylation via AMPK and GSK3.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"These results indicate that AMPK activity is impaired by Ab42 in the neuronal cells in which tau phosphor- ylation increased. \", \"key\": \"fcb4fab5bed6abc35d361042dbac0bc5bbb986cd6eebdb46545e61ce8ee30b64a4352b9174a4bd90e722a1fa962111a3d8e5f5596fb000f526a33b9ec2814aff\", \"line\": 135, \"relation\": \"negativeCorrelation\", \"source\": 154, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 286}, {\"annotations\": {\"Species\": {\"6239\": true}}, \"citation\": {\"authors\": [\"Choudhary B\", \"Mandelkow E\", \"Pir GJ\"], \"date\": \"2017-12-01\", \"first\": \"Pir GJ\", \"last\": \"Mandelkow E\", \"name\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\", \"pages\": \"5137-5148\", \"reference\": \"29191965\", \"title\": \"&lt;i&gt;Caenorhabditis elegans&lt;/i&gt; models of tauopathy.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"Loss of bas-1 function improved the motor function, reduced insoluble tau and its phosphorylation and ameliorated the tau-induced neurodegeneration without increasing the longevity in TauV337M worms\", \"key\": \"f138fc2e6aa0c6b95a44c141312592ea4c2f9bf7dbd3828c538370857de45c0efdd76b30bdf4c9b3ed51cad0f0d071410f9dc831c17df6ce25ada524f3728de0\", \"line\": 354, \"relation\": \"increases\", \"source\": 151, \"target\": 286}, {\"citation\": {\"authors\": [\"Blair LJ\", \"Koren J 3rd\", \"Shelton LB\"], \"date\": \"2017-01-01\", \"first\": \"Shelton LB\", \"last\": \"Blair LJ\", \"name\": \"Frontiers in neuroscience\", \"pages\": \"724\", \"reference\": \"29311797\", \"title\": \"Imbalances in the Hsp90 Chaperone Machinery: Implications for Tauopathies.\", \"type\": \"PubMed\", \"volume\": \"11\"}, \"evidence\": \" Another N-terminal Hsp90 ATPase inhibitor, 17- AAG, was shown to decrease levels of phosphorylated tau in cells, and a related N-terminal Hsp90 ATPase inhibitor, PU- DZ8, reduced soluble and insoluble tau in tauP301L mice (Luo et al., 2007).\", \"key\": \"31e2ff96f2298cc08b903238e0ab1dab90192136e7bd0b415e540a0b7cb57b9db3ab84f259d062e3546e4d3fec8c57b7488f627aabfa286d735961cc17705980\", \"line\": 492, \"relation\": \"decreases\", \"source\": 32, \"target\": 286}, {\"citation\": {\"authors\": [\"Dickey CA\", \"Gestwicki JE\", \"Kiray J\", \"Koren J\", \"Miyata Y\"], \"date\": \"2011-09-01\", \"first\": \"Miyata Y\", \"last\": \"Gestwicki JE\", \"name\": \"Future medicinal chemistry\", \"pages\": \"1523-37\", \"reference\": \"21882945\", \"title\": \"Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.\", \"type\": \"PubMed\", \"volume\": \"3\"}, \"evidence\": \"However, this issue is more complicated, as other work has shown that chemical inhibition of Hsp90 by 17-AAG and other inhibitors reduces cellular levels of two phospho- tau species, pS202/T205 and pS396/S404, both of which are relevant to AD pathogenesis [119].\", \"key\": \"f635cb43f9a545a26383f679481046964f9190a5f53476256cfd3a263958e46873220adb15b008be77e0981f016fd7462d35785d60cbd068dce2177d15d7623f\", \"line\": 327, \"relation\": \"decreases\", \"source\": 32, \"target\": 305}, {\"citation\": {\"authors\": [\"Dickey CA\", \"Gestwicki JE\", \"Kiray J\", \"Koren J\", \"Miyata Y\"], \"date\": \"2011-09-01\", \"first\": \"Miyata Y\", \"last\": \"Gestwicki JE\", \"name\": \"Future medicinal chemistry\", \"pages\": \"1523-37\", \"reference\": \"21882945\", \"title\": \"Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.\", \"type\": \"PubMed\", \"volume\": \"3\"}, \"evidence\": \"However, this issue is more complicated, as other work has shown that chemical inhibition of Hsp90 by 17-AAG and other inhibitors reduces cellular levels of two phospho- tau species, pS202/T205 and pS396/S404, both of which are relevant to AD pathogenesis [119].\", \"key\": \"4dafdddbdedab1820e86aeda242b34dbaea2c0e5182dfcf5379daa98771328cfa17583ce18800d3c21c106551d7f319b80387d8bcc74fde6ea64d46f2feb9ecf\", \"line\": 326, \"relation\": \"decreases\", \"source\": 32, \"target\": 291}, {\"annotations\": {\"MeSHAnatomy\": {\"Choroid Plexus\": true}}, \"citation\": {\"authors\": [\"Axel L\", \"Blennow K\", \"Butler T\", \"Carare RO\", \"Fieremans E\", \"Frangione B\", \"Glodzik L\", \"Mnard J\", \"Nicholson C\", \"Osorio RS\", \"Rusinek H\", \"Tarasoff-Conway JM\", \"Wisniewski T\", \"Zetterberg H\", \"Zlokovic BV\", \"de Leon MJ\"], \"date\": \"2015-08-01\", \"first\": \"Tarasoff-Conway JM\", \"last\": \"de Leon MJ\", \"name\": \"Nature reviews. Neurology\", \"pages\": \"457-70\", \"reference\": \"26195256\", \"title\": \"Clearance systems in the brain-implications for Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"11\"}, \"evidence\": \"Phosphorylation of tau by protein kinase A increases its resistance to degradation by calpain\", \"key\": \"aa79d8afc1f25faeddbf6ba759ecf8828d54752c7572e85892b767f0b8f1827be5f2985bd8baccfe63c49a0cf1ceebf8a00235f601f542063ecfafecd4152048\", \"line\": 269, \"relation\": \"increases\", \"source\": 200, \"target\": 286}, {\"citation\": {\"authors\": [\"Cao X\", \"Tan L\", \"Xin SH\", \"Yu JT\"], \"date\": \"2018-10-01\", \"first\": \"Xin SH\", \"last\": \"Tan L\", \"name\": \"Neurotoxicity research\", \"pages\": \"733-748\", \"reference\": \"29626319\", \"title\": \"Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.\", \"type\": \"PubMed\", \"volume\": \"34\"}, \"evidence\": \"Wogonin, rapamycin, and temsirolimus have been considered to improve the activity of autophagy to increase A clearance and inhibit tau phosphorylation via targeting mTOR signaling (Caccamo et al. 2010; Jiang et al. 2014c; Jiang et al. 2014d; Spilman et al. 2010; Zhu andWang 2015)\", \"key\": \"3cda551e1439a3443cda803f0b8f065abfcf9120c4fa855663ae82b9be41256bc33fb4ede3d7ed453b2c72615cab50743dbe8503a6b826dd4e022e817ee4fea2\", \"line\": 650, \"relation\": \"decreases\", \"source\": 33, \"target\": 286}, {\"citation\": {\"authors\": [\"Cao X\", \"Tan L\", \"Xin SH\", \"Yu JT\"], \"date\": \"2018-10-01\", \"first\": \"Xin SH\", \"last\": \"Tan L\", \"name\": \"Neurotoxicity research\", \"pages\": \"733-748\", \"reference\": \"29626319\", \"title\": \"Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.\", \"type\": \"PubMed\", \"volume\": \"34\"}, \"evidence\": \"Wogonin, rapamycin, and temsirolimus have been considered to improve the activity of autophagy to increase A clearance and inhibit tau phosphorylation via targeting mTOR signaling (Caccamo et al. 2010; Jiang et al. 2014c; Jiang et al. 2014d; Spilman et al. 2010; Zhu andWang 2015)\", \"key\": \"39699cdb3d6605e81422afad24dcaeb0423e2c273ad980535aa7e91c7d5f0d600dccc6e5d5abde427344dfbf6f8f75a63ed14a545b17369fd911cd640d4b1bcc\", \"line\": 653, \"relation\": \"decreases\", \"source\": 30, \"target\": 286}, {\"citation\": {\"authors\": [\"Cao X\", \"Tan L\", \"Xin SH\", \"Yu JT\"], \"date\": \"2018-10-01\", \"first\": \"Xin SH\", \"last\": \"Tan L\", \"name\": \"Neurotoxicity research\", \"pages\": \"733-748\", \"reference\": \"29626319\", \"title\": \"Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.\", \"type\": \"PubMed\", \"volume\": \"34\"}, \"evidence\": \"Wogonin, rapamycin, and temsirolimus have been considered to improve the activity of autophagy to increase A clearance and inhibit tau phosphorylation via targeting mTOR signaling (Caccamo et al. 2010; Jiang et al. 2014c; Jiang et al. 2014d; Spilman et al. 2010; Zhu andWang 2015)\", \"key\": \"ec10221f8c9f087affb2e687da739617142c86070990c9381a05db518472ac1d1c6f7db83e95190252805bb2db5d50cea72234574ba547393f3e36f1a0b8f582\", \"line\": 656, \"relation\": \"decreases\", \"source\": 16, \"target\": 286}, {\"citation\": {\"authors\": [\"Cao X\", \"Tan L\", \"Xin SH\", \"Yu JT\"], \"date\": \"2018-10-01\", \"first\": \"Xin SH\", \"last\": \"Tan L\", \"name\": \"Neurotoxicity research\", \"pages\": \"733-748\", \"reference\": \"29626319\", \"title\": \"Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.\", \"type\": \"PubMed\", \"volume\": \"34\"}, \"evidence\": \"Epigallocatechin-3-gallate enhances the clearance of ADrelevant phosphorylated tau species via increasing mRNA expression of autophagy adaptor proteins NDP52 and p62 (Chesser et al. 2016)\", \"key\": \"461e8d847795901e01de5b48d05495306fff261f7e154c8d4b56503cb5022913ffaf5e1c80a4a1fcbc7a3d1e6df80d3cdbf5127bf7a3923ea84017dfa5a82857\", \"line\": 681, \"relation\": \"decreases\", \"source\": 1, \"target\": 286}, {\"key\": \"d1641565b18def1b0f78ba11a137055e95b02b9e168251a1074efb0ee425abe6226897ee4f2235ec0dc1c85b92a1ae5cfaf3ff2e00f7a0dfc4b8e8f972612e6f\", \"relation\": \"hasReactant\", \"source\": 381, \"target\": 286}, {\"annotations\": {\"Method\": {\"Dephosphorylation Assay, Colorimetric\": true, \"Enhanced Chemioluminescence visualization (ECL)\": true, \"Microtubule Co-Sedimentation Assay\": true, \"SDS-PAGE\": true, \"Western Blot\": true}, \"TauIsoform\": {\"Isoform F (441 aa)\": true}}, \"citation\": {\"authors\": [\"Bloom GS\", \"Brandt R\", \"Kamibayashi C\", \"Kuret J\", \"Lee G\", \"Mumby MC\", \"Nunbhakdi-Craig V\", \"Sontag E\", \"White CL 3rd\"], \"date\": \"1999-09-03\", \"first\": \"Sontag E\", \"last\": \"Bloom GS\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"25490-8\", \"reference\": \"10464280\", \"title\": \"Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies.\", \"type\": \"PubMed\", \"volume\": \"274\"}, \"evidence\": \"Thus, MTs inhibited the rate of tau dephosphorylation by ABaC.\", \"key\": \"290c140387c8d71ace7b766f9b796bc304d58c6f13c798ba166ec714ade7ffae6d7684df058c27c4145781c2ecaa1b3f473d874c7a657e8cf76aabd596b26c60\", \"line\": 288, \"relation\": \"negativeCorrelation\", \"source\": 381, \"target\": 286}, {\"annotations\": {\"Method\": {\"Dot Blot\": true, \"Immunoprecipitation\": true, \"SDS-PAGE\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Avila J\", \"Lim F\", \"Moreno F\", \"Perez M\", \"Santa-Maria I\", \"Tortosa E\"], \"date\": \"2009-01-01\", \"first\": \"Tortosa E\", \"last\": \"Avila J\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"319-25\", \"reference\": \"19363271\", \"title\": \"Binding of Hsp90 to tau promotes a conformational change and aggregation of tau protein.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"To test the effect of Hsp90 on tau phosphorylation, this protein was mixed with tau protein in the presence of GSK-3 and ATP. Figure 4 shows that tau phosphorylation increases in the presence of increased added amounts of Hsp90.\", \"key\": \"eb0f56fed75d745c95c288e7a6807cf3142d73276ef5290c55df6626aca654cd5bf8fe65fdc342580d07c4ba93ea63ca180f0b5b20f1157b2dbc23fb365b9f3d\", \"line\": 331, \"relation\": \"positiveCorrelation\", \"source\": 206, \"target\": 286}, {\"annotations\": {\"Method\": {\"Chromatography, Affinity\": true, \"Chromatography, FPLC\": true, \"Phosphorylation Assay\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Baudier J\", \"Cole RD\"], \"date\": \"1988-04-25\", \"first\": \"Baudier J\", \"last\": \"Cole RD\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"5876-83\", \"reference\": \"2833519\", \"title\": \"Interactions between the microtubule-associated tau proteins and S100b regulate tau phosphorylation by the Ca2+/calmodulin-dependent protein kinase II.\", \"type\": \"PubMed\", \"volume\": \"263\"}, \"evidence\": \"We here confirmed the interaction of SlOOb with tau through affinity chromatography and crosslinking and demonstrated that such an interaction also inhibited mode I phosphorylation by a Ca2+/CaM-dependent kinase. Increasing Ca2+c oncentration to the 100 M range potentiated the SlOOb effect. Therefore, although Ca2+-independent interactions may occur between SlOOb and protein tau, it is the Ca2+ form of SlOOb that has significant affinity for protein tau. In any case, Znz+ and Ca2+ both appear to be capabble of inducing a conformation in SlOOb that promotes its binding to target proteinins, including tau.\", \"key\": \"108056bbd0dc88d4f76a7771e905c7e3db5b37d08ccfa002ca35d059466a4f379fea41ef14b37eeb303bb9e6db9d0c464b8b670571638c9253a3226fb28ab923\", \"line\": 697, \"relation\": \"increases\", \"source\": 205, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 286}, {\"annotations\": {\"Cell_Line\": {\"N2a\": true}, \"Disease\": {\"Alzheimer's disease\": true}, \"Method\": {\"Western Blot\": true}}, \"citation\": {\"authors\": [\"Nunbhakdi-Craig V\", \"Sontag E\", \"Sontag JM\"], \"date\": \"2013-09-20\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"27396-405\", \"reference\": \"23943618\", \"title\": \"Leucine carboxyl methyltransferase 1 (LCMT1)-dependent methylation regulates the association of protein phosphatase 2A and Tau protein with plasma membrane microdomains in neuroblastoma cells.\", \"type\": \"PubMed\", \"volume\": \"288\"}, \"evidence\": \"Notably, methylation of PP2A catalytic C subunit on the Leu- 309 residue by leucine carboxyl methyltransferase 1 (LCMT1) promotes the biogenesis and stabilization of PP2A/B\\u0001 enzymes (20). We have shown that decreased LCMT1 activity and/or expression levels correlate with down-regulation of PP2A methylation and PP2A/B\\u0001 expression levels and with concomitant accumulation of phospho-Tau in AD-affected brain regions (21), in cultured N2a neuroblastoma cells and in vivo\", \"key\": \"86d398a589a6ae48dc8f7982e97f954723191a2e31bd45e3caa3ab61b322d699c84a17a7e8bdc758393c273ee51a4c71809ae528223d6521ff9512b563b3a9da\", \"line\": 328, \"relation\": \"negativeCorrelation\", \"source\": 116, \"target\": 286}, {\"citation\": {\"authors\": [\"An FM\", \"Chen S\", \"Gao XD\", \"Liu AR\", \"Yao WB\", \"Yin DK\", \"Yin L\"], \"date\": \"2014-01-03\", \"first\": \"Chen S\", \"last\": \"Gao XD\", \"name\": \"Neuroscience\", \"pages\": \"137-46\", \"reference\": \"24183963\", \"title\": \"Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation.\", \"type\": \"PubMed\", \"volume\": \"256\"}, \"evidence\": \"Recently, Li et al. (2012b) have demonstrated in their study that AGEs can induce tau hyperphosphorylation through receptor for advanced glycation end product (RAGE)-mediated glycogen synthase kinase 3 (GSK-3) activation and targeting RAGE/GSK-3 pathway can improve AD-like changes.\", \"key\": \"14ea1b527b8f304f9f72aae40e14ac6b558c4db3612983616bb353a0c98090a1719f6abf6caf177b0864637de671ca5ddc3e1beda9ba5c16dd3791893189445a\", \"line\": 388, \"relation\": \"increases\", \"source\": 4, \"target\": 286}, {\"annotations\": {\"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Cuadrado A\", \"Kgler S\", \"Lastres-Becker I\"], \"date\": \"2018-04-01\", \"first\": \"Cuadrado A\", \"last\": \"Lastres-Becker I\", \"name\": \"Redox biology\", \"pages\": \"522-534\", \"reference\": \"29121589\", \"title\": \"Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \"Taken together, our results show that DMF reduces GSK-3 activity in vivo as determined by a significant and subtle reduction in the phosphorylation levels of its two substrates TAU and CRMP2 respectively.\", \"key\": \"942f7f9f3110f39f35c883819fe8728eeb726ebc7bdb5fb071d41816d4f96868b564d1e3c1041f5a3fa1fdc007ab2d630839435a85310b99f76d0315797c49ae\", \"line\": 1027, \"relation\": \"decreases\", \"source\": 8, \"target\": 286}, {\"annotations\": {\"Ki\": {\"4-80 nM\": true}}, \"citation\": {\"authors\": [\"Bibb JA\", \"Biernat J\", \"Greengard P\", \"Gussio R\", \"Kunick C\", \"Leost M\", \"Link A\", \"Mandelkow EM\", \"Meijer L\", \"Sausville EA\", \"Schultz C\", \"Senderowicz AM\", \"Snyder GL\", \"Wu YZ\", \"Zaharevitz DW\"], \"date\": \"2000-10-01\", \"first\": \"Leost M\", \"last\": \"Meijer L\", \"name\": \"European journal of biochemistry\", \"pages\": \"5983-94\", \"reference\": \"10998059\", \"title\": \"Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25.\", \"type\": \"PubMed\", \"volume\": \"267\"}, \"evidence\": \"Alsterpaullone, the most active paullone, was demonstrated to act by competing with ATP for binding to GSK-3beta. Alsterpaullone inhibits the phosphorylation of tau in vivo at sites which are typically phosphorylated by GSK-3beta in Alzheimer's disease. Alsterpaullone also inhibits the CDK5/p25-dependent phosphorylation of DARPP-32 in mouse striatum slices in vitro. \", \"key\": \"13f5b385c8804d468560df0e05816e5e25f6a0e05948dfcd24a4ea4e0414c6f33067ad1599398ee1bb3c3fa6c37f7755a21c77477ed8e0fa553ce371f66df707\", \"line\": 1200, \"relation\": \"decreases\", \"source\": 18, \"target\": 286}, {\"key\": \"8c352ac59f8310c47a039a7f3cb3203666a2b4760147e838866d86e47de620bba194bcca4a994ef618e1ab9d11c2444d9250eaf2d567b4f92dbb985a02672bf1\", \"relation\": \"hasComponent\", \"source\": 139, \"target\": 286}, {\"citation\": {\"authors\": [\"Asada A\", \"Hasegawa M\", \"Hisanaga S\", \"Ishiguro K\", \"Kimura T\", \"Oikawa T\", \"Saito T\", \"Uchida C\", \"Uchida T\", \"Yotsumoto K\"], \"date\": \"2009-06-19\", \"first\": \"Yotsumoto K\", \"last\": \"Hisanaga S\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"16840-7\", \"reference\": \"19401603\", \"title\": \"Effect of Pin1 or microtubule binding on dephosphorylation of FTDP-17 mutant Tau.\", \"type\": \"PubMed\", \"volume\": \"284\"}, \"evidence\": \"Taken together, these results indicate that the binding of P-Tau to microtubules suppresses its dephosphorylation.\", \"key\": \"e5b383b0d0497bb4b5c995c29155c0c78a04d5b650491c20d91ddc34ab0f90e284656e4dddc2149049e54be96a259488102927ba792acca3b07ee2c3bd48766d\", \"line\": 4015, \"relation\": \"positiveCorrelation\", \"source\": 106, \"target\": 286}, {\"annotations\": {\"Confidence\": {\"High\": true}, \"MeSHDisease\": {\"Alzheimer Disease\": true}, \"Subgraph\": {\"MAPK-JNK subgraph\": true, \"Nitric oxide subgraph\": true, \"Tau protein subgraph\": true}}, \"citation\": {\"authors\": [\"Olsen I\", \"Singhrao SK\"], \"date\": \"2016-06-15\", \"first\": \"Olsen I\", \"last\": \"Singhrao SK\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"45-53\", \"reference\": \"27314526\", \"title\": \"Inflammasome Involvement in Alzheimer's Disease.\", \"type\": \"PubMed\", \"volume\": \"54\"}, \"evidence\": \" Additionally, it can induce phosphorylation of the tau protein and promote for- mation of neurobrillary tangles through the mitogen activated protein kinases-p38 (MAPK-p38) stress pathway [22, 54].\", \"key\": \"bc536ed7b70306f2719258f84430b8bea7fcc130de630fd8449a6a898a7f528950fe40b0e718806217dfe3b95cff140ab58e31c087f2395345c64db4d4405b76\", \"line\": 218, \"relation\": \"increases\", \"source\": 10, \"target\": 286}, {\"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Knock-down of PP2A catalytic subunit (Kins et al.,2001) or PP2A B (or PPP2R5D) regulatory subunit (Louis et al.,2011), and expression of the methylation-site L309A C subunit mutant (Schild et al.,2006) all induce AD-like tau phosphorylation in transgenic mice\", \"key\": \"6a00966ce849359f388a4759b393d44d916eee28255ae5e9ba2f1e4b98ef1087503110785c61f63d4ef71a17b61cf5a7e09313db0357d262b47c90032b0c76d7\", \"line\": 357, \"relation\": \"increases\", \"source\": 348, \"target\": 286}, {\"citation\": {\"authors\": [\"Chung KM\", \"Hernndez N\", \"Sproul AA\", \"Yu WH\"], \"date\": \"2018-05-18\", \"first\": \"Chung KM\", \"last\": \"Yu WH\", \"name\": \"Neuroscience letters\", \"reference\": \"29758300\", \"title\": \"Alzheimer's disease and the autophagic-lysosomal system.\", \"type\": \"PubMed\"}, \"evidence\": \"For example, in tau A152T iPSC-derived cortical neurons, total and phosphorylated Tau levels are elevated, particularly the insoluble forms [133], which is associated with decreases in UPS function as measured by total polyubiquitinated proteins and an upregulation of macroautophagy markers.\", \"key\": \"c0d33ca076ec1219beb3d25553e0ae14d0909c6dac7e4b5cbab8bc06c5015ffd3bca8731ea43e597c545322adccfff179fb299887685f3f77e449743e05575f4\", \"line\": 682, \"relation\": \"positiveCorrelation\", \"source\": 326, \"target\": 286}, {\"annotations\": {\"Anatomy\": {\"temporal cortex\": true}, \"Cell_Line\": {\"HCN2A\": true}, \"Method\": {\"Pull-down Assay, His-tagged\": true, \"SDS-PAGE\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Kosik KS\", \"Miura-Shimura Y\", \"Shimura H\"], \"date\": \"2004-04-23\", \"first\": \"Shimura H\", \"last\": \"Kosik KS\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"17957-62\", \"reference\": \"14963027\", \"title\": \"Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival.\", \"type\": \"PubMed\", \"volume\": \"279\"}, \"evidence\": \"Here we show that heat shock protein 27 (Hsp27) preferentially binds pathological hyperphosphorylated tau and paired helical filaments tau directly but not non-phosphorylated tau. The formation of this complex altered the conformation of pathological hyperphosphorylated tau and reduced its concentration by facilitating its degradation and dephosphorylation.\", \"key\": \"91501fb65c5ed0d2fa57b29cadec7018160803eb7665b365155e7003e414b1d6589e5f17af3cd1b90bd4c87de0a163c6fe282d9ce9ee8ffa5233a1824c04ba94\", \"line\": 354, \"relation\": \"association\", \"source\": 234, \"target\": 286}, {\"annotations\": {\"Anatomy\": {\"temporal cortex\": true}, \"Cell_Line\": {\"HCN2A\": true}, \"Method\": {\"Pull-down Assay, His-tagged\": true, \"SDS-PAGE\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Kosik KS\", \"Miura-Shimura Y\", \"Shimura H\"], \"date\": \"2004-04-23\", \"first\": \"Shimura H\", \"last\": \"Kosik KS\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"17957-62\", \"reference\": \"14963027\", \"title\": \"Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival.\", \"type\": \"PubMed\", \"volume\": \"279\"}, \"evidence\": \"Taken together, pathological hyperphosphorylated tau caused cell death, and Hsp27 attenuated the cell toxicity of pathological hyperphosphorylated tau.\", \"key\": \"c379008734c9ee36301de1cfbec0968136eb65f447b81a7c19e71cf5797436c4edb816a476cc2602a49314473c08df1603538b6f5639c5c410f5b04b43d3e0ec\", \"line\": 365, \"object\": {\"modifier\": \"Activity\"}, \"relation\": \"decreases\", \"source\": 234, \"target\": 286}, {\"citation\": {\"authors\": [\"Blair LJ\", \"Koren J 3rd\", \"Shelton LB\"], \"date\": \"2017-01-01\", \"first\": \"Shelton LB\", \"last\": \"Blair LJ\", \"name\": \"Frontiers in neuroscience\", \"pages\": \"724\", \"reference\": \"29311797\", \"title\": \"Imbalances in the Hsp90 Chaperone Machinery: Implications for Tauopathies.\", \"type\": \"PubMed\", \"volume\": \"11\"}, \"evidence\": \"This study found that reductions in S100A1 also led to massive reductions in both phospho- and total tau levels in cells (Jinwal et al., 2013).\", \"key\": \"8717b727c2093e57e0a32cef9c933fc7d2b13cffabeb2edf2b587143c0d3b2e1b86ea01a3f6cbc27c8a91cd6fd1d1b3565938becf1cd181e35b07b2e30ece9ed\", \"line\": 364, \"relation\": \"increases\", \"source\": 359, \"target\": 286}, {\"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Knock-down of PP2A catalytic subunit (Kins et al.,2001) or PP2A B (or PPP2R5D) regulatory subunit (Louis et al.,2011), and expression of the methylation-site L309A C subunit mutant (Schild et al.,2006) all induce AD-like tau phosphorylation in transgenic mice\", \"key\": \"735738c3d0ad93420f54b21cf28f40a7ba26136eb4f1e369a46bc9fbc2216ff4f1af8fd8f86d60e28f09be6dbde90488e7c1c3096dcfe47c3acfcda6e0135c2d\", \"line\": 356, \"relation\": \"decreases\", \"source\": 352, \"target\": 286}, {\"annotations\": {\"Disease\": {\"Alzheimer's disease\": true, \"Down syndrome\": true}, \"Method\": {\"Immunohistochemistry\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Ando K\", \"Authelet M\", \"Belkouch M\", \"Brion JP\", \"Duyckaerts C\", \"Ndjim M\", \"Potier MC\", \"Sazdovitch V\", \"Suain V\", \"Tomimura K\", \"Vergara C\", \"Yilmaz Z\"], \"date\": \"2016-10-01\", \"first\": \"Ando K\", \"last\": \"Brion JP\", \"name\": \"Neurobiology of disease\", \"pages\": \"32-43\", \"reference\": \"27260836\", \"title\": \"Level of PICALM, a key component of clathrin-mediated endocytosis, is correlated with levels of phosphotau and autophagy-related proteins and is associated with tau inclusions in AD, PSP and Pick disease.\", \"type\": \"PubMed\", \"volume\": \"94\"}, \"evidence\": \"Phosphatidylinositol binding clathrin assembly protein, PICALM (aka CALM) assembles adaptor protein-2 (AP-2) to clathrin, thus participating in clathrin-mediated endocytosis. We have previously reported that the level of full-length PICALM is decreased in AD brains; PICALM was co-localised with phosphorylated tau in NFTs and in granulovacuolar degenerations (GVDs) in the brains of AD patients and of individuals with Down syndrome but was not observed in amyloid plaques (Ando et al., 2013).\", \"key\": \"a7ea98aad6f927db35ca9a44c9da4f4473d14e1349a5732000b8586658c03a29dbec4e0289ad621a4d766b96fc9ea3838a92ef5bda172eca4bb6bd93aa637305\", \"line\": 227, \"relation\": \"association\", \"source\": 341, \"target\": 286}, {\"annotations\": {\"Anatomy\": {\"striatum\": true}, \"Disease\": {\"progressive supranuclear palsy\": true}, \"Method\": {\"Immunohistochemistry\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Ando K\", \"Authelet M\", \"Belkouch M\", \"Brion JP\", \"Duyckaerts C\", \"Ndjim M\", \"Potier MC\", \"Sazdovitch V\", \"Suain V\", \"Tomimura K\", \"Vergara C\", \"Yilmaz Z\"], \"date\": \"2016-10-01\", \"first\": \"Ando K\", \"last\": \"Brion JP\", \"name\": \"Neurobiology of disease\", \"pages\": \"32-43\", \"reference\": \"27260836\", \"title\": \"Level of PICALM, a key component of clathrin-mediated endocytosis, is correlated with levels of phosphotau and autophagy-related proteins and is associated with tau inclusions in AD, PSP and Pick disease.\", \"type\": \"PubMed\", \"volume\": \"94\"}, \"evidence\": \"In PSP cases, both coiled bodies (Fig. 2 D-F) and NFTs (Fig. 2G-I) in the striatum showed a complete co-localisation of PICALM and phosphotau immunoreactivies.\", \"key\": \"b37a6798e7294687bf4abab4e2ad1817f4a948cd73a6ca33b2357a5db390b7e67b0986ca23b1a4cfb011c720242d0ef3616a735ff8aa23bb26bf32ced7c07b74\", \"line\": 245, \"relation\": \"association\", \"source\": 341, \"target\": 286}, {\"annotations\": {\"Cell_Line\": {\"COS7\": true}, \"Method\": {\"Deglycosylation Assay\": true, \"Dephosphorylation Assay\": true, \"Immunoblotting\": true, \"Immunocytochemistry\": true, \"Phosphorylation Assay\": true, \"Pull-down Assay, His-tagged\": true, \"SDS-PAGE\": true, \"Ubiquitination Assay\": true}}, \"citation\": {\"authors\": [\"Gygi SP\", \"Kosik KS\", \"Schwartz D\", \"Shimura H\"], \"date\": \"2004-02-06\", \"first\": \"Shimura H\", \"last\": \"Kosik KS\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"4869-76\", \"reference\": \"14612456\", \"title\": \"CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival.\", \"type\": \"PubMed\", \"volume\": \"279\"}, \"evidence\": \"These data indicated that phosphorylation of PP2A dephosphorylation sites is an important recognition signal for ubiquitination. We used 200 g of amino-terminal His-tagged full-length recombinant human tau in an in vitro phosphorylation reaction with GSK-3Beta. When phosphorylated, the tau protein reacted on immunoblots with PHF1 (25, 26) and AT8 (24), indicating that at least sites Ser202, Thr205, Ser396, and Ser404 were phosphorylated. Following GSK-3Beta incubation, this tau served as an excellent substrate for in vitro ubiquitination using UbcH5B and the cofactor fraction from AD tau immunoprecipitates (Fig. 2a). This finding suggested that GSK-3Beta can place phosphates on tau that create recognition sites for an E3 Ub ligase.\", \"key\": \"aec0dc3de8508ef19b13f835d1b4679cb6571edf9c3ac9518eb84ccd0c8934c162bff46fa65cf4457b2a15244a8d8ac08d572333a7cfbc47967a75041bb68175\", \"line\": 393, \"relation\": \"isA\", \"source\": 290, \"target\": 286}, {\"citation\": {\"authors\": [\"Dorval V\", \"Fraser PE\"], \"date\": \"2006-04-14\", \"first\": \"Dorval V\", \"last\": \"Fraser PE\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"9919-24\", \"reference\": \"16464864\", \"title\": \"Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein.\", \"type\": \"PubMed\", \"volume\": \"281\"}, \"evidence\": \"Both brain proteins were preferentially modified by SUMO1, as compared with SUMO2 or SUMO3. Tau contains two SUMO consensus sequences with Lys(340) as the major sumoylation site. Although both tau and alpha-synuclein are targets for proteasomal degradation, only tau sumoylation was affected by inhibitors of the proteasome pathway. Treatment with the phosphatase inhibitor, okadaic acid, or the microtubule depolymerizing drug, colchicine, up-regulated tau sumoylation.\", \"key\": \"11bb0e7ff90066697583dac13041756c2036c5356a8af0445b30b90bfca0ae573a176d00b7be7bda450d18dd5a4dbea6b9f693940f234502a5a2a0747cdf6f42\", \"line\": 3718, \"relation\": \"positiveCorrelation\", \"source\": 290, \"target\": 322}, {\"annotations\": {\"MeSHAnatomy\": {\"Dendrites\": true}}, \"citation\": {\"authors\": [\"Balaji V\", \"Kaniyappan S\", \"Mandelkow E\", \"Mandelkow EM\", \"Wang Y\"], \"date\": \"2018-01-01\", \"first\": \"Balaji V\", \"last\": \"Mandelkow EM\", \"name\": \"Autophagy\", \"pages\": \"2139-2154\", \"reference\": \"30145931\", \"title\": \"Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \"In addition, it has been reported that in cultured neurons, A oligomers induce MAPT missorting into the somatodendritic compartment, and the missorted MAPT is phosphorylated mainly at the 12E8 (p-S262/p-S356) and AT8 (p-S202/p-T205) sites [6].\", \"key\": \"ed12c0d5e736f489e117c4550e319e2a141332e49f54fd7fbe0a569c303089412ebbfb506b743815131298d52c01001d75a46b2836c5af7ea2f9f85808927392\", \"line\": 146, \"relation\": \"positiveCorrelation\", \"source\": 290, \"target\": 52}, {\"annotations\": {\"Method\": {\"Electron Microscopy, Transmission\": true, \"NMR Spectroscopy\": true, \"Thioflavin T Assay\": true}, \"Tau_Epitope\": {\"AT8\": true}}, \"citation\": {\"authors\": [\"Baulieu EE\", \"Byrne C\", \"Cantrelle FX\", \"Chambraud B\", \"Despres C\", \"Huvent I\", \"Jacquot Y\", \"Landrieu I\", \"Lippens G\", \"Qi H\", \"Smet-Nocca C\"], \"date\": \"2017-08-22\", \"first\": \"Despres C\", \"last\": \"Smet-Nocca C\", \"name\": \"Proceedings of the National Academy of Sciences of the United States of America\", \"pages\": \"9080-9085\", \"reference\": \"28784767\", \"title\": \"Identification of the Tau phosphorylation pattern that drives its aggregation.\", \"type\": \"PubMed\", \"volume\": \"114\"}, \"evidence\": \"When combined with ERK2 catalyzed phosphorylation, the turn-like disrupting G207V mutation in TauF8 hence leads to fast aggregation that already occurs during the phosphorylation reaction.\", \"key\": \"0baf1d8af8fd3d3fe680e0233a872d3c72594ddd48e087a7357c22704da9c32fb8ec1a0a7dfb464d31357dedf5a4db834f443d523622a8d54633a638ae7f6811\", \"line\": 83, \"relation\": \"partOf\", \"source\": 290, \"target\": 187}, {\"citation\": {\"authors\": [\"Kawakami F\", \"Ohtsuki K\", \"Suzuki K\"], \"date\": \"2008-02-01\", \"first\": \"Kawakami F\", \"last\": \"Ohtsuki K\", \"name\": \"Biological &amp; pharmaceutical bulletin\", \"pages\": \"193-200\", \"reference\": \"18239272\", \"title\": \"A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"Epitopes S198, S199, S202, T205, S422 (Lund 2013)\", \"key\": \"fffada5e71eced6f441ca2f0137fb86b13b18eb41c035311e95eb0db97bd9dfd44b730245b09e8b1f1906601bae3c14e737b00eeccd14609de2fc864c0f1ef95\", \"line\": 1294, \"relation\": \"partOf\", \"source\": 290, \"target\": 187}, {\"annotations\": {\"Confidence\": {\"High\": true}, \"MeSHAnatomy\": {\"Intracellular Space\": true}, \"PublicationType\": {\"Review\": true}}, \"citation\": {\"authors\": [\"Binder LI\", \"Himmelstein DS\", \"Lancia JK\", \"Ward SM\"], \"date\": \"2012-08-01\", \"first\": \"Ward SM\", \"last\": \"Binder LI\", \"name\": \"Biochemical Society transactions\", \"pages\": \"667-71\", \"reference\": \"22817713\", \"title\": \"Tau oligomers and tau toxicity in neurodegenerative disease.\", \"type\": \"PubMed\", \"volume\": \"40\"}, \"evidence\": \"TNT1 also co-localizes in tissue with the phospho-epitope defined by the AT8 antibody, indicating that PAD exposure represents an early event in AD pathology\", \"key\": \"6b76c80236abcfb510a41233c920f6f16d15dd297e1891fe9e0cf868c46128354b53a2ead8c119d8d89b3226301128dfbaa93f9ae24565b7a79e3a7575030b86\", \"line\": 170, \"relation\": \"association\", \"source\": 290, \"target\": 39}, {\"annotations\": {\"Confidence\": {\"High\": true}, \"MeSHAnatomy\": {\"Intracellular Space\": true}, \"PublicationType\": {\"Review\": true}}, \"citation\": {\"authors\": [\"Binder LI\", \"Himmelstein DS\", \"Lancia JK\", \"Ward SM\"], \"date\": \"2012-08-01\", \"first\": \"Ward SM\", \"last\": \"Binder LI\", \"name\": \"Biochemical Society transactions\", \"pages\": \"667-71\", \"reference\": \"22817713\", \"title\": \"Tau oligomers and tau toxicity in neurodegenerative disease.\", \"type\": \"PubMed\", \"volume\": \"40\"}, \"evidence\": \"TNT1 also co-localizes in tissue with the phospho-epitope defined by the AT8 antibody, indicating that PAD exposure represents an early event in AD pathology\", \"key\": \"e764735d5492924730edb803f223c7ebad11dd1b6fab7adce4c343a8b628537387a7e7ce1b89eb388e20074fd736c700b753b3b082c4f883d49b52f416d82e63\", \"line\": 172, \"relation\": \"association\", \"source\": 290, \"target\": 46}, {\"annotations\": {\"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Cornwell LB\", \"Gylys KH\", \"Henkins KM\", \"Miller CA\", \"Poon WW\", \"Saing T\", \"Sokolow S\", \"Vinters HV\"], \"date\": \"2012-11-01\", \"first\": \"Henkins KM\", \"last\": \"Gylys KH\", \"name\": \"Brain pathology (Zurich, Switzerland)\", \"pages\": \"826-33\", \"reference\": \"22486774\", \"title\": \"Extensive p-tau pathology and SDS-stable p-tau oligomers in Alzheimer's cortical synapses.\", \"type\": \"PubMed\", \"volume\": \"22\"}, \"evidence\": \"Oligomers positive for pS202/pT205 accumulate at synapses in AD\", \"key\": \"1e53f6ac5a07cb870842c51ad62bc21cd3d7e5a4dcbcd0521a648b8a2370247597e7f1718a9fa777f315162c92be4fd173a5af12a43e4067cf1586334a80c223\", \"line\": 2630, \"relation\": \"partOf\", \"source\": 290, \"target\": 46}, {\"annotations\": {\"Method\": {\"Chromatography, Gel filtration\": true, \"Chromatography, Ni-NTA-Sepharose\": true, \"Chymotrypsin Assay\": true, \"Co-Immunoprecipitation\": true, \"Immunofluorescence\": true, \"Immunohistochemistry\": true, \"Microtubule polzmerization Assay\": true, \"Protease-coupled Assay\": true, \"RNA Interference, siRNA\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Blair LJ\", \"Borysov SI\", \"Buchner J\", \"Cox MB\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"O'Leary JC 3rd\", \"Schmid AB\", \"Shults CL\"], \"date\": \"2010-01-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"591-9\", \"reference\": \"20071522\", \"title\": \"The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules.\", \"type\": \"PubMed\", \"volume\": \"30\"}, \"evidence\": \"We found that FKBP51 indeed could interact with tau from both AD patients and control cases (Fig. 3D), further suggesting a functionally relevant relationship between FKBP51 and tau. We then investigated whether FKBP51 would preferentially interact with phosphorylated tau species. We increased the number of samples per group (4 for AD and 4 for normal) and again co-immunoprecipitated FKBP51. After gel electrophoresis, immunoblotting showed increased association of pS396 and pS199-S202 tau species with FKBP51 in AD tissue (Fig S1). Indeed, we found that FKBP51 over-expression increased phospho- and total tau levels (by 80%) in HeLa cells stably expressing normal human tau, while FKBP52 over-expression had no affect (Fig.4A). These experiments were repeated multiple times and Student t-test of these replicates demonstrated that FKBP51 significantly increased total tau levels (p= 0.0104).\", \"key\": \"731f095cd488eb5c38184086b520c94f1d590fcce931da64f54aadb45e5ef1d1bb626be3c26477d35dc06236a6cadbdce027969cd1a247af5fad9250db2d2ba4\", \"line\": 591, \"relation\": \"isA\", \"source\": 290, \"target\": 204}, {\"annotations\": {\"Method\": {\"Chromatography, Gel filtration\": true, \"Chromatography, Ni-NTA-Sepharose\": true, \"Chymotrypsin Assay\": true, \"Co-Immunoprecipitation\": true, \"Immunofluorescence\": true, \"Immunohistochemistry\": true, \"Microtubule polzmerization Assay\": true, \"Protease-coupled Assay\": true, \"RNA Interference, siRNA\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Blair LJ\", \"Borysov SI\", \"Buchner J\", \"Cox MB\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"O'Leary JC 3rd\", \"Schmid AB\", \"Shults CL\"], \"date\": \"2010-01-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"591-9\", \"reference\": \"20071522\", \"title\": \"The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules.\", \"type\": \"PubMed\", \"volume\": \"30\"}, \"evidence\": \"We found that FKBP51 indeed could interact with tau from both AD patients and control cases (Fig. 3D), further suggesting a functionally relevant relationship between FKBP51 and tau. We then investigated whether FKBP51 would preferentially interact with phosphorylated tau species. We increased the number of samples per group (4 for AD and 4 for normal) and again co-immunoprecipitated FKBP51. After gel electrophoresis, immunoblotting showed increased association of pS396 and pS199-S202 tau species with FKBP51 in AD tissue (Fig S1). Indeed, we found that FKBP51 over-expression increased phospho- and total tau levels (by 80%) in HeLa cells stably expressing normal human tau, while FKBP52 over-expression had no affect (Fig.4A). These experiments were repeated multiple times and Student t-test of these replicates demonstrated that FKBP51 significantly increased total tau levels (p= 0.0104).\", \"key\": \"fb0b736797117809d6d2ae694747ec7b504aa8963b15525147d1a3fcda3dae8c01724b2ab757b49e64f63e8bf2ed9ec69cb18c9076635dc093f45b5a3d6c98c4\", \"line\": 594, \"relation\": \"association\", \"source\": 290, \"target\": 122}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"ecbdeab17d837213ab6ea2ce3f49da93de740cfad726d4c1b25154abe37dcb9ded28c31e45bfa45066717ef68d7639b63588edd1081c5dd5269871ea491622d1\", \"line\": 1123, \"relation\": \"positiveCorrelation\", \"source\": 290, \"target\": 164}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"47725076bc805bea33fecc283d9507ebe8ac688565a8abdc03a08f909ac15055f7a86505d96027a4cc310313a3dba15738f42526fda7fcd39491641eebdfd250\", \"line\": 1148, \"relation\": \"partOf\", \"source\": 290, \"target\": 117}, {\"annotations\": {\"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Bachmeier C\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Jin C\", \"Laco G\", \"Lin Y\", \"Mullan M\", \"Paris D\"], \"date\": \"2014-12-05\", \"first\": \"Paris D\", \"last\": \"Mullan M\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"33927-44\", \"reference\": \"25331948\", \"title\": \"The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid- production and Tau hyperphosphorylation.\", \"type\": \"PubMed\", \"volume\": \"289\"}, \"evidence\": \"We further validated Syk as a target-regulating A by showing that pharmacological inhibition of Syk or down-regulation of Syk expression reduces A production and increases the clearance of A across the BBB mimicking (-)-nilvadipine effects. Moreover, treatment of transgenic mice overexpressing A and transgenic Tau P301S mice with a selective Syk inhibitor respectively decreased brain A accumulation and Tau hyperphosphorylation at multiple AD relevant epitopes.\", \"key\": \"2710ccb8bf7e09fac02a578d26d2a292826064c69f3add3150a9a50b00f2c0ee405741d93015f78a7a1c5b0334e9985c5db1737265a15630e20dd7e122aba625\", \"line\": 2264, \"relation\": \"equivalentTo\", \"source\": 290, \"target\": 44}, {\"annotations\": {\"Species\": {\"10116\": true}}, \"citation\": {\"authors\": [\"Ai J\", \"Ban T\", \"Bao YN\", \"Chen QX\", \"Hu XL\", \"Jiang XM\", \"Liu CD\", \"Pei SC\", \"Su XL\", \"Sun LH\", \"Sun LL\", \"Wang X\", \"Yan ML\", \"Zhao LJ\", \"Zong DK\"], \"date\": \"2015-09-01\", \"first\": \"Sun LH\", \"last\": \"Ai J\", \"name\": \"Journal of neurochemistry\", \"pages\": \"1139-51\", \"reference\": \"26118667\", \"title\": \"Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.\", \"type\": \"PubMed\", \"volume\": \"134\"}, \"evidence\": \"Endogenous miR-195 was knocked down using over-expression of its antisense molecule (pre-AMO-miR-195) via a lentivirus (lenti-pre-AMO-miR-195); this knockdown increased the tau phosphorylation at Ser202/Thr205, Ser262, Thr231, Ser422, and the Cdk5/p25 activation, but over-expression of miR-195 using lenti-pre-miR-195 decreased the tau phosphorylation and Cdk5/p25 activation.\", \"key\": \"df20d0c28d944c873f143d0d0c4457c3fe4bbb2423c3f823a187d0ec78cc86a470a96ce08cb2306c8dc74e9fe23d8f59a60aa1bb684347e0a41752f542161d11\", \"line\": 2331, \"relation\": \"negativeCorrelation\", \"source\": 290, \"target\": 153}, {\"citation\": {\"authors\": [\"Gamblin TC\", \"Sun Q\"], \"date\": \"2009-06-30\", \"first\": \"Sun Q\", \"last\": \"Gamblin TC\", \"name\": \"Biochemistry\", \"pages\": \"6002-11\", \"reference\": \"19459590\", \"title\": \"Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization.\", \"type\": \"PubMed\", \"volume\": \"48\"}, \"evidence\": \"Because S199/S202/T205E, S396/S404E, 6-Phos and 7-Phos all demonstrated an AD-like shift in mobility as a result of phosphorylation-like changes, we conclude that they have the characteristics of hyperphosphorylated tau. These mutants will therefore be referred to as pseudo-hyperphosphorylated tau throughout the manuscript. On the basis of the observations that pseudohyperphosphorylated tau has decreased affinity for microtubules and reduced inducer-initiated rates of nucleation and polymerization, we propose that this combination could be the cause of the increased cytotoxicity of hyperphosphorylated tau in Alzheimer's disease and also explain the potentially beneficial role of tau polymerization and NFT formation.\", \"key\": \"8b307c65647a2c97be2adabbd4b107fcd63872382c3f863a39d1d8fe2697441d2f3a640600c4a7476cbd2cdb33088ae27ef30197dbb5ebc6af410ac15c3afd9e\", \"line\": 2468, \"relation\": \"equivalentTo\", \"source\": 290, \"target\": 188}, {\"annotations\": {\"Anatomy\": {\"CA1 field of hippocampus\": true, \"CA3 field of hippocampus\": true, \"cerebral cortex\": true, \"dentate gyrus granule cell layer\": true}, \"Research_Model\": {\"hTau E391 transgenic mice\": true}, \"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Kraemer BC\", \"Leverenz JB\", \"McMillan PJ\", \"Raskind M\", \"Robinson L\", \"Schellenberg G\"], \"date\": \"2011-11-01\", \"first\": \"McMillan PJ\", \"last\": \"Schellenberg G\", \"name\": \"Journal of neuropathology and experimental neurology\", \"pages\": \"1006-19\", \"reference\": \"22002427\", \"title\": \"Truncation of tau at E391 promotes early pathologic changes in transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"70\"}, \"evidence\": \"E391-3610 mice (higher expressers) exhibit robust somatodendritic distribution of phospho- Ser 202/Thr 205 tau throughout the cortex, in hippocampal CA3 pyramidal neurons, CA1 apical dendrites and cell bodies and dentate granule cells.\", \"key\": \"0fc30b501566033787c57d8072449624c9a17243dc8ada1d285d16b6e59196b1919b6a7d82af9d20a5dd5183808ada2545707b3ede8879949318a913f5ed74d8\", \"line\": 2580, \"relation\": \"positiveCorrelation\", \"source\": 290, \"target\": 35}, {\"annotations\": {\"Disease_Progression\": {\"Late Stage\": true}, \"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Castillo-Carranza DL\", \"Jackson GR\", \"Kayed R\", \"Lasagna-Reeves CA\", \"Sarmiento J\", \"Sengupta U\", \"Troncoso J\"], \"date\": \"2012-05-01\", \"first\": \"Lasagna-Reeves CA\", \"last\": \"Kayed R\", \"name\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\", \"pages\": \"1946-59\", \"reference\": \"22253473\", \"title\": \"Identification of oligomers at early stages of tau aggregation in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"26\"}, \"evidence\": \"Phosphorylation at the epitope Ser202/Thr205 is regarded as a good marker for late-stage NFTs (5, 72). Hyman and colleagues (5) demonstrated that AT8 immunoreactivity is present primarily in eNFTs and in certain cases in iNFTs. These investigators also found that AT8 revealed dense neuropil thread staining.\", \"key\": \"2014d618334200e0f6130a080cc68987d583eb0766bad680ba1283f9651242cbd62bf6cb401864dd2b9ea7fbfeeead1d0473b149e3f0f7c44ad1f1d6fe61973f\", \"line\": 2620, \"relation\": \"partOf\", \"source\": 290, \"target\": 35}, {\"citation\": {\"authors\": [\"Dorval V\", \"Fraser PE\"], \"date\": \"2006-04-14\", \"first\": \"Dorval V\", \"last\": \"Fraser PE\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"9919-24\", \"reference\": \"16464864\", \"title\": \"Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein.\", \"type\": \"PubMed\", \"volume\": \"281\"}, \"evidence\": \"Both brain proteins were preferentially modified by SUMO1, as compared with SUMO2 or SUMO3. Tau contains two SUMO consensus sequences with Lys(340) as the major sumoylation site. Although both tau and alpha-synuclein are targets for proteasomal degradation, only tau sumoylation was affected by inhibitors of the proteasome pathway. Treatment with the phosphatase inhibitor, okadaic acid, or the microtubule depolymerizing drug, colchicine, up-regulated tau sumoylation.\", \"key\": \"d78c76f6eb18ce13bd1359ff9bd1baac44049cf1f46cb6398613c95bcf8a54ddbd38182cac5fae1beb55254a68f697e3d3e85c38c3cf379c3db13cea2141b7f6\", \"line\": 3717, \"relation\": \"positiveCorrelation\", \"source\": 290, \"target\": 11}, {\"annotations\": {\"Research_Model\": {\"rTg4510 mice\": true}}, \"citation\": {\"authors\": [\"Boehm J\", \"Bourgeois C\", \"Dudilot A\", \"Lauzon M\", \"Leclerc N\", \"Mondragn-Rodrguez S\", \"Trillaud-Doppia E\"], \"date\": \"2012-09-14\", \"first\": \"Mondragn-Rodrguez S\", \"last\": \"Boehm J\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"32040-53\", \"reference\": \"22833681\", \"title\": \"Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.\", \"type\": \"PubMed\", \"volume\": \"287\"}, \"evidence\": \"Acute treatment of rTg4510 mice with an O-GlcNAcase inhibitor transiently reduced tau phosphorylation at epitopes implicated in tau pathology. More importantly, long-term inhibitor treatment strongly increased tau O-GlcNAcylation, reduced the number of dystrophic neurons, and protected against the formation of pathological tau species without altering the phosphorylation of non-pathological tau.\", \"key\": \"65f36ef4b0f02c75ade243d3c727b69fa57984ab7b2e698116766238e5d9f86c18ccb30e164a2b062fec2375677e1c537c6d5bee6a177473ed73761efb2a0818\", \"line\": 2506, \"relation\": \"positiveCorrelation\", \"source\": 290, \"target\": 272}, {\"annotations\": {\"Method\": {\"Immunocytochemistry\": true, \"RNA Interference, siRNA\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"Lawson LY\", \"Li Q\", \"O'Leary JC 3rd\", \"Trotter JH\", \"Vestal GD\", \"Weeber EJ\"], \"date\": \"2011-05-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"16976-83\", \"reference\": \"21367866\", \"title\": \"The Hsp90 kinase co-chaperone Cdc37 regulates tau stability and phosphorylation dynamics.\", \"type\": \"PubMed\", \"volume\": \"286\"}, \"evidence\": \"Quantification of the Western blot showed that Cdc37 knockdown reduced phospho-Thr-231, phospho-Ser-199/Ser-202, phospho-Ser-396/Ser-404, and phospho-Ser-262/Ser-356 tau.\", \"key\": \"b0d299651e6857b24365e9f3e8688d55a58755727cda14687de092e501d00d17034baff0a28185010d7c00df210e8023d73017858ed729a029139f6d72b719cc\", \"line\": 632, \"relation\": \"positiveCorrelation\", \"source\": 290, \"target\": 214}, {\"annotations\": {\"Research_Model\": {\"pR5 mice\": true}, \"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Dinekov M\", \"Gtz J\", \"Khler C\"], \"date\": \"2013-05-01\", \"first\": \"Khler C\", \"last\": \"Gtz J\", \"name\": \"Neurobiology of aging\", \"pages\": \"1369-79\", \"reference\": \"23294633\", \"title\": \"Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"34\"}, \"evidence\": \"We studied underlying pathomechanisms in tauopathies using pR5 mice that express the P301L tau mutation found in familial forms of frontotemporal dementia. In a longitudinal study we investigated the functional status of glycogen synthase kinase-3 and correlated it with the appearance of distinct tau phospho-epitopes. Neurons displaying increases in activating phosphorylation of glycogen synthase kinase-3/ at tyrosine 279/216 also showed an intense rather than moderate AT8 (phospho-Ser202/Thr205 tau) immunoreactivity, and immunoreactivity for AT100 (phospho-Ser212/Thr214 tau) and phosphorylated Ser422, phospho-epitopes associated with fibrillar tau pathology.\", \"key\": \"001783fcf0cf1de501ebabd8f76e747aca963d8e5c573a47c1cbdf844d44d7adad2a4979f9ad6a065d0cb6f4e30d9ba6a84e66e3bdddbbc7055480505980bcf0\", \"line\": 2542, \"relation\": \"positiveCorrelation\", \"source\": 290, \"target\": 329}, {\"annotations\": {\"Method\": {\"Chromatography, Gel filtration\": true, \"Chromatography, Ni-NTA-Sepharose\": true, \"Chymotrypsin Assay\": true, \"Co-Immunoprecipitation\": true, \"Immunofluorescence\": true, \"Immunohistochemistry\": true, \"Microtubule polzmerization Assay\": true, \"Protease-coupled Assay\": true, \"RNA Interference, siRNA\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Blair LJ\", \"Borysov SI\", \"Buchner J\", \"Cox MB\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"O'Leary JC 3rd\", \"Schmid AB\", \"Shults CL\"], \"date\": \"2010-01-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"591-9\", \"reference\": \"20071522\", \"title\": \"The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules.\", \"type\": \"PubMed\", \"volume\": \"30\"}, \"evidence\": \"We found that FKBP51 indeed could interact with tau from both AD patients and control cases (Fig. 3D), further suggesting a functionally relevant relationship between FKBP51 and tau. We then investigated whether FKBP51 would preferentially interact with phosphorylated tau species. We increased the number of samples per group (4 for AD and 4 for normal) and again co-immunoprecipitated FKBP51. After gel electrophoresis, immunoblotting showed increased association of pS396 and pS199-S202 tau species with FKBP51 in AD tissue (Fig S1). Indeed, we found that FKBP51 over-expression increased phospho- and total tau levels (by 80%) in HeLa cells stably expressing normal human tau, while FKBP52 over-expression had no affect (Fig.4A). These experiments were repeated multiple times and Student t-test of these replicates demonstrated that FKBP51 significantly increased total tau levels (p= 0.0104).\", \"key\": \"ef2cfe6eb959c26510850e0763cb40726d26cc6cd36d0074b480aac6208b8ef5998a5ca39b22b8453fae1f2517993f9bd2d368041980ee21604e9f6a0e00f5a5\", \"line\": 597, \"relation\": \"positiveCorrelation\", \"source\": 290, \"target\": 229}, {\"annotations\": {\"Research_Model\": {\"TPR50 mice\": true}, \"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Hattori M\", \"Horiguchi T\", \"Iwashita H\", \"Matsumoto Y\", \"Nakamura K\", \"Obayashi Y\", \"Onishi T\", \"Yano T\"], \"date\": \"2014-03-01\", \"first\": \"Onishi T\", \"last\": \"Iwashita H\", \"name\": \"Neuroscience research\", \"pages\": \"76-85\", \"reference\": \"24406748\", \"title\": \"Early-onset cognitive deficits and axonal transport dysfunction in P301S mutant tau transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"80\"}, \"evidence\": \"We developed a transgenic mouse, named TPR50, harboring human P301S tau. Tau phosphorylation in the hippocampus of TPR50 mice increased with age, particularly at S202/T205. Therefore, cognitive dysfunction in TPR50 mice may result from early MT dysfunction and impaired axonal transport rather than accumulation of insoluble tau and neurodegeneration.\", \"key\": \"3bd383265d263b43553760435fea9846a349c1cbae1c2c6fd7afb033032aac428ee67eb0ea6f625490bdb04080542352e6515350ef84bb7fad826301048a4af9\", \"line\": 2523, \"relation\": \"positiveCorrelation\", \"source\": 290, \"target\": 330}, {\"annotations\": {\"Anatomy\": {\"CA1 field of hippocampus\": true, \"CA3 field of hippocampus\": true, \"cerebral cortex\": true, \"dentate gyrus granule cell layer\": true}, \"Research_Model\": {\"hTau E391 transgenic mice\": true}, \"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Kraemer BC\", \"Leverenz JB\", \"McMillan PJ\", \"Raskind M\", \"Robinson L\", \"Schellenberg G\"], \"date\": \"2011-11-01\", \"first\": \"McMillan PJ\", \"last\": \"Schellenberg G\", \"name\": \"Journal of neuropathology and experimental neurology\", \"pages\": \"1006-19\", \"reference\": \"22002427\", \"title\": \"Truncation of tau at E391 promotes early pathologic changes in transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"70\"}, \"evidence\": \"E391-3610 mice (higher expressers) exhibit robust somatodendritic distribution of phospho- Ser 202/Thr 205 tau throughout the cortex, in hippocampal CA3 pyramidal neurons, CA1 apical dendrites and cell bodies and dentate granule cells.\", \"key\": \"996ba4db2b821403912f6920c967d1348b549dd0ec073e22458dd9266755a5a3f15c255f93d557806fd8ce9cac7f8bc2c63defe8e833537cb84fa0e8784acbb8\", \"line\": 2578, \"relation\": \"positiveCorrelation\", \"source\": 290, \"target\": 327}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Protein phosphatase 1 (PP1), PP2A, PP2B, PP2C and PP5 have all been implicated in the dephosphorylation of tau\", \"key\": \"295ae6ce8c7ab00959bebfbfdb975d0588975ce4d96a751ed7c4b63f4c70f28ed58165c96d1636f47d5391dbb8788db4eeaf1317013be4c9553574c1d5d133bd\", \"line\": 195, \"relation\": \"directlyDecreases\", \"source\": 344, \"target\": 286}, {\"citation\": {\"authors\": [\"Dewachter I\", \"Terwel D\", \"Van Leuven F\"], \"date\": \"2002-01-01\", \"first\": \"Terwel D\", \"last\": \"Van Leuven F\", \"name\": \"Neuromolecular medicine\", \"pages\": \"151-65\", \"reference\": \"12428809\", \"title\": \"Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"2\"}, \"evidence\": \"Other serine and threonine residues, not followed by proline, are phosphorylated by other protein kinases, including microtubule-affinity-regulating kinase (MARK) (Drewes et al., 1993), calcium/ calmodulin kinase II (CAMKII), cAMP-dependent kinase (PKA) (Johnson et al., 1992), and casein kinase II (Greenwood et al., 1994).\", \"key\": \"5e6d6d4043c71a176181f13b903f24fd6a837b3e204c28ea7328d63470f767285dc5f682a7ee3a9e3d39395c5308ea94b63d9ce4490920a867d76c3f1a32360c\", \"line\": 125, \"relation\": \"increases\", \"source\": 213, \"target\": 286}, {\"annotations\": {\"Species\": {\"6239\": true}}, \"citation\": {\"authors\": [\"Choudhary B\", \"Mandelkow E\", \"Pir GJ\"], \"date\": \"2017-12-01\", \"first\": \"Pir GJ\", \"last\": \"Mandelkow E\", \"name\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\", \"pages\": \"5137-5148\", \"reference\": \"29191965\", \"title\": \"&lt;i&gt;Caenorhabditis elegans&lt;/i&gt; models of tauopathy.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"Dephosphorylation of tau is achieved mainly by protein phosphatase (PP)2A, PP2B (calcineurin), and PP-1 (92).\", \"key\": \"7430092cde6af694657f77f2ad0e124055792ff8b5958cf23af7da5fe9c54371657d88de7ca1e6ba51079bc44cd0556c28c3c46d29d24c678fba09fa16e1d361\", \"line\": 259, \"relation\": \"directlyDecreases\", \"source\": 346, \"target\": 286}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Protein phosphatase 1 (PP1), PP2A, PP2B, PP2C and PP5 have all been implicated in the dephosphorylation of tau\", \"key\": \"d51ebbcb5654ef782d501b4a7ba4e950dd8b83cc315d9e1d5df7d623b3b13472f097739fc9f2cbee15e05799006382440fd570aebcc0aff06f6ca887545e087d\", \"line\": 194, \"relation\": \"directlyDecreases\", \"source\": 346, \"target\": 286}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Depending on the sites, the acetylation of tau could inhibit its degradation (for example, when at Lys163, Lys280, Lys281 or Lys369) or, by contrast, facilitate its degradation and suppress its phosphorylation and aggregation (for example, when at Lys259, Lys290, Lys321 or Lys353)\", \"key\": \"99cd1d007de0e6bce7642d0aaf572347be6872b504b193154b9ef47bad82eee0c42f8c4900afa09d69e9a379c76be74222aa736ff5c7d6ff4b3ff0ed4f98fcda\", \"line\": 268, \"relation\": \"decreases\", \"source\": 254, \"target\": 286}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Depending on the sites, the acetylation of tau could inhibit its degradation (for example, when at Lys163, Lys280, Lys281 or Lys369) or, by contrast, facilitate its degradation and suppress its phosphorylation and aggregation (for example, when at Lys259, Lys290, Lys321 or Lys353)\", \"key\": \"1b93b3196f33f84bef8ed684bc813577a260b3929fa0af8a392b48b5a4e899cd7e082e98ea1b340d1a419cdcc3cb6a222bf88dc4a20a8073022b7e381e81aa5b\", \"line\": 267, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 254, \"target\": 254}, {\"citation\": {\"authors\": [\"Burlingame AL\", \"Ioanoviciu A\", \"Knudsen GM\", \"Maeda S\", \"Morris M\", \"Mucke L\", \"Trinidad JC\"], \"date\": \"2015-08-01\", \"first\": \"Morris M\", \"last\": \"Mucke L\", \"name\": \"Nature neuroscience\", \"pages\": \"1183-9\", \"reference\": \"26192747\", \"title\": \"Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"18\"}, \"evidence\": \"Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.\", \"key\": \"59d0784f8142565faa298d7de2dc0d57230c92dc421f6d4325f11b50242edaad4929031a8457c8e2d3a93a969bc50293d499f2bdbe8b332093e49b37a934e5ab\", \"line\": 3218, \"relation\": \"isA\", \"source\": 254, \"target\": 247}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Depending on the sites, the acetylation of tau could inhibit its degradation (for example, when at Lys163, Lys280, Lys281 or Lys369) or, by contrast, facilitate its degradation and suppress its phosphorylation and aggregation (for example, when at Lys259, Lys290, Lys321 or Lys353)\", \"key\": \"77089f24f592a956ea6a158d883866ed1606dd0326e4f0c4c0c77f364280fec628a8ef506c8b10742f4eb583e6ca67e932ea923f8fd16ea24a2ad3c717a52ff7\", \"line\": 269, \"relation\": \"decreases\", \"source\": 254, \"target\": 39}, {\"citation\": {\"authors\": [\"Burlingame AL\", \"Ioanoviciu A\", \"Knudsen GM\", \"Maeda S\", \"Morris M\", \"Mucke L\", \"Trinidad JC\"], \"date\": \"2015-08-01\", \"first\": \"Morris M\", \"last\": \"Mucke L\", \"name\": \"Nature neuroscience\", \"pages\": \"1183-9\", \"reference\": \"26192747\", \"title\": \"Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"18\"}, \"evidence\": \"Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.\", \"key\": \"a2092d54a943cca87881e69e9bc5b111f1c9f887ec5feaba0e89226c2c9f443af9c314704c67c4d9d234dda723a8da70f5dabbb468ef43ac2c349329100e5010\", \"line\": 3228, \"relation\": \"partOf\", \"source\": 254, \"target\": 55}, {\"citation\": {\"authors\": [\"Chung KM\", \"Hernndez N\", \"Sproul AA\", \"Yu WH\"], \"date\": \"2018-05-18\", \"first\": \"Chung KM\", \"last\": \"Yu WH\", \"name\": \"Neuroscience letters\", \"reference\": \"29758300\", \"title\": \"Alzheimer's disease and the autophagic-lysosomal system.\", \"type\": \"PubMed\"}, \"evidence\": \"Modulation of mTOR can influence the levels of tau, with upregulation increasing tau phosphorylation and accumulation by reducing autophagic clearance [87], and conversely, pharmacological treatment with rapamycin reducing tau levels and rescuing motor deficits in the Tau P301S mice [53]\", \"key\": \"9f84be732484f65bdbe723f23dd6e1f9c0190da14077aeeb8f03aef61d285df7609a614848400201ec2c7e492dc9f41192be525f752a3103e59c8302a2c6327c\", \"line\": 462, \"relation\": \"positiveCorrelation\", \"source\": 336, \"target\": 286}, {\"annotations\": {\"MeSHAnatomy\": {\"Cerebrospinal Fluid\": true}, \"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Chung KM\", \"Hernndez N\", \"Sproul AA\", \"Yu WH\"], \"date\": \"2018-05-18\", \"first\": \"Chung KM\", \"last\": \"Yu WH\", \"name\": \"Neuroscience letters\", \"reference\": \"29758300\", \"title\": \"Alzheimer's disease and the autophagic-lysosomal system.\", \"type\": \"PubMed\"}, \"evidence\": \"In a more recent GWAS investigation, TREM2 (triggering receptor expressed on myeloid cells 2) was identified as one of the markers strongly associated with increased levels of tau and phosphorylated tau in cerebrospinal fluid from AD patients [91].\", \"key\": \"70abaf0719067ddcfd74a1cc3d1c0ded8a337751d4355bf43539dc79c9a975d91288821a9f0e767c9d5fb3391baa20d0daca6ebdfaef93a75bec8f3a71ec981d\", \"line\": 571, \"relation\": \"positiveCorrelation\", \"source\": 373, \"target\": 286}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Other phosphorylation sites in or near the repeat domain are phosphorylated by microtubule affinity-regulating kinases (MARKs; also known as PAR1 kinases), cyclic AMP-dependent protein kinase (PKA) and Ca2+- or calmodulin-dependent protein kinase II (CaMKII), among others\", \"key\": \"edcaae426f6166d78dcd7f105c3f3c5f1b7d9a97c30692d13e030e0892ad68fa93d8b59105c4ebe0e13a957a4fe8b3f1f6d8f6779c6248d568cffa3a29ee1ec5\", \"line\": 167, \"relation\": \"directlyIncreases\", \"source\": 212, \"target\": 286}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"For example,the phosphorylation of KXGS motifs (particularly Ser262) in the repeat domain of tau by MARK, PKA or CaMKII can reduce the affinity of tau to microtubules\", \"key\": \"0b7aa5b2c2cc7fad0b9692d361e42f6178567c9e1691b3979b082f50d0f0c7f3935bd1dd03b5f52a3ac744b8cbde64f35f1c2153d936c6cf35d9e7996984accb\", \"line\": 208, \"relation\": \"directlyIncreases\", \"source\": 212, \"target\": 297}, {\"citation\": {\"authors\": [\"Dewachter I\", \"Terwel D\", \"Van Leuven F\"], \"date\": \"2002-01-01\", \"first\": \"Terwel D\", \"last\": \"Van Leuven F\", \"name\": \"Neuromolecular medicine\", \"pages\": \"151-65\", \"reference\": \"12428809\", \"title\": \"Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"2\"}, \"evidence\": \" Among the specific proline-dependent kinases that can phosphorylate protein tau at dif- ferent sites in vitro, special attention is dedicated to glycogen-synthase kinase-3 (GSK-3) (Michel et al., 1998), mitogen-activated protein kinase (MAPK) (Drewes et al., 1992), stress-activated protein kinases (SAPKs) (Goedert et al., 1997) and cyclin-dependent kinases (CDKs) including cdc2 and cdk5 (Baumann et al., 1993; Patrick et al., 1999).\", \"key\": \"61b4ff5af86055321a6920c1cb19c7169901714a971f3b76a0e180f011b78fb57784c7ae4ebca724c2489eae55e25c24ccddd685642608a8151b55fd1a8a919a\", \"line\": 113, \"relation\": \"increases\", \"source\": 243, \"target\": 286}, {\"citation\": {\"authors\": [\"Dickey CA\", \"Gestwicki JE\", \"Kiray J\", \"Koren J\", \"Miyata Y\"], \"date\": \"2011-09-01\", \"first\": \"Miyata Y\", \"last\": \"Gestwicki JE\", \"name\": \"Future medicinal chemistry\", \"pages\": \"1523-37\", \"reference\": \"21882945\", \"title\": \"Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.\", \"type\": \"PubMed\", \"volume\": \"3\"}, \"evidence\": \"However, another related BAG family member, BAG2, interacts with Hsp70 and tau but, unlike BAG1, assists clearance of phosphorylated tau [132]\", \"key\": \"bfb0b7e4213b282cf953d598dfcaca0aeb14c1033e6495dd107b35f7cff52ec1d660a72db734212e574c8e6afc79f52f87762268153af8cc87dfe291a174afb1\", \"line\": 381, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"association\", \"source\": 211, \"target\": 286}, {\"citation\": {\"authors\": [\"Dickey CA\", \"Gestwicki JE\", \"Kiray J\", \"Koren J\", \"Miyata Y\"], \"date\": \"2011-09-01\", \"first\": \"Miyata Y\", \"last\": \"Gestwicki JE\", \"name\": \"Future medicinal chemistry\", \"pages\": \"1523-37\", \"reference\": \"21882945\", \"title\": \"Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.\", \"type\": \"PubMed\", \"volume\": \"3\"}, \"evidence\": \"In general, phosphorylation of tau reduces its affinity for microtubules [30], while dephosphorylation via enzymes such as PP2A and PP5 restores binding\", \"key\": \"59ecc2f143e11b1542c965786533f0eb12bff4daa43bb62e8cdb17c8adc0bcb1571d0ba1797632015262a96493aee44ac89fdb9bdb0d1019f45392f0504f3fc2\", \"line\": 112, \"relation\": \"decreases\", \"source\": 354, \"target\": 286}, {\"annotations\": {\"MeSHAnatomy\": {\"Cerebral Cortex\": true}}, \"citation\": {\"authors\": [\"Blair LJ\", \"Koren J 3rd\", \"Shelton LB\"], \"date\": \"2017-01-01\", \"first\": \"Shelton LB\", \"last\": \"Blair LJ\", \"name\": \"Frontiers in neuroscience\", \"pages\": \"724\", \"reference\": \"29311797\", \"title\": \"Imbalances in the Hsp90 Chaperone Machinery: Implications for Tauopathies.\", \"type\": \"PubMed\", \"volume\": \"11\"}, \"evidence\": \"Studies have shown that PP5 is able to dephosphorylate tau at several phosphorylation sites connected to AD pathology (Gong et al., 2004). \", \"key\": \"b468e52c6d32bde5015fed464a60d81c40f9597b6d32f2b4dffa0a5df184b5ffc65fda13d0f15b1b39a0bd2d35e0c69a805d45ac28cc25d0cf3a11ba9849f733\", \"line\": 257, \"relation\": \"decreases\", \"source\": 354, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 286}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Protein phosphatase 1 (PP1), PP2A, PP2B, PP2C and PP5 have all been implicated in the dephosphorylation of tau\", \"key\": \"7f39467855d30e2a275992f27b19bb064a3170068e03d8d6a5c0f28941f52ab8b92d9338efd80bc78bfbd91d03215e18a7884236f315b3568a1e381dd26878b1\", \"line\": 196, \"relation\": \"directlyDecreases\", \"source\": 354, \"target\": 286}, {\"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Knock-down of PP2A catalytic subunit (Kins et al.,2001) or PP2A B (or PPP2R5D) regulatory subunit (Louis et al.,2011), and expression of the methylation-site L309A C subunit mutant (Schild et al.,2006) all induce AD-like tau phosphorylation in transgenic mice\", \"key\": \"a80f3778f78d11b2552f3b8821b92b6345ed2bc5d6e37928e6752da607e38d0552c29348acd8da68444f703d350b5e0d6b5045cfb66078344c0a533fda592ca2\", \"line\": 358, \"relation\": \"increases\", \"source\": 350, \"target\": 286}, {\"citation\": {\"authors\": [\"Blair LJ\", \"Koren J 3rd\", \"Shelton LB\"], \"date\": \"2017-01-01\", \"first\": \"Shelton LB\", \"last\": \"Blair LJ\", \"name\": \"Frontiers in neuroscience\", \"pages\": \"724\", \"reference\": \"29311797\", \"title\": \"Imbalances in the Hsp90 Chaperone Machinery: Implications for Tauopathies.\", \"type\": \"PubMed\", \"volume\": \"11\"}, \"evidence\": \"Inhibition of p23 in an siRNA screen of Hsp90 co-chaperones showed that silencing p23 reduced both total and phospho-tau (Jinwal et al., 2012, 2013).\", \"key\": \"80a50e590cd709fb877153b11e5e0a5f7f958c9fffa2f11f24dabe0f7203beb20d2295243be791198bb411332d38942c3b06f5c74b3d7f9feba2f5905633dcf1\", \"line\": 348, \"relation\": \"increases\", \"source\": 356, \"target\": 286}, {\"citation\": {\"authors\": [\"Cao X\", \"Tan L\", \"Xin SH\", \"Yu JT\"], \"date\": \"2018-10-01\", \"first\": \"Xin SH\", \"last\": \"Tan L\", \"name\": \"Neurotoxicity research\", \"pages\": \"733-748\", \"reference\": \"29626319\", \"title\": \"Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.\", \"type\": \"PubMed\", \"volume\": \"34\"}, \"evidence\": \"Neuronal PAS domain protein 4 has been found to facilitate the autophagic clearance of endogenous total and phosphorylated tau in cortical neurons of rats\", \"key\": \"2de07e88271b8ec3a4fe889c279574fa9a4fde83baaa40ca71c54cb2a4c0a78c86bc90d87c27d2bcd421ec2ca1aa5dc77cccaf231b18129ea150d536d9b08b7b\", \"line\": 703, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 337, \"target\": 286}, {\"citation\": {\"authors\": [\"Sontag E\", \"Sontag JM\"], \"date\": \"2014-01-01\", \"first\": \"Sontag JM\", \"last\": \"Sontag E\", \"name\": \"Frontiers in molecular neuroscience\", \"pages\": \"16\", \"reference\": \"24653673\", \"title\": \"Protein phosphatase 2A dysfunction in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Knock-down of PP2A catalytic subunit (Kins et al.,2001) or PP2A B (or PPP2R5D) regulatory subunit (Louis et al.,2011), and expression of the methylation-site L309A C subunit mutant (Schild et al.,2006) all induce AD-like tau phosphorylation in transgenic mice\", \"key\": \"2c9a995ef3e1e4c8717b77559353162381b283f81bff49ddfbdae65e444fea06d22b66a7187087b817f0549498e47fb3fe3647d54cff36445c3a8b5e5b965918\", \"line\": 355, \"relation\": \"decreases\", \"source\": 349, \"target\": 286}, {\"annotations\": {\"Km\": {\"8-15 M\": true}, \"Km_ATP\": {\"2 M\": true}, \"Vmax\": {\"0.8-4 M/min/mg\": true}}, \"citation\": {\"authors\": [\"Kawakami F\", \"Ohtsuki K\", \"Suzuki K\"], \"date\": \"2008-02-01\", \"first\": \"Kawakami F\", \"last\": \"Ohtsuki K\", \"name\": \"Biological &amp; pharmaceutical bulletin\", \"pages\": \"193-200\", \"reference\": \"18239272\", \"title\": \"A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"Tau-phosphorylation properties dependent on co-factors (Km 8 to 15 uM, Vmax 0.8 to 4 uM/min/mg protein) and Km for ATP is 2uM\", \"key\": \"6ad96a748c26f17f655c23eb65138c29eabad0ec3be35185b9cddc2d0564e3c153314a55fdc2758b39bcad64f4d935ced21f9b5d364a09c1daa41f76b0ed3129\", \"line\": 1279, \"relation\": \"increases\", \"source\": 224, \"target\": 286}, {\"annotations\": {\"Species\": {\"6239\": true}}, \"citation\": {\"authors\": [\"Choudhary B\", \"Mandelkow E\", \"Pir GJ\"], \"date\": \"2017-12-01\", \"first\": \"Pir GJ\", \"last\": \"Mandelkow E\", \"name\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\", \"pages\": \"5137-5148\", \"reference\": \"29191965\", \"title\": \"&lt;i&gt;Caenorhabditis elegans&lt;/i&gt; models of tauopathy.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"Dephosphorylation of tau is achieved mainly by protein phosphatase (PP)2A, PP2B (calcineurin), and PP-1 (92).\", \"key\": \"262ba5aad824765e88ec748e996b44a62bc4703ee4176b384b6fe6d42d798e7affb8074cd01a6bda82424cbbb98aa7ab42da49186f25fa3d84eab374b136a7ab\", \"line\": 258, \"relation\": \"directlyDecreases\", \"source\": 353, \"target\": 286}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Protein phosphatase 1 (PP1), PP2A, PP2B, PP2C and PP5 have all been implicated in the dephosphorylation of tau\", \"key\": \"d70f0e0e9b83b0eff96d70ad3cf642d7e37c97afbd408a8c739b81b0dc9fd2def552f3abdcc13dd92529de1aa6d3d899d325b7f8f28be2ac7efd26ff8cf39ca0\", \"line\": 193, \"relation\": \"directlyDecreases\", \"source\": 353, \"target\": 286}, {\"citation\": {\"authors\": [\"Dewachter I\", \"Terwel D\", \"Van Leuven F\"], \"date\": \"2002-01-01\", \"first\": \"Terwel D\", \"last\": \"Van Leuven F\", \"name\": \"Neuromolecular medicine\", \"pages\": \"151-65\", \"reference\": \"12428809\", \"title\": \"Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"2\"}, \"evidence\": \"Other serine and threonine residues, not followed by proline, are phosphorylated by other protein kinases, including microtubule-affinity-regulating kinase (MARK) (Drewes et al., 1993), calcium/ calmodulin kinase II (CAMKII), cAMP-dependent kinase (PKA) (Johnson et al., 1992), and casein kinase II (Greenwood et al., 1994).\", \"key\": \"b011072efd2756c1b7cf7c81245795fb1bbebbe92b2092a47145eab24ba34763fe6a367dc8c40535b75f6ab9e8119f4499c8b1f0c715991c85cb20f60f5f9016\", \"line\": 124, \"relation\": \"increases\", \"source\": 333, \"target\": 286}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Other phosphorylation sites in or near the repeat domain are phosphorylated by microtubule affinity-regulating kinases (MARKs; also known as PAR1 kinases), cyclic AMP-dependent protein kinase (PKA) and Ca2+- or calmodulin-dependent protein kinase II (CaMKII), among others\", \"key\": \"bfa18418535ac7f3dcd5969a801346fe0208530ed8a42bd023f4a3766e490a61a087ccaaeb6731c83dd9cbda9a9c2e5e389efccf292fc779575af9041e301334\", \"line\": 168, \"relation\": \"directlyIncreases\", \"source\": 333, \"target\": 286}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"For example,the phosphorylation of KXGS motifs (particularly Ser262) in the repeat domain of tau by MARK, PKA or CaMKII can reduce the affinity of tau to microtubules\", \"key\": \"b4fe3a76f33ad7fb524eccb7e302aba9ec413373903f781f2d33273a2d482080b43be7ef4f0054de60d0b3890327a951e1063d031e731c2f0b3cacafff72ac33\", \"line\": 207, \"relation\": \"directlyIncreases\", \"source\": 333, \"target\": 297}, {\"citation\": {\"authors\": [\"Chen GC\", \"Chen RH\", \"Chen YH\", \"Chien CT\", \"Chou HJ\", \"Huang YP\", \"Kimchi A\", \"Lin MY\", \"Tsai PI\", \"Wu PR\"], \"date\": \"2011-09-01\", \"first\": \"Wu PR\", \"last\": \"Chen RH\", \"name\": \"Cell death and differentiation\", \"pages\": \"1507-20\", \"reference\": \"21311567\", \"title\": \"DAPK activates MARK1/2 to regulate microtubule assembly, neuronal differentiation, and tau toxicity.\", \"type\": \"PubMed\", \"volume\": \"18\"}, \"evidence\": \"Furthermore, silencing of both MARK1 and MARK2 blocked DAPK-induced tau S262 phosphorylation (Figure 3e). More importantly, a decrease of pS262 tau, but not total tau, was observed in brain extracts derived from DAPK/ mice, compared with that from DAPK+/+ mice (Figure 3f). These results strongly suggest a role of endogenous DAPK in stimulating the activity of endogenous MARK, which in turn phosphorylates tau in neurons.\", \"key\": \"bca6870a443c4b7fd69b0cbd5375b3ade8a4070bd4d1416ae3c7e0e7e0acde289be710aa0b57a7d1323f32e9975afeda909499ad64c321dbef88d067acbee084\", \"line\": 2012, \"relation\": \"increases\", \"source\": 333, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 297}, {\"annotations\": {\"Species\": {\"7227\": true}}, \"citation\": {\"authors\": [\"Iijima KM\", \"Iijima-Ando K\", \"Lu B\", \"Maruko-Otake A\", \"Ohtake Y\", \"Sekiya M\", \"Suzuki E\"], \"date\": \"2012-01-01\", \"first\": \"Iijima-Ando K\", \"last\": \"Iijima KM\", \"name\": \"PLoS genetics\", \"pages\": \"e1002918\", \"reference\": \"22952452\", \"title\": \"Loss of axonal mitochondria promotes tau-mediated neurodegeneration and Alzheimer's disease-related tau phosphorylation via PAR-1.\", \"type\": \"PubMed\", \"volume\": \"8\"}, \"evidence\": \"Using transgenic Drosophila expressing human tau, we found that RNAi-mediated knockdown of milton or Miro, an adaptor protein essential for axonal transport of mitochondria, enhanced human tau-induced neurodegeneration. Tau phosphorylation at an AD-related site Ser262 increased with knockdown of milton or Miro; and partitioning defective-1 (PAR-1), the Drosophila homolog of mammalian microtubule affinity-regulating kinase, mediated this increase of tau phosphorylation. Tau phosphorylation at Ser262 has been reported to promote tau detachment from microtubules, and we found that the levels of microtubule-unbound free tau increased by milton knockdown. Blocking tau phosphorylation at Ser262 site by PAR-1 knockdown or by mutating the Ser262 site to unphosphorylatable alanine suppressed the enhancement of tau-induced neurodegeneration caused by milton knockdown. Furthermore, knockdown of milton or Miro increased the levels of active PAR-1.\", \"key\": \"7ba6187e9cb4ec6be9a5863473ba90c3360d2dcbced4af3352667e5722bf7a4cf9d1f722dcde0ac88cd0de544e4745db5910e03b4d0c478311908f1ba1db6b3a\", \"line\": 2758, \"relation\": \"directlyIncreases\", \"source\": 333, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 297}, {\"citation\": {\"authors\": [\"Dickey CA\", \"Gestwicki JE\", \"Kiray J\", \"Koren J\", \"Miyata Y\"], \"date\": \"2011-09-01\", \"first\": \"Miyata Y\", \"last\": \"Gestwicki JE\", \"name\": \"Future medicinal chemistry\", \"pages\": \"1523-37\", \"reference\": \"21882945\", \"title\": \"Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.\", \"type\": \"PubMed\", \"volume\": \"3\"}, \"evidence\": \"In general, phosphorylation of tau reduces its affinity for microtubules [30], while dephosphorylation via enzymes such as PP2A and PP5 restores binding\", \"key\": \"bc135ca34aacbf7dac9ff73e8189d8f3a70b9bc5bacf0eec03566e36c6943bb40ee26a8b23eed1d4a837467c008389ed94c9baa73684c77efa3b79e559adf661\", \"line\": 113, \"relation\": \"decreases\", \"source\": 351, \"target\": 286}, {\"annotations\": {\"MeSHAnatomy\": {\"Hippocampus\": true}, \"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Dickey CA\", \"Gestwicki JE\", \"Kiray J\", \"Koren J\", \"Miyata Y\"], \"date\": \"2011-09-01\", \"first\": \"Miyata Y\", \"last\": \"Gestwicki JE\", \"name\": \"Future medicinal chemistry\", \"pages\": \"1523-37\", \"reference\": \"21882945\", \"title\": \"Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.\", \"type\": \"PubMed\", \"volume\": \"3\"}, \"evidence\": \"This co-chaperone is of interest in tauopathies because Hsp110 knockout mice show an age-dependent accumulation of phosphorylated tau in the hippocampus [135].\", \"key\": \"541248e1a11017ff21557cfde331dc9c1978bc397fdbbbe8cc836636d60bd1de8154c98d755bc8c3777c04011ccf8dfdf647eeb9969137f63ef31557d202bc27\", \"line\": 388, \"relation\": \"decreases\", \"source\": 235, \"target\": 286}, {\"citation\": {\"authors\": [\"Chung KM\", \"Hernndez N\", \"Sproul AA\", \"Yu WH\"], \"date\": \"2018-05-18\", \"first\": \"Chung KM\", \"last\": \"Yu WH\", \"name\": \"Neuroscience letters\", \"reference\": \"29758300\", \"title\": \"Alzheimer's disease and the autophagic-lysosomal system.\", \"type\": \"PubMed\"}, \"evidence\": \"TFEB has been shown to effectively clear phosphorylated tau proteins through A-LS, resulting in ameliorated neuronal loss and neuroinflammation, as well as improved cognitive performance [89].\", \"key\": \"ca33596f983cc30d6b2970f705f3f5b7010e7e38552759bf462dbe880e5d7124b1524aaaf6e0d2131bfde208b82b61f3a85d75823decda8085387cc9f29d8c59\", \"line\": 504, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 370, \"target\": 286}, {\"citation\": {\"authors\": [\"Cao X\", \"Tan L\", \"Xin SH\", \"Yu JT\"], \"date\": \"2018-10-01\", \"first\": \"Xin SH\", \"last\": \"Tan L\", \"name\": \"Neurotoxicity research\", \"pages\": \"733-748\", \"reference\": \"29626319\", \"title\": \"Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.\", \"type\": \"PubMed\", \"volume\": \"34\"}, \"evidence\": \"For example, like A, clearance of pTau/NFT also can be regulated by TFEB, which increases the activity of autophagy and lysosome (Polito et al. 2014)\", \"key\": \"3ae4e49fa952c3a7cbc6ad003d4122e0344ab9ccab764b654459098df94eb86a67ef766a1d3a6a7d62b2c262434b805101169ae78981ec4cf065cf4471f851e1\", \"line\": 586, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"regulates\", \"source\": 370, \"target\": 286}, {\"annotations\": {\"Cell_Line\": {\"neural stem cell\": true}, \"Method\": {\"Electrophoretic Mobility Shift Assay\": true, \"Immunofluorescence\": true, \"RNA Interference, siRNA\": true, \"RT-PCR\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"De Filippis D\", \"Esposito G\", \"Iuvone T\", \"Lu J\", \"Savani C\", \"Scuderi C\", \"Sheen V\", \"Steardo L\", \"Steardo L Jr\"], \"date\": \"2008-06-01\", \"first\": \"Esposito G\", \"last\": \"Steardo L\", \"name\": \"Journal of cellular and molecular medicine\", \"pages\": \"914-27\", \"reference\": \"18494933\", \"title\": \"S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells.\", \"type\": \"PubMed\", \"volume\": \"12\"}, \"evidence\": \"In addition, as revealed by Western blot, small interfering RNA and immunofluorescence analysis, S100B-induced JNK activation increased expression of Dickopff-1 that, in turn, promoted glycogen synthase kinase 3-beta phosphorylation and beta-catenin degradation, causing canonical Wnt pathway disruption and tau protein hyperphosphorylation.\", \"key\": \"076a7b245cb524a5362115a7cd09e9ab116d97020e145b2804f4148fbbd7e2fec6c64f1656bcbaba797cc0a4e76b6e40758c350804e8ac794d98c149e54c1070\", \"line\": 670, \"relation\": \"increases\", \"source\": 360, \"target\": 286}, {\"citation\": {\"authors\": [\"Choi H\", \"Gwon Y\", \"Jung YK\", \"Kam TI\", \"Kim C\", \"Kim Y\", \"Koh JY\", \"Park H\"], \"date\": \"2012-06-15\", \"first\": \"Park H\", \"last\": \"Jung YK\", \"name\": \"Human molecular genetics\", \"pages\": \"2725-37\", \"reference\": \"22419736\", \"title\": \"Neuropathogenic role of adenylate kinase-1 in A-mediated tau phosphorylation via AMPK and GSK3.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"The data suggest that the increased expres- sion of AK1 can enhance tau aggregation as well as tau phos- phorylation.\", \"key\": \"f38a076fec72f08a41e3b0def00155dfe6ae0971bd433e50cec0d4bf3c91864fa53a30aefa05048a26b5b69c8f241190fe965b85f53a49f9e6aa195c71794e2e\", \"line\": 121, \"relation\": \"increases\", \"source\": 209, \"target\": 286}, {\"annotations\": {\"Cell_Line\": {\"COS7\": true}, \"Method\": {\"Deglycosylation Assay\": true, \"Dephosphorylation Assay\": true, \"Immunoblotting\": true, \"Immunocytochemistry\": true, \"Phosphorylation Assay\": true, \"Pull-down Assay, His-tagged\": true, \"SDS-PAGE\": true, \"Ubiquitination Assay\": true}}, \"citation\": {\"authors\": [\"Gygi SP\", \"Kosik KS\", \"Schwartz D\", \"Shimura H\"], \"date\": \"2004-02-06\", \"first\": \"Shimura H\", \"last\": \"Kosik KS\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"4869-76\", \"reference\": \"14612456\", \"title\": \"CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival.\", \"type\": \"PubMed\", \"volume\": \"279\"}, \"evidence\": \"These data indicated that phosphorylation of PP2A dephosphorylation sites is an important recognition signal for ubiquitination. We used 200 g of amino-terminal His-tagged full-length recombinant human tau in an in vitro phosphorylation reaction with GSK-3Beta. When phosphorylated, the tau protein reacted on immunoblots with PHF1 (25, 26) and AT8 (24), indicating that at least sites Ser202, Thr205, Ser396, and Ser404 were phosphorylated. Following GSK-3Beta incubation, this tau served as an excellent substrate for in vitro ubiquitination using UbcH5B and the cofactor fraction from AD tau immunoprecipitates (Fig. 2a). This finding suggested that GSK-3Beta can place phosphates on tau that create recognition sites for an E3 Ub ligase.\", \"key\": \"84f4e527cd36927186505451a3a33e4d033f86ac8f4a43d2049f5422b32a88b9bbfa6de8bb8bee44553c925a711c75f98c3faeccd6be2298d624dbca679e7909\", \"line\": 396, \"relation\": \"isA\", \"source\": 306, \"target\": 286}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"d5aa4bb1b39d7e9e51802aad236230175d006b30ef397fed427e0d1bd59db325f0f099843999558a366f0a306490f5c6740d82bd9dacfa83ef9ce8e0a6aafc72\", \"line\": 1130, \"relation\": \"negativeCorrelation\", \"source\": 306, \"target\": 164}, {\"citation\": {\"authors\": [\"El-Akkad E\", \"Gong CX\", \"Grundke-Iqbal I\", \"Iqbal K\", \"Liang Z\", \"Liu F\", \"Shi J\", \"Yin D\"], \"date\": \"2006-11-13\", \"first\": \"Liu F\", \"last\": \"Gong CX\", \"name\": \"FEBS letters\", \"pages\": \"6269-74\", \"reference\": \"17078951\", \"title\": \"PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.\", \"type\": \"PubMed\", \"volume\": \"580\"}, \"evidence\": \"Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.\", \"key\": \"e5b3afafbcd41cc8afaa7bba2a5ef948da4ab2759f54fe92e1e8d10128b4d0bdd5521660ca5a612e004b2f855e6b8cf53704ff5006cbac6ca373ed058d5f0741\", \"line\": 1154, \"relation\": \"partOf\", \"source\": 306, \"target\": 119}, {\"annotations\": {\"Enzyme_Acitvity\": {\"1 U/ml\": true}}, \"citation\": {\"authors\": [\"Bue-Scherrer V\", \"Goedert M\"], \"date\": \"2002-03-27\", \"first\": \"Bue-Scherrer V\", \"last\": \"Goedert M\", \"name\": \"FEBS letters\", \"pages\": \"151-4\", \"reference\": \"11943212\", \"title\": \"Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.\", \"type\": \"PubMed\", \"volume\": \"515\"}, \"evidence\": \"The AD2 epitope, which corresponds to phosphorylated S396 and S404 in tau, was generated most effectively by SAPK3/p38gamma and SAPK4/p38delta\", \"key\": \"6c810eed44d51464e10be75ff7d1b28c137d3a13ef863d9957a22463f9f9307c046e418569f9dcb8578dbdeb1113ee69a04efab7e1e73f2ff771b2d19b74ac01\", \"line\": 1522, \"relation\": \"partOf\", \"source\": 306, \"target\": 183}, {\"citation\": {\"authors\": [\"Lu B\", \"Malenka R\", \"Polepalli J\", \"Rajadas J\", \"Wagh D\", \"Yu W\"], \"date\": \"2012-03-15\", \"first\": \"Yu W\", \"last\": \"Lu B\", \"name\": \"Human molecular genetics\", \"pages\": \"1384-90\", \"reference\": \"22156579\", \"title\": \"A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of A on synapses and dendritic spines.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"We first confirmed that expression of an MKI-GFP fusion protein in rat hippocampal neurons effectively attenuated MARK4-mediated phosphorylation of both endogenous tau (Fig. 3A) and transfected human tau at the 12E8 sites (Fig. 3B). Phosphorylation of tau at the PHF-1 site was also reduced by MKI (Fig. 3A). It is possible that the PHF-1 site is also targeted by PAR-1/MARKs in vivo, or that the phosphorylation of tau at the 12E8 sites is a prerequisite for PHF-1 site phosphorylation, as the 12E8 sites were previously shown to be required for tau phosphorylation at other sites\", \"key\": \"1804f23f7941d5a8d885a25db7dcabe0ba00b433f13549a1c667538b01c6fb00bbaa8423cb18fd61da22fff86d88b3ffd77c8e7000c6c71b801a9bf599a00174\", \"line\": 1807, \"relation\": \"positiveCorrelation\", \"source\": 306, \"target\": 45}, {\"annotations\": {\"TextLocation\": {\"Results\": true}}, \"citation\": {\"authors\": [\"Arnal I\", \"Borel E\", \"Buisson A\", \"De Seranno S\", \"Elie A\", \"Frandemiche ML\", \"Lant F\", \"Rush T\"], \"date\": \"2014-04-23\", \"first\": \"Frandemiche ML\", \"last\": \"Buisson A\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"6084-97\", \"reference\": \"24760868\", \"title\": \"Activity-dependent tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-beta oligomers.\", \"type\": \"PubMed\", \"volume\": \"34\"}, \"evidence\": \"We observed that synaptic activation promoted EGFP-Tau T205A translocation to the spine but FRAP experiments revealed a shorter tau turnover time in the spine (Fig. 9B), whereas Abetao driven translocation to the spine was no longer observable in EGFP-Tau S404A-transfected neurons (Fig. 9F,G). These experiments highlight the pivotal role of these phosphorylations in tau translocation features to the spine.\", \"key\": \"abf8989fcdaf455dbd4cd703eafd68bf86dfe5b90d38d7ce477811bf7f75119c6e0d8592c3b75b346989b179325621e6b4283037355529526f3b3169b20f49de\", \"line\": 324, \"object\": {\"location\": {\"name\": \"Dendritic Spines\", \"namespace\": \"MESH\"}}, \"relation\": \"increases\", \"source\": 306, \"target\": 244}, {\"annotations\": {\"Method\": {\"Immunocytochemistry\": true, \"RNA Interference, siRNA\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"Lawson LY\", \"Li Q\", \"O'Leary JC 3rd\", \"Trotter JH\", \"Vestal GD\", \"Weeber EJ\"], \"date\": \"2011-05-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"16976-83\", \"reference\": \"21367866\", \"title\": \"The Hsp90 kinase co-chaperone Cdc37 regulates tau stability and phosphorylation dynamics.\", \"type\": \"PubMed\", \"volume\": \"286\"}, \"evidence\": \"Quantification of the Western blot showed that Cdc37 knockdown reduced phospho-Thr-231, phospho-Ser-199/Ser-202, phospho-Ser-396/Ser-404, and phospho-Ser-262/Ser-356 tau.\", \"key\": \"ef124475e6498bbbb2f43007093262257eeee9a19319d256bdec3ecf3efc78d340ddc293b97989e9e6d4912045a1d34c18ba99e67729426343666e9a56134141\", \"line\": 634, \"relation\": \"positiveCorrelation\", \"source\": 306, \"target\": 214}, {\"annotations\": {\"CellLine\": {\"HEK293\": true}, \"MeSHAnatomy\": {\"Hippocampus\": true}, \"Method\": {\"Degradation Assay, 20S Proteasomal\": true, \"Immunohistochemistry\": true, \"Immunoprecipitation\": true, \"Pull-down Assay, GST\": true, \"SDS-PAGE\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Elliott E\", \"Ginzburg I\", \"Tsvetkov P\"], \"date\": \"2007-12-21\", \"first\": \"Elliott E\", \"last\": \"Ginzburg I\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"37276-84\", \"reference\": \"17954934\", \"title\": \"BAG-1 associates with Hsc70.Tau complex and regulates the proteasomal degradation of Tau protein.\", \"type\": \"PubMed\", \"volume\": \"282\"}, \"evidence\": \"We further show that BAG-1 can inhibit the degradation of Tau protein by the 20 S proteasome but does not affect the ubiquitination of Tau protein.RNA-me- diated interference depletion of BAG-1 leads to a decrease in total Tau protein levels as well as promoting hyperphosphorylation of the remaining protein.\", \"key\": \"99125755aa5ed06a0d8d8a416954f5b21ddef484658da6d111d0965d411933824dc6e34a2dbe1c120a6d79c8ab1c8309ed63c469e371efbf2287657f1d616a6f\", \"line\": 432, \"relation\": \"negativeCorrelation\", \"source\": 210, \"target\": 286}, {\"citation\": {\"authors\": [\"Dorval V\", \"Fraser PE\"], \"date\": \"2006-04-14\", \"first\": \"Dorval V\", \"last\": \"Fraser PE\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"9919-24\", \"reference\": \"16464864\", \"title\": \"Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein.\", \"type\": \"PubMed\", \"volume\": \"281\"}, \"evidence\": \"Both brain proteins were preferentially modified by SUMO1, as compared with SUMO2 or SUMO3. Tau contains two SUMO consensus sequences with Lys(340) as the major sumoylation site. Although both tau and alpha-synuclein are targets for proteasomal degradation, only tau sumoylation was affected by inhibitors of the proteasome pathway. Treatment with the phosphatase inhibitor, okadaic acid, or the microtubule depolymerizing drug, colchicine, up-regulated tau sumoylation.\", \"key\": \"494845cb74a7c93eb8172030ca31e54520cff10c07e0a2f51d6dd20d03c9803aa7172e258cef94c7fcb23f1ad458588fa2985c49b2ff6bba780473eb9e29b38f\", \"line\": 3716, \"relation\": \"increases\", \"source\": 20, \"target\": 322}, {\"citation\": {\"authors\": [\"Dorval V\", \"Fraser PE\"], \"date\": \"2006-04-14\", \"first\": \"Dorval V\", \"last\": \"Fraser PE\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"9919-24\", \"reference\": \"16464864\", \"title\": \"Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein.\", \"type\": \"PubMed\", \"volume\": \"281\"}, \"evidence\": \"Both brain proteins were preferentially modified by SUMO1, as compared with SUMO2 or SUMO3. Tau contains two SUMO consensus sequences with Lys(340) as the major sumoylation site. Although both tau and alpha-synuclein are targets for proteasomal degradation, only tau sumoylation was affected by inhibitors of the proteasome pathway. Treatment with the phosphatase inhibitor, okadaic acid, or the microtubule depolymerizing drug, colchicine, up-regulated tau sumoylation.\", \"key\": \"9c9b2e1c2885110f43fad8aea98d3e0df99c3fd43683ff4c12a41e54fbefd6b24ddc59d153f4160d70c0960acea8dff71bc4fbbe44908b0044059aced0626559\", \"line\": 3713, \"relation\": \"increases\", \"source\": 365, \"target\": 322}, {\"key\": \"09c016d301aee387b70cc05a8cdeecfd924cdf428c14695b747e55ece45ec37885bfc1e5295c44a7ddc272733b430802989eac8cd212cb8759ea54bcdb5464f7\", \"relation\": \"hasComponent\", \"source\": 117, \"target\": 290}, {\"annotations\": {\"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Ait-Ghezala G\", \"Bachmeier C\", \"Beaulieu-Abdelahad D\", \"Crawford F\", \"Jin C\", \"Laco G\", \"Lin Y\", \"Mullan M\", \"Paris D\"], \"date\": \"2014-12-05\", \"first\": \"Paris D\", \"last\": \"Mullan M\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"33927-44\", \"reference\": \"25331948\", \"title\": \"The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid- production and Tau hyperphosphorylation.\", \"type\": \"PubMed\", \"volume\": \"289\"}, \"evidence\": \"We further validated Syk as a target-regulating A by showing that pharmacological inhibition of Syk or down-regulation of Syk expression reduces A production and increases the clearance of A across the BBB mimicking (-)-nilvadipine effects. Moreover, treatment of transgenic mice overexpressing A and transgenic Tau P301S mice with a selective Syk inhibitor respectively decreased brain A accumulation and Tau hyperphosphorylation at multiple AD relevant epitopes.\", \"key\": \"da85c8849c7539aa5ca766f90dfcb313266ef0f5be9c26a05ac7c45b729dd3cd597b50b3217b4228fa78178043f3a9eb4c2d4fee5fe67146148f38519e818a14\", \"line\": 2264, \"relation\": \"equivalentTo\", \"source\": 44, \"target\": 290}, {\"citation\": {\"authors\": [\"Gamblin TC\", \"Sun Q\"], \"date\": \"2009-06-30\", \"first\": \"Sun Q\", \"last\": \"Gamblin TC\", \"name\": \"Biochemistry\", \"pages\": \"6002-11\", \"reference\": \"19459590\", \"title\": \"Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization.\", \"type\": \"PubMed\", \"volume\": \"48\"}, \"evidence\": \"Because S199/S202/T205E, S396/S404E, 6-Phos and 7-Phos all demonstrated an AD-like shift in mobility as a result of phosphorylation-like changes, we conclude that they have the characteristics of hyperphosphorylated tau. These mutants will therefore be referred to as pseudo-hyperphosphorylated tau throughout the manuscript. On the basis of the observations that pseudohyperphosphorylated tau has decreased affinity for microtubules and reduced inducer-initiated rates of nucleation and polymerization, we propose that this combination could be the cause of the increased cytotoxicity of hyperphosphorylated tau in Alzheimer's disease and also explain the potentially beneficial role of tau polymerization and NFT formation.\", \"key\": \"03309c5ce3bbfb4809fc4c888c2a1c33f32708df1ca79e6def9f8240919e159ee9bbbbc33253b01804696aa7632ac86ffac166538e618c58ab5e76bfa4c58db2\", \"line\": 2468, \"relation\": \"equivalentTo\", \"source\": 188, \"target\": 290}, {\"citation\": {\"authors\": [\"Cohen TJ\", \"Madden V\", \"Tripathy A\", \"Trzeciakiewicz H\", \"Tseng JH\", \"Wander CM\", \"Yuan CX\"], \"date\": \"2017-03-13\", \"first\": \"Trzeciakiewicz H\", \"last\": \"Cohen TJ\", \"name\": \"Scientific reports\", \"pages\": \"44102\", \"reference\": \"28287136\", \"title\": \"A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Surprisingly, we show that tau acetylation alters phosphorylation at residues S202/T205 (comprising the AT8 epitope), indicating acetylation-dephosphorylation cross-talk. Using a series of biochemical approaches, we found that K280/K281 acetylation impaired tau-mediated MT assembly function and also significantly enhanced tau aggregation. We also demonstrate that methylene blue, a reported tau aggregation inhibitor, modulates tau acetylation, a novel mechanism of action for this class of compounds\", \"key\": \"25dae601a845d61800e78d7396f77167ef49cdee627242aa9a4464f1f9e9adebb8385bf07f74386dfbc2e2c8a7e24b645da7ca81e735d765987afb38de639a33\", \"line\": 3136, \"relation\": \"decreases\", \"source\": 256, \"target\": 290}, {\"citation\": {\"authors\": [\"Burlingame AL\", \"Ioanoviciu A\", \"Knudsen GM\", \"Maeda S\", \"Morris M\", \"Mucke L\", \"Trinidad JC\"], \"date\": \"2015-08-01\", \"first\": \"Morris M\", \"last\": \"Mucke L\", \"name\": \"Nature neuroscience\", \"pages\": \"1183-9\", \"reference\": \"26192747\", \"title\": \"Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"18\"}, \"evidence\": \"Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.\", \"key\": \"07cf63a9c481a8f597999b52eee7f93779ef73b99916e6798faecf91b759cd267d72f3efdd017b1943e5ab302483183fa215408c3ca821d49ba23c8c70b74b23\", \"line\": 3219, \"relation\": \"isA\", \"source\": 256, \"target\": 247}, {\"annotations\": {\"Species\": {\"7227\": true}}, \"citation\": {\"authors\": [\"Burnouf S\", \"Dols J\", \"Gorsky MK\", \"Mandelkow E\", \"Partridge L\"], \"date\": \"2016-03-04\", \"first\": \"Gorsky MK\", \"last\": \"Partridge L\", \"name\": \"Scientific reports\", \"pages\": \"22685\", \"reference\": \"26940749\", \"title\": \"Acetylation mimic of lysine 280 exacerbates human Tau neurotoxicity in vivo.\", \"type\": \"PubMed\", \"volume\": \"6\"}, \"evidence\": \"hTau-K280Q mutants showed significantly increased phosphorylation on S262 as compared to both hTau-wt and hTau-K280R flies, when normalised to total hTau (K9JA) levels (**p<0.01, one-way ANOVA, Fig. 4b,c). Mis-expression of pseudo-acetylated K280Q-hTau in the adult fly nervous system potently exacerbated fly locomotion defects and photoreceptor neurodegeneration.\", \"key\": \"d2cb24163a5d213c8f01aa70207270f04a0a3b8e3596f4a1398aca6b401ef465e0a3a6815078389b35e3b50970ffd29c1fab1771b6681cb881004cdb9a9b1426\", \"line\": 3189, \"relation\": \"increases\", \"source\": 256, \"target\": 297}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Depending on the sites, the acetylation of tau could inhibit its degradation (for example, when at Lys163, Lys280, Lys281 or Lys369) or, by contrast, facilitate its degradation and suppress its phosphorylation and aggregation (for example, when at Lys259, Lys290, Lys321 or Lys353)\", \"key\": \"342153dfcee0e4ca8edf0cdb5d33bbb9823355c68e841463550648e1dfdfaf7577c56a044f282b5ac4daaa271e7219bfd1f1e2ccc8d29f63b45b710c3a9f0d7c\", \"line\": 264, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"decreases\", \"source\": 256, \"target\": 256}, {\"annotations\": {\"Braak_Stage\": {\"Stage I\": true}, \"MeSHDisease\": {\"Alzheimer Disease\": true}}, \"citation\": {\"authors\": [\"Lucke-Wold B\", \"Nolan R\", \"Omalu B\", \"Ornstein M\", \"Rosen C\", \"Ross J\", \"Seidel K\", \"Udo R\"], \"date\": \"2017-01-01\", \"first\": \"Lucke-Wold B\", \"last\": \"Ross J\", \"name\": \"Journal of neurology and neurosurgery\", \"reference\": \"29276758\", \"title\": \"Role of Tau Acetylation in Alzheimer's Disease and Chronic Traumatic Encephalopathy: The Way Forward for Successful Treatment.\", \"type\": \"PubMed\", \"volume\": \"4\"}, \"evidence\": \"We also tested for ac-tau 280 in early stage Alzheimer's disease (Braak stage 1). Histopathological examination using the ac tau 280 antibody was performed in three Alzheimer's cases and three CTE patients. Presence of ac-tau 280 was confirmed in all cases at early sites of disease manifestation. These findings suggest that tau acetylation may precede tau phosphorylation and could be the first \", \"key\": \"40530defa28d13bb1b7923fec6c09ea16513a1301044fac43f511b84c517daf05b1c4a5cd927bb946c648e0647962612d41ea71b3aff409d9986301f6c373d4b\", \"line\": 3073, \"relation\": \"decreases\", \"source\": 256, \"target\": 72}, {\"annotations\": {\"Species\": {\"7227\": true}}, \"citation\": {\"authors\": [\"Augustin H\", \"Burnouf S\", \"Dols J\", \"Gorsky MK\", \"Grnke S\", \"Partridge L\", \"Sofola-Adesakin O\", \"Weigelt CM\"], \"date\": \"2017-08-30\", \"first\": \"Gorsky MK\", \"last\": \"Partridge L\", \"name\": \"Scientific reports\", \"pages\": \"9984\", \"reference\": \"28855586\", \"title\": \"Pseudo-acetylation of multiple sites on human Tau proteins alters Tau phosphorylation and microtubule binding, and ameliorates amyloid beta toxicity.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"We have used a knock-out/knock-in strategy in Drosophila to generate a strain with hTau inserted into the endogenous fly tau locus and expressed under the control of the endogenous fly tau promoter, thus avoiding potential toxicity due to genetic over-expression. hTau knock-in (KI) proteins were expressed at normal, endogenous levels, bound to fly microtubules and were post-translationally modified, hence displaying physiological properties. We used this new model to investigate the effects of acetylation on hTau toxicity in vivo. The simultaneous pseudo-acetylation of hTau at lysines 163, 280, 281 and 369 drastically decreased hTau phosphorylation and significantly reduced its binding to microtubules in vivo. These molecular alterations were associated with ameliorated amyloid beta toxicity. Our results indicate acetylation of hTau on multiple sites regulates its biology and ameliorates amyloid beta toxicity in vivo.\", \"key\": \"7884ce5b5efde416b89ab5d1dcca059f9cafa981b00c94fa8b91f5a42ca168f3147285193c8f79d6ac486ea74493b9002e55e7fd62a931a36ca9acf0f3a5b3c6\", \"line\": 3123, \"relation\": \"association\", \"source\": 256, \"target\": 152}, {\"citation\": {\"authors\": [\"Cohen TJ\", \"Madden V\", \"Tripathy A\", \"Trzeciakiewicz H\", \"Tseng JH\", \"Wander CM\", \"Yuan CX\"], \"date\": \"2017-03-13\", \"first\": \"Trzeciakiewicz H\", \"last\": \"Cohen TJ\", \"name\": \"Scientific reports\", \"pages\": \"44102\", \"reference\": \"28287136\", \"title\": \"A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Surprisingly, we show that tau acetylation alters phosphorylation at residues S202/T205 (comprising the AT8 epitope), indicating acetylation-dephosphorylation cross-talk. Using a series of biochemical approaches, we found that K280/K281 acetylation impaired tau-mediated MT assembly function and also significantly enhanced tau aggregation. We also demonstrate that methylene blue, a reported tau aggregation inhibitor, modulates tau acetylation, a novel mechanism of action for this class of compounds\", \"key\": \"5108ef103f969f531136c9c1afb4dc219dc1755fc3a0b423948a7c538912d4e95239f2ef564639f2d82f730b9273b2fdd19312d4c929b8ca3cb3206cb986fd2d\", \"line\": 3138, \"relation\": \"increases\", \"source\": 256, \"target\": 39}, {\"citation\": {\"authors\": [\"Cohen TJ\", \"Madden V\", \"Tripathy A\", \"Trzeciakiewicz H\", \"Tseng JH\", \"Wander CM\", \"Yuan CX\"], \"date\": \"2017-03-13\", \"first\": \"Trzeciakiewicz H\", \"last\": \"Cohen TJ\", \"name\": \"Scientific reports\", \"pages\": \"44102\", \"reference\": \"28287136\", \"title\": \"A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"Surprisingly, we show that tau acetylation alters phosphorylation at residues S202/T205 (comprising the AT8 epitope), indicating acetylation-dephosphorylation cross-talk. Using a series of biochemical approaches, we found that K280/K281 acetylation impaired tau-mediated MT assembly function and also significantly enhanced tau aggregation. We also demonstrate that methylene blue, a reported tau aggregation inhibitor, modulates tau acetylation, a novel mechanism of action for this class of compounds\", \"key\": \"d6734aa0dff91715586ab3649af2076abf03ace8480a38d40d714801852c25039d5df7e27be8f33e57f5bfd291497ca3b5ace0ac5180ed4304a0cc2f280623ea\", \"line\": 3141, \"relation\": \"partOf\", \"source\": 256, \"target\": 191}, {\"annotations\": {\"Species\": {\"7227\": true}}, \"citation\": {\"authors\": [\"Burnouf S\", \"Dols J\", \"Gorsky MK\", \"Mandelkow E\", \"Partridge L\"], \"date\": \"2016-03-04\", \"first\": \"Gorsky MK\", \"last\": \"Partridge L\", \"name\": \"Scientific reports\", \"pages\": \"22685\", \"reference\": \"26940749\", \"title\": \"Acetylation mimic of lysine 280 exacerbates human Tau neurotoxicity in vivo.\", \"type\": \"PubMed\", \"volume\": \"6\"}, \"evidence\": \"hTau-K280Q mutants showed significantly increased phosphorylation on S262 as compared to both hTau-wt and hTau-K280R flies, when normalised to total hTau (K9JA) levels (**p<0.01, one-way ANOVA, Fig. 4b,c). Mis-expression of pseudo-acetylated K280Q-hTau in the adult fly nervous system potently exacerbated fly locomotion defects and photoreceptor neurodegeneration.\", \"key\": \"245b9b5d92129f174d8d3961f05b2217331007bb958964daa5e4ca80daf18939912205600759d42d7387b7564654b23adadbb7898e816f75d0644ea03e1a445e\", \"line\": 3190, \"relation\": \"increases\", \"source\": 256, \"target\": 62}, {\"citation\": {\"authors\": [\"Burlingame AL\", \"Ioanoviciu A\", \"Knudsen GM\", \"Maeda S\", \"Morris M\", \"Mucke L\", \"Trinidad JC\"], \"date\": \"2015-08-01\", \"first\": \"Morris M\", \"last\": \"Mucke L\", \"name\": \"Nature neuroscience\", \"pages\": \"1183-9\", \"reference\": \"26192747\", \"title\": \"Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"18\"}, \"evidence\": \"Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.\", \"key\": \"3ebe3353da84002c3af1f0a675cb56b1b3a1a175e381ba8611f953d2f883860a01aa5e22f22eecf6a84cd05cd6a19b75ad3103c90bf195824328399b01d6b9fd\", \"line\": 3229, \"relation\": \"partOf\", \"source\": 256, \"target\": 55}, {\"annotations\": {\"Anatomy\": {\"CA1 field of hippocampus\": true, \"CA3 field of hippocampus\": true, \"cerebral cortex\": true, \"dentate gyrus granule cell layer\": true}, \"Research_Model\": {\"hTau E391 transgenic mice\": true}, \"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Kraemer BC\", \"Leverenz JB\", \"McMillan PJ\", \"Raskind M\", \"Robinson L\", \"Schellenberg G\"], \"date\": \"2011-11-01\", \"first\": \"McMillan PJ\", \"last\": \"Schellenberg G\", \"name\": \"Journal of neuropathology and experimental neurology\", \"pages\": \"1006-19\", \"reference\": \"22002427\", \"title\": \"Truncation of tau at E391 promotes early pathologic changes in transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"70\"}, \"evidence\": \"E391-3610 mice (higher expressers) exhibit robust somatodendritic distribution of phospho- Ser 202/Thr 205 tau throughout the cortex, in hippocampal CA3 pyramidal neurons, CA1 apical dendrites and cell bodies and dentate granule cells.\", \"key\": \"f4f54bdd83c2bf669bab3c5bcb40562447da359a76f0b3e11a3fed00cbd97b0348f43aae3c205632817470aad9c9471416cece5bc8a8d854bb22d862d44368d3\", \"line\": 2578, \"relation\": \"positiveCorrelation\", \"source\": 327, \"target\": 290}, {\"annotations\": {\"MeSHAnatomy\": {\"Dendrites\": true}}, \"citation\": {\"authors\": [\"Balaji V\", \"Kaniyappan S\", \"Mandelkow E\", \"Mandelkow EM\", \"Wang Y\"], \"date\": \"2018-01-01\", \"first\": \"Balaji V\", \"last\": \"Mandelkow EM\", \"name\": \"Autophagy\", \"pages\": \"2139-2154\", \"reference\": \"30145931\", \"title\": \"Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \" Thus, the dendritic and axonal MAPT are differentially phosphorylated. Based on this observation, we can conclude that the dendritic MAPT degraded by autophagy or proteasomal pathways is phosphorylated mainly at the 12E8 site. \", \"key\": \"308f21cb67c5dfe8800cd7766461cce10552aabd3307100dd819935a9f139b83b15a039e679e11fac34112073ede06d6ca971194e40343eedcab08ff5b0316ad\", \"line\": 173, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 172, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 303}, {\"annotations\": {\"MeSHAnatomy\": {\"Dendrites\": true}}, \"citation\": {\"authors\": [\"Balaji V\", \"Kaniyappan S\", \"Mandelkow E\", \"Mandelkow EM\", \"Wang Y\"], \"date\": \"2018-01-01\", \"first\": \"Balaji V\", \"last\": \"Mandelkow EM\", \"name\": \"Autophagy\", \"pages\": \"2139-2154\", \"reference\": \"30145931\", \"title\": \"Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \" Thus, the dendritic and axonal MAPT are differentially phosphorylated. Based on this observation, we can conclude that the dendritic MAPT degraded by autophagy or proteasomal pathways is phosphorylated mainly at the 12E8 site. \", \"key\": \"1805698e74840e8def6c27d9e421dd9387add4e9b1a2f169cdf0514c5cc0756609f2a6d6c31e60bd9a99cbaceca41372d8ff066d6d63528c228574190ccff3fc\", \"line\": 172, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"increases\", \"source\": 172, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 297}, {\"annotations\": {\"MeSHAnatomy\": {\"Dendrites\": true}}, \"citation\": {\"authors\": [\"Balaji V\", \"Kaniyappan S\", \"Mandelkow E\", \"Mandelkow EM\", \"Wang Y\"], \"date\": \"2018-01-01\", \"first\": \"Balaji V\", \"last\": \"Mandelkow EM\", \"name\": \"Autophagy\", \"pages\": \"2139-2154\", \"reference\": \"30145931\", \"title\": \"Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \"In addition, it has been reported that in cultured neurons, A oligomers induce MAPT missorting into the somatodendritic compartment, and the missorted MAPT is phosphorylated mainly at the 12E8 (p-S262/p-S356) and AT8 (p-S202/p-T205) sites [6].\", \"key\": \"ff4e70aafdd359798d083f88e4e6de728b57b4def6bffaeb837d9540d4781d78dfb937572b9bf2d3d9f7cf1fa92ce617fc267ddceef4e93aecbe4c504402d64e\", \"line\": 145, \"relation\": \"positiveCorrelation\", \"source\": 303, \"target\": 52}, {\"annotations\": {\"MeSHAnatomy\": {\"Dendrites\": true}}, \"citation\": {\"authors\": [\"Balaji V\", \"Kaniyappan S\", \"Mandelkow E\", \"Mandelkow EM\", \"Wang Y\"], \"date\": \"2018-01-01\", \"first\": \"Balaji V\", \"last\": \"Mandelkow EM\", \"name\": \"Autophagy\", \"pages\": \"2139-2154\", \"reference\": \"30145931\", \"title\": \"Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \" Missorted dendritic MAPT showed phosphorylation mainly at the 12E8 sites upon treatment with either the autophagy inhibitor wortmannin (Fig. 4B; 57.29.4% dendrites) or the proteasomal inhibitor epoxomicin (Fig. 4C, 62.97.4% dendrites) (Fig. 4A-C, quantification in Fig. 4D), but not at the AT8 and the PHF1 (p-S396/p-S404) sites (Fig. S5, Fig 4D).\", \"key\": \"1814799e5ed2692342cca178fbbbce49278d71aed3ecff33f77e7ae87536a91cf3ec9986b9531acd8a44594c7b57e87911d0890a2e7d9439355309ff171f373b\", \"line\": 157, \"relation\": \"positiveCorrelation\", \"source\": 303, \"target\": 34}, {\"annotations\": {\"MeSHAnatomy\": {\"Dendrites\": true}}, \"citation\": {\"authors\": [\"Balaji V\", \"Kaniyappan S\", \"Mandelkow E\", \"Mandelkow EM\", \"Wang Y\"], \"date\": \"2018-01-01\", \"first\": \"Balaji V\", \"last\": \"Mandelkow EM\", \"name\": \"Autophagy\", \"pages\": \"2139-2154\", \"reference\": \"30145931\", \"title\": \"Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \" Missorted dendritic MAPT showed phosphorylation mainly at the 12E8 sites upon treatment with either the autophagy inhibitor wortmannin (Fig. 4B; 57.29.4% dendrites) or the proteasomal inhibitor epoxomicin (Fig. 4C, 62.97.4% dendrites) (Fig. 4A-C, quantification in Fig. 4D), but not at the AT8 and the PHF1 (p-S396/p-S404) sites (Fig. S5, Fig 4D).\", \"key\": \"d36e1a562cdc9b366edaa20e1de36fb51e9d3eb54805772b65d76a4cfe062884a65b259d879198b795e2e3a47fc38b28960bb1df7a536e3df9d8eb07ac257658\", \"line\": 159, \"relation\": \"positiveCorrelation\", \"source\": 303, \"target\": 21}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Cabrales Fontela Y\", \"Kadavath H\", \"Mandelkow E\", \"Riedel D\", \"Zweckstetter M\"], \"date\": \"2017-12-07\", \"first\": \"Cabrales Fontela Y\", \"last\": \"Zweckstetter M\", \"name\": \"Nature communications\", \"pages\": \"1981\", \"reference\": \"29215007\", \"title\": \"Multivalent cross-linking of actin filaments and microtubules through the microtubule-associated protein Tau.\", \"type\": \"PubMed\", \"volume\": \"8\"}, \"evidence\": \"The NMR experiments demonstrate that MARK2- phosphorylation of Tau attenuates its binding to F-actin. Consistent with a reduced affinity, MARK2-phosphorylated Tau failed in bundling actin filaments (Fig. 4e)\", \"key\": \"a0053cb80de77ce914139a8b09a3844248bcf6bc26af50b6f29fc6f88f05aaf27fa27476e07a5b7721b59089ba58bb5436f6ea4b9760ca3beb7cd13fed687c67\", \"line\": 266, \"relation\": \"decreases\", \"source\": 303, \"target\": 107}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Cabrales Fontela Y\", \"Kadavath H\", \"Mandelkow E\", \"Riedel D\", \"Zweckstetter M\"], \"date\": \"2017-12-07\", \"first\": \"Cabrales Fontela Y\", \"last\": \"Zweckstetter M\", \"name\": \"Nature communications\", \"pages\": \"1981\", \"reference\": \"29215007\", \"title\": \"Multivalent cross-linking of actin filaments and microtubules through the microtubule-associated protein Tau.\", \"type\": \"PubMed\", \"volume\": \"8\"}, \"evidence\": \"The NMR experiments demonstrate that MARK2- phosphorylation of Tau attenuates its binding to F-actin. Consistent with a reduced affinity, MARK2-phosphorylated Tau failed in bundling actin filaments (Fig. 4e)\", \"key\": \"2359a3bdb19dd623bdbfeea6d2fa832465bb2fbeb86f76b47788d8921d9e67040c0d2b3ce64d601b27f1035090e3603740a640615debd977bc3159d21e465e19\", \"line\": 272, \"relation\": \"decreases\", \"source\": 303, \"target\": 75}, {\"annotations\": {\"Anatomy\": {\"brain\": true}, \"Species\": {\"9606\": true}, \"TauIsoform\": {\"Isoform F (441 aa)\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"von Bergen M\"], \"date\": \"2007-01-01\", \"first\": \"Mandelkow E\", \"last\": \"Mandelkow EM\", \"name\": \"Brain pathology (Zurich, Switzerland)\", \"pages\": \"83-90\", \"reference\": \"17493042\", \"title\": \"Structural principles of tau and the paired helical filaments of Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"The lysine-isoleucine-glycineserine motif (KIGS) or lysine-cysteineglycine-serine motif (KCGS) motifs in the repeat domain (S262, S293, S324, S356) can be phosphorylated by MARK, PKA, SAD kinases, CaMKII and p70S6K, which strongly reduces the tau microtubule interactions (36, 74, 96), [note that phosphorylation at these sites also inhibits tau aggregation, illustrating an analogous role for the repeat domain in the physiological and pathological functions of tau (106)].\", \"key\": \"4e9841fc60f55fa5ecd39426a5f409444ed2974003d6b3da2eb062a360fa09e2257c6bdd1e8f70b2c55706664df00b1d66450e8179f00ed18d6dd5c3f7fa3cbb\", \"line\": 156, \"relation\": \"decreases\", \"source\": 303, \"target\": 137}, {\"annotations\": {\"Anatomy\": {\"brain\": true}, \"Species\": {\"9606\": true}, \"TauIsoform\": {\"Isoform F (441 aa)\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"von Bergen M\"], \"date\": \"2007-01-01\", \"first\": \"Mandelkow E\", \"last\": \"Mandelkow EM\", \"name\": \"Brain pathology (Zurich, Switzerland)\", \"pages\": \"83-90\", \"reference\": \"17493042\", \"title\": \"Structural principles of tau and the paired helical filaments of Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"The lysine-isoleucine-glycineserine motif (KIGS) or lysine-cysteineglycine-serine motif (KCGS) motifs in the repeat domain (S262, S293, S324, S356) can be phosphorylated by MARK, PKA, SAD kinases, CaMKII and p70S6K, which strongly reduces the tau microtubule interactions (36, 74, 96), [note that phosphorylation at these sites also inhibits tau aggregation, illustrating an analogous role for the repeat domain in the physiological and pathological functions of tau (106)].\", \"key\": \"01364aef29fafc48a9b88808551dd3b1132e35f01983c0c696bb59e83b97a8f5888954602ed692e81d6bbea746a7d3efb74beb4c4176f4aebbe2f74d316896bc\", \"line\": 161, \"relation\": \"decreases\", \"source\": 303, \"target\": 86}, {\"annotations\": {\"Tau_Motif\": {\"KXGS\": true}}, \"citation\": {\"authors\": [\"Lu B\", \"Malenka R\", \"Polepalli J\", \"Rajadas J\", \"Wagh D\", \"Yu W\"], \"date\": \"2012-03-15\", \"first\": \"Yu W\", \"last\": \"Lu B\", \"name\": \"Human molecular genetics\", \"pages\": \"1384-90\", \"reference\": \"22156579\", \"title\": \"A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of A on synapses and dendritic spines.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"We first confirmed that expression of an MKI-GFP fusion protein in rat hippocampal neurons effectively attenuated MARK4-mediated phosphorylation of both endogenous tau (Fig. 3A) and transfected human tau at the 12E8 sites (Fig. 3B). Phosphorylation of tau at the PHF-1 site was also reduced by MKI (Fig. 3A). It is possible that the PHF-1 site is also targeted by PAR-1/MARKs in vivo, or that the phosphorylation of tau at the 12E8 sites is a prerequisite for PHF-1 site phosphorylation, as the 12E8 sites were previously shown to be required for tau phosphorylation at other sites\", \"key\": \"13d8c8174c6b7d2b0ac645866ce644d327470232d7dce67043a648ed1da85162e498f9f42f21cb97920a1efa9e685c359cae53992a9b9de71d0e3002aad13f69\", \"line\": 1801, \"object\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"relation\": \"positiveCorrelation\", \"source\": 303, \"target\": 198}, {\"annotations\": {\"Tau_Motif\": {\"KXGS\": true}}, \"citation\": {\"authors\": [\"Lu B\", \"Malenka R\", \"Polepalli J\", \"Rajadas J\", \"Wagh D\", \"Yu W\"], \"date\": \"2012-03-15\", \"first\": \"Yu W\", \"last\": \"Lu B\", \"name\": \"Human molecular genetics\", \"pages\": \"1384-90\", \"reference\": \"22156579\", \"title\": \"A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of A on synapses and dendritic spines.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"We first confirmed that expression of an MKI-GFP fusion protein in rat hippocampal neurons effectively attenuated MARK4-mediated phosphorylation of both endogenous tau (Fig. 3A) and transfected human tau at the 12E8 sites (Fig. 3B). Phosphorylation of tau at the PHF-1 site was also reduced by MKI (Fig. 3A). It is possible that the PHF-1 site is also targeted by PAR-1/MARKs in vivo, or that the phosphorylation of tau at the 12E8 sites is a prerequisite for PHF-1 site phosphorylation, as the 12E8 sites were previously shown to be required for tau phosphorylation at other sites\", \"key\": \"02db8be044b823652c2745808d0fd1d1e1a6fdd3bdf6908ffd1fda88e3ddad0b00b96a5f6bca434dfc6379f47d39405d0354e1419ee3594d8dd8770a033d52fc\", \"line\": 1803, \"relation\": \"partOf\", \"source\": 303, \"target\": 42}, {\"annotations\": {\"Research_Model\": {\"rTg4510 mice\": true}}, \"citation\": {\"authors\": [\"Boehm J\", \"Bourgeois C\", \"Dudilot A\", \"Lauzon M\", \"Leclerc N\", \"Mondragn-Rodrguez S\", \"Trillaud-Doppia E\"], \"date\": \"2012-09-14\", \"first\": \"Mondragn-Rodrguez S\", \"last\": \"Boehm J\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"32040-53\", \"reference\": \"22833681\", \"title\": \"Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.\", \"type\": \"PubMed\", \"volume\": \"287\"}, \"evidence\": \"Acute treatment of rTg4510 mice with an O-GlcNAcase inhibitor transiently reduced tau phosphorylation at epitopes implicated in tau pathology. More importantly, long-term inhibitor treatment strongly increased tau O-GlcNAcylation, reduced the number of dystrophic neurons, and protected against the formation of pathological tau species without altering the phosphorylation of non-pathological tau.\", \"key\": \"8704fdf47e89d1ed04e144341ed955b80affd57d5cf583ed51fe4fe92bb5fb896a93d8e9fe8377963971650a86fb221e97a049a3098989246ca4ffe04d3aa9b1\", \"line\": 2509, \"relation\": \"positiveCorrelation\", \"source\": 303, \"target\": 272}, {\"annotations\": {\"Method\": {\"Immunocytochemistry\": true, \"RNA Interference, siRNA\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"Lawson LY\", \"Li Q\", \"O'Leary JC 3rd\", \"Trotter JH\", \"Vestal GD\", \"Weeber EJ\"], \"date\": \"2011-05-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"16976-83\", \"reference\": \"21367866\", \"title\": \"The Hsp90 kinase co-chaperone Cdc37 regulates tau stability and phosphorylation dynamics.\", \"type\": \"PubMed\", \"volume\": \"286\"}, \"evidence\": \"Quantification of the Western blot showed that Cdc37 knockdown reduced phospho-Thr-231, phospho-Ser-199/Ser-202, phospho-Ser-396/Ser-404, and phospho-Ser-262/Ser-356 tau.\", \"key\": \"45adeea9285acb82d47d3ab023f6646b3b306dbdf509e9c79b524c8b0b4afbcbc3afb5f6e8a3215daf7bc480bc10d795bf77f7063f56616b683dcd5608ae9dc7\", \"line\": 636, \"relation\": \"positiveCorrelation\", \"source\": 303, \"target\": 214}, {\"annotations\": {\"Tau_Motif\": {\"KXGS\": true}}, \"citation\": {\"authors\": [\"Lu B\", \"Malenka R\", \"Polepalli J\", \"Rajadas J\", \"Wagh D\", \"Yu W\"], \"date\": \"2012-03-15\", \"first\": \"Yu W\", \"last\": \"Lu B\", \"name\": \"Human molecular genetics\", \"pages\": \"1384-90\", \"reference\": \"22156579\", \"title\": \"A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of A on synapses and dendritic spines.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"We first confirmed that expression of an MKI-GFP fusion protein in rat hippocampal neurons effectively attenuated MARK4-mediated phosphorylation of both endogenous tau (Fig. 3A) and transfected human tau at the 12E8 sites (Fig. 3B). Phosphorylation of tau at the PHF-1 site was also reduced by MKI (Fig. 3A). It is possible that the PHF-1 site is also targeted by PAR-1/MARKs in vivo, or that the phosphorylation of tau at the 12E8 sites is a prerequisite for PHF-1 site phosphorylation, as the 12E8 sites were previously shown to be required for tau phosphorylation at other sites\", \"key\": \"e52e3cb037634fcce5c2b36e330169e28fc5e6175b83133e3b6cf7425cad9e200bb53f66ca48b727888c9743878ef316e9eb694d04572a7493e39cd7c709991d\", \"line\": 1801, \"relation\": \"positiveCorrelation\", \"source\": 198, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 303}, {\"annotations\": {\"Tau_Motif\": {\"KXGS\": true}}, \"citation\": {\"authors\": [\"Lu B\", \"Malenka R\", \"Polepalli J\", \"Rajadas J\", \"Wagh D\", \"Yu W\"], \"date\": \"2012-03-15\", \"first\": \"Yu W\", \"last\": \"Lu B\", \"name\": \"Human molecular genetics\", \"pages\": \"1384-90\", \"reference\": \"22156579\", \"title\": \"A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of A on synapses and dendritic spines.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"We first confirmed that expression of an MKI-GFP fusion protein in rat hippocampal neurons effectively attenuated MARK4-mediated phosphorylation of both endogenous tau (Fig. 3A) and transfected human tau at the 12E8 sites (Fig. 3B). Phosphorylation of tau at the PHF-1 site was also reduced by MKI (Fig. 3A). It is possible that the PHF-1 site is also targeted by PAR-1/MARKs in vivo, or that the phosphorylation of tau at the 12E8 sites is a prerequisite for PHF-1 site phosphorylation, as the 12E8 sites were previously shown to be required for tau phosphorylation at other sites\", \"key\": \"7b41398cea9e95773639591461e89c8db361c9263b11a247b6b8c98376db9c2294a71139b4a5825daf4ff5c7fb5c6f2d6271455f44ee836e2e042617a80db34a\", \"line\": 1800, \"relation\": \"positiveCorrelation\", \"source\": 198, \"subject\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"target\": 297}, {\"citation\": {\"authors\": [\"Berry R\", \"Binder LI\", \"Fu Y\", \"Guillozet-Bongaarts AL\", \"Horowitz PM\", \"Reyes JF\", \"Reynolds MR\"], \"date\": \"2008-08-01\", \"first\": \"Reyes JF\", \"last\": \"Binder LI\", \"name\": \"Neurobiology of disease\", \"pages\": \"198-208\", \"reference\": \"18562203\", \"title\": \"A possible link between astrocyte activation and tau nitration in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"This antibody detects nitrated tau in soluble preparations from both severe AD brains (Braak stage V, VI) and age-matched controls, suggesting that nitration at Tyr 18 may be linked to astrocyte activation, an early event associated with amyloid plaque formation\", \"key\": \"af4ea2c071b6fd1d4a14115aee590cf76efa8bf9e1480583412b66b6dfe6d3a3aee8072842f00f2d3c383eba8134bb105f0cbda915262e7ac2fc6725ee02cdb1\", \"line\": 835, \"relation\": \"association\", \"source\": 0, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 280}, {\"annotations\": {\"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Cho SH\", \"Cole PA\", \"Gan L\", \"Haroutunian V\", \"Huang EJ\", \"Masliah E\", \"Meyers D\", \"Min SW\", \"Mukherjee C\", \"Ott M\", \"Schroeder S\", \"Seeley WW\", \"Shen Y\", \"Zhou Y\"], \"date\": \"2010-09-23\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"Neuron\", \"pages\": \"953-66\", \"reference\": \"20869593\", \"title\": \"Acetylation of tau inhibits its degradation and contributes to tauopathy.\", \"type\": \"PubMed\", \"volume\": \"67\"}, \"evidence\": \"Thus, the increase in ac-tau induced by SIRT1 deficiency is accompanied by accumulation of pathogenic p-tau in primary neurons. In mouse brains, deleting SIRT1, which elevated ac-tau, also increased AT8-positive p-tau.\", \"key\": \"123bacf913592cb00bc29d22a76cdaca3e1c2734654fa8002d49a5b2911ec85a11ef0bb6edbfa11ac19970f9c51bdd40e33cf90a9e6bcdca285fa22ff20b5927\", \"line\": 3321, \"relation\": \"positiveCorrelation\", \"source\": 187, \"target\": 247}, {\"annotations\": {\"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Devidze N\", \"Gan L\", \"Gestwicki JE\", \"Johnson JR\", \"Krogan NJ\", \"Li Y\", \"Masliah E\", \"Min SW\", \"Mok SA\", \"Sohn PD\"], \"date\": \"2018-04-11\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"3680-3688\", \"reference\": \"29540553\", \"title\": \"SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.\", \"type\": \"PubMed\", \"volume\": \"38\"}, \"evidence\": \"After pretreating hTau neurons with oligo A-42 (1000 ng/ml), Sirt3 levels were reduced (Fig. 6b and e). This reduction in Sirt3 was translated into an increase in total tau and Ac-tau.\", \"key\": \"8c15bf198407ba1ea2a05e55bb5a32610c9a163452572edbf6725ebc1308e3a8ae235f11fb0cddfe1e2d96655e0be12ed3de0b7749c8f328366e9db2d8aee265\", \"line\": 3055, \"relation\": \"negativeCorrelation\", \"source\": 247, \"target\": 203}, {\"annotations\": {\"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Cho SH\", \"Cole PA\", \"Gan L\", \"Haroutunian V\", \"Huang EJ\", \"Masliah E\", \"Meyers D\", \"Min SW\", \"Mukherjee C\", \"Ott M\", \"Schroeder S\", \"Seeley WW\", \"Shen Y\", \"Zhou Y\"], \"date\": \"2010-09-23\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"Neuron\", \"pages\": \"953-66\", \"reference\": \"20869593\", \"title\": \"Acetylation of tau inhibits its degradation and contributes to tauopathy.\", \"type\": \"PubMed\", \"volume\": \"67\"}, \"evidence\": \"Thus, the increase in ac-tau induced by SIRT1 deficiency is accompanied by accumulation of pathogenic p-tau in primary neurons. In mouse brains, deleting SIRT1, which elevated ac-tau, also increased AT8-positive p-tau.\", \"key\": \"4fa19688170652ec68b9185b03e0aecc0dea2908a539904fd46f1b488e5c8ee9b6c722fe16347b4f3cd81291d44a109370551bd2394fea30a099c223412e7fbc\", \"line\": 3321, \"relation\": \"positiveCorrelation\", \"source\": 247, \"target\": 187}, {\"citation\": {\"authors\": [\"Cho SH\", \"Cole PA\", \"Gan L\", \"Haroutunian V\", \"Huang EJ\", \"Masliah E\", \"Meyers D\", \"Min SW\", \"Mukherjee C\", \"Ott M\", \"Schroeder S\", \"Seeley WW\", \"Shen Y\", \"Zhou Y\"], \"date\": \"2010-09-23\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"Neuron\", \"pages\": \"953-66\", \"reference\": \"20869593\", \"title\": \"Acetylation of tau inhibits its degradation and contributes to tauopathy.\", \"type\": \"PubMed\", \"volume\": \"67\"}, \"evidence\": \"Thus, the increase in ac-tau induced by SIRT1 deficiency is accompanied by accumulation of pathogenic p-tau in primary neurons. In mouse brains, deleting SIRT1, which elevated ac-tau, also increased AT8-positive p-tau.\", \"key\": \"8a57ca510d6d965a54c74426e2496322c6028b9241b15359061bee2f6e0f0a25696d2f554a573207825543ebd0789be443f307631ff32aef18144174b987ce91\", \"line\": 3319, \"object\": {\"modifier\": \"Activity\"}, \"relation\": \"negativeCorrelation\", \"source\": 247, \"target\": 361}, {\"citation\": {\"authors\": [\"Cong X\", \"Ellerby LM\", \"Gan L\", \"Huganir RL\", \"Le D\", \"Li Y\", \"Lo I\", \"Min SW\", \"Minami SS\", \"Ponnusamy R\", \"Schilling B\", \"Sohn PD\", \"Tracy TE\", \"Wang C\", \"Zhou Y\"], \"date\": \"2016-04-20\", \"first\": \"Tracy TE\", \"last\": \"Gan L\", \"name\": \"Neuron\", \"pages\": \"245-60\", \"reference\": \"27041503\", \"title\": \"Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss.\", \"type\": \"PubMed\", \"volume\": \"90\"}, \"evidence\": \"Here we report abnormal acetylation of K274 and K281 on tau, identified in AD brains, promotes memory loss and disrupts synaptic plasticity by reducing postsynaptic KIdney/BRAin (KIBRA) protein, a memory-associated protein.Transgenic mice expressing human tau with lysine-to-glutamine mutations to mimic K274 and K281 acetylation (tauKQ) exhibit AD-related memory deficits and impaired hippocampal long-term potentiation (LTP). TauKQ reduces synaptic KIBRA levels and disrupts activity-induced postsynaptic actin remodeling and AMPA receptor insertion. The LTP deficit was rescued by promoting actin polymerization or by KIBRA expression. In AD patients with dementia, we found enhanced tau acetylation is linked to loss of KIBRA.\", \"key\": \"f823aba01a9e1af71d666199c21671ebed8dfcb8c1c5e79f8c0387e2070b0852c836ac36f5cdbb42a87945a623b905c259cb661bdcad4acc9b481705d5bc2b49\", \"line\": 3181, \"relation\": \"decreases\", \"source\": 247, \"target\": 379}, {\"annotations\": {\"Cell_Line\": {\"HEK293\": true}}, \"citation\": {\"authors\": [\"Cohen TJ\", \"Guo JL\", \"Hurtado DE\", \"Kwong LK\", \"Lee VM\", \"Mills IP\", \"Trojanowski JQ\"], \"date\": \"2011-01-01\", \"first\": \"Cohen TJ\", \"last\": \"Lee VM\", \"name\": \"Nature communications\", \"pages\": \"252\", \"reference\": \"21427723\", \"title\": \"The acetylation of tau inhibits its function and promotes pathological tau aggregation.\", \"type\": \"PubMed\", \"volume\": \"2\"}, \"evidence\": \"Although low-level tau acetylation was observed in untreated HEK-T40 cells, treatment with the pan histone deacetylase (HDAC) inhibitor trichostatin A (TSA), but not the Sir2 class inhibitor nicotinamide, resulted in a dramatic increase in acetylated tau levels.\", \"key\": \"20d6b50679c62c007a2df5d9bbaa46c4e614371758f18784fdf4d1d1518a970877ca911b1d3acb6984e5827438fa0234c9775c6fd9265ee132450d84dfbedb07\", \"line\": 3273, \"relation\": \"decreases\", \"source\": 161, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 247}, {\"annotations\": {\"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Devidze N\", \"Gan L\", \"Gestwicki JE\", \"Johnson JR\", \"Krogan NJ\", \"Li Y\", \"Masliah E\", \"Min SW\", \"Mok SA\", \"Sohn PD\"], \"date\": \"2018-04-11\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"pages\": \"3680-3688\", \"reference\": \"29540553\", \"title\": \"SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.\", \"type\": \"PubMed\", \"volume\": \"38\"}, \"evidence\": \"After pretreating hTau neurons with oligo A-42 (1000 ng/ml), Sirt3 levels were reduced (Fig. 6b and e). This reduction in Sirt3 was translated into an increase in total tau and Ac-tau.\", \"key\": \"f1b839bf5b99a8b03209fbf7903a14aaff879d339b6e4f1ba7c7ef1d2d02ba8646c0cc9c7fda0815c91da7430ce677dcb799e76c97234758435321f1480ff46b\", \"line\": 3055, \"relation\": \"negativeCorrelation\", \"source\": 203, \"target\": 247}, {\"citation\": {\"authors\": [\"Cohen TJ\", \"Friedmann D\", \"Hwang AW\", \"Lee VM\", \"Marmorstein R\", \"Trzeciakiewicz H\", \"Yuan CX\"], \"date\": \"2016-01-01\", \"first\": \"Hwang AW\", \"last\": \"Cohen TJ\", \"name\": \"PloS one\", \"pages\": \"e0168913\", \"reference\": \"28002468\", \"title\": \"Conserved Lysine Acetylation within the Microtubule-Binding Domain Regulates MAP2/Tau Family Members.\", \"type\": \"PubMed\", \"volume\": \"11\"}, \"evidence\": \"Similar to tau, MAP2 acetylation can occur in a cysteine-dependent auto-regulatory manner in the presence of acetyl-CoA. Tubulin reduced MAP2 acetylation, suggesting tubulin binding dictates MAP acetylation status.\", \"key\": \"489df1729c7a206303eb6069a51e3d0679976e801a374d678efd589abf7bd81afa0f47f81abdf60de3b5e249ed16c4af974260b84c25e98a910c4cf0bdcbba9f\", \"line\": 3160, \"relation\": \"increases\", \"source\": 53, \"target\": 247}, {\"annotations\": {\"Cell_Line\": {\"HEK293\": true}}, \"citation\": {\"authors\": [\"Cohen TJ\", \"Guo JL\", \"Hurtado DE\", \"Kwong LK\", \"Lee VM\", \"Mills IP\", \"Trojanowski JQ\"], \"date\": \"2011-01-01\", \"first\": \"Cohen TJ\", \"last\": \"Lee VM\", \"name\": \"Nature communications\", \"pages\": \"252\", \"reference\": \"21427723\", \"title\": \"The acetylation of tau inhibits its function and promotes pathological tau aggregation.\", \"type\": \"PubMed\", \"volume\": \"2\"}, \"evidence\": \"Although low-level tau acetylation was observed in untreated HEK-T40 cells, treatment with the pan histone deacetylase (HDAC) inhibitor trichostatin A (TSA), but not the Sir2 class inhibitor nicotinamide, resulted in a dramatic increase in acetylated tau levels.\", \"key\": \"07736ffd713dc5329c8a66d309c2e386c7497004ca3a85b7747742768ee54e54fe6b4037011248b18f4f10db0d34d4abe52f7b84d0495b45482fbf1b1cfee4f5\", \"line\": 3274, \"relation\": \"increases\", \"source\": 12, \"target\": 247}, {\"citation\": {\"authors\": [\"Cho SH\", \"Cole PA\", \"Gan L\", \"Haroutunian V\", \"Huang EJ\", \"Masliah E\", \"Meyers D\", \"Min SW\", \"Mukherjee C\", \"Ott M\", \"Schroeder S\", \"Seeley WW\", \"Shen Y\", \"Zhou Y\"], \"date\": \"2010-09-23\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"Neuron\", \"pages\": \"953-66\", \"reference\": \"20869593\", \"title\": \"Acetylation of tau inhibits its degradation and contributes to tauopathy.\", \"type\": \"PubMed\", \"volume\": \"67\"}, \"evidence\": \"Next, we treated primary neurons with C646, a pyrazolone-containing small-molecule inhibitor of p300 with a Ki of 400 nM (Bowers et al., 2010). Under cell-free conditions, C646 at 10 M inhibits p300 in a highly selective manner (86% inhibition vs. <10% for the six other acetyltransferases) (Bowers et al., 2010). Inhibition of p300 with C646 (20 M) drastically reduced levels of ac-tau in primary neurons within 8 h.\", \"key\": \"02ae66197019bdf2ba5ce500410ad2249e57435e20ca09f6ab6f12c3cc286f15db5a10117fe65622364dc431373bd7e7b0c12eff3e9cdad405ed59612687a9d4\", \"line\": 3315, \"relation\": \"decreases\", \"source\": 58, \"target\": 247}, {\"citation\": {\"authors\": [\"Burlingame AL\", \"Ioanoviciu A\", \"Knudsen GM\", \"Maeda S\", \"Morris M\", \"Mucke L\", \"Trinidad JC\"], \"date\": \"2015-08-01\", \"first\": \"Morris M\", \"last\": \"Mucke L\", \"name\": \"Nature neuroscience\", \"pages\": \"1183-9\", \"reference\": \"26192747\", \"title\": \"Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"18\"}, \"evidence\": \"Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.\", \"key\": \"33f9591b6b633190ec6a0314042aa555d9b71a254cc97a58c0a8e371aea31da045198cbcd0e4d9ec1fc84da0623a3c11c57f0a0e8d895e1fb5aaed2edda7c926\", \"line\": 3217, \"relation\": \"isA\", \"source\": 252, \"target\": 247}, {\"citation\": {\"authors\": [\"Burlingame AL\", \"Ioanoviciu A\", \"Knudsen GM\", \"Maeda S\", \"Morris M\", \"Mucke L\", \"Trinidad JC\"], \"date\": \"2015-08-01\", \"first\": \"Morris M\", \"last\": \"Mucke L\", \"name\": \"Nature neuroscience\", \"pages\": \"1183-9\", \"reference\": \"26192747\", \"title\": \"Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"18\"}, \"evidence\": \"Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.\", \"key\": \"a20a0c625f7d70ea4eb1d534ee6bd5a9df9808da97bf7a9da3209c9fdb1b0cc6e1f932b3a617734a06eb4d6d6e528db38bd189472cef3fc0aef88fb8f1b0837f\", \"line\": 3220, \"relation\": \"isA\", \"source\": 260, \"target\": 247}, {\"citation\": {\"authors\": [\"Burlingame AL\", \"Ioanoviciu A\", \"Knudsen GM\", \"Maeda S\", \"Morris M\", \"Mucke L\", \"Trinidad JC\"], \"date\": \"2015-08-01\", \"first\": \"Morris M\", \"last\": \"Mucke L\", \"name\": \"Nature neuroscience\", \"pages\": \"1183-9\", \"reference\": \"26192747\", \"title\": \"Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"18\"}, \"evidence\": \"Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.\", \"key\": \"f96c9a05d686a75c8a1d91b16db59bec170ea47ebc4d7f8a33dc9325f58696a7ee6fe99a0466cdfc89ffdc842a6fce37b576c3396b3911b747371c5a2dc4fccd\", \"line\": 3230, \"relation\": \"partOf\", \"source\": 260, \"target\": 55}, {\"citation\": {\"authors\": [\"Burlingame AL\", \"Ioanoviciu A\", \"Knudsen GM\", \"Maeda S\", \"Morris M\", \"Mucke L\", \"Trinidad JC\"], \"date\": \"2015-08-01\", \"first\": \"Morris M\", \"last\": \"Mucke L\", \"name\": \"Nature neuroscience\", \"pages\": \"1183-9\", \"reference\": \"26192747\", \"title\": \"Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"18\"}, \"evidence\": \"Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.\", \"key\": \"aae1cf51469216a6deb56d3a373c087565bd66e3bc01298fbab06f0cd194206d1d70b98ad88d3496933ff26ead7cff811d8d41ad8df411b400687a30aaba826e\", \"line\": 3224, \"relation\": \"isA\", \"source\": 264, \"target\": 247}, {\"citation\": {\"authors\": [\"Burlingame AL\", \"Ioanoviciu A\", \"Knudsen GM\", \"Maeda S\", \"Morris M\", \"Mucke L\", \"Trinidad JC\"], \"date\": \"2015-08-01\", \"first\": \"Morris M\", \"last\": \"Mucke L\", \"name\": \"Nature neuroscience\", \"pages\": \"1183-9\", \"reference\": \"26192747\", \"title\": \"Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"18\"}, \"evidence\": \"Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.\", \"key\": \"9a06bdadbf9dcb0a6d999a44e08eb8e3e5b71bce1ae7f7002adb10b85ef216538b141600c40bc07014663129ddd1875ff6814df2528acb8445bec4cc0fad556c\", \"line\": 3216, \"relation\": \"isA\", \"source\": 249, \"target\": 247}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"Depending on the sites, the acetylation of tau could inhibit its degradation (for example, when at Lys163, Lys280, Lys281 or Lys369) or, by contrast, facilitate its degradation and suppress its phosphorylation and aggregation (for example, when at Lys259, Lys290, Lys321 or Lys353)\", \"key\": \"391ee22d062e261a9a8c97334304820ab6ea25b81829758f98014f0cc750ca4d384f06bcb30971092c54ff91cfb98e463c0c948e0a75f91bc487c30bfbed9226\", \"line\": 263, \"object\": {\"modifier\": \"Degradation\"}, \"relation\": \"decreases\", \"source\": 249, \"target\": 249}, {\"annotations\": {\"Species\": {\"7227\": true}}, \"citation\": {\"authors\": [\"Augustin H\", \"Burnouf S\", \"Dols J\", \"Gorsky MK\", \"Grnke S\", \"Partridge L\", \"Sofola-Adesakin O\", \"Weigelt CM\"], \"date\": \"2017-08-30\", \"first\": \"Gorsky MK\", \"last\": \"Partridge L\", \"name\": \"Scientific reports\", \"pages\": \"9984\", \"reference\": \"28855586\", \"title\": \"Pseudo-acetylation of multiple sites on human Tau proteins alters Tau phosphorylation and microtubule binding, and ameliorates amyloid beta toxicity.\", \"type\": \"PubMed\", \"volume\": \"7\"}, \"evidence\": \"We have used a knock-out/knock-in strategy in Drosophila to generate a strain with hTau inserted into the endogenous fly tau locus and expressed under the control of the endogenous fly tau promoter, thus avoiding potential toxicity due to genetic over-expression. hTau knock-in (KI) proteins were expressed at normal, endogenous levels, bound to fly microtubules and were post-translationally modified, hence displaying physiological properties. We used this new model to investigate the effects of acetylation on hTau toxicity in vivo. The simultaneous pseudo-acetylation of hTau at lysines 163, 280, 281 and 369 drastically decreased hTau phosphorylation and significantly reduced its binding to microtubules in vivo. These molecular alterations were associated with ameliorated amyloid beta toxicity. Our results indicate acetylation of hTau on multiple sites regulates its biology and ameliorates amyloid beta toxicity in vivo.\", \"key\": \"7c0d0fa2858b48079bb554bafb146e500706881321a87ad57e91e859cbb87705e1981fd9bbdc4cd3ad3c542cbf2a916c761a9e6a39df1dff8d1a574d42492e85\", \"line\": 3122, \"relation\": \"association\", \"source\": 249, \"target\": 152}, {\"citation\": {\"authors\": [\"Burlingame AL\", \"Ioanoviciu A\", \"Knudsen GM\", \"Maeda S\", \"Morris M\", \"Mucke L\", \"Trinidad JC\"], \"date\": \"2015-08-01\", \"first\": \"Morris M\", \"last\": \"Mucke L\", \"name\": \"Nature neuroscience\", \"pages\": \"1183-9\", \"reference\": \"26192747\", \"title\": \"Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"18\"}, \"evidence\": \"Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.\", \"key\": \"4294cd0db49ba6c2868a1ef656567e5b514cc1524a6d45f235ba0e9f040bcd46d4d372e36a83b010209b6dea6a9422614bf3032edc7a3d55a7f7dcc5f39c8ba9\", \"line\": 3222, \"relation\": \"isA\", \"source\": 262, \"target\": 247}, {\"citation\": {\"authors\": [\"Burlingame AL\", \"Ioanoviciu A\", \"Knudsen GM\", \"Maeda S\", \"Morris M\", \"Mucke L\", \"Trinidad JC\"], \"date\": \"2015-08-01\", \"first\": \"Morris M\", \"last\": \"Mucke L\", \"name\": \"Nature neuroscience\", \"pages\": \"1183-9\", \"reference\": \"26192747\", \"title\": \"Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"18\"}, \"evidence\": \"Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.\", \"key\": \"dddc0a8a363251590567113c472aec4373946a2d45263eb8a7dd06403f5b30d1be7b4d510d5af8fdc17cf8497dbe98e5cde6ff9c4ccb35126f565f681d9dfb52\", \"line\": 3232, \"relation\": \"partOf\", \"source\": 262, \"target\": 55}, {\"citation\": {\"authors\": [\"Burlingame AL\", \"Ioanoviciu A\", \"Knudsen GM\", \"Maeda S\", \"Morris M\", \"Mucke L\", \"Trinidad JC\"], \"date\": \"2015-08-01\", \"first\": \"Morris M\", \"last\": \"Mucke L\", \"name\": \"Nature neuroscience\", \"pages\": \"1183-9\", \"reference\": \"26192747\", \"title\": \"Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.\", \"type\": \"PubMed\", \"volume\": \"18\"}, \"evidence\": \"Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.\", \"key\": \"0a50bdae79563995b6cf623c784e67430af79e42510e8ad7a526264024496e2d9fe3f9172204f11ad3f2882c68ffc416a10f4f861f98a65dd5c1d4748bc908d2\", \"line\": 3223, \"relation\": \"isA\", \"source\": 263, \"target\": 247}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"The phosphorylation of tau at Tyr394 and Tyr18 is present in PHFs in the brains of individuals with AD.\", \"key\": \"5351bb706674aebcfffdce5c1cefca919a10e08804777af447c9a565ba1e2e644953ac1922c3afd94cd1ae664a9c07a89996571b2b3617357042d07535007139\", \"line\": 183, \"relation\": \"association\", \"source\": 321, \"target\": 56}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"In addition, tau can be phosphorylated by tyrosine kinases such as the SRC family members LCK, SYK and FYN at Tyr18, and the ABL family members ARG and ABL1 at Tyr394 (REF. 45).\", \"key\": \"0acddb6b788258ba63ea4e25f91ed93bf6cce8992b1a8e8ad667a2e05e319aa1296f6716cb6b9796e5dc4c0319b257f154a85f242ecdf4b3d18c0399c548206d\", \"line\": 176, \"relation\": \"directlyIncreases\", \"source\": 208, \"target\": 321}, {\"annotations\": {\"Research_Model\": {\"PS19 mice\": true}, \"Species\": {\"10090\": true}}, \"citation\": {\"authors\": [\"Chen X\", \"Cong X\", \"Defensor E\", \"Ellerby L\", \"Gan L\", \"Gestwicki J\", \"Gibson BW\", \"Johnson J\", \"Krogan N\", \"Li Y\", \"Masliah E\", \"Min SW\", \"Minami SS\", \"Mok SA\", \"Schilling B\", \"Shamloo M\", \"Shirakawa K\", \"Sohn PD\", \"Tracy TE\", \"Verdin E\", \"Wang C\", \"Zhou Y\"], \"date\": \"2015-10-01\", \"first\": \"Min SW\", \"last\": \"Gan L\", \"name\": \"Nature medicine\", \"pages\": \"1154-62\", \"reference\": \"26390242\", \"title\": \"Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"The acetyl-mimicking mutant K174Q slows tau turnover and induces cognitive deficits in vivo. Acetyltransferase p300-induced tau acetylation is inhibited by salsalate and salicylate, which enhance tau turnover and reduce tau levels. In the PS19 transgenic mouse model of FTD, administration of salsalate after disease onset inhibited p300 activity, lowered levels of total tau and tau acetylated at K174, rescued tau-induced memory deficits and prevented hippocampal atrophy.\", \"key\": \"b3dd4c2537cadb38dc37922f9b8ea6efe8db09e0df1bb03c943a6177fc16254a9b338db225c67c9f8b39c0f2d69c19c640439d8cb221f4e7c4f0564e22cc8349\", \"line\": 3208, \"relation\": \"decreases\", \"source\": 29, \"target\": 250}, {\"key\": \"1ed4b76e7759bb7b306993dfde8a7a8dfe2858bfd32d4bab982eb8eb2702ae989a3a81600d34e82002a9f48560e2348f820a742255017a5f4e49b351d2c10ece\", \"relation\": \"hasComponent\", \"source\": 119, \"target\": 306}, {\"annotations\": {\"Method\": {\"Electron Microscopy, Transmission\": true, \"NMR Spectroscopy\": true, \"Thioflavin T Assay\": true}, \"Tau_Epitope\": {\"AT8\": true}}, \"citation\": {\"authors\": [\"Baulieu EE\", \"Byrne C\", \"Cantrelle FX\", \"Chambraud B\", \"Despres C\", \"Huvent I\", \"Jacquot Y\", \"Landrieu I\", \"Lippens G\", \"Qi H\", \"Smet-Nocca C\"], \"date\": \"2017-08-22\", \"first\": \"Despres C\", \"last\": \"Smet-Nocca C\", \"name\": \"Proceedings of the National Academy of Sciences of the United States of America\", \"pages\": \"9080-9085\", \"reference\": \"28784767\", \"title\": \"Identification of the Tau phosphorylation pattern that drives its aggregation.\", \"type\": \"PubMed\", \"volume\": \"114\"}, \"evidence\": \"When combined with ERK2 catalyzed phosphorylation, the turn-like disrupting G207V mutation in TauF8 hence leads to fast aggregation that already occurs during the phosphorylation reaction.\", \"key\": \"3efef572861f74499b497cfb8bb8ba1197da6ab71479762185fcbde51699b20cd7dfd0285b64757c7247081690768bca1c8e073cbe7c563a0844977c11a63078\", \"line\": 86, \"relation\": \"increases\", \"source\": 291, \"target\": 38}, {\"citation\": {\"authors\": [\"Amniai L\", \"Fauquant C\", \"Huvent I\", \"Landrieu I\", \"Leroy A\", \"Lippens G\", \"Sibille N\", \"Verdegem D\", \"Wieruszeski JM\"], \"date\": \"2012-02-01\", \"first\": \"Sibille N\", \"last\": \"Landrieu I\", \"name\": \"Proteins\", \"pages\": \"454-62\", \"reference\": \"22072628\", \"title\": \"Structural characterization by nuclear magnetic resonance of the impact of phosphorylation in the proline-rich region of the disordered Tau protein.\", \"type\": \"PubMed\", \"volume\": \"80\"}, \"evidence\": \"In this study, we address the structural impact of phosphorylation of the Tau protein by Nuclear Magnetic Resonance (NMR) spectroscopy on a functional fragment of Tau (Tau[Ser208-Ser324] = TauF4). TauF4 was phosphorylated by the proline-directed CDK2/CycA3 kinase on Thr231 (generating the AT180 epitope), Ser235, and equally on Thr212 and Thr217 in the Proline-rich region (Tau[Ser208-Gln244] or PRR). These modifications strongly decrease the capacity of TauF4 to polymerize tubulin into microtubules. While all the NMR parameters are consistent with a globally disordered Tau protein fragment, local clusters of structuration can be defined. The most salient result of our NMR analysis is that phosphorylation in the PRR stabilizes a short -helix that runs from pSer235 till the very beginning of the microtubule-binding region (Tau[Thr245-Ser324] or MTBR of TauF4).\", \"key\": \"ca4f2427e999a01d69191bc883339913132f5ff64c167a57cce4fbac3172cd1617b91166dd55c5d8542f6da9e3e86229f77f94c39349355fe81392cf5aa5155c\", \"line\": 2790, \"relation\": \"partOf\", \"source\": 295, \"target\": 193}, {\"citation\": {\"authors\": [\"Buosi V\", \"Eichner T\", \"Kern D\", \"Kutter S\", \"Labeikovsky W\"], \"date\": \"2016-05-08\", \"first\": \"Eichner T\", \"last\": \"Kern D\", \"name\": \"Journal of molecular biology\", \"pages\": \"1760-75\", \"reference\": \"26996941\", \"title\": \"Molecular Mechanism of Pin1-Tau Recognition and Catalysis.\", \"type\": \"PubMed\", \"volume\": \"428\"}, \"evidence\": \"We find that phosphorylated (p-) SER235-PRO, but not pTHR231-PRO, is exclusively catalyzed by full-length Pin1 and isolated PPIase domain.\", \"key\": \"221299fd5560db135d50ab127dcd2835ae9b33a9e6f881a55f14198096be761e9b3b76d523f529fb36f80913db55fa9f12aa6cb5f0d9fb13080664a6eb4b6817\", \"line\": 3967, \"object\": {\"modifier\": \"Activity\"}, \"relation\": \"association\", \"source\": 295, \"target\": 342}, {\"citation\": {\"authors\": [\"Chung KM\", \"Hernndez N\", \"Sproul AA\", \"Yu WH\"], \"date\": \"2018-05-18\", \"first\": \"Chung KM\", \"last\": \"Yu WH\", \"name\": \"Neuroscience letters\", \"reference\": \"29758300\", \"title\": \"Alzheimer's disease and the autophagic-lysosomal system.\", \"type\": \"PubMed\"}, \"evidence\": \"A recent study has demonstrated that activation of AMPK1 enhances tau phosphorylation, while inhibition reduces tau phosphorylation at Ser-262, an epitope that is increased in early stages of AD, which promotes the autophagic degradation of tau [87]\", \"key\": \"4165b5aef266c47b2f7c8d8a290a875c47b061da2fe18214384fb0d5d2331d2012aea862fcdef28607ae66078781a999c3b1287b4d6acb4145912fccc26d9a63\", \"line\": 479, \"relation\": \"increases\", \"source\": 297, \"target\": 93}, {\"annotations\": {\"MeSHAnatomy\": {\"Dendrites\": true}}, \"citation\": {\"authors\": [\"Balaji V\", \"Kaniyappan S\", \"Mandelkow E\", \"Mandelkow EM\", \"Wang Y\"], \"date\": \"2018-01-01\", \"first\": \"Balaji V\", \"last\": \"Mandelkow EM\", \"name\": \"Autophagy\", \"pages\": \"2139-2154\", \"reference\": \"30145931\", \"title\": \"Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \"In addition, it has been reported that in cultured neurons, A oligomers induce MAPT missorting into the somatodendritic compartment, and the missorted MAPT is phosphorylated mainly at the 12E8 (p-S262/p-S356) and AT8 (p-S202/p-T205) sites [6].\", \"key\": \"d19fa17a61cabeccb28150b7ca703a360ba97b34012dde6c05b00dc8bed8cad7ff432eef0727b93d4fef19378be1d98f8df980f649808d0071d9c70598d5e9fa\", \"line\": 144, \"relation\": \"positiveCorrelation\", \"source\": 297, \"target\": 52}, {\"annotations\": {\"MeSHAnatomy\": {\"Dendrites\": true}}, \"citation\": {\"authors\": [\"Balaji V\", \"Kaniyappan S\", \"Mandelkow E\", \"Mandelkow EM\", \"Wang Y\"], \"date\": \"2018-01-01\", \"first\": \"Balaji V\", \"last\": \"Mandelkow EM\", \"name\": \"Autophagy\", \"pages\": \"2139-2154\", \"reference\": \"30145931\", \"title\": \"Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \" Missorted dendritic MAPT showed phosphorylation mainly at the 12E8 sites upon treatment with either the autophagy inhibitor wortmannin (Fig. 4B; 57.29.4% dendrites) or the proteasomal inhibitor epoxomicin (Fig. 4C, 62.97.4% dendrites) (Fig. 4A-C, quantification in Fig. 4D), but not at the AT8 and the PHF1 (p-S396/p-S404) sites (Fig. S5, Fig 4D).\", \"key\": \"805963a7e6c46d495ed21d965af757f52e602f67a7b8ca834237606f04fa6d914860ecaf25dd4dd32c3fe319df7fdc1dfc2ba08cbf579bc604fc29986c935eef\", \"line\": 156, \"relation\": \"positiveCorrelation\", \"source\": 297, \"target\": 34}, {\"annotations\": {\"MeSHAnatomy\": {\"Dendrites\": true}}, \"citation\": {\"authors\": [\"Balaji V\", \"Kaniyappan S\", \"Mandelkow E\", \"Mandelkow EM\", \"Wang Y\"], \"date\": \"2018-01-01\", \"first\": \"Balaji V\", \"last\": \"Mandelkow EM\", \"name\": \"Autophagy\", \"pages\": \"2139-2154\", \"reference\": \"30145931\", \"title\": \"Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems.\", \"type\": \"PubMed\", \"volume\": \"14\"}, \"evidence\": \" Missorted dendritic MAPT showed phosphorylation mainly at the 12E8 sites upon treatment with either the autophagy inhibitor wortmannin (Fig. 4B; 57.29.4% dendrites) or the proteasomal inhibitor epoxomicin (Fig. 4C, 62.97.4% dendrites) (Fig. 4A-C, quantification in Fig. 4D), but not at the AT8 and the PHF1 (p-S396/p-S404) sites (Fig. S5, Fig 4D).\", \"key\": \"135dcce458d0ab8be90712c78b27ede5b6595a8ab2ebb5aa295469a7e707b0822ea81ddb4428c9b7e0e8b0cc53e0d2c1f1b1c0e69ff36f2faf71f187a6b2f990\", \"line\": 158, \"relation\": \"positiveCorrelation\", \"source\": 297, \"target\": 21}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Cabrales Fontela Y\", \"Kadavath H\", \"Mandelkow E\", \"Riedel D\", \"Zweckstetter M\"], \"date\": \"2017-12-07\", \"first\": \"Cabrales Fontela Y\", \"last\": \"Zweckstetter M\", \"name\": \"Nature communications\", \"pages\": \"1981\", \"reference\": \"29215007\", \"title\": \"Multivalent cross-linking of actin filaments and microtubules through the microtubule-associated protein Tau.\", \"type\": \"PubMed\", \"volume\": \"8\"}, \"evidence\": \"The NMR experiments demonstrate that MARK2- phosphorylation of Tau attenuates its binding to F-actin. Consistent with a reduced affinity, MARK2-phosphorylated Tau failed in bundling actin filaments (Fig. 4e)\", \"key\": \"6cc568841ab9e2518767ac8d2ed2d4bdc4904b0c8c1f8422c039592bcee7d622c93f69940359fcf69524fbbcf19b398abb28f88788cfcc0509c3179942baf308\", \"line\": 262, \"relation\": \"decreases\", \"source\": 297, \"target\": 107}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Cabrales Fontela Y\", \"Kadavath H\", \"Mandelkow E\", \"Riedel D\", \"Zweckstetter M\"], \"date\": \"2017-12-07\", \"first\": \"Cabrales Fontela Y\", \"last\": \"Zweckstetter M\", \"name\": \"Nature communications\", \"pages\": \"1981\", \"reference\": \"29215007\", \"title\": \"Multivalent cross-linking of actin filaments and microtubules through the microtubule-associated protein Tau.\", \"type\": \"PubMed\", \"volume\": \"8\"}, \"evidence\": \"The NMR experiments demonstrate that MARK2- phosphorylation of Tau attenuates its binding to F-actin. Consistent with a reduced affinity, MARK2-phosphorylated Tau failed in bundling actin filaments (Fig. 4e)\", \"key\": \"100fa08d2815ab348472aaabb5ad082b937562c4512f82824b8a1494ea905b5251db2eff23a7b97f25b3176d8a1d55e4aba477374f5b287ab1eee7383a555829\", \"line\": 268, \"relation\": \"decreases\", \"source\": 297, \"target\": 75}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Cabrales Fontela Y\", \"Kadavath H\", \"Mandelkow E\", \"Riedel D\", \"Zweckstetter M\"], \"date\": \"2017-12-07\", \"first\": \"Cabrales Fontela Y\", \"last\": \"Zweckstetter M\", \"name\": \"Nature communications\", \"pages\": \"1981\", \"reference\": \"29215007\", \"title\": \"Multivalent cross-linking of actin filaments and microtubules through the microtubule-associated protein Tau.\", \"type\": \"PubMed\", \"volume\": \"8\"}, \"evidence\": \"In addition, attachment of a phosphate group to S262 in the peptide Tau (254284) decreased the affinity of the peptide for F-actin (Supplementary Fig. 1) and lowered the amount of Tau (254284)-promoted actin bundles (Fig. 4f)\", \"key\": \"932c1c11a9b54e624436b46ed01d478250c31792cc35bcc4a886de906207cff80f7e2dfc673b9fb9e461375225acc42e5d8d16fabf140a12e344ca7c7ab06af1\", \"line\": 282, \"relation\": \"decreases\", \"source\": 297, \"target\": 75}, {\"annotations\": {\"Confidence\": {\"High\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Cabrales Fontela Y\", \"Kadavath H\", \"Mandelkow E\", \"Riedel D\", \"Zweckstetter M\"], \"date\": \"2017-12-07\", \"first\": \"Cabrales Fontela Y\", \"last\": \"Zweckstetter M\", \"name\": \"Nature communications\", \"pages\": \"1981\", \"reference\": \"29215007\", \"title\": \"Multivalent cross-linking of actin filaments and microtubules through the microtubule-associated protein Tau.\", \"type\": \"PubMed\", \"volume\": \"8\"}, \"evidence\": \"In addition, attachment of a phosphate group to S262 in the peptide Tau (254284) decreased the affinity of the peptide for F-actin (Supplementary Fig. 1) and lowered the amount of Tau (254284)-promoted actin bundles (Fig. 4f)\", \"key\": \"4d98bae49f76c8ddecbf86892bbe01f55a8d9ab67b94d9a6f50957258370fac8660d2b07ce2f306ab8cf5e306e1fbb4a9cf7b1ba1e5901c6027822023e5573ae\", \"line\": 281, \"relation\": \"decreases\", \"source\": 297, \"target\": 108}, {\"citation\": {\"authors\": [\"Hyman BT\", \"Kay KR\", \"Mandelkow EM\", \"Polydoro M\", \"Saidi LJ\", \"Sanchez L\", \"Spires-Jones TL\"], \"date\": \"2015-01-01\", \"first\": \"Saidi LJ\", \"last\": \"Spires-Jones TL\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"937-47\", \"reference\": \"25374103\", \"title\": \"Carboxy terminus heat shock protein 70 interacting protein reduces tau-associated degenerative changes.\", \"type\": \"PubMed\", \"volume\": \"44\"}, \"evidence\": \"Probing for phospho-tau with the 12E8 antibody in cell lysates from K18K280 transfected cells reveals that tau phosphorylation is also decreased by CHIP overexpression (Fig. 1).\", \"key\": \"982f3b7f518d9efee3f335a843471992bf390bea96ec6b222d5562cb2bdcfd68ae024800ec5bd69b69b28e48922bd37706f205a2bbb9c9a69401463897be71de\", \"line\": 165, \"relation\": \"negativeCorrelation\", \"source\": 297, \"target\": 150}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"For example,the phosphorylation of KXGS motifs (particularly Ser262) in the repeat domain of tau by MARK, PKA or CaMKII can reduce the affinity of tau to microtubules\", \"key\": \"8f153d672f3093176f33751d947cb25eee4463dc386b976f249209be549330ab02da8c7b22496e2b350b750e66dd80914f1e4405383514e0e085e24b53a85730\", \"line\": 209, \"relation\": \"decreases\", \"source\": 297, \"target\": 111}, {\"annotations\": {\"Anatomy\": {\"brain\": true}, \"Species\": {\"9606\": true}, \"TauIsoform\": {\"Isoform F (441 aa)\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"von Bergen M\"], \"date\": \"2007-01-01\", \"first\": \"Mandelkow E\", \"last\": \"Mandelkow EM\", \"name\": \"Brain pathology (Zurich, Switzerland)\", \"pages\": \"83-90\", \"reference\": \"17493042\", \"title\": \"Structural principles of tau and the paired helical filaments of Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"The lysine-isoleucine-glycineserine motif (KIGS) or lysine-cysteineglycine-serine motif (KCGS) motifs in the repeat domain (S262, S293, S324, S356) can be phosphorylated by MARK, PKA, SAD kinases, CaMKII and p70S6K, which strongly reduces the tau microtubule interactions (36, 74, 96), [note that phosphorylation at these sites also inhibits tau aggregation, illustrating an analogous role for the repeat domain in the physiological and pathological functions of tau (106)].\", \"key\": \"3a39f31a36b0927d79651fe48a2f36987123aae2655d2a06c1a38eb6ee24912c0c6aa1583ef52fc3bf4067ec0a17fc4075281b1e2f1526157b465a9596968624\", \"line\": 153, \"relation\": \"decreases\", \"source\": 297, \"target\": 137}, {\"annotations\": {\"Anatomy\": {\"brain\": true}, \"Species\": {\"9606\": true}, \"TauIsoform\": {\"Isoform F (441 aa)\": true}}, \"citation\": {\"authors\": [\"Biernat J\", \"Mandelkow E\", \"Mandelkow EM\", \"von Bergen M\"], \"date\": \"2007-01-01\", \"first\": \"Mandelkow E\", \"last\": \"Mandelkow EM\", \"name\": \"Brain pathology (Zurich, Switzerland)\", \"pages\": \"83-90\", \"reference\": \"17493042\", \"title\": \"Structural principles of tau and the paired helical filaments of Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"The lysine-isoleucine-glycineserine motif (KIGS) or lysine-cysteineglycine-serine motif (KCGS) motifs in the repeat domain (S262, S293, S324, S356) can be phosphorylated by MARK, PKA, SAD kinases, CaMKII and p70S6K, which strongly reduces the tau microtubule interactions (36, 74, 96), [note that phosphorylation at these sites also inhibits tau aggregation, illustrating an analogous role for the repeat domain in the physiological and pathological functions of tau (106)].\", \"key\": \"e9aa4296fecc1811012c842972e0f75097d0f9b36cf2cbdf945991826fe51054d85530267bc7e46bcdeefcc0b8e1c5af1d49659e0ed9a97f13c4dcf588304f82\", \"line\": 158, \"relation\": \"decreases\", \"source\": 297, \"target\": 86}, {\"annotations\": {\"Disease\": {\"Alzheimer's disease\": true}}, \"citation\": {\"authors\": [\"Bue-Scherrer V\", \"Goedert M\"], \"date\": \"2002-03-27\", \"first\": \"Bue-Scherrer V\", \"last\": \"Goedert M\", \"name\": \"FEBS letters\", \"pages\": \"151-4\", \"reference\": \"11943212\", \"title\": \"Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.\", \"type\": \"PubMed\", \"volume\": \"515\"}, \"evidence\": \"Immunohistochemical analyses using isoform-selective antibodies demonstrated that MARK4 in a phosphorylated form colocalizes with p-tau Ser262 in granulovacuolar degeneration bodies (GVDs) that progressively accumulate in AD.\", \"key\": \"ef38de7e10ad61eba5656004f1391a605282c706a69b88ccfe32913ab72a731ec37da92a2c6475c32b459531b6bdb23deeb34e1510b68eee689b673f862d8a02\", \"line\": 1770, \"relation\": \"positiveCorrelation\", \"source\": 297, \"target\": 54}, {\"citation\": {\"authors\": [\"Chen C\", \"Dong XP\", \"Gong HS\", \"Guo Y\", \"Liu Y\", \"Shi Q\", \"Tian C\", \"Wang SB\", \"Xie WL\", \"Xu Y\", \"Zhang BY\", \"Zhang J\"], \"date\": \"2012-09-01\", \"first\": \"Gong HS\", \"last\": \"Dong XP\", \"name\": \"International journal of molecular medicine\", \"pages\": \"569-78\", \"reference\": \"22692785\", \"title\": \"Reduction of protein kinase MARK4 in the brains of experimental scrapie rodents and human prion disease correlates with deposits of PrP(Sc).\", \"type\": \"PubMed\", \"volume\": \"30\"}, \"evidence\": \"It has been reported that serine 262 in tau, which is specifically phosphorylated by MARK, is in a hyperphosphorylated form in the neurofibrillary deposits found in Alzheimers disease brains (15).\", \"key\": \"08ae7cf48353f898f06142001e91c8eb894e782b518304a1fd767f2e29b91893fd2e4017756f7e7a6e14584a54029ca79f1e8d8ad1daa60ec55c2b2dfaa6d165\", \"line\": 1775, \"relation\": \"partOf\", \"source\": 297, \"target\": 35}, {\"annotations\": {\"Tau_Motif\": {\"KXGS\": true}}, \"citation\": {\"authors\": [\"Lu B\", \"Malenka R\", \"Polepalli J\", \"Rajadas J\", \"Wagh D\", \"Yu W\"], \"date\": \"2012-03-15\", \"first\": \"Yu W\", \"last\": \"Lu B\", \"name\": \"Human molecular genetics\", \"pages\": \"1384-90\", \"reference\": \"22156579\", \"title\": \"A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of A on synapses and dendritic spines.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"We first confirmed that expression of an MKI-GFP fusion protein in rat hippocampal neurons effectively attenuated MARK4-mediated phosphorylation of both endogenous tau (Fig. 3A) and transfected human tau at the 12E8 sites (Fig. 3B). Phosphorylation of tau at the PHF-1 site was also reduced by MKI (Fig. 3A). It is possible that the PHF-1 site is also targeted by PAR-1/MARKs in vivo, or that the phosphorylation of tau at the 12E8 sites is a prerequisite for PHF-1 site phosphorylation, as the 12E8 sites were previously shown to be required for tau phosphorylation at other sites\", \"key\": \"3fe9b4921687fef769242ce91f79ce2c79dff377c1dfdaf8df93feb1f34dc1c1f97a8920a2afbb4b2b362942a201a6aa8e21874a445e4bf4d2511a6aaf52220a\", \"line\": 1800, \"object\": {\"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}, \"modifier\": \"Activity\"}, \"relation\": \"positiveCorrelation\", \"source\": 297, \"target\": 198}, {\"annotations\": {\"Tau_Motif\": {\"KXGS\": true}}, \"citation\": {\"authors\": [\"Lu B\", \"Malenka R\", \"Polepalli J\", \"Rajadas J\", \"Wagh D\", \"Yu W\"], \"date\": \"2012-03-15\", \"first\": \"Yu W\", \"last\": \"Lu B\", \"name\": \"Human molecular genetics\", \"pages\": \"1384-90\", \"reference\": \"22156579\", \"title\": \"A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of A on synapses and dendritic spines.\", \"type\": \"PubMed\", \"volume\": \"21\"}, \"evidence\": \"We first confirmed that expression of an MKI-GFP fusion protein in rat hippocampal neurons effectively attenuated MARK4-mediated phosphorylation of both endogenous tau (Fig. 3A) and transfected human tau at the 12E8 sites (Fig. 3B). Phosphorylation of tau at the PHF-1 site was also reduced by MKI (Fig. 3A). It is possible that the PHF-1 site is also targeted by PAR-1/MARKs in vivo, or that the phosphorylation of tau at the 12E8 sites is a prerequisite for PHF-1 site phosphorylation, as the 12E8 sites were previously shown to be required for tau phosphorylation at other sites\", \"key\": \"172b4f80ff8146fa156aa5a3e69b7e359ef69e53ec0fff8b577703b5a2192d6348c455b2f4a0cddc1c02f61a2b78dd7d3e1dda566b456d2749458536363c66d9\", \"line\": 1802, \"relation\": \"partOf\", \"source\": 297, \"target\": 42}, {\"citation\": {\"authors\": [\"Chai GS\", \"Chen NN\", \"Cheng XS\", \"Duan DX\", \"Hu Y\", \"Liu GP\", \"Luo Y\", \"Ni ZF\", \"Wang JZ\"], \"date\": \"2013-01-01\", \"first\": \"Duan DX\", \"last\": \"Liu GP\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"795-808\", \"reference\": \"23948915\", \"title\": \"Phosphorylation of tau by death-associated protein kinase 1 antagonizes the kinase-induced cell apoptosis.\", \"type\": \"PubMed\", \"volume\": \"37\"}, \"evidence\": \"These data suggest that tau hyperphosphorylation at Thr231, Ser262, and Ser396 by DAPK1 renders the cells more resistant to the kinase-induced apoptotic cell death, providing new insights into the tau-involved apoptotic abortion in the course of chronic neurodegeneration.\", \"key\": \"cb354457e55dae9d9ae05b935efd51696e6bc1192f69c9a4f3d89241413827ec4a9f77e736292ffebdd8806440ce79883155cd1bd67f169c8c8ac4dd89fdb1c2\", \"line\": 2000, \"relation\": \"negativeCorrelation\", \"source\": 297, \"target\": 78}, {\"annotations\": {\"Species\": {\"10116\": true}}, \"citation\": {\"authors\": [\"Ai J\", \"Ban T\", \"Bao YN\", \"Chen QX\", \"Hu XL\", \"Jiang XM\", \"Liu CD\", \"Pei SC\", \"Su XL\", \"Sun LH\", \"Sun LL\", \"Wang X\", \"Yan ML\", \"Zhao LJ\", \"Zong DK\"], \"date\": \"2015-09-01\", \"first\": \"Sun LH\", \"last\": \"Ai J\", \"name\": \"Journal of neurochemistry\", \"pages\": \"1139-51\", \"reference\": \"26118667\", \"title\": \"Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.\", \"type\": \"PubMed\", \"volume\": \"134\"}, \"evidence\": \"Endogenous miR-195 was knocked down using over-expression of its antisense molecule (pre-AMO-miR-195) via a lentivirus (lenti-pre-AMO-miR-195); this knockdown increased the tau phosphorylation at Ser202/Thr205, Ser262, Thr231, Ser422, and the Cdk5/p25 activation, but over-expression of miR-195 using lenti-pre-miR-195 decreased the tau phosphorylation and Cdk5/p25 activation.\", \"key\": \"8dc295ba2cbee47919f40cbc242a1aa8fb019653f38e59fcc6964a45d2f69d01d82108f4ad0f77ad2afeb3f8b3d5b616b84ba024403a4a6776ad1288c8c93857\", \"line\": 2333, \"relation\": \"negativeCorrelation\", \"source\": 297, \"target\": 153}, {\"annotations\": {\"Species\": {\"7227\": true}}, \"citation\": {\"authors\": [\"Iijima KM\", \"Iijima-Ando K\", \"Lu B\", \"Maruko-Otake A\", \"Ohtake Y\", \"Sekiya M\", \"Suzuki E\"], \"date\": \"2012-01-01\", \"first\": \"Iijima-Ando K\", \"last\": \"Iijima KM\", \"name\": \"PLoS genetics\", \"pages\": \"e1002918\", \"reference\": \"22952452\", \"title\": \"Loss of axonal mitochondria promotes tau-mediated neurodegeneration and Alzheimer's disease-related tau phosphorylation via PAR-1.\", \"type\": \"PubMed\", \"volume\": \"8\"}, \"evidence\": \"Using transgenic Drosophila expressing human tau, we found that RNAi-mediated knockdown of milton or Miro, an adaptor protein essential for axonal transport of mitochondria, enhanced human tau-induced neurodegeneration. Tau phosphorylation at an AD-related site Ser262 increased with knockdown of milton or Miro; and partitioning defective-1 (PAR-1), the Drosophila homolog of mammalian microtubule affinity-regulating kinase, mediated this increase of tau phosphorylation. Tau phosphorylation at Ser262 has been reported to promote tau detachment from microtubules, and we found that the levels of microtubule-unbound free tau increased by milton knockdown. Blocking tau phosphorylation at Ser262 site by PAR-1 knockdown or by mutating the Ser262 site to unphosphorylatable alanine suppressed the enhancement of tau-induced neurodegeneration caused by milton knockdown. Furthermore, knockdown of milton or Miro increased the levels of active PAR-1.\", \"key\": \"f4b88f465c6a572761ce36c72df5739ccaf9880fe71cf66239d7c2d9ca6d1633080d2ec9f794144439765ece33a7b4dbf563b1a65c72b3d0300531e0254d107e\", \"line\": 2759, \"relation\": \"positiveCorrelation\", \"source\": 297, \"target\": 62}, {\"annotations\": {\"Research_Model\": {\"rTg4510 mice\": true}}, \"citation\": {\"authors\": [\"Boehm J\", \"Bourgeois C\", \"Dudilot A\", \"Lauzon M\", \"Leclerc N\", \"Mondragn-Rodrguez S\", \"Trillaud-Doppia E\"], \"date\": \"2012-09-14\", \"first\": \"Mondragn-Rodrguez S\", \"last\": \"Boehm J\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"32040-53\", \"reference\": \"22833681\", \"title\": \"Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.\", \"type\": \"PubMed\", \"volume\": \"287\"}, \"evidence\": \"Acute treatment of rTg4510 mice with an O-GlcNAcase inhibitor transiently reduced tau phosphorylation at epitopes implicated in tau pathology. More importantly, long-term inhibitor treatment strongly increased tau O-GlcNAcylation, reduced the number of dystrophic neurons, and protected against the formation of pathological tau species without altering the phosphorylation of non-pathological tau.\", \"key\": \"e2e3c918cf9306ca3c8291bc0ca33a4e77b6d87a3fdd302fe4affe56ccf2d55d25eb98e0c32774b2ee7483594eeb0784d0a4e9dfe9a1ae6afd6749d1099deded\", \"line\": 2508, \"relation\": \"positiveCorrelation\", \"source\": 297, \"target\": 272}, {\"annotations\": {\"Method\": {\"Immunocytochemistry\": true, \"RNA Interference, siRNA\": true, \"Western Blot\": true}}, \"citation\": {\"authors\": [\"Abisambra JF\", \"Dickey CA\", \"Jin Y\", \"Jinwal UK\", \"Johnson AG\", \"Jones JR\", \"Koren J 3rd\", \"Lawson LY\", \"Li Q\", \"O'Leary JC 3rd\", \"Trotter JH\", \"Vestal GD\", \"Weeber EJ\"], \"date\": \"2011-05-13\", \"first\": \"Jinwal UK\", \"last\": \"Dickey CA\", \"name\": \"The Journal of biological chemistry\", \"pages\": \"16976-83\", \"reference\": \"21367866\", \"title\": \"The Hsp90 kinase co-chaperone Cdc37 regulates tau stability and phosphorylation dynamics.\", \"type\": \"PubMed\", \"volume\": \"286\"}, \"evidence\": \"Quantification of the Western blot showed that Cdc37 knockdown reduced phospho-Thr-231, phospho-Ser-199/Ser-202, phospho-Ser-396/Ser-404, and phospho-Ser-262/Ser-356 tau.\", \"key\": \"e939f96641b0d13c4e566f57894fcbb564f6efce17da16a12a2f8326cdc46890e4f5e94fdc319445571c546b24d3b2c4b564c0c1d304c7d11e740745a18c33f4\", \"line\": 635, \"relation\": \"positiveCorrelation\", \"source\": 297, \"target\": 214}, {\"annotations\": {\"Disease\": {\"Alzheimer's disease\": true}}, \"citation\": {\"authors\": [\"Bue-Scherrer V\", \"Goedert M\"], \"date\": \"2002-03-27\", \"first\": \"Bue-Scherrer V\", \"last\": \"Goedert M\", \"name\": \"FEBS letters\", \"pages\": \"151-4\", \"reference\": \"11943212\", \"title\": \"Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.\", \"type\": \"PubMed\", \"volume\": \"515\"}, \"evidence\": \"Immunohistochemical analyses using isoform-selective antibodies demonstrated that MARK4 in a phosphorylated form colocalizes with p-tau Ser262 in granulovacuolar degeneration bodies (GVDs) that progressively accumulate in AD.\", \"key\": \"c34daad4093e6e66ef19712d94ef6d5240099dd2c0c169aa711cf5d1a81aaa26aec3c08980640a1c5a08ed8d6da1b51592216f4e25699f553c9e07adbe86b4a0\", \"line\": 1768, \"relation\": \"positiveCorrelation\", \"source\": 297, \"target\": 335}, {\"citation\": {\"authors\": [\"Hyman BT\", \"Kay KR\", \"Mandelkow EM\", \"Polydoro M\", \"Saidi LJ\", \"Sanchez L\", \"Spires-Jones TL\"], \"date\": \"2015-01-01\", \"first\": \"Saidi LJ\", \"last\": \"Spires-Jones TL\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"937-47\", \"reference\": \"25374103\", \"title\": \"Carboxy terminus heat shock protein 70 interacting protein reduces tau-associated degenerative changes.\", \"type\": \"PubMed\", \"volume\": \"44\"}, \"evidence\": \"Probing for phospho-tau with the 12E8 antibody in cell lysates from K18K280 transfected cells reveals that tau phosphorylation is also decreased by CHIP overexpression (Fig. 1).\", \"key\": \"613ca14823767c4c7b9c63e781e84e3fe155d5d7470e45093a30988d93c332c4374b3a8d8f4865a39a6a0e4c20a562dff208dd904ed62af1ef308db14dd978ad\", \"line\": 165, \"relation\": \"negativeCorrelation\", \"source\": 150, \"target\": 297}, {\"annotations\": {\"Species\": {\"7227\": true}}, \"citation\": {\"authors\": [\"Iijima KM\", \"Iijima-Ando K\", \"Lu B\", \"Maruko-Otake A\", \"Ohtake Y\", \"Sekiya M\", \"Suzuki E\"], \"date\": \"2012-01-01\", \"first\": \"Iijima-Ando K\", \"last\": \"Iijima KM\", \"name\": \"PLoS genetics\", \"pages\": \"e1002918\", \"reference\": \"22952452\", \"title\": \"Loss of axonal mitochondria promotes tau-mediated neurodegeneration and Alzheimer's disease-related tau phosphorylation via PAR-1.\", \"type\": \"PubMed\", \"volume\": \"8\"}, \"evidence\": \"Using transgenic Drosophila expressing human tau, we found that RNAi-mediated knockdown of milton or Miro, an adaptor protein essential for axonal transport of mitochondria, enhanced human tau-induced neurodegeneration. Tau phosphorylation at an AD-related site Ser262 increased with knockdown of milton or Miro; and partitioning defective-1 (PAR-1), the Drosophila homolog of mammalian microtubule affinity-regulating kinase, mediated this increase of tau phosphorylation. Tau phosphorylation at Ser262 has been reported to promote tau detachment from microtubules, and we found that the levels of microtubule-unbound free tau increased by milton knockdown. Blocking tau phosphorylation at Ser262 site by PAR-1 knockdown or by mutating the Ser262 site to unphosphorylatable alanine suppressed the enhancement of tau-induced neurodegeneration caused by milton knockdown. Furthermore, knockdown of milton or Miro increased the levels of active PAR-1.\", \"key\": \"c525077e7344a009bc819a71316d1dbd018d7b1015b7c9604f85d9e39c7e48bd711df865a33ffc7a23c912a0269214f367e9fcf59981e2a9a6ec3711afa494ac\", \"line\": 2759, \"relation\": \"positiveCorrelation\", \"source\": 62, \"target\": 297}, {\"annotations\": {\"Cell_Line\": {\"NIH/3T3\": true}}, \"citation\": {\"authors\": [\"Agerman K\", \"Eckersley S\", \"Gu GJ\", \"Kamali-Moghaddam M\", \"Kvist AJ\", \"Landegren U\", \"Lund H\", \"Milner R\", \"Nilsson LN\", \"Sunnemark D\", \"Wu D\"], \"date\": \"2013-01-01\", \"first\": \"Gu GJ\", \"last\": \"Kamali-Moghaddam M\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"699-713\", \"reference\": \"23001711\", \"title\": \"Elevated MARK2-dependent phosphorylation of Tau in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"33\"}, \"evidence\": \"Several kinases such as microtubule-affinity regulating kinase (MARK), protein kinase A, calcium calmodulin kinase II, and checkpoint kinase 2 are known to phosphorylate tau on Ser(262) in vitro. In this study, we took advantage of the in situ proximity ligation assay to investigate the role of MARK2, one of the four MARK isoforms, in AD. We demonstrate that MARK2 interacts with tau and phosphorylates tau at Ser(262) in stably transfected NIH/3T3 cells expressing human recombinant tau. Staurosporine, a protein kinase inhibitor, significantly reduced the interaction between MARK2 and tau, and also phosphorylation of tau at Ser(262).\", \"key\": \"f49227ef09e124976ddc76284a4c2d05c924e128b677207c7c15f71fa883200e631cdfd91d93f879f6958f424007a534a9254bdb3367bb83e4be99d8a512b2f1\", \"line\": 2777, \"relation\": \"decreases\", \"source\": 31, \"target\": 297}, {\"annotations\": {\"Disease\": {\"Alzheimer's disease\": true}}, \"citation\": {\"authors\": [\"Bue-Scherrer V\", \"Goedert M\"], \"date\": \"2002-03-27\", \"first\": \"Bue-Scherrer V\", \"last\": \"Goedert M\", \"name\": \"FEBS letters\", \"pages\": \"151-4\", \"reference\": \"11943212\", \"title\": \"Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.\", \"type\": \"PubMed\", \"volume\": \"515\"}, \"evidence\": \"Immunohistochemical analyses using isoform-selective antibodies demonstrated that MARK4 in a phosphorylated form colocalizes with p-tau Ser262 in granulovacuolar degeneration bodies (GVDs) that progressively accumulate in AD.\", \"key\": \"1c1051cd20b8f06cb6ebcf903717d83b3497a5642ec63ae83d6911c0623da4e7e55f2cbd3bf5b7b805bb4c953bfe47a340e552f048808308eb713674b6ec6f56\", \"line\": 1770, \"relation\": \"positiveCorrelation\", \"source\": 54, \"target\": 297}, {\"annotations\": {\"Cell_Line\": {\"PC12\": true, \"SK-N-SH\": true}}, \"citation\": {\"authors\": [\"Chen C\", \"Dong XP\", \"Gong HS\", \"Guo Y\", \"Liu Y\", \"Shi Q\", \"Tian C\", \"Wang SB\", \"Xie WL\", \"Xu Y\", \"Zhang BY\", \"Zhang J\"], \"date\": \"2012-09-01\", \"first\": \"Gong HS\", \"last\": \"Dong XP\", \"name\": \"International journal of molecular medicine\", \"pages\": \"569-78\", \"reference\": \"22692785\", \"title\": \"Reduction of protein kinase MARK4 in the brains of experimental scrapie rodents and human prion disease correlates with deposits of PrP(Sc).\", \"type\": \"PubMed\", \"volume\": \"30\"}, \"evidence\": \"These finding highlight that treatment of PrP106-126 in cultured cells does not alter the level of total tau, but induces a reduction of p-tau262.\", \"key\": \"4b144f62dc76bf95dca7b02b506102e09089f299ec0a7c61665b7baf056eef6acfce1c67a217c4fe27d12d817ee43a0b5f22a049d6520125cceb3c0765e0b062\", \"line\": 1785, \"relation\": \"decreases\", \"source\": 177, \"target\": 297}, {\"citation\": {\"authors\": [\"Blokzijl A\", \"Classon C\", \"Gu GJ\", \"Kamali-Moghaddam M\", \"Landegren U\", \"Lund H\", \"Sunnemark D\", \"Wu D\", \"von Euler G\"], \"date\": \"2013-09-01\", \"first\": \"Gu GJ\", \"last\": \"Kamali-Moghaddam M\", \"name\": \"Neuromolecular medicine\", \"pages\": \"458-69\", \"reference\": \"23666762\", \"title\": \"Role of individual MARK isoforms in phosphorylation of tau at Ser in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"15\"}, \"evidence\": \"In parallel, phosphorylation of tau at Ser262 in MARK-transfected cells was investigated using a rabbit antibody recognizing phosphorylated Ser262 of tau (AGG5759) and a mouse anti-tau antibody (SC-21796) (Fig. S1a3). Tau was shown to interact with each of the transfected MARK isoforms (Fig. 1) and to be phosphorylated at Ser262 (Fig. 2). Staurosporine, a non-selective kinase inhibitor, significantly inhibited interactions between tau and each of the four MARK isoforms after treatment with 20 lM staurosporine for 1 h (Fig. 1; p = 0.02 for MARK1, MARK2 and MARK3tau interactions and p = 3 9 10-6 for MARK4tau interaction). Treatment with staurosporine also significantly reduced PLA signals for tau phosphorylation at Ser262 (Fig. 2; p = 0.04 for MARK1- and p = 0.02 for MARK2- and MARK3- and p = 1 9 10-5 for MARK4-mediated tau phosphorylation)\", \"key\": \"c40535811c31665b3e7a7bc11a8b309bef44907728065b1e2fe40f51c869e0708498fd6ae543bd7e4b71bab5ea5499862f5c442185069f2a30958f42dd6fa803\", \"line\": 1848, \"relation\": \"increases\", \"source\": 179, \"target\": 297}, {\"citation\": {\"authors\": [\"Blokzijl A\", \"Classon C\", \"Gu GJ\", \"Kamali-Moghaddam M\", \"Landegren U\", \"Lund H\", \"Sunnemark D\", \"Wu D\", \"von Euler G\"], \"date\": \"2013-09-01\", \"first\": \"Gu GJ\", \"last\": \"Kamali-Moghaddam M\", \"name\": \"Neuromolecular medicine\", \"pages\": \"458-69\", \"reference\": \"23666762\", \"title\": \"Role of individual MARK isoforms in phosphorylation of tau at Ser in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"15\"}, \"evidence\": \"In parallel, phosphorylation of tau at Ser262 in MARK-transfected cells was investigated using a rabbit antibody recognizing phosphorylated Ser262 of tau (AGG5759) and a mouse anti-tau antibody (SC-21796) (Fig. S1a3). Tau was shown to interact with each of the transfected MARK isoforms (Fig. 1) and to be phosphorylated at Ser262 (Fig. 2). Staurosporine, a non-selective kinase inhibitor, significantly inhibited interactions between tau and each of the four MARK isoforms after treatment with 20 lM staurosporine for 1 h (Fig. 1; p = 0.02 for MARK1, MARK2 and MARK3tau interactions and p = 3 9 10-6 for MARK4tau interaction). Treatment with staurosporine also significantly reduced PLA signals for tau phosphorylation at Ser262 (Fig. 2; p = 0.04 for MARK1- and p = 0.02 for MARK2- and MARK3- and p = 1 9 10-5 for MARK4-mediated tau phosphorylation)\", \"key\": \"13ccfcc8eebc08886a15ddba40086d47fcdc2d464dc62f364eb07bfe1f51272ef1eeb9723b2397a3734b8f6e52b549d2d1c5e8590b50182c13ec340c8c939e75\", \"line\": 1849, \"relation\": \"increases\", \"source\": 181, \"target\": 297}, {\"citation\": {\"authors\": [\"Agerman K\", \"Eckersley S\", \"Gu GJ\", \"Kamali-Moghaddam M\", \"Kvist AJ\", \"Landegren U\", \"Lund H\", \"Milner R\", \"Nilsson LN\", \"Sunnemark D\", \"Wu D\"], \"date\": \"2013-01-01\", \"first\": \"Gu GJ\", \"last\": \"Kamali-Moghaddam M\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"699-713\", \"reference\": \"23001711\", \"title\": \"Elevated MARK2-dependent phosphorylation of Tau in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"33\"}, \"evidence\": \"Several kinases such as microtubule-affinity regulating kinase (MARK), protein kinase A, calcium calmodulin kinase II, and checkpoint kinase 2 are known to phosphorylate tau on Ser(262) in vitro. In this study, we took advantage of the in situ proximity ligation assay to investigate the role of MARK2, one of the four MARK isoforms, in AD. We demonstrate that MARK2 interacts with tau and phosphorylates tau at Ser(262) in stably transfected NIH/3T3 cells expressing human recombinant tau. Staurosporine, a protein kinase inhibitor, significantly reduced the interaction between MARK2 and tau, and also phosphorylation of tau at Ser(262).\", \"key\": \"55b9e8a60b276979107f91aa5271b4b1adc041018340f47d4c3bc4cfae83726f4627f79dbb14e875a4092a3c84f7f1d6d45c577d9bca9cd5ba8e49632a064a70\", \"line\": 2772, \"relation\": \"increases\", \"source\": 155, \"target\": 297}, {\"citation\": {\"authors\": [\"Agerman K\", \"Eckersley S\", \"Gu GJ\", \"Kamali-Moghaddam M\", \"Kvist AJ\", \"Landegren U\", \"Lund H\", \"Milner R\", \"Nilsson LN\", \"Sunnemark D\", \"Wu D\"], \"date\": \"2013-01-01\", \"first\": \"Gu GJ\", \"last\": \"Kamali-Moghaddam M\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"pages\": \"699-713\", \"reference\": \"23001711\", \"title\": \"Elevated MARK2-dependent phosphorylation of Tau in Alzheimer's disease.\", \"type\": \"PubMed\", \"volume\": \"33\"}, \"evidence\": \"Several kinases such as microtubule-affinity regulating kinase (MARK), protein kinase A, calcium calmodulin kinase II, and checkpoint kinase 2 are known to phosphorylate tau on Ser(262) in vitro. In this study, we took advantage of the in situ proximity ligation assay to investigate the role of MARK2, one of the four MARK isoforms, in AD. We demonstrate that MARK2 interacts with tau and phosphorylates tau at Ser(262) in stably transfected NIH/3T3 cells expressing human recombinant tau. Staurosporine, a protein kinase inhibitor, significantly reduced the interaction between MARK2 and tau, and also phosphorylation of tau at Ser(262).\", \"key\": \"508ce9704b93864de6c4bd6bc1c2ab3b78123ac619dacf0fb4f86ba1f1a4491e80a5ed9f4251163fabb1ccc351ea5ac8ef85845634b6c0fbdc4fe811dba28312\", \"line\": 2773, \"relation\": \"increases\", \"source\": 218, \"target\": 297}, {\"citation\": {\"authors\": [\"Chung KM\", \"Hernndez N\", \"Sproul AA\", \"Yu WH\"], \"date\": \"2018-05-18\", \"first\": \"Chung KM\", \"last\": \"Yu WH\", \"name\": \"Neuroscience letters\", \"reference\": \"29758300\", \"title\": \"Alzheimer's disease and the autophagic-lysosomal system.\", \"type\": \"PubMed\"}, \"evidence\": \"A recent study has demonstrated that activation of AMPK1 enhances tau phosphorylation, while inhibition reduces tau phosphorylation at Ser-262, an epitope that is increased in early stages of AD, which promotes the autophagic degradation of tau [87]\", \"key\": \"3ea541aaad4f2817bae3fd8c67c3bd18615a58d7368085572c4ac0d0b400d829650cd38e2c85939a7f8dd2a3a5ea6d7b3164e76a13947a7837a970001274f2d9\", \"line\": 477, \"relation\": \"directlyIncreases\", \"source\": 355, \"target\": 297}, {\"annotations\": {\"Species\": {\"7227\": true}}, \"citation\": {\"authors\": [\"Iijima KM\", \"Iijima-Ando K\", \"Lu B\", \"Maruko-Otake A\", \"Ohtake Y\", \"Sekiya M\", \"Suzuki E\"], \"date\": \"2012-01-01\", \"first\": \"Iijima-Ando K\", \"last\": \"Iijima KM\", \"name\": \"PLoS genetics\", \"pages\": \"e1002918\", \"reference\": \"22952452\", \"title\": \"Loss of axonal mitochondria promotes tau-mediated neurodegeneration and Alzheimer's disease-related tau phosphorylation via PAR-1.\", \"type\": \"PubMed\", \"volume\": \"8\"}, \"evidence\": \"Using transgenic Drosophila expressing human tau, we found that RNAi-mediated knockdown of milton or Miro, an adaptor protein essential for axonal transport of mitochondria, enhanced human tau-induced neurodegeneration. Tau phosphorylation at an AD-related site Ser262 increased with knockdown of milton or Miro; and partitioning defective-1 (PAR-1), the Drosophila homolog of mammalian microtubule affinity-regulating kinase, mediated this increase of tau phosphorylation. Tau phosphorylation at Ser262 has been reported to promote tau detachment from microtubules, and we found that the levels of microtubule-unbound free tau increased by milton knockdown. Blocking tau phosphorylation at Ser262 site by PAR-1 knockdown or by mutating the Ser262 site to unphosphorylatable alanine suppressed the enhancement of tau-induced neurodegeneration caused by milton knockdown. Furthermore, knockdown of milton or Miro increased the levels of active PAR-1.\", \"key\": \"346c9820a596bfdd38caaed70588aecde7d44b8c8e5e12e64ccc0d67bd8bf7c432ca179ff2d6c599f54716e9f9f380cf9b5807d690851dac5039098b2bce5556\", \"line\": 2756, \"relation\": \"decreases\", \"source\": 372, \"target\": 297}, {\"annotations\": {\"Disease\": {\"Alzheimer's disease\": true}}, \"citation\": {\"authors\": [\"Bue-Scherrer V\", \"Goedert M\"], \"date\": \"2002-03-27\", \"first\": \"Bue-Scherrer V\", \"last\": \"Goedert M\", \"name\": \"FEBS letters\", \"pages\": \"151-4\", \"reference\": \"11943212\", \"title\": \"Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.\", \"type\": \"PubMed\", \"volume\": \"515\"}, \"evidence\": \"Immunohistochemical analyses using isoform-selective antibodies demonstrated that MARK4 in a phosphorylated form colocalizes with p-tau Ser262 in granulovacuolar degeneration bodies (GVDs) that progressively accumulate in AD.\", \"key\": \"114b585a4f63a28d5cf2150812f3202577e9d5b2cae695c61c1aa0ba43ee724ba3cc30df6e049edd4ddc10454e9ef0f36c6d559400ee5bbfa895a5669f7daa00\", \"line\": 1768, \"relation\": \"positiveCorrelation\", \"source\": 335, \"target\": 297}, {\"annotations\": {\"Species\": {\"7227\": true}}, \"citation\": {\"authors\": [\"Iijima KM\", \"Iijima-Ando K\", \"Lu B\", \"Maruko-Otake A\", \"Ohtake Y\", \"Sekiya M\", \"Suzuki E\"], \"date\": \"2012-01-01\", \"first\": \"Iijima-Ando K\", \"last\": \"Iijima KM\", \"name\": \"PLoS genetics\", \"pages\": \"e1002918\", \"reference\": \"22952452\", \"title\": \"Loss of axonal mitochondria promotes tau-mediated neurodegeneration and Alzheimer's disease-related tau phosphorylation via PAR-1.\", \"type\": \"PubMed\", \"volume\": \"8\"}, \"evidence\": \"Using transgenic Drosophila expressing human tau, we found that RNAi-mediated knockdown of milton or Miro, an adaptor protein essential for axonal transport of mitochondria, enhanced human tau-induced neurodegeneration. Tau phosphorylation at an AD-related site Ser262 increased with knockdown of milton or Miro; and partitioning defective-1 (PAR-1), the Drosophila homolog of mammalian microtubule affinity-regulating kinase, mediated this increase of tau phosphorylation. Tau phosphorylation at Ser262 has been reported to promote tau detachment from microtubules, and we found that the levels of microtubule-unbound free tau increased by milton knockdown. Blocking tau phosphorylation at Ser262 site by PAR-1 knockdown or by mutating the Ser262 site to unphosphorylatable alanine suppressed the enhancement of tau-induced neurodegeneration caused by milton knockdown. Furthermore, knockdown of milton or Miro increased the levels of active PAR-1.\", \"key\": \"c01091559c7c2ccc6203c605ae3fc7b9a15faf8b363b6b3c77b1d530414ff559556522e39825ec8ae8c2b2063309d83e0f44ab3fccd7f9166df2f93f93e3af85\", \"line\": 2757, \"relation\": \"decreases\", \"source\": 358, \"target\": 297}, {\"citation\": {\"authors\": [\"Mandelkow E\", \"Wang Y\"], \"date\": \"2016-01-01\", \"first\": \"Wang Y\", \"last\": \"Mandelkow E\", \"name\": \"Nature reviews. Neuroscience\", \"pages\": \"5-21\", \"reference\": \"26631930\", \"title\": \"Tau in physiology and pathology.\", \"type\": \"PubMed\", \"volume\": \"17\"}, \"evidence\": \"In a line of the JNPL3 tauopathy mouse model, which expresses human 0N4R tau bearing the missense P301L mutation, the overall increase in Tyr phosphorylation of tau correlated with the formation of tau aggregates, suggesting that overall Tyr phosphorylation might contribute to tau aggregation\", \"key\": \"d68b11bf78ba267f241e82836e5c57c00476ddd306fc6d583a74dc42e0e7ab0b2ab40f41eb2af4de3c90981d4bb6c0d2c58eb34a77f1f977bd58dbd6e5cf9b35\", \"line\": 188, \"relation\": \"increases\", \"source\": 317, \"target\": 39}, {\"citation\": {\"authors\": [\"Brown LA\", \"Buckingham SD\", \"Jones AK\", \"Sattelle DB\"], \"date\": \"2009-03-01\", \"first\": \"Buckingham SD\", \"last\": \"Sattelle DB\", \"name\": \"Pharmacological reviews\", \"pages\": \"39-61\", \"reference\": \"19293145\", \"title\": \"Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection.\", \"type\": \"PubMed\", \"volume\": \"61\"}, \"evidence\": \"FYN physically interacts with and phosphorylates tau protein, and the affinity of this physical interaction is enhanced in AD-associated mutations in tau protein (Bhaskar et al., 2005). Abeta rapidly induces tyrosine phosphorylation of many proteins (including tau protein) in human and cultured rat cortical neurons (Williamson et al., 2002). This phosphorylation is concomitant with phosphorylation and inactivation of focal adhesion kinase 1 (FADK1, a major downstream target of FYN), is blocked by inhibitors of SRC kinases and PI3K, and involves FYN associating physically with FADK1 (Williamson et al., 2002).\", \"key\": \"e750955cfd67b5bda690a02f2046a1265ec809b86805cc89380fd9363ae24446c1036cd1099b450f32ba309fe71f7f641f4ac88a5fbf16dd3abf339644de98b6\", \"line\": 715, \"relation\": \"association\", \"source\": 317, \"target\": 357}, {\"citation\": {\"authors\": [\"Brown LA\", \"Buckingham SD\", \"Jones AK\", \"Sattelle DB\"], \"date\": \"2009-03-01\", \"first\": \"Buckingham SD\", \"last\": \"Sattelle DB\", \"name\": \"Pharmacological reviews\", \"pages\": \"39-61\", \"reference\": \"19293145\", \"title\": \"Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection.\", \"type\": \"PubMed\", \"volume\": \"61\"}, \"evidence\": \"FYN physically interacts with and phosphorylates tau protein, and the affinity of this physical interaction is enhanced in AD-associated mutations in tau protein (Bhaskar et al., 2005). Abeta rapidly induces tyrosine phosphorylation of many proteins (including tau protein) in human and cultured rat cortical neurons (Williamson et al., 2002). This phosphorylation is concomitant with phosphorylation and inactivation of focal adhesion kinase 1 (FADK1, a major downstream target of FYN), is blocked by inhibitors of SRC kinases and PI3K, and involves FYN associating physically with FADK1 (Williamson et al., 2002).\", \"key\": \"05156658a976ee4e20de3772d170d7419cb5e918b28f979c2bafd652fa2a31fb377d2370aaadd3aa8b2c83bec5695e1427783f9c5628866f3670a329ed6deed6\", \"line\": 715, \"relation\": \"association\", \"source\": 357, \"target\": 317}, {\"annotations\": {\"Species\": {\"6239\": true}}, \"citation\": {\"authors\": [\"Choudhary B\", \"Mandelkow E\", \"Pir GJ\"], \"date\": \"2017-12-01\", \"first\": \"Pir GJ\", \"last\": \"Mandelkow E\", \"name\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\", \"pages\": \"5137-5148\", \"reference\": \"29191965\", \"title\": \"&lt;i&gt;Caenorhabditis elegans&lt;/i&gt; models of tauopathy.\", \"type\": \"PubMed\", \"volume\": \"31\"}, \"evidence\": \"The responsible kinases include 1) proline-directed protein kinases (PDPKs) targeting SP or TP motifs [e.g., GSK3b, cyclindependent kinase (CDK)-5, and MAPKs]; 2) nonproline directed protein kinases targeting KXGS-motifs [e.g., PKA, microtubule affinity-regulating kinase and synapses of the amphid defective (SADK)]; 3) protein kinases specific for tyrosines (e.g., Src, Lck, Syk, Fyn, and c-Abl kinase) (91).\", \"key\": \"8b741c5e49a89efa8500d78cae9916c35dbc0a3f5d9e06ef5f1efff1e179c3f48ccea712c63cb5664b93a59a8d53a6abb56d53cdb0e97cb90ca2a20eeff62bed\", \"line\": 249, \"relation\": \"directlyIncreases\", \"source\": 363, \"target\": 317}, {\"annotations\": {\"TextLocation\": {\"Review\": true}}, \"citation\": {\"authors\": [\"Chesser AS\", \"Johnson GV\", \"Pritchard SM\"], \"date\": \"2013-09-03\", \"first\": \"Chesser AS\", \"last\": \"Johnson GV\", \"name\": \"Frontiers in neurology\", \"pages\": \"122\", \"reference\": \"24027553\", \"title\": \"Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease.\", \"type\": \"PubMed\", \"volume\": \"4\"}, \"evidence\": \"In M1C neuroblastoma cells that inducibly express full-length wild-type tau (4R0N), treatment with CQ also significantly slowed down tau degradation, and caused its accumulation (92). Treatment of hippocampal slices with the cathepsin modulator ZPAD (which stimulates cathepsin D very strongly) appears to increase the proteolysis of full-length tau resulting in the production of smaller fragments, including a phosphorylated 29kDa fragment (86, 89). This partial degradation of tau was inhibited by inclusion of a selective cathepsin D inhibitor (86). \", \"key\": \"eaa592535b2dc319d9b3021108661389174ec4896922fde0cef52e5fb01887ec16862bd89bab540792114181ed4ab82cdc510ffb538c1cec86f993f5f0fcb880\", \"line\": 737, \"relation\": \"increases\", \"source\": 225, \"subject\": {\"modifier\": \"Activity\"}, \"target\": 246}], \"multigraph\": true, \"nodes\": [{\"bel\": \"a(BRCO:Astrocyte)\", \"function\": \"Abundance\", \"id\": \"2fec279f2e12d4bfb586fd5d872a6ead4cd7637e5b2897e657949084e1f467b1a41353b471782ac3c8767897d279fa56f7bb4fb3e37af488a9f056172a742cf0\", \"name\": \"Astrocyte\", \"namespace\": \"BRCO\"}, {\"bel\": \"a(CHEBI:\\\"(-)-epigallocatechin 3-gallate\\\")\", \"function\": \"Abundance\", \"id\": \"6ab1c80d3de724e6d924795da884f193d598624c7407acbe86dd59da673081130206c19bcf6637d2372ba76d86fdbe737a1dff9f7a9b685fb82284147388c222\", \"name\": \"(-)-epigallocatechin 3-gallate\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:\\\"2-[[7-(3,4-dimethoxyphenyl)-5-imidazo[1,2-c]pyrimidinyl]amino]-3-pyridinecarboxamide\\\")\", \"function\": \"Abundance\", \"id\": \"54b0c6ea730466f8f3f41625e834099430db6ef99fe402aa42d33e393ed96a714476734c831a2a2304575f711a209f3f31621970a2d5725b87712dbb8771bfa5\", \"name\": \"2-[[7-(3,4-dimethoxyphenyl)-5-imidazo[1,2-c]pyrimidinyl]amino]-3-pyridinecarboxamide\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:\\\"D-ribose\\\")\", \"function\": \"Abundance\", \"id\": \"4e55f2d0bd4599b2ded20771d4e4ba963f59fbf352143a04034667125b357beb094f6481bb81cbb5276330fe1f5ef61d8aa4d1a39a3aa446497d6aa98d2bb656\", \"name\": \"D-ribose\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:\\\"advanced glycation end-product\\\")\", \"function\": \"Abundance\", \"id\": \"2f857e8764edb78fd3e91a0abd86df1cf1f943bf98ce167f9a565f27728ade7bd90dd4b46b6bb24babab810ddd8f82ea72daea90fb536895e1c16f2b9b3ca3e3\", \"name\": \"advanced glycation end-product\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:\\\"all-trans-retinoic acid\\\")\", \"function\": \"Abundance\", \"id\": \"df1be1712b53ebbc3b8db7a99db20febb6ac30c8b6a3e24bb07b9b6e2f24bd7076b55afab356b4900766c8828c79a533b2abb4f9be2f6e4b2d809eabdc5f2807\", \"name\": \"all-trans-retinoic acid\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:\\\"amyloid-beta polypeptide 42\\\")\", \"function\": \"Abundance\", \"id\": \"c2da54109c90719396dfdfb558be74582b8522863849a50f3f5029b7d60f4d53df3cfa1a97b787e760a2f74ea1f74012eb49273beeded42a2873d788953b4a13\", \"name\": \"amyloid-beta polypeptide 42\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:\\\"amyloid-beta\\\")\", \"function\": \"Abundance\", \"id\": \"a9487b29439483c6840095610dd3e496e3ca9cccc3a8d71e0385a39b570f3c0a26965ac06d83265e1c08deaae7998272d4f4c21ec0534f8be3fd8e4e57dbb3a2\", \"name\": \"amyloid-beta\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:\\\"dimethyl fumarate\\\")\", \"function\": \"Abundance\", \"id\": \"7d04ed27f9e6af6d1386bffd879cea36cd42822fef1e520dcfd3d7d4443e87689087df9fe0e7feff2c19ef8795ba47b9da2dd0a50d0f64384c4a72ecff01889b\", \"name\": \"dimethyl fumarate\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:\\\"methylene blue\\\")\", \"function\": \"Abundance\", \"id\": \"bc17e9a0bb9e81081bd8fd81201449228e606bb9013e59ebf8a144c733531a8fbfe4e53776b79be7832ae7ea593e80a36ccc93367f04919f6241c7f32ab8e9f7\", \"name\": \"methylene blue\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:\\\"nitric oxide\\\")\", \"function\": \"Abundance\", \"id\": \"fd0dcffbd4e00c161d74c931890123439e35f86a92cbcf20c1efaed0bb8b8469434bbafd8364de8822b9af6368de418ed1728b1534bb8eeb47320d5a9c895548\", \"name\": \"nitric oxide\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:\\\"okadaic acid\\\")\", \"function\": \"Abundance\", \"id\": \"676b3ff5997541b41ef095d98283a202a12cc877b431c8467f956ef1acf990f281c503ef40951a8135be2af35c9c46ccdfc87e4af3ac93d9f086dd911f85683c\", \"name\": \"okadaic acid\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:\\\"trichostatin A\\\")\", \"function\": \"Abundance\", \"id\": \"8c8269fc63126d8bacd63c3b16d5a192e864dcb954f7c1ba24df2c409bb1e0c622f0e213d1c88064ff72a4e30c866f5e7716318547299bc0588a4c568c6058dd\", \"name\": \"trichostatin A\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:Anatabine)\", \"function\": \"Abundance\", \"id\": \"c77d4080804731f0ef07ad52ed2fbccdac5d02fb2620d8800d273e925feebcbf90b94a2399efeb42a91e65413550e0f713cd431329129e1cdd90329cae6b3ff6\", \"name\": \"Anatabine\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:LY294002)\", \"function\": \"Abundance\", \"id\": \"59d55e7fbc9f6ab21fe25d8207c3cf38ca7257a8c70e06ea9d72deb9682098f07c20990b576a320fe6e79e6d4292322f1d3f2e53d4fd4a527f0bb489a20d5cd4\", \"name\": \"LY294002\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:Nilvadipine)\", \"function\": \"Abundance\", \"id\": \"8947c1d5cc222b9ddab1d201b50db6d7b63709282cfa1bd37e44f59d1346952d2271c98963eb6950447f8b5a928b418e15fb56adca21b476a8e64fa6267306d3\", \"name\": \"Nilvadipine\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:Temsirolimus)\", \"function\": \"Abundance\", \"id\": \"6eb519f2ad4d46a6ed4151fc8fc609049b5a772cad25e88cf9c625d12370b056fee390606fd6d862c7544e539a500c9c5a0fc4eba471ccc4f90bb74e9f603024\", \"name\": \"Temsirolimus\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:Thrombin)\", \"function\": \"Abundance\", \"id\": \"bc68bb7b1ce4d529ff43e4ae576707c6817a91b64e6394ef07f6869fc70bd2d52b4efbd63513461b9fc7c5d1a243039b62bfbe4b6cedd75b964ba8fc029dc981\", \"name\": \"Thrombin\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:alsterpaullone)\", \"function\": \"Abundance\", \"id\": \"705482bdfcfe21dad824136f3454a9dabc7e0609f463062e3701efa3fd9a6438a714c395d84a4094636f375a95e6b8e3c28c725bc8dbdf2423b9d1a3f775a94e\", \"name\": \"alsterpaullone\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:cilostazol)\", \"function\": \"Abundance\", \"id\": \"9a9fc863375a0a8fb0f267c2c120528f381f2060312a574cf5a9d9c205f9530144f95335f491adec62c9337983ddce2b1f32ede9421bc887ccaf3349403116c5\", \"name\": \"cilostazol\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:colchicine)\", \"function\": \"Abundance\", \"id\": \"163e44dea110e538be40965635ddb8c88448cb360eaf67456221344e3dbe1635dd37f84108a8541eb8ca0e16e0858d5f3d0bec2362065ae9423688efb3d0e7ed\", \"name\": \"colchicine\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:epoxomicin)\", \"function\": \"Abundance\", \"id\": \"eb3b7101078c7a148059bc56af98e555e9389a80d6c8b98294209380a5edcaeac8037a8ac7a5c1dac375687ecf37eacb17293b8cbebf6a8c4a42adab21774386\", \"name\": \"epoxomicin\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:folates)\", \"function\": \"Abundance\", \"id\": \"cbc3a991fb6f2d7d0e8b8d644426e4477aed396d0f3ec4c79d0b3c02320af60b92502ecc17e33b36699c7e7eda9c241beccbb1e1b5809c17ff6ac4a673ae6a05\", \"name\": \"folates\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:geldanamycin)\", \"function\": \"Abundance\", \"id\": \"495a46f0ccb373f38cd5fc5172590ae53a0619efd473182ef38981d4f2d7d2e6631c171ef484aac26e3891e0d5ef27e716420629b6f3c62aed15ac224ad41430\", \"name\": \"geldanamycin\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:glucose)\", \"function\": \"Abundance\", \"id\": \"ad228f723834a0438254651fae75410bfa5cb8ee6d9baa98af0240115b1e5ec55edb5d001429c764d8785ec034b6b90edc76a4b83d14572cae3624feacf85491\", \"name\": \"glucose\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:glyceraldehyde)\", \"function\": \"Abundance\", \"id\": \"2fe0ade741c61088d74dbdad3d1419f6d84f90566fc41b50fc216894b7f680fa37a69c304076bfffdf00c36ebc9e71dc27ddbdc230c2c5bdb0dff10a92e880bf\", \"name\": \"glyceraldehyde\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:homocysteine)\", \"function\": \"Abundance\", \"id\": \"7a15d69a1f5e63ea5883fdd1570ec1c58c8f891e16cc845d39de3cac7cea8f12c8d936c03cebb64958c2adc3df7c2e36ead35db704f152e5abc1825a20872da3\", \"name\": \"homocysteine\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:metformin)\", \"function\": \"Abundance\", \"id\": \"8e168527ae6f3d001318f64311463a40ace1c41edb9de6f8a7763dbd9c4d9637ed7f886451804e6d45214868ad615fd57c3d6fb052bb97c661b4affe8ee2b50b\", \"name\": \"metformin\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:peroxynitrite)\", \"function\": \"Abundance\", \"id\": \"fe63a43025ec98b86b63f7a0ff59747da6d8d6bdb82dd95d68e59448e6125933848846d8ba1dcb68dbe9928a6c904be0be53c06869cbc1844a302a0d9650304d\", \"name\": \"peroxynitrite\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:salsalate)\", \"function\": \"Abundance\", \"id\": \"6b61e1b1e803aa49edfb3a1a6755b0947054505736a27db51cc6d6507acce3b4ec6fabd0d074e6d502657a0f3d0cf56b1c0cded454a8b36485d7601288c3d743\", \"name\": \"salsalate\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:sirolimus)\", \"function\": \"Abundance\", \"id\": \"102b031a00eed78fd9e5c4236defb90a8995463980f9060493bb5fd3159a3eb666cbb2b6a33a213c749a2b279ef6d149796b4f0b568e03b82eb5c89b0da77426\", \"name\": \"sirolimus\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:staurosporine)\", \"function\": \"Abundance\", \"id\": \"464d650f48027f6208c3bdf2689f01f41f8c4ceb454982e034ae863bd23e0deb8aac1be1b8ceea61fd5fcddbe1c837a1eb816b3193df4b76f754b0b7959c7c07\", \"name\": \"staurosporine\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:tanespimycin)\", \"function\": \"Abundance\", \"id\": \"409d39722f4d5c9457a215c12a920d2bf82d03e7f143571a2ce44293d3b8a741f96f61f35a43f0580f6588e3a11c62fc1888fcdc048311e8b3180dc20f703944\", \"name\": \"tanespimycin\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:wogonin)\", \"function\": \"Abundance\", \"id\": \"eec47f7ee4a9d4cc98914010c6abf560803b8a6d2e0782db0d99f6f58a4b8a859c557ef3f9dccf4ec19fd4e5c71e93a5704a4331cf6c7c62fb74e27049f5b3e7\", \"name\": \"wogonin\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(CHEBI:wortmannin)\", \"function\": \"Abundance\", \"id\": \"dcc61e41e7984480a5acce6dae10d1b3e8e41867fe2cdbcc588699e1c59b9972cb453cd7d5fccdf18f0b097aca6e1fc115bd6005e81e719e2ed50eb7e82dd344\", \"name\": \"wortmannin\", \"namespace\": \"CHEBI\"}, {\"bel\": \"a(GO:\\\"neurofibrillary tangle\\\")\", \"function\": \"Abundance\", \"id\": \"3b50c674ff9633f408e5173562a06cf3a856abc95a8b034db8e940b464f1cea72df6f9fa9b7b02b5daf4eb86a37a155f203289451f7203a7b9c9e6c65313eadf\", \"name\": \"neurofibrillary tangle\", \"namespace\": \"GO\"}, {\"bel\": \"a(GO:microtubule)\", \"function\": \"Abundance\", \"id\": \"0c753f37efe0eb149a47a1dd700eda093a03b462374275c68480b6aed3be0f81aa9793a179dfd97f8e0834f1fb9be4b4a6cff2165b176d9e8a8744f5e0d5bc2c\", \"name\": \"microtubule\", \"namespace\": \"GO\"}, {\"bel\": \"a(GO:synapse)\", \"function\": \"Abundance\", \"id\": \"cc12602eef45267795bef1781b57fdcfc0800fd22ea1a8c57746d2be9789ec52c582f9244ba1318f068bf1cfa150d96ad79553596c1e96633df8fa625ad1af74\", \"name\": \"synapse\", \"namespace\": \"GO\"}, {\"bel\": \"a(HBP:\\\"Tau Protein Secondary Structure, Turn\\\")\", \"function\": \"Abundance\", \"id\": \"7d89c1e535e9fa2cde5b013604ec41c497023cf2a3ecc20026f668df5d02dc041836007094b47a40c4e5b6c85c548bce14241f16d8832e8df19cdeb8ad16835f\", \"name\": \"Tau Protein Secondary Structure, Turn\", \"namespace\": \"HBP\"}, {\"bel\": \"a(HBP:\\\"Tau aggregates\\\")\", \"function\": \"Abundance\", \"id\": \"2f93b798e33773ea9681389870bbee41f6fa7ee04c087bda4bd1492520385f58d089a7261b1353e15c31d3e29a96ff31884886e6ab9fa477ef8f63f19cf154f7\", \"name\": \"Tau aggregates\", \"namespace\": \"HBP\"}, {\"bel\": \"a(HBP:\\\"Tau antibody, 40E8\\\")\", \"function\": \"Abundance\", \"id\": \"b9dc79a894f3563277e1780335b6b791671aed2b5c99c4cff346dd7dc034cf7a2f45aff6aa7a6c5a68b004a8a90a7cc651a36c5faedbac5019bc83f21261302d\", \"name\": \"Tau antibody, 40E8\", \"namespace\": \"HBP\"}, {\"bel\": \"a(HBP:\\\"Tau antibody, pS396\\\")\", \"function\": \"Abundance\", \"id\": \"bce171e6abc27abe31bbf906c70cafa1a52e04542d8f15aca67aa1a53cd2ad9a3fbde4bee5c0d4128c35953c56c45a11f9e57de3c2359edf498b1acfae246eab\", \"name\": \"Tau antibody, pS396\", \"namespace\": \"HBP\"}, {\"bel\": \"a(HBP:\\\"Tau epitope, 12E8\\\")\", \"function\": \"Abundance\", \"id\": \"c34be6135c1bcd4e691269a37f289417ef6eedb6703788075919639ed0c6acb23ba43df0be54976b5421f588702fdbbf831494230c26c570783d44d889d4a1aa\", \"name\": \"Tau epitope, 12E8\", \"namespace\": \"HBP\"}, {\"bel\": \"a(HBP:\\\"Tau epitope, AT180\\\")\", \"function\": \"Abundance\", \"id\": \"b0b8cf64217d1ea9b2008e088c9190a538f9500a5238b79b7b7cd9c21003676daf0558c7665e06bd43d8390679ea61b08cafe4c0b6c9f997603dd3e5ee84fda7\", \"name\": \"Tau epitope, AT180\", \"namespace\": \"HBP\"}, {\"bel\": \"a(HBP:\\\"Tau epitope, CP13\\\")\", \"function\": \"Abundance\", \"id\": \"b265db51adfba5abdc9e0d401f21f82fa16dac7ae7b814311cfeb6e07bc5a9b5a348ba99b8eec10d87c3e3edf1dad111f32026d30dd93ea36983c6c22653836a\", \"name\": \"Tau epitope, CP13\", \"namespace\": \"HBP\"}, {\"bel\": \"a(HBP:\\\"Tau epitope, PHF1\\\")\", \"function\": \"Abundance\", \"id\": \"c133b6c209011d4109489ea5c061c0e42f0d3de18c0fed8add35868a1e7b4e855ef0807c5408696433a43e16957e93313e67d611f53a51cb81089f561d7069a7\", \"name\": \"Tau epitope, PHF1\", \"namespace\": \"HBP\"}, {\"bel\": \"a(HBP:\\\"Tau oligomers\\\")\", \"function\": \"Abundance\", \"id\": \"d4ceff8aa5a5d05770aaa29b828d003b85d64e7e5337c6624b7c5a84111845897462b589e7b259b0eed6bcfc63f34cdaf1f9b988c788804799aea026d8731d98\", \"name\": \"Tau oligomers\", \"namespace\": \"HBP\"}, {\"bel\": \"a(HBP:\\\"Tubastatin A\\\")\", \"function\": \"Abundance\", \"id\": \"543d83ed00654be5a30b1189970df285c3a3dbbc5e4a9b7f8ed08986e84aa64aa6dca0804cad71b9bfef8f9ce23e468fd9b2f3e8dc8f2d61fce603243c374e11\", \"name\": \"Tubastatin A\", \"namespace\": \"HBP\"}, {\"bel\": \"a(HBP:\\\"advanced glycation end product\\\")\", \"function\": \"Abundance\", \"id\": \"b606da9926a6aedd95a3e3bc39323e5326a30baae889e95c54f504370752dfb683372116ca5fa32d4145709a3ee24347cacc159cb1f2d3462a7e3a1b0fe18ed3\", \"name\": \"advanced glycation end product\", \"namespace\": \"HBP\"}, {\"bel\": \"a(HBP:\\\"amyloid-beta antibody, NU1\\\")\", \"function\": \"Abundance\", \"id\": \"a29a235bd4cb1e77c9c01542986b531e9ed9f3a3a90066bd7ebcc8a9806fa43f01065ce178e2d7e145b54c0ca11ab0faec08500c6978933862f9a9ff2794dbbb\", \"name\": \"amyloid-beta antibody, NU1\", \"namespace\": \"HBP\"}, {\"bel\": \"a(HBP:\\\"amyloid-beta derived diffusible ligands\\\")\", \"function\": \"Abundance\", \"id\": \"bb1bf00d89b855bbc846286bc0389eba22194342acf023f66bc324ceacf0ba483cee9dc67d56822bb7efa028804229cb820f4c45346b8131ec4cc58b8ff7f06a\", \"name\": \"amyloid-beta derived diffusible ligands\", \"namespace\": \"HBP\"}, {\"bel\": \"a(HBP:\\\"amyloid-beta fibrils\\\")\", \"function\": \"Abundance\", \"id\": \"67b4c76bd9f06b116883a58eaa40e8453f2fda318ae9313477ebc24c6d04613ea373fdf611fd8a740de5a090826662d88c39f2ab166bca226cc8237cb0c71a1a\", \"name\": \"amyloid-beta fibrils\", \"namespace\": \"HBP\"}, {\"bel\": \"a(HBP:\\\"amyloid-beta oligomers\\\")\", \"function\": \"Abundance\", \"id\": \"a0fc661406161db12bdd89333a13d0ee89b3aa089d5eb16676962cae3efd25d4d3dd6e593dbcaebf5fc0c26f9c8c070a98f2ff0fb94a0d52412c0fa0bf6c5b3b\", \"name\": \"amyloid-beta oligomers\", \"namespace\": \"HBP\"}, {\"bel\": \"a(HBP:\\\"cystein-dependent auto-acetylation\\\")\", \"function\": \"Abundance\", \"id\": \"00ed3d399dca2a1ae08fcc6a0b03496fd11344857eaf3d952bfb5ae75c2ea4210d908ef34c7983754458bff3601c89ebe74de40b76f1c165fa627038f67051aa\", \"name\": \"cystein-dependent auto-acetylation\", \"namespace\": \"HBP\"}, {\"bel\": \"a(HBP:\\\"granulovacuolar degeneration\\\")\", \"function\": \"Abundance\", \"id\": \"54b3df161c7ebc26f946c45b1ae5ca5b615f2be1fa76d947ef8072095dc05e7bf8be6f8b752b892d7440ec2fc1dde20db7c94c0717767859053d266cdd2616d8\", \"name\": \"granulovacuolar degeneration\", \"namespace\": \"HBP\"}, {\"bel\": \"a(HBP:\\\"microtubule-binding region\\\")\", \"function\": \"Abundance\", \"id\": \"284e708151d3cdbad19b4883cd8b646d2cc4aca4e6b25b4267105e4c9dfe435cae86b0db038162e48956fb2de06ded489d92170df9e0c06d0d16a3b3376903c6\", \"name\": \"microtubule-binding region\", \"namespace\": \"HBP\"}, {\"bel\": \"a(HBP:\\\"paired helical filaments\\\")\", \"function\": \"Abundance\", \"id\": \"8d87710f8ebf7593b6b0020396d36a868362a39b367908774a967b0efb7397212d51216da225ac3218af26e6abb0338cdd1d676c9db11cf8e6c16c127fd2305b\", \"name\": \"paired helical filaments\", \"namespace\": \"HBP\"}, {\"bel\": \"a(HBP:AOs)\", \"function\": \"Abundance\", \"id\": \"7c3a4223d3c2ac1376941a05c1ac568d3a03c6086543a5abc115cf771493cdcd33001634a0f97e0ad0ccdb4c18b2a1b08899896dcbcfafb35ca26246f9ee6dcc\", \"name\": \"AOs\", \"namespace\": \"HBP\"}, {\"bel\": \"a(HBP:C646)\", \"function\": \"Abundance\", \"id\": \"07dc705c39483d5077f038aeb34262e11d5c7e30166f8c555aff7e3af00f9c06f4b9fec85b554e2b5bc0607eee111da80db060006b0af350fe8d21755cc0a672\", \"name\": \"C646\", \"namespace\": \"HBP\"}, {\"bel\": \"a(HBP:EC102)\", \"function\": \"Abundance\", \"id\": \"cd1b77d343ac7873cbf6d1066342dd8eee407e8297ea1aa90b07af67324e9d2865b440c27ac952d2d8d0827a77ea0f2f72d98df1748933412d7af7a1db168417\", \"name\": \"EC102\", \"namespace\": \"HBP\"}, {\"bel\": \"a(HBP:HBP00006)\", \"function\": \"Abundance\", \"id\": \"9b1d89d922db273dc91b96b20d332236f065e4b4c3d625fb7f3bb266d7559cfc3e316823ea339ea3dd3e4905c14ea1a3af7b7cf5551ffa2696a1fb7c2a6c5739\", \"name\": \"HBP00006\", \"namespace\": \"HBP\"}, {\"bel\": \"a(HBP:MPT0G211)\", \"function\": \"Abundance\", \"id\": \"6d3500e4fd41afa1436b3dcbc82c09c9c9db4d376179493bf80bfb418709f0b69cacef45c1481ef683b3c9b3ebb2f05dea9370c2845f5fdd81ab02bd0cbbd000\", \"name\": \"MPT0G211\", \"namespace\": \"HBP\"}, {\"bel\": \"a(HBP:Neurodegeneration)\", \"function\": \"Abundance\", \"id\": \"52fac4ee7f9b3b0fbfcb98add48ce6b5926d97ec8d5b2d7be5e26abd9856e9a5fb4751523d7874eb2444348b726fedf3c0e18a99cf5383b69f3380c3be2f91ff\", \"name\": \"Neurodegeneration\", \"namespace\": \"HBP\"}, {\"bel\": \"a(HBP:pretangles)\", \"function\": \"Abundance\", \"id\": \"82ed31423f81cad1748e2f7a16b9461807d9401881de4ddec0756f537a6ce0f7fe9877f6f38c94ed3dc43ae275d5943b7aa413e13689f0b98be0f1239ed0edfb\", \"name\": \"pretangles\", \"namespace\": \"HBP\"}, {\"bel\": \"a(MESH:\\\"(S)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro(4.5)decan-3-one\\\")\", \"function\": \"Abundance\", \"id\": \"38e1843a906b6279ca2a95c5dc6dc834704e57c748aa0b4f88f0c8100d80f1a6e9fdb1cb9085ba0caebac6ca3fd53d022433d91ed309b03dd9287f7f56f57aae\", \"name\": \"(S)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro(4.5)decan-3-one\", \"namespace\": \"MESH\"}, {\"bel\": \"a(MESH:\\\"4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine\\\")\", \"function\": \"Abundance\", \"id\": \"974e7ea9cc24b53a13a49a8b96f777bd1ad3ae7e05c95f6d5961be51aa632c5384005c993a0b73c10f9450c1ec83f053668bbd613052a502083874397f2e5779\", \"name\": \"4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine\", \"namespace\": \"MESH\"}, {\"bel\": \"a(MESH:\\\"HSP70 Heat-Shock Proteins\\\")\", \"function\": \"Abundance\", \"id\": \"ca8a7f5a3b3fea4bbbc2cdea03a15dcf41cfdb2c5635ce8c6a6c3f4335e6e6cee15e2224563864ba0eca76f22249f663ca4e5a5cf21144139376d24d77d77e41\", \"name\": \"HSP70 Heat-Shock Proteins\", \"namespace\": \"MESH\"}, {\"bel\": \"a(MESH:\\\"Neurofibrillary Tangles\\\")\", \"function\": \"Abundance\", \"id\": \"3d83c65a7f42e71c4a115c5beea8400b29c090a6f7cf81c3efd0ebadf5e1fcc2605b24f0d4e381f1625802594fc6c4bdc3a07a222f58e34aee7c3125b1b037db\", \"name\": \"Neurofibrillary Tangles\", \"namespace\": \"MESH\"}, {\"bel\": \"a(MESH:\\\"Neuropil Threads\\\")\", \"function\": \"Abundance\", \"id\": \"2674bac52da2313938bd01c8084dfe37febb56df5167432b356a373831e12c13e7969e7778ff158687e9280ce94b2c53fe1403bcc9d38c2cadb42f0f65f18e79\", \"name\": \"Neuropil Threads\", \"namespace\": \"MESH\"}, {\"bel\": \"a(MESH:\\\"Receptors, Nicotinic\\\")\", \"function\": \"Abundance\", \"id\": \"ab9ab8a42f27ea8b317e817b34a7ed7609808e3ccad71f0ce8685fa7b9e53fd847534ce7483452cc11f2166657f178e8e6804466c34019ef9674372b725b155d\", \"name\": \"Receptors, Nicotinic\", \"namespace\": \"MESH\"}, {\"bel\": \"a(MESH:Bungarotoxins)\", \"function\": \"Abundance\", \"id\": \"e82ea3e9e348ccc642bfadc616f1a99ecd72a491d90148c9f3dab9d287736cbe6dc1c75aa356f12fe0d4f03ed52017ac9fd4193be328c15a06a0c26397db3fd2\", \"name\": \"Bungarotoxins\", \"namespace\": \"MESH\"}, {\"bel\": \"a(MESH:Exosomes)\", \"function\": \"Abundance\", \"id\": \"8c18d3f2857c6224d1a64c194590d5feb768c6b5702894793347106f0934e6decd18cf29c425ecfaa587372a5c68f3c16a00ba0691d54652a5fa1872105f09ad\", \"name\": \"Exosomes\", \"namespace\": \"MESH\"}, {\"bel\": \"a(MESH:Neurons)\", \"function\": \"Abundance\", \"id\": \"130131072f276d163b9e361a4ca4814f1d254907d297db502ccb4f6e75dff10db1f2b384bb435c9b46e91310d585aea1db3108e00905a31bb1388ccda1f0c643\", \"name\": \"Neurons\", \"namespace\": \"MESH\"}, {\"bel\": \"a(PUBCHEM:11249342)\", \"function\": \"Abundance\", \"id\": \"a46738b941738ccd9850de2ee68d8707ed2370bd9a91e2bde28f56a100b25e932132c325e594949b4600c31fca28105cfb8c05197d03d2cb1cac44c0983130ad\", \"name\": \"11249342\", \"namespace\": \"PUBCHEM\"}, {\"bel\": \"a(PUBCHEM:5757)\", \"function\": \"Abundance\", \"id\": \"7577fa22a8008e0bc6af94bd7cd8fa97da4431bddb82aca7ee4d960d54c184b03dbf1cf816b024df1255d3db6f96c54dc2146d368611c369ea920fa935bae58f\", \"name\": \"5757\", \"namespace\": \"PUBCHEM\"}, {\"bel\": \"bp(GO:\\\"actin filament bundle assembly\\\")\", \"function\": \"BiologicalProcess\", \"id\": \"30fffe26a2e0e4facdb719ea8224550e39147fcfc8206bbb45d262167b03a2cd1e944799a44f07c06a7f0841000f52ee050947a6b94fb7d2ffaa2ffcdc831765\", \"name\": \"actin filament bundle assembly\", \"namespace\": \"GO\"}, {\"bel\": \"bp(GO:\\\"actin filament polymerization\\\")\", \"function\": \"BiologicalProcess\", \"id\": \"0504af10703db0820e218db3c64b2815cc2bdff1e2adf121b143d4020ea5ebb1311bbd6f5e75fcb1f4e44b5cb7803bbe57e7c2c683a769577623120eda102f5f\", \"name\": \"actin filament polymerization\", \"namespace\": \"GO\"}, {\"bel\": \"bp(GO:\\\"anterograde axonal transport\\\")\", \"function\": \"BiologicalProcess\", \"id\": \"3e2a461cd655539ec9974778be985c658ff333fb9fa15a9f30d1c37ab22b3e9026879c53df6ea417eeb9f5e4378442b8d4a592cd24b9f15164cbf979e7988fcd\", \"name\": \"anterograde axonal transport\", \"namespace\": \"GO\"}, {\"bel\": \"bp(GO:\\\"apoptotic process\\\")\", \"function\": \"BiologicalProcess\", \"id\": \"1c5172472cbecf29eeb8e86a4cac2d13123fe572356f00e2f98302422560bbda2854e3b1f8fdf85396655393cf5ddb42e0db210c3d3fc146fa358cc8d0ed0254\", \"name\": \"apoptotic process\", \"namespace\": \"GO\"}, {\"bel\": \"bp(GO:\\\"axonal transport\\\")\", \"function\": \"BiologicalProcess\", \"id\": \"05b46e2a47c4835f765deb7eb33b970b7abbb53b690b7881e2beda6bc739337253a12aaafa51ebf63ed9f7ad7f09bcd7f5ce4fda7373ed3f4f0eadedaf2c14d0\", \"name\": \"axonal transport\", \"namespace\": \"GO\"}, {\"bel\": \"bp(GO:\\\"cell death in response to oxidative stress\\\")\", \"function\": \"BiologicalProcess\", \"id\": \"fde42377a4eefea9dfcf9fd6bdafa4bad0037a7589e55f63818def5cbb9348eaf12ae719d6268e1de6c66acbc81bd659712acbbf18048aab6613ee37cd62b0c1\", \"name\": \"cell death in response to oxidative stress\", \"namespace\": \"GO\"}, {\"bel\": \"bp(GO:\\\"chaperone-mediated autophagy\\\")\", \"function\": \"BiologicalProcess\", \"id\": \"1becad934ecf26ef0dbbb6985a45169a688cfeb4825fbe7b3534fe465a70623a05fbff45ee7812a49cff207a8c0fdfbb7a9f2083bcbeb7f609f31b3d9d0ca6b0\", \"name\": \"chaperone-mediated autophagy\", \"namespace\": \"GO\"}, {\"bel\": \"bp(GO:\\\"long-term synaptic potentiation\\\")\", \"function\": \"BiologicalProcess\", \"id\": \"90aca567c87981f32f4001b6386423cf473ef52decf04004bd136ab80fd9088c2698b76c8baf740f8e282b107790d3c88130dc99225bab73b22516859dc4203a\", \"name\": \"long-term synaptic potentiation\", \"namespace\": \"GO\"}, {\"bel\": \"bp(GO:\\\"maintenance of synapse structure\\\")\", \"function\": \"BiologicalProcess\", \"id\": \"5514e9c0fb26f9cad6245a5efe4f1d6693212fcd749a1f98f2d6d27201a35f94971555d04233bff6154b1eb0688ef9df0a31b7170c37adef8378e2e2baf69b75\", \"name\": \"maintenance of synapse structure\", \"namespace\": \"GO\"}, {\"bel\": \"bp(GO:\\\"microtubule depolymerization\\\")\", \"function\": \"BiologicalProcess\", \"id\": \"cbc62aa7f87ffe4350701ec23c8ddf1148abf26bacc57be664ea8437f6626d6e51e860b0f28c5ae7aadf04cd58501bdc8cc60156643ce38b9fbc927d1522a6d5\", \"name\": \"microtubule depolymerization\", \"namespace\": \"GO\"}, {\"bel\": \"bp(GO:\\\"microtubule polymerization\\\")\", \"function\": \"BiologicalProcess\", \"id\": \"96a7816f8b02933054d24cccfe2f73fb8beb845049ee361c408761f17dbfda8aa44e9e83f8ee54cf90d9984d0676e2208acff137deee1e66e4c3c9bac2f35dcd\", \"name\": \"microtubule polymerization\", \"namespace\": \"GO\"}, {\"bel\": \"bp(GO:\\\"neurofibrillary tangle assembly\\\")\", \"function\": \"BiologicalProcess\", \"id\": \"ddb806442eeaf16c4573d02545b21939cd739066593dc5fde6d82f5d5b7bad5b274420d38fb8d36b39d6ab68d6de55b663d56fca339fd516217d141e702e5815\", \"name\": \"neurofibrillary tangle assembly\", \"namespace\": \"GO\"}, {\"bel\": \"bp(GO:\\\"neuron apoptotic process\\\")\", \"function\": \"BiologicalProcess\", \"id\": \"b9dabb1ef70e6265bcd2b24c2109961235bb35268bf9525a7ce468bd3244274273d156fc8c743c001d71896f7e3fc4dd9cf8a2e06ecf33e2f55fba778d2fa6d7\", \"name\": \"neuron apoptotic process\", \"namespace\": \"GO\"}, {\"bel\": \"bp(GO:\\\"neuron death\\\")\", \"function\": \"BiologicalProcess\", \"id\": \"ad7c90f2bc746a5118759fd1c8857478c02207d574a26faaac9d6e4d6fa4661d8d87446139db0024a4011aae26027d3cabdfba663aec0ac0a8242868efb81dcd\", \"name\": \"neuron death\", \"namespace\": \"GO\"}, {\"bel\": \"bp(GO:\\\"one-carbon metabolic process\\\")\", \"function\": \"BiologicalProcess\", \"id\": \"94821c43bf83be88fff4b23eca29ea1b76ac0fd43925555753fd2c246cada3388f3610a4a5e75366bee987a14b92d87d8ddaebb23d781816833feb4690b34322\", \"name\": \"one-carbon metabolic process\", \"namespace\": \"GO\"}, {\"bel\": \"bp(GO:\\\"proteasomal protein catabolic process\\\")\", \"function\": \"BiologicalProcess\", \"id\": \"324086c86308e796be8d2ae554cb050d6b8e76fee968291bd1fb3369778f50d22bdfa1b56bc1b1987d5c75f119311e55eb2a0b2809f440341177c8fe7b879576\", \"name\": \"proteasomal protein catabolic process\", \"namespace\": \"GO\"}, {\"bel\": \"bp(GO:\\\"synaptic signaling\\\")\", \"function\": \"BiologicalProcess\", \"id\": \"a8b13fd2aaaa14131c785eef00ad6089f96f7bb6842c63429368576305a6bcc1f0d4e8ef883db38eafd1e7ee262705d86552839efbc53b7a27665d853ffc4fd3\", \"name\": \"synaptic signaling\", \"namespace\": \"GO\"}, {\"bel\": \"bp(GO:\\\"tubulin complex assembly\\\")\", \"function\": \"BiologicalProcess\", \"id\": \"6f0669952c4b7e7a0970c1be7ba291acf5805a584a0359cb504bfc666ecee115a2c5f765102936f026e36c56c575414e8ec75ce2f8408e5e672ff413af584415\", \"name\": \"tubulin complex assembly\", \"namespace\": \"GO\"}, {\"bel\": \"bp(GO:autophagy)\", \"function\": \"BiologicalProcess\", \"id\": \"f1a3202be460e565f65c1445ee061e99f63cc05f9ab70c5d4d8d93ba180d6a94f65cb8d1ac6c5ba53c0a4d2e153db32135e6a0bffcfdfd4d84e6727594a70b0a\", \"name\": \"autophagy\", \"namespace\": \"GO\"}, {\"bel\": \"bp(GO:cognition)\", \"function\": \"BiologicalProcess\", \"id\": \"8d73f2caa1c473289d5f37cbdd4ad391a120cdbdf2356b373070c2a7b2bc0c785eaa620782fa2dd947c666100f0a169e81f35864f359cadf3e1550962fcc4127\", \"name\": \"cognition\", \"namespace\": \"GO\"}, {\"bel\": \"bp(GO:macroautophagy)\", \"function\": \"BiologicalProcess\", \"id\": \"568e5f70e05a1543c9a1d54019c461ab0802ff3556801ad06f2231e0687a80f2cbd21d12f808f5d72752f7cc8c484e0b32d830256321af323cfd08b1b63cc765\", \"name\": \"macroautophagy\", \"namespace\": \"GO\"}, {\"bel\": \"bp(MESH:\\\"Hot Temperature\\\")\", \"function\": \"BiologicalProcess\", \"id\": \"e2fdd0bcaae16da3a0744518cfdb3cdfe63c64465dbbb8fc6a28da0848b132099b6951f0b0745f864bef44ef0e19d0975a512ea5fab410826271489dc20df5b5\", \"name\": \"Hot Temperature\", \"namespace\": \"MESH\"}, {\"bel\": \"bp(MESH:\\\"Oxidative Stress\\\")\", \"function\": \"BiologicalProcess\", \"id\": \"32bd3ab5e8a3a26be3209856c88741f0f0e2dff98d2587599a6a21b0f4793c5d8feb1194ea2166cf3cece076e7095530b116270e6655bc8feb35a437fda42cf6\", \"name\": \"Oxidative Stress\", \"namespace\": \"MESH\"}, {\"bel\": \"bp(MESH:Autophagy)\", \"function\": \"BiologicalProcess\", \"id\": \"f1913e2aaf121752a9a1f2363a1eb831bad94f6c5afb7f43bd8977fa957b599b3e70e774d6b4d053db3f7542f7b226221a7c10496e832f2c1f493e86d4369410\", \"name\": \"Autophagy\", \"namespace\": \"MESH\"}, {\"bel\": \"bp(MESH:Mitosis)\", \"function\": \"BiologicalProcess\", \"id\": \"de110ec7edef1d9337ca58f73bb8a1c9c35117595f597e27b1a58d8bd3d93f35f26a760f3bdb49c3106ee542458ec2b8d1064aedeb1d7322034edb6e62763fd8\", \"name\": \"Mitosis\", \"namespace\": \"MESH\"}, {\"bel\": \"complex(GO:\\\"Cajal body\\\")\", \"function\": \"Complex\", \"id\": \"c080a187f662c99df4fdfacde67daea96a018634140d335b5841558b541ae1e4d9d293de7e1a26e3a90611f05118ded969c51ca97c76d720354fa7bc85bec09c\", \"name\": \"Cajal body\", \"namespace\": \"GO\"}, {\"bel\": \"complex(GO:\\\"Pick body\\\")\", \"function\": \"Complex\", \"id\": \"9c5d3ca57357e60048354eaffd134a2872126b0004b4d1a78b1f7ab20d3d2b1d73445c6a3d4cdc9c6f0dcb0925e7cf91abddff7902c498b7b5bd450f089c78be\", \"name\": \"Pick body\", \"namespace\": \"GO\"}, {\"bel\": \"complex(GO:\\\"filamentous actin\\\")\", \"function\": \"Complex\", \"id\": \"98934728511be71546a4951fdd9499b480b537fdff6fd0200467db38b82c1e26e09f23752a3170ed1ec9dc72e172624ebbab04ebeed002d77e606af519e2dc58\", \"name\": \"filamentous actin\", \"namespace\": \"GO\"}, {\"bel\": \"complex(GO:\\\"neurofibrillary tangle\\\")\", \"function\": \"Complex\", \"id\": \"83563b0bf7b4e8223bab3bc7bfc5d3f34eef173b06c17dc9313fe7f786eebd3eda569f012c7293bdcece2a95a9c825fee6f7643ff2c31525f6806be2449fbdcb\", \"name\": \"neurofibrillary tangle\", \"namespace\": \"GO\"}, {\"bel\": \"complex(GO:\\\"proteasome complex\\\")\", \"function\": \"Complex\", \"id\": \"5deb6bcfdcfa66f95c4979205b8144cf23a26c8da492c2d4b71750a7f8e440a3d40a37452d67ccbdccfba2bd5cea7bf1bbba3d66e18875bae3fd8abd8d3d68f4\", \"name\": \"proteasome complex\", \"namespace\": \"GO\"}, {\"bel\": \"complex(GO:\\\"protein phosphatase type 2A complex\\\")\", \"function\": \"Complex\", \"id\": \"052c9f5cf99d0c5c2e8b92b4b64bc3bd8f6ef3ea6ee659342b48b1d99644fa41f03b2c5c8519e63b12f671cbd835982cd3887c7e54fdfe3ef915a1477a60a50b\", \"name\": \"protein phosphatase type 2A complex\", \"namespace\": \"GO\"}, {\"bel\": \"complex(GO:\\\"tubulin complex\\\")\", \"function\": \"Complex\", \"id\": \"f618178fd46029e57d801459ce09e17907a2d566094b7f8dd4ff98faaf3de150c4118b96f7b36e71f49cf77e1bf6425f775ca94adb9697c0e208ccf633110294\", \"name\": \"tubulin complex\", \"namespace\": \"GO\"}, {\"bel\": \"complex(a(GO:\\\"filamentous actin\\\"), p(HGNC:MAPT))\", \"function\": \"Complex\", \"id\": \"6d372af6f25effe4ff72671a811eabacaec5aa3c5d4bb41ee8c50846756d37d0024f0529e67e28369fefc3b74dc6284923229c565d898063a63f84e6542efa35\", \"members\": [{\"bel\": \"a(GO:\\\"filamentous actin\\\")\", \"function\": \"Abundance\", \"id\": \"5527d5652cdac735338ae3e1099fe49deb61ba7d536b6bf3ad06d1052de4d85c2f0f267cab9603e3143db3c9dbb98e7e0a2a87118800eef92a0a292691f1aa7b\", \"name\": \"filamentous actin\", \"namespace\": \"GO\"}, {\"bel\": \"p(HGNC:MAPT)\", \"function\": \"Protein\", \"id\": \"ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1\", \"name\": \"MAPT\", \"namespace\": \"HGNC\"}]}, {\"bel\": \"complex(a(GO:\\\"filamentous actin\\\"), p(HGNC:MAPT, frag(\\\"254_284\\\")))\", \"function\": \"Complex\", \"id\": \"916c41685bfa53f238c7b92bb643b61465dc8569cb58c70280327e3a2fb3670e0a773c2010fca004a9525af005900b05d05e445a71a88e5a527bb6378827a859\", \"members\": [{\"bel\": \"a(GO:\\\"filamentous actin\\\")\", \"function\": \"Abundance\", \"id\": \"5527d5652cdac735338ae3e1099fe49deb61ba7d536b6bf3ad06d1052de4d85c2f0f267cab9603e3143db3c9dbb98e7e0a2a87118800eef92a0a292691f1aa7b\", \"name\": \"filamentous actin\", \"namespace\": \"GO\"}, {\"bel\": \"p(HGNC:MAPT, frag(\\\"254_284\\\"))\", \"function\": \"Protein\", \"id\": \"731135c41eebb9e6b7537dadf81f09079695a7688328c25f6677759a1baedb8e43f084bb6d143631fb9df434d46104cf96d90d4d676ceda0cd5ec6d6c4b72052\", \"name\": \"MAPT\", \"namespace\": \"HGNC\", \"variants\": [{\"kind\": \"frag\", \"start\": 254, \"stop\": 284}]}]}, {\"bel\": \"complex(a(GO:\\\"proteasome regulatory particle\\\"), p(HGNC:MAPT, pmod(HBP:hyperphosphorylation)))\", \"function\": \"Complex\", \"id\": \"e029bcdf26e8cbe3243796479d4c81ba1bea8554f0088ba3a36ec0b2859c76ef948c010824b597eda3123df33dea548d449d317b044e055076afcfbe97f14031\", \"members\": [{\"bel\": \"a(GO:\\\"proteasome regulatory particle\\\")\", \"function\": \"Abundance\", \"id\": \"b6efe0e4581a73dcf96c1605ffca2101cf3eeaa54cad898e5ab785791ab5714d6e0ed42d638eca45cd0c51233f2233f7a85e1ac5f2e6125d66d3ff004b5510cc\", \"name\": \"proteasome regulatory particle\", \"namespace\": \"GO\"}, {\"bel\": \"p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))\", \"function\": \"Protein\", \"id\": \"ede67fb639f29861d91976fefa16d8279b53ae13a659f35d70ed12e01bf3f339ffcf701fc54c7c4e908fee9902c02aac3e0022dcae5a7afa217ed2d4dba133b0\", \"name\": \"MAPT\", \"namespace\": \"HGNC\", \"variants\": [{\"identifier\": {\"name\": \"hyperphosphorylation\", \"namespace\": \"HBP\"}, \"kind\": \"pmod\"}]}]}, {\"bel\": \"complex(a(GO:\\\"protein phosphatase type 2A complex\\\"), p(HGNC:MAPT))\", \"function\": \"Complex\", \"id\": \"222fdd5310a7b8a62bc7f811bfab057d3ce50af7eaafb58600b2a6cd5e8d41029c5d0e145f8a634a8fc4089e3adad92488c65aadbf8268a523c15240a3e27b80\", \"members\": [{\"bel\": \"a(GO:\\\"protein phosphatase type 2A complex\\\")\", \"function\": \"Abundance\", \"id\": \"ab8bf5c69e168c1203a35cfdec34b2b88774b68fe888c92852a884b2ee707ab9f485ab7b972f3228af5072ca200824eadca8ff0974f875da04eb3bc807dbd38a\", \"name\": \"protein phosphatase type 2A complex\", \"namespace\": \"GO\"}, {\"bel\": \"p(HGNC:MAPT)\", \"function\": \"Protein\", \"id\": \"ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1\", \"name\": \"MAPT\", \"namespace\": \"HGNC\"}]}, {\"bel\": \"complex(a(GO:microtubule), p(HGNC:MAPT))\", \"function\": \"Complex\", \"id\": \"d7f2684793c3c1a57485b55fb8f794739e78d15404986239556841672a48127c8ba3d10a4d9c685163f7442d36972062fdc0329cb3373c4d2cc787e67c185da0\", \"members\": [{\"bel\": \"a(GO:microtubule)\", \"function\": \"Abundance\", \"id\": \"0c753f37efe0eb149a47a1dd700eda093a03b462374275c68480b6aed3be0f81aa9793a179dfd97f8e0834f1fb9be4b4a6cff2165b176d9e8a8744f5e0d5bc2c\", \"name\": \"microtubule\", \"namespace\": \"GO\"}, {\"bel\": \"p(HGNC:MAPT)\", \"function\": \"Protein\", \"id\": \"ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1\", \"name\": \"MAPT\", \"namespace\": \"HGNC\"}]}, {\"bel\": \"complex(a(HBP:\\\"amyloid-beta derived diffusible ligands\\\"), p(HGNC:MAPT))\", \"function\": \"Complex\", \"id\": \"89b26633e25e6cc1b729314c465b6e5b8d5c259712d38d46d3504562484ffd6445c5fa0443b28c58c0acab4336029eb1cfa4d1b45a8e58e7000059019c956d21\", \"members\": [{\"bel\": \"a(HBP:\\\"amyloid-beta derived diffusible ligands\\\")\", \"function\": \"Abundance\", \"id\": \"bb1bf00d89b855bbc846286bc0389eba22194342acf023f66bc324ceacf0ba483cee9dc67d56822bb7efa028804229cb820f4c45346b8131ec4cc58b8ff7f06a\", \"name\": \"amyloid-beta derived diffusible ligands\", \"namespace\": \"HBP\"}, {\"bel\": \"p(HGNC:MAPT)\", \"function\": \"Protein\", \"id\": \"ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1\", \"name\": \"MAPT\", \"namespace\": \"HGNC\"}]}, {\"bel\": \"complex(a(HBP:HBP00172), p(HGNC:CDK5))\", \"function\": \"Complex\", \"id\": \"d0984fbcfc223f9f22b239db7421a50ca20af50ed0c62c0c418d6208561d069732e762402bc0fffe15d47a3f44221e45c8607a3f7153d389a1cf5b469000eac9\", \"members\": [{\"bel\": \"a(HBP:HBP00172)\", \"function\": \"Abundance\", \"id\": \"db6eca991deb3a59fb0633e05378ff9273fa350d21923bdf4b59bb818845e4b01d46e36f5eaa025ec748f7a6665509b07f2759061232fd6e7ea69cb8299a7939\", \"name\": \"HBP00172\", \"namespace\": \"HBP\"}, {\"bel\": \"p(HGNC:CDK5)\", \"function\": \"Protein\", \"id\": \"a85beb5b2b9417fabbbcc2135b9533cb0766b38688caf02242632843ae455bad332fb625d6e8296ff77b40e841485a56854fc14e300552425d596e8a8e70fd3f\", \"name\": \"CDK5\", \"namespace\": \"HGNC\"}]}, {\"bel\": \"complex(a(MESH:Actins), p(HGNC:MAPT))\", \"function\": \"Complex\", \"id\": \"e7f680ca107b84e877055ccce9e0d3535e56716090479324c8cee8a6133cfde171c880bd2a89479147b19d12f8b14a50eca116aedde712641fe114ae6b944759\", \"members\": [{\"bel\": \"a(MESH:Actins)\", \"function\": \"Abundance\", \"id\": \"862200ff31493e4d10c53a98d76a02636aa7bee5e8e2194a9b3e6c9450307e08f32a0534c01c984f703640b802f28e4417f810275cf9e24ae71b0c179c1db426\", \"name\": \"Actins\", \"namespace\": \"MESH\"}, {\"bel\": \"p(HGNC:MAPT)\", \"function\": \"Protein\", \"id\": \"ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1\", \"name\": \"MAPT\", \"namespace\": \"HGNC\"}]}, {\"bel\": \"complex(p(FPLX:HSP90), p(HGNC:FKBP5))\", \"function\": \"Complex\", \"id\": \"f6d435bb0f57fea31ad0705da13d03742ecdc06c987ffb03a38353e7e211b28178628dd9824cad41356633ed25380a9a2ee76fc767f12f48c81cc6ec80c1fa25\", \"members\": [{\"bel\": \"p(FPLX:HSP90)\", \"function\": \"Protein\", \"id\": \"a5bdfe1366faea602e03fefece5805427ae4af29a007d93291e6224dc74a8cab597169f580be49b50b4c24e83fa743fefa44549edb827a4dd531224d7d373245\", \"name\": \"HSP90\", \"namespace\": \"FPLX\"}, {\"bel\": \"p(HGNC:FKBP5)\", \"function\": \"Protein\", \"id\": \"235130a6aad5392b8d93ce87ee8c3548278ee308274731183499ce12dda8591cebd72053e22806a7c74a50cea9078cc291520f2bb9b1af2eb56e3880dd8d73ab\", \"name\": \"FKBP5\", \"namespace\": \"HGNC\"}]}, {\"bel\": \"complex(p(FPLX:PPP2), p(HGNC:MAPT))\", \"function\": \"Complex\", \"id\": \"79aa983460cb57b7dda5f4a3e58eb0734dae8f8fad4ca7576262fe7518213f9eca6b82af2b1389e5f7e8e97e4006d4a524e094b4bee1b6bf1ecfd6e48ff42808\", \"members\": [{\"bel\": \"p(FPLX:PPP2)\", \"function\": \"Protein\", \"id\": \"a9377307576389f08c186ac62c6f48293be2fe1495d38cb53c33f9185f3625cb580b310ee4f6d15c636acf1f460f4b54f0dc8c94808295084b9484f709c91fdd\", \"name\": \"PPP2\", \"namespace\": \"FPLX\"}, {\"bel\": \"p(HGNC:MAPT)\", \"function\": \"Protein\", \"id\": \"ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1\", \"name\": \"MAPT\", \"namespace\": \"HGNC\"}]}, {\"bel\": \"complex(p(HGNC:CDK5), p(HGNC:MAPT, pmod(Ph, Ser, 202)))\", \"function\": \"Complex\", \"id\": \"2c557434654268472f2d0a780e143ac8719313a6beccd0e2806f7641a44be71b36a6e20984c2f3ab6d04801ff5b25d7330da5f0f086accd439fca4166c915d5f\", \"members\": [{\"bel\": \"p(HGNC:CDK5)\", \"function\": \"Protein\", \"id\": \"a85beb5b2b9417fabbbcc2135b9533cb0766b38688caf02242632843ae455bad332fb625d6e8296ff77b40e841485a56854fc14e300552425d596e8a8e70fd3f\", \"name\": \"CDK5\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(HGNC:MAPT, pmod(Ph, Ser, 202))\", \"function\": \"Protein\", \"id\": \"49b56446b699c749fbb01c4560254bbf621f44bd52a02cb74e212fb0ef1b9b1616a31cfe6ca06023fee3689ef552a3e8fe71211987ebad4180c2d78535f4ad7a\", \"name\": \"MAPT\", \"namespace\": \"HGNC\", \"variants\": [{\"code\": \"Ser\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 202}]}]}, {\"bel\": \"complex(p(HGNC:CDK5), p(HGNC:MAPT, pmod(Ph, Ser, 396)))\", \"function\": \"Complex\", \"id\": \"91afd2772ad68decda74c18795c8335d7fcb26c86899d2e78752a212b90fa64ddf07d03131e31a47d44cf4c91e1a19bfc82eb6263baf3623174dff1dba85b114\", \"members\": [{\"bel\": \"p(HGNC:CDK5)\", \"function\": \"Protein\", \"id\": \"a85beb5b2b9417fabbbcc2135b9533cb0766b38688caf02242632843ae455bad332fb625d6e8296ff77b40e841485a56854fc14e300552425d596e8a8e70fd3f\", \"name\": \"CDK5\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(HGNC:MAPT, pmod(Ph, Ser, 396))\", \"function\": \"Protein\", \"id\": \"233ebce30d7505cee42acc956f9d268e5b725e14853bd56fab3b87a93a4e0c8141a6fdec062d10e9c4924f6e13a61184600872c2f5080656e3ca27227eb4cb93\", \"name\": \"MAPT\", \"namespace\": \"HGNC\", \"variants\": [{\"code\": \"Ser\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 396}]}]}, {\"bel\": \"complex(p(HGNC:CDK5), p(HGNC:MAPT, pmod(Ph, Ser, 404)))\", \"function\": \"Complex\", \"id\": \"f9ccbb4594b3be2ee1fc804701c59b97dba109cc2c9e5c059625cb2f4b0ec64d92212b8bd24411be2715e3eaf16b6f4a55535077930176d1881767ef9a925388\", \"members\": [{\"bel\": \"p(HGNC:CDK5)\", \"function\": \"Protein\", \"id\": \"a85beb5b2b9417fabbbcc2135b9533cb0766b38688caf02242632843ae455bad332fb625d6e8296ff77b40e841485a56854fc14e300552425d596e8a8e70fd3f\", \"name\": \"CDK5\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(HGNC:MAPT, pmod(Ph, Ser, 404))\", \"function\": \"Protein\", \"id\": \"a448f901ddc919f32d50fa5284355b4eb4ed52e9ebf8705052086706d728d8ebef0cc66616b7fbfda3aeffd49db6e41134fb39996aa9b996a73bce331de95767\", \"name\": \"MAPT\", \"namespace\": \"HGNC\", \"variants\": [{\"code\": \"Ser\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 404}]}]}, {\"bel\": \"complex(p(HGNC:CDK5), p(HGNC:MAPT, pmod(Ph, Thr, 212)))\", \"function\": \"Complex\", \"id\": \"acf5d610041ea8286504c48dc7c7a05852c2c895bfe05679d1935030f84ed500267993e61e728df917eb51a94da3ab1da54e4149ac20c2d211cdc0b3d0d8248c\", \"members\": [{\"bel\": \"p(HGNC:CDK5)\", \"function\": \"Protein\", \"id\": \"a85beb5b2b9417fabbbcc2135b9533cb0766b38688caf02242632843ae455bad332fb625d6e8296ff77b40e841485a56854fc14e300552425d596e8a8e70fd3f\", \"name\": \"CDK5\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(HGNC:MAPT, pmod(Ph, Thr, 212))\", \"function\": \"Protein\", \"id\": \"d10f7602e71867be5adc0f8e0dc989e83163432837ca2c5869ab7d763dad95b87dc4ebcacb9c440ac7c30a31e1b7f42adbacd9bac529384743ab44360f7dc34e\", \"name\": \"MAPT\", \"namespace\": \"HGNC\", \"variants\": [{\"code\": \"Thr\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 212}]}]}, {\"bel\": \"complex(p(HGNC:CDK5), p(HGNC:MAPT, pmod(Ph, Thr, 217)))\", \"function\": \"Complex\", \"id\": \"d68db9b01b417c2184955c62832ecd3e97e03d0e0546cda3a4feb19856f5e3bc3519bad74e567c5367efb093ea02b9bfb91d0f48268f00192e5dd1198e48c9a0\", \"members\": [{\"bel\": \"p(HGNC:CDK5)\", \"function\": \"Protein\", \"id\": \"a85beb5b2b9417fabbbcc2135b9533cb0766b38688caf02242632843ae455bad332fb625d6e8296ff77b40e841485a56854fc14e300552425d596e8a8e70fd3f\", \"name\": \"CDK5\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(HGNC:MAPT, pmod(Ph, Thr, 217))\", \"function\": \"Protein\", \"id\": \"b4d5af93a5669d322815fe554157d6084d3e61d0d7575b2364599e24718be87f316e289a0c882f7c5316ffdbc939554716d4349e10d245154edcc6ff90e53b13\", \"name\": \"MAPT\", \"namespace\": \"HGNC\", \"variants\": [{\"code\": \"Thr\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 217}]}]}, {\"bel\": \"complex(p(HGNC:FKBP5), p(HGNC:MAPT))\", \"function\": \"Complex\", \"id\": \"0cbb5bcb442e40c827a60f8abf6de23136cb949d36cbd17e555971637850cdebad7c9a43cfd6cd46c0f63bba2d80eb49b5a6c59882c6d04f4f6ed172810d772f\", \"members\": [{\"bel\": \"p(HGNC:FKBP5)\", \"function\": \"Protein\", \"id\": \"235130a6aad5392b8d93ce87ee8c3548278ee308274731183499ce12dda8591cebd72053e22806a7c74a50cea9078cc291520f2bb9b1af2eb56e3880dd8d73ab\", \"name\": \"FKBP5\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(HGNC:MAPT)\", \"function\": \"Protein\", \"id\": \"ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1\", \"name\": \"MAPT\", \"namespace\": \"HGNC\"}]}, {\"bel\": \"complex(p(HGNC:FYN), p(HGNC:MAPT))\", \"function\": \"Complex\", \"id\": \"01d824ca10de347035229275725e6b2849ef7fadbbdf5484b8648e951a01eed70e1d6bcb3831ff41da4179ac44cbcf3cb218e3de3165d47b68b7ca0968403bc3\", \"members\": [{\"bel\": \"p(HGNC:FYN)\", \"function\": \"Protein\", \"id\": \"ecffd0427f2e321c9ed5143ca2510464c2fef5432457c332ee991bda79dbdd12ace6375208ee66760cc5b9b7990248651b41a370f16eb9459d2b8682cb0da86b\", \"name\": \"FYN\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(HGNC:MAPT)\", \"function\": \"Protein\", \"id\": \"ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1\", \"name\": \"MAPT\", \"namespace\": \"HGNC\"}]}, {\"bel\": \"complex(p(HGNC:GRB2), p(HGNC:MAPT))\", \"function\": \"Complex\", \"id\": \"e8a55a0b8924f769f8705953053f3b82c29afa309dd39d48c6b739f70e8751502e2079db909c35757247fcccdfb2e98eb6d15ce29c4907a38b60dead19fbddf2\", \"members\": [{\"bel\": \"p(HGNC:GRB2)\", \"function\": \"Protein\", \"id\": \"f94af8faaaccda960957759a32709642d7b4d818e8c8ba3ed97d7ba05833b4af9c016e3eb270995a8fbcd1fa75f839418fc6a71673178efd3786e4f881a3df32\", \"name\": \"GRB2\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(HGNC:MAPT)\", \"function\": \"Protein\", \"id\": \"ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1\", \"name\": \"MAPT\", \"namespace\": \"HGNC\"}]}, {\"bel\": \"complex(p(HGNC:HSPA8), p(HGNC:MAPT, pmod(HBP:hyperphosphorylation)), p(HGNC:STUB1))\", \"function\": \"Complex\", \"id\": \"13d4239f544ec4182c46f0bebd5813aa70f0ad001dca58fa0ed042af6e8664fb75270ef7877daabb2de9d65628b333bf990327be56c392be0929889345bc81e1\", \"members\": [{\"bel\": \"p(HGNC:HSPA8)\", \"function\": \"Protein\", \"id\": \"adbb7eb799b12cc7b0d44de87e8712515e7d06740dfc632ca77e4c00a3741a8efeb9259665e8deac8c5fe2184cbce4b0a228311a757c8571b706689f43aec19c\", \"name\": \"HSPA8\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))\", \"function\": \"Protein\", \"id\": \"ede67fb639f29861d91976fefa16d8279b53ae13a659f35d70ed12e01bf3f339ffcf701fc54c7c4e908fee9902c02aac3e0022dcae5a7afa217ed2d4dba133b0\", \"name\": \"MAPT\", \"namespace\": \"HGNC\", \"variants\": [{\"identifier\": {\"name\": \"hyperphosphorylation\", \"namespace\": \"HBP\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(HGNC:STUB1)\", \"function\": \"Protein\", \"id\": \"7edf63ec4c2eaacc63944e79144be59c6ded86334f97e772d1e6ccbca7065106451bd7861e8acfbda8051ed22ecf6451dd68a33a35fc2d3b91083a48b53e1c68\", \"name\": \"STUB1\", \"namespace\": \"HGNC\"}]}, {\"bel\": \"complex(p(HGNC:HSPA8), p(HGNC:MAPT, pmod(Ub)), p(HGNC:STUB1))\", \"function\": \"Complex\", \"id\": \"b5b8b59d53f883faf3b455b0d074046bd9aeebff519a0588d103db2b653985b6adaeb86516464e24c0f47b57bd508f270a3cbb513ca2c3f6dddf34b0e1f83ac7\", \"members\": [{\"bel\": \"p(HGNC:HSPA8)\", \"function\": \"Protein\", \"id\": \"adbb7eb799b12cc7b0d44de87e8712515e7d06740dfc632ca77e4c00a3741a8efeb9259665e8deac8c5fe2184cbce4b0a228311a757c8571b706689f43aec19c\", \"name\": \"HSPA8\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(HGNC:MAPT, pmod(Ub))\", \"function\": \"Protein\", \"id\": \"b82dd479625165a1698c7d2d4c226eda11a649423410a6c490322188f1626aa059f6c0ab1052a838dd260fb3b0cde95fa88b8b559dbf59e85e7ad83f6a623350\", \"name\": \"MAPT\", \"namespace\": \"HGNC\", \"variants\": [{\"identifier\": {\"name\": \"Ub\", \"namespace\": \"bel\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(HGNC:STUB1)\", \"function\": \"Protein\", \"id\": \"7edf63ec4c2eaacc63944e79144be59c6ded86334f97e772d1e6ccbca7065106451bd7861e8acfbda8051ed22ecf6451dd68a33a35fc2d3b91083a48b53e1c68\", \"name\": \"STUB1\", \"namespace\": \"HGNC\"}]}, {\"bel\": \"complex(p(HGNC:HSPB1), p(HGNC:MAPT, pmod(HBP:hyperphosphorylation)))\", \"function\": \"Complex\", \"id\": \"a2b2d7173cca132c0d7981a088e46885b4a68825da6ac8839ec066d243717ffe5b2a24e8d6f948d4b0b351304c49625cf17f626fcf849520a97864d8b50d8c1c\", \"members\": [{\"bel\": \"p(HGNC:HSPB1)\", \"function\": \"Protein\", \"id\": \"96c2e5e8f77aed7e051078529a022b3f2749abfafa85556c562ca52d96ef14965065c600e95bd3a593a68254aee443067dbb3631852f09acc84313fc5cf9015d\", \"name\": \"HSPB1\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))\", \"function\": \"Protein\", \"id\": \"ede67fb639f29861d91976fefa16d8279b53ae13a659f35d70ed12e01bf3f339ffcf701fc54c7c4e908fee9902c02aac3e0022dcae5a7afa217ed2d4dba133b0\", \"name\": \"MAPT\", \"namespace\": \"HGNC\", \"variants\": [{\"identifier\": {\"name\": \"hyperphosphorylation\", \"namespace\": \"HBP\"}, \"kind\": \"pmod\"}]}]}, {\"bel\": \"complex(p(HGNC:HSPB1), p(HGNC:MAPT, pmod(Ph)))\", \"function\": \"Complex\", \"id\": \"0dbf63e3e52f2ab58f824482fa547c06c9e37dd0d8d72fce69a98e25f37e63efa0b245717c980408abf57eac33086e93711fc910f58f5e21b1cbe13d8199f6e5\", \"members\": [{\"bel\": \"p(HGNC:HSPB1)\", \"function\": \"Protein\", \"id\": \"96c2e5e8f77aed7e051078529a022b3f2749abfafa85556c562ca52d96ef14965065c600e95bd3a593a68254aee443067dbb3631852f09acc84313fc5cf9015d\", \"name\": \"HSPB1\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(HGNC:MAPT, pmod(Ph))\", \"function\": \"Protein\", \"id\": \"526bae251987f8c4f55f6e2451662fa55e087c57585beae7c389b020d73487c739834e9b8ec841783de6a5b5fb9df8b138e9eff4406a9ec5e606766575dcac0e\", \"name\": \"MAPT\", \"namespace\": \"HGNC\", \"variants\": [{\"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\"}]}]}, {\"bel\": \"complex(p(HGNC:MAPK8IP1), p(HGNC:MAPT, pmod(HBP:hyperphosphorylation)))\", \"function\": \"Complex\", \"id\": \"024a09ba1b1713864de6db2aceb9f7daadffd84ba7d17420ea6501cd4fc2e6ca35729906b161fbf51270aa9d75eafcddab70ea7beca14740e5a2120ff9ef70ea\", \"members\": [{\"bel\": \"p(HGNC:MAPK8IP1)\", \"function\": \"Protein\", \"id\": \"a073766ac0227f5390160cba6eec4f0b7ab48434dc97665d1a35003c3572d56c84a91d8841abc77e5613071f9129661a27f2a80919141379d20e8436c0631163\", \"name\": \"MAPK8IP1\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))\", \"function\": \"Protein\", \"id\": \"ede67fb639f29861d91976fefa16d8279b53ae13a659f35d70ed12e01bf3f339ffcf701fc54c7c4e908fee9902c02aac3e0022dcae5a7afa217ed2d4dba133b0\", \"name\": \"MAPT\", \"namespace\": \"HGNC\", \"variants\": [{\"identifier\": {\"name\": \"hyperphosphorylation\", \"namespace\": \"HBP\"}, \"kind\": \"pmod\"}]}]}, {\"bel\": \"complex(p(HGNC:MAPT), p(HGNC:OTUB1))\", \"function\": \"Complex\", \"id\": \"5673409255ef1df4bbf2a0839a2a7807071e9789448d35d5f2b221e67373a329c3aca7b13431573516e45049eced4ed15975e9c08cbf4741cf0c7535dc2bb539\", \"members\": [{\"bel\": \"p(HGNC:MAPT)\", \"function\": \"Protein\", \"id\": \"ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1\", \"name\": \"MAPT\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(HGNC:OTUB1)\", \"function\": \"Protein\", \"id\": \"c5530195d4619e843ad17db2ea12c5656dfd25436dabe62d2c00422360874468d8f3faa3ff16d617f97fabf2cfc89e0314cb1cfa8216a6085c890074563ecb01\", \"name\": \"OTUB1\", \"namespace\": \"HGNC\"}]}, {\"bel\": \"complex(p(HGNC:MAPT), p(HGNC:PIK3R1))\", \"function\": \"Complex\", \"id\": \"5b05448d3ee2f267894aaaeb5f22de44b5f33c3545050823e9cc2bf1f198aa0be82bae52eebe73483a3cc2c1d0ede7be8a064d4fc7b03f326e19f39e81111d64\", \"members\": [{\"bel\": \"p(HGNC:MAPT)\", \"function\": \"Protein\", \"id\": \"ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1\", \"name\": \"MAPT\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(HGNC:PIK3R1)\", \"function\": \"Protein\", \"id\": \"6736b1202cc0649ef0ea06f06b85b3ff637ede613f094e79ed09fe970a863e9daf79ec723946d9f64058dd50b9b15fec66ef3e9e9d95d6858ec6827707c6bedb\", \"name\": \"PIK3R1\", \"namespace\": \"HGNC\"}]}, {\"bel\": \"complex(p(HGNC:MAPT), p(HGNC:PLCG1))\", \"function\": \"Complex\", \"id\": \"e94b8effda5f001ccda9e6fd0e94f81c9f53e825547d63bfa24bab36dea74b21c237356269fa3ba0422ed78873f879e46e8318f3611fa1b776fe51b14dbc213c\", \"members\": [{\"bel\": \"p(HGNC:MAPT)\", \"function\": \"Protein\", \"id\": \"ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1\", \"name\": \"MAPT\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(HGNC:PLCG1)\", \"function\": \"Protein\", \"id\": \"1512790a6177cbcb3e1fa3670ab32a1e96cb66ceb251a6717153f95adb12b12bc42d7a8b96a468e6b27fb7365da5f4c302ebb64b5bb611fec1d9c50a25d334f1\", \"name\": \"PLCG1\", \"namespace\": \"HGNC\"}]}, {\"bel\": \"complex(p(HGNC:MAPT), p(HGNC:PPP2CA), p(HGNC:PPP2R1A), p(INTERPRO:\\\"Protein phosphatase 2A regulatory subunit PR55\\\"))\", \"function\": \"Complex\", \"id\": \"3a9ef8d1cd42bf1fe81bf7165dc1623f5c5dcc791db564960443968ed6d5c725d2525014b44e87aee417446ddcb3aaff30cdbe83708ef15f2a7becc658e12ebe\", \"members\": [{\"bel\": \"p(HGNC:MAPT)\", \"function\": \"Protein\", \"id\": \"ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1\", \"name\": \"MAPT\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(HGNC:PPP2CA)\", \"function\": \"Protein\", \"id\": \"6baa9d09125d1244431e7a8a8d8788f573889554982a8abcbd5c5d85b5f5c28771ff34971f8ab09e92bd0d7517b229ff34958f0f1278cc23410b7141982490a1\", \"name\": \"PPP2CA\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(HGNC:PPP2R1A)\", \"function\": \"Protein\", \"id\": \"c29bb0de3b6311b523212a8d21c1523fe42b9fed99f67e041f3a52a9ea9dd64740ca756b0fd909a5583546074c414e883e15e704ad48248566c64a2663c56b87\", \"name\": \"PPP2R1A\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(INTERPRO:\\\"Protein phosphatase 2A regulatory subunit PR55\\\")\", \"function\": \"Protein\", \"id\": \"17928230b43b7fd87f1181708a849e1bea646ca3eb7ca11b585260762dd199b711ca023a461a57f8f3f8c7489f1b2a35f368b404c533fdc6e57d92b404186ad0\", \"name\": \"Protein phosphatase 2A regulatory subunit PR55\", \"namespace\": \"INTERPRO\"}]}, {\"bel\": \"complex(p(HGNC:MAPT), p(HGNC:PPP2CB), p(HGNC:PPP2R1A), p(INTERPRO:\\\"Protein phosphatase 2A regulatory subunit PR55\\\"))\", \"function\": \"Complex\", \"id\": \"cc840cb73e5355ea35028236e028355a0dceb7e992c72938f54be5d1c8af91494ddb5a7eb5f9c976db78015238824ee0539bedb89088b298985581f032f2fc22\", \"members\": [{\"bel\": \"p(HGNC:MAPT)\", \"function\": \"Protein\", \"id\": \"ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1\", \"name\": \"MAPT\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(HGNC:PPP2CB)\", \"function\": \"Protein\", \"id\": \"67732a285b15db2be42c869cc075162c0c34f334f4c3985bdf7bbcd89ea83f5142cd2cb6462bcc4e80aa48dc653786e9426fe315643b3b49b79797231f33d02f\", \"name\": \"PPP2CB\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(HGNC:PPP2R1A)\", \"function\": \"Protein\", \"id\": \"c29bb0de3b6311b523212a8d21c1523fe42b9fed99f67e041f3a52a9ea9dd64740ca756b0fd909a5583546074c414e883e15e704ad48248566c64a2663c56b87\", \"name\": \"PPP2R1A\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(INTERPRO:\\\"Protein phosphatase 2A regulatory subunit PR55\\\")\", \"function\": \"Protein\", \"id\": \"17928230b43b7fd87f1181708a849e1bea646ca3eb7ca11b585260762dd199b711ca023a461a57f8f3f8c7489f1b2a35f368b404c533fdc6e57d92b404186ad0\", \"name\": \"Protein phosphatase 2A regulatory subunit PR55\", \"namespace\": \"INTERPRO\"}]}, {\"bel\": \"complex(p(HGNC:MAPT), p(HGNC:SRC))\", \"function\": \"Complex\", \"id\": \"f3708001443325b8f2b3e28a7a1fb909966b0d56c11fc0d44384d3c31d32e05b54996063cd65a6f15d2ea7f81e02b4582fd890f18094608d8ca17bde6a9d7190\", \"members\": [{\"bel\": \"p(HGNC:MAPT)\", \"function\": \"Protein\", \"id\": \"ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1\", \"name\": \"MAPT\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(HGNC:SRC)\", \"function\": \"Protein\", \"id\": \"89cf6fe86000d59fa342b801d809a06408db3c65a224250ba500634f4976a061da0e71d6f72c101186d9032a0624af6fc3b50e209815858d6bdb51831883be6a\", \"name\": \"SRC\", \"namespace\": \"HGNC\"}]}, {\"bel\": \"complex(p(HGNC:MAPT), p(HGNC:STUB1))\", \"function\": \"Complex\", \"id\": \"e35d9d62e04e3db7e0117b9ae52f144b1719ae1911ac2e10d915d06c41d8809d804a59b18a6e6c958429ab425fa666499cc589f896f6a67f4830442834539f68\", \"members\": [{\"bel\": \"p(HGNC:MAPT)\", \"function\": \"Protein\", \"id\": \"ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1\", \"name\": \"MAPT\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(HGNC:STUB1)\", \"function\": \"Protein\", \"id\": \"7edf63ec4c2eaacc63944e79144be59c6ded86334f97e772d1e6ccbca7065106451bd7861e8acfbda8051ed22ecf6451dd68a33a35fc2d3b91083a48b53e1c68\", \"name\": \"STUB1\", \"namespace\": \"HGNC\"}]}, {\"bel\": \"complex(p(HGNC:MAPT), p(HGNCGENEFAMILY:Tubulins))\", \"function\": \"Complex\", \"id\": \"7720634adb53551c988b660b0db9cb73945e42743f07ba913a87074d8d5964b81eaaf78f465056f80c57bbc5c66b42137d18a412db8ed2ad25a2bb86ebd9b2e2\", \"members\": [{\"bel\": \"p(HGNC:MAPT)\", \"function\": \"Protein\", \"id\": \"ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1\", \"name\": \"MAPT\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(HGNCGENEFAMILY:Tubulins)\", \"function\": \"Protein\", \"id\": \"324eb02c65169e7a583a43ee128ed844b5c108fc4d0a4ae7ad0d5cc6db3c3da60b70719f5de9b87efc1f0e09bb8d753028201d1f815f971a39d6fa306086dce7\", \"name\": \"Tubulins\", \"namespace\": \"HGNCGENEFAMILY\"}]}, {\"bel\": \"complex(p(HGNC:MAPT, pmod(HBP:hyperphosphorylation)), p(HGNC:STUB1))\", \"function\": \"Complex\", \"id\": \"b785d6ffb7e72afa41b98e09e451615e46afec8528bcfe4b7bf0c6f703e7fdcbd39083136b6b115e1ea0f0d003d374fa407bdfdca0c94d84608234b0d2c6b25e\", \"members\": [{\"bel\": \"p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))\", \"function\": \"Protein\", \"id\": \"ede67fb639f29861d91976fefa16d8279b53ae13a659f35d70ed12e01bf3f339ffcf701fc54c7c4e908fee9902c02aac3e0022dcae5a7afa217ed2d4dba133b0\", \"name\": \"MAPT\", \"namespace\": \"HGNC\", \"variants\": [{\"identifier\": {\"name\": \"hyperphosphorylation\", \"namespace\": \"HBP\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(HGNC:STUB1)\", \"function\": \"Protein\", \"id\": \"7edf63ec4c2eaacc63944e79144be59c6ded86334f97e772d1e6ccbca7065106451bd7861e8acfbda8051ed22ecf6451dd68a33a35fc2d3b91083a48b53e1c68\", \"name\": \"STUB1\", \"namespace\": \"HGNC\"}]}, {\"bel\": \"complex(p(HGNC:MAPT, pmod(Ph)), p(HGNC:SMAD2))\", \"function\": \"Complex\", \"id\": \"9f8cced36ab45dc2bfa8ecaa02959b96f098e7aeb605feddb69ef831880304adef3daa41fcabca971b3915c51e7835e727b34caf97f04a2e7dab3d0e181210d6\", \"members\": [{\"bel\": \"p(HGNC:MAPT, pmod(Ph))\", \"function\": \"Protein\", \"id\": \"526bae251987f8c4f55f6e2451662fa55e087c57585beae7c389b020d73487c739834e9b8ec841783de6a5b5fb9df8b138e9eff4406a9ec5e606766575dcac0e\", \"name\": \"MAPT\", \"namespace\": \"HGNC\", \"variants\": [{\"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(HGNC:SMAD2)\", \"function\": \"Protein\", \"id\": \"ac9eb6340da114bccc3be554fb1b60e05ad8a2d5ea0ed8e6071fca40d08c35057421eb77165117ab24cd8b2d03f168ccd7ab57f9c60e050758f697c37fea433e\", \"name\": \"SMAD2\", \"namespace\": \"HGNC\"}]}, {\"bel\": \"complex(p(HGNC:MAPT, pmod(Ph)), p(HGNC:STUB1), p(HGNC:UBE2D2))\", \"function\": \"Complex\", \"id\": \"e2052877bf958e048b04586c8dc61edf8fab71c96c6fe1eb37756acfc571668d319c3d5b4e52ed277ec78548e2f783c5d0f561434a52c436bd3e43b239c9ba54\", \"members\": [{\"bel\": \"p(HGNC:MAPT, pmod(Ph))\", \"function\": \"Protein\", \"id\": \"526bae251987f8c4f55f6e2451662fa55e087c57585beae7c389b020d73487c739834e9b8ec841783de6a5b5fb9df8b138e9eff4406a9ec5e606766575dcac0e\", \"name\": \"MAPT\", \"namespace\": \"HGNC\", \"variants\": [{\"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(HGNC:STUB1)\", \"function\": \"Protein\", \"id\": \"7edf63ec4c2eaacc63944e79144be59c6ded86334f97e772d1e6ccbca7065106451bd7861e8acfbda8051ed22ecf6451dd68a33a35fc2d3b91083a48b53e1c68\", \"name\": \"STUB1\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(HGNC:UBE2D2)\", \"function\": \"Protein\", \"id\": \"6f612ba174bda858d8de19ad46bd8fd67a1f46f4b2d01f726a7b677b2b1e94d41d6b121d551928994ab861e4efd1232ce7990a80fba180b8f9f983660e088b9f\", \"name\": \"UBE2D2\", \"namespace\": \"HGNC\"}]}, {\"bel\": \"complex(p(HGNC:MAPT, pmod(Ph, Thr, 231)), p(HGNC:PIN1, frag(\\\"5_39\\\")))\", \"function\": \"Complex\", \"id\": \"b7460e54d180a99b740a79d33f69b5ceedd06ac8d8ea5c3029e7fc35d865905eb0ec08b73b1b56c9db3497146bea24e49d831194643d4540e778728c2338ca85\", \"members\": [{\"bel\": \"p(HGNC:MAPT, pmod(Ph, Thr, 231))\", \"function\": \"Protein\", \"id\": \"fd67fbe5c0c0911e8bffaf415eb40748a781d8776f2e2cdf8a3f4f97f0f2f312aaa680c7b670dc27b11d220f0079b4d5e41cbcf095a568bc644b6e9eaefc50b3\", \"name\": \"MAPT\", \"namespace\": \"HGNC\", \"variants\": [{\"code\": \"Thr\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 231}]}, {\"bel\": \"p(HGNC:PIN1, frag(\\\"5_39\\\"))\", \"function\": \"Protein\", \"id\": \"9481742935d1ff7ea36a2ef53093e28f4e6467e76ea1686f49d9818b07f5a9079b440cf8369a630cb5a7f1925404d070008f8fb7014836be4e6c97ae832f0204\", \"name\": \"PIN1\", \"namespace\": \"HGNC\", \"variants\": [{\"kind\": \"frag\", \"start\": 5, \"stop\": 39}]}]}, {\"bel\": \"complex(p(HGNC:PPP2CA), p(HGNC:PPP2R1A))\", \"function\": \"Complex\", \"id\": \"953fd07cb094105888ad27c6fa8dad0fead037ce369ce6cee5514c4a9e829764c30b3ddce657fc7eea7a79847ae9ca01179a90b70b8c45db2d32215e2b8e10e1\", \"members\": [{\"bel\": \"p(HGNC:PPP2CA)\", \"function\": \"Protein\", \"id\": \"6baa9d09125d1244431e7a8a8d8788f573889554982a8abcbd5c5d85b5f5c28771ff34971f8ab09e92bd0d7517b229ff34958f0f1278cc23410b7141982490a1\", \"name\": \"PPP2CA\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(HGNC:PPP2R1A)\", \"function\": \"Protein\", \"id\": \"c29bb0de3b6311b523212a8d21c1523fe42b9fed99f67e041f3a52a9ea9dd64740ca756b0fd909a5583546074c414e883e15e704ad48248566c64a2663c56b87\", \"name\": \"PPP2R1A\", \"namespace\": \"HGNC\"}]}, {\"bel\": \"complex(p(HGNC:PPP2CA), p(HGNC:PPP2R1A), p(INTERPRO:\\\"Protein phosphatase 2A regulatory subunit PR55\\\"))\", \"function\": \"Complex\", \"id\": \"a1cd2d3dc6c1be0f82b9f576434a266b5bcc7504242bc16f0de7536f4d1529cc1fbcc7e671efc8dbfa9ad5562547d3cd04e524512d02f94243113bfdfa01a409\", \"members\": [{\"bel\": \"p(HGNC:PPP2CA)\", \"function\": \"Protein\", \"id\": \"6baa9d09125d1244431e7a8a8d8788f573889554982a8abcbd5c5d85b5f5c28771ff34971f8ab09e92bd0d7517b229ff34958f0f1278cc23410b7141982490a1\", \"name\": \"PPP2CA\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(HGNC:PPP2R1A)\", \"function\": \"Protein\", \"id\": \"c29bb0de3b6311b523212a8d21c1523fe42b9fed99f67e041f3a52a9ea9dd64740ca756b0fd909a5583546074c414e883e15e704ad48248566c64a2663c56b87\", \"name\": \"PPP2R1A\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(INTERPRO:\\\"Protein phosphatase 2A regulatory subunit PR55\\\")\", \"function\": \"Protein\", \"id\": \"17928230b43b7fd87f1181708a849e1bea646ca3eb7ca11b585260762dd199b711ca023a461a57f8f3f8c7489f1b2a35f368b404c533fdc6e57d92b404186ad0\", \"name\": \"Protein phosphatase 2A regulatory subunit PR55\", \"namespace\": \"INTERPRO\"}]}, {\"bel\": \"complex(p(HGNC:PPP2CA), p(HGNC:PPP2R1A), p(INTERPRO:\\\"Protein phosphatase 2A, regulatory B subunit, B56\\\"))\", \"function\": \"Complex\", \"id\": \"38284b41c2accb7d5b21d16ad51c380201e0c3b0a47b1f465d7397008b4f8c0f37da361ff0d7b5d62719ecc09a962518891dc9902055a6fb561395dda1a2e9c3\", \"members\": [{\"bel\": \"p(HGNC:PPP2CA)\", \"function\": \"Protein\", \"id\": \"6baa9d09125d1244431e7a8a8d8788f573889554982a8abcbd5c5d85b5f5c28771ff34971f8ab09e92bd0d7517b229ff34958f0f1278cc23410b7141982490a1\", \"name\": \"PPP2CA\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(HGNC:PPP2R1A)\", \"function\": \"Protein\", \"id\": \"c29bb0de3b6311b523212a8d21c1523fe42b9fed99f67e041f3a52a9ea9dd64740ca756b0fd909a5583546074c414e883e15e704ad48248566c64a2663c56b87\", \"name\": \"PPP2R1A\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(INTERPRO:\\\"Protein phosphatase 2A, regulatory B subunit, B56\\\")\", \"function\": \"Protein\", \"id\": \"240548fcd8d67b57083afdcef7c84e7ce5a3b3f0364de3ad38b198a32d83954df301f0e607e0a9469bb9121f62dd50847f5ddc0d84290c7f2d90ad4efb60d1c6\", \"name\": \"Protein phosphatase 2A, regulatory B subunit, B56\", \"namespace\": \"INTERPRO\"}]}, {\"bel\": \"complex(p(HGNC:PPP2CB), p(HGNC:PPP2R1A), p(INTERPRO:\\\"Protein phosphatase 2A regulatory subunit PR55\\\"))\", \"function\": \"Complex\", \"id\": \"71996f8dbef654fd032f017ce4b5aa1f910f976c258adec17cb38e5e6ab13d43cdac464ed2995b01518ee87d24a20f6fad5f3bbb391d31f1d9879d8fec679a91\", \"members\": [{\"bel\": \"p(HGNC:PPP2CB)\", \"function\": \"Protein\", \"id\": \"67732a285b15db2be42c869cc075162c0c34f334f4c3985bdf7bbcd89ea83f5142cd2cb6462bcc4e80aa48dc653786e9426fe315643b3b49b79797231f33d02f\", \"name\": \"PPP2CB\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(HGNC:PPP2R1A)\", \"function\": \"Protein\", \"id\": \"c29bb0de3b6311b523212a8d21c1523fe42b9fed99f67e041f3a52a9ea9dd64740ca756b0fd909a5583546074c414e883e15e704ad48248566c64a2663c56b87\", \"name\": \"PPP2R1A\", \"namespace\": \"HGNC\"}, {\"bel\": \"p(INTERPRO:\\\"Protein phosphatase 2A regulatory subunit PR55\\\")\", \"function\": \"Protein\", \"id\": \"17928230b43b7fd87f1181708a849e1bea646ca3eb7ca11b585260762dd199b711ca023a461a57f8f3f8c7489f1b2a35f368b404c533fdc6e57d92b404186ad0\", \"name\": \"Protein phosphatase 2A regulatory subunit PR55\", \"namespace\": \"INTERPRO\"}]}, {\"bel\": \"composite(a(HBP:\\\"Tau antibody, TNT1\\\"), a(HBP:TOC1), p(HGNC:MAPT, pmod(Ph), var(\\\"p.S422E\\\")))\", \"function\": \"Composite\", \"id\": \"c48e9a38c1dad44073e9195157c4211ce8881d92ea6b5639be61d0fe35db58228a13cebe67abbd78ec5c3f0d727c45562e9f65fb25b53a1397a9e28057cfdc7c\", \"members\": [{\"bel\": \"a(HBP:\\\"Tau antibody, TNT1\\\")\", \"function\": \"Abundance\", \"id\": \"c796a83d992a31f44fd416a82c553ea69886271a8874826c38794337517edd3598e1d7600b8d88fccbe5d7f4b89aa744c88b53c8ef340e5a8aba804b3feda576\", \"name\": \"Tau antibody, TNT1\", \"namespace\": \"HBP\"}, {\"bel\": \"a(HBP:TOC1)\", \"function\": \"Abundance\", \"id\": \"ca4bed88212c59b16a3d939b6c1a7112e87f5bca22e342ace6e89c004a9a34fc8a22a22010319b00cef2616e545301afa10f90ce5eb2420cd5eadb1a3d368141\", \"name\": \"TOC1\", \"namespace\": \"HBP\"}, {\"bel\": \"p(HGNC:MAPT, pmod(Ph), var(\\\"p.S422E\\\"))\", \"function\": \"Protein\", \"id\": \"5f9b1d87c6074f2184be9054194e05be32f520a4e0bae05f4c337ab48a00f2aedf9f9ce0486bd9be25d1f99a1d45e21c3403833cb80e56823b9999f72e9f8202\", \"name\": \"MAPT\", \"namespace\": \"HGNC\", \"variants\": [{\"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\"}, {\"identifier\": \"p.S422E\", \"kind\": \"hgvs\"}]}]}, {\"bel\": \"composite(a(MESH:Ubiquitin), p(HGNC:MAPT))\", \"function\": \"Composite\", \"id\": \"b163b2c2cf8af84031541465b0e76bd0e3d8f89c461022e3b6600e76fd4adb9991b5010073fbdc2f17747ca114211f9fa2c1a8c1f78853da85ab8025eeac2e1a\", \"members\": [{\"bel\": \"a(MESH:Ubiquitin)\", \"function\": \"Abundance\", \"id\": \"d52f4bae02d9b28ad0bf343e71172d16e96d34504d998cb580daa40a421624b7379a23ad54be6da81df2e2fe7442ffe7a6972e6a3ac2dadb5bda6ae422b99956\", \"name\": \"Ubiquitin\", \"namespace\": \"MESH\"}, {\"bel\": \"p(HGNC:MAPT)\", \"function\": \"Protein\", \"id\": \"ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1\", \"name\": \"MAPT\", \"namespace\": \"HGNC\"}]}, {\"bel\": \"composite(p(FPLX:ERK), p(HGNC:CHRNA7))\", \"function\": \"Composite\", \"id\": \"4ff71ef86d2c7fa3cae5de1b1fb99087d9e540f8dd1331a75000af1ba33223e3548c7ced5b725c31b15b6e39eba7323e9ebe7a27c6de7c7ae5e9c09d339d2b20\", \"members\": [{\"bel\": \"p(FPLX:ERK)\", \"function\": \"Protein\", \"id\": \"d47253e059ce1284f4d182a53246f4d993b24c69ceb8bee74fb2a12d7d07c4a0ea65603dbb5d741283f27159ddf01ff72e2c045c05128734b83ba3ef067837b4\", \"name\": \"ERK\", \"namespace\": \"FPLX\"}, {\"bel\": \"p(HGNC:CHRNA7)\", \"function\": \"Protein\", \"id\": \"6f517aad2a254d42d4e0bd5118246057049b85324ab857629d0caa2da5e997bfcc08f9a0a2cd83bbb2b536c048ce402c0d521604c43b1b9c720f4e20b4dacd99\", \"name\": \"CHRNA7\", \"namespace\": \"HGNC\"}]}, {\"bel\": \"composite(p(FPLX:JNK), p(HGNC:CHRNA7))\", \"function\": \"Composite\", \"id\": \"9edb22938f3cf6783505234c2587b1112645b1c9528448490ad049ef96ad077d178d4485709d0c2c717eded0ffb3cb8d010bb2c47716468b314a275db40c4dc9\", \"members\": [{\"bel\": \"p(FPLX:JNK)\", \"function\": \"Protein\", \"id\": \"a9ed6db257ad5286099b1c787f20b6023ae9588e34100f98373865a084224f3815988fd9eafd8a85f974c668ef8c48bad8bee8de58c6e414fc8b084d8d066d6d\", \"name\": \"JNK\", \"namespace\": \"FPLX\"}, {\"bel\": \"p(HGNC:CHRNA7)\", \"function\": \"Protein\", \"id\": \"6f517aad2a254d42d4e0bd5118246057049b85324ab857629d0caa2da5e997bfcc08f9a0a2cd83bbb2b536c048ce402c0d521604c43b1b9c720f4e20b4dacd99\", \"name\": \"CHRNA7\", \"namespace\": \"HGNC\"}]}, {\"bel\": \"composite(p(HBP:\\\"4R tau\\\", var(\\\"p.Lys280del\\\")), p(HGNC:STUB1))\", \"function\": \"Composite\", \"id\": \"4d42c7da05d12758791503304cd68d389426a15d879745e30d222cefc8b6787bb5c1f011dd08c4c227e576b45d314ca9be0bd16756fd753d8713a1c48680a739\", \"members\": [{\"bel\": \"p(HBP:\\\"4R tau\\\", var(\\\"p.Lys280del\\\"))\", \"function\": \"Protein\", \"id\": \"6407947c5b4571fde2e291bc449c2511c67665ec48ba9e656955728de4a43898c8edf9b21471f263e220161c21715068d23495712a3afe769c01fe5cf623dd33\", \"name\": \"4R tau\", \"namespace\": \"HBP\", \"variants\": [{\"identifier\": \"p.Lys280del\", \"kind\": \"hgvs\"}]}, {\"bel\": \"p(HGNC:STUB1)\", \"function\": \"Protein\", \"id\": \"7edf63ec4c2eaacc63944e79144be59c6ded86334f97e772d1e6ccbca7065106451bd7861e8acfbda8051ed22ecf6451dd68a33a35fc2d3b91083a48b53e1c68\", \"name\": \"STUB1\", \"namespace\": \"HGNC\"}]}, {\"bel\": \"composite(p(HBP:\\\"Tau isoform E (412 aa)\\\", var(\\\"p.Val337Met\\\")), p(HGNC:DDC))\", \"function\": \"Composite\", \"id\": \"2a238af3b7a2b2ff8846dbe5e3dfe1afc44ccb172009ef34b755b6f3d6158a68aeb3715dfe5555459c7546cc30a4b486a459f4689c3469566d296c6cb04aee3f\", \"members\": [{\"bel\": \"p(HBP:\\\"Tau isoform E (412 aa)\\\", var(\\\"p.Val337Met\\\"))\", \"function\": \"Protein\", \"id\": \"5a5827c3a4e68632bdcdaa795c93ad678aac9129a15328c7ba554fc7abfff03adc82ed1fcb12778cb3ce610f2c089c1afd805338d5cbb98aa2611c6196c57e1e\", \"name\": \"Tau isoform E (412 aa)\", \"namespace\": \"HBP\", \"variants\": [{\"identifier\": \"p.Val337Met\", \"kind\": \"hgvs\"}]}, {\"bel\": \"p(HGNC:DDC)\", \"function\": \"Protein\", \"id\": \"2fad87d0f555bbe73b99323534b76beec3c65e240f107134b0503f7e17e00d2bbaf35319a098411d55872c3c051c25459bc8931bd9c9d0c6b3b358cf4c2aea2b\", \"name\": \"DDC\", \"namespace\": \"HGNC\"}]}, {\"bel\": \"composite(p(HGNC:MAPT, pmod(Ac, Lys, 163)), p(HGNC:MAPT, pmod(Ac, Lys, 280)), p(HGNC:MAPT, pmod(Ac, Lys, 281)), p(HGNC:MAPT, pmod(Ac, Lys, 369)))\", \"function\": \"Composite\", \"id\": \"14a3aa5ebd9a80abbd60d2a854b814b2e50962b1d3dd79c6abf09f228202b77ba5d3d3f25f59d8345a2f1c95e111d9a72124e52284f5f381bec8576dee2532b5\", \"members\": [{\"bel\": \"p(HGNC:MAPT, pmod(Ac, Lys, 163))\", \"function\": \"Protein\", \"id\": \"924504e9d7736e6c101c69e8a2261f17d7d97c71b3d4da275e041d73e8ad108278c367e68b262b052e0d0d094b60db33c42030774355866c0c7cf719093d0eeb\", \"name\": \"MAPT\", \"namespace\": \"HGNC\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 163}]}, {\"bel\": \"p(HGNC:MAPT, pmod(Ac, Lys, 280))\", \"function\": \"Protein\", \"id\": \"b3327a6bc072250a5fef544daab0adc8ed547e58a4c383a553009a015e532a34fda6016098f9ee83a94b315f11839b828a120df0ed08f97a336886c88160ae67\", \"name\": \"MAPT\", \"namespace\": \"HGNC\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 280}]}, {\"bel\": \"p(HGNC:MAPT, pmod(Ac, Lys, 281))\", \"function\": \"Protein\", \"id\": \"16f5587b2883e91281ed04533207788ad03b349f3eea2ce26d77e44869e98e8531b4dc0551c6dc5a052867fa18f996e8d1c01ac2170f3c7da637cf12963f8bee\", \"name\": \"MAPT\", \"namespace\": \"HGNC\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 281}]}, {\"bel\": \"p(HGNC:MAPT, pmod(Ac, Lys, 369))\", \"function\": \"Protein\", \"id\": \"adcb21423be952f37e9362c05da0bb337a9f42816c78be70c10ba771e4e82debfae8c2a9797454d4cd3f306c6912d5b13154d84a9164e8e9b5c4cff86a55ea9f\", \"name\": \"MAPT\", \"namespace\": \"HGNC\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 369}]}]}, {\"bel\": \"m(MIRBASE:\\\"rno-mir-195\\\")\", \"function\": \"miRNA\", \"id\": \"f236af56a802ae2461edc4a961b4b625735112a7fa5e73f81044e31aa15f17d0aaa08634e6896d48935b242b560f0874e1d4817e322b0dc1089ed7445ad121b8\", \"name\": \"rno-mir-195\", \"namespace\": \"MIRBASE\"}, {\"bel\": \"p(ECCODE:\\\"2.7.11.31\\\")\", \"function\": \"Protein\", \"id\": \"f60e7e1179900b766710b570982cf7308d1b7c72e588efae2c2358330d67acb6a0867cca617329d21b0d30a5f12579beab4fb1470df6bfe2c3e3ed87e7e6de75\", \"name\": \"2.7.11.31\", \"namespace\": \"ECCODE\"}, {\"bel\": \"p(FPLX:\\\"CAMK2_complex\\\")\", \"function\": \"Protein\", \"id\": \"2c6d989e05bba1439ed18819e9d74c2d3a247c0c70287041ff8f1085c44c631acbd1c98b8726b0dc365e3ac3089319e14d3837f2225ff67307609b1bd1e4d8d3\", \"name\": \"CAMK2_complex\", \"namespace\": \"FPLX\"}, {\"bel\": \"p(FPLX:CHRN)\", \"function\": \"Protein\", \"id\": \"2d70e5187bc44ed8ee9d64163e62e209522d576460d28ee8c947c1bda63c6d1f2233f349d74a2bae45ed4d59044c0e1be1f56ea9944bc08740426eb8678d6df5\", \"name\": \"CHRN\", \"namespace\": \"FPLX\"}, {\"bel\": \"p(FPLX:CK2)\", \"function\": \"Protein\", \"id\": \"a291fc6a26ba96211a47c155dae813c80cd48240bb6b03442e30c47daa552db9d9f9127d7f92b850e6cbb5cf8fc195c60a1e252054815457196d5148ee2e7464\", \"name\": \"CK2\", \"namespace\": \"FPLX\"}, {\"bel\": \"p(FPLX:CSNK1)\", \"function\": \"Protein\", \"id\": \"a2dd0b6a7ea9eb45902dfde6051ab7e4d1de56bc2440fb441b5de5fb1c70513d3c927dc7bb1eefdd069b533fe297145d520f4e942891160073490a7c3a7413b1\", \"name\": \"CSNK1\", \"namespace\": \"FPLX\"}, {\"bel\": \"p(FPLX:ERK)\", \"function\": \"Protein\", \"id\": \"d47253e059ce1284f4d182a53246f4d993b24c69ceb8bee74fb2a12d7d07c4a0ea65603dbb5d741283f27159ddf01ff72e2c045c05128734b83ba3ef067837b4\", \"name\": \"ERK\", \"namespace\": \"FPLX\"}, {\"bel\": \"p(FPLX:GSK3)\", \"function\": \"Protein\", \"id\": \"9347360e58cdec3f018064a4eae9a0cf197c9015fadd80cad6dc56b240cdfc8314a61b84f05cab89c9d7443d29cf27d675faf92154227319f92956f11c74c1bb\", \"name\": \"GSK3\", \"namespace\": \"FPLX\"}, {\"bel\": \"p(FPLX:HDAC)\", \"function\": \"Protein\", \"id\": \"d2e8833ff804c3b8c5a045ac8a4096c1c66c61101c9ed5ce1f0c355bf74149b9cec6584bc3e5186e942bbd700bdafa9ccf9bab0127fad62731702159604e5ab5\", \"name\": \"HDAC\", \"namespace\": \"FPLX\"}, {\"bel\": \"p(FPLX:HSP90)\", \"function\": \"Protein\", \"id\": \"a5bdfe1366faea602e03fefece5805427ae4af29a007d93291e6224dc74a8cab597169f580be49b50b4c24e83fa743fefa44549edb827a4dd531224d7d373245\", \"name\": \"HSP90\", \"namespace\": \"FPLX\"}, {\"bel\": \"p(FPLX:MAPK)\", \"function\": \"Protein\", \"id\": \"d5a4fba57d4e7f692f376029d628a2e921f430f50117c1db1ebae2bf2d76991ee3be15c962abcc1c8c20ebd8317b3afcbfa298bb3d83c9a46e53d44643a99339\", \"name\": \"MAPK\", \"namespace\": \"FPLX\"}, {\"bel\": \"p(FPLX:PKA)\", \"function\": \"Protein\", \"id\": \"a312e28f30d661eb58c0cc3c07cda6812a6290acaa1b8c513be7a895fe1b15f1feb278ee6095359cd3e44eb43cf1864de0fd70d89d3cbcc5b18361fd31276f17\", \"name\": \"PKA\", \"namespace\": \"FPLX\"}, {\"bel\": \"p(FPLX:PKC)\", \"function\": \"Protein\", \"id\": \"12137fadfdc5eb838cd33edabcf36ac0b775609d7303971d52755e1335928a559973fe26211ce3ac9a8599ee75c77a978b44d1d7114437a922a8911d9016aceb\", \"name\": \"PKC\", \"namespace\": \"FPLX\"}, {\"bel\": \"p(FPLX:PPP1)\", \"function\": \"Protein\", \"id\": \"988419e86b60ec5d3089171f7ee147a5508044bd5e1f8fea8bf4c0fa388359ecda28e3df00821a28c84199c166df2f863b5396accdf0835c02a484c1a5ddf3d3\", \"name\": \"PPP1\", \"namespace\": \"FPLX\"}, {\"bel\": \"p(FPLX:PPP2)\", \"function\": \"Protein\", \"id\": \"a9377307576389f08c186ac62c6f48293be2fe1495d38cb53c33f9185f3625cb580b310ee4f6d15c636acf1f460f4b54f0dc8c94808295084b9484f709c91fdd\", \"name\": \"PPP2\", \"namespace\": \"FPLX\"}, {\"bel\": \"p(FPLX:PPP2, pmod(Me))\", \"function\": \"Protein\", \"id\": \"e2cfa32e4a576164a82bc105d31e17ce8d8bf4bf49329be63f01a601dde3c4c43d5fff1e5ae80bc3b1a2a8fd4657f08937aea05ff902a895db639028d3cca59b\", \"name\": \"PPP2\", \"namespace\": \"FPLX\", \"variants\": [{\"identifier\": {\"name\": \"Me\", \"namespace\": \"bel\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(FPLX:PPP2, pmod(Me, Tyr, 307))\", \"function\": \"Protein\", \"id\": \"cc53442fa125c8202bad9eac199cfe2b847b2321dcef084c71c1a3f64b780f52c47a146646ab64a8a605b1884b30f9b78b05a4a82c0faf1f346f0d24cc5d3e35\", \"name\": \"PPP2\", \"namespace\": \"FPLX\", \"variants\": [{\"code\": \"Tyr\", \"identifier\": {\"name\": \"Me\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 307}]}, {\"bel\": \"p(FPLX:PPP3)\", \"function\": \"Protein\", \"id\": \"29288b04a9dfd793412bfa5b26e36982faa941a95bbaf64d4ac8d44e635fa5e343524f32f98c3d32d8b2d9209ef7f8c7a820e61057365fda98ba43ddcd2b5d52\", \"name\": \"PPP3\", \"namespace\": \"FPLX\"}, {\"bel\": \"p(FPLX:PRKG)\", \"function\": \"Protein\", \"id\": \"7278f3fd90c62f7c42ae1d699e21c1d498129b53432ae5295f7f3c84bcf3389ea7f4fb3d3bc931d0b023eea3407691afc9150d41aafa27e914c9bc4d7e5e7a2e\", \"name\": \"PRKG\", \"namespace\": \"FPLX\"}, {\"bel\": \"p(FPLX:Proteasome)\", \"function\": \"Protein\", \"id\": \"645bfb1e8fc6c1ec119c660999773cfddcb4cf0f2f8f8c0e07af96aceec91f6e5218098423451401e3da7ba628a36a7437a426ca75f5ca004f97d56d7bbfd541\", \"name\": \"Proteasome\", \"namespace\": \"FPLX\"}, {\"bel\": \"p(FPLX:Ubiquitin)\", \"function\": \"Protein\", \"id\": \"718b9f707565a371c7d1223e4a8fe26dd963ecffba7d4ca9bdaacb3b6b1a9846dc629674a6720d37c0ad27129fef976d82613e096660153bfbc1407d8bba493b\", \"name\": \"Ubiquitin\", \"namespace\": \"FPLX\"}, {\"bel\": \"p(GFAM:\\\"Protein phosphatase catalytic subunits\\\")\", \"function\": \"Protein\", \"id\": \"e5a6ee449dfd337e6fcbfd2fe92cb4ea136e301ca69e893e64ba6ff86548792e7367b252a67dedffcc148d24acf1e67938fef764aeba9db80e54442fbe5977b7\", \"name\": \"Protein phosphatase catalytic subunits\", \"namespace\": \"GFAM\"}, {\"bel\": \"p(HBP:\\\"APP, ACR\\\")\", \"function\": \"Protein\", \"id\": \"989a7e7b0aedce985a8cce172a5083bb9272a1e5bb6c8eda163ecb75e971041cbf5d3097c1605cde7f2a61a8f8e251feb9430aebdcbfc1bdcfcb137dd27d0950\", \"name\": \"APP, ACR\", \"namespace\": \"HBP\"}, {\"bel\": \"p(HBP:\\\"AT8 tau\\\", pmod(Ph))\", \"function\": \"Protein\", \"id\": \"64541a31527aae2288a7fdfde43b8120d01ee44f88f8b705beb605d5ec19432ebf43ed48c81b24924214c153d5312bc32e4e519030f1a490e51ceda5f3ce5c60\", \"name\": \"AT8 tau\", \"namespace\": \"HBP\", \"variants\": [{\"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(HBP:\\\"PrP106-126\\\")\", \"function\": \"Protein\", \"id\": \"19168ec84399fd45c2295c1dfc1f714156122dac79e7e28b26c462df1ba3f560712458ab698c89ca76620b1331df09cbe60e592e4f19ebcb57d626c47cbe7a0f\", \"name\": \"PrP106-126\", \"namespace\": \"HBP\"}, {\"bel\": \"p(HBP:\\\"Tau aggregates\\\")\", \"function\": \"Protein\", \"id\": \"1c9d48fe854c1832b8539731374dc5bf3dc2079c9e5fb4e074524c6557c9d37042d9cd5ea71ca88458e22e15fd3f713284ef876909910dc47484812b0a150983\", \"name\": \"Tau aggregates\", \"namespace\": \"HBP\"}, {\"bel\": \"p(HBP:\\\"Tau antibody, AGG5759\\\")\", \"function\": \"Protein\", \"id\": \"6a7561f031e207c353920647220e9b54e60b810c09de314af6a47119c0154f84a64b399bd7d67eb46a795f10cefa707ec5dbdbbe1a40e7111dd609324ebebe92\", \"name\": \"Tau antibody, AGG5759\", \"namespace\": \"HBP\"}, {\"bel\": \"p(HBP:\\\"Tau antibody, RG7345\\\")\", \"function\": \"Protein\", \"id\": \"7dc822dfb4d3e3d8eac9d658cf5c76ff9408fdf426c71326429ed2bd183212f0b504ec71f5d687c5891276c988d983bc1fe69de64b0b6a541aac80e151598916\", \"name\": \"Tau antibody, RG7345\", \"namespace\": \"HBP\"}, {\"bel\": \"p(HBP:\\\"Tau antibody, Tau-13\\\")\", \"function\": \"Protein\", \"id\": \"5b14c438a84a0d672fdd91149ba13d708be8538552d0fada0d49f1842c8a017ea2526fccc5a766e58aa55cfa0316b618bd20fc4eeb3bb494e40667b4177cc718\", \"name\": \"Tau antibody, Tau-13\", \"namespace\": \"HBP\"}, {\"bel\": \"p(HBP:\\\"Tau dimers\\\")\", \"function\": \"Protein\", \"id\": \"03fe8e048185733d4e2d42f460b76ca0accb4c08988b62a3516b6c64dca4a948fb711ffdaae1b2acc75c06a693d0395b500a336175efac78fd6a5cdf9f5bb94a\", \"name\": \"Tau dimers\", \"namespace\": \"HBP\"}, {\"bel\": \"p(HBP:\\\"Tau epitope, AD2\\\")\", \"function\": \"Protein\", \"id\": \"9287eff0cc9374b6798f4c4cb9ef16bb5c98af5e353d69de29fa8b0334906ebce982277c73306766299349a0ab30426cf4a87dbc999636458e5043ee17d04bfb\", \"name\": \"Tau epitope, AD2\", \"namespace\": \"HBP\"}, {\"bel\": \"p(HBP:\\\"Tau epitope, AP422\\\")\", \"function\": \"Protein\", \"id\": \"18c511f6925dbfb3ad1cf262963acec87901b9fb43fa4bc34824ad3d61cbab3775e4751b7988a600a604f72ba9d3f9ee0f7944f8dcb0ffc873c589cad2273612\", \"name\": \"Tau epitope, AP422\", \"namespace\": \"HBP\"}, {\"bel\": \"p(HBP:\\\"Tau epitope, AT180\\\")\", \"function\": \"Protein\", \"id\": \"5a98bb14668e1fa319d2fbbde552597c4742e9b49a3eafb28a2c34bf6e0e50700e25f2ab9c060cf6e86910012ccbbd0d3461dbf5ae01d577a59534c1ecee89e5\", \"name\": \"Tau epitope, AT180\", \"namespace\": \"HBP\"}, {\"bel\": \"p(HBP:\\\"Tau epitope, AT270\\\")\", \"function\": \"Protein\", \"id\": \"912fb22fb015a2b76d8a41a210c66064e32218c9a35889fe569d8b5c822df1207f9dfc4c2d1f1ef17624ce075d0a732c572a44e4afe4e8eafea900b6a03889fa\", \"name\": \"Tau epitope, AT270\", \"namespace\": \"HBP\"}, {\"bel\": \"p(HBP:\\\"Tau epitope, AT8\\\")\", \"function\": \"Protein\", \"id\": \"41962f318cfbbdc940cf240c51ccc8748ed33b59785b3f776e1cc1907c3e0b69b3340d9fa53ac1108ad1894a38c564cf329d40fbfe4a60ba76cdbd228bebf859\", \"name\": \"Tau epitope, AT8\", \"namespace\": \"HBP\"}, {\"bel\": \"p(HBP:\\\"Tau epitope, CP13\\\")\", \"function\": \"Protein\", \"id\": \"bbb9ee4e3f9ca7818c9cf1402c4ee5ff38de6800052d3f233d920b5a450a0a6309792905db6290265d662b0b14b268fdfdd2b934f873e08983b5452e8bcd832e\", \"name\": \"Tau epitope, CP13\", \"namespace\": \"HBP\"}, {\"bel\": \"p(HBP:\\\"Tau isoform F (441 aa)\\\", var(\\\"p.Arg406Tyr\\\"))\", \"function\": \"Protein\", \"id\": \"f658f180734bcebfd95936cc38072fb065f290034e692f0a25217c0214f5be7152d9afcc3dc30fe4a43bcc507d22d084431e3be5ac6ff254d45eb4151e465f94\", \"name\": \"Tau isoform F (441 aa)\", \"namespace\": \"HBP\", \"variants\": [{\"identifier\": \"p.Arg406Tyr\", \"kind\": \"hgvs\"}]}, {\"bel\": \"p(HBP:\\\"Tau oligomers\\\", var(\\\"p.Lys280del\\\"))\", \"function\": \"Protein\", \"id\": \"d5673c200b0ea53d4e79e9315588432d3c6fefeeee2a6ea3f994527ca7477831f71f905d9f0953e466a7d812fee3989c0832ddc96f066945943eb1b5f2886544\", \"name\": \"Tau oligomers\", \"namespace\": \"HBP\", \"variants\": [{\"identifier\": \"p.Lys280del\", \"kind\": \"hgvs\"}]}, {\"bel\": \"p(HBP:\\\"VQIINK motif\\\")\", \"function\": \"Protein\", \"id\": \"be3ed4113769fe92465e29467200db59861dbf232ebbe7fde78112fcfcda51d1905ed9f6701fa5bf19dfff7c09af4d350e3d43ae4c3fc27b9b650315ac67bd69\", \"name\": \"VQIINK motif\", \"namespace\": \"HBP\"}, {\"bel\": \"p(HBP:\\\"phosphatase-activating domain\\\")\", \"function\": \"Protein\", \"id\": \"13b79ee497a2b5239e3ade45a0755015d95761404ee260005b56b78d57a40582afa3f4758ec8271987e918bdbc8ac86349e5ce62a2de5005a88a948eecbeec43\", \"name\": \"phosphatase-activating domain\", \"namespace\": \"HBP\"}, {\"bel\": \"p(HBP:\\\"proline-rich region 2\\\", pmod(Ph))\", \"function\": \"Protein\", \"id\": \"a8ed9f065b836022521f4a9884a9bc4cc130dc84f0a39054907ecd5417b8ff1d1334a2488cf5b162fef9072f47d7440f2c89d1f311b85234777fa9f32e489edb\", \"name\": \"proline-rich region 2\", \"namespace\": \"HBP\", \"variants\": [{\"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(HBP:\\\"tubulin-binding repeat 2\\\")\", \"function\": \"Protein\", \"id\": \"03ab3f7416f5c92ed862db8ac2122c116ec3f1e1c6b2dffb2fcc1c3ea7ed3ae4479e1d37350995c75c001558f62453782d6f60e3776ea8769debb8a601aa7059\", \"name\": \"tubulin-binding repeat 2\", \"namespace\": \"HBP\"}, {\"bel\": \"p(HBP:\\\"tubulin-binding repeat 4\\\")\", \"function\": \"Protein\", \"id\": \"1498e07780888f3c7b76873f3ebfad3a0371e52a239450c0a4255feaec6cd69c1635b7f65869fc1e0b78723e1a39f6ebd77437e17588aeeb222536a85681ef03\", \"name\": \"tubulin-binding repeat 4\", \"namespace\": \"HBP\"}, {\"bel\": \"p(HGNCGENEFAMILY:\\\"Cholinergic receptors nicotinic subunits\\\")\", \"function\": \"Protein\", \"id\": \"d55bebfe65f49c8e66d1ed0b491af0f01aba4b030a649599e59150e53ed4d3e4cd2199be8863b95c7033ab2185d8d7ea9203e5418faea9d7dcc86757b9bcf4dd\", \"name\": \"Cholinergic receptors nicotinic subunits\", \"namespace\": \"HGNCGENEFAMILY\"}, {\"bel\": \"p(HGNCGENEFAMILY:Proteasome)\", \"function\": \"Protein\", \"id\": \"306e6d993d64bc5764a4fd4cc05a1fac0b8337d09978cf1472b9372ebdceb68066f9285baeea42ed1bcb387fda530502da60f615863b6f0dee63dba5fd511cc5\", \"name\": \"Proteasome\", \"namespace\": \"HGNCGENEFAMILY\"}, {\"bel\": \"p(INTERPRO:\\\"Kinase associated domain 1 (KA1)\\\")\", \"function\": \"Protein\", \"id\": \"f985a7a001f12251daca2e3a0010feedd29fb50a2233a1e2bd87e7a5d563f67a5fa0e89df6fd6c167661c2f634029ac3dde0e148c413fdae15f6799dd95f887b\", \"name\": \"Kinase associated domain 1 (KA1)\", \"namespace\": \"INTERPRO\"}, {\"bel\": \"p(INTERPRO:\\\"Protein phosphatase 2A regulatory subunit PR55\\\")\", \"function\": \"Protein\", \"id\": \"17928230b43b7fd87f1181708a849e1bea646ca3eb7ca11b585260762dd199b711ca023a461a57f8f3f8c7489f1b2a35f368b404c533fdc6e57d92b404186ad0\", \"name\": \"Protein phosphatase 2A regulatory subunit PR55\", \"namespace\": \"INTERPRO\"}, {\"bel\": \"p(MESH:\\\"Cyclic AMP-Dependent Protein Kinases\\\")\", \"function\": \"Protein\", \"id\": \"ee9a8850def1c6c0a93482d8d5c04086543f33fe5ab23c7c0f667149ea6d1b7b2eec7dfa67785a7199d05fff966640fc48cdd54d49b47adf5af492c9addf8337\", \"name\": \"Cyclic AMP-Dependent Protein Kinases\", \"namespace\": \"MESH\"}, {\"bel\": \"p(MESH:Calpain)\", \"function\": \"Protein\", \"id\": \"740d3413dc934649da1bf44e02f9cd18e771bdf56c0832ac8c60c2dc8f335fe12848d079804bb8ad7e18ad7f1a7198b3024cae5664420eb631807bd265b46ce7\", \"name\": \"Calpain\", \"namespace\": \"MESH\"}, {\"bel\": \"p(MGI:Itpkb)\", \"function\": \"Protein\", \"id\": \"787f3a90a7a0ed1df7f045e263e5e306566446cdd8301487415f96f65c75c8f62416dda391b87d73ffef3ebc2fa2c1ca4096cd4c07ebaea59f30d4f86c892258\", \"name\": \"Itpkb\", \"namespace\": \"MGI\"}, {\"bel\": \"p(MGI:Sirt3)\", \"function\": \"Protein\", \"id\": \"6d5d0b48d18aa0ca1467c99fc69c3fcb88b65f887878fc05974b1cd0b87155fa47392df610f7ca0756f62d84cd4315a308b77d75d70c6ef5dcf651a3b76a7684\", \"name\": \"Sirt3\", \"namespace\": \"MGI\"}, {\"bel\": \"p(RGD:Mapt, pmod(Ph))\", \"function\": \"Protein\", \"id\": \"3b0967909beeb3e40181b42fd6d8b686507dc30354899f69d27bf9a7ea2017d23c8c8eacece7f76cec5a6edf1718c6a64dcbe256459eaf7543b8049d477f0c96\", \"name\": \"Mapt\", \"namespace\": \"RGD\", \"variants\": [{\"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(SFAM:\\\"CAMK2 Family\\\")\", \"function\": \"Protein\", \"id\": \"6272e7f1cdbe0dd7facc750301230f73b0438a4330e89404e5b9b025ee8ae4eb28917f5738057014e93a09941c41bdec68e7ad3ab0dbc7b8754409a90fd48e7a\", \"name\": \"CAMK2 Family\", \"namespace\": \"SFAM\"}, {\"bel\": \"p(SFAM:\\\"HSP90 Family\\\")\", \"function\": \"Protein\", \"id\": \"1f08351a0a73246a35f18a54510f3ebd89b3f520d4eec714a258af4f7f36fc70c6770bef120aada195dcbafd014997c657135019603821d6789109936410f4ce\", \"name\": \"HSP90 Family\", \"namespace\": \"SFAM\"}, {\"bel\": \"p(hgnc:ABL1)\", \"function\": \"Protein\", \"id\": \"0aba2eecc59f7e22e71ec79bd4231a9b5c2bdc6f18ba84a05412dd0bc3440a5797c3b8903201dc14863b22dad5ad3be9158e8a93fda330ca8d96326e3112eb32\", \"identifier\": \"76\", \"name\": \"ABL1\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:ABL2)\", \"function\": \"Protein\", \"id\": \"656f58ab6547c15d7c9a8fa905e3cc9eb12227e346b03e752740e6bb4611d1cc0ec0d4096de7b0adecec635193b6d19aa88e8acf1726141de0ed860001ddc72f\", \"identifier\": \"77\", \"name\": \"ABL2\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:AK1)\", \"function\": \"Protein\", \"id\": \"8da96e9d104ca47bd8b229b70180822a8b5851ee0cbc6ed7989ed02d78dd02f800ee027db2ad0e99eca2ce4525a6d960a36a084655e2fdb2e4f16934a2355586\", \"identifier\": \"361\", \"name\": \"AK1\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:BAG1)\", \"function\": \"Protein\", \"id\": \"3b29e1ca3b218c71821835fea34a4d41c59baab9e74efff1e820294f5bd6db00f9a1ace58e5e023d056dc9bf645923d5692bacdc77ed879b28a57bbbb59ea56e\", \"identifier\": \"937\", \"name\": \"BAG1\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:BAG2)\", \"function\": \"Protein\", \"id\": \"93f1d5f5ef79e42b609796e191135762dc38f39158a6a47e2b74bb9e7be61bb37d7ba7e6e6a419af203428f11e18385a25a08bae659c6ab0d3f4701cc32cc22a\", \"identifier\": \"938\", \"name\": \"BAG2\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:CAMK2A)\", \"function\": \"Protein\", \"id\": \"e2e385fbaee5543a22d750392d84df0dbe2f66224680662de32fade1a3db58eadfb27a8e1c2d38475520f0b82ac5593b949d6804fab0003534bb8257bdb14dda\", \"identifier\": \"1460\", \"name\": \"CAMK2A\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:CAMK2B)\", \"function\": \"Protein\", \"id\": \"b6e59c13f554363995be2fe4118300c90369601bd3abcb3cf81554a7853e757c53db7601074e8c95b004854acd15c618d7e90b61dd0db2ce4f51ad3136df84a9\", \"identifier\": \"1461\", \"name\": \"CAMK2B\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:CDC37)\", \"function\": \"Protein\", \"id\": \"d207f18ff4e0bd773893af957542912e41e4081b6a20b096694e73eae623537e3fefcdebab0f63a8da558ee146b587578f63794188d3cdf91db0dc4dde6325e7\", \"identifier\": \"1735\", \"name\": \"CDC37\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:CDK1)\", \"function\": \"Protein\", \"id\": \"dae6ad5693292693f5af780e17889cf31a4dd4a5a096c22fdf840b43b5d38cc274241a5e00c1c24709fa8d0eb6f33584b5fb09fe8e12a970d164955c7216e4d7\", \"identifier\": \"1722\", \"name\": \"CDK1\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:CDK2)\", \"function\": \"Protein\", \"id\": \"b9b4f2c71af045953423f99bdb65f4063fe17fa7ee99da69cb81064c4cb4446eeca16370807c9b44a74d919dbb22f892b3ba59e219cc23e21755d726cc05bd45\", \"identifier\": \"1771\", \"name\": \"CDK2\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:CDK5)\", \"function\": \"Protein\", \"id\": \"46c5b3856f7b9085d83860fbaf6a85489b4dd4a7de1eaccf218c9b09f2eb9117ec71ee544899a7812cae7e1573b821428792eddf588ebf6707b76078a440cab5\", \"identifier\": \"1774\", \"name\": \"CDK5\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:CHEK2)\", \"function\": \"Protein\", \"id\": \"d4bd66bb9ed17c36145e05a5b8d3490d4b7333395673a89d016724f8d8d72268eb30386e07884811f635d37ae212ee331caca56ac294f8761d039f01a2d53b78\", \"identifier\": \"16627\", \"name\": \"CHEK2\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:CHRM1)\", \"function\": \"Protein\", \"id\": \"523250575ad44981c56048741dcd9c33fb22346a4e70efea9372abda6bcfa6972905b481ea0c3fc98516eef5d6368979f4749e0fce60f12ccf290de6c5febec9\", \"identifier\": \"1950\", \"name\": \"CHRM1\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:CHRNA4)\", \"function\": \"Protein\", \"id\": \"90cc562968891cecf8f2e0128216c050c1eb418d1fbdcdfb2d86221f8221377d39a2a6dd09941f9aa651af3dde46aeb485d3f5182b06eed1cd53e96244acdc1f\", \"identifier\": \"1958\", \"name\": \"CHRNA4\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:CHRNA7)\", \"function\": \"Protein\", \"id\": \"bce6fac3e0fe80e3944fff2bdb3f017c4ed26b422110b5848545cf5205e6755db494a99d2af91a9141a3d53b7cf88203d1e31289bfd821b09bf5a1920e20bd50\", \"identifier\": \"1960\", \"name\": \"CHRNA7\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:CREBBP)\", \"function\": \"Protein\", \"id\": \"8dfb8126a0a183c40371ed69db58d5e6348d0a30cbc344fc5716c96821c91296ae5acd8064f1cd96755c613cb792baed5f23868545b8c339bbaa297148e78d02\", \"identifier\": \"2348\", \"name\": \"CREBBP\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:CSNK1A1)\", \"function\": \"Protein\", \"id\": \"0e4a99959d6ee31a337403001ad2571fb34d7ffefb47d415e12c61da91960a9eb83825b2bb86e7681edac30e34c7c181f13f932a00b322982abf33bfcd724763\", \"identifier\": \"2451\", \"name\": \"CSNK1A1\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:CSNK1D)\", \"function\": \"Protein\", \"id\": \"25f10ed9dc67f59e9024a02dcbf7067d63ae49e4f94702a86971cd9d44eca11f7b05ef011bb1af4f4e513c43a134fea318a7de9ac3d5f629f554d6bc4ec9e4e1\", \"identifier\": \"2452\", \"name\": \"CSNK1D\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:CTSD)\", \"function\": \"Protein\", \"id\": \"04a3fd03092e041193e6b115e49722e1e1099ce93eecec259ff6e866074a5a36b1d95aca6305074577fc2fac2710c4f6d984c7990ef56b9329a37471636979a4\", \"identifier\": \"2529\", \"name\": \"CTSD\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:DAPK1)\", \"function\": \"Protein\", \"id\": \"47546bbc3e597084922b0c1424df78ce244382bed33d36aa5bf1009815431bf2c9e513cdb033a55f4d4ce45d6cad9fc0d6e405b330ff637da7e8abce591c5ea5\", \"identifier\": \"2674\", \"name\": \"DAPK1\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:EP300)\", \"function\": \"Protein\", \"id\": \"7c5f0a52f86f968fb599be06f2c168ca382e4542497800c2b3334719ca89dec16cdf76c69cc3d6afe41926ede964b607813d6a18bb436c92f97ff32106f38ea9\", \"identifier\": \"3373\", \"name\": \"EP300\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:ESR1)\", \"function\": \"Protein\", \"id\": \"a7fe030379c91a359ab46733216b6d6b2f95dacd2d889a5d0da6da65d675f7e0ab58a9995586652a591f5531fddc77d59e9904af95ad3e6a91edae26919f6ce4\", \"identifier\": \"3467\", \"name\": \"ESR1\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:FKBP5)\", \"function\": \"Protein\", \"id\": \"6b3533ec3612a1ae3516fc80f45f32be8de75e317a48de934065408e0fa7ad365df274a7ae5d48e8462147b8936965e9c8f379f514d01ff75b31664947c91ac0\", \"identifier\": \"3721\", \"name\": \"FKBP5\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:FYN)\", \"function\": \"Protein\", \"id\": \"284595d5fc2a0b782c403470789686ff7b2b23106918d20495504857ae470308764d0904bdc15f2d82ac056cffaff46eab4bca6ecbdbe049fb99d4866e95c6ce\", \"identifier\": \"4037\", \"name\": \"FYN\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:GLP1R)\", \"function\": \"Protein\", \"id\": \"21ab6019151fbc859ff34793af37143123331c7157abde1d6b1adc0a79ee91d976c6d8d2b96858d4e64356d4028a018d275cfd887d4e5c950a501b0cd46ed05e\", \"identifier\": \"4324\", \"name\": \"GLP1R\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:GSK3B)\", \"function\": \"Protein\", \"id\": \"f4b86efe3f0131391213e65749ef4f1cf395267f0df5641e5bedf1e0ae2aa5e75197bd42d96817105170b27746ba632ffd878d9b4bd3a7c78d2cf8b7132f2f80\", \"identifier\": \"4617\", \"name\": \"GSK3B\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:HDAC6)\", \"function\": \"Protein\", \"id\": \"9c892cb49df31546a9b99187a302a601d1bb99e3ab99477f79f128f802b2684ca782bbfe681b5edc70c98eb061eaa6a8b2633534015c84dcdc713a4bfd4a331e\", \"identifier\": \"14064\", \"name\": \"HDAC6\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:HSPB1)\", \"function\": \"Protein\", \"id\": \"45eaa4f2f3bcb264e1844c6fd8e0ad7bcac8b6cfd40410812ac0637c213acd28fe8e91e00200a279f27cb89c121f07a8851b6bfd7dfa0467003280ed27185837\", \"identifier\": \"5246\", \"name\": \"HSPB1\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:HSPH1)\", \"function\": \"Protein\", \"id\": \"cdc53cac04b9e943f8792d91e411e446af95b433943eca00b091a2a2c0ae61afbc2259d849467c0bb8b37460c6f528271d74e036fc981d599bc9d8127964a191\", \"identifier\": \"16969\", \"name\": \"HSPH1\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:LCK)\", \"function\": \"Protein\", \"id\": \"7bbf9407c070c9926c5e598a3888f3bdf13315a20c9cbca846a8f61cda50e74ac8363273caf69c91fb5a8e96a7341b5941b143b6a55041f4e67b4515fa8df5ea\", \"identifier\": \"6524\", \"name\": \"LCK\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:MAPK1)\", \"function\": \"Protein\", \"id\": \"3c251625774339e39ee54ef4be9705822569944222d95fa9c4b09a6ccf6751d25f6995d5976b844ebfa4681b588dc66e5d622ec906014a1d88196fed1f404adf\", \"identifier\": \"6871\", \"name\": \"MAPK1\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:MAPK11)\", \"function\": \"Protein\", \"id\": \"fcb344c77feeb98c6d94c5be0e8e6755f30eb0ae44cd996bb0f1f7c8cce01beb72f9767c960a15cc23b28e351ca0a0eee9f144103745c92907aa4e3e51484f4f\", \"identifier\": \"6873\", \"name\": \"MAPK11\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:MAPK12)\", \"function\": \"Protein\", \"id\": \"4f8a7a855aee538623cc610d423db9f58d3674fd8d0dc1cdbc962f5e59a06de2015503c8760aaf1b1a525c67145b33be9aa5929e002ffa3793118744bcae1914\", \"identifier\": \"6874\", \"name\": \"MAPK12\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:MAPK13)\", \"function\": \"Protein\", \"id\": \"7bb21f65eee640ee1468d0bd7339dfe19afaf4284bce33e6bd3f947921799505e6614a5e159756b7534156b95423d9c69d3325562d3f6a3d531efdc7c119dd9b\", \"identifier\": \"6875\", \"name\": \"MAPK13\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:MAPK14)\", \"function\": \"Protein\", \"id\": \"59a8fc1f1de4094a77cf8d0d9dddd2e479cf0f442cc487378b561b5b841bc26ac0d144ac8bf0daed7f99ea0f304429e79a49be812c2024f67ca90f0c79650500\", \"identifier\": \"6876\", \"name\": \"MAPK14\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:MAPK8)\", \"function\": \"Protein\", \"id\": \"fa92b4953d1c2e5309606f66c712273d1026c26ed8b0c4d0e173f5536aab563a7ddbe669eac1fb71c4cf77020e60ac5061e55c15a7936b002851f4ead6e0121f\", \"identifier\": \"6881\", \"name\": \"MAPK8\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:MAPK9)\", \"function\": \"Protein\", \"id\": \"31cd971f4c5464ee9b455118bccf26429fc2b79eb908d90e89eb775133b0650db4899128565803b66df081fe39c0dc473141a94e4d21ba8a91f0bed7032b8f02\", \"identifier\": \"6886\", \"name\": \"MAPK9\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:MAPT)\", \"function\": \"Protein\", \"id\": \"75ac052d10d9c36a24437908ebde27a24642cd6780dd93b2a8f6754e2eb0f4ed426269793e92438bff32aa2d71f00857c38f3db9d3d5f0ea5e108baf465920f9\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:MAPT, frag(\\\"?\\\"))\", \"function\": \"Protein\", \"id\": \"4098c60172fd02f4dbd1d05fa89a2e12d4c0e99639d6b40e5a06c09971c3ef0951ecde61199d29cedd31e9cff3429f38d84f18b786f224fb5c0a66805fc7e34c\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"kind\": \"frag\", \"missing\": \"?\"}]}, {\"bel\": \"p(hgnc:MAPT, frag(\\\"?\\\", \\\"29kD\\\"), pmod(Ph))\", \"function\": \"Protein\", \"id\": \"d6e248a0aeab303ac9b380117107bf8af2763a792e2ae0c1de125bae49e120fd6bb8b55e690f63773274b1cf075bc4ec72b4d5636f7ba890af2afea5b60eed65\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"description\": \"29kD\", \"kind\": \"frag\", \"missing\": \"?\"}, {\"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ac))\", \"function\": \"Protein\", \"id\": \"086007502eb8870b9deadf44edabe3108b427c39b4f23cb2a48365a82798681e35859fa246d83af2d04e0514c5fe75d4b7ef04a9db976c53c41467f0c54894b5\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ac, Lys))\", \"function\": \"Protein\", \"id\": \"db3dc39b4e2987d2fc6b57b379f33981aa4b39205f8aec2f7aae45ded915a3910f7f6a7764193ccd1ca221b164bcfcaea8a17fbe9b6445e342d1b8076fc3970d\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ac, Lys, 163))\", \"function\": \"Protein\", \"id\": \"23eb5f1b6aaf6132e585aeb57751efbc8a8fb83cfdbe86b0f7a19555fce83e3cfdf8c1d3d9a2f66846e5adaf4a6fa4e4577bb3c0573d9239af839a288255513f\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 163}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ac, Lys, 174))\", \"function\": \"Protein\", \"id\": \"2554ab719d61232ae2313193e3900eef9b9edeae7b34d278ca298a2ab64a83332471593aa54736293d851a374edc16fefa44b4a2c26e9a177b316b8900f2095f\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 174}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ac, Lys, 180))\", \"function\": \"Protein\", \"id\": \"01bba18f815352bce6ea23ca1b97e6e65fcbae050cf7609e36cec6992f694251bd3714d0a8e3fb29c539f5b71ee2e8d206e204215010e14b29d02ebda16c3d1f\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 180}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ac, Lys, 225))\", \"function\": \"Protein\", \"id\": \"6fb7d98132411f1b1c218866d7b0ad61c9ab91ae28b3bc490a2bca5bfbfdb1f2c7de67244eef772d331c231a1a78deadb5c3c11ac33788738edc226190829a84\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 225}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ac, Lys, 254))\", \"function\": \"Protein\", \"id\": \"178975c891a59fbc9408df93317a1f9ff428c4e6ac71599b76f483851a4fff8a76e93b320e4886f8401e0944acfcc105f635eb16141269f393ed7c54e1e07c55\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 254}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ac, Lys, 259))\", \"function\": \"Protein\", \"id\": \"f3c40a725008f3e8df00638f170da4bef9afbfaec5a0c159a054164bfdc23d2bb5ef527e8bc4a04790fa75e564fe00b6ca7d30ed784f73365a0d89483bc9511e\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 259}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ac, Lys, 274))\", \"function\": \"Protein\", \"id\": \"fb8c850cda1b9c9b1099d58516c45f74f14008c1e11eda10a9013e278428a72d5f576b73ab9f21b3cde2fd3dcce34993774ce14231c58da95ed0056373d6521d\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 274}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ac, Lys, 280))\", \"function\": \"Protein\", \"id\": \"6660abe8ad915f3939dd91bd835bf0d734c7fd1de339b422f39de338d39f153c5063c05aabc6670418e66f9b99c247fd1e916fe9dac7b7463c5fd82c82e39e61\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 280}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ac, Lys, 281))\", \"function\": \"Protein\", \"id\": \"c67e052d631123351caea3b6d154a3db0260b4002b0b6a54e676f72ae977b5c3482136cabff1cee79f230a7713ad7871686fe2592c08a938d5cc232f90b407e9\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 281}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ac, Lys, 290))\", \"function\": \"Protein\", \"id\": \"e056ca1774256bd99a3d04609e35740a095ea645ecfe03ec08ecde2787b3556e61fc1c16c5a547a3189cdc684461f57942ec9badf8aaf59fd5b098e00e8d83c5\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 290}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ac, Lys, 298))\", \"function\": \"Protein\", \"id\": \"22243e4d5056355c65fb1750312111509c0011231ebc599275b2090debe324c380b0b1398b5abe4c89c3e2f8a06c3cd59afa02f4812cf259ca5d9c972bdd111f\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 298}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ac, Lys, 317))\", \"function\": \"Protein\", \"id\": \"119f64d980bc7a6caf21d42dbb62742ba346e3115a054748c915f16cbfac6431b46fc3d8fb420b12f8c7120fba3509d00c1b65c460aa35ef1aea4142846bdf1f\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 317}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ac, Lys, 321))\", \"function\": \"Protein\", \"id\": \"fadf17cfc492ba8813ad7a14a98bbf2e281c63db4c284c11be96ad37aea955f7226b33a31e947c4d1f24f72667ec237fe6a09d380e43c9245088ef7765088ebb\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 321}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ac, Lys, 331))\", \"function\": \"Protein\", \"id\": \"72acec32321391e7ee979b6ac942f546e5cd742ca34b7bb1a264a4451f8165707d09b76b66c3646f771b917658840014a0e9acb011fe8e390bac9adcd1d689da\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 331}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ac, Lys, 343))\", \"function\": \"Protein\", \"id\": \"0e520c074919609e88ffc435cc257cbe0109d08cdfc2bed2ec3a2d75a6d50ced852e5b015420d7898b26b9655c332aa645ee7785faea9f61476681020b6fef6f\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 343}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ac, Lys, 347))\", \"function\": \"Protein\", \"id\": \"503847542f7aad812d9d9ed1898e48d5ca68b1c648f66153d795005936f4a20cd25d2971e4bc6828dd53ce11fd2f734b96f08dc797ef7d28f7c33a7e8219bc1a\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 347}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ac, Lys, 352))\", \"function\": \"Protein\", \"id\": \"d477b66e2f111ebcb3622491c67ca7018d9d2eb70534de03b0f89ec51ceb85014b288148c91a6c9d3b032f2a621eeaeab7c3773b72f5fb28b67cfd8cf7b91d08\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 352}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ac, Lys, 353))\", \"function\": \"Protein\", \"id\": \"244b6cbe87abeb59df8e74265181362659365c7848fb45ed77300a466d6e0eeb6ff731daa9450b2d88a2dc779fe2fc698e6876f283fbb8539e1415f35748c769\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 353}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ac, Lys, 369))\", \"function\": \"Protein\", \"id\": \"5fa7c43ef3015fcbfacca16595ce270e8eca7ae648023339f832399c4b23883f3589d33cd782413ee9cb00bed21a52d42a06ebfb60c6ba83216a7caeaf5379de\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 369}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ac, Lys, 370))\", \"function\": \"Protein\", \"id\": \"9c976536ac3d74cbc8584945a80901e4fff35d18ae96ea2f03f9d2a0a9d71b8654efe32ce75a853dcf88fca34df150e692cd89b2f0f149a91e71a80a77b49319\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 370}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ac, Lys, 383))\", \"function\": \"Protein\", \"id\": \"a1385ec8b8f6a7cf98b27121b44798f1dcc220c55ee9217d83139a4ed7014f6e0a762066dfdc47501431720c7053cad6bbe4223d7e3cd8c12e9e35196484db3f\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 383}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ac, Lys, 385))\", \"function\": \"Protein\", \"id\": \"8fae4c19307a10a5b441f025c1680022d1496bbeef410b91b0a5917edef093db7182def2a8503f1bc3367b7eeab058760a3096dcdc513f258a81621a109189b8\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 385}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ac, Lys, 395))\", \"function\": \"Protein\", \"id\": \"f9bd28bfb50dc2bdaf12c36a32c9ad5a14714493de537e65993c0cac8ea359a77a2e310a9e0a94ae08f0cd6fd278a47685c3515e69d7702881a7735c248a2363\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Ac\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 395}]}, {\"bel\": \"p(hgnc:MAPT, pmod(HBP:\\\"O-GlcNAcylation\\\"))\", \"function\": \"Protein\", \"id\": \"7973c9cfb3417499b65714b709805c69e02542a408108f9add27612d331b540f4aafde1aaf8afe043d1eeb87cc08c9846496c18899d94ceabd6381020b81d69e\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"identifier\": {\"name\": \"O-GlcNAcylation\", \"namespace\": \"HBP\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(hgnc:MAPT, pmod(HBP:HBP00007))\", \"function\": \"Protein\", \"id\": \"c9f184555a3fdb0ce6b08931194953da928d4eb31d94ca0ed9168a0f4e878d312dfbdb91743504fe01850900ed55bcc75d4a68bbdcd04b007123da9e7c789565\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"identifier\": {\"name\": \"HBP00007\", \"namespace\": \"HBP\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(hgnc:MAPT, pmod(HBP:formylation, Lys))\", \"function\": \"Protein\", \"id\": \"e54cfcc300685d78a422384136cd53425cf809133ff5540fb1f7966dd39fd80657fa98a933d9dee6a6ec6d8667d3adb6c4716aa149e854d26389852442bab90c\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"formylation\", \"namespace\": \"HBP\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(hgnc:MAPT, pmod(HBP:glycation))\", \"function\": \"Protein\", \"id\": \"aa90c1723c86b1acd7d3be1d31c9e8f9fcfbe4fac8cdd878bbed2050b2252c50db95e39f9f267a3e7b138ba551687a567922a003fa5ddcdd6e2c27dc1b92bdce\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"identifier\": {\"name\": \"glycation\", \"namespace\": \"HBP\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(hgnc:MAPT, pmod(HBP:hyperphosphorylation))\", \"function\": \"Protein\", \"id\": \"fb2505a5d216ff85090c9fda277c4ef7b48872321e871fe8c7609b0f79b84594268f0e278bfd410fa6cfd47a1d226d7fb09c77069330c0f6d9c2835925d8a2de\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"identifier\": {\"name\": \"hyperphosphorylation\", \"namespace\": \"HBP\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(hgnc:MAPT, pmod(HBP:misfolded))\", \"function\": \"Protein\", \"id\": \"b73940d03780eca32d2f13db7388e9aa31961ff080f7dba05cb430faa2a61fc59ddeb9f0f361e707976eb246209800ee1d2927126c5c9416be9d06c0e44e7494\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"identifier\": {\"name\": \"misfolded\", \"namespace\": \"HBP\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(hgnc:MAPT, pmod(HBP:misfolding))\", \"function\": \"Protein\", \"id\": \"633704173d7069d824242e4a9fd6dedcfbda6897b387e69ed920ce2a13c6e51a9bc07beaef0645737134ae3b6df46b66ec76e26744aeebe294d7ce72b0e8825b\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"identifier\": {\"name\": \"misfolding\", \"namespace\": \"HBP\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(hgnc:MAPT, pmod(HBP:nitration))\", \"function\": \"Protein\", \"id\": \"16aa45c7eec57dba655afff0c73d955a1b816aa25bc952845a6257705948e071b58221fe6b26a9fe5cbc72d0160dbe267afe041d166cf365bad34270f8fb6421\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"identifier\": {\"name\": \"nitration\", \"namespace\": \"HBP\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(hgnc:MAPT, pmod(HBP:nitration, Tyr, 18))\", \"function\": \"Protein\", \"id\": \"d4cb72dd3a530c651f2eac8c51caea094ec78285bc26a1e36a4d7dc5081b138032a14c7756bb0bd6b15b3b17150cd5c282b593079d94ae3b87e237f548f1bacb\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Tyr\", \"identifier\": {\"name\": \"nitration\", \"namespace\": \"HBP\"}, \"kind\": \"pmod\", \"pos\": 18}]}, {\"bel\": \"p(hgnc:MAPT, pmod(HBP:nitration, Tyr, 197))\", \"function\": \"Protein\", \"id\": \"176dfca55febaefa2a15b7d6df5420e539e3ce1e52c1278d74c8780d7dc6625b7c8aeaf6bbd8bff06b429fb969ab733875b114cc2c2d0d492748b41bf748cfd5\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Tyr\", \"identifier\": {\"name\": \"nitration\", \"namespace\": \"HBP\"}, \"kind\": \"pmod\", \"pos\": 197}]}, {\"bel\": \"p(hgnc:MAPT, pmod(HBP:nitration, Tyr, 29))\", \"function\": \"Protein\", \"id\": \"05eb433703ae983caa8370a8e97a27c94df5495c6145a6cecff2b063df568c343778fad0d3b58b1318a7226a1224bbe7d4932b6a7ac77c88f352775301e686a5\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Tyr\", \"identifier\": {\"name\": \"nitration\", \"namespace\": \"HBP\"}, \"kind\": \"pmod\", \"pos\": 29}]}, {\"bel\": \"p(hgnc:MAPT, pmod(HBP:nitration, Tyr, 394))\", \"function\": \"Protein\", \"id\": \"cb758cea9c2796418bdc0e77e1549162ff7890837a51c10db96542b1a780bddbdc92ebcebc836ab32f738456d7928d340f4f17c6b516ce62cc38f356bcf800f1\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Tyr\", \"identifier\": {\"name\": \"nitration\", \"namespace\": \"HBP\"}, \"kind\": \"pmod\", \"pos\": 394}]}, {\"bel\": \"p(hgnc:MAPT, pmod(NGlyco))\", \"function\": \"Protein\", \"id\": \"0db5dfadede05cd120c51cda1ee52039ded2c85ce1f96b20807e10b542d45edcf2e11cb0afab046dc2a0e0ccec86b957693857c4e2f1f7f7b3443527450cabdb\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"identifier\": {\"name\": \"NGlyco\", \"namespace\": \"bel\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(hgnc:MAPT, pmod(OGlyco))\", \"function\": \"Protein\", \"id\": \"78a540c6a67f8b0aaee585d034e09ff623ee68bc32a45f21e1c0217d7168bf37864c1f638015b5b25131fd137ff91eb390f1fa3684127964fda34f6a01453f23\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"identifier\": {\"name\": \"OGlyco\", \"namespace\": \"bel\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph))\", \"function\": \"Protein\", \"id\": \"d3aa092293df7ba44bf320e83e90dc53a270a4aa13cdfebcc65a08b816478d62a78aae13d0cbb886a74da3390afc9aad1b80d39fd3d1f416c814bfa2c586e211\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Ser, 189))\", \"function\": \"Protein\", \"id\": \"70ba75d0b28c2bf3bfdc2c69837345ef7a5fd6b2f9f44a6b72d6f7b433871be0f29e64dddf3e05523098b17101d5753287f473151a9d6b53389d9878bb40777c\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Ser\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 189}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Ser, 198))\", \"function\": \"Protein\", \"id\": \"276e121c6d551193fc0c78f41ba684688aad6fda71bc891ba850586eb75a2842780129b857e42826465f9ac6d0430fab0d1c1bf5d20c29349df7e72d24552fd5\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Ser\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 198}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Ser, 199))\", \"function\": \"Protein\", \"id\": \"486601a5004f2a91fd4fe8d8a85f3adba789217c83dbe9d643c619af901f0d134d4f6dc59d17fc9222dd258c605be914fb7ae4b1333e163b26628516230cf385\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Ser\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 199}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Ser, 202))\", \"function\": \"Protein\", \"id\": \"f6b5755edd0c5d28be817d3ce66c4b2f914bcb67c1ea0f76ff668d99a87769e1a719b20f771f6c6735052360c333ccfba4d1cf0d16582c48fc2c56373637cdf0\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Ser\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 202}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Ser, 202), pmod(Ph, Thr, 205))\", \"function\": \"Protein\", \"id\": \"b4614c4007d8db0d9fa1c9ade081662b63dfe3aafb74d4b5c43e69fab6cb5a83bb511f2341bc317e0487ba6713596e57deddeccbe502fe8d2f2716f88c5b04bd\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Ser\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 202}, {\"code\": \"Thr\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 205}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Ser, 208))\", \"function\": \"Protein\", \"id\": \"dd8c8dd446d0e26d978b622fba14bd735163bccded38229a82c5f8a4678dd5b9f4e63be618da83e409e110c89789b3b4b0872de213bfc37c600e894a9ce182b0\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Ser\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 208}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Ser, 210))\", \"function\": \"Protein\", \"id\": \"24689a23c1108601d844824af75ed6e21e8a174b6cc5bc9ca111ec9a0480a7ffc613eed7d21a08ef20c06e3b02654510e28e3870c3b0f47eb51c17508d7e78f1\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Ser\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 210}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Ser, 214))\", \"function\": \"Protein\", \"id\": \"bb550621c2a4ce6d2f4f06186c8436ee37bf7d78491359fd862088d9d6fb46c5f4dd0e02106b6dd6a66635c91756e976a4cef56f64d7e0da610ffe16f3c5e01f\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Ser\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 214}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Ser, 235))\", \"function\": \"Protein\", \"id\": \"99a4c0588008dd4972d4c7b908fa9d3679ec2a88fcbeeb39f67174dc7e4ff5192e02af435ca2e22b83af90ea1983d31ec984d2acbc73c151720200552fdabe68\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Ser\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 235}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Ser, 242))\", \"function\": \"Protein\", \"id\": \"65d8073339d590b84109bfb4afc26355100c91d6595f2b19036307ad7f62a943bbf5d5c9d058aaf6a63c7196fdce9780eb6115866d14bdb6f075a4e412e4aa8f\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Ser\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 242}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Ser, 262))\", \"function\": \"Protein\", \"id\": \"b951b2d1026ecceeb7e3712b3fff29350f55f6ebf605b4913c8b876f604d2025542c84c59016f3d6e22d3e82400f0d6c42488351edfb0510eaeb1b406bdf3dc6\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Ser\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 262}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Ser, 262), pmod(Ph, Ser, 356))\", \"function\": \"Protein\", \"id\": \"c454fadcd0ca436fd00be0f4e4cf83e91daccd284afbcce3a103ca599380de45581ec5e4519296319488e03e1c2f262beac51c141a215797ec44176a6c8eda32\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Ser\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 262}, {\"code\": \"Ser\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 356}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Ser, 293))\", \"function\": \"Protein\", \"id\": \"7befe3f3c3fcf50816036c1c6b326f36ea594bd469638f3bd27da588cc06efb55ccd8ed165ef2842790381d956b48d729ff3c30b4818f7f2fca34df0ca50c395\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Ser\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 293}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Ser, 305))\", \"function\": \"Protein\", \"id\": \"429fe275dac3fc5f571b82fe1cc2d854b2e7b7ee2019f20fafb8a6b09c5b4439e331b7d1d816ea3842ce1a01c0efba145db4772385f1d4885231534767647e4c\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Ser\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 305}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Ser, 324))\", \"function\": \"Protein\", \"id\": \"7510b22fc6967ea05bd541e1945300a7efb52eb957bbd96ee3da235171d86bb7f397153a2719549b37a1e343bc46abfee872cb9908d43dc812471b3a242ed502\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Ser\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 324}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Ser, 352))\", \"function\": \"Protein\", \"id\": \"555f14672b5cf856f63edbafc0e7f3cb1c4c5a2bfecbe6ad8551427ee7938e098d3558482efa8399e63ba91468f33a4ae0397bd44a99eb92a1ac828eb42e696d\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Ser\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 352}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Ser, 356))\", \"function\": \"Protein\", \"id\": \"58ce747f4a0d600d79bf5ada0ce6ca90a52d098d6894c1a73462f151fdbe74a57aaa23e2220fbbbf9032b64cdc6b38e3ad501ccc777c8e33ed0da67165ba4396\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Ser\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 356}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Ser, 396))\", \"function\": \"Protein\", \"id\": \"3d5a4dc72dff0c31ec10ac26842fa1e5a8282dc5b9ecf36b9f0c7984ad7bc040b97d1cebd7900a063578f8b03f5da311959b05fa00aa5789d52693d6ea1a5838\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Ser\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 396}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Ser, 396), pmod(Ph, Ser, 404))\", \"function\": \"Protein\", \"id\": \"4362394c9322e0bae8da9c96c1663f9ae51d2d118aa9b335cfe7678a23b0c42f1efa161403a00191e6def0d6abdd3902e8e19634ab3c7cd1577b5659ceb5f135\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Ser\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 396}, {\"code\": \"Ser\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 404}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Ser, 404))\", \"function\": \"Protein\", \"id\": \"760fdc2b24f0ef3736af03dc5d55c84c0110a6d7bf963a80556a75b17e0b95b52b496af73ec3f4662d98577d4236ac553621c08885ad944e34ccd96614969370\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Ser\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 404}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Ser, 413))\", \"function\": \"Protein\", \"id\": \"b9cd58162b4039e70d9d680422ddac300be0d1d72ab0cd92af61d26fa564d7a692393ac04537b73dab4f5a32c802014543017f435849c239e29c84c47c170558\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Ser\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 413}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Ser, 416))\", \"function\": \"Protein\", \"id\": \"fe16ddcaa5795955419c8d76e768c117f1fb6a6e1d48e299854a1e3aad7ba362ad487e3007396bd16f55db397ec6ac2335e1390e1c41f98735731375df4c0632\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Ser\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 416}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Ser, 422))\", \"function\": \"Protein\", \"id\": \"425498102a7e164493bfbec2efd07be573e65194c1cfcd55f5084abd7d7b1ef51fd77b821afc54dc5f0d2f5cf23b8c12daa0e9ddeaf8bcad2aca3a6d0973bdbb\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Ser\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 422}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Thr, 17))\", \"function\": \"Protein\", \"id\": \"934513087d3aeb8d18428a82aa4186cef2958ef0de7c10f8ddd38d6f31ed3db2ad5fd5682cc7e3b1b851aaf9c3ebd887528f75766160960eaf327ccbedc51822\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Thr\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 17}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Thr, 181))\", \"function\": \"Protein\", \"id\": \"0ff1dc02897af7ce19c6caeeeefad8a687df05a4179d6b53477870d359604ef60c642222b59b51d6e3231d46cefea0ffbb7a7d6c77d1da0f3e446027cb98664f\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Thr\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 181}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Thr, 205))\", \"function\": \"Protein\", \"id\": \"248ed001e89a69e58fdaa9580c5e8296d80c6ef6efcc1d2b31400e9350924bb1e9fa45cc210157da13e5ff8b6cc3bf659b1098f60db12cbfed71628bea62f436\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Thr\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 205}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Thr, 212))\", \"function\": \"Protein\", \"id\": \"963830c7d3153666d45f6417f6bfa9b3fceda076cd8b9546836c281fd3929b222be62d1bf4bc4ddf207c6181e494d4c40f13f46a32010bb6e675c38bebcef2eb\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Thr\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 212}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Thr, 217))\", \"function\": \"Protein\", \"id\": \"f74435ef7d43b3600c86de494a82371ca1f9202a7b674f3426170ab90876d7ea33fb90b09ef6b3df011e4f5ba5faaf2c32e03003d0216e699c90edc258aff036\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Thr\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 217}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Thr, 231))\", \"function\": \"Protein\", \"id\": \"6f0436813a5a39cc07ddb9bbb752734fd4536af4c0a0c442292467d59093ffb1037be8d82543aef81f40d1ccbd318655127c1827b9d0d0e79276cff3ecfb955d\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Thr\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 231}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Thr, 396))\", \"function\": \"Protein\", \"id\": \"a44df6564ddacc760f7352f2ee67ebd3e49cb93dd19b09e88a8c6f807738fe86415092cc806d73da6b155cba62a1611584803c58626eaa9b10cda8797e0e0784\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Thr\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 396}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Tyr))\", \"function\": \"Protein\", \"id\": \"e59574f3cf233d7a5ae13fd8c876cc33fd44327bec0e842d97f78c0fd1a579b2d1ac18a187a18a61fcbd9d6af5c8126588f8e87e2e0417e4933eae779c530a3c\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Tyr\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Tyr, 18))\", \"function\": \"Protein\", \"id\": \"81b17ac87b4e70b73122f7ec44962a3370a63219fb4a05b0bba0e0b573e8890d2287e127ac109507ba117e008efd4305180e90c6e14a2ff8e0b54d04d543c6b6\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Tyr\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 18}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Tyr, 197))\", \"function\": \"Protein\", \"id\": \"f2a07330883c9f831618eb3187a2d0ae67c6c906ac2623928c2f2a30eb891ea54ef98559167f54719b187221bf075b9a349f94d53b0a8eaf256255d17382eebd\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Tyr\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 197}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Tyr, 363))\", \"function\": \"Protein\", \"id\": \"a533d8f8fbb234a0fafc1ae040f5359e606797e5f2e04fc8518d282193179762b8da510f99b8be3fa5e1d8f1afd144e1e0c9acea745ccec7e97d4bffc6930224\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Tyr\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 363}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ph, Tyr, 394))\", \"function\": \"Protein\", \"id\": \"08399aa5c62a1fdd40e7e18348f4dbe571af0c60a397d3db64463c708400e296a0dc8c80fa0e3e9c23a88197bc46af01273d317bb43f6ce42a8ee49cd203bc78\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Tyr\", \"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 394}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Sumo, Lys, 340))\", \"function\": \"Protein\", \"id\": \"466c4f893ebc99ac545ead2184ee55e72ef6b8ef3dda6615d4cdbaf0b045cc49448ed1ace7a575b09fcd2bece7b50acdb739a99b131f6890d7b13bafb4950975\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"code\": \"Lys\", \"identifier\": {\"name\": \"Sumo\", \"namespace\": \"bel\"}, \"kind\": \"pmod\", \"pos\": 340}]}, {\"bel\": \"p(hgnc:MAPT, pmod(Ub))\", \"function\": \"Protein\", \"id\": \"1dd38047aaa27ab58a7196eb7ac24a892b4a07a2841eb92cc797089fb390fa5ab3229834eb56f9eb9cac3bf4dfb8488c6b3b148c1032e26068062506a4a5b929\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"identifier\": {\"name\": \"Ub\", \"namespace\": \"bel\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(hgnc:MAPT, pmod(UbK48))\", \"function\": \"Protein\", \"id\": \"5bd48fc8d9463d3c6aa5ddc1cbd334d821a6b8d9f2faf18ce485322f9d0ab61f8b6f2c4870827686ce5ab71283d73d9f0c0e213d498dabc2138f8a6f2a170e40\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"identifier\": {\"name\": \"UbK48\", \"namespace\": \"bel\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(hgnc:MAPT, pmod(UbK63))\", \"function\": \"Protein\", \"id\": \"8ecd67db99884c80a4253a4bf06075ad8b218fa646e19291afd1c33f8aa90df1ba05d5d2474c1ca02330a4774c7c12f90d777880fbf7be65d1ffedc682142f11\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"identifier\": {\"name\": \"UbK63\", \"namespace\": \"bel\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(hgnc:MAPT, var(\\\"p.Ala152Thr\\\"))\", \"function\": \"Protein\", \"id\": \"2e76ed6ace6c8c4c9097e1314ee911e46eaa69a07a9f3ec54ae517d14e1ca9f064853a4b612fa27804e434b2654ae10ed922e27d4b42eaff65f74aae49ee6fb1\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"identifier\": \"p.Ala152Thr\", \"kind\": \"hgvs\"}]}, {\"bel\": \"p(hgnc:MAPT, var(\\\"p.Glu391*\\\"))\", \"function\": \"Protein\", \"id\": \"96196fe4d539e0fd6d7cd6c5390494696156a5e96e2a42955294de4e290c17aed0c6935c5baadb640650021abb4b3cb69c8f8af80d2b68f003193a3a28689e53\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"identifier\": \"p.Glu391*\", \"kind\": \"hgvs\"}]}, {\"bel\": \"p(hgnc:MAPT, var(\\\"p.Lys280del\\\"))\", \"function\": \"Protein\", \"id\": \"4c06a347fb5902edccf35855b371054a4ea4294bdd9cbf5043a98e33b65cdcac9f5a172a86d56eaec69e501fbe61809310feda88befad16c2d337e74796c0e0b\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"identifier\": \"p.Lys280del\", \"kind\": \"hgvs\"}]}, {\"bel\": \"p(hgnc:MAPT, var(\\\"p.Pro301Leu\\\"))\", \"function\": \"Protein\", \"id\": \"eb702b5f359b2901e378770f52f7ba79942bfb43f4e31f30d0a44f5f395142d13afd9c53ae0db9290955caded01f0e4950f91e973610e10a85aecdb085067e16\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"identifier\": \"p.Pro301Leu\", \"kind\": \"hgvs\"}]}, {\"bel\": \"p(hgnc:MAPT, var(\\\"p.Pro301Ser\\\"))\", \"function\": \"Protein\", \"id\": \"cb0e0fd62b75898bf75dfc626520b5fe9dd67746836f43b5d5958bb9555fc3708e469cd4217d47180a1dba6e5c7580756d41bb4bfbd595b7473cc885e57599a6\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"identifier\": \"p.Pro301Ser\", \"kind\": \"hgvs\"}]}, {\"bel\": \"p(hgnc:MAPT, var(\\\"p.Val277Met\\\"))\", \"function\": \"Protein\", \"id\": \"df2d6c93f41250c2e2c88a95fdd4456d6674e4cc650d02b54b2d6e7df0894e82ea2f098ae0679ed021a15f340fa8c5f54f5e677b69e0a25b9f312f26b15961fc\", \"identifier\": \"6893\", \"name\": \"MAPT\", \"namespace\": \"hgnc\", \"variants\": [{\"identifier\": \"p.Val277Met\", \"kind\": \"hgvs\"}]}, {\"bel\": \"p(hgnc:MARCH7)\", \"function\": \"Protein\", \"id\": \"6dd4d5ad07504b614c5cb774f1c846cbb91de3d55886122c91e9a2e92171cfa4c98ca0181d105dc92e361d58ff386dfca26f4b609428135545896cc97c0b6a91\", \"identifier\": \"17393\", \"name\": \"MARCH7\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:MARK1)\", \"function\": \"Protein\", \"id\": \"12e0f1d5e3921472c12b8933bfd9036735dcea62beef682f73cb363608d71653fdf08b8093acb7a5c66cfe6b3f032618cced75da7fbc1f4f1207b94ef1e65667\", \"identifier\": \"6896\", \"name\": \"MARK1\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:MARK2)\", \"function\": \"Protein\", \"id\": \"3f932499325649ca72e0522212aad503750bbd3fb3c25bbbf2e53d4e299edaa5f31147c5a09969deb6c9dc95050a58e35345f48cc54b777b9c66bde6afcb7513\", \"identifier\": \"3332\", \"name\": \"MARK2\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:MARK4, pmod(Ph))\", \"function\": \"Protein\", \"id\": \"53dde41020ee00009c78e7e39cd17f9c98c14f61e23abc4a6e0fb3b72519141e8cf890c0f44f48ef04e3adcc3652d239ef119c8dd59ceb1cb42343cc90c85bb9\", \"identifier\": \"13538\", \"name\": \"MARK4\", \"namespace\": \"hgnc\", \"variants\": [{\"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(hgnc:MTOR)\", \"function\": \"Protein\", \"id\": \"37e19050569cf8012683870a729abe0f5dfe94ebcc25a0bf6336017b6b55679c33aae51bf40f041bb75522ce5b69a6c3926fcf8be34e784a7940989d0f9748a9\", \"identifier\": \"3942\", \"name\": \"MTOR\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:NPAS4)\", \"function\": \"Protein\", \"id\": \"b705a1bfd7f1ec7544896d4b6f71684d7c504002c4cfe0ba30900c513b937e5fc78df9f29d1faf68941497b0c7a7ecfe3d711cd881fa57b4c1575d7ec5b60e24\", \"identifier\": \"18983\", \"name\": \"NPAS4\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:OTUB1)\", \"function\": \"Protein\", \"id\": \"f0608aba74788a9f5d4125bd388ebadff6b937773d2bc050600489de6ebcc6fec36132613332ae2ea8b69086e610b7cf7a38532a13d516bba809b079d4e765ce\", \"identifier\": \"23077\", \"name\": \"OTUB1\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:OTUB1, frag(\\\"?\\\"))\", \"function\": \"Protein\", \"id\": \"f019b21a6ccac50520ac2e6dbefa36eeaf4576a029d82a89a7d154c1eb0515a67c744a9d5276fe6bc137380795958a1d4deb0e54c3d4f184f73992cc4b099432\", \"identifier\": \"23077\", \"name\": \"OTUB1\", \"namespace\": \"hgnc\", \"variants\": [{\"kind\": \"frag\", \"missing\": \"?\"}]}, {\"bel\": \"p(hgnc:OTUB1, var(\\\"p.Cys91Ala\\\"))\", \"function\": \"Protein\", \"id\": \"7e86f4d033e4701b2e405316d844d6adaa6fd5addb5d98326b1faf66d27759b0517e188c7af65d464c1c5aceb2bbcad4ba19daaf3f5fab23722cc195ddc90ed3\", \"identifier\": \"23077\", \"name\": \"OTUB1\", \"namespace\": \"hgnc\", \"variants\": [{\"identifier\": \"p.Cys91Ala\", \"kind\": \"hgvs\"}]}, {\"bel\": \"p(hgnc:PICALM)\", \"function\": \"Protein\", \"id\": \"8c65a97f81e64681f4c5c3f95851af94126d57ecf926680724e931d31283d3ff2e697dc62e12b086135393ae5db99b339639b6ce79b4e6d3de55c2306e44fc7b\", \"identifier\": \"15514\", \"name\": \"PICALM\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:PIN1)\", \"function\": \"Protein\", \"id\": \"960c231fda41c244c5ddf4459408f22715eed9fe028fd5d7a437df1bd1148b590a4b4debde42630bbbcc03d08a38ac2bfbafe4cf3013bc6c2bf0cc4a4ab00191\", \"identifier\": \"8988\", \"name\": \"PIN1\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:PIN1, frag(\\\"5_39\\\"))\", \"function\": \"Protein\", \"id\": \"7063154ac564847f7b8843991121881f081697d72b30a92ffea1c0c66345c1c8c36d21739323cab70a5841d32c7eb36315714179931f4b11fa6388a3c804de77\", \"identifier\": \"8988\", \"name\": \"PIN1\", \"namespace\": \"hgnc\", \"variants\": [{\"kind\": \"frag\", \"start\": 5, \"stop\": 39}]}, {\"bel\": \"p(hgnc:PPM1A)\", \"function\": \"Protein\", \"id\": \"aa36365d1891084e838481b3f8786e94d535743f8ad22dcae15cf6f63ef2ab8ee45de327933f1d2fc48a52295015c2083c923b161e9d4ebb6cd16da23d099492\", \"identifier\": \"9275\", \"name\": \"PPM1A\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:PPP1CA)\", \"function\": \"Protein\", \"id\": \"50698a37bd57a9f9ac9066c85f2bda1f1effd2f94b4a28e8ab339c00f3aa8900c82be0dbc4b6e0509854d64f3fc9da13f93d9de57620663c96c77780196e139b\", \"identifier\": \"9281\", \"name\": \"PPP1CA\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:PPP1R8)\", \"function\": \"Protein\", \"id\": \"243cf5539e2f62cfcc407d969af1c703ac4c3ad2fcd815cadc18f11e44e43fd32870a14a23d8daf2bdaa7bedd91fb496e8f0a4b8ad0e47b31444d0a55587dfcd\", \"identifier\": \"9296\", \"name\": \"PPP1R8\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:PPP2CA)\", \"function\": \"Protein\", \"id\": \"fbdab59cc08a2c74804e382ba3ae1179daa22384485fc66e6563e9c3bb925f518b801b1fddafbfcba3f8b56b311691f59595c060149b8c4b1270be139bd1e9cd\", \"identifier\": \"9299\", \"name\": \"PPP2CA\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:PPP2CA, var(\\\"p.Leu309Ala\\\"))\", \"function\": \"Protein\", \"id\": \"bcec24a934549fb65471cfc5f8fb640ceef6f60a97360bf57f0ee885b416fdd159a39456dbe1275f507797e653b0cdd0c448f1d20722f3e67f25cff016f2fdc0\", \"identifier\": \"9299\", \"name\": \"PPP2CA\", \"namespace\": \"hgnc\", \"variants\": [{\"identifier\": \"p.Leu309Ala\", \"kind\": \"hgvs\"}]}, {\"bel\": \"p(hgnc:PPP2CB)\", \"function\": \"Protein\", \"id\": \"0a975216cb5345749d6cbc85781679a3919cc5855937963ecb3d71ac77142409d7d58b246660e134e66bf6489e3575584c51fd5ab7d95f05b74d6806e8701327\", \"identifier\": \"9300\", \"name\": \"PPP2CB\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:PPP2CB, var(\\\"p.Leu309Ala\\\"))\", \"function\": \"Protein\", \"id\": \"0ad58734b28bdead4742bfacdfb987db8b6ff0a716ec45db1737e1e93beafccd0daf8f7b2a94dd528b1e90d6170a8d641276825a6ef2a4f385e26c9d8d60087b\", \"identifier\": \"9300\", \"name\": \"PPP2CB\", \"namespace\": \"hgnc\", \"variants\": [{\"identifier\": \"p.Leu309Ala\", \"kind\": \"hgvs\"}]}, {\"bel\": \"p(hgnc:PPP2R5B)\", \"function\": \"Protein\", \"id\": \"e998a674da2a676e9c16d3acd9f6299c6c81193d702638c894fad4c707bb31adaeec6f726fa355b1c8e2b92917ea89d4df541a12a6af6f9b384f3444ac0182c1\", \"identifier\": \"9310\", \"name\": \"PPP2R5B\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:PPP2R5D)\", \"function\": \"Protein\", \"id\": \"81b9d76f9274fb4728a5244846284454bd79df5773499cb9d220651a2c55c44b80cf3b54d03f51e961f782ccd0a27bff089c2ef629e11bd751cd09c62766938c\", \"identifier\": \"9312\", \"name\": \"PPP2R5D\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:PPP3CB)\", \"function\": \"Protein\", \"id\": \"c45d9100928417cab19ea92560200682f50d18279b282ded90dd58c9ba67ded86f35936d7ad7d85eef31f8426572b5c862a769637796dc570d5540050cf7ba72\", \"identifier\": \"9315\", \"name\": \"PPP3CB\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:PPP5C)\", \"function\": \"Protein\", \"id\": \"79ef5524da15c4d8f932d99c02c01f1ad9bfabf616a19858773d9e5c92b9f4a060f3a0e6a3dc43a39112472887fb40f6bcf254bb95e846d93bb1f8b55dad8cad\", \"identifier\": \"9322\", \"name\": \"PPP5C\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:PRKAA1)\", \"function\": \"Protein\", \"id\": \"b54957de3270bd8e6a3ca39c2f399a2c9f98ff0f941af96ed282a53e13a9992b648ffde4220226c5e46fad0fbc53a20cc116e26bfee9945e489e3b642841d6ab\", \"identifier\": \"9376\", \"name\": \"PRKAA1\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:PTGES3)\", \"function\": \"Protein\", \"id\": \"32dc91f1aec848f32b441fcf5621ff1d8969f3b5201892610b9c36a73810128e3bc62a47f4dd037b7b61bf73d8693900e204dc4de799e6c4dd8d12115a88d78c\", \"identifier\": \"16049\", \"name\": \"PTGES3\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:PTK2, pmod(Ph))\", \"function\": \"Protein\", \"id\": \"a6c02e346290af28aca663955db5c89690ca0b768beb083fdc90bbe46dce7cfd8dff110059a4877904cf2e08dcba8861e0d9468f84a0069b669c10b56304c72e\", \"identifier\": \"9611\", \"name\": \"PTK2\", \"namespace\": \"hgnc\", \"variants\": [{\"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(hgnc:RHOT1)\", \"function\": \"Protein\", \"id\": \"fe43690d8aa93b0b48cb80032c4eeebab75c3c4a22f9245941be7ea9add203b9f7c639080bf1c7693acf46ba7b34c6758d60b9573aedb42ad8558811be123fc4\", \"identifier\": \"21168\", \"name\": \"RHOT1\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:S100A1)\", \"function\": \"Protein\", \"id\": \"4ae9ae115e1e1615845002c071c17f55b544a7d9baf2f9c83254ee015104d8faff8f48447cbf76aa9d0b37db658d45d8f27c23f80741ccb4e13275e94efa3a93\", \"identifier\": \"10486\", \"name\": \"S100A1\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:S100B)\", \"function\": \"Protein\", \"id\": \"4d1ab6a503339914a342ea1c9ee48fc6cc23f60b14a79e33103d35fa4517a43a0e2339037a2d2d8f210ae26d09b9c5834b8c83b1b21a0bc724cbce82d1b69fa0\", \"identifier\": \"10500\", \"name\": \"S100B\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:SIRT1)\", \"function\": \"Protein\", \"id\": \"71442a8d2fff50f7ec534576a7316a0ef66db75d8320494f593658009a0969c976f35a144594965d1786b9848b1b0c71e475e776b37b4460b9c372ed7947c4bd\", \"identifier\": \"14929\", \"name\": \"SIRT1\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:SQSTM1)\", \"function\": \"Protein\", \"id\": \"fd345095c37da2ad50b8ad44ec69c6126495dc5a41f8fc7326d61566bdc482e35e97bdbcf8c021016f17de8d18e654b33f4717eb3d5ff12def38d7601c0143e0\", \"identifier\": \"11280\", \"name\": \"SQSTM1\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:SRC)\", \"function\": \"Protein\", \"id\": \"0eb9c147ac0bd1aca7f31cc9ad86ab7a36b0137937a244d03e7431e2276702cbb088c1d423677c39e0cb11367f67cd0a8e30736930e8d11fd7cbc4a927057797\", \"identifier\": \"11283\", \"name\": \"SRC\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:STUB1)\", \"function\": \"Protein\", \"id\": \"f2b1e4c183165e58beca5638967ecb5141b412c7d69be2b8d408bc39863aeb47e7a30b0bdf9b89ffb8f53c3d9d9f9b9e3dd29f533be66a2be5ba31f091a0a760\", \"identifier\": \"11427\", \"name\": \"STUB1\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:SUMO1)\", \"function\": \"Protein\", \"id\": \"63031d70c9096b6a6c6378241432525d5905851648650e4a575f7518c018b17785b32a5ff72001973833b074e821e5ddd1220696fae0c92a89fb18d2a2848994\", \"identifier\": \"12502\", \"name\": \"SUMO1\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:SYK)\", \"function\": \"Protein\", \"id\": \"335f0751c774e2d443449cf644e2d26be1286038279f414da336f5969c453f7af59975b771bc8fbe5d40ad8cb7493aba27f2e6d9f8309280395978bbc91d4b06\", \"identifier\": \"11491\", \"name\": \"SYK\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:SYK, pmod(Ph))\", \"function\": \"Protein\", \"id\": \"367f41a23357f83e554deffd2b229c9294221349d06d5d3406ebeaf5b396e92e008560a3b784393835cf271d1fb71c1b56e5b9ffc6b753ef5715a3ec2a596284\", \"identifier\": \"11491\", \"name\": \"SYK\", \"namespace\": \"hgnc\", \"variants\": [{\"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\"}]}, {\"bel\": \"p(hgnc:TAOK1)\", \"function\": \"Protein\", \"id\": \"8169aac18282233a98268baa8758890fe35ca70a23040828fe6abde748099da45315c41292483b2a4e8c2e066603fc35c4992c8d23f5b0c1bf3bec937f28b375\", \"identifier\": \"29259\", \"name\": \"TAOK1\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:TAOK2)\", \"function\": \"Protein\", \"id\": \"4a06157f985d3a03ff4f2a8fc0e2c34fbd5069e881360bfd5ecacbfba7fd2142d6b1078d485c52a0112ccc9b9f4a227c2d837de48f9840cda467fd80262b6d0d\", \"identifier\": \"16835\", \"name\": \"TAOK2\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:TFEB)\", \"function\": \"Protein\", \"id\": \"091cf9eebb8bd6c65701e4d3451c12db201fc7f41757e13f865edcd2667573a4bec0e16665766b8243c062ab96fff618f6e700efaa2366328af6052f5bd01ef5\", \"identifier\": \"11753\", \"name\": \"TFEB\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:TRAF6)\", \"function\": \"Protein\", \"id\": \"474bbb3940dd8fadeeb5921437e6adfc2bdad5101a3b7534ee4ad364b98bc36237a006ea94e46905cad5d802bdb2bd96bbb132affe42cccb7364ce08b6fe0773\", \"identifier\": \"12036\", \"name\": \"TRAF6\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:TRAK1)\", \"function\": \"Protein\", \"id\": \"4c21043e801e8d9649045cfdac39ea491c920e67a7f8082dc95904efd3ad39f5ab1f030b9a78a0c25690af2e707320ca4ba96f34dc8b3dacd903a944add2cb88\", \"identifier\": \"29947\", \"name\": \"TRAK1\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:TREM2)\", \"function\": \"Protein\", \"id\": \"da8af8dcc325c3cb42e6e000bf758d99987ac3f37ce746fe55e16aff9c963c6f43eff6ded70791a5a8b105468f537cd88beba56413cbc3d6c71073fa2a1b9597\", \"identifier\": \"17761\", \"name\": \"TREM2\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:TTBK1)\", \"function\": \"Protein\", \"id\": \"2182fc59e9f8f92d9b71f3bd3b0e4fad995c126c4a580f9e025a35ff5448650f8bd0409b731e79daa5cc6b0d784f614a1f95146cd8b600153319ea71420a6c54\", \"identifier\": \"19140\", \"name\": \"TTBK1\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:TTBK2)\", \"function\": \"Protein\", \"id\": \"e3e833a1fd47add0c04af30a54d52fa0a45c581d345915dac5a156db8a2e4531ef10d99494d30436b81df7d6765e46f0158e1b6200dfc02b5e1690bb6fb5549a\", \"identifier\": \"19141\", \"name\": \"TTBK2\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:UBE2D2)\", \"function\": \"Protein\", \"id\": \"d7db601b5ec4032cdfcb1c948de20f1861a35c92983a200352240c4eaa76a4371aba97ac34c3e45e65cca0d93df92aa7bcb45a4fc41553b79aca6dce466b06d4\", \"identifier\": \"12475\", \"name\": \"UBE2D2\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:USP5)\", \"function\": \"Protein\", \"id\": \"7da3719d577846bdc01c49d312849a741bd5049696848d3d3d7f62348a34f562fe59d65f333264199582e81d3eeaca2197abb04bd7e0f26fb253eb46e9f30ba0\", \"identifier\": \"12628\", \"name\": \"USP5\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:USP9X)\", \"function\": \"Protein\", \"id\": \"af1e38af6be151250b2413693b52a2f3769371903a41176180c891732f79c0d830a45bcf2b9b0d97efea2730a6af55977286fcb4e9db2bfa8de3d5d37fd35cec\", \"identifier\": \"12632\", \"name\": \"USP9X\", \"namespace\": \"hgnc\"}, {\"bel\": \"p(hgnc:WWC1)\", \"function\": \"Protein\", \"id\": \"30813d6daa3a63181378fdcb5071a3e579411db0db0db451e864fd72db2a02fb330f46dde0ea1623c20cdda3adb12fc8eeb1d47d3d23900ffdd1e5c95e1a8f48\", \"identifier\": \"29435\", \"name\": \"WWC1\", \"namespace\": \"hgnc\"}, {\"bel\": \"rxn(reactants(p(HGNC:MAPT)), products(p(HGNC:MAPT, pmod(Ph))))\", \"function\": \"Reaction\", \"id\": \"a844112ec2f1b740fe01c197021ee1258fa8bd9eaf2f9c4ea2190bc85dc5d967150ed5938d0e3346a079e726c6cbc11d3aee2337772d624bd6979752ba3e30ba\", \"products\": [{\"bel\": \"p(HGNC:MAPT, pmod(Ph))\", \"function\": \"Protein\", \"id\": \"526bae251987f8c4f55f6e2451662fa55e087c57585beae7c389b020d73487c739834e9b8ec841783de6a5b5fb9df8b138e9eff4406a9ec5e606766575dcac0e\", \"name\": \"MAPT\", \"namespace\": \"HGNC\", \"variants\": [{\"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\"}]}], \"reactants\": [{\"bel\": \"p(HGNC:MAPT)\", \"function\": \"Protein\", \"id\": \"ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1\", \"name\": \"MAPT\", \"namespace\": \"HGNC\"}]}, {\"bel\": \"rxn(reactants(p(HGNC:MAPT, pmod(Ph))), products(a(CHEBI:\\\"phosphate(3-)\\\"), p(HGNC:MAPT)))\", \"function\": \"Reaction\", \"id\": \"109c8d27b2935c6380f7bf04bf181a906b06fbfbbc647d137df4991b95a94c614c7cb0ca66976458f8b227b34d31992b4fd3945058d9d77184a3a55507aac521\", \"products\": [{\"bel\": \"a(CHEBI:\\\"phosphate(3-)\\\")\", \"function\": \"Abundance\", \"id\": \"8766b90e9eefbc5a7e02d2527e3fd48dea0a2fc6185218c99162adf376fc5cf7add59b057bf54498d274ae89e4e2277691d1df45bff72f174af3a8ed19abb21e\", \"name\": \"phosphate(3-)\", \"namespace\": \"CHEBI\"}, {\"bel\": \"p(HGNC:MAPT)\", \"function\": \"Protein\", \"id\": \"ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1\", \"name\": \"MAPT\", \"namespace\": \"HGNC\"}], \"reactants\": [{\"bel\": \"p(HGNC:MAPT, pmod(Ph))\", \"function\": \"Protein\", \"id\": \"526bae251987f8c4f55f6e2451662fa55e087c57585beae7c389b020d73487c739834e9b8ec841783de6a5b5fb9df8b138e9eff4406a9ec5e606766575dcac0e\", \"name\": \"MAPT\", \"namespace\": \"HGNC\", \"variants\": [{\"identifier\": {\"name\": \"Ph\", \"namespace\": \"bel\"}, \"kind\": \"pmod\"}]}]}]}, \"#zxbueavsrqkjythd\", 1000, 650, {'Protein': '#1F77B4', 'Pathology': '#FF7F0E', 'BiologicalProcess': '#2CA02C', 'miRNA': '#D62728', 'Complex': '#98DF8A', 'Composite': '#9467BD', 'Reaction': '#000000', 'Gene': '#FFBB78', 'Abundance': '#AEC7E8', 'RNA': '#FF9896'});\n",
       "});"
      ],
      "text/plain": [
       "<IPython.core.display.Javascript object>"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "to_jupyter(ptm_graph)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Extract all PubMed identifiers from the graph, and write them to a file in this directory called `tau-phosphorylation-pmids.txt`."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "there are 136 PubMed references\n"
     ]
    }
   ],
   "source": [
    "pmids = {\n",
    "    data['citation']['reference']\n",
    "    for _, _, data in ptm_graph.edges(data=True)\n",
    "    if 'citation' in data\n",
    "}\n",
    "\n",
    "with open('tau-ptm-pmids.txt', 'w') as file:\n",
    "    for pmid in sorted(pmids):\n",
    "        print(f'pmid:{pmid}', file=file)\n",
    "\n",
    "print(f'there are {len(pmids)} PubMed references')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Enrich Proteins in the Subgraph with their Corresponding Drugs"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Enrich the targets contained within the subgraph using [Bio2BEL DrugBank](https://github.com/bio2bel/drugbank)."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "None vNone\n",
      "Number of Nodes: 964\n",
      "Number of Edges: 2725\n",
      "Number of Citations: 527\n",
      "Number of Authors: 788\n",
      "Network Density: 2.94E-03\n",
      "Number of Components: 1\n",
      "Number of Warnings: 0\n"
     ]
    }
   ],
   "source": [
    "drugbank_manager.enrich_targets(ptm_graph)\n",
    "ptm_graph.summarize()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Identify all proteins in the subgraph that have a chemical that regulates them. These relationships were likely added by the enrichment with DrugBank."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "There are 49 proteins that have been previously drugged by 580 unique chemicals\n"
     ]
    }
   ],
   "source": [
    "target_to_chemical = defaultdict(set)\n",
    "chemical_to_target = defaultdict(set)\n",
    "for chemical, target, key, data in ptm_graph.edges(keys=True, data=True):\n",
    "    if (\n",
    "        isinstance(chemical, Abundance) \n",
    "        and data['relation'] == 'regulates' \n",
    "        and not target.variants\n",
    "    ):\n",
    "        target_to_chemical[target].add(chemical)\n",
    "        chemical_to_target[chemical].add(target)\n",
    "\n",
    "        \n",
    "n_drugged_targets = len(target_to_chemical)\n",
    "n_chemicals = len(set(\n",
    "    chemical\n",
    "    for chemicals in target_to_chemical.values()\n",
    "    for chemical in chemicals\n",
    "))\n",
    "print(f'There are {n_drugged_targets} proteins that have been previously drugged by {n_chemicals} unique chemicals')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Output an OBO-style list of the proteins in the subgraph that have been drugged to the file `targeted-tau-ptm-controllers.txt`. Additionally, print them here for posterity."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "hgnc:76\thgnc.symbol:ABL1\tpmod(Ph, Tyr);pmod(Ph, Tyr, 363);pmod(Ph, Tyr, 394)\n",
      "hgnc:77\thgnc.symbol:ABL2\tpmod(Ph, Tyr, 394)\n",
      "hgnc:361\thgnc.symbol:AK1\tpmod(Ph)\n",
      "hgnc:937\thgnc.symbol:BAG1\t\n",
      "hgnc:1460\thgnc.symbol:CAMK2A\tpmod(Ph);pmod(Ph, Ser, 262)\n",
      "hgnc:1461\thgnc.symbol:CAMK2B\tpmod(Ph)\n",
      "hgnc:1722\thgnc.symbol:CDK1\tpmod(Ph);pmod(Ph, Thr, 231)\n",
      "hgnc:1771\thgnc.symbol:CDK2\tpmod(Ph);pmod(Ph, Ser, 199);pmod(Ph, Ser, 202);pmod(Ph, Ser, 235);pmod(Ph, Ser, 396);pmod(Ph, Ser, 404);pmod(Ph, Thr, 212);pmod(Ph, Thr, 217)\n",
      "hgnc:1774\thgnc.symbol:CDK5\tpmod(HBP:hyperphosphorylation);pmod(Ph);pmod(Ph, Ser, 199);pmod(Ph, Ser, 202);pmod(Ph, Ser, 235);pmod(Ph, Ser, 396);pmod(Ph, Ser, 404);pmod(Ph, Ser, 422);pmod(Ph, Thr, 181);pmod(Ph, Thr, 205);pmod(Ph, Thr, 231)\n",
      "hgnc:16627\thgnc.symbol:CHEK2\tpmod(Ph, Ser, 262)\n",
      "hgnc:1950\thgnc.symbol:CHRM1\tpmod(HBP:hyperphosphorylation);pmod(Ph)\n",
      "hgnc:1958\thgnc.symbol:CHRNA4\t\n",
      "hgnc:1960\thgnc.symbol:CHRNA7\t\n",
      "hgnc:2348\thgnc.symbol:CREBBP\tpmod(Ac, Lys)\n",
      "hgnc:2451\thgnc.symbol:CSNK1A1\tpmod(Ph);pmod(Ph, Thr, 17)\n",
      "hgnc:2529\thgnc.symbol:CTSD\tpmod(Ph)\n",
      "hgnc:2674\thgnc.symbol:DAPK1\tpmod(Ph, Ser, 262);pmod(Ph, Ser, 396);pmod(Ph, Thr, 231)\n",
      "hgnc:3467\thgnc.symbol:ESR1\t\n",
      "hgnc:4037\thgnc.symbol:FYN\tpmod(Ph);pmod(Ph, Tyr);pmod(Ph, Tyr, 18)\n",
      "hgnc:4324\thgnc.symbol:GLP1R\tpmod(Ph, Thr, 205)\n",
      "hgnc:4617\thgnc.symbol:GSK3B\tpmod(HBP:hyperphosphorylation);pmod(Ph);pmod(Ph, Ser, 199);pmod(Ph, Ser, 202);pmod(Ph, Ser, 396);pmod(Ph, Ser, 396)/pmod(Ph, Ser, 404);pmod(Ph, Ser, 404);pmod(Ph, Ser, 422);pmod(Ph, Thr, 181);pmod(Ph, Thr, 205);pmod(Ph, Thr, 212);pmod(Ph, Thr, 217);pmod(Ph, Thr, 231)\n",
      "hgnc:14064\thgnc.symbol:HDAC6\tpmod(Ac, Lys)\n",
      "hgnc:5246\thgnc.symbol:HSPB1\tpmod(Ph)\n",
      "hgnc:16969\thgnc.symbol:HSPH1\tpmod(Ph)\n",
      "hgnc:6524\thgnc.symbol:LCK\tpmod(Ph, Tyr);pmod(Ph, Tyr, 18)\n",
      "hgnc:6871\thgnc.symbol:MAPK1\tpmod(Ph, Ser, 202);pmod(Ph, Thr, 205)\n",
      "hgnc:6875\thgnc.symbol:MAPK13\tpmod(Ph);pmod(Ph, Ser, 404);pmod(Ph, Ser, 422);pmod(Ph, Thr, 181);pmod(Ph, Thr, 396)\n",
      "hgnc:6876\thgnc.symbol:MAPK14\tpmod(Ph, Thr, 181)\n",
      "hgnc:6881\thgnc.symbol:MAPK8\tpmod(Ph, Thr, 181)\n",
      "hgnc:6886\thgnc.symbol:MAPK9\tpmod(Ph)\n",
      "hgnc:6893\thgnc.symbol:MAPT\tpmod(Ac, Lys, 280)\n",
      "hgnc:6896\thgnc.symbol:MARK1\tpmod(Ph);pmod(Ph, Ser, 262)\n",
      "hgnc:3332\thgnc.symbol:MARK2\tpmod(Ph);pmod(Ph, Ser, 262);pmod(Ph, Ser, 293);pmod(Ph, Ser, 305);pmod(Ph, Ser, 324);pmod(Ph, Ser, 352);pmod(Ph, Ser, 356);pmod(Ph, Ser, 413);pmod(Ph, Ser, 416)\n",
      "hgnc:3942\thgnc.symbol:MTOR\t\n",
      "hgnc:8988\thgnc.symbol:PIN1\tpmod(Ph, Thr, 212);pmod(Ph, Thr, 231)\n",
      "hgnc:9281\thgnc.symbol:PPP1CA\tpmod(HBP:hyperphosphorylation)\n",
      "hgnc:9299\thgnc.symbol:PPP2CA\tpmod(Ph);pmod(Ph, Thr, 212);pmod(Ph, Thr, 231)\n",
      "hgnc:9300\thgnc.symbol:PPP2CB\tpmod(Ph)\n",
      "hgnc:9322\thgnc.symbol:PPP5C\tpmod(Ph)\n",
      "hgnc:9376\thgnc.symbol:PRKAA1\tpmod(Ph, Ser, 262)\n",
      "hgnc:16049\thgnc.symbol:PTGES3\tpmod(Ph)\n",
      "hgnc:10486\thgnc.symbol:S100A1\tpmod(Ph)\n",
      "hgnc:10500\thgnc.symbol:S100B\tpmod(Ph)\n",
      "hgnc:14929\thgnc.symbol:SIRT1\tpmod(Ac, Lys)\n",
      "hgnc:11283\thgnc.symbol:SRC\tpmod(Ph, Tyr)\n",
      "hgnc:11491\thgnc.symbol:SYK\tpmod(HBP:misfolded);pmod(Ph, Ser, 202);pmod(Ph, Ser, 396)/pmod(Ph, Ser, 404);pmod(Ph, Tyr);pmod(Ph, Tyr, 18)\n",
      "hgnc:29259\thgnc.symbol:TAOK1\tpmod(Ph, Thr, 17)\n",
      "hgnc:16835\thgnc.symbol:TAOK2\tpmod(Ph, Thr, 17)\n",
      "hgnc:12475\thgnc.symbol:UBE2D2\t\n"
     ]
    }
   ],
   "source": [
    "with open('targeted-tau-ptm-controllers.txt', 'w') as file:\n",
    "    for t in sorted(target_to_chemical, key=attrgetter('name')):\n",
    "        t_modifications = [\n",
    "            '/'.join(sorted(map(str, [v for v in x.variants if isinstance(v, ProteinModification)])))\n",
    "            for x in controller_to_modification[t]\n",
    "        ]\n",
    "        s = f'hgnc:{t.identifier}', f'hgnc.symbol:{t.name}', \";\".join(sorted(t_modifications))\n",
    "        print(*s, sep='\\t')\n",
    "        print(*s, sep='\\t', file=file)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Get the PubMed identifiers of just the relationships attached to targets that are known to be drugged. This is provides a filter for which articles should be checked for assay information later - keeping in mind that all of the relationships for these proteins are either from the DrugBank enrichment, or were added to the subgraph because they regulate the phosphorylation of the Tau protein. This means that all of their other relations' articles should contain interesting assay information on how that phosphorylation was measured."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "there are 64 PubMed references for relationships containing a drugged target\n"
     ]
    }
   ],
   "source": [
    "drugged_pmids = {\n",
    "    d[\"citation\"][\"reference\"]\n",
    "    for u, v, d in ptm_graph.edges(data=True)\n",
    "    if (\n",
    "        'citation' in d \n",
    "        and (u in target_to_chemical or v in target_to_chemical) \n",
    "        and d['evidence'] != 'From DrugBank'\n",
    "    )\n",
    "}\n",
    "\n",
    "print(f'there are {len(drugged_pmids)} PubMed references for relationships containing a drugged target')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Get extra information about the articles, including their PubMed Central (PMC) identifiers, when available."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [],
   "source": [
    "pmid_to_targets = defaultdict(set)\n",
    "for u, v, d in ptm_graph.edges(data=True):\n",
    "    citation = d.get('citation')\n",
    "    if citation is None or d['evidence'] == 'From DrugBank':\n",
    "        continue\n",
    "    reference = citation['reference']\n",
    "    if u in target_to_chemical:\n",
    "        pmid_to_targets[reference].add(u)\n",
    "    if v in target_to_chemical:\n",
    "        pmid_to_targets[reference].add(v)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [],
   "source": [
    "pubmed_response = get_pubmed_citation_response(pmid_to_targets)\n",
    "\n",
    "pmid_pmc_map = {}\n",
    "\n",
    "for pmid in pubmed_response['result']['uids']:\n",
    "    for article_id in pubmed_response['result'][pmid]['articleids']:\n",
    "        if 'pmc' == article_id['idtype']:\n",
    "            pmid_pmc_map[pmid] = article_id['value']"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Output an exploded table connecting the PubMed identifiers (PMIDs), PMC identifiers, and the proteins. Some articles are not in PMC, and only have PMIDs."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>hgnc.symbol</th>\n",
       "      <th>hgnc</th>\n",
       "      <th>pmid</th>\n",
       "      <th>pmc</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>114</th>\n",
       "      <td>ABL1</td>\n",
       "      <td>76</td>\n",
       "      <td>17493042</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>113</th>\n",
       "      <td>ABL1</td>\n",
       "      <td>76</td>\n",
       "      <td>23687953</td>\n",
       "      <td>PMC3750680</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>ABL1</td>\n",
       "      <td>76</td>\n",
       "      <td>26631930</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>62</th>\n",
       "      <td>ABL1</td>\n",
       "      <td>76</td>\n",
       "      <td>29191965</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>ABL2</td>\n",
       "      <td>77</td>\n",
       "      <td>26631930</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>118</th>\n",
       "      <td>AK1</td>\n",
       "      <td>361</td>\n",
       "      <td>22419736</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>103</th>\n",
       "      <td>BAG1</td>\n",
       "      <td>937</td>\n",
       "      <td>17954934</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>CAMK2A</td>\n",
       "      <td>1460</td>\n",
       "      <td>26631930</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>CAMK2B</td>\n",
       "      <td>1461</td>\n",
       "      <td>12428809</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>CDK1</td>\n",
       "      <td>1722</td>\n",
       "      <td>10391244</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>CDK1</td>\n",
       "      <td>1722</td>\n",
       "      <td>12428809</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>82</th>\n",
       "      <td>CDK2</td>\n",
       "      <td>1771</td>\n",
       "      <td>22072628</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>79</th>\n",
       "      <td>CDK2</td>\n",
       "      <td>1771</td>\n",
       "      <td>8282104</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>CDK5</td>\n",
       "      <td>1774</td>\n",
       "      <td>12428809</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>CDK5</td>\n",
       "      <td>1774</td>\n",
       "      <td>17078951</td>\n",
       "      <td>PMC1828604</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>52</th>\n",
       "      <td>CDK5</td>\n",
       "      <td>1774</td>\n",
       "      <td>21882945</td>\n",
       "      <td>PMC3190966</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>CDK5</td>\n",
       "      <td>1774</td>\n",
       "      <td>25001178</td>\n",
       "      <td>PMC4194100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>74</th>\n",
       "      <td>CDK5</td>\n",
       "      <td>1774</td>\n",
       "      <td>27314526</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>57</th>\n",
       "      <td>CDK5</td>\n",
       "      <td>1774</td>\n",
       "      <td>29191965</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>CDK5</td>\n",
       "      <td>1774</td>\n",
       "      <td>29758300</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>78</th>\n",
       "      <td>CDK5</td>\n",
       "      <td>1774</td>\n",
       "      <td>8282104</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>93</th>\n",
       "      <td>CHEK2</td>\n",
       "      <td>16627</td>\n",
       "      <td>23001711</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>77</th>\n",
       "      <td>CHRM1</td>\n",
       "      <td>1950</td>\n",
       "      <td>24590577</td>\n",
       "      <td>PMC5562652</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>76</th>\n",
       "      <td>CHRM1</td>\n",
       "      <td>1950</td>\n",
       "      <td>26813123</td>\n",
       "      <td>PMC4787279</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>CHRNA4</td>\n",
       "      <td>1958</td>\n",
       "      <td>17009926</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>CHRNA7</td>\n",
       "      <td>1960</td>\n",
       "      <td>17009926</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>CREBBP</td>\n",
       "      <td>2348</td>\n",
       "      <td>26631930</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>84</th>\n",
       "      <td>CSNK1A1</td>\n",
       "      <td>2451</td>\n",
       "      <td>25974414</td>\n",
       "      <td>PMC4431475</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>CSNK1A1</td>\n",
       "      <td>2451</td>\n",
       "      <td>30444369</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>119</th>\n",
       "      <td>CTSD</td>\n",
       "      <td>2529</td>\n",
       "      <td>24027553</td>\n",
       "      <td>PMC3759803</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>88</th>\n",
       "      <td>MARK2</td>\n",
       "      <td>3332</td>\n",
       "      <td>29215007</td>\n",
       "      <td>PMC5719408</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>MTOR</td>\n",
       "      <td>3942</td>\n",
       "      <td>29758300</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>108</th>\n",
       "      <td>PIN1</td>\n",
       "      <td>8988</td>\n",
       "      <td>19401603</td>\n",
       "      <td>PMC2719320</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>111</th>\n",
       "      <td>PIN1</td>\n",
       "      <td>8988</td>\n",
       "      <td>22926167</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>112</th>\n",
       "      <td>PIN1</td>\n",
       "      <td>8988</td>\n",
       "      <td>26996941</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>PPP1CA</td>\n",
       "      <td>9281</td>\n",
       "      <td>25001178</td>\n",
       "      <td>PMC4194100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>107</th>\n",
       "      <td>PPP2CA</td>\n",
       "      <td>9299</td>\n",
       "      <td>19401603</td>\n",
       "      <td>PMC2719320</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>110</th>\n",
       "      <td>PPP2CA</td>\n",
       "      <td>9299</td>\n",
       "      <td>24653673</td>\n",
       "      <td>PMC3949405</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>PPP2CA</td>\n",
       "      <td>9299</td>\n",
       "      <td>26631930</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>101</th>\n",
       "      <td>PPP2CA</td>\n",
       "      <td>9299</td>\n",
       "      <td>29062069</td>\n",
       "      <td>PMC5653760</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>60</th>\n",
       "      <td>PPP2CA</td>\n",
       "      <td>9299</td>\n",
       "      <td>29191965</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>109</th>\n",
       "      <td>PPP2CB</td>\n",
       "      <td>9300</td>\n",
       "      <td>24653673</td>\n",
       "      <td>PMC3949405</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>54</th>\n",
       "      <td>PPP5C</td>\n",
       "      <td>9322</td>\n",
       "      <td>21882945</td>\n",
       "      <td>PMC3190966</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>PPP5C</td>\n",
       "      <td>9322</td>\n",
       "      <td>26631930</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>67</th>\n",
       "      <td>PPP5C</td>\n",
       "      <td>9322</td>\n",
       "      <td>29311797</td>\n",
       "      <td>PMC5744016</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50</th>\n",
       "      <td>PRKAA1</td>\n",
       "      <td>9376</td>\n",
       "      <td>29758300</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>64</th>\n",
       "      <td>PTGES3</td>\n",
       "      <td>16049</td>\n",
       "      <td>29311797</td>\n",
       "      <td>PMC5744016</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>65</th>\n",
       "      <td>S100A1</td>\n",
       "      <td>10486</td>\n",
       "      <td>29311797</td>\n",
       "      <td>PMC5744016</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>S100B</td>\n",
       "      <td>10500</td>\n",
       "      <td>18494933</td>\n",
       "      <td>PMC3538024</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>94</th>\n",
       "      <td>SIRT1</td>\n",
       "      <td>14929</td>\n",
       "      <td>20869593</td>\n",
       "      <td>PMC3035103</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>SIRT1</td>\n",
       "      <td>14929</td>\n",
       "      <td>26631930</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>95</th>\n",
       "      <td>SIRT1</td>\n",
       "      <td>14929</td>\n",
       "      <td>29540553</td>\n",
       "      <td>PMC5895994</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>56</th>\n",
       "      <td>SRC</td>\n",
       "      <td>11283</td>\n",
       "      <td>29191965</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>SYK</td>\n",
       "      <td>11491</td>\n",
       "      <td>25331948</td>\n",
       "      <td>PMC4256331</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>SYK</td>\n",
       "      <td>11491</td>\n",
       "      <td>26631930</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>SYK</td>\n",
       "      <td>11491</td>\n",
       "      <td>28877763</td>\n",
       "      <td>PMC5588676</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>59</th>\n",
       "      <td>SYK</td>\n",
       "      <td>11491</td>\n",
       "      <td>29191965</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>TAOK1</td>\n",
       "      <td>29259</td>\n",
       "      <td>25974414</td>\n",
       "      <td>PMC4431475</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>83</th>\n",
       "      <td>TAOK2</td>\n",
       "      <td>16835</td>\n",
       "      <td>25974414</td>\n",
       "      <td>PMC4431475</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>UBE2D2</td>\n",
       "      <td>12475</td>\n",
       "      <td>14612456</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>120 rows  4 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    hgnc.symbol   hgnc      pmid         pmc\n",
       "114        ABL1     76  17493042        None\n",
       "113        ABL1     76  23687953  PMC3750680\n",
       "8          ABL1     76  26631930        None\n",
       "62         ABL1     76  29191965        None\n",
       "19         ABL2     77  26631930        None\n",
       "118         AK1    361  22419736        None\n",
       "103        BAG1    937  17954934        None\n",
       "10       CAMK2A   1460  26631930        None\n",
       "30       CAMK2B   1461  12428809        None\n",
       "4          CDK1   1722  10391244        None\n",
       "31         CDK1   1722  12428809        None\n",
       "82         CDK2   1771  22072628        None\n",
       "79         CDK2   1771   8282104        None\n",
       "27         CDK5   1774  12428809        None\n",
       "40         CDK5   1774  17078951  PMC1828604\n",
       "52         CDK5   1774  21882945  PMC3190966\n",
       "25         CDK5   1774  25001178  PMC4194100\n",
       "74         CDK5   1774  27314526        None\n",
       "57         CDK5   1774  29191965        None\n",
       "48         CDK5   1774  29758300        None\n",
       "78         CDK5   1774   8282104        None\n",
       "93        CHEK2  16627  23001711        None\n",
       "77        CHRM1   1950  24590577  PMC5562652\n",
       "76        CHRM1   1950  26813123  PMC4787279\n",
       "21       CHRNA4   1958  17009926        None\n",
       "20       CHRNA7   1960  17009926        None\n",
       "7        CREBBP   2348  26631930        None\n",
       "84      CSNK1A1   2451  25974414  PMC4431475\n",
       "45      CSNK1A1   2451  30444369        None\n",
       "119        CTSD   2529  24027553  PMC3759803\n",
       "..          ...    ...       ...         ...\n",
       "88        MARK2   3332  29215007  PMC5719408\n",
       "47         MTOR   3942  29758300        None\n",
       "108        PIN1   8988  19401603  PMC2719320\n",
       "111        PIN1   8988  22926167        None\n",
       "112        PIN1   8988  26996941        None\n",
       "26       PPP1CA   9281  25001178  PMC4194100\n",
       "107      PPP2CA   9299  19401603  PMC2719320\n",
       "110      PPP2CA   9299  24653673  PMC3949405\n",
       "12       PPP2CA   9299  26631930        None\n",
       "101      PPP2CA   9299  29062069  PMC5653760\n",
       "60       PPP2CA   9299  29191965        None\n",
       "109      PPP2CB   9300  24653673  PMC3949405\n",
       "54        PPP5C   9322  21882945  PMC3190966\n",
       "16        PPP5C   9322  26631930        None\n",
       "67        PPP5C   9322  29311797  PMC5744016\n",
       "50       PRKAA1   9376  29758300        None\n",
       "64       PTGES3  16049  29311797  PMC5744016\n",
       "65       S100A1  10486  29311797  PMC5744016\n",
       "33        S100B  10500  18494933  PMC3538024\n",
       "94        SIRT1  14929  20869593  PMC3035103\n",
       "17        SIRT1  14929  26631930        None\n",
       "95        SIRT1  14929  29540553  PMC5895994\n",
       "56          SRC  11283  29191965        None\n",
       "37          SYK  11491  25331948  PMC4256331\n",
       "11          SYK  11491  26631930        None\n",
       "24          SYK  11491  28877763  PMC5588676\n",
       "59          SYK  11491  29191965        None\n",
       "85        TAOK1  29259  25974414  PMC4431475\n",
       "83        TAOK2  16835  25974414  PMC4431475\n",
       "38       UBE2D2  12475  14612456        None\n",
       "\n",
       "[120 rows x 4 columns]"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = pd.DataFrame(\n",
    "    data=[\n",
    "        (\n",
    "            target.name,\n",
    "            target.identifier,\n",
    "            pmid,\n",
    "            pmid_pmc_map.get(pmid),\n",
    "        )\n",
    "    for pmid, targets in pmid_to_targets.items()\n",
    "    for target in targets\n",
    "    ], \n",
    "    columns=['hgnc.symbol', 'hgnc', 'pmid', 'pmc']\n",
    ").sort_values(['hgnc.symbol', 'pmid'])\n",
    "\n",
    "# Output\n",
    "df.to_csv('tau-ptm-article-targets.tsv', sep='\\t', index=False)\n",
    "\n",
    "# Show in notebook\n",
    "df"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
